HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 6.06 MAC1. 29NOV23:07:52:4129NOV23:07:52:41 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADSL_2 SASDATA 6.06 29NOV23:07:52:4129NOV23:07:52:41 Subject-Level Analysis Dataset HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000023400000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier SUBJID Subject Identifier for the Study SITEID Study Site Identifier &AGE Age BEST *AGEU Age Units 2SEX Sex 7SEXN Sex (N) BEST 8) RACE Race @ RACEN Race (N) BEST iETHNIC Ethnicity qETHNICN Ethnicity (N) BEST ‡ RACIALD Racial Designation ŹRACIALDNRacial Designation (N) BEST —COUNTRY Country źSAFFL Safety Population Flag ˘RANDFL Randomized Population Flag ŁENRLFL Enrolled Population Flag ¤DTHFL Subject Death Flag ĄARM Description of Planned Arm ¦ ARMCD Planned Arm Code ÁACTARM Description of Actual Arm Ę ACTARMCDActual Arm Code ĺTRT01P Planned Treatment for Period 01 îTRT01PN Planned Treatment for Period 01 (N) BEST TRT02P Planned Treatment for Period 02 TRT02PN Planned Treatment for Period 02 (N) BEST ,TRT01A Actual Treatment for Period 01 4TRT01AN Actual Treatment for Period 01 (N) BEST OTRT02A Actual Treatment for Period 02 WTRT02AN Actual Treatment for Period 02 (N) BEST r& TRTSEQP Planned Sequence of Treatments z&!TRTSEQA Actual Sequence of Treatments "BRTHDT Date of Birth Ć#BRTHDTF Date of Birth Imput. Flag Ě$DTHDTC Date/Time of Death Í%DTHDT Date of Death DATE Î&DTHDTF Date of Death Imputation Flag Ö'RANDDT Date of Randomization DATE ×(RANDNO Randomization Number ß)RFSTDT Subject Reference Start Date DATE ĺ*RFSTTM Subject Reference Start Time TIME í+RFENDT Subject Reference End Date DATE ő,RFENTM Subject Reference End Time TIME ý-RFPENDT Date of End of Participation DATE .RFICDT Date of Informed Consent DATE /TRTSDT Date of First Exposure to Treatment DATE 0TRTSTM Time of First Exposure to Treatment TIME 1TRTEDT Date of Last Exposure to Treatment DATE %2TRTETM Time of Last Exposure to Treatment TIME -3TR01SDT Date of First Exposure in Period 01 DATE 54TR01STM Time of First Exposure in Period 01 TIME =5TR01EDT Date of Last Exposure in Period 01 DATE E6TR01ETM Time of Last Exposure in Period 01 TIME M7TR02SDT Date of First Exposure in Period 02 DATE U8TR02STM Time of First Exposure in Period 02 TIME ]9TR02EDT Date of Last Exposure in Period 02 DATE e:TR02ETM Time of Last Exposure in Period 02 TIME m;TRTSDTM Datetime of First Exposure to Treatment DATETIME uTR01EDTMDatetime of Last Exposure in Period 01 DATETIME Ť?TR02SDTMDatetime of First Exposure in Period 02 DATETIME •@TR02EDTMDatetime of Last Exposure in Period 02 DATETIME ťAVAX101DTVaccination Date 01 DATE ĄBVAX102DTVaccination Date 02 DATE CVAX201DTVaccination Date 03 DATE µDVAX202DTVaccination Date 04 DATE ˝EAGETR01 Age at Vaccination 01 BEST ĹFAGETRU01Age Units at Vaccination 01 ÍGAGETR03 Age at Vaccination 03 BEST ŇHAGETRU03Age Units at Vaccination 03 ÚIAGEGR1 Pooled Age Group 1 ßJAGEGR1N Pooled Age Group 1 (N) BEST ę)KARACE Analysis Race ňLARACEN Analysis Race (N) BEST MRACEGR1 Pooled Race Group 1 #NRACEGR1NPooled Race Group 1 (N) BEST <OEOSDCDT End Of Study Discontinuation Date DATE D$PEOSDCRS End Of Study Discontinuation Reason LQEOTDCDT End Of Treatment Discontinuation Date DATE p$REOTDCRS End Of Treatment Discontinuation Reason xSTRTDELT Adjusted Treatment for Rel. Efficacy śTTRTDELTNAdjusted Treatment for Rel. Efficacy (N)BEST ·UEVASEFFLEvaluable Efficacy Pop Flag - Asympt żVEVSCEFFLEvaluable Efficacy Pop Flag - Seroconv ŔWEXCL17FLExclusion Flag 17 ÁXINCL18FLNo PD prior to 1st N-Binding test PD2 ÂYEXCL18FLExclusion Flag 18 Ă§ZEXCRIT18Exclusion Criterion 18 Ä[INCL9FL Have valid immuno within timeframe 2 k\INCL17FLHave N-Binding result PD2 l]EXCL4FL Exclusion Flag 4 m^EXCL9FL Exclusion Flag 9 n_SURVICDTAsymptomatic Surveillance Consented DateDATE o$`VAX202 Vaccination 04 waVAX10UDTVaccination Date Unplanned DATE ›bVAX20UDTVaccination Date Unplanned in Period 02 DATE Ł$cVAX10U Vaccination Unplanned «dVAX20U Vaccination Unplanned in Period 02 ĎeVAX101TMVaccination Time 01 TIME ĐfVAX102TMVaccination Time 02 TIME ŘgVAX10UTMVaccination Time Unplanned TIME ŕhVAX201TMVaccination Time 03 TIME čiVAX202TMVaccination Time 04 TIME đjVAX20UTMVaccination Time Unplanned in Period 02 TIME řkINVID Investigator Identifier lINVNAM Investigator Name mDOSALVL Actual Dosing Level nDOSPLVL Planned Dosing Level !oDOSPLVLNPlanned Dosing Level (N) BEST "pDOSALVLNActual Dosing Level (N) BEST *qREACTOFLReactogenicity Population Flag 2rCOHORT Cohort Group 3sCOHORTN Cohort Group (N) BEST 4tPHASEN Study Phase (N) BEST <uPHASE Study Phase D vAGEGR2 Pooled Age Group 2 KwAGEGR3 Pooled Age Group 3 TxAGEGR4 Pooled Age Group 4 UyAGEGR4N Pooled Age Group 4 (N) BEST `zAGEGR2N Pooled Age Group 2 (N) BEST h{AGEGR3N Pooled Age Group 3 (N) BEST p|AGETGR3 Age Group at Vaccination 03 x}AGETGR3NAge Group at Vaccination 03 (N) BEST y$~VAX101 Vaccination 01 $VAX102 Vaccination 02 Ą$€VAX201 Vaccination 03 ÉUNBLNDDTTreatment Unblinded Date DATE í‚REVXICDTRe-Informed Consent Date DATE őEOTXDCDTEnd Of Open Label Treatment D/C Date DATE ý„EOTXDCRSEnd Of Open Label Treatment D/C Reason …BMICAT Baseline BMI Category †BMICATN Baseline BMI Category (N) BEST '‡OBESEFL Obese Flag for Adolescent /COMBODFLFlag for Comorbodities 0‰NIGV1FL N-binding Antibody Neg at Visit 1 Flag 1ŠNAATNFL NAAT Negative at Visit 1 Flag 2‹COVBLST Baseline SARS-CoV-2 Status 3ŚV01DT Date of Unblinding or Visit at 1MPD2 DATE 6ŤV02DT Date of Unblinding or Visit at 6MPD2 DATE >ŽV02OBDT Date of Dose 3 or Visit at 6MPD2 DATE FŹV03DT Date of Visit at 1M after Vax3/4 DATE NV04DT Date of Visit at 6M after Vax3/4 DATE V‘V3C19NIGC19NIG Result at Visit 3 ^’DVSTDT Start Date of Important PD DATE a“POP1PDDTFirst PD date for safety DATE i”POP2PDDTFirst PD date for efficacy DATE q•POP3PDDTFirst PD date for immunogenicity DATE y–BLDV1FL Blood Sample Drawn before Vax 1 —BLDV2FL Blood Sample Drawn 1 Week after Vax 1 ‚BLDV3FL Blood Sample Drawn before Vax 2 ™BLDV4FL Blood Sample Drawn 1 Week after Vax 2 „šBLDV5FL Blood Sample Drawn 2 Weeks after Vax 2 …›BLDV6FL Blood Sample Drawn 1 Month after Vax 2 †śBLDV7FL Blood Sample Drawn 6 Months after Vax 2 ‡ťBLDV1DT Blood Sample Date before Vax 1 DATE žBLDV2DT Blood Sample Date 1 Week after Vax 1 DATE źBLDV3ADTAdditional Bld Sample Date 3W after Vax1DATE BLDV4ADTAdditional Bld Sample Date 4W after Vax1DATE ˇBLDV5ADTAdditional Bld Sample Date 5W after Vax1DATE ¨˘BLDV6ADTAdditional Bld Sample Date 7W after Vax1DATE °ŁBLDV3DT Blood Sample Date before Vax 2 DATE ¸¤BLDV4DT Blood Sample Date 1 Week after Vax 2 DATE ŔĄBLDV5DT Blood Sample Date 2 Weeks after Vax 2 DATE Č¦BLDV6DT Blood Sample Date 1 Month after Vax 2 DATE Đ§BLDV7DT Blood Sample Date 6 Months after Vax 2 DATE Ř¨INCL1FL Are eligible for the study at rand ŕ©INCL2FL Have received Vax 1 as randomized áŞINCL3FL Have valid and DTM immuno result 1 â«INCL6FL No important PD determined by clinician ă¬INCL7FL Received 2 doses as rand within window äINCL8FL Have valid and DTM immuno result 3 ĺ®INCL10FLUnblinded after 1M post Dose 2 visit ćŻEXCL1FL Exclusion Flag 1 ç+°EXCRIT1 Exclusion Criterion 1 č±EXCL2FL Exclusion Flag 2 $˛EXCRIT2 Exclusion Criterion 2 łEXCL3FL Exclusion Flag 3 8´EXCRIT3 Exclusion Criterion 3 9µEXCRIT4 Exclusion Criterion 4 :¶EXCL6FL Exclusion Flag 6 ;¬·EXCRIT6 Exclusion Criterion 6 <¸RSEXSAF Reason for Exclusion from Safety Pop čąEXCL7FL Exclusion Flag 7 éşEXCRIT7 Exclusion Criterion 7 ę»EXCL8FL Exclusion Flag 8 kPĽEXCRIT8 Exclusion Criterion 8 lb˝EXCRIT9 Exclusion Criterion 9 ĽľEXCL10FLExclusion Flag 10 IżEXCRIT10Exclusion Criterion 10 MŔEXCRIT17Exclusion Criterion 17 hÁAAI01FL Dose 1 all-available Immun Popu Flag µÂAAI02FL Dose 2 all-available Immun Popu Flag ¶ĂEVALEFFLEvaluable Efficacy Popu Flag ·ÄEV14EFFLEvaluable Efficacy Popu Flag - 14 days ¸ĹAAI1EFFLDose 1 all-available Efficacy Popu Flag ąĆAAI2EFFLDose 2 all-available Efficacy Popu Flag şÇAAI2ASFLDose 2 all-available Asympt Popu Flag »ČEVAL02FLDose 2 evaluable Immun Popu Flag ĽÉINCL4FL Have valid immuno within timeframe 1 ˝ĘEVAL01FLDose 1 evaluable Immun Popu Flag ľËSCREEN Screening żĚDS3KFL FU to 6MPD2 ŔÍDS30KFL Phase 3 30k Subjects Flag ÁÎOPBOUFL Subjects Received Placebo & unblinded ÂĎJPNFL Japanese Subject Flag ĂĐPEDREAFLPhase 2/3 Pop for 12-25 Reacto Subset ÄŃPEDIMMFLPop for Non-inferiority Assessement ĹŇHIVFL HIV Positive Subjects Flag ĆÓEV1MD2FLSubject without Evidence 1MPD2 ÇÔBDCSRDT Double Blinded Follow-up Censor Date DATE ČŐX1CSRDT Crossover Dose1 Censor Date DATE ĐÖSTCSRDT Study Censor Date DATE Ř×FUP2CUT PD2 FU Time in Days: to Cutoff BEST ŕŘFUP2UNB PD2 FU Time in Days: to Unblinding BEST čŮFPX1CUT Post Xover D1 FUTM in Days: to Cutoff BEST đÚFUNBCUT Unblinding FUTM in Days: to Cutoff BEST řŰFUP1CUT PD1 FU Time in Days: to Cutoff BEST ÜFUP1UNB PD1 FU Time in Days: to Unblinding BEST ÝFUP2CAT1PD2 FU Time Cat 1: to Cutoff ŢFUP2CA1NPD2 FU Time Cat 1 (N): to Cutoff BEST ßFUP2CAT2PD2 FU Time Cat 2: to Unblinding $ŕFUP2CA2NPD2 FU Time Cat 2 (N): to Unblinding BEST 0 áFPX1CAT1Post Xover D1 FUTM Cat 1: to Cutoff 8âFPX1CA1NPost Xover D1 FUTM Cat 1 (N): to Cutoff BEST BăFUP1CAT1PD1 FU Time Cat 1: to Cutoff JäFUP1CA1NPD1 FU Time Cat 1 (N): to Cutoff BEST VĺRNACAT HIV RNA Category ^ćRNACATN HIV RNA Category (N) BEST _çCD4CAT CD4 Category for HIV-positive gčCD4CATN CD4 Category for HIV-positive (N) BEST héCOMPLDT Date of Completion DATE pęPD1POSDTPost-dose Positive Swab Result Date DATE x HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051317100513171005AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20158 DVŔD†ÄDWŤ.DWŤDVŔDVŔD†ÄDV×DřDVŔD†ÄDV×Dř....Hr^¦ÄHr|ňxHr^¦ÄHr|ňx..DVŔDV×..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D†ÄDř....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW8. Normal weightA NNYYNEGDVřDW†DW†..NEG....YNNNNYYDVŔ........DVřDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCpB¶BqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1005 10051328100513281005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20159 DVŔD°DWŤ.DWŤDVŔDVŔD°DVÖD› DVŔD°DVÖD› ....Hr^ĐHr{Ľ Hr^ĐHr{Ľ ..DVŔDVÖ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D°D› ....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NNYYNEGDVôDWŠDWŠ..NEG....YNNNNYYDVŔ........DVôDWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýC€B·BqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1005 10051339100513391005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20160 DVÁD¤LDWÄ.DWÄDVÁDVÁD¤LDW¨DLDVÁD¤LDVÖDŇDW‘DŇđDW¨DLHr`ĚHsLHr`ĚHr{óHsr|pHsLDVÁDVÖDW‘DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤LDŇ.DŇđDL.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDVňDWŠDWŠDWÄDXeNEG....YNNNNYYDVÁ........DVňDWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýC€B·BmBqCĐBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1005 10051410100514101005AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň20163 DVňDëČDWÄ.DWÄDVňDVňDëČDW¨D×(DVňDëČDWD›dDW“DŇ´DW¨D×(Hr öČHsÓ(Hr öČHr»dHsu4HsÓ(DVňDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëČD›d.DŇ´D×(.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Underweight ANNYYNEGDW#DW‘DW’DWÄDXeNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBřBŚBkBlCŔB 8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051412100514121005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22270 DV÷DŠDW˝.DW˝DV÷DV÷DŠDW D‚ŚDV÷DŠDW D‚Ś....Hr§,ŚHrÄ&Hr§,ŚHrÄ&..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DŠD‚Ś....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW0. Obese A@YNYYNEGDW0DWDW˝..NEG....YNNNNYYDV÷........DW0DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńB„BmCpBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051413100514131005AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22269 DV÷D†DW×.DW×DV÷DV÷D†DWD‰DV÷D†DWD‰....Hr§(HrÂŰHr§(HrÂŰ..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADW×OTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. D†D‰....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWcDW(. Overweight A0YNYYNEGDW(DWbDWĽ..NEG....YNNNNYYDV÷........DW(DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWbDW×DW×BĚBWBuBáBl7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051414100514141005AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22273 DV÷DŁ DWÔ.DWÔDV÷DV÷DŁ DW¸Dž¬DV÷DŁ DWD DW™DěôDW¸Dž¬Hr§E HsĄ˛¬Hr§E HrÂňHs}"tHsĄ˛¬DV÷DWDW™DW¸AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ D .DěôDž¬.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW™. Overweight A0NNYYNEGDW(DW‘DWDWÔDXuNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBňB†BeBlCpB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051415100514151005AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22274 DV÷DçDWĹ.DWĹDV÷DV÷DçDW©DÚ¬DV÷DçDWDÝôDW”DÇtDW©DÚ¬Hr§‰Hs’(,Hr§‰HrĂ/ôHsvetHs’(,DV÷DWDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDÝô.DÇtDÚ¬.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Normal weightA NNYYNEGDW(DW‘DW“DWĹDXfNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBňB†BjBlCpB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051417100514171005AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22785 DVůD®śDWę..DVůDVůD®śDWéD™DVůD®śDWDśDWŃD¬řDWéD™Hr©ôHsćFŚHr©ôHrĹ…śHsĆ¶xHsćFŚDVůDWDWŃDWéAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. D®śDś.D¬řD™.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÍDWŃ. Normal weightA NNYYNEGDW1DWËDWËDXDX¦NEG....YNNNNYYDVů........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĚDWýDWýBđBżB-B1CPBÔ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWiC4591001C4591001 1005 10051418100514181005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22786 DVůDŻČDWÍ.DWÍDVůDVůDŻČDWD‘DVůDŻČDWD‘....Hr©őHHrĹ†Hr©őHHrĹ†..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. DŻČD‘....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWÍDW7. Normal weightA NYYYNEGDW1DWËDWË..NEG....YNNNNYYDVů........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĚDWýDWýBđBżB1CPBÔ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1005 10051419100514191005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22794 DVůDŕLDWˇ..DVůDVůDŕLDWTD×(DVůDŕLDWD¬ĽDW?D×ÜDWTD×(HrŞ%ĚHs"(HrŞ%ĚHrÂţĽHsf\Hs"(DVůDWDW?DWTAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕLD¬Ľ.D×ÜD×(.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW?. Normal weightA NNYYNEGDW(DW5DW>DWpDXNEG....YNNNNYNDVů........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW5DWýDWýBňB*BżBČCPB=8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1005 10051420100514201005AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22792 DVůDŢ¨DWĐ.DWĐDVůDVůDŢ¨DWD«ĚDVůDŢ¨DWD«Ě....HrŞ$(HrÂýĚHrŞ$(HrÂýĚ..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DŢ¨D«Ě....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW(. Underweight ANNYYNEGDW(DW‘DWĐ..NEG....YNNNNYYDVů........DW(DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBňB†BlCPB™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051421100514211005AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23097 DVúDŢ0DWĐ.DWĐDVúDVúDŢ0DW¨DÓ¤DVúDŢ0DWDŰ$DW’DäDW¨DÓ¤Hr«u0HsĎ¤Hr«u0HrÇ!¤HssßHsĎ¤DVúDWDW’DW¨AĐYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢ0DŰ$.DäDÓ¤.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW/DWŚDW‘DWĐDXeNEG....YNNNNYNDVú........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BlBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051422100514221005AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23098 DVúDŕDWĐ.DWĐDVúDVúDŕDW¨DÓhDVúDŕDWDŰŘDW’DäHDW¨DÓhHr«wHsĎhHr«wHrÇ"XHssßHHsĎhDVúDWDW’DW¨AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕDŰŘ.DäHDÓh.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW/DWŚDW‘DWĐDXeNEG....YNNNNYNDVú........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BlBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051424100514241005AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23100 DVűD‡DWÉ.DWÉDVűDVűD‡DWDDDVűD‡DWDD....Hr¬o€HrČDHr¬o€HrČD..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. D‡DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW DW3. Underweight ANNYYNEGDW3DWźDWÉ..NEG....YNNNNYYDVű........DW3DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWźDWýDWýBîBB^C0BĄ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1005 10051425100514251005AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23101 DVűD«ĚDWĹ.DWĹDVűDVűD«ĚDWD«ĚDVűD«ĚDWD«Ě....Hr¬”LHrČCĚHr¬”LHrČCĚ..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D«ĚD«Ě....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW0. Normal weightA NYYYNEGDW0DW‘DWĹ..NEG....YNNNNYYDVű........DW0DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBîB‚BlC0B—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051427100514271005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23589 DVţDťDDWĹ.DWĹDVţDVţDťDDW¦D¬řDVţDťDDWDĐDW‘D°@DW¦D¬řHr°zDHsŽřHr°zDHrĚ%PHsrYŔHsŽřDVţDWDW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDDĐ.D°@D¬ř.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW/DWŚDWDWĹDXcNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBmBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051428100514281005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23596 DVţDÍŚDWË.DWËDVţDVţDÍŚDWD|DVţDÍŚDWD|....Hr°ŞŚHrÎ˛üHr°ŞŚHrÎ˛ü..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DÍŚD|....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW1. Normal weightA NNYYNEGDW1DW’DWË..NEG....YNNNNYYDVţ........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBéB~BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051429100514291005AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23597 DVţDŐDWÍ.DWÍDVţDVţDŐDWDäŔDVţDŐDWDäŔ....Hr°˛HrĚq@Hr°˛HrĚq@..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DŐDäŔ....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW6. Underweight ANNYYNEGDW6DW‘DWÍ..NEG....YNNNNYYDVţ........DW6DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBëBBlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051430100514301005AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23600 DV˙D{ŔDWĐ.DWĐDV˙DV˙D{ŔDWŤD•DV˙D{ŔDWDŹ4DWxD¤DWŤD•Hr±Ş@HslřHr±Ş@HrÍm4HsQ<¤HslřDV˙DWDWxDWŤAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. D{ŔDŹ4.D¤D•.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWuDWx. Normal weightA NNYYNEGDW0DWtDWwDWDXJNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWtDWýDWýBęBaB†B‰B˙Bv8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1005 10051431100514311005AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23890 DV˙D‡đDWŃ.DWŃDV˙DV˙D‡đDWD¦ŕDV˙D‡đDWD¦ŕ....Hr±¶pHrÍ„ŕHr±¶pHrÍ„ŕ..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D‡đD¦ŕ....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Obese A@YNYYNEGDW0DWŚDWŃ..NEG....YNNNNYYDV˙........DW0DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051436100514361005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23897 DV˙D®ŘDWĹ.DWĹDV˙DV˙D®ŘDWDĘĽDV˙D®ŘDWDĘĽ....Hr±ÝXHrÍ¨ĽHr±ÝXHrÍ¨Ľ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D®ŘDĘĽ....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW6. Underweight ANNYYNEGDW6DW‘DWĹ..NEG....YNNNNYYDV˙........DW6DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBęB~BlB˙B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051437100514371005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23894 DV˙DpDWĐ.DWĐDV˙DV˙DpDW°D™üDV˙DpDWDĘřDW›D’@DW°D™üHr±ŰđHs›!üHr±ŰđHrÍ¨řHsjŔHs›!üDV˙DWDW›DW°AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpDĘř.D’@D™ü.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW›. Overweight A0NNYYNEGDW6DW‘DWšDWĐDXmNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBęB~BcBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051438100514381005AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23892 DV˙D«ĚDW×.DW×DV˙DV˙D«ĚDW°D™„DV˙D«ĚDWDÍŚDW›D‘ČDW°D™„Hr±ÚLHs›!„Hr±ÚLHrÍ«ŚHsjHHs›!„DV˙DWDW›DW°AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. D«ĚDÍŚ.D‘ČD™„.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW›. Underweight ANNYYNEGDW6DW‘DWšDWĐDXmNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBęB~BcBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051439100514391005AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24039 DV˙DÔ”DWÉ.DWÉDV˙DV˙DÔ”DWDŐüDV˙DÔ”DWDŐü....Hr˛HrĚb|Hr˛HrĚb|..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DÔ”DŐü....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW0. Normal weightA NNYYNEGDW0DWDWÉ..NEG....YNNNNYYDV˙........DW0DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBëB~BmB˙B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051440100514401005AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24041 DV˙DŐHDWÄ.DWÄDV˙DV˙DŐHDW¨DÄhDV˙DŐHDWDŐDW“D¬ĽDW¨DÄhHr˛ČHsŔhHr˛ČHrĚaŚHstů<HsŔhDV˙DWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐHDŐ.D¬ĽDÄh.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Overweight A0YNYYNEGDW0DWDW’DWÄDXeNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBëB~BkBmB˙B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051441100514411005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24034 DV˙DŇđDWá.DWáDV˙DV˙DŇđDWDČ(DV˙DŇđDWDČ(....Hr˛pHrÍ¦(Hr˛pHrÍ¦(..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWáOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DŇđDČ(....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW1. Overweight A0NNYYNEGDW1DW’DWÄ..NEG....YNNNNYYDV˙........DW1DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWáDWáBÎBBOBăB”7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1005 10051444100514441005AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24043 DV˙DćdDW×..DV˙DV˙DćdDW©D0ŔDV˙DćdDWDŮDW”DÖěDW©D0ŔHr˛äHs‘~@Hr˛äHrÍ·HsvtěHs‘~@DV˙DWDW”DW©AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DćdDŮ.DÖěD0Ŕ.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Overweight A0YNYYNEGDW0DW‘DW“DWĹDXfNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBęB~BjBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051445100514451005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24130 DV˙Dě¸DWĚ.DWĚDV˙DV˙Dě¸DWŻD~ĚDV˙Dě¸DWDśTDWšD€¬DWŻD~ĚHr˛8Hs™µLHr˛8HrÍzTHs~¬Hs™µLDV˙DWDWšDWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě¸DśT.D€¬D~Ě.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DWš. Normal weightA NNYYNEGDW0DW‘DW™DWĚDXlNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBęB~BdBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWbC4591001C4591001 1005 10051447100514471005AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24134 DWD—ŕDW×.DW×DWDWD—ŕDW(DŽDDWD—ŕDW(DŽD....HrĚ$`HrçĘDHrĚ$`HrçĘD..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. D—ŕDŽD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWD. Overweight A0NNYYNEGDWDDW‘DW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBÖBjBlBëB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051448100514481005AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24138 DWD¶”DWĐ.DWĐDWDWD¶”DWŻDÂDWD¶”DW(D DWšD‡đDWŻDÂHrĚCHs™řHrĚCHrçÜHs~đHs™řDWDW(DWšDWŻAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶”D .D‡đDÂ.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWš. Normal weightA NNYYNEGDWDDWDW™DWĐDXlNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÖBiBdBmBëB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1005 10051449100514491005AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24137 DWD´DWŢ.DWŢDWDWD´DW(DźśDWD´DW(Dźś....HrĚ@€HrçŰśHrĚ@€HrçŰś..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´Dźś....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Overweight A0NNYYNEGDWDDWDWŢ..NEG....YNNNNYYDW........DWDDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÖBiBmBëB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051450100514501005AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26654 DWDŃDWĐ.DWĐDWDWDŃDWDŮřDWDŃDW(DÜPDWDá<DWDŮřHrĚ^Hs—mxHrĚ^HrčPHs{Ĺ<Hs—mxDWDW(DWDWAŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃDÜP.Dá<DŮř.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW. Normal weightA NNYYNEGDWDDW‘DW—DWĐDXjNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÖBjBfBlBëB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1005 10051451100514511005AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26655 DWDĚ`DWĺ.DWĺDWDWDĚ`DW*D¶DWDĚ`DW*D¶....HrÍŞ`Hrę•HrÍŞ`Hrę•..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DĚ`D¶....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĺDWF. Underweight ANYYYNEGDWFDWäDWĺ..NEG....YNNNNYYDW........DWFDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWäDWýDWýBÔB»BBęBŃ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1006 10061183100611831006AŕYEARSMAMULTIPLE A`HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20339 DVéD„0DWÉ.DWÉDVéDVéD„0DW§D‚DVéD„0DWD†DW”D‘ČDW§D‚Hr”±°HsŹ,”Hr”±°HrĆĚHsv/ČHsŹ,”DVéDWDW”DW§AŕYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D„0D†.D‘ČD‚.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Obese A@YNYYNEGDW0DW‘DW“DWÉDXdNEG....YNNNNYNDVé........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBďBBjBlCPB©8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061184100611841006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20340 DVéD©tDW.DWDVéDVéD©tDVţD›ÜDVéD©tDVţD›Ü....Hr”ÖôHr°xÜHr”ÖôHr°xÜ..DVéDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. D©tD›Ü....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¦DWp. Normal weightA NNYYNEGDWDWĄDW..NEG....YNNNNYYDVé........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWĄDWýDWýCB¨BXCPB˝9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1006 10061188100611881006AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20341 DVęDô°DWÉ.DWÉDVęDVęDô°DW¦DďÄDVęDô°DV˙DúŚDW’DđDW¦DďÄHr–s°HsŽHÄHr–s°Hr˛)HssëHsŽHÄDVęDV˙DW’DW¦AŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dô°DúŚ.DđDďÄ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDWDWŤDW‘DWÉDXcNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB˙BŹBlBpC@B¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061189100611891006AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20348 DVęDô°DW®.DW®DVęDVęDô°DV˙DîÔDVęDô°DV˙DîÔ....Hr–s°Hr˛THr–s°Hr˛T..DVęDV˙..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. Dô°DîÔ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Normal weightA NNYYNEGDWDWŚDW®..NEG....YNNNNYYDVę........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB˙BŽBqC@BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DWUC4591001C4591001 1006 10061190100611901006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20638 DVëD|°DW°.DW°DVëDVëD|°DV˙D’¸DVëD|°DV˙D’¸....Hr—M0Hr±Á8Hr—M0Hr±Á8..DVëDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D|°D’¸....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWU. Overweight A0NNNYPOSDWDW‘DW°..POS....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‘DWýDWýB˙B“BlC0B§9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DWzC4591001C4591001 1006 10061191100611911006AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20640 DVëDśĚDW±.DW±DVëDVëDśĚDV˙D—¤DVëDśĚDV˙D—¤....Hr—mLHr±Ć$Hr—mLHr±Ć$..DVëDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DśĚD—¤....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWL. Normal weightA NYYYNEGDWDW‘DW±..NEG....YNNNNYYDVë........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýB˙B“BlC0B§9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061196100611961006AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20644 DVëDý DWĂ.DWĂDVëDVëDý DW§D©tDVëDý DVţD÷ĽDW“DĹĐDW§D©tHr—Í HsŹSôHr—Í Hr°ÔĽHsuPHsŹSôDVëDVţDW“DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dý D÷Ľ.DĹĐD©t.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Normal weightA NNYYNEGDWDW‘DW’DWĂDXdNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýCB”BkBlC0B§9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061200100612001006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20647 DVěDŇ´DWö.DWöDVěDVěDŇ´DWiD–đDVěDŇ´DWDŹ4DWSDďLDWiD–đHrô´Hs=„pHrô´Hr´`´Hs ŰĚHs=„pDVěDWDWSDWiAđYEARSBYEARS12-15 YearsAWHITE AWHITE ADWöLOST TO FOLLOW-UP . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ´DŹ4.DďLD–đ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWFDWS. Overweight A0NNYYNEGDW$DWEDWRDW‹DX&NEG....YNNNNYNDVě........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWEDWöDWöBöBEB¤B±C°BZ8-9 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1006 10061201100612011006AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20867 DVěDŇxDWÄ.DWÄDVěDVěDŇxDWDŹpDVěDŇxDWDŹp....HrôxHr´`đHrôxHr´`đ..DVěDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇxDŹp....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Overweight A0YNYYNEGDW$DW‘DWÄ..NEG....YNNNNYYDVě........DW$DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBýB‘BlC B¦9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061203100612031006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20871 DVěDňXDW°.DW°DVěDVěDňXDV˙D©8DVěDňXDV˙D©8....Hr™XHr±×¸Hr™XHr±×¸..DVěDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. DňXD©8....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWšDWS. Normal weightA NNYYNEGDWDW™DW°..NEG....YNNNNYYDVě........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW™DWýDWýB˙B›BdC B®9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061206100612061006AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVí20872 DVíD‚PDW’.DW’DVíDVíD‚PDWDDDVíD‚PDWDD....Hr™őĐHr˛˙DHr™őĐHr˛˙D..DVíDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW’WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‚PDD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW’.. Normal weightA NNYYNEGDWDW‘DW˝..POS....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‘DW’DW’B“B’AB¦BĄ5-6 months A`5-6 months A`0-1 month A5-6 months A` . ..DW C4591001C4591001 1006 10061207100612071006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVí20874 DVíD‚ŚDW’.DW’DVíDVíD‚ŚDWDDVíD‚ŚDWD....Hr™öHr˛˙Hr™öHr˛˙..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW’WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‚ŚD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW’.. Underweight ANYYYNEGDWDW‘DW˝..POS....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‘DW’DW’B“B’AB¦BĄ5-6 months A`5-6 months A`0-1 month A5-6 months A` . ..DWC4591001C4591001 1006 10061209100612091006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20998 DVíDŞÜDWµ.DWµDVíDVíDŞÜDWDžčDVíDŞÜDWDžč....Hrš\HrłčHrš\Hrłč..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DŞÜDžč....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWO. Normal weightA NNNNPOSDW"DW‘DWµ..POS....YNNNNYYDVí........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDW‘DWýDWýBţB’BlCBĄ9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061212100612121006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20999 DVíDĘ€DWĹ.DWĹDVíDVíDĘ€DW§DĂ<DVíDĘ€DWD™üDW’D›(DW§DĂ<Hrš>HsŹmĽHrš>HrłüHss–(HsŹmĽDVíDWDW’DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘ€D™ü.D›(DĂ<.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDWDWDW‘DWĹDXdNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýBţB‘BlBmCB¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061213100612131006AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21000 DVíDĘDDWŻ.DWŻDVíDVíDĘDDWDŠŔDVíDĘDDWDŠŔ....Hrš=ÄHrł ŔHrš=ÄHrł Ŕ..DVíDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DĘDDŠŔ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWO. Normal weightA NNYYNEGDWDWDWŻ..NEG....YNNNNYYDVí........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBţB‘BmCB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061214100612141006AŕYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí21001 DVíDßDWĐ.DWĐDVíDVíDßDW´DŐ„DVíDßDWDÚ¬DW’Dâ¤DW´DŐ„HršSHs Ł„HršSHrłZ¬HssÝ¤Hs Ł„DVíDWDW’DW´AŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DßDÚ¬.Dâ¤DŐ„.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Overweight A0YNYYNEGDWDWŚDW‘DWĐDXqNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBlBqCB 9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ..DWxC4591001C4591001 1006 10061219100612191006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21141 DVđD‹tDWü.DWüDVđDVđD‹tDWŰDŰ$DVđD‹tDWDśDW®DŠHDWŰDŰ$HrťótHsÔ¤HrťótHr´SHsoHHsÔ¤DVđDWDW®DWŰAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‹tDś.DŠHDŰ$.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW®DW®. Normal weightA NNYYNEGDW!DWDWDWüDXNEG....YNNNNYNDVđ........DW!.YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWDWýDWýBýBBPBPCŕBľ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ..DW~C4591001C4591001 1006 10061220100612201006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21143 DVđDš8DW¶..DVđDVđDš8DWDŤDVđDš8DWDŤ....Hrž8Hrą¤Hrž8Hrą¤..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dš8DŤ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW7.. Normal weightA NNYYNEGDW%DW6DW¶..NEG....YNNNNYYDVđ........DW%DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW6DWýDWýBůB2BÇCŕBG8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1006 10061221100612211006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21147 DVđDŞÜDWŢ.DWŢDVđDVđDŞÜDWDĄ´DVđDŞÜDWDĄ´....HržÜHrą˝4HržÜHrą˝4..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DŞÜDĄ´....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWV. Normal weightA NNYYNEGDW%DW‘DWµ..NEG....YNNNNYYDVđ........DW%DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWŢDWŢBÚBŤBMBďB˘7-8 months A€5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1006 10061223100612231006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21152 DVđDÂDWĹ.DWĹDVđDVđDÂDW§DťDDVđDÂDWDóüDW‘D{DW§DťDHrž*HsŹGÄHrž*HrĽ®|Hsr$ŚHsŹGÄDVđDWDW‘DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂDóü.D{DťD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANYYYNEGDW)DWŤDWDWĹDXdNEG....YNNNNYNDVđ........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BmBpCŕBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061224100612241006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21261 DVđDŐHDWĹ.DWĹDVđDVđDŐHDWDŠHDVđDŐHDWDŠH....Hrž=HHrąˇČHrž=HHrąˇČ..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DŐHDŠH....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWb. Overweight A0NNYYNEGDW%DW‘DWĹ..NEG....YNNNNYYDVđ........DW%DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBůBŤBlCŕB˘8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061226100612261006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21262 DVđDçĚDWĹ.DWĹDVđDVđDçĚDWŁD™ŔDVđDçĚDWDőÜDWŽDź$DWŁD™ŔHržOĚHs‰ţ@HržOĚHrş \HsnT$Hs‰ţ@DVđDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçĚDőÜ.Dź$D™Ŕ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW!DWŚDWŤDWĹDX`NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBpBqCŕBť8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061227100612271006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21264 DVđDčDW´.DW´DVđDVđDčDWDöDVđDčDWDö....HržPHrş HržPHrş ..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DčDö....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Normal weightA NNYYNEGDW!DWŚDW´..NEG....YNNNNYYDVđ........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCŕBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061228100612281006AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21267 DVńD™ŔDWĹ.DWĹDVńDVńD™ŔDWŁDË4DVńD™ŔDWDĆHDWŽDź$DWŁDË4HrźS@HsŠ/´HrźS@Hr»/HHsnT$HsŠ/´DVńDWDWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D™ŔDĆH.Dź$DË4.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW$DWŚDWŤDWĹDX`NEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BpBqCĐBś8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061229100612291006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21442 DVńD¶ĐDW¶.DW¶DVńDVńD¶ĐDWNDč€DVńD¶ĐDWD®$DW9DéčDWNDč€HrźpPHs=€HrźpPHr»$HrţŹhHs=€DVńDWDW9DWNAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶ĐD®$.DéčDč€.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW9. Normal weightA NNYYNEGDW(DW5DW8DWjDXNEG....YNNNNYNDVń........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýBřB0BĹBČCĐBE8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1006 10061230100612301006AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21446 DVńDđđDWć.DWćDVńDVńDđđDWD±0DVńDđđDWD±0....HrźŞpHr˝˝0HrźŞpHr˝˝0..DVńDW..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DđđD±0....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”.. Normal weightA NNYNPOSDW)DW“DWĂ..POS....YNNNNYYDVń........DW)DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDW“DWýDWýBöBŚBjCĐBŁ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061231100612311006AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21448 DVńDöĚDWě.DWěDVńDVńDöĚDWDŽĽDVńDöĚDWDŽĽ....Hrź°LHrą¦<Hrź°LHrą¦<..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DöĚDŽĽ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Normal weightA NNYYNEGDW"DWŚDW´..NEG....YNNNNYYDVń........DW"DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061232100612321006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21450 DVńDü0DWĹ.DWĹDVńDVńDü0DW§D÷ĽDVńDü0DWDţDW’Dű@DW§D÷ĽHrźµ°HsŹ˘<Hrźµ°Hr»gHssö@HsŹ˘<DVńDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dü0Dţ.Dű@D÷Ľ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW#DWŤDW‘DWĹDXdNEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBřBBlBpCĐBť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061233100612331006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21561 DVńDűDWĹ.DWĹDVńDVńDűDW§D÷řDVńDűDWDţÄDW’Dű|DW§D÷řHrź´„HsŹ˘xHrź´„Hr»gÄHssö|HsŹ˘xDVńDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DűDţÄ.Dű|D÷ř.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW#DWŤDW‘DWĹDXdNEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBřBBlBpCĐBť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061234100612341006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21563 DVňD~TDW¶.DW¶DVňDVňD~TDWD}(DVňD~TDWD}(....Hr ‰THrĽ7¨Hr ‰THrĽ7¨..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D~TD}(....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWU. Underweight ANNYYNEGDW#DWDW¶..NEG....YNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýB÷BŠBmCŔBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061235100612351006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21568 DVňD~DWË.DWËDVňDVňD~DW§D~DVňD~DWD}dDW“DÉDW§D~Hr ‰HsŹ)Hr ‰HrĽ7äHsuHsŹ)DVňDWDW“DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D~D}d.DÉD~.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Underweight ANNYYNEGDW#DWDW’DWĂDXdNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB÷BŠBkBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061236100612361006AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21571 DVňDź`DW´.DW´DVňDVňDź`DWDČ DVňDź`DWDČ ....Hr Ş`Hrąŕ Hr Ş`Hrąŕ ..DVňDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. Dź`DČ ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWT. Normal weightA NNYYNEGDW!DWŤDW´..NEG....YNNNNYYDVň........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBůB‰BpCŔBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061237100612371006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21696 DVňDŁÔDW˝..DVňDVňDŁÔDWˇDÁ\DVňDŁÔDWD¸ěDWŽDŐDWˇDÁ\Hr ®ÔHs‡‚ÜHr ®ÔHrąĐlHsnŠHs‡‚ÜDVňDWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁÔD¸ě.DŐDÁ\.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW#DWŚDWŤDW˝DX^NEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBpBqCŔB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061239100612391006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21699 DVňD®ŘDWĆ.DWĆDVňDVňD®ŘDW¨DřčDVňD®ŘDWDŞ DW‘Dů`DW¨DřčHr ąŘHsôčHr ąŘHrĽe Hsr˘ŕHsôčDVňDWDW‘DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D®ŘDŞ .Dů`Dřč.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDW#DWŤDWDWĆDXeNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BmBpCŔBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061241100612411006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21702 DVňDÉĚDWµ..DVňDVňDÉĚDWDŇDVňDÉĚDWDŇ....Hr ÔĚHrąé€Hr ÔĚHrąé€..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DÉĚDŇ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW]. Normal weightA NNYYNEGDW#DWŤDWµ..NEG....YNNNNYYDVň........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBůB‰BpCŔBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061242100612421006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21704 DVňDć DWĂ.DWĂDVňDVňDć DWD~TDVňDć DWD~T....Hr ń Hrą•ÔHr ń Hrą•Ô..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. Dć D~T....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW[. Underweight ANNYYNEGDW%DW‘DWż..NEG....YNNNNYYDVň........DW%DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBůBŤBlCŔB 8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061243100612431006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21864 DVóDŽDDWĽ..DVóDVóDŽDDWD~TDVóDŽDDWD~T....HrˇęÄHrşçTHrˇęÄHrşçT..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DŽDD~T....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWV. Normal weightA NNYYNEGDW"DWŤDWĽ..NEG....YNNNNYYDVó........DW"DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBřBBpC°B›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061244100612441006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21865 DVóD«DWµ.DWµDVóDVóD«DWDŁ DVóD«DWDŁ ....Hr˘Hr» Hr˘Hr» ..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. D«DŁ ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWY. Normal weightA NNYYNEGDW"DWŚDWµ..NEG....YNNNNYYDVó........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBřB‡BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061245100612451006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21869 DVóD«TDWĹ.DWĹDVóDVóD«TDW¨DÓhDVóD«TDWDŁ\DW’Dě¸DW¨DÓhHr˘ÔHsĎhHr˘ÔHr»\Hssç¸HsĎhDVóDWDW’DW¨AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D«TDŁ\.Dě¸DÓh.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDW"DWDW‘DWĹDXeNEG....YNNNNYNDVó........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹BlBmC°Bž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061247100612471006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21871 DVóE@DWÉ.DWÉDVóDVóE@DWŁDďLDVóE@DWD÷ĽDWŽDů`DWŁDďLHr˘^HsŠSĚHr˘^Hr»`ĽHsn®`HsŠSĚDVóDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. E@D÷Ľ.Dů`DďL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDW$DWŤDWŤDWÉDX` ....YNNNNNNDVó..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBřBBpBpC°B›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061248100612481006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22046 DVôD$DWĆ.DWĆDVôDVôD$DW¨D‹°DVôD$DWD’ôDW“D¤DW¨D‹°HrŁ/$Hs‡°HrŁ/$HrĽMtHstđHs‡°DVôDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D$D’ô.D¤D‹°.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Underweight ANNYYNEGDW%DWDW’DWĆDXeNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýB÷BŠBkBmC Bť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061249100612491006AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22047 DVôDš°DW¸.DW¸DVôDVôDš°DWD› DVôDš°DWD› ....HrŁH°Hr˝§ HrŁH°Hr˝§ ..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. Dš°D› ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWV. Obese A@YNYYNEGDW+DWDW¸..NEG....YNNNNYYDVô........DW+DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBöB‰BmC Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061250100612501006AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22050 DVôD›dDWŘ.DWŘDVôDVôD›dDW»Dő DVôD›dDWD›ÜDW”D‚PDW»Dő HrŁIdHs©ţ HrŁIdHr˝§ÜHsv PHs©ţ DVôDWDW”DW»AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D›dD›Ü.D‚PDő .82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Overweight A0YNYYNEGDW+DWDW“DWŘDXxNEG....YNNNNYNDVô........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBöB‰BjBmC Bť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061252100612521006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22051 DVôD˛DWÉ.DWÉDVôDVôD˛DWD¬DDVôD˛DWD¬D....HrŁ`Hr˝¸DHrŁ`Hr˝¸D..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. D˛D¬D....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW]. Underweight ANNYYNEGDW$DWŤDW¸..NEG....YNNNNYYDVô........DW$DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBöB†BpC Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061253100612531006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22173 DVôDČdDWĹ.DWĹDVôDVôDČdDW§DĐDVôDČdDWDŁ DW‘D~DW§DĐHrŁvdHsŹCPHrŁvdHrĽ] Hsr'HsŹCPDVôDWDW‘DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DČdDŁ .D~DĐ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDW(DWŤDWDWĹDXdNEG....YNNNNYNDVô........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BmBpC Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061254100612541006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22174 DVôDÄŕDWĂ.DWĂDVôDVôDÄŕDWDÇtDVôDÄŕDWDÇt....HrŁrŕHrĽôHrŁrŕHrĽô..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DÄŕDÇt....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWV. Obese A@YNYYNEGDW)DWŤDWĂ.. ....YNNNNYYDVô........DW)DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýB÷B‡BpC Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061256100612561006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22176 DVôDűôDWÄ.DWÄDVôDVôDűôDWDî\DVôDűôDWDî\....HrŁ©ôHrĽ¨ÜHrŁ©ôHrĽ¨Ü..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DűôDî\....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWZ. Overweight A0NNYYNEGDW(DWŤDWÄ..NEG....YNNNNYYDVô........DW(DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýB÷B‡BpC Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWZC4591001C4591001 1006 10061257100612571006AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22182 DVôDúČDWk..DVôDVôDúČDWODĹ”DVôDúČDWDäüDW:Dî\DWODĹ”HrŁ¨ČHslHrŁ¨ČHrĽź|Hr˙ĺ\HslDVôDWDW:DWOAđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DúČDäü.Dî\DĹ”.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW:. Normal weightA NNYYNEGDW$DW5DW9DWkDXNEG....YNNNNYNDVô........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýB÷B/BÄBČC BB8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1006 10061258100612581006AŕYEARSMANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPNOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22296 DV÷D‚DWĆ.DWĆDV÷DV÷D‚DW D}ÜDV÷D‚DW D}Ü....Hr§$”HrÄ!\Hr§$”HrÄ!\..DV÷DW ..AŕYEARS. 12-15 YearsANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. D‚D}Ü....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWO. Normal weightA NNYYNEGDW/DW‘DWĆ..NEG....YNNNNYYDV÷........DW/DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBńB…BlCpB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061259100612591006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22300 DV÷D–xDW‹.DW‹DV÷DV÷D–xDWoD„lDV÷D–xDW DŹ¬DWVD‡´DWoD„lHr§8řHsEZěHr§8řHrÄ3,Hs$h´HsEZěDV÷DW DWVDWoAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–xDŹ¬.D‡´D„l.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW@DWV. Underweight ANNYYNEGDW)DW?DWUDW‹DX,POS....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW?DWýDWýBńB3B¨BľCpBI8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ..DWC4591001C4591001 1006 10061260100612601006AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22302 DV÷D–đDWĆ.DWĆDV÷DV÷D–đDW¦Dš8DV÷D–đDW DŹčDW‘D‡´DW¦Dš8Hr§9pHsŤó8Hr§9pHrÄ3hHsr14HsŤó8DV÷DW DW‘DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D–đDŹč.D‡´Dš8.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW)DWŤDWDWĆDXcNEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBńBBmBpCpB—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061261100612611006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22303 DV÷Dß DW˝.DW˝DV÷DV÷Dß DW D$DV÷Dß DW D$....Hr§ HrÄ3¤Hr§ HrÄ3¤..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. Dß D$....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWV. Underweight ANNYYNEGDW)DWDW˝..NEG....YNNNNYYDV÷........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńB„BmCpBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061262100612621006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22426 DV÷DřpDWü.DWüDV÷DV÷DřpDWÄD”\DV÷DřpDWDá<DW™DřčDWÄD”\Hr§šđHsµz\Hr§šđHrĹÖ<Hs}.hHsµz\DV÷DWDW™DWÄAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DřpDá<.DřčD”\.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Normal weightA NNYYNEGDW0DWŤDWDWçDXNEG....YNNNNYNDV÷........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BeBpCpB—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061263100612631006AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22428 DV÷DöDWÄ.DWÄDV÷DV÷DöDWDî\DV÷DöDWDî\....Hr§HrĂ@\Hr§HrĂ@\..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DöDî\....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWT. Underweight ANNYYNEGDW,DW‘DWÄ..NEG....YNNNNYYDV÷........DW,DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBňB†BlCpB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061264100612641006AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22429 DV÷Dý DWĂ.DWĂDV÷DV÷Dý DWDöDV÷Dý DWDö....Hr§ź HrĂHHr§ź HrĂH..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. Dý Dö....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWU. Overweight A0YNYYNEGDW*DWŤDWĂ..NEG....YNNNNYYDV÷........DW*DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBňB‚BpCpB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061265100612651006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23313 DVűDŚ DWŽ.DWŽDVřDVűDŚ DWD{DVűDŚ DWD{....Hr¬u HrĹpHr¬u HrĹp..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŽNO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DŚ D{....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW]. Underweight ANYYYNEGDW+DWŤDWË..NEG....YNNNNYNDVű........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWŤDWŽDWŽBB€AB”B“4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061266100612661006AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22433 DVřDž4DWp..DVřDVřDž4DWTDštDVřDž4DWD›dDW?DžčDWTDštHr¨’4Hs!ŘtHr¨’4HrĹdHs-hHs!ŘtDVřDWDW?DWTAđYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4D›d.DžčDšt.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW>DW?. Overweight A0NNYYNEGDW1DW=DW>DWpDXPOS....YNNNNYNDVř........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW=DWýDWýBđB0BżBŔC`BF8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ..DW#C4591001C4591001 1006 10061267100612671006AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22558 DVřDĽ¬DWé..DVřDVřDĽ¬DWéDÝ¸DVřDĽ¬DWDŹ¬DWŇDřpDWéDÝ¸Hr¨°¬Hsć‹8Hr¨°¬HrÚś¬HsČSpHsć‹8DVřDWDWŇDWéAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽ¬DŹ¬.DřpDÝ¸.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŇDWŇ. Normal weightA NNYYNEGDW:DWŃDWŃDXDX¦POS....YNNNNYNDVř........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŃDWýDWýBŕB´B,B,C`BÚ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWC4591001C4591001 1006 10061269100612691006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22561 DVřD÷€DWĽ.DWĽDVřDVřD÷€DWDĺěDVřD÷€DWDĺě....Hr¨ë€HrĹÚěHr¨ë€HrĹÚě..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D÷€Dĺě....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW[. Underweight ANNYYNEGDW1DWŤDWĽ.. ....YNNNNYYDVř........DW1DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBđB€BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061270100612701006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22562 DVůD™ŔDWk..DVůDVůD™ŔDWNDčDVůD™ŔDWDŤTDW9D‰XDWNDčHr©ß@Hs=Hr©ß@HrĹ‚THrţ.ŘHs=DVůDWDW9DWNAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™ŔDŤT.D‰XDč.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW9. Normal weightA NNYYNEGDW*DW5DW8DWkDXNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýBđB(BĹBČCPB=8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1006 10061271100612711006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22566 DVůDĄ´DWÄ.DWÄDVůDVůDĄ´DW DĘřDVůDĄ´DW DĘř....Hr©ë4HrÄnxHr©ë4HrÄnx..DVůDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DĄ´DĘř....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW[. Normal weightA NNYYNEGDW*DWŤDWÄ..NEG....YNNNNYYDVů........DW*DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBńBBpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061272100612721006AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22821 DVůDŞdDWč.DWčDVůDVůDŞdDW‘DęśDVůDŞdDW‘Dęś....Hr©ďäHsr”Hr©ďäHsr”..DVů...AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NN . DW‘.BNT162b2 (30 (*ESC*){unicode 03BC}g) DŞd.Dęś...82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NYYYNEGDWŤDWŤDXN..NEGDVů.DVůDVůYNNNNYYDVů........DW/DW˝NY NNN Ynot eligible for the study at randomization Yhad important protocol deviation(s) as determined by the clinician for Immunogenicity (on or before 3 weeks post Dose 1) Population(s) NNNYNNN YNNNNY NNDWŤDWýDWýBpCPB•0-1 month A0-1 month A0-1 month A9-10 months A . ...C4591001C4591001 1006 10061273100612731006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22823 DVůDâ,DWĹ.DWĹDVůDVůDâ,DW©DďLDVůDâ,DWDŇDW’DÖ°DW©DďLHrŞ'¬Hs’<ĚHrŞ'¬HrČjHssŃ°Hs’<ĚDVůDWDW’DW©AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ,DŇ.DÖ°DďL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NYYYNEGDW,DWŚDW‘DWĹDXfNEG....YNNNNYNDVů........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BlBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061274100612741006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22830 DVůDúPDWÄ.DWÄDVůDVůDúPDWD™ŔDVůDúPDWD™Ŕ....HrŞ?ĐHrČ1ŔHrŞ?ĐHrČ1Ŕ..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DúPD™Ŕ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWR. Underweight ANNYYNEGDW,DWŤDWÄ..NEG....YNNNNYYDVů........DW,DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061276100612761006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22831 DVúD´đDWŃ.DWŃDVúDVúD´đDWµD“¨DVúD´đDWDá´DW“D¸DWµD“¨Hr«KđHsˇł(Hr«KđHrĹÖ´HstĐ8Hsˇł(DVúDWDW“DWµAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D´đDá´.D¸D“¨.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Normal weightA NNYYNEGDW,DWŤDW’DWŃDXrNEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BkBpC@B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061277100612771006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23159 DVúDŮřDWó.DWóDVúDVúDŮřDW¦Dß DVúDŮřDWDŘDW’DĄDW¦Dß Hr«přHsŽ8 Hr«přHrČpHss HsŽ8 DVúDWDW’DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮřDŘ.DĄDß .82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDW/DWŤDW‘DWĹDXcNEG....YNNNNYNDVú........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BlBpC@B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061278100612781006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23162 DVúDń¤DWż.DWżDVúDVúDń¤DW D«DVúDń¤DW D«....Hr«¤HrÄOHr«¤HrÄO..DVúDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. Dń¤D«....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWľDWR. Underweight ANNYYNEGDW)DW˝DWż.. ....YNNNNYYDVú........DW)DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW˝DWýDWýBńB±B@C@BÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1006 10061279100612791006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23166 DVúDöTDWç.DWçDVúDVúDöTDW¦DńŕDVúDöTDW DôtDW‘D™HDW¦DńŕHr«ŤTHsŽJŕHr«ŤTHrÄ—ôHsrBČHsŽJŕDVúDW DW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DöTDôt.D™HDńŕ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Obese A@YYYYNEGDW)DWŤDWDWĹDXcNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBńBBmBpC@B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061280100612801006AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23168 DVúDř¬DWŢ.DWŢDVúDVúDř¬DWDďÄDVúDř¬DWDďÄ....Hr«Ź¬HrÇ6DHr«Ź¬HrÇ6D..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. Dř¬DďÄ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWR. Obese A@YYYYNEGDW1DWŤDWĂ..NEG....YNNNNYYDVú........DW1DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWŢDWŢBĐBBQBĺB”7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1006 10061282100612821006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23314 DVűDŁ\DWż.DWżDVűDVűDŁ\DWDštDVűDŁ\DWDšt....Hr¬‹ÜHrČ2tHr¬‹ÜHrČ2t..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DŁ\Dšt....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWO. Underweight ANNYYNEGDW3DWŤDWż..NEG....YNNNNYYDVű........DW3DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061283100612831006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23315 DVűDŻPDWĹ.DWĹDVűDVűDŻPDW©DĹ”DVűDŻPDWDŘDW”DđxDW©DĹ”Hr¬—ĐHs’Hr¬—ĐHrČpHsvŽxHs’DVűDWDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŻPDŘ.DđxDĹ”.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDW,DWŤDW“DWĹDXfNEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BjBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061284100612841006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23318 DVűD÷€DWű.DWűDVűDVűD÷€DW®DŕLDVűD÷€DWDí0DW™D$DW®DŕLHr¬ŕHsĹLHr¬ŕHrČ…0Hs|¶¤HsĹLDVűDWDW™DW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷€Dí0.D$DŕL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Overweight A0YNYYNEGDW,DWDWDWĚDXkPOS....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWýDWýBîBBeBmC0B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061285100612851006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23702 DVţD¨„DWŘ..DVţDVţD¨„DWµDĂ´DVţD¨„DWDépDW˘DŹpDWµDĂ´Hr°…„Hsˇă4Hr°…„HrÍÇpHs˘pHsˇă4DVţDWDW˘DWµAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨„Dép.DŹpDĂ´.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWˇDW˘. Normal weightA NNYYNEGDW7DW DWˇDWŘDXrNEG....YNNNNYNDVţ........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW DWýDWýBęBŤB\B]CBŁ8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061286100612861006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23704 DVţDĘřDWÉ.DWÉDVţDVţDĘřDWDěôDVţDĘřDWDěô....Hr°§řHrĚytHr°§řHrĚyt..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DĘřDěô....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWV. Underweight ANNYYNEGDW0DW‘DWÉ..NEG....YNNNNYYDVţ........DW0DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBëBBlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061287100612871006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23706 DVţDâŕDW™.DW™DVţDVţDâŕDWD÷řDVţDâŕDWD÷ř....Hr°żŕHrĚ„xHr°żŕHrĚ„x..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW™WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. DâŕD÷ř....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽDW`. Underweight ANNYYNEGDW/DWŤDWĐ..NEGDWŽ.DWŽDWŽYNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDW™DW™B‡B{AŔBśB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061288100612881006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23708 DVţDăDWŢ.DWŢDVţDVţDăDWD÷ĽDVţDăDWD÷Ľ....Hr°ŔHrĚ„<Hr°ŔHrĚ„<..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DăD÷Ľ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Normal weightA NNYYNEGDW/DW?DWĐ..NEG....YNNNNYYDVţ........DW/DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW?DWŢDWŢBĚB-BźBáBB7-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1006 10061289100612891006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23941 DV˙D‚ČDWď.DWďDV˙DV˙D‚ČDWDě|DV˙D‚ČDWDě|....Hr±±HHrĎüHr±±HHrĎü..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D‚ČDě|....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DW`. Normal weightA NYYYNEGDW6DW”DWŃ..NEG....YNNNNYYDV˙........DW6DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBéB€BiB˙B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061290100612901006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23943 DV˙DDWô.DWôDV˙DV˙DDWDě¸DV˙DDWDě¸....Hr±±„HrĎ8Hr±±„HrĎ8..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. DDě¸....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DW`. Normal weightA NYYYNEGDW6DW”DWŃ..NEG....YNNNNYYDV˙........DW6DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBéB€BiB˙B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061291100612911006AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23946 DV˙D@DWĘ.DWĘDV˙DV˙D@DWDęŘDV˙D@DWDěôDWDô°DWDęŘHr±±ŔHs—~XHr±±ŔHrĎtHs{Ř°Hs—~XDV˙DWDWDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. D@Děô.Dô°DęŘ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW. Underweight ANNYYNEGDW6DW”DW—DWĘDXjNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýBéB€BfBiB˙B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061292100612921006AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23948 DV˙DĂ<DW˝.DW˝DV˙DV˙DĂ<DWˇDřDV˙DĂ<DWD‚ŚDWŽD|DWˇDřHr±ńĽHs‡AxHr±ńĽHrÍ`ŚHsn8|Hs‡AxDV˙DWDWŽDWˇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂ<D‚Ś.D|Dř.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW1DWŚDWŤDW˝DX^NEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBpBqB˙BŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061293100612931006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24050 DV˙DĂDWË..DV˙DV˙DĂDWD‚ČDV˙DĂDWD‚Č....Hr±ń€HrÍ`ČHr±ń€HrÍ`Č..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DĂD‚Č....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Overweight A0NNYNPOSDW1DWŚDWË..POS....YNNNNYYDV˙........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061294100612941006AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24054 DV˙DëDWĹ.DWĹDV˙DV˙DëDW§DçDV˙DëDWDÔ”DW”DÉDW§DçHr˛”HsŹ’Hr˛”HrÍ˛”HsvgHsŹ’DV˙DWDW”DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DëDÔ”.DÉDç.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Overweight A0NNYYNEGDW0DWDW“DWĹDXdNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBęB}BjBmB˙B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061295100612951006AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24056 DWD‘ŚDW˝.DW˝DWDWD‘ŚDWˇD€4DWD‘ŚDWDDWŽD¸DWˇD€4Hr´cHs‡A´Hr´cHrÍaHsn8¸Hs‡A´DWDWDWŽDWˇAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‘ŚD.D¸D€4.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANYYYNEGDW1DWŚDWŤDW˝DX^NEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBpBqBýBŚ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061296100612961006AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24611 DWD‹8DW›.DW›DWDWD‹8DWDáđDWD‹8DWDáđ....Hrşô8HrÖúpHrşô8HrÖúp..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW›LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. D‹8Dáđ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW›DW\. Underweight ANNYYNEGDW7DWšDWŘ..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWšDW›DW›BB€AB–B•4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061297100612971006AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24612 DWD‹tDW›.DW›DWDWD‹tDWDá´DWD‹tDWDá´....HrşôtHrÖú4HrşôtHrÖú4..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW›LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. D‹tDá´....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW›DW\. Normal weightA NNNYPOSDW7DWšDWŘ..POS....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NNDWšDW›DW›BB€AB–B•4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061298100612981006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24617 DWDĐÔDWĆ..DWDWDĐÔDW¨D‰ĐDWDĐÔDWD¶DW“D’@DW¨D‰ĐHr»9ÔHs…ĐHr»9ÔHrŘ HstŢŔHs…ĐDWDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐÔD¶.D’@D‰Đ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Overweight A0YYYYNEGDW8DWŤDW’DWĆDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBâBrBkBpBřB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1006 10061299100612991006AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24618 DWD¤LDW×.DW×DWDWD¤LDWDđ´DWD¤LDWDđ´....Hr˝°LHrÚý´Hr˝°LHrÚý´..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. D¤LDđ´....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWZ. Underweight ANNYYNEGDW?DWDWÍ..NEG....YNNNNYYDW........DW?DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŕBsBmBöB‰8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1006 10061300100613001006AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26122 DWDęśDWÓ.DWÓDWDWDęśDW$DčĽDWDęśDW$DčĽ....HrÇ1HrâŢĽHrÇ1HrâŢĽ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DęśDčĽ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWO. Underweight ANNYYNEGDWADWŤDWÓ..NEG....YNNNNYYDW........DWADWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071409100714091007AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20265 DVÂDˇ|DWľ.DWľDVÂDVÂDˇ|DW›D–DVÂDˇ|DW›D–....Hrad|Hsn€Hrad|Hsn€..DVÂ...AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . DW›.BNT162b2 (30 (*ESC*){unicode 03BC}g) Dˇ|.D–...13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANYYYNEGDWDWDXX..NEG....YNNNNYYDVÂ........DVřDWŠYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDWDWýDWýBmCŔBĎ0-1 month A0-1 month A0-1 month A11-12 monthsAŔ . ..DVÍC4591001C4591001 1007 10071414100714141007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20268 DVÂD¬ĽDWÉ.DWÉDVÂDVÂD¬ĽDWDÍČDVÂD¬ĽDV×D¸°DW“D·üDWDÍČHraoĽHs—aHHraoĽHr}+0Hsu|Hs—aHDVÂDV×DW“DWAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬ĽD¸°.D·üDÍČ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Underweight ANNYYNEGDVóDW†DW†DWÉDXjNEG....YNNNNYYDVÂ........DVóDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCpBµBkBrCŔBĘ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1007 10071415100714151007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVÂ20271 DVÂD¶DW¦.DW¦DVÂDVÂD¶DVóDśDVÂD¶DVóDś....HrayHrˇŢHrayHrˇŢ..DVÂDVó..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN NYhad important protocol deviation(s) as determined by the clinician for Efficacy (prior to the first post(*ESC*){unicode 2013}Dose 2 N-binding antibody test) PopulationNY YDWG .. D¶Dś....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDWG. Underweight ANNYYNEGDWDW‹DW¦..NEGDV5.DV5DV5YNNNNYYDVÂ........DWDW¦YY NNNY Yhad important protocol deviation(s) as determined by the clinician for Efficacy (within 7 days post Dose 2), Immunogenicity (on or before 3 weeks post Dose 1) Population(s) Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDW‹DWýDWýC°B™BrCŔBĘ9-10 months A 5-6 months A`0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1007 10071417100714171007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20272 DVÂDľPDW†.DW†DVÂDVÂDľPDV×D°ôDVÂDľPDV×D°ô....HraPHr}#tHraPHr}#t..DVÂDV×..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DľPD°ô....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Overweight A0NNYYNEGDVóDW?DW†..NEG....YNNNNYYDVÂ........DVóDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW?DWýDWýCpBiBľCŔB~10-11 monthsA°3-4 months A@0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1007 10071428100714281007AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVÂ20292 DVÂDĺ°DWŤ.DWŤDVÂDVÂDĺ°DV×DçDVÂDĺ°DV×Dç....Hra¨°Hr}YHra¨°Hr}Y..DVÂDV×..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dĺ°Dç....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDV÷DWŠDWŠ..NEGDW….DW…DW…YNNNNYYDVÂ........DV÷DWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCpB¶BqCŔBË10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1007 10071429100714291007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVÂ20295 DVÂDčřDWŐ.DWŐDVÂDVÂDčřDV×Dę`DVÂDčřDV×Dę`....Hra«řHr}\ŕHra«řHr}\ŕ..DVÂDV×..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DčřDę`....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDVóDWŠDWŠ..NEGDWŤ.DWŤDWŤYNNNNYYDVÂ........DVóDWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCpBµBrCŔBĘ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1007 10071467100714671007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20296 DVéD’¸DW..DVéDVéD’¸DVţDŚdDVéD’¸DVţDŚd....Hr”Ŕ8Hr°idHr”Ŕ8Hr°id..DVéDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D’¸DŚd....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWS.. Normal weightA NNYYNEGDWDWRDW..NEG....YNNNNYYDVé........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWRDWýDWýCBUB«CPBj9-10 months A 3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1007 10071469100714691007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20298 DVéDźŘDW´..DVéDVéDźŘDVţDźŘDVéDźŘDVţDźŘ....Hr”ÍXHr°|ŘHr”ÍXHr°|Ř..DVéDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DźŘDźŘ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDWDWDW´..NEG....YNNNNYYDVé........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCB“BmCPB¨9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071471100714711007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20374 DVéD®śDW.DWDVéDVéD®śDVţD˘0DVéD®śDVţD˘0....Hr”ÜHr°0Hr”ÜHr°0..DVéDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®śD˘0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDWŚDW..NEG....YNNNNYYDVé........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBŹBqCPB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071472100714721007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20375 DVéDÄ,DWÉ.DWÉDVéDVéDÄ,DW¦DÓhDVéDÄ,DVţDŤĚDW‘DµŕDW¦DÓhHr”ń¬HsŽ,hHr”ń¬Hr°jĚHsr_`HsŽ,hDVéDVţDW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄ,DŤĚ.DµŕDÓh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDWDW‹DWDWÉDXcNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCBŽBmBrCPBŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071475100714751007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20378 DVéDÓhDW.DWDVéDVéDÓhDVţDÎDVéDÓhDVţDÎ....Hr•čHr°«Hr•čHr°«..DVéDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÓhDÎ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDWDW‘DW..NEG....YNNNNYYDVé........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýCB”BlCPB©9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071476100714761007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20446 DVéDóHDW.DWDVéDVéDóHDVţDĄ´DVéDóHDVţDĄ´....Hr• ČHr°‚´Hr• ČHr°‚´..DVéDVţ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DóHDĄ´....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWDW‹DW..NEG....YNNNNYYDVé........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýCBŽBrCPBŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071478100714781007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20384 DVéDďDWĘ.DWĘDVéDVéDďDW¨DĹDVéDďDVţDäHDW”DÂLDW¨DĹHr•HsÁHr•Hr°ÁHHsv`LHsÁDVéDVţDW”DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DďDäH.DÂLDĹ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW”. Overweight A0NNYYNEGDWDW‹DW“DWĘDXeNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCBŽBjBrCPBŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071480100714801007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20447 DVéDóüDWĘ.DWĘDVéDVéDóüDW§Dź$DVéDóüDVţDŐŔDW‘DĂxDW§Dź$Hr•!|HsŹI¤Hr•!|Hr°˛ŔHsrlřHsŹI¤DVéDVţDW‘DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DóüDŐŔ.DĂxDź$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Obese A@YNYYNEGDWDW‹DWDWĘDXdNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCBŽBmBrCPBŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071481100714811007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20449 DVęD¤DWÝ..DVęDVęD¤DW»D‰XDVęD¤DV˙DŚ DW¦DˇôDW»D‰XHr–¤Hs©‘ŘHr–¤Hr±» HsŤúôHs©‘ŘDVęDV˙DW¦DW»AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤DŚ .DˇôD‰X.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW¦. Underweight ANNYYNEGDWDWDWĄDWÝDXxNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýB˙B’BXBmC@B§9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071482100714821007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20455 DVęDŤĚDWĚ.DWĚDVęDVęDŤĚDV˙D” DVęDŤĚDV˙D” ....Hr–ĚHr±Â Hr–ĚHr±Â ..DVęDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŤĚD” ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWDW‹DWĚ..NEG....YNNNNYYDVę........DWDWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB˙BŤBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071483100714831007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20496 DVęDź`DW’.DW’DVęDVęDź`DWvDŰ$DVęDź`DV˙D4DWaDçĚDWvDŰ$Hr–`HsNě$Hr–`Hr±Ű´Hs3ILHsNě$DVęDV˙DWaDWvAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dź`D4.DçĚDŰ$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWa. Underweight ANNYYNEGDW"DWJDW`DW’DX3NEG....YNNNNYNDVę........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWJDWýDWýB˙BLBťBłC@Ba9-10 months A 2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1007 10071484100714841007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20497 DVęDžpDWÄ.DWÄDVęDVęDžpDW¨Dß DVęDžpDV˙DčDW“DÇěDW¨Dß Hr–pHsŰ Hr–pHr±ÜhHsulHsŰ DVęDV˙DW“DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DžpDč.DÇěDß .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDW"DW‹DW’DWÄDXeNEG....YNNNNYNDVę........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBkBrC@B˘9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071485100714851007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20503 DVęDĹĐDW®.DW®DVęDVęDĹĐDVţDÓ,DVęDĹĐDVţDÓ,....Hr–DĐHr°°,Hr–DĐHr°°,..DVęDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĹĐDÓ,....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWDW‹DW®..NEG....YNNNNYYDVę........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýCBŽBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071488100714881007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20504 DVęDŕDW®.DW®DVęDVęDŕDV˙D¨ŔDVęDŕDV˙D¨Ŕ....Hr–_Hr±×@Hr–_Hr±×@..DVęDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŕD¨Ŕ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Overweight A0NNYYNEGDWDW‹DW®..NEG....YNNNNYYDVę........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB˙BŤBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071490100714901007AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20605 DVęDí¨DWŻ.DWŻDVęDVęDí¨DV˙D¨HDVęDí¨DV˙D¨H....Hr–l¨Hr±ÖČHr–l¨Hr±ÖČ..DVęDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dí¨D¨H....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWDW‹DWŻ..NEG....YNNNNYYDVę........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB˙BŤBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071492100714921007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVę20606 DVęDô8DW·..DVęDVęDô8DVţDÝ|DVęDô8DVţDÝ|....Hr–s8Hr°ş|Hr–s8Hr°ş|..DVęDVţ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. Dô8DÝ|....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDWL. Normal weightA NNYYNEGDWDW‹DW·..NEGDWŤ.DWŤDWŤYNNNNYYDVę........DWDW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýCBŽBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071494100714941007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20608 DVëDˇ|DW´.DW´DVëDVëDˇ|DVţDŐDVëDˇ|DVţDŐ....Hr—qüHr°˛Hr—qüHr°˛..DVëDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. Dˇ|DŐ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Normal weightA NNYYNEGDWDW‹DW´..NEG....YNNNNYYDVë........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýCBŽBrC0Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071495100714951007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20610 DVëDŐüDWĘ.DWĘDVëDVëDŐüDWD©tDVëDŐüDV˙DĆDW™DÝ¸DWD©tHr—¦|Hs—<ôHr—¦|Hr±ôŚHs}8Hs—<ôDVëDV˙DW™DWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐüDĆ.DÝ¸D©t.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Normal weightA NNYYNEGDWDW‹DWDWĘDXjNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBeBrC0Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071496100714961007AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20750 DVëDńŕDWÉ.DWÉDVëDVëDńŕDWD˝ŘDVëDńŕDV˙D‹°DWDŇDWD˝ŘHr—Â`Hs—QXHr—Â`Hr±ş0Hs{¶Hs—QXDVëDV˙DWDWAŕYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DńŕD‹°.DŇD˝Ř.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Underweight ANNYYNEGDWDW‹DW—DWÉDXjNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBfBrC0Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071497100714971007AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20746 DVëDô8DWŻ.DWŻDVëDVëDô8DV˙DŠHDVëDô8DV˙DŠH....Hr—Ä¸Hr±¸ČHr—Ä¸Hr±¸Č..DVëDV˙..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. Dô8DŠH....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Underweight ANNYYNEGDWDW‹DWŻ..NEG....YNNNNYYDVë........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB˙BŤBrC0Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071499100714991007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVě20753 DVěDĺěDW».DW»DVěDVěDĺěDV˙D×(DVěDĺěDV˙D×(....Hr™ěHr˛¨Hr™ěHr˛¨..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DĺěD×(....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDWU. Underweight ANNYYNEGDWDW‹DW»..NEGDWŤ.DWŤDWŤYNNNNYYDVě........DWDW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBrC B 9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071500100715001007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20756 DVěDí¨DWµ.DWµDVěDVěDí¨DV˙D’¸DVěDí¨DV˙D’¸....Hr™¨Hr±Á8Hr™¨Hr±Á8..DVěDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dí¨D’¸....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDWDW=DWµ..NEG....YNNNNYYDVě........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW=DWýDWýB˙B?BŔC BR9-10 months A 2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071504100715041007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21085 DVđD,DW¶.DW¶DVđDVđD,DWD”ÔDVđD,DWD”Ô....Hrťđ,HrĽOTHrťđ,HrĽOT..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D,D”Ô....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Overweight A0NNYYNEGDW#DW=DW¶..NEG....YNNNNYYDVđ........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWýDWýB÷B7BŔCŕBN8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071505100715051007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21087 DVđD`DWÓ.DWÓDVđDVđD`DW¶DÂDVđD`DWDé¬DWˇDťĽDW¶DÂHrťř`HsŁ3Hrťř`Hrş,Hs‡_<HsŁ3DVđDWDWˇDW¶AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`Dé¬.DťĽDÂ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWˇ. Normal weightA NYYYNEGDW(DWŤDW DWÓDXs ....YNNNNYNDVđ........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBůB‰B]BpCŕBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071506100715061007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21089 DVđD–xDW´.DW´DVđDVđD–xDWDâ,DVđD–xDWDâ,....HrťţxHrąů¬HrťţxHrąů¬..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–xDâ,....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW}.. Normal weightA NNYYNEGDW!DW|DW´..NEG....YNNNNYYDVđ........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW|DWýDWýBůBxBCŕBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071507100715071007AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21090 DVđDŞdDWĆ.DWĆDVđDVđDŞdDW©DÇ8DVđDŞdDWD¦ŕDW“DŔ¨DW©DÇ8HrždHs’¸HrždHrąľ`Hsu (Hs’¸DVđDWDW“DW©AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞdD¦ŕ.DŔ¨DÇ8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDW!DW‹DW’DWĆDXfNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BkBrCŕBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071508100715081007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21192 DVđDÁÔDW´.DW´DVđDVđDÁÔDWDÁDVđDÁÔDWDÁ....Hrž)ÔHrąŮHrž)ÔHrąŮ..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÁÔDÁ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDW$DW‘DW´..NEG....YNNNNYYDVđ........DW$DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBůBŤBlCŕB˘8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071509100715091007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21197 DVđDÎ¸DWÄ.DWÄDVđDVđDÎ¸DW¨D¬€DVđDÎ¸DWD”ÔDW”D¤DW¨D¬€Hrž6¸Hs¨€Hrž6¸HrĽOTHsv&¤Hs¨€DVđDWDW”DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ¸D”Ô.D¤D¬€.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW”. Overweight A0NNYYNEGDW#DW‹DW“DWÄDXeNEG....YNNNNYNDVđ........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB÷B…BjBrCŕBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071511100715111007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21198 DVđDě¸DWĘ.DWĘDVđDVđDě¸DW§DŚÜDVđDě¸DWD¤DW’D… DW§DŚÜHržT¸HsŹ7\HržT¸Hrą»Hss€ HsŹ7\DVđDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě¸D¤.D… DŚÜ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW!DW‹DW‘DWĘDXdNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BlBrCŕBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071512100715121007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21276 DVđDňXDWć.DWćDVđDVđDňXDWDëČDVđDňXDWDëČ....HržZXHrşHHržZXHrşH..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DňXDëČ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW!DW=DW´..NEG....YNNNNYYDVđ........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWýDWýBůB9BŔCŕBN8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071514100715141007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21199 DVđDń¤DW´.DW´DVđDVđDń¤DWDÎDVđDń¤DWDÎ....HržY¤Hrąĺ„HržY¤Hrąĺ„..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dń¤DÎ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW$DW‹DW´..NEG....YNNNNYYDVđ........DW$DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBůB‡BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071515100715151007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21283 DVńDŠHDW·.DW·DVńDVńDŠHDWDŹčDVńDŠHDWDŹč....HrźCČHrşřčHrźCČHrşřč..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠHDŹč....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW"DW‹DW·..NEGDWŽ.DWŽDWŽYNNNNYYDVń........DW"DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BrCĐB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071516100715161007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21282 DVńD¤DWĘ.DWĘDVńDVńD¤DW§D•LDVńD¤DWD PDW’DÔ”DW§D•LHrźB$HsŹ?ĚHrźB$Hr» PHssĎ”HsŹ?ĚDVńDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤D P.DÔ”D•L.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNNYPOSDW"DW‹DW‘DWĘDXdPOS....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBřB†BlBrCĐB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071517100715171007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21284 DVńD—,DWµ.DWµDVńDVńD—,DWDßÔDVńD—,DWDßÔ....HrźP¬Hr»HÔHrźP¬Hr»HÔ..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D—,DßÔ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW"DW‹DWµ..NEG....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrCĐB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071518100715181007AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21369 DVńDź`DWľ.DWľDVńDVńDź`DWD‡xDVńDź`DWD‡x....HrźXŕHrşđxHrźXŕHrşđx..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dź`D‡x....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Obese A@YNYYNEGDW"DW=DWľ..NEG....YNNNNYYDVń........DW"DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW=DWýDWýBřB8BŔCĐBM8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071519100715191007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21374 DVńD¨HDW¨.DW¨DVńDVńD¨HDWwDÇtDVńD¨HDWD DWbD™HDWwDÇtHrźaČHsP)ôHrźaČHr» Hs4LHHsP)ôDVńDWDWbDWwAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨HD .D™HDÇt.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWaDWb. Normal weightA NNYYNEGDW#DW`DWaDW“DX4NEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW`DWýDWýBřB[BśBťCĐBp8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1007 10071520100715201007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21375 DVńD©tDWÝ.DWÝDVńDVńD©tDWľDŚ(DVńD©tDWDˇ|DW¨Dż@DWľDŚ(HrźbôHs‰(HrźbôHr» |Hs»@Hs‰(DVńDWDW¨DWľAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. D©tDˇ|.Dż@DŚ(.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW¨. Normal weightA NNYYNEGDW#DW‹DW§DWÝDX{NEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BVBrCĐB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071521100715211007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21376 DVńDÂDWĐ.DWĐDVńDVńDÂDWDŃLDVńDÂDWDŃL....Hrź|Hr»:LHrź|Hr»:L..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÂDŃL....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDW$DW‘DWµ..NEG....YNNNNYYDVń........DW$DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBřBŚBlCĐBˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071522100715221007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21458 DVńDŰŘDWÍ.DWÍDVńDVńDŰŘDWŻDÓŕDVńDŰŘDWDÎ|DWšD˘0DWŻDÓŕHrź•XHsš `Hrź•XHr»7|Hs~)0Hsš `DVńDWDWšDWŻAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰŘDÎ|.D˘0DÓŕ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWš. Overweight A0NNYYNEGDW$DW‹DW™DWÍDXlNEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BdBrCĐB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071523100715231007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21453 DVńDŮřDWő.DWőDVńDVńDŮřDWD¤DVńDŮřDWD¤....Hrź“xHr» Hrź“xHr» ..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮřD¤....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Underweight ANNYYNEGDW"DW‘DWµ..NEG....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBřBŚBlCĐBˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071524100715241007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21462 DVńDíäDWv..DVńDVńDíäDWUDăDVńDíäDWD DW@DŃLDWUDăHrź§dHs#rśHrź§dHr» Hs±LHs#rśDVńDWDW@DWUAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DíäD .DŃLDă.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW1DW@. Normal weightA NNYYNEGDW*DW0DW?DWvDXNEG....YNNNNYNDVń........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW0DWýDWýBřB+BľBÍCĐB@8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1007 10071525100715251007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21463 DVńDě@DW·.DW·DVńDVńDě@DWDˇ@DVńDě@DWDˇ@....HrźĄŔHr» @HrźĄŔHr» @..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dě@Dˇ@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW*DW‹DW·..NEG....YNNNNYYDVń........DW*DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrCĐB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071526100715261007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21515 DVńDóHDW×.DW×DVńDVńDóHDWDÄhDVńDóHDWDÄh....Hrź¬ČHr»-hHrź¬ČHr»-h..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DóHDÄh....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW"DWŚDWµ..NEG....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071527100715271007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21514 DVńDń,DWŇ.DWŇDVńDVńDń,DWµDÇ°DVńDń,DWDĹXDW˘D©ěDWµDÇ°HrźŞ¬Hsˇç0HrźŞ¬Hr».XHsĽěHsˇç0DVńDWDW˘DWµAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dń,DĹX.D©ěDÇ°.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW˘. Underweight ANYYYNEGDW"DWŚDWˇDWŇDXrPOS....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBřB‡B\BqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071528100715281007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21521 DVňD‡đDW¶.DW¶DVňDVňD‡đDWDż@DVňD‡đDWDż@....Hr ’đHrĽyŔHr ’đHrĽyŔ..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‡đDż@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW#DW‹DW¶..NEGDWŤ.DWŤDWŤYNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071529100715291007AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21524 DVňD“0DWĽ.DWĽDVňDVňD“0DWD‘ČDVňD“0DWD‘Č....Hr ž0HrĽLHHr ž0HrĽLH..DVňDW..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D“0D‘Č....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Normal weightA NNYYNEGDW#DW‹DWĽ..NEG....YNNNNYYDVň........DW#DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071530100715301007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21589 DVňD–DWĘ.DWĘDVňDVňD–DWDçDVňD–DWDç....Hr ˇHr»PHr ˇHr»P..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–Dç....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDW#DWŚDWµ..NEG....YNNNNYYDVň........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBřB‡BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071531100715311007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21590 DVňD—hDWŮ.DWŮDVňDVňD—hDWµD…\DVňD—hDWDęŘDW™DŞdDWµD…\Hr ˘hHsˇ¤ÜHr ˘hHr»SŘHs|ßäHsˇ¤ÜDVňDWDW™DWµAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—hDęŘ.DŞdD…\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW™. Overweight A0NNYYNEGDW#DWŚDWDWŮDXrNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BeBqCŔB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071533100715331007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21591 DVňDĄxDWĐ.DWĐDVňDVňDĄxDWŻD›dDVňDĄxDWD§ĐDWšDť€DWŻD›dHr °xHs™ŃäHr °xHrĽbPHs~$€Hs™ŃäDVňDWDWšDWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄxD§Đ.Dť€D›d.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWš. Overweight A0YNNNPOSDW#DW‹DW™DWĐDXlPOS....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýB÷B…BdBrCŔBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071535100715351007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21596 DVňD¨DW÷.DW÷DVňDVňD¨DWD´<DVňD¨DWD´<....Hr łHrĽnĽHr łHrĽnĽ..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨D´<....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNNNPOSDW#DW=DW»..POS....YNNNNYYDVň........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW=DWýDWýB÷B7BŔCŔBL8-9 months A1-2 months A 0-1 month A9-10 months A . ..DWC4591001C4591001 1007 10071536100715361007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21681 DVňD´DW°.DW°DVňDVňD´DWDßDVňD´DWDß....Hr żHr»HHr żHr»H..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. D´Dß....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWL. Underweight ANNYYNEGDW"DW‹DW°..NEG....YNNNNYYDVň........DW"DW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWxC4591001C4591001 1007 10071537100715371007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21683 DVňDÇ°DW¶.DW¶DVňDVňDÇ°DWDćÜDVňDÇ°DWDćÜ....Hr Ň°HrĽˇ\Hr Ň°HrĽˇ\..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇ°DćÜ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Overweight A0NNYYNEGDW#DW‹DW¶..NEG....YNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071539100715391007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21689 DVňDŘTDWú.DWúDVňDVňDŘTDW¶DË¬DVňDŘTDWDĘ€DWˇDË4DW¶DË¬Hr ăTHsŁ<¬Hr ăTHrĽ…Hs‡Ś´HsŁ<¬DVňDWDWˇDW¶AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘTDĘ€.DË4DË¬.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWˇ. Underweight ANNYYNEGDW#DW‹DW DWŇDXsNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB÷B…B]BrCŔBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071540100715401007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21685 DVňDŮřDWú.DWúDVňDVňDŮřDW¶DČ(DVňDŮřDWDËpDWˇDĚ$DW¶DČ(Hr äřHsŁ9(Hr äřHrĽ…đHs‡Ť¤HsŁ9(DVňDWDWˇDW¶AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮřDËp.DĚ$DČ(.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWˇ. Normal weightA NNYYNEGDW#DW‹DW DWÓDXsNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB÷B…B]BrCŔBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071541100715411007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21767 DVňDě¸DWô.DWôDVňDVňDě¸DWEDÖ8DVňDě¸DWDÓhDW0DŰśDWEDÖ8Hr ÷¸HsM¸Hr ÷¸HrĽŤčHrňŁśHsM¸DVňDWDW0DWEAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě¸DÓh.DŰśDÖ8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW/DW0. Normal weightA NNYYNEGDW$DW.DW/DWaDWôNEG....YNNNNYNDVň........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW.DWýDWýB÷B(BÎBĎCŔB=8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1007 10071542100715421007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21769 DVňDđDW¶.DW¶DVňDVňDđDWDçDVňDđDWDç....Hr űHrĽ˘Hr űHrĽ˘..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DđDç....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Normal weightA NNYYNEGDW(DW‹DW¶..NEG....YNNNNYYDVň........DW(DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071543100715431007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21771 DVňDđ<DWě.DWěDVňDVňDđ<DWDĆHDVňDđ<DWDĆH....Hr ű<HrĽ€ČHr ű<HrĽ€Č..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dđ<DĆH....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NYYYNEGDW#DWŚDW¶..NEGDWŤ.DWŤDWŤYNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071544100715441007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21773 DVňDń,DWě.DWěDVňDVňDń,DWDÇěDVňDń,DWDÇě....Hr ü,HrĽ‚lHr ü,HrĽ‚l..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dń,DÇě....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW#DWŤDWľ..NEG....YNNNNYYDVň........DW#DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB÷B‡BpCŔBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071546100715461007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21827 DVóD‹8DW¶.DW¶DVóDVóD‹8DWD–DVóD‹8DWD–....Hrˇç¸HrĽP€Hrˇç¸HrĽP€..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹8D–....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW#DW=DW¶..NEG....YNNNNYYDVó........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWýDWýB÷B7BŔC°BK8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071547100715471007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21830 DVóDštDWĘ.DWĘDVóDVóDštDW©D› DVóDštDWDťĽDW”DÄ¤DW©D› HrˇöôHs‘é HrˇöôHrĽX<Hsvb¤Hs‘é DVóDWDW”DW©AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DštDťĽ.DÄ¤D› .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW#DWŚDW“DWĘDXfNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BjBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071550100715501007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21832 DVóD× DW·..DVóDVóD× DWDŐüDVóD× DWDŐü....Hr˘4 HrĽ|Hr˘4 HrĽ|..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D× DŐü....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANYYYNEGDW$DW‹DW·..NEG....YNNNNYYDVó........DW$DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB÷B…BrC°B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071551100715511007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21835 DVóDÔĐDWú.DWúDVóDVóDÔĐDWDĐ\DVóDÔĐDWDĆŔDWDÂÄDWDĐ\Hr˘1PHs—cÜHr˘1PHr»/ŔHs{¦ÄHs—cÜDVóDWDWDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔĐDĆŔ.DÂÄDĐ\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Normal weightA NNYYNEGDW$DW‹DW—DWÉDXjNEG....YNNNNYNDVó........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBřB†BfBrC°B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071552100715521007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21976 DVóDę`DWÍ.DWÍDVóDVóDę`DWŻDŃDVóDę`DWDĆ„DWšDĎlDWŻDŃHr˘FŕHsšHr˘FŕHr»/„Hs~VlHsšDVóDWDWšDWŻAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę`DĆ„.DĎlDŃ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWš. Normal weightA NNYYNEGDW#DW‹DW™DWÍDXlNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BdBrC°B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071554100715541007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVó21977 DVóDíäDWŕ.DWŕDVóDVóDíäDWDŮĽDVóDíäDWDŮĽ....Hr˘JdHrĽ”<Hr˘JdHrĽ”<..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DíäDŮĽ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNNYPOSDW$DW‹DW·..POSDW–.DW–DW–YNNNNYYDVó........DW$DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýB÷B…BrC°B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071555100715551007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21979 DVóDépDWµ..DVóDVóDépDWDŢ0DVóDépDWDŢ0....Hr˘EđHr»G0Hr˘EđHr»G0..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. DépDŢ0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWK. Underweight ANNYYNEGDW"DW‹DWµ..NEG....YNNNNYYDVó........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrC°B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071557100715571007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21980 DV÷DhDWć..DV÷DV÷DhDWDśDV÷DhDWDś....Hr§*čHrÂîHr§*čHrÂî..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DhDś....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Normal weightA NNNYPOSDW+DW‹DWÓ..POS....YNNNNYYDV÷........DW+DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‹DWýDWýBňB€BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071558100715581007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22284 DV÷DŠüDW».DW»DV÷DV÷DŠüDWD†LDV÷DŠüDWD†L....Hr§-|HrÂŘLHr§-|HrÂŘL..DV÷DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠüD†L....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDW*DW‘DW»..NEG....YNNNNYYDV÷........DW*DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBňB†BlCpB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071559100715591007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22285 DV÷D¦ŕDWú.DWúDV÷DV÷D¦ŕDW°DĄđDV÷D¦ŕDWDÜŚDW›DŢ0DW°DĄđHr§I`Hs›-đHr§I`HrĂ.ŚHs¶°Hs›-đDV÷DWDW›DW°AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¦ŕDÜŚ.DŢ0DĄđ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Normal weightA NNYYNEGDW/DWŚDWšDWÍDXmPOS....YNNNNYNDV÷........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBňBBcBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071560100715601007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22286 DV÷DÉĚDWĂ.DWĂDV÷DV÷DÉĚDW¦DŇDV÷DÉĚDW DŠHDW‘D´<DW¦DŇHr§lLHsŽ+Hr§lLHrÄ-ČHsr]ĽHsŽ+DV÷DW DW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉĚDŠH.D´<DŇ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW)DWŚDWDWĂDXcNEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBńB€BmBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071561100715611007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22288 DV÷DÔĐDWď.DWďDV÷DV÷DÔĐDWDÓŕDV÷DÔĐDWDÓŕ....Hr§wPHrĂ%ŕHr§wPHrĂ%ŕ..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÔĐDÓŕ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW)DW‹DW»..NEG....YNNNNYYDV÷........DW)DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBňB€BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071562100715621007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22385 DV÷DčDWĂ.DWĂDV÷DV÷DčDW¦D®ŘDV÷DčDWDđ<DW‘D DW¦D®ŘHr§ŠHsŽŘHr§ŠHrĂB<HsrI”HsŽŘDV÷DWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDđ<.D D®Ř.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNNYPOSDW(DW‹DWDWĂDXcPOS....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDW‹DWýDWýBňB€BmBrCpB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071563100715631007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22386 DV÷DĺěDWĂ.DWĂDV÷DV÷DĺěDW¦D°DV÷DĺěDWDîDW‘DˇDW¦D°Hr§lHsŽ Hr§lHrĂ@HsrJ„HsŽ DV÷DWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĺěDî.DˇD°.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Overweight A0YNNYPOSDW(DW‹DWDWĂDXcPOS....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBňB€BmBrCpB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071564100715641007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22387 DV÷DńhDW˝.DW˝DV÷DV÷DńhDWDŰŘDV÷DńhDWDŰŘ....Hr§“čHrĹĐŘHr§“čHrĹĐŘ..DV÷DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DńhDŰŘ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNNYPOSDW/DW‹DW˝..POS....YNNNNYYDV÷........DW/DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDW‹DWýDWýBđB~BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071565100715651007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22388 DV÷Dô8DW˝.DW˝DV÷DV÷Dô8DWDÝ@DV÷Dô8DWDÝ@....Hr§–¸HrĹŇ@Hr§–¸HrĹŇ@..DV÷DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dô8DÝ@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW/DW‹DW˝..NEG....YNNNNYYDV÷........DW/DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBđB~BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071566100715661007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22402 DV÷DňXDWÄ.DWÄDV÷DV÷DňXDWDé4DV÷DňXDWDé4....Hr§”ŘHrĂ;4Hr§”ŘHrĂ;4..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DňXDé4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWL. Normal weightA NNYYNEGDW(DW‘DWÄ.. ....YNNNNYYDV÷........DW(DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‘DWýDWýBňB†BlCpB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071567100715671007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22407 DVřDŽDWĽ.DWĽDVřDVřDŽDW DŘDVřDŽDW DŘ....Hr¨‚HrÄ%XHr¨‚HrÄ%X..DVřDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽDŘ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW)DW‹DWĽ..NEG....YNNNNYYDVř........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBńBBrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071568100715681007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22409 DVřD`DWÓ.DWÓDVřDVřD`DWµD…\DVřD`DW DâŕDW DŤDWµD…\Hr¨„`Hsˇ¤ÜHr¨„`HrÄ†`Hs…ýHsˇ¤ÜDVřDW DW DWµAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`Dâŕ.DŤD…\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW . Normal weightA NNYYNEGDW)DW’DWźDWÓDXrNEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBńB†B^BkC`B›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071569100715691007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22411 DVřDťDWÓ.DWÓDVřDVřDťDW¶D‘ŚDVřDťDW DĂ<DW˘D§XDW¶D‘ŚHr¨‘HsŁŚHr¨‘HrÄfĽHsşXHsŁŚDVřDW DW˘DW¶AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDĂ<.D§XD‘Ś.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW˘. Normal weightA NNYYNEGDW*DW‹DWˇDWÓDXsNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBńBB\BrC`B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071570100715701007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22521 DVřD PDWÓ.DWÓDVřDVřD PDW¶D“0DVřD PDW DÂLDW˘D¨„DW¶D“0Hr¨”PHsŁ0Hr¨”PHrÄeĚHs»„HsŁ0DVřDW DW˘DW¶AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D PDÂL.D¨„D“0.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW˘. Obese A@YNN POSDW*DW‹DWˇDWÓDXsPOS....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBńBB\BrC`B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071571100715711007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22528 DVřDÁDW˝.DW˝DVřDVřDÁDWDč€DVřDÁDWDč€....Hr¨µHrĹÝ€Hr¨µHrĹÝ€..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DÁDč€....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Normal weightA NNYYNEGDW*DW‹DW˝..NEG....YNNNNYYDVř........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBđB~BrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071572100715721007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22529 DVřDđ<DWĂ.DWĂDVřDVřDđ<DW Dá´DVřDđ<DW Dá´....Hr¨ä<HrÄ…4Hr¨ä<HrÄ…4..DVřDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dđ<Dá´....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW)DW‹DWĂ..NEG....YNNNNYYDVř........DW)DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBńBBrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071573100715731007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVř22532 DVřDňXDW˝.DW˝DVřDVřDňXDWDŐüDVřDňXDWDŐü....Hr¨ćXHrĂ'üHr¨ćXHrĂ'ü..DVřDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DňXDŐü....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW*DW‹DW˝..NEGDW˘.DW˘DW˘YNNNNYYDVř........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071574100715741007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22727 DVůDŚ DWô.DWôDVůDVůDŚ DWD˝ŘDVůDŚ DWD˝Ř....Hr©Ň HrĹ˛ŘHr©Ň HrĹ˛Ř..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DŚ D˝Ř....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>DWT. Normal weightA NNYYNEGDW+DW=DWĂ..NEG....YNNNNYYDVů........DW+DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWýDWýBđB0BŔCPBE8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071575100715751007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22728 DVůDŐ„DW˝.DW˝DVůDVůDŐ„DWDŇDVůDŐ„DWDŇ....HrŞHrĹÇHrŞHrĹÇ..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŐ„DŇ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW*DW=DW˝..NEG....YNNNNYYDVů........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWýDWýBđB0BŔCPBE8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071576100715761007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22733 DVůDÚ4DWľ.DWľDVůDVůDÚ4DW˘DçDVůDÚ4DWDŢ¨DWŚDďDW˘DçHrŞ´HsúHrŞ´HrĹÓ¨HslHsúDVůDWDWŚDW˘AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚ4DŢ¨.DďDç.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW}DWŚ. Normal weightA NNYYNEGDW*DW|DW‹DWľDX_NEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW|DWýDWýBđBoBrBCPB„8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1007 10071577100715771007AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22918 DVůDöDW§.DW§DVůDVůDöDW‹DŽĽDVůDöDWDŢäDWuD‘DW‹DŽĽHrŞ<HsjO<HrŞ<HrĹÓäHsMP”HsjO<DVůDWDWuDW‹AđYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DöDŢä.D‘DŽĽ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWpDWu. Normal weightA NYYYNEGDW+DWoDWtDW§DXHNEG....YNNNNYNDVů........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWoDWýDWýBđBbB‰BŽCPBw8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1007 10071578100715781007AŔYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22736 DVůDő(DWÉ.DWÉDVůDVůDő(DWDĂđDVůDő(DWDŕLDWDż¸DWDĂđHrŞ:¨Hs—WpHrŞ:¨HrĹŐLHs{Ł¸Hs—WpDVůDWDWDWAŔYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dő(DŕL.Dż¸DĂđ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Normal weightA NNYYNEGDW+DW‹DW—DWÉDXjNEG....YNNNNYNDVů........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBđB~BfBrCPB“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071579100715791007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22920 DVůD÷€DWÄ.DWÄDVůDVůD÷€DWDŇDVůD÷€DWDŇ....HrŞ=HrĹÇHrŞ=HrĹÇ..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D÷€DŇ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWS. Underweight ANNYYNEGDW/DW‹DWÄ..NEG....YNNNNYYDVů........DW/DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBđB~BrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071580100715801007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22921 DVůDů`DW˝.DW˝DVůDVůDů`DWDëŚDVůDů`DWDëŚ....HrŞ>ŕHrĹŕŚHrŞ>ŕHrĹŕŚ..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dů`DëŚ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW+DW‹DW˝..NEG....YNNNNYYDVů........DW+DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBđB~BrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071581100715811007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22928 DVúDŢlDWĘ.DWĘDVúDVúDŢlDWD DVúDŢlDWDŢlDWDŞdDWD Hr«ulHs—3”Hr«ulHrÇ$ěHs{ŽdHs—3”DVúDWDWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢlDŢl.DŞdD .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Normal weightA NNYYNEGDW+DW‹DW—DWĘDXjNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBďB}BfBrC@B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071582100715821007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23087 DVúDŕÄDWĹ.DWĹDVúDVúDŕÄDWDÝDVúDŕÄDWDÝ....Hr«wÄHrÇ#„Hr«wÄHrÇ#„..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DŕÄDÝ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Normal weightA NNYYNEGDW+DW‹DWĹ..NEG....YNNNNYYDVú........DW+DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBďB}BrC@B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071583100715831007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23146 DVúDęśDWĆ.DWĆDVúDVúDęśDW¨DĂxDVúDęśDWDŕLDW’D×(DW¨DĂxHr«śHsżxHr«śHrÇ&ĚHssŇ(HsżxDVúDWDW’DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DęśDŕL.D×(DĂx.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Overweight A0YNYYNEGDW+DW‹DW‘DWĆDXeNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBďB}BlBrC@B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071584100715841007AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23091 DVúDćÜDW÷.DW÷DVúDVúDćÜDWDăĐDVúDćÜDWDăĐ....Hr«}ÜHrÇ*PHr«}ÜHrÇ*P..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DćÜDăĐ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW+DWŤDWľ..NEG....YNNNNYYDVú........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBďBBpC@B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071585100715851007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23094 DVúDçTDWĂ.DWĂDVúDVúDçTDW§DÂDVúDçTDWDŕDW‘DŐŔDW§DÂHr«~THsŹlHr«~THrÇ'Hsr@HsŹlDVúDWDW‘DW§AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçTDŕ.DŐŔDÂ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Obese A@YNYYNEGDW+DW‹DWDWĂDXdNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBďB}BmBrC@B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071586100715861007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23096 DVúDčřDWŇ.DWŇDVúDVúDčřDWµDŠDVúDčřDWDŢ0DW DŽDWµDŠHr«řHsˇ©ŚHr«řHrÇ$°Hs…ţHsˇ©ŚDVúDWDW DWµAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčřDŢ0.DŽDŠ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW . Overweight A0NNYYNEGDW+DW‹DWźDWŇDXrNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBďB}B^BrC@B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071587100715871007AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23148 DVúDěDWľ.DWľDVúDVúDěDWDäŔDVúDěDWDäŔ....Hr«HrÇ+@Hr«HrÇ+@..DVúDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DěDäŔ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW+DW‹DWľ..NEG....YNNNNYYDVú........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBďB}BrC@B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071588100715881007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23151 DWD‘DWŘ.DWŘDWDWD‘DWD@DWD‘DWD@....Hrą¨”Hr×í@Hrą¨”Hr×í@..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D‘D@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Normal weightA NNYYNEGDW8DW‹DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071589100715891007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23155 DWD ŚDWÄ.DWÄDWDWD ŚDW¨DÇ°DWD ŚDWDŠHDW’DÎDW¨DÇ°Hrą¸HsĂ°Hrą¸HrÖ˘ČHssÉHsĂ°DWDWDW’DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. D ŚDŠH.DÎDÇ°.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNYYNEGDW8DW‹DW‘DWÄDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071590100715901007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24372 DWD¬DWË.DWËDWDWD¬DWDŢlDWD¬DWDŢl....HrąĹ,HrŘHlHrąĹ,HrŘHl..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D¬DŢl....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Normal weightA NNYYNEGDW8DW‹DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071591100715911007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24378 DWDµŕDWÓ.DWÓDWDWDµŕDW¶DôDWDµŕDWD‚ČDWˇD ŚDW¶DôHrąÍ`Hs˘ôôHrąÍ`HrÖ›HHs‡bHs˘ôôDWDWDWˇDW¶AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DµŕD‚Č.D ŚDô.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWˇ. Normal weightA NNYYNEGDW>DWŚDW DWÓDXsPOS....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBăBrB]BqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1007 10071592100715921007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24377 DWD´xDWĘ.DWĘDWDWD´xDWD…\DWD´xDWD…\....HrąËřHrÖťÜHrąËřHrÖťÜ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. D´xD…\....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Underweight ANNYYNEGDW?DW‹DWĘ..NEG....YNNNNYYDW........DW?DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071593100715931007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24380 DWD¶DW3.DW3DWDWD¶DWD¶DWD¶DWD¶....HrąÍśHrąÍśHrąÍśHrąÍś..DW...AđYEARS. 12-15 YearsAWHITE AWHITE ADW3PROTOCOL DEVIATION DWPROTOCOL DEVIATION BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. D¶.....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo DW3.. Normal weightA NYYYNEGDW2DW2DWŮ.. DW.DWDWYNNNNNNDW..........YY NNN Yhad important protocol deviation(s) as determined by the clinician for Immunogenicity (on or before 1 month post Dose 2) Population(s) Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW2DW3DW3AB/B.0-1 month A0-1 month A0-1 month A1-2 months A . ...C4591001C4591001 1007 10071594100715941007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24453 DWDÉĚDWĐ.DWĐDWDWDÉĚDWDíäDWDÉĚDWDíä....HrąáLHr×dHrąáLHr×d..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DÉĚDíä....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Underweight ANNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071595100715951007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24454 DWDĐDWŕ.DWŕDWDWDĐDW©D™üDWDĐDWDĐDW’Dź$DW©D™üHrąčHs‘ç|HrąčHrÖ±PHssš$Hs‘ç|DWDWDW’DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐDĐ.Dź$D™ü.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW8DW‹DW‘DWĹDXfNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071596100715961007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24456 DWDŮDWÉ.DWÉDWDWDŮDWDˇôDWDŮDWDÚpDWDĐÔDWDˇôHrąđHs—5tHrąđHrŘDpHs{´ÔHs—5tDWDWDWDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDÚp.DĐÔDˇô.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Underweight ANNYYNEGDW8DW‹DW—DWÉDXjNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpBfBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071597100715971007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24460 DWDŰ$DWĚ.DWĚDWDWDŰ$DWDăXDWDŰ$DWDăX....Hrąň¤HrÖűŘHrąň¤HrÖűŘ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DŰ$DăX....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Underweight ANNYYNEGDW>DWŚDWĚ..NEG....YNNNNYYDW........DW>DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071599100715991007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24478 DWDę`DWĘ.DWĘDWDWDę`DWDŞ(DWDę`DWDŞ(....HrşŕHrÖÂ¨HrşŕHrÖÂ¨..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. Dę`DŞ(....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Underweight ANNYYNEGDW8DW‹DWĘ..NEG....YNNNNYYDW........DW8DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071600100716001007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24479 DWDëPDWč..DWDWDëPDWËD˘¨DWDëPDWD©8DW D˘lDWËD˘¨HrşĐHsľĂ(HrşĐHrÖÁ¸Hs†lHsľĂ(DWDWDW DWËAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëPD©8.D˘lD˘¨.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW . Underweight ANNYYNEGDW8DW‹DWźDWčDXNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqB^BrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071601100716011007AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24481 DWDí¨DWÚ.DWÚDWDWDí¨DWDÚ4DWDí¨DWDÚ4....Hrş(HrÖň´Hrş(HrÖň´..DWDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. Dí¨DÚ4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDWS. Normal weightA NNYYNEGDWSDW‹DWÚ..NEGDWŤ.DWŤDWŤYNNNNYYDW........DWSDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071602100716021007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24483 DWDďDWŃ.DWŃDWDWDďDWDî DWDďDWDî ....HrşHr× HrşHr× ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DďDî ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Underweight ANNYYNEGDW8DW‹DWŃ..NEG....YNNNNYYDW........DW8DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071603100716031007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24539 DWDŽ€DWŃ.DWŃDWDWDŽ€DWDëŚDWDŽ€DWDëŚ....Hrş÷€Hr×Hrş÷€Hr×..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽ€DëŚ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NYYYNEGDW>DWŚDWŃ..NEGDW¤.DW¤DW¤YNNNNYYDW........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ..DW>C4591001C4591001 1007 10071604100716041007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24538 DWD‡đDWË.DWËDWDWD‡đDWDé¬DWD‡đDWDé¬....HrşđđHr×,HrşđđHr×,..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D‡đDé¬....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDW8. Overweight A0NNYYNEGDW8DW‹DWË..NEGDWŤ.DWŤDWŤYNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071605100716051007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24544 DWD”\DWĘ.DWĘDWDWD”\DWDŚÜDWD”\DWDŚÜ....Hrşý\HrÖĄ\Hrşý\HrÖĄ\..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. D”\DŚÜ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW>. Underweight ANNYYNEGDW>DW‹DWĘ..NEG....YNNNNYYDW........DW>DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071606100716061007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24545 DWD¬DDWĐ.DWĐDWDWD¬DDWDépDWD¬DDWDép....Hr»DHr×đHr»DHr×đ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. D¬DDép....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWG. Normal weightA NNYYNEGDWGDWŚDWĐ..NEG....YNNNNYYDW........DWGDWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071607100716071007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24683 DWDË4DWű.DWűDWDWDË4DW©DÇ8DWDË4DWDć DW’D®ŘDW©DÇ8Hr»44Hs’¸Hr»44HrÖ˙ Hss©ŘHs’¸DWDWDW’DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DË4Dć .D®ŘDÇ8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Overweight A0NNYYNEGDW?DW‹DW‘DWĘDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrBřB†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071608100716081007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24684 DWDÉĚDWĘ..DWDWDÉĚDW©DĆDWDÉĚDWDçTDW’DŻŚDW©DĆHr»2ĚHs’ŚHr»2ĚHrÖ˙ÔHssŞŚHs’ŚDWDWDW’DW©AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉĚDçT.DŻŚDĆ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNYYNEGDW?DW‹DW‘DWĘDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrBřB†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071609100716091007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24685 DWDĐ\DWĐ..DWDWDĐ\DWDëČDWDĐ\DWDëČ....Hr»9\Hr×HHr»9\Hr×H..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DĐ\DëČ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Normal weightA NNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071610100716101007AđYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24730 DWDÔDWÓ.DWÓDWDWDÔDWDáDWDÔDWDá....Hr»=HrŮś€Hr»=HrŮś€..DWDW..AđYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DÔDá....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW}DW9. Obese A@YNYYNEGDW9DW|DWÓ..NEG....YNNNNYYDW........DW9DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW|DWýDWýBáB`BBřBw8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071612100716121007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24692 DWDŇđDWĘ.DWĘDWDWDŇđDWDăĐDWDŇđDWDăĐ....Hr»;đHrÖüPHr»;đHrÖüP..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DŇđDăĐ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW@. Normal weightA NNYYNEGDW@DW‹DWĘ..NEG....YNNNNYYDW........DW@DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071613100716131007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24732 DWDäDWĘ.DWĘDWDWDäDW®D‡DWDäDWDĎ¨DW™DĄ´DW®D‡Hr»MHslHr»MHrÖč(Hs|Ű4HslDWDWDW™DW®AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäDĎ¨.DĄ´D‡.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Normal weightA NNYYNEGDW8DW‹DWDWĘDXkNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBeBrBřB†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ..DWRC4591001C4591001 1007 10071614100716141007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24734 DWDę`DWö.DWöDWDWDę`DW»DĆüDWDę`DWDçDW”DÓ,DW»DĆüHr»S`Hs©Ď|Hr»S`HrÖ˙Hsvq,Hs©Ď|DWDWDW”DW»AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę`Dç.DÓ,DĆü.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW”. Normal weightA NNYYNEGDW>DW‹DW“DW×DXxNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBjBrBřB†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071615100716151007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24740 DWDăĐDWú.DWúDWDWDăĐDWDčřDWDăĐDWDčř....Hr»LĐHr×xHr»LĐHr×x..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DăĐDčř....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW>. Normal weightA NNYYNEGDW>DW‹DWĚ..NEG....YNNNNYYDW........DW>DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071616100716161007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24777 DWDčDDWŮ.DWŮDWDWDčDDWDĂ´DWDčDDWDĂ´....Hr»QDHrÖÜ4Hr»QDHrÖÜ4..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DčDDĂ´....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Normal weightA NNYYNEGDW>DWŚDWŮ..NEG....YNNNNYYDW........DW>DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071617100716171007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24781 DWDňXDW¨.DW¨DWDWDňXDWŠDďÄDWDňXDWDâhDWuDhDWŠDďÄHr»[XHsi^ÄHr»[XHrŘLhHsMGčHsi^ÄDWDWDWuDWŠAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DňXDâh.DhDďÄ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWjDW8. Normal weightA NNYYNEGDW8DWiDWtDW¨DXGNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWiDWýDWýBâBNB‰B”BřBd8-9 months A2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1007 10071618100716181007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24784 DWDňDW×.DW×DWDWDňDWD„0DWDňDWD„0....Hr»[HrÖś°Hr»[HrÖś°..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DňD„0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW?DW‹DW×..NEGDWŤ.DWŤDWŤYNNNNYYDW........DW?DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071619100716191007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24785 DWD‰DWË.DWËDWDWD‰DWD€¬DWD‰DWD€¬....HrĽCśHr×ę¬HrĽCśHr×ę¬..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. D‰D€¬....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Underweight ANNYYNEGDW?DW‹DWË..NEG....YNNNNYYDW........DW?DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071620100716201007AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24828 DWD’¸DWË.DWËDWDWD’¸DWDčDWD’¸DWDč....HrĽM8HrŘRHrĽM8HrŘR..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D’¸Dč....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW9DWDWË..NEG....YNNNNYYDW........DW9DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWýDWýBâBuBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071621100716211007AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24830 DWD—,DWË.DWËDWDWD—,DWDčĽDWD—,DWDčĽ....HrĽQ¬HrŘRĽHrĽQ¬HrŘRĽ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D—,DčĽ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW‘.. Underweight ANNYNPOSDW9DWDWË..NEG....YNNNNYYDW........DW9DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWýDWýBâBuBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071622100716221007AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24831 DWD•ÄDWË.DWËDWDWD•ÄDWD•ÄDWD•ÄDWD•Ä....HrĽPDHrĽPDHrĽPDHrĽPD..DW...AđYEARS. 12-15 YearsAWHITE AWHITE A. DWOTHER BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. D•Ä.....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW6.. Normal weightA NNYYNEGDW5DW5DWË.. ....YNNNNYYDW........DW9DWËYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDW5DWýDWýBČB÷B/0-1 month A0-1 month A0-1 month A8-9 months A . ..DWC4591001C4591001 1007 10071623100716231007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24832 DWDštDWŃ.DWŃDWDWDštDWµDÇěDWDštDWDçTDW DÜČDWµDÇěHrĽTôHsˇçlHrĽTôHrŮ˘ÔHs†LČHsˇçlDWDWDW DWµAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DštDçT.DÜČDÇě.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW . Underweight ANYYYNEGDW?DW‹DWźDWŃDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBáBoB^BrB÷B…8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071624100716241007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24910 DWDŞ DWÄ.DWÄDWDWDŞ DW¦DË4DWDŞ DW"DŚdDW“DĚŘDW¦DË4HrĽe HsŽ$4HrĽe HrßßdHsuXHsŽ$4DWDW"DW“DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞ DŚd.DĚŘDË4.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW>DWŚDW’DWÄDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBkBqB÷B†7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DW…C4591001C4591001 1007 10071625100716251007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24915 DWD¬ĽDWÄ.DWÄDWDWD¬ĽDW¦DÉĚDWD¬ĽDW"D‹tDW“DĚ$DW¦DÉĚHrĽg<HsŽ"ĚHrĽg<HrßŢtHsu¤HsŽ"ĚDWDW"DW“DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬ĽD‹t.DĚ$DÉĚ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW>DWŚDW’DWÄDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBkBqB÷B†7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DWwC4591001C4591001 1007 10071626100716261007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24917 DWDĆDWË.DWËDWDWDĆDWD…DWDĆDWD…....HrĽ€ŚHr×ďHrĽ€ŚHr×ď..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DĆD…....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Underweight ANNYYNEGDW8DW‹DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071627100716271007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24919 DWDĚśDWŇ.DWŇDWDWDĚśDWD~DWDĚśDWD~....HrĽ‡Hr×čHrĽ‡Hr×č..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DĚśD~....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Normal weightA NYYYNEGDW8DW‹DWŇ..NEG....YNNNNYYDW........DW8DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071628100716281007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24997 DWDăXDWŢ.DWŢDWDWDăXDWDĆ„DWDăXDWDĆ„....HrĽťŘHrŘ0„HrĽťŘHrŘ0„..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DăXDĆ„....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Underweight ANNYYNEGDW=DW‹DWŢ..NEG....YNNNNYYDW........DW=DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071629100716291007AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24994 DWDÝ|DWŃ.DWŃDWDWDÝ|DWµD°DWDÝ|DWD@DW DĚśDWµD°HrĽ—üHsˇĎ„HrĽ—üHr×í@Hs†<śHsˇĎ„DWDWDW DWµAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝ|D@.DĚśD°.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW . Overweight A0NYYYNEGDW?DW‹DWźDWŃDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpB^BrB÷B…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071630100716301007AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24993 DWDÜDWŃ.DWŃDWDWDÜDWµD±¨DWDÜDWD‚ŚDW DÎôDWµD±¨HrĽ–”HsˇŃ(HrĽ–”Hr×ěŚHs†>ôHsˇŃ(DWDWDW DWµAĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜD‚Ś.DÎôD±¨.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW . Normal weightA NNYYNEGDW?DW‹DWźDWŃDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpB^BrB÷B…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071631100716311007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25003 DWDçDWĚ.DWĚDWDWDçDWDáđDWDçDWDáđ....HrĽˇHrŮťpHrĽˇHrŮťp..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DçDáđ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW@DWŚDWĚ..NEG....YNNNNYYDW........DW@DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBáBpBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071632100716321007AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25062 DWDëŚDWÄ.DWÄDWDWDëŚDW§DŽ€DWDëŚDWD˘lDW’D‘PDW§DŽ€HrĽ¦HsŹ9HrĽ¦HrŮ]ěHssŚPHsŹ9DWDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëŚD˘l.D‘PDŽ€.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW?DW‹DW‘DWÄDXdNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBáBoBlBrB÷B…8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071633100716331007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25058 DWDęśDWĚ.DWĚDWDWDęśDWDäüDWDęśDWDäü....HrĽĄHrŮ |HrĽĄHrŮ |..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DęśDäü....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW>. Normal weightA NNYYNEGDW>DWŤDWĚ..NEG....YNNNNYYDW........DW>DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBáBqBpB÷B‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071634100716341007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25064 DWD”DWĐ.DWĐDWDWD”DW!DšěDWD”DW!Dšě....HrÂćHrŢślHrÂćHrŢśl..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D”Dšě....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071635100716351007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25063 DWDŽĽDWŚ.DWŚDWDWDŽĽDW!DĹĐDWDŽĽDW!DĹĐ....HrÂŕĽHrŢÇPHrÂŕĽHrŢÇP..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŚWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DŽĽDĹĐ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDW=. Normal weightA NYYYNEGDW=DW‹DWŢ..NEGDWŽ.DWŽDWŽYNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWŚDWŚBlBkABB€3-4 months A@3-4 months A@0-1 month A4-5 months AP . ...C4591001C4591001 1007 10071636100716361007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25149 DWDźśDWĐ.DWĐDWDWDźśDW!DŚ DWDźśDW!DŚ ....HrÂńśHrŢŽ HrÂńśHrŢŽ ..DWDW!..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DźśDŚ ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Overweight A0YNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071638100716381007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25153 DWDĄ<DWŢ.DWŢDWDWDĄ<DW!D†DWDĄ<DW!D†....HrÂ÷<HrŢ‡HrÂ÷<HrŢ‡..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DĄ<D†....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Normal weightA NNYYNEGDW?DW‹DWŢ..NEG....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071639100716391007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25154 DWD«DW .DW DWDWD«DW!D€4DWD«DW!D€4....HrÂýHrŢ´HrÂýHrŢ´..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW WITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. D«D€4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDWD. Normal weightA NNYYNEGDWDDWŚDWŢ..NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW DW B€BlBB•B4-5 months AP3-4 months A@0-1 month A5-6 months A` . ...C4591001C4591001 1007 10071640100716401007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25156 DWD˝ŘDWŇ.DWŇDWDWD˝ŘDWµDÄhDWD˝ŘDW!DäŔDW˘DĂDWµDÄhHrĂŘHsˇăčHrĂŘHrŢć@HsÖHsˇăčDWDW!DW˘DWµAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝ŘDäŔ.DĂDÄh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW˘. Normal weightA NNYYNEGDWEDWŚDWˇDWŇDXrNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlB\BqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071641100716411007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25202 DWDČ(DWĺ.DWĺDWDWDČ(DW"DÚčDWDČ(DW"DÚč....HrĂ(Hrŕ-čHrĂ(Hrŕ-č..DWDW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DČ(DÚč....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Normal weightA NNYYNEGDW?DWŚDW×..NEG....YNNNNYYDW........DW?DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071642100716421007AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25205 DWDÓ,DWĺ.DWĺDWDWDÓ,DW›DÎ¸DWDÓ,DW›DÎ¸....HrĂ%,Hs§8HrĂ%,Hs§8..DW...AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . DW›.BNT162b2 (30 (*ESC*){unicode 03BC}g) DÓ,.DÎ¸...13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWŚDWŚDXX.. ....YNNNNYYDW........DW=DWŮYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDWŚDWýDWýBqBňB0-1 month A0-1 month A0-1 month A8-9 months A . ..DWC4591001C4591001 1007 10071643100716431007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25204 DWDŃÄDWů.DWůDWDWDŃÄDW·Dť€DWDŃÄDW!DÖěDW›DĐDW·Dť€HrĂ#ÄHs¤`HrĂ#ÄHrŢŘlHs©Hs¤`DWDW!DW›DW·AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃÄDÖě.DĐDť€.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDW=DW‹DWšDWÓDXt ....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBÝBkBcBrBňB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071644100716441007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25294 DWDépDWĐ..DWDWDépDW!DÚčDWDépDW!DÚč....HrĂ;pHrŢÜhHrĂ;pHrŢÜh..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DépDÚč....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Underweight ANNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071645100716451007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25208 DWDć(DWË.DWËDWDWDć(DWŻD’DWDć(DW!Dá´DWšD§DWŻD’HrĂ8(Hs™Č„HrĂ8(HrŢă4Hs~.Hs™Č„DWDW!DWšDWŻAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć(Dá´.D§D’.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWš. Normal weightA NNYYNEGDW=DW‹DW™DWËDXlNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBdBrBňB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071646100716461007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25299 DWDń,DWŃ.DWŃDWDWDń,DWµDŘTDWDń,DW!DŕLDW˘DÍPDWµDŘTHrĂC,Hsˇ÷ÔHrĂC,HrŢáĚHsŕPHsˇ÷ÔDWDW!DW˘DWµAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dń,DŕL.DÍPDŘT.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW˘. Underweight ANNYYNEGDW=DWŚDWˇDWŃDXrNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlB\BqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071647100716471007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25302 DWDó„DWĐ.DWĐDWDWDó„DW!DÖěDWDó„DW!DÖě....HrĂE„HrŢŘlHrĂE„HrŢŘl..DWDW!..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. Dó„DÖě....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW@. Normal weightA NYYYNEGDW@DWŤDWĐ..NEG....YNNNNYYDW........DW@DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071648100716481007AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25304 DW D„äDW§.DW§DW DW D„äDW‹D¨ŔDW D„äDW"DřDWvD±¨DW‹D¨ŔHrÄ(dHsji@HrÄ(dHrßŇřHsNÂ¨Hsji@DW DW"DWvDW‹AđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D„äDř.D±¨D¨Ŕ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWuDWv. Normal weightA NNYYNEGDW>DWtDWuDW§DXHNEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWtDWýDWýBÜBSBB‰BńBh7-8 months A€2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1007 10071649100716491007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25369 DW D‹tDWŃ.DWŃDW DW D‹tDW"DÖěDW D‹tDW"DÖě....HrÄ.ôHrŕ)ěHrÄ.ôHrŕ)ě..DW DW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. D‹tDÖě....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Normal weightA NNYYNEGDW>DWŚDWŃ..NEG....YNNNNYYDW ........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071650100716501007AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25370 DW DśĚDWě..DW DW DśĚDW®DÍDW DśĚDW"D†DW™DËpDW®DÍHrÄ@LHs˛HrÄ@LHrßŮHs}đHs˛DW DW"DW™DW®AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśĚD†.DËpDÍ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Obese A@YNYYNEGDW@DW‹DWDWĘDXkNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÜBjBeBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071651100716511007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25373 DW D™„DWÓ.DWÓDW DW D™„DW"D—ŕDW D™„DW"D—ŕ....HrÄ=HrßęŕHrÄ=Hrßęŕ..DW DW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. D™„D—ŕ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW>. Underweight ANNYYNEGDW>DW‹DWÓ..NEG....YNNNNYYDW ........DW>DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071652100716521007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25376 DW Dž¬DWĐ.DWĐDW DW Dž¬DW´Dž¬DW Dž¬DW"D…\DW™D‘ČDW´Dž¬HrÄB,Hs l¬HrÄB,HrßŘ\Hs|ÇHHs l¬DW DW"DW™DW´AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž¬D…\.D‘ČDž¬.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Normal weightA NNYYNEGDW>DW‹DWDWĐDXqNEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÜBjBeBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071653100716531007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25437 DW DĘĽDWŃ.DWŃDW DW DĘĽDW"DÎ¸DW DĘĽDW"DÎ¸....HrÄn<Hrŕ!¸HrÄn<Hrŕ!¸..DW DW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DĘĽDÎ¸....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Overweight A0YNYYNEGDW>DWŚDWŃ..NEG....YNNNNYYDW ........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071654100716541007AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25443 DW DČ(DWÓ.DWÓDW DW DČ(DW"DĎäDW DČ(DW"DĎä....HrÄk¨Hrŕ"äHrÄk¨Hrŕ"ä..DW DW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DČ(DĎä....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Underweight ANNYYNEGDW>DW‹DWÓ.. DW‘.DW‘DW‘YNNNNNNDW ..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNYNY NNDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071655100716551007AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25445 DWD†ÄDWĂ.DWĂDWDWD†ÄDW¦DâhDWD†ÄDW#D†LDW‘DŮĽDW¦DâhHrĹ{ÄHsŽ;hHrĹ{ÄHrá*ĚHsr<HsŽ;hDWDW#DW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D†ÄD†L.DŮĽDâh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDW?DW‹DWDWĂDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBmBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071656100716561007AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25448 DWDŹčDWŘ.DWŘDWDWDŹčDW#DŇDWDŹčDW#DŇ....HrĹ„čHráv€HrĹ„čHráv€..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DŹčDŇ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWE. Normal weightA NNYYNEGDWEDW‘DWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŰBoBlBđB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071658100716581007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25838 DWDńŕDWÉ.DWÉDWDWDńŕDW¦DÔĐDWDńŕDW#D”DW‘DÖěDW¦DÔĐHrĹćŕHsŽ-ĐHrĹćŕHrá9Hsr€lHsŽ-ĐDWDW#DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DńŕD”.DÖěDÔĐ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Overweight A0NNYYNEGDW?DW‹DWDWÉDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBmBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071659100716591007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25834 DWDî\DWŇ..DWDWDî\DW#DŕDWDî\DW#Dŕ....HrĹă\Hrá„HrĹă\Hrá„..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. Dî\Dŕ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW?. Normal weightA NNYYNEGDW?DW‘DWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŰBoBlBđB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071660100716601007AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25833 DWDílDWÓ..DWDWDílDW·DĚ$DWDílDW#Dß\DWˇDŻŚDW·DĚ$HrĹâlHs¤Ž¤HrĹâlHráÜHs‡qHs¤Ž¤DWDW#DWˇDW·AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DílDß\.DŻŚDĚ$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DWˇ. Underweight ANNYYNEGDW?DW‘DW DWÓDXtNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBŰBoB]BlBđB„7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DWrC4591001C4591001 1007 10071661100716611007AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25840 DWDŮřDWí.DWíDWDWDŮřDW$DâhDWDŮřDW$Dâh....HrÇ xHrâŘhHrÇ xHrâŘh..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DŮřDâh....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW@. Normal weightA NNYYNEGDW@DW‘DWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBÚBnBlBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071662100716621007AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26061 DWDâ¤DWč.DWčDWDWDâ¤DW$D†LDWDâ¤DW$D†L....HrÇ)$Hrâ|LHrÇ)$Hrâ|L..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dâ¤D†L....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNNNPOSDW@DWŚDWč..POSDW¤.DW¤DW¤YNNNNYYDW........DW@DWčYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DW$C4591001C4591001 1008 10081751100817511008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20520 DVęD› DWż.DWżDVęDVęD› DWŁDŽDDVęD› DWD“0DWŽDÇ°DWŁDŽDHr– Hs‰ňÄHr– Hrł0Hsn|°Hs‰ňÄDVęDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. D› D“0.DÇ°DŽD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Overweight A0YNYYNEGDW!DW‹DWŤDWżDX`NEG....YNNNNYNDVę........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBţBŚBpBrC@B˘9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081752100817521008AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20525 DVęDŮDWż.DWżDVęDVęDŮDWŁDÂDVęDŮDV˙DÔĐDWŤD‡DWŁDÂHr–XHsŠ'Hr–XHr˛PHslę€HsŠ'DVęDV˙DWŤDWŁAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDÔĐ.D‡DÂ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDWDW‹DWŚDWżDX`NEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBqBrC@B˘9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081753100817531008AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20521 DVęDŮDDW°.DW°DVęDVęDŮDDV˙DÔDVęDŮDDV˙DÔ....Hr–XDHr˛śHr–XDHr˛ś..DVęDV˙..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. DŮDDÔ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWS. Normal weightA NNYYNEGDWDW‹DW°..NEG....YNNNNYYDVę........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB˙BŤBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1008 10081754100817541008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20527 DVëDÂDWŻ.DWŻDVëDVëDÂDV˙D|8DVëDÂDV˙D|8....Hr—“Hr±Ş¸Hr—“Hr±Ş¸..DVëDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÂD|8....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDWDW‹DWŻ..NEG....YNNNNYYDVë........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB˙BŤBrC0Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1008 10081755100817551008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20702 DVëDÄ,DW°.DW°DVëDVëDÄ,DWDš°DVëDÄ,DWDš°....Hr—”¬Hrł°Hr—”¬Hrł°..DVëDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÄ,Dš°....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWo.. Normal weightA NNYYNEGDWDWnDW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWnDWýDWýBţBoBŹC0B„9-10 months A 3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1008 10081756100817561008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20704 DVëDĘĽDW.DWDVëDVëDĘĽDWŚDÔĐDVëDĘĽDV˙DÖ°DWxDÖ8DWŚDÔĐHr—›<HskćĐHr—›<Hr˛0HsQŠ8HskćĐDVëDV˙DWxDWŚAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘĽDÖ°.DÖ8DÔĐ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWwDWx. Underweight ANYYYNEGDWDWvDWwDWDXINEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWvDWýDWýB˙BxB†B‡C0BŚ9-10 months A 4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081757100817571008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20705 DVëDĘDWÄ.DWÄDVëDVëDĘDW¦DˇDVëDĘDV˙DŐüDW‘DĂ´DW¦DˇHr—šHsŤúHr—šHr˛|Hsrm4HsŤúDVëDV˙DW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWkBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘDŐü.DĂ´Dˇ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDWDW‹DWDWÄDXcNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB˙BŤBmBrC0Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081758100817581008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20707 DVëDÔDWŢ.DWŢDVëDVëDÔDWD”ÔDVëDÔDWD”Ô....Hr—¤śHrłÔHr—¤śHrłÔ..DVëDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DÔD”Ô....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWN. Overweight A0NNYYNEGDW!DW‹DW·..NEG....YNNNNYYDVë........DW!DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWŢDWŢBßBŚBSBôBˇ7-8 months A€5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1008 10081760100817601008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21257 DVđDß\DWĂ.DWĂDVđDVđDß\DWDťDDVđDß\DWDťD....HržG\Hrą´ÄHržG\Hrą´Ä..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. Dß\DťD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWR. Normal weightA NNYYNEGDW"DW‹DWľ..NEG....YNNNNYYDVđ........DW"DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBůB‡BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081761100817611008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21256 DVđDŇđDW™.DW™DVđDVđDŇđDW}DŇDVđDŇđDWD’ôDWgDŘDW}DŇHrž:đHsX€Hrž:đHrąŞtHs;"HsX€DVđDWDWgDW}AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇđD’ô.DŘDŇ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWgDWg. Obese A@YNYYNEGDW%DWfDWfDW™DX:POS....YNNNNYNDVđ........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWfDWýDWýBůBbB—B—CŕBw8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1008 10081763100817631008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21260 DVđDçDWĹ.DWĹDVđDVđDçDW¨DŔäDVđDçDWD·üDW“DÄ¤DW¨DŔäHržOHsĽäHržOHrĽr|Hsu$HsĽäDVđDWDW“DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçD·ü.DÄ¤DŔä.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Obese A@YNYYNEGDW!DW‹DW’DWĹDXeNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýB÷B…BkBrCŕBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081764100817641008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21258 DVđDćdDW¸.DW¸DVđDVđDćdDWD ČDVđDćdDWD Č....HržNdHrĽ[HHržNdHrĽ[H..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DćdD Č....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWO. Overweight A0NNYYNEGDW!DW‹DW¸..NEG....YNNNNYYDVđ........DW!DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB÷B…BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ..DW–C4591001C4591001 1008 10081767100817671008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21468 DVńDÍDWľ.DWľDVńDVńDÍDW˘DĽ¬DVńDÍDWDŹčDWŤDëŚDW˘DĽ¬Hrź†”HsĎ¬Hrź†”HrşřčHsmOHsĎ¬DVńDWDWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍDŹč.DëŚDĽ¬.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW"DW‹DWŚDWľDX_NEG....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BqBrCĐB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081768100817681008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21469 DVńDŃDWĽ.DWĽDVńDVńDŃDWD˝śDVńDŃDWD˝ś....HrźŠHr»&śHrźŠHr»&ś..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DŃD˝ś....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDWO. Normal weightA NNYYNEGDW%DW‹DWĽ..NEG....YNNNNYYDVń........DW%DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BrCĐB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081769100817691008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21475 DVńDÔĐDWĺ.DWĺDVńDVńDÔĐDWD•ÄDVńDÔĐDWD•Ä....HrźŽPHrşţÄHrźŽPHrşţÄ..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DÔĐD•Ä....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWvDW>. Underweight ANYYYNEGDW>DWuDWż..NEG....YNNNNYYDVń........DW>DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWuDWýDWýBřBpBCĐB…8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081770100817701008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21476 DVňD™üDW¶.DW¶DVňDVňD™üDWD˘äDVňD™üDWD˘ä....Hr ¤üHrĽ]dHr ¤üHrĽ]d..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. D™üD˘ä....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWN. Normal weightA NNNYPOSDW#DW‹DW¶..POS....YNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1008 10081771100817711008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21662 DVňDXDW¶.DW¶DVňDVňDXDWDŁDVňDXDWDŁ....Hr ŁXHrĽ^Hr ŁXHrĽ^..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DXDŁ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWN. Normal weightA NNYYNEGDW#DW‹DW¶..NEG....YNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB÷B…BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081773100817731008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21664 DVňDČ(DWż..DVňDVňDČ(DWŁDžčDVňDČ(DWD¤DWŽD«DWŁDžčHr Ó(HsŠhHr Ó(Hr» Hsn`HsŠhDVňDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DČ(D¤.D«Džč.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW#DW‹DWŤDWżDX`NEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BpBrCŔBš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081774100817741008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21668 DVňDŇđDW˝.DW˝DVňDVňDŇđDWDŞ(DVňDŇđDWDŞ(....Hr ÝđHrąÁ¨Hr ÝđHrąÁ¨..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DŇđDŞ(....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWF. Normal weightA NNYYNEGDW$DW‹DW˝..NEG....YNNNNYYDVň........DW$DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBůB‡BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081775100817751008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21667 DVňDŇ<DWÍ.DWÍDVňDVňDŇ<DW±DÍČDVňDŇ<DWD©8DW•DČ DW±DÍČHr Ý<Hsś§HHr Ý<HrąŔ¸Hsw¸ Hsś§HDVňDWDW•DW±AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ<D©8.DČ DÍČ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW•. Underweight ANNYYNEGDW$DW‹DW”DWÍDXnNEG....YNNNNYNDVň........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BiBrCŔBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081777100817771008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21873 DVóDźŘDW».DW»DVóDVóDźŘDWD„äDVóDźŘDWD„ä....HrˇüXHr˝äHrˇüXHr˝ä..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DźŘD„ä....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Underweight ANNYYNEGDW$DW‹DW»..NEG....YNNNNYYDVó........DW$DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBöB„BrC°B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081780100817801008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21875 DVóDŃÄDWÄ.DWÄDVóDVóDŃÄDW¦DhDVóDŃÄDWDĽDW‘DŠüDW¦DhHr˘.DHsŤáhHr˘.DHrşčĽHsr4|HsŤáhDVóDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃÄDĽ.DŠüDh.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDW#DW‹DWDWÄDXcNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BmBrC°B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081781100817811008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21878 DVóDÓhDWÄ.DWÄDVóDVóDÓhDW¨DŽDVóDÓhDWD©8DW”D‘ČDW¨DŽHr˘/čHsŠHr˘/čHr˝µ8Hsv/ČHsŠDVóDWDW”DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓhD©8.D‘ČDŽ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW”. Normal weightA NNYYNEGDW)DW‹DW“DWÄDXeNEG....YNNNNYNDVó........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBöB„BjBrC°B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081785100817851008AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô21880 DVôDÍŚDW¸.DW¸DVôDVôDÍŚDWD”\DVôDÍŚDWD”\....HrŁ{ŚHrĽNÜHrŁ{ŚHrĽNÜ..DVôDW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DÍŚD”\....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWY. Normal weightA NNYYNEGDW%DW‹DW¸..NEG....YNNNNYYDVô........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýB÷B…BrC B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081788100817881008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22317 DV÷DśDWľ.DWľDV÷DV÷DśDW˘DŃLDV÷DśDWDŁ DWŤDśTDW˘DŃLHr§3HsäLHr§3HrÂő Hsl˙ÔHsäLDV÷DWDWŤDW˘AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DśDŁ .DśTDŃL.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW(DWŚDWŚDWľDX_NEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBqBqCpB–8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081789100817891008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22321 DV÷D’DWĹ.DWĹDV÷DV÷D’DWD¸8DV÷D’DWD¸8....Hr§4„HrĂ 8Hr§4„HrĂ 8..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. D’D¸8....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWR. Normal weightA NNYYNEGDW+DW‹DWĹ..NEG....YNNNNYYDV÷........DW+DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBňB€BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081790100817901008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22322 DV÷DĘDWć.DWćDV÷DV÷DĘDW˘DşDV÷DĘDWDĄxDWŤD`DW˘DşHr§lHsÍHr§lHrÂ÷xHsläŕHsÍDV÷DWDWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘDĄx.D`Dş.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW)DW‹DWŚDWľDX_NEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BqBrCpB•8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081791100817911008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22357 DV÷DŐ„DWż.DWżDV÷DV÷DŐ„DWDłDV÷DŐ„DWDł....Hr§xHrĂHr§xHrĂ..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DŐ„Dł....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Underweight ANNYYNEGDW(DW‹DWż..NEG....YNNNNYYDV÷........DW(DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBňB€BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081792100817921008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22323 DV÷DÖtDWż.DWżDV÷DV÷DÖtDWDłDV÷DÖtDWDł....Hr§xôHrĂHr§xôHrĂ..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DÖtDł....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Normal weightA NNYYNEGDW(DW‹DWż..NEG....YNNNNYYDV÷........DW(DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBňB€BrCpB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081793100817931008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22359 DV÷D×ÜDWľ.DWľDV÷DV÷D×ÜDW˘DĆŔDV÷D×ÜDWDłLDWŤDĆ„DW˘DĆŔHr§z\HsŮŔHr§z\HrĂLHsm*HsŮŔDV÷DWDWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D×ÜDłL.DĆ„DĆŔ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW(DW‹DWŚDWľDX_NEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BqBrCpB•8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081794100817941008AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22358 DV÷DŮDWľ.DWľDV÷DV÷DŮDW˘DĆüDV÷DŮDWD˛DWŤDÍŚDW˘DĆüHr§{HsŮüHr§{HrĂHsm1HsŮüDV÷DWDWŤDW˘AŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮD˛.DÍŚDĆü.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW(DW‹DWŚDWľDX_NEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BqBrCpB•8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081795100817951008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22363 DVřD¤LDWĂ.DWĂDVřDVřD¤LDWDŻDVřD¤LDWDŻ....Hr¨LHrĆő”Hr¨LHrĆő”..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D¤LDŻ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Normal weightA NNYYNEGDW+DW‹DWĂ..NEG....YNNNNYYDVř........DW+DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBďB}BrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081796100817961008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22570 DVřDĆ„DWĂ.DWĂDVřDVřDĆ„DW˘D DVřDĆ„DW DŇDWŽDŽDDW˘D Hr¨ş„HsłHr¨ş„HrÄu€HsnCDHsłDVřDW DWŽDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆ„DŇ.DŽDD .424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW)DW‹DWŤDWĂDX_NEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBńBBpBrC`B”8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081797100817971008AŕYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22574 DVřDÔĐDWĂ.DWĂDVřDVřDÔĐDW DŰ`DVřDÔĐDW DŰ`....Hr¨ČĐHrÄ~ŕHr¨ČĐHrÄ~ŕ..DVřDW ..AŕYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. DÔĐDŰ`....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWG. Overweight A0NNYYNEGDW*DW‹DWĂ..NEG....YNNNNYYDVř........DW*DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBńBBrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081798100817981008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22575 DVřDÖ°DWÉ.DWÉDVřDVřDÖ°DWŁDĹXDVřDÖ°DW DÚ4DWŽD4DWŁDĹXHr¨Ę°HsŠ)ŘHr¨Ę°HrÄ}´Hsnb4HsŠ)ŘDVřDW DWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖ°DÚ4.D4DĹX.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANYYYNEGDW)DW‹DWŤDWżDX`NEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBńBBpBrC`B”8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081799100817991008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22577 DVřD×ÜDWÉ.DWÉDVřDVřD×ÜDW D‘ČDVřD×ÜDW D‘Č....Hr¨ËÜHrÄ5HHr¨ËÜHrÄ5H..DVřDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D×ÜD‘Č....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWK. Normal weightA NNYYNEGDW)DW‹DWÉ..NEG....YNNNNYYDVř........DW)DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBńBBrC`B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081800100818001008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22775 DVůDź`DWÄ.DWÄDVůDVůDź`DWD»DDVůDź`DWD»D....Hr©äŕHrĹ°DHr©äŕHrĹ°D..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dź`D»D....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANYYYNEGDW*DW‹DWÄ..NEG....YNNNNYYDVů........DW*DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBđB~BrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081801100818011008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22776 DVúD›(DWĂ.DWĂDVúDVúD›(DW¦DŔlDVúD›(DWDDW‘DÄŕDW¦DŔlHr«2(HsŽlHr«2(HrČHsrn`HsŽlDVúDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D›(D.DÄŕDŔl.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NYYYNEGDW,DW‹DWDWĂDXcNEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBîB|BmBrC@B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081802100818021008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22780 DVúDĹĐDWé.DWéDVúDVúDĹĐDWDhDVúDĹĐDWDh....Hr«\ĐHrĆÎčHr«\ĐHrĆÎč..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĹĐDh....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW+DW‹DWľ..NEG....YNNNNYYDVú........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBďB}BrC@B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081803100818031008AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22783 DVúDÇěDW‹.DW‹DVúDVúDÇěDWkDĂxDVúDÇěDWDĄ´DWVDĹ”DWkDĂxHr«^ěHs@SřHr«^ěHrĆě4Hs$¦”Hs@SřDVúDWDWVDWkAđYEARSBYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇěDĄ´.DĹ”DĂx.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWV. Obese A@YNYYNEGDW+DWJDWUDW‹DX(NEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWJDWýDWýBďB<B¨BłC@BQ8-9 months A2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1008 10081804100818041008AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23122 DVúDÎ¸DWľ.DWľDVúDVúDÎ¸DW˘DČÜDVúDÎ¸DWDŘDWŤDÎ@DW˘DČÜHr«e¸HsŰÜHr«e¸HrÇHsm1ŔHsŰÜDVúDWDWŤDW˘AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ¸DŘ.DÎ@DČÜ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW2DW‹DWŚDWľDX_NEG....YNNNNYNDVú........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBďB}BqBrC@B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081805100818051008AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23123 DVúDÚ¬DWż.DWżDVúDVúDÚ¬DWDÚpDVúDÚ¬DWDÚp....Hr«q¬HrÇ đHr«q¬HrÇ đ..DVúDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DÚ¬DÚp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWZ. Normal weightA NNYYNEGDW,DW‹DWż..NEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBďB}BrC@B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081806100818061008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23127 DVúDÝ|DWĆ..DVúDVúDÝ|DWDÔDVúDÝ|DWDÔ....Hr«t|HrÇśHr«t|HrÇś..DVúDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DÝ|DÔ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWZ. Normal weightA NNYYNEGDW+DW‹DWĆ..NEG....YNNNNYYDVú........DW+DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBďB}BrC@B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081807100818071008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23129 DVűD’|DWĂ.DWĂDVűDVűD’|DWŁD‡´DVűD’|DWD§”DWŽDŽřDWŁD‡´Hr¬züHs‰ě4Hr¬züHrČ?”HsnCřHs‰ě4DVűDWDWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D’|D§”.DŽřD‡´.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Overweight A0YNYYNEGDW,DW‹DWŤDWĂDX`NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBîB|BpBrC0B‘8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081808100818081008AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23301 DVűD–DWĂ.DWĂDVűDVűD–DW¦D‰ĐDVűD–DWD¦¤DW‘D‰”DW¦D‰ĐHr¬~€HsŤâĐHr¬~€HrČ>¤Hsr3HsŤâĐDVűDWDW‘DW¦AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–D¦¤.D‰”D‰Đ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDW3DW‹DWDWĂDXcNEG....YNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW‹DWýDWýBîB|BmBrC0B‘8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081809100818091008AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23306 DVűDŁ DWË.DWËDVűDVűDŁ DW˘DŞÜDVűDŁ DWD±0DWŤDě@DW˘DŞÜHr¬‹ Hs˝ÜHr¬‹ HrČI0HsmOŔHs˝ÜDVűDWDWŤDW˘AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ D±0.Dě@DŞÜ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW0DW‹DWŚDWËDX_NEG....YNNNNYNDVű........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBîB|BqBrC0B‘8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081810100818101008AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23307 DVűD§ĐDWż.DWżDVűDVűD§ĐDWDź$DVűD§ĐDWDź$....Hr¬PHrČ7$Hr¬PHrČ7$..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D§ĐDź$....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW`. Normal weightA NNYYNEGDW,DW‹DWż..NEG....YNNNNYYDVű........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081811100818111008AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23308 DVűD¦,DWż.DWżDVűDVűD¦,DWDžpDVűD¦,DWDžp....Hr¬Ž¬HrČ6pHr¬Ž¬HrČ6p..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D¦,Džp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW`. Overweight A0NNYYNEGDW,DW‹DWż..NEG....YNNNNYYDVű........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081812100818121008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23385 DVűDÉDWż.DWżDVűDVűDÉDWŁD¤DVűDÉDWDÎôDWŤDĺtDWŁD¤Hr¬˛Hs‰í$Hr¬˛HrČfôHsmHôHs‰í$DVűDWDWŤDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉDÎô.DĺtD¤.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW1DW‹DWŚDWżDX`NEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBîB|BqBrC0B‘8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081813100818131008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23392 DVűDÎ¸DWÉ.DWÉDVűDVűDÎ¸DWDĄ<DVűDÎ¸DWDĄ<....Hr¬·8HrČ=<Hr¬·8HrČ=<..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÎ¸DĄ<....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW/DW‹DWÉ..NEG....YNNNNYYDVű........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081814100818141008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23394 DVűDŐŔDWż.DWżDVűDVűDŐŔDWDŐŔDVűDŐŔDWDŐŔ....Hr¬ľ@HrČmŔHr¬ľ@HrČmŔ..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DŐŔDŐŔ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW. Normal weightA NNYYNEGDW,DW‹DWż..NEG....YNNNNYYDVű........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081815100818151008AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23396 DVűDŘDWĹ.DWĹDVűDVűDŘDW©D„äDVűDŘDWDĐDW”Dż¸DW©D„äHr¬ŔHs‘ŇdHr¬ŔHrČhHsv]¸Hs‘ŇdDVűDWDW”DW©AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘDĐ.Dż¸D„ä.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW,DWŚDW“DWĹDXfNEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BjBqC0B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081816100818161008AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23412 DVűD×dDWż.DWżDVűDVűD×dDWDŃDVűD×dDWDŃ....Hr¬żäHrČiHr¬żäHrČi..DVűDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. D×dDŃ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWY. Normal weightA NNYYNEGDW,DW‹DWż..NEG....YNNNNYYDVű........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081817100818171008AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23413 DVűDÜČDWż.DWżDVűDVűDÜČDWŁD¨HDVűDÜČDWD× DWŽD±äDWŁD¨HHr¬ĹHHsŠČHr¬ĹHHrĹĚ HsnfäHsŠČDVűDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČD× .D±äD¨H.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW3DW‹DWŤDWżDX`NEG....YNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBđB~BpBrC0B‘8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081818100818181008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23415 DVűDŢ¨DWĹ.DWĹDVűDVűDŢ¨DWDËpDVűDŢ¨DWDËp....Hr¬Ç(HrČcpHr¬Ç(HrČcp..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DŢ¨DËp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWN. Underweight ANYYYNEGDW,DW‹DWĹ..NEG....YNNNNYYDVű........DW,DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081819100818191008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23418 DVţDŹpDWĂ.DWĂDVţDVţDŹpDW§D… DVţDŹpDWDÓ,DW’D€čDW§D… Hr°lpHsŹ/ Hr°lpHrĚ_¬Hss{čHsŹ/ DVţDWDW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹpDÓ,.D€čD… .424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNYYNEGDW/DW‹DW‘DWĂDXdNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBlBrCBŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081820100818201008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23629 DVţDŘDWĘ.DWĘDVţDVţDŘDW®DşĚDVţDŘDWD»€DW™DŔ0DW®DşĚHr°mŘHsźĚHr°mŘHrĚHHs|ő°HsźĚDVţDWDW™DW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘD»€.DŔ0DşĚ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Normal weightA NNYYNEGDW1DW‹DWDWĘDXkNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBeBrCBŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081821100818211008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23634 DVţDDWĆ.DWĆDVţDVţDDWDÓ¤DVţDDWDÓ¤....Hr°uHrÍ±¤Hr°uHrÍ±¤..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. DDÓ¤....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWK. Underweight ANNYYNEGDW/DW‹DWĆ..NEG....YNNNNYYDVţ........DW/DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081822100818221008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23635 DVţD›ÜDWĂ.DWĂDVţDVţD›ÜDWŁDŹ4DVţD›ÜDWDŐüDWŽD®ŘDWŁDŹ4Hr°xÜHs‰ó´Hr°xÜHrĚb|HsncŘHs‰ó´DVţDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. D›ÜDŐü.D®ŘDŹ4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW1DW‹DWŤDWĂDX`NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081823100818231008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23636 DVţDťDWô.DWôDVţDVţDťDWD}dDVţDťDWD}d....Hr°zHrĚ äHr°zHrĚ ä..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DťD}d....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWR. Normal weightA NNYYNEGDW6DW‹DWĂ..NEG....YNNNNYYDVţ........DW6DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBëByBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081824100818241008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23654 DVţDĄ<DWÍ.DWÍDVţDVţDĄ<DWD‡DVţDĄ<DWD‡....Hr°‚<HrĚ€Hr°‚<HrĚ€..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. DĄ<D‡....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWS. Underweight ANNYYNEGDW3DW‹DWÍ..NEG....YNNNNYYDVţ........DW3DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBëByBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081825100818251008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23656 DVţDĆ„DWľ.DWľDVţDVţDĆ„DW˘Dž4DVţDĆ„DWDŔäDWŤDĂxDW˘Dž4Hr°Ł„Hs±4Hr°Ł„HrĚMdHsm&řHs±4DVţDWDWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆ„DŔä.DĂxDž4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW2DW‹DWŚDWľDX_NEG....YNNNNYNDVţ........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBqBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081826100818261008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23659 DVţDÇěDWŮ.DWŮDVţDVţDÇěDWDż|DVţDÇěDWDż|....Hr°¤ěHrÍť|Hr°¤ěHrÍť|..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DÇěDż|....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWZ. Normal weightA NNYYNEGDW6DW‹DWĹ..NEG....YNNNNYYDVţ........DW6DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081827100818271008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23821 DVţDÔ”DWÄ.DWÄDVţDVţDÔ”DWDŃDVţDÔ”DWDŃ....Hr°±”HrĚ]Hr°±”HrĚ]..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DÔ”DŃ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Underweight ANNNYPOSDW3DW‹DWÄ..POS....YNNNNYYDVţ........DW3DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‹DWýDWýBëByBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081828100818281008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23660 DVţDŇDWÄ.DWÄDVţDVţDŇDW§DÄ,DVţDŇDWDĎlDWŽDŁ\DW§DÄ,Hr°ŻHsŹn¬Hr°ŻHrÚÜlHsnX\HsŹn¬DVţDWDWŽDW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇDĎl.DŁ\DÄ,.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW@DW‹DWŤDWÄDXdNEG....YNNNNYNDVţ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŕBnBpBrCBŽ8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081829100818291008AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙23824 DV˙D‹°DWŤ.DWŤDV˙DV˙D‹°DWDŐDV˙D‹°DWDŐ....Hr±ş0HrÍłHr±ş0HrÍł..DV˙DW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DWŤWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹°DŐ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Underweight ANNYYNEGDW0DW‹DWŃ..NEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWŤDWŤBzBxA BŹBŤ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1008 10081830100818301008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23825 DV˙DŤDWÄ.DWÄDV˙DV˙DŤDW¨DˇDV˙DŤDWDÍPDW“DĂđDW¨DˇHr±»HsťHr±»HrÎüĐHsupHsťDV˙DWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤDÍP.DĂđDˇ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Underweight ANNYYNEGDW1DW‹DW’DWÄDXeNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBéBwBkBrB˙BŤ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081831100818311008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23827 DV˙D—hDWĂ.DWĂDV˙DV˙D—hDWD{ŔDV˙D—hDWD{Ŕ....Hr±ĹčHrÍYŔHr±ĹčHrÍYŔ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW: .. D—hD{Ŕ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW:. Overweight A0NNYYNEGDW6DW‹DWĂ..NEG....YNNNNYYDV˙........DW6DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrB˙BŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081832100818321008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23986 DV˙DśDWđ.DWđDV˙DV˙DśDWD‚ŚDV˙DśDWD‚Ś....Hr±ĘHrÍ`ŚHr±ĘHrÍ`Ś..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. DśD‚Ś....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‡DWM. Obese A@YNYYNEGDW0DW†DWđ..NEG....YNNNNYYDV˙........DW0DWđYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW†DWýDWýBęBsBwB˙B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081833100818331008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23988 DV˙DšěDWż.DWżDV˙DV˙DšěDWŁD$DV˙DšěDWD‚DWŽDşĚDWŁD$Hr±ÉlHs‰ô¤Hr±ÉlHrÍ`HsnoĚHs‰ô¤DV˙DWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DšěD‚.DşĚD$.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW0DW‹DWŤDWżDX`NEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBęBxBpBrB˙BŤ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081834100818341008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙23991 DV˙D´xDWŤ.DWŤDV˙DV˙D´xDWDŃDV˙D´xDWDŃ....Hr±âřHrĎHr±âřHrĎ..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŤWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´xDŃ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW1DW‹DWŇ..NEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWŤDWŤByBwA BŹBŤ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1008 10081835100818351008AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23993 DV˙DÉDWĂ.DWĂDV˙DV˙DÉDWDŇxDV˙DÉDWDŇx....Hr±÷HrÍ°xHr±÷HrÍ°x..DV˙DW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DÉDŇx....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWY. Normal weightA NNYYNEGDW0DW‹DWĂ..NEG....YNNNNYYDV˙........DW0DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrB˙BŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081836100818361008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24088 DV˙DŇ´DWż.DWżDV˙DV˙DŇ´DWŁD–xDV˙DŇ´DWD}(DWŽD–đDWŁD–xHr˛4Hs‰úřHr˛4HrÍ[(HsnKđHs‰úřDV˙DWDWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ´D}(.D–đD–x.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW2DW‹DWŤDWżDX`NEG....YNNNNYNDV˙........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBęBxBpBrB˙BŤ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081837100818371008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24089 DV˙DÜPDWü.DWüDV˙DV˙DÜPDW¨DÁÔDV˙DÜPDWDŮDDW“DĹĐDW¨DÁÔHr˛ ĐHs˝ÔHr˛ ĐHrÍ·DHsuPHs˝ÔDV˙DWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜPDŮD.DĹĐDÁÔ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDW3DW‹DW’DWÄDXeNEG....YNNNNYNDV˙........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBęBxBkBrB˙BŤ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081838100818381008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24090 DV˙DÝ@DWĹ.DWĹDV˙DV˙DÝ@DWDŘTDV˙DÝ@DWDŘT....Hr˛ŔHrÍ¶THr˛ŔHrÍ¶T..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DÝ@DŘT....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWO. Overweight A0NNYYNEGDW3DW‹DWĹ..NEG....YNNNNYYDV˙........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrB˙BŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081839100818391008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24091 DV˙DŢ¨DWĐ.DWĐDV˙DV˙DŢ¨DWDËpDV˙DŢ¨DWDËp....Hr˛ (HrÍ©pHr˛ (HrÍ©p..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DŢ¨DËp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Normal weightA NNYYNEGDW6DW‹DWĐ..NEG....YNNNNYYDV˙........DW6DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrB˙BŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081840100818401008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24193 DWD‡đDWż.DWżDWDWD‡đDWŁDĂDWD‡đDWDŇ´DWŽDÓ¤DWŁDĂHrłđHsŠ'€HrłđHrĎ4Hsn¤HsŠ'€DWDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡đDŇ´.DÓ¤DĂ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW1DW‹DWŤDWżDX`NEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBéBwBpBrBţBŚ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081841100818411008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24195 DWDŕDWĘ.DWĘDWDWDŕDWDĘřDWDŕDWDĘř....HrłŕHrÎúxHrłŕHrÎúx..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŕDĘř....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW3DW‹DWĘ..NEG....YNNNNYYDW........DW3DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBéBwBrBţBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081842100818421008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24196 DWD‰ĐDWĹ.DWĹDWDWD‰ĐDW¨DżôDWD‰ĐDWDy¤DW“Dą DW¨DżôHrł ĐHs»ôHrł ĐHrÍW¤Hsu Hs»ôDWDWDW“DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‰ĐDy¤.Dą Dżô.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Underweight ANNYYNEGDW:DW‹DW’DWĹDXePOS....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBęBxBkBrBţBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1008 10081843100818431008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24198 DWDŽĽDWÄ.DWÄDWDWDŽĽDWDÓ¤DWDŽĽDWDÓ¤....HrłĽHrĎ$HrłĽHrĎ$..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. DŽĽDÓ¤....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWg. Normal weightA NYYYNEGDW1DW‹DWÄ..NEG....YNNNNYYDW........DW1DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBéBwBrBţBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081844100818441008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24201 DWDŹ¬DWĹ.DWĹDWDWDŹ¬DW¨D×(DWDŹ¬DWDÓŕDW“DŽDDW¨D×(Hrł¬HsÓ(Hrł¬HrĎ`HstÚÄHsÓ(DWDWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹ¬DÓŕ.DŽDD×(.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDW1DW‹DW’DWĹDXeNEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBéBwBkBrBţBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081845100818451008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24207 DWDž4DWç.DWçDWDWDž4DW§D‰DWDž4DWD|DW‘DĹXDW§D‰Hrł4HsŹ3śHrł4HrĚüHsrnŘHsŹ3śDWDWDW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4D|.DĹXD‰.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDW3DW‹DWDWĹDXdNEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBmBrBţBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081846100818461008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24212 DWD PDWĹ.DWĹDWDWD PDWD‚ČDWD PDWD‚Č....Hrł PHrĚHHrł PHrĚH..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. D PD‚Č....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWg. Normal weightA NNYYNEGDW3DW‹DWĹ..NEG....YNNNNYYDW........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBëByBrBţBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081847100818471008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24206 DWDśĚDWĹ.DWĹDWDWDśĚDWDÂÄDWDśĚDWDÂÄ....HrłĚHrÎňDHrłĚHrÎňD..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DśĚDÂÄ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWT. Obese A@YNYYNEGDW3DW‹DWĹ..NEG....YNNNNYYDW........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBéBwBrBţBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081848100818481008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24216 DWDˇôDWü.DWüDWDWDˇôDWDÔĐDWDˇôDWDÔĐ....Hrł!ôHrĐUĐHrł!ôHrĐUĐ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. DˇôDÔĐ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWd. Underweight ANNYYNEGDW3DW‹DWĆ..NEG....YNNNNYYDW........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBčBvBrBţBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081849100818491008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24219 DWDŁ\DWż.DWżDWDWDŁ\DWŁD¨DWDŁ\DWD´xDWŽDĹ”DWŁD¨Hrł#\HsŠŚHrł#\HrĐ5xHsnz”HsŠŚDWDWDWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW9BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ\D´x.DĹ”D¨.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDW9DW‹DWŤDWżDX`NEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBčBvBpBrBţBŚ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081850100818501008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24221 DWD¨HDWÉ.DWÉDWDWD¨HDWDČÜDWD¨HDWDČÜ....Hrł(HHrĐIÜHrł(HHrĐIÜ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. D¨HDČÜ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWVDWH. Normal weightA NYYYNEGDW7DWUDWÉ..NEG....YNNNNYYDW........DW7DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWUDWýDWýBčB@B¨BţBV8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1008 10081851100818511008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24222 DWD˛ÔDWĂ.DWĂDWDWD˛ÔDW§D‚ČDWD˛ÔDWDą DW’D€4DW§D‚ČHrł2ÔHsŹ-HHrł2ÔHrŃŚ Hss{4HsŹ-HDWDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ÔDą .D€4D‚Č.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW9DW‹DW‘DWĂDXdNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBçBuBlBrBţBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081852100818521008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24249 DWDłÄDWĂ.DWĂDWDWDłÄDW§D@DWDłÄDWDşĚDW’D€¬DW§D@Hrł3ÄHsŹ-ŔHrł3ÄHrŃŤLHss{¬HsŹ-ŔDWDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DłÄDşĚ.D€¬D@.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Overweight A0YNYYNEGDW9DW‹DW‘DWĂDXdNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBçBuBlBrBţBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081853100818531008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24250 DWDŘDWĂ.DWĂDWDWDŘDW¦DÁ DWDŘDWD‡đDW‘DÄhDW¦DÁ Hrą¨XHsŽ Hrą¨XHrŐNđHsrmčHsŽ DWDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘD‡đ.DÄhDÁ .424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDW6DW‹DWDWĂDXcNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBmBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081854100818541008AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24253 DWD›ÜDWĆ.DWĆDWDWD›ÜDWD‹tDWD›ÜDWD‹t....Hrął\HrŐRtHrął\HrŐRt..DWDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. D›ÜD‹t....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWV. Underweight ANNYYNEGDW6DW‹DWĆ..NEG....YNNNNYYDW........DW6DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081855100818551008AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24257 DWD ČDW×.DW×DWDWD ČDWDŇDWD ČDWDŇ....Hrą¸HHrŐ™Hrą¸HHrŐ™..DWDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW: .. D ČDŇ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW:. Normal weightA NNYYNEGDW:DW‹DW×..NEG....YNNNNYYDW........DW:DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081856100818561008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24395 DWDŁÔDWß.DWßDWDWDŁÔDW¨DŽĽDWDŁÔDWD†LDW“DĘ€DW¨DŽĽHrą»THsŠĽHrą»THrŐMLHsuHsŠĽDWDWDW“DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁÔD†L.DĘ€DŽĽ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDW:DW‹DW’DWĹDXeNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBkBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081857100818571008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24396 DWDÓ¤DWĘ.DWĘDWDWDÓ¤DWD×ÜDWDÓ¤DWD×Ü....Hrąë$HrÖđ\Hrąë$HrÖđ\..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DÓ¤D×Ü....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWV. Underweight ANNYYNEGDW7DW‹DWĘ..NEG....YNNNNYYDW........DW7DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081858100818581008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24397 DWDŇđDWü.DWüDWDWDŇđDWKDĐDWDŇđDWD× DW8D±lDWKDĐHrąępHs1HrąępHrÖđ HrýlHs1DWDWDW8DWKAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇđD× .D±lDĐ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW7DW8. Normal weightA NNYYNEGDW6DW6DW7DWiDWüNEG....YNNNNYNDW........DW7.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW6DWýDWýBăBBĆBÇBůB28-9 months A1-2 months A 7-8 monthsA€8-9 months A . ...C4591001C4591001 1008 10081859100818591008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24402 DWDŐHDWÉ.DWÉDWDWDŐHDWDĄ´DWDŐHDWDĄ´....HrąěČHrŐl´HrąěČHrŐl´..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW: .. DŐHDĄ´....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW:. Normal weightA NNYYNEGDW:DW‹DWÉ..NEG....YNNNNYYDW........DW:DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081860100818601008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24465 DWDÖ°DWĐ..DWDWDÖ°DWDĆDWDÖ°DWDĆ....Hrąî0HrŐŤHrąî0HrŐŤ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DÖ°DĆ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWH. Normal weightA NYYYNEGDW6DW‹DWĐ..NEG....YNNNNYYDW........DW6DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081861100818611008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24469 DWD’|DW˝.DW˝DWDWD’|DWˇDĹXDWD’|DWD«DWŽDÍDWˇDĹXHrşű|Hs‡†ŘHrşű|HrŐrHsn‚Hs‡†ŘDWDWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. D’|D«.DÍDĹX.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW8DW‹DWŤDW˝DX^NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBpBrBřB†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081862100818621008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24471 DWDž4DWâ.DWâDWDWDž4DWDŹpDWDž4DWDŹp....Hr»4Hr×ůpHr»4Hr×ůp..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dž4DŹp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW8DW‹DWâ..NEG....YNNNNYYDW........DW8DWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081863100818631008AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24472 DWD PDWĂ.DWĂDWDWD PDW¦D‰XDWD PDWDťřDW‘D‰ĐDW¦D‰XHr» PHsŤâXHr» PHrŐdřHsr3PHsŤâXDWDWDW‘DW¦AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. D PDťř.D‰ĐD‰X.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDW7DW‹DWDWĂDXcNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBmBrBřB†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081864100818641008AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24639 DWDˇ|DW×.DW×DWDWDˇ|DWDť€DWDˇ|DWDť€....Hr» |HrŐd€Hr» |HrŐd€..DWDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. Dˇ|Dť€....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWS. Underweight ANNYYNEGDW7DW‹DW×..NEG....YNNNNYYDW........DW7DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ..DW§C4591001C4591001 1008 10081865100818651008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24641 DWD˘äDWĺ.DWĺDWDWD˘äDWDĐDWD˘äDWDĐ....Hr»äHrÖéHr»äHrÖé..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. D˘äDĐ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW>. Normal weightA NYYYNEGDW7DW‹DWĘ..NEG....YNNNNYYDW........DW7DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081866100818661008AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24644 DWDĎäDWż.DWżDWDWDĎäDWŁD‰ĐDWDĎäDWD´DWŽDŘDWŁD‰ĐHr»8äHs‰îPHr»8äHrŐ{HsnEŘHs‰îPDWDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĎäD´.DŘD‰Đ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW8DW‹DWŤDWżDX`NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBpBrBřB†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081867100818671008AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24642 DWDĐÔDWÓ.DWÓDWDWDĐÔDWŁDŠDWDĐÔDWD´´DWŽD‘ČDWŁDŠHr»9ÔHs‰îŚHr»9ÔHrŐ{´HsnFČHs‰îŚDWDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐÔD´´.D‘ČDŠ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW8DW‹DWŤDWżDX`NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBäBrBpBrBřB†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081868100818681008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24765 DWDŇDWË.DWËDWDWDŇDWDÁÔDWDŇDWDÁÔ....Hr»;HrÖÚTHr»;HrÖÚT..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DŇDÁÔ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Normal weightA NNYYNEGDW8DW‹DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081869100818691008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24766 DWDŐüDW˝.DW˝DWDWDŐüDWˇDˇ¸DWDŐüDWD|tDWŽD”ÔDWˇDˇ¸Hr»>üHs‡c8Hr»>üHrÖ”ôHsnIÔHs‡c8DWDWDWŽDWˇAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW9BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐüD|t.D”ÔDˇ¸.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW9DW‹DWŤDW˝DX^NEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBpBrBřB†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081870100818701008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24775 DWDÚ¬DWĆ.DWĆDWDWDÚ¬DWD¬€DWDÚ¬DWD¬€....Hr»C¬HrŐs€Hr»C¬HrŐs€..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DÚ¬D¬€....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Normal weightA NNYYNEGDW9DW‹DWĆ..NEG....YNNNNYYDW........DW9DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081871100818711008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24776 DWD–DWż.DWżDWDWD–DW˘D»DDWD–DWD–DWŤDĎ0DW˘D»DHrĽP€HsÎDHrĽP€HrĽP€Hsm2°HsÎDDW.DWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. DWTOTHER Placebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–..DĎ0D»D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NYYYNEGDWTDW‹DWŚDWżDX_POS....YNNNNYNDW........DWT.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW‹DWýDWýBqBrB÷B…0-1 month A0-1 month A4-5 monthsAP8-9 months A . ..DWC4591001C4591001 1008 10081872100818721008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24885 DWDť€DW .DW DWDWDť€DW~DĐÔDWDť€DWDĚ$DWkDŃÄDW~DĐÔHrĽXHsYmÔHrĽXHrÚŮ$Hs@bDHsYmÔDWDWDWkDW~AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dť€DĚ$.DŃÄDĐÔ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWiDWk. Underweight ANNYYNEGDW:DWhDWjDW DX;NEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWhDWýDWýBŕBKB“B•B÷Bb8-9 months A2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1008 10081873100818731008AĐYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24891 DWDžpDWŰ.DWŰDWDWDžpDWDDWDžpDWD....HrĽXđHrŐJHrĽXđHrŐJ..DWDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DžpD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Overweight A0NNYYNEGDW9DW‹DWŰ..NEG....YNNNNYYDW........DW9DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBäBrBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081874100818741008AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24895 DWDĄ<DWË.DWËDWDWDĄ<DWDŘDWDĄ<DWDŘ....HrĽ_ĽHr×úŘHrĽ_ĽHr×úŘ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DĄ<DŘ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWE. Overweight A0YNYYNEGDW8DW‹DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081875100818751008AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24893 DWD¦,DWľ.DWľDWDWD¦,DW˘D$DWD¦,DWDśDWŤD¸DW˘D$HrĽ`¬Hs”$HrĽ`¬Hr×úśHslç8Hs”$DWDWDWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¦,Dś.D¸D$.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW8DW‹DWŚDWľDX_NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpBqBrB÷B…8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081876100818761008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24982 DWDĘDWŇ..DWDWDĘDWD»DDWDĘDWD»D....HrĽ„HrŘ%DHrĽ„HrŘ%D..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DĘD»D....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Underweight ANNYYNEGDW?DW‹DWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081877100818771008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24983 DWDÍPDWÄ.DWÄDWDWDÍPDW¦D˝$DWDÍPDWDĚŘDW‘DĂ´DW¦D˝$HrĽ‡ĐHsŽ$HrĽ‡ĐHrŘ6ŘHsrm4HsŽ$DWDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍPDĚŘ.DĂ´D˝$.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDW?DW‹DWDWÄDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpBmBrB÷B…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081878100818781008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24984 DWDÎ¸DWÍ.DWÍDWDWDÎ¸DWDĚ$DWDÎ¸DWDĚ$....HrĽ‰8HrŘ6$HrĽ‰8HrŘ6$..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DÎ¸DĚ$....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW8. Normal weightA NNYYNEGDW8DW‹DWÍ..NEG....YNNNNYYDW........DW8DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081879100818791008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24989 DWDĎäDWÍ.DWÍDWDWDĎäDWD—ŕDWDĎäDWD—ŕ....HrĽŠdHrŘŕHrĽŠdHrŘŕ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DĎäD—ŕ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDW8. Overweight A0YNYYNEGDW8DW‹DWÍ..NEGDW•.DW•DW•YNNNNYYDW........DW8DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpBrB÷B…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1008 10081880100818801008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25011 DWDÔĐDWĂ.DWĂDWDWDÔĐDW§DË4DWDÔĐDWDÓhDW’DÓŕDW§DË4HrĽŹPHsŹu´HrĽŹPHrÖëčHssÎŕHsŹu´DWDWDW’DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔĐDÓh.DÓŕDË4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNYYNEGDW9DW‹DW‘DWĂDXdNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrB÷B…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081881100818811008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25009 DWDŐŔDWĂ.DWĂDWDWDŐŔDW§DËpDWDŐŔDWDÔ”DW’DÔXDW§DËpHrĽ@HsŹuđHrĽ@HrÖíHssĎXHsŹuđDWDWDW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐŔDÔ”.DÔXDËp.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Underweight ANNYYNEGDW9DW‹DW‘DWĂDXdNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBlBrB÷B…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081882100818821008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25012 DWDXDWě.DWěDWDWDXDWDŇđDWDXDWDŇđ....Hr˝¤XHrŮŽpHr˝¤XHrŮŽp..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DXDŇđ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW9DW‹DWě..NEG....YNNNNYYDW........DW9DWěYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBáBoBrBöB„8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081883100818831008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25016 DWD™„DWÍ.DWÍDWDWD™„DWDŇ<DWD™„DWDŇ<....Hr˝Ą„HrŮŤĽHr˝Ą„HrŮŤĽ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. D™„DŇ<....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‹DW@. Normal weightA NNYYNEGDW@DWŠDWÍ..NEG....YNNNNYYDW........DW@DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŠDWýDWýBáBnBsBöB8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081884100818841008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25114 DWDˇ¸DWĆ.DWĆDWDWDˇ¸DW˘DąÜDWDˇ¸DWDˇ¸DWŤDć(DW˘DąÜHr˝¸HsĚÜHr˝¸Hr˝¸HsmI¨HsĚÜDW.DWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. DWVOTHER Placebo ANNYY NN DWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ¸..Dć(DąÜ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Obese A@YNYYNEGDWVDW‹DWŚDWĆDX_POS....YNNNNYNDW........DWV.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW‹DWýDWýBqBrBöB„0-1 month A0-1 month A4-5 monthsAP8-9 months A . ..DWC4591001C4591001 1008 10081885100818851008AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25116 DWD¦¤DWÚ.DWÚDWDWD¦¤DWD‰DWD¦¤DWD‰....Hr˝˛¤HrŮDśHr˝˛¤HrŮDś..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. D¦¤D‰....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Underweight ANNYYNEGDW9DW‹DWŇ..NEG....YNNNNYYDW........DW9DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBáBoBrBöB„8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081886100818861008AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25115 DWD§XDWŇ.DWŇDWDWD§XDWD‰ĐDWD§XDWD‰Đ....Hr˝łXHrŮEPHr˝łXHrŮEP..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. D§XD‰Đ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Underweight ANNYYNEGDW9DW‹DWŇ..NEG....YNNNNYYDW........DW9DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBáBoBrBöB„8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081887100818871008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25121 DWD“äDWľ.DWľDWDWD“äDW˘D€4DWD“äDW!DÁ\DWŤDčDW˘D€4HrÂĺäHs“4HrÂĺäHrŢÂÜHsmKHs“4DWDW!DWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D“äDÁ\.DčD€4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW=DW‹DWŚDWľDX_NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBqBrBňB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081888100818881008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25161 DWD–DWľ.DWľDWDWD–DW˘DĆDWD–DW!DŃÄDWŤDçTDW˘DĆHrÂčHsŮHrÂčHrŢÓDHsmJÔHsŮDWDW!DWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–DŃÄ.DçTDĆ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW=DW‹DWŚDWľDX_NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBqBrBňB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081889100818891008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25163 DWD PDW×.DW×DWDWD PDW!D€pDWD PDW!D€p....HrÂňPHrŢđHrÂňPHrŢđ..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. D PD€p....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Normal weightA NNYYNEGDW=DW‹DW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081890100818901008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25164 DWDźśDW×.DW×DWDWDźśDW!D} DWDźśDW!D} ....HrÂńśHrŢ HrÂńśHrŢ ..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DźśD} ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Overweight A0YNYYNEGDW=DW‹DW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081891100818911008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25172 DWDˇôDWĂ.DWĂDWDWDˇôDW§D|8DWDˇôDW!D`DW’D€4DW§D|8HrÂóôHsŹ&¸HrÂóôHrŢ‚ŕHss{4HsŹ&¸DWDW!DW’DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DˇôD`.D€4D|8.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW=DW‹DW‘DWĂDXdNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBlBrBňB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DW’C4591001C4591001 1008 10081892100818921008AŕYEARSMAAMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25245 DWDĚ`DWĘ.DWĘDWDWDĚ`DW®D|8DWDĚ`DW!DĐDW™D~DW®D|8HrĂ`Hsa8HrĂ`HrŢŇHs|´Hsa8DWDW!DW™DW®AŕYEARSAŕYEARS12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĚ`DĐ.D~D|8.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW™. Overweight A0NNYYNEGDW=DW‹DWDWĘDXkNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBeBrBňB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081893100818931008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25248 DWDÍŚDW×.DW×DWDWDÍŚDW!DČdDWDÍŚDW!DČd....HrĂŚHrŢÉäHrĂŚHrŢÉä..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DÍŚDČd....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Overweight A0NYYYNEGDW=DW‹DW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081894100818941008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25250 DWD×ÜDWŇ.DWŇDWDWD×ÜDW#DŽDWD×ÜDW#DŽ....HrĂ)ÜHrá2HrĂ)ÜHrá2..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. D×ÜDŽ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWh. Normal weightA NNYYNEGDWEDW‹DWŇ..NEG....YNNNNYYDW........DWEDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŰBiBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081895100818951008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25269 DWDŮ€DWĐ.DWĐDWDWDŮ€DW!DĎlDWDŮ€DW!DĎl....HrĂ+€HrŢĐěHrĂ+€HrŢĐě..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DŮ€DĎl....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Underweight ANNYYNEGDW=DW‹DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÝBkBrBňB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081896100818961008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25256 DWDŮDWĂ.DWĂDWDWDŮDWŁD¶XDWDŮDW!DÎôDWŽDČÜDWŁD¶XHrĂ+HsŠŘHrĂ+HrŢĐtHsn}ÜHsŠŘDWDW!DWŽDWŁAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDÎô.DČÜD¶X.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW=DW‹DWŤDWĂDX`NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBpBrBňB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081897100818971008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25273 DW D™HDWú.DWúDW DW D™HDW"DŚ DW D™HDW"DŚ ....HrÄ<ČHrßß HrÄ<ČHrßß ..DW DW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. D™HDŚ ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Underweight ANNYYNEGDWDDW‹DWÔ..NEG....YNNNNYYDW ........DWDDWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081898100818981008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25279 DW D›ÜDWľ.DWľDW DW D›ÜDWˇDż@DW D›ÜDW!D‡xDWŤD$DWˇDż@HrÄ?\Hs‡€ŔHrÄ?\HrŢřHslä¤Hs‡€ŔDW DW!DWŤDWˇAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D›ÜD‡x.D$Dż@.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW?DW‹DWŚDWľDX^NEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÝBkBqBrBńB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081899100818991008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25274 DW DśTDWľ.DWľDW DW DśTDWˇDżDW DśTDW!D‡đDWŤDŘDWˇDżHrÄ?ÔHs‡€„HrÄ?ÔHrŢ‰pHslĺXHs‡€„DW DW!DWŤDWˇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśTD‡đ.DŘDż.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNNYPOSDW?DW‹DWŚDWľDX^POS....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBÝBkBqBrBńB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081900100819001008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25509 DW DĎ0DWç.DWçDW DW DĎ0DW"DĐ DW DĎ0DW"DĐ ....HrÄr°Hrŕ# HrÄr°Hrŕ# ..DW DW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DĎ0DĐ ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW>. Overweight A0NNYYNEGDW>DW‹DWŃ..NEG....YNNNNYYDW ........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081901100819011008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25516 DW DĐDWű.DWűDW DW DĐDWKDĹXDW DĐDW"DŃLDW6Dš8DWKDĹXHrÄtHs%ŘHrÄtHrŕ$LHrúK8Hs%ŘDW DW"DW6DWKAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. DW3OTHER Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐDŃL.Dš8DĹX.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW3DW6. Overweight A0YNYYNEGDW2DW2DW5DWgDWű ....YNNNNNNDW ..........YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW2DWýDWýBÜBBČBËBńB&7-8 months A€0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1008 10081902100819021008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25518 DW DÓhDWľ.DWľDW DW DÓhDW˘DŇ<DW DÓhDW"DÂDWŤDä„DW˘DŇ<HrÄvčHsĺ<HrÄvčHrŕHsmHHsĺ<DW DW"DWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓhDÂ.Dä„DŇ<.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW>DW‹DWŚDWľDX_NEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÜBjBqBrBńB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081903100819031008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25520 DW DÔ”DWÍ.DWÍDW DW DÔ”DW"DŠHDW DÔ”DW"DŠH....HrÄxHrßÝHHrÄxHrßÝH..DW DW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DÔ”DŠH....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW@. Underweight ANNYYNEGDW>DW‹DWÍ..NEG....YNNNNYYDW ........DW>DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081904100819041008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25549 DW DŘĚDWľ.DWľDW DW DŘĚDW˘DÇěDW DŘĚDW"DÄŕDWŤDŰ$DW˘DÇěHrÄ|LHsÚěHrÄ|LHrŕŕHsm>¤HsÚěDW DW"DWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘĚDÄŕ.DŰ$DÇě.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Overweight A0YYYYNEGDW@DW‹DWŚDWľDX_NEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÜBjBqBrBńB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081905100819051008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25552 DWD“0DWÚ.DWÚDWDWD“0DW%DĚśDWD“0DW%DĚś....HrĹ0HräHrĹ0Hrä..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D“0DĚś....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWF. Underweight ANNYYNEGDWFDW‹DWÚ..NEG....YNNNNYYDW........DWFDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081906100819061008AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25555 DWDš8DWŇ.DWŇDWDWDš8DW#D•LDWDš8DW#D•L....HrĹŹ8Hrá9ĚHrĹŹ8Hrá9Ě..DWDW#..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. Dš8D•L....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWF. Normal weightA NNYYNEGDWFDW‹DWŇ..NEG....YNNNNYYDW........DWFDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŰBiBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081907100819071008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25556 DWDźŘDWż.DWżDWDWDźŘDWŁDĆDWDźŘDW#D‘ČDWŽDĚ$DWŁDĆHrĹ”ŘHsŠ*ŚHrĹ”ŘHrá6HHsn$HsŠ*ŚDWDW#DWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DźŘD‘Č.DĚ$DĆ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNNYPOSDW?DW‹DWŤDWżDX`POS....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBŰBiBpBrBđB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081908100819081008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25689 DWDžčDWŇ.DWŇDWDWDžčDW#D‘PDWDžčDW#D‘P....HrĹ“čHrá5ĐHrĹ“čHrá5Đ..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DžčD‘P....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Normal weightA NNYYNEGDW?DW‹DWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŰBiBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081909100819091008AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25690 DWDˇ@DWÄ.DWÄDWDWDˇ@DW¦D©ěDWDˇ@DW#DŃDW“DĆŔDW¦D©ěHrĹ–@HsŽěHrĹ–@HráuHsu@HsŽěDWDW#DW“DW¦AŕYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ@DŃ.DĆŔD©ě.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDWADW‹DW’DWÄDXcNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBkBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081910100819101008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25691 DWDĎ¨DWŮ.DWŮDWDWDĎ¨DW#D»ĽDWDĎ¨DW#D»Ľ....HrĹÄ¨Hrá`<HrĹÄ¨Hrá`<..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DĎ¨D»Ľ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW?. Normal weightA NNYYNEGDW?DW‹DWŮ..NEG....YNNNNYYDW........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŰBiBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081911100819111008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25695 DWDŃDWż.DWżDWDWDŃDWŁD‰DWDŃDW$D—¤DWŽDŹčDWŁD‰HrĹĆHs‰íśHrĹĆHrâŤ¤HsnDčHs‰íśDWDW$DWŽDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃD—¤.DŹčD‰.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDWADW‹DWŤDWżDX`NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBpBrBđB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081912100819121008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25818 DWDÚ4DWŢ.DWŢDWDWDÚ4DW$DÓ,DWDÚ4DW$DÓ,....HrĹĎ4HrâÉ,HrĹĎ4HrâÉ,..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DÚ4DÓ,....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWA. Normal weightA NNYYNEGDWADW‹DWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081913100819131008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25816 DWD× DWĂ.DWĂDWDWD× DW¦Dż|DWD× DW$DÎ@DW‘DŠ„DW¦Dż|HrĹĚ HsŽ|HrĹĚ HrâÄ@Hsr4HsŽ|DWDW$DW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D× DÎ@.DŠ„Dż|.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDWADW‹DWDWĂDXcNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBmBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081914100819141008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25817 DWDÖtDW˝.DW˝DWDWDÖtDWˇDľDWDÖtDW3DťřDWŤDÜDWˇDľHrĹËtHs‡”HrĹËtHröZxHsm?”Hs‡”DWDW3DWŤDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖtDťř.DÜDľ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Obese A@YYYYNEGDWODW‹DWŚDW˝DX^NEG....YNNNNYNDW........DWO.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBËBYBqBrBđB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081915100819151008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25820 DWD™üDWÓ.DWÓDWDWD™üDW$D’|DWD™üDW$D’|....HrĆŕ|Hrâ|HrĆŕ|Hrâ|..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D™üD’|....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Overweight A0NYYYNEGDW@DW‹DWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBďB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081916100819161008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25929 DWDťĽDWÓ.DWÓDWDWDťĽDW$DÍDWDťĽDW$DÍ....HrĆä<HrâĂHrĆä<HrâĂ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DťĽDÍ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW@. Overweight A0NNYYNEGDW@DW‹DWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBďB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081917100819171008AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25931 DWDśDWĆ.DWĆDWDWDśDW©D{„DWDśDW$DĚ`DW“DŹ4DW©D{„HrĆâHs‘ÉHrĆâHrâÂ`HstŰ´Hs‘ÉDWDW$DW“DW©AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśDĚ`.DŹ4D{„.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNNYPOSDW@DW‹DW’DWĆDXfPOS....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBÚBhBkBrBďB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081918100819181008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25933 DWDĎlDWÓ.DWÓDWDWDĎlDW$DĆ„DWDĎlDW$DĆ„....HrÇěHrâĽ„HrÇěHrâĽ„..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DĎlDĆ„....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW@. Underweight ANNYYNEGDW@DW‹DWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBďB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081919100819191008AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25937 DWDŇ<DWĹ.DWĹDWDWDŇ<DW©D»ĽDWDŇ<DW%DĐÔDW“DĂ<DW©D»ĽHrÇĽHs’ <HrÇĽHräTHsuĽHs’ <DWDW%DW“DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ<DĐÔ.DĂ<D»Ľ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDWADW‹DW’DWĹDXfNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŮBgBkBrBďB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DW~C4591001C4591001 1008 10081920100819201008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26085 DWDÖěDW×.DW×DWDWDÖěDW$DÄŕDWDÖěDW$DÄŕ....HrÇlHrâşŕHrÇlHrâşŕ..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DÖěDÄŕ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Normal weightA NNYYNEGDWDDW‹DW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBďB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081921100819211008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26087 DWDÜČDWÉ.DWÉDWDWDÜČDW‘DÍŚDWDÜČDW%DĎ¨DW|DŔlDW‘DÍŚHrÇ#HHsrwHrÇ#HHrä(HsVşlHsrwDWDW%DW|DW‘AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDĎ¨.DŔlDÍŚ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWyDW|. Normal weightA NNYYNEGDWEDWxDW{DWDXNNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWxDWýDWýBŮBTB‚B…BďBj7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081922100819221008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26089 DWD“0DWÔ.DWÔDWDWD“0DW%DÎ¸DWD“0DW%DÎ¸....HrČ+0Hrä8HrČ+0Hrä8..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D“0DÎ¸....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWADW‹DWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081923100819231008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26091 DWD•DWľ.DWľDWDWD•DW˘D¤ÄDWD•DW%D‡xDWŤDÄ¤DW˘D¤ÄHrČ-Hs·ÄHrČ-HrăÎřHsm($Hs·ÄDWDW%DWŤDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D•D‡x.DÄ¤D¤Ä.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNNYPOSDWADW‹DWŚDWľDX_POS....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBŮBgBqBrBîB|7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081924100819241008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26205 DWDDWĂ.DWĂDWDWDDWŁD§XDWDDW%D‹ěDWŽD“¨DWŁD§XHrČ0HsŠŘHrČ0HrăÓlHsnH¨HsŠŘDWDW%DWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DD‹ě.D“¨D§X.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDWADW‹DWŤDWĂDX`NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŮBgBpBrBîB|7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081925100819251008AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26209 DWDˇDWŮ.DWŮDWDWDˇDW%DŇ<DWDˇDW%DŇ<....HrČ9HräĽHrČ9HräĽ..DWDW%..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DˇDŇ<....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDWADW‹DWŮ..NEG....YNNNNYYDW........DWADWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081926100819261008AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26216 DWDŐüDWÄ.DWÄDWDWDŐüDWŁDÁÔDWDŐüDW%D»řDWŽDÎDWŁDÁÔHrČmüHsŠ&THrČmüHräxHsnHsŠ&TDWDW%DWŽDWŁAŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐüD»ř.DÎDÁÔ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDWADW‹DWŤDWÄDX`NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŮBgBpBrBîB|7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081927100819271008AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26211 DWDĎ0DWŢ.DWŢDWDWDĎ0DW%D»DWDĎ0DW%D»....HrČg0HräHrČg0Hrä..DWDW%..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DĎ0D»....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWF. Underweight ANNYYNEGDWADW‹DWŢ..NEG....YNNNNYYDW........DWADWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081928100819281008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26362 DWDŘTDWŰ.DWŰDWDWDŘTDW%DĘřDWDŘTDW%DĘř....HrČpTHräxHrČpTHräx..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DŘTDĘř....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW9. Overweight A0YNYYNEGDWADW‹DWŰ..NEG....YNNNNYYDW........DWADWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081929100819291008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26366 DWDŰśDWŘ.DWŘDWDWDŰśDW%DÍŚDWDŰśDW%DÍŚ....HrČsśHräHrČsśHrä..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DŰśDÍŚ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWE. Underweight ANNYYNEGDWEDW‹DWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081930100819301008AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26368 DWD–<DWĂ.DWĂDWDWD–<DWŁD§ĐDWD–<DW(D©8DWŤDĹXDWŁD§ĐHrĚ"ĽHsŠPHrĚ"ĽHrçĺ8Hsm(ŘHsŠPDWDW(DWŤDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. D–<D©8.DĹXD§Đ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANYYYNEGDWDDW‹DWŚDWĂDX`NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBqBrBëBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081931100819311008AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26369 DWD—ŕDWÉ.DWÉDWDWD—ŕDW¨DŚÜDWD—ŕDW(DśDW“DŽ€DW¨DŚÜHrĚ$`HsÜHrĚ$`Hrç˝śHstŰHsÜDWDW(DW“DW¨AŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D—ŕDś.DŽ€DŚÜ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NYYYNEGDWDDW‹DW’DWÉDXeNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBkBrBëBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081932100819321008AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26579 DWDĐDWÄ.DWÄDWDWDĐDW¨DŤTDWDĐDW(D`DW“DŽDW¨DŤTHrĚ%PHs‰THrĚ%PHrç˝`HstÚHs‰TDWDW(DW“DW¨AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐD`.DŽDŤT.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Normal weightA NNYYNEGDWDDW‹DW’DWÄDXeNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBkBrBëBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081933100819331008AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26580 DWDÂLDWĂ.DWĂDWDWDÂLDW¦DĆ„DWDÂLDW)DÉDW‘DĚ`DW¦DĆ„HrĚNĚHsŽ„HrĚNĚHréVHsruŕHsŽ„DWDW)DW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂLDÉ.DĚ`DĆ„.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Underweight ANNYYNEGDWEDW‹DWDWĂDXcNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŐBcBmBrBëBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081934100819341008AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26587 DWDË4DWŘ.DWŘDWDWDË4DW(DŃDWDË4DW(DŃ....HrĚW´Hrč HrĚW´Hrč ..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DË4DŃ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Underweight ANNNYPOSDWDDW‹DWŘ..POS....YNNNNYYDW........DWDDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‹DWýDWýBÖBdBrBëBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081935100819351008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26588 DWDŇ<DWé.DWéDWDWDŇ<DW*DČ(DWDŇ<DW*DČ(....HrĚ^ĽHrę§(HrĚ^ĽHrę§(..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇ<DČ(....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWF.. Overweight A0NNYYNEGDWEDWEDWé..NEG....YNNNNYYDW........DWFDWéYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDWEDWýDWýBÔBB¸BëB37-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1008 10081936100819361008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26687 DWDÔXDW˝.DW˝DWDWDÔXDWˇDŤDWDÔXDW(DĚ`DWŽD–DWˇDŤHrĚ`ŘHs‡OHrĚ`ŘHrč`HsnKHs‡ODWDW(DWŽDWˇAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔXDĚ`.D–DŤ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDWDDW‹DWŤDW˝DX^NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBpBrBëBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081937100819371008AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26689 DWDŮDDW×.DW×DWDWDŮDDW(DĐ\DWDŮDDW(DĐ\....HrĚeÄHrč\HrĚeÄHrč\..DWDW(..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DŮDDĐ\....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWD. Normal weightA NNYYNEGDWDDW‹DW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÖBdBrBëBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081938100819381008AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26690 DWDŰ`DWĂ.DWĂDWDWDŰ`DW¦D DWDŰ`DW)DĚśDW‘DŠüDW¦D HrĚgŕHsŤůHrĚgŕHréZHsr4|HsŤůDWDW)DW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWHBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰ`DĚś.DŠüD .424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDWEDW‹DWDWĂDXcNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŐBcBmBrBëBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1008 10081940100819401008AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26693 DWD¦,DWŘ.DWŘDWDWD¦,DW)D…DWD¦,DW)D…....HrÍ„,HréHrÍ„,Hré..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. D¦,D…....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWE. Normal weightA NYYYNEGDWEDW‹DWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŐBcBrBęBx7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1008 10081941100819411008AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26877 DWDĚŘDWż.DWżDWDWDĚŘDWŁDĂđDWDĚŘDW)DË4DWŽDĆ„DWŁDĂđHrÍŞŘHsŠ(pHrÍŞŘHréX´Hsn{„HsŠ(pDWDW)DWŽDWŁAŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĚŘDË4.DĆ„DĂđ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANYYYNEGDWEDW‹DWŤDWżDX`NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŐBcBpBrBęBx7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081942100819421008AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26879 DWDÍDWż.DWżDWDWDÍDWŁDĂxDWDÍDW)DË¬DWŽDĆüDWŁDĂxHrÍ«HsŠ'řHrÍ«HréY,Hsn{üHsŠ'řDWDW)DWŽDWŁAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍDË¬.DĆüDĂx.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NYYYNEGDWEDW‹DWŤDWżDX`NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŐBcBpBrBęBx7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1008 10081943100819431008AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26880 DWDÎ@DWŕ.DWŕDWDWDÎ@DW)DŇ´DWDÎ@DW)DŇ´....HrÍ¬@Hré`4HrÍ¬@Hré`4..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DÎ@DŇ´....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWF. Normal weightA NNYYNEGDWFDW‹DWŕ..NEG....YNNNNYYDW........DWFDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŐBcBrBęBx7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091204100912041009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20017 DV»DŽřDWó..DV»DV»DŽřDWóDßDV»DŽřDVÎDŮřDWŢDáđDWóDßHrXxHsóĽHrXxHrqnřHsŘđHsóĽDV»DVÎDWŢDWóAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽřDŮř.DáđDß.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDWŢ. Underweight ANNYYNEGDVěDW€DW€DXDX°NEG....YNNNNYYDV»........DVěDW€YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW—DWýDWýCBĘB BfC0BÝ10-11 monthsA°7-8 months A€1-2 monthsA 11-12 monthsAŔ . ...C4591001C4591001 1009 10091205100912051009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20018 DV»D¶XDW©.DW©DV»DV»D¶XDVŃDëŚDV»D¶XDVŃDëŚ....HrX>ŘHruuHrX>ŘHruu..DV»DVŃ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. D¶XDëŚ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW„DWV. Normal weightA NNYYNEGDVíDW€DW€..NEG....YNNNNYYDV»........DVíDW€YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCĐBłBzC0BÉ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091208100912081009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20020 DV»DĽpDWy..DV»DV»DĽpDW\DáxDV»DĽpDVŃDŤDWHD¬DDW\DáxHrXDđHs,«xHrXDđHruHsDHs,«xDV»DVŃDWHDW\AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽpDŤ.D¬DDáx.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWH. Underweight ANNYYNEGDVíDW<DWGDWyDXNEG....YNNNNYNDV»........DVí.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýCĐBlB¶BÁC0B‚10-11 monthsA°3-4 months A@6-7 monthsAp11-12 monthsAŔ . ..DWC4591001C4591001 1009 10091209100912091009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20022 DV»Dí0DW•.DW•DV»DV»Dí0DVĎDćÜDV»Dí0DVĎDćÜ....HrXu°HrrÍ\HrXu°HrrÍ\..DV»DVĎ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. Dí0DćÜ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DW[. Normal weightA NNYYNEGDVëDW~DW~..NEG....YNNNNYYDV»........DVëDW~YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýCđBĆBiC0BÚ10-11 monthsA°7-8 months A€0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091212100912121009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20061 DVĽD‰DWĹ.DWĹDVĽDVĽD‰DW©DŮĽDVĽD‰DVŰDé4DW•D©ěDW©DŮĽHrYcHs’'<HrYcHr‚ˇ´Hsw™lHs’'<DVĽDVŰDW•DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‰Dé4.D©ěDŮĽ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Underweight ANNYYNEGDVűDWŤDW”DWĹDXfNEG....YNNNNYNDVĽ........DVű.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýC0BłBiBpC BŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1009 10091213100912131009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20062 DVĽD‘ŚDWr..DVĽDVĽD‘ŚDWSDĽDVĽD‘ŚDVĎD× DW=DÝ¸DWSDĽHrYkŚHs l<HrYkŚHrrľ HsÉ8Hs l<DVĽDVĎDW=DWSAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‘ŚD× .DÝ¸DĽ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW7DW=. Underweight ANNYYNEGDVůDW6DW<DWrDXPOS....YNNNNYNDVĽ........DVů.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW6DWýDWýCđBhBÁBÇC B{10-11 monthsA°3-4 months A@6-7 monthsAp11-12 monthsAŔ . ..DVëC4591001C4591001 1009 10091216100912161009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVĽ20067 DVĽD¨HDWŽ.DWŽDVĽDVĽD¨HDVŃDŁDVĽD¨HDVŃDŁ....HrY‚HHru-HrY‚HHru-..DVĽDVŃ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨HDŁ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDVíDW‡DW‡..NEG....YNNNNYYDVĽ........DVíDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýCĐB˝BpC BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091218100912181009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVĽ20072 DVĽD©tDWŽ.DWŽDVĽDVĽD©tDVŃDĄDVĽD©tDVŃDĄ....HrYtHru.€HrYtHru.€..DVĽDVŃ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D©tDĄ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NYYYNEGDVíDW‡DW‡..NEG....YNNNNYYDVĽ........DVíDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýCĐB˝BpC BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091220100912201009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVż20133 DVżDĂ<DWî.DWîDVżDVżDĂ<DVŇDť€DVżDĂ<DVŇDť€....Hr]‘ĽHrvx€Hr]‘ĽHrvx€..DVżDVŇ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWk .. DĂ<Dť€....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDWk. Underweight ANNYYNEGDVóDWŚDWŽ..NEG....YNNNNYYDVż........DVóDWŽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCŔB»BqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ..DWçC4591001C4591001 1009 10091221100912211009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20134 DVżDÄhDWŽ.DWŽDVżDVżDÄhDVŇDťDVżDÄhDVŇDť....Hr]’čHrvxHr]’čHrvx..DVżDVŇ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWk .. DÄhDť....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWk. Underweight ANNYYNEGDVóDWŚDWŽ..NEG....YNNNNYYDVż........DVóDWŽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCŔB»BqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091223100912231009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20139 DVżDÇtDWŽ.DWŽDVżDVżDÇtDVŐDÇtDVżDÇtDVŐDÇt....Hr]•ôHrz–ôHr]•ôHrz–ô..DVżDVŐ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇtDÇt....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Overweight A0YNYYNEGDVńDW„DW„..NEG....YNNNNYYDVż........DVńDW„YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýCBąBpCđBĎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091226100912261009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20141 DVŔDąÜDWË.DWËDVŔDVŔDąÜDWŞDśDVŔDąÜDVÔDşDW”DŻPDWŞDśHr^ŮÜHs“;Hr^ŮÜHry8HsvMPHs“;DVŔDVÔDW”DWŞAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DąÜDş.DŻPDś.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDVđDWŤDWŤDWËDXgNEG....YNNNNYYDVŔ........DVđDWŤYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýC BşBjBpCŕBÎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1009 10091227100912271009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20207 DVŔDě|DW×.DW×DVŔDVŔDě|DVŐDäŔDVŔDě|DVŐDäŔ....Hr_|Hrz´@Hr_|Hrz´@..DVŔDVŐ..AđYEARS. 12-15 YearsAWHITE AWHITE ADW×OTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dě|DäŔ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Normal weightA NNYYNEGDVňDW<DW‹..NEG....YNNNNYYDVŔ........DVňDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW<DW×DW×C0BhB›C€B}9-10 months A 3-4 months A@0-1 month A10-11 monthsA° . ...C4591001C4591001 1009 10091229100912291009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20209 DVŔDóüDWĘ.DWĘDVŔDVŔDóüDWŞDŢ0DVŔDóüDWUDóDW•DăXDWŞDŢ0Hr_üHs“}0Hr_üHs#‚ŚHswŇŘHs“}0DVŔ.DW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g)DWU.Placebo Dóü.DóDăXDŢ0.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NYYYNEGDWxDWŤDW”DWĘDXgNEG....YNNNNYNDVŔ........DVţ.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWŤDWýDWýBiBpCŕBÎ0-1 month A0-1 month A3-4 monthsA@11-12 monthsAŔ . ..DVâC4591001C4591001 1009 10091231100912311009AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20210 DVŔEDW“.DW“DVŔDVŔEDVÔDŕDVŔEDVÔDŕ....Hr_ ŕHry^Hr_ ŕHry^..DVŔDVÔ..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. EDŕ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“.. Normal weightA NNYYNEGDVóDW…DW…..NEG....YNNNNYYDVŔ........DVóDW…YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýC BżBkCŕBÓ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091233100912331009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20211 DVÁD—hDWÓ.DWÓDVÁDVÁD—hDW¶D§XDVÁD—hDV×DóDWˇDđxDW¶D§XHr`čHsŁXHr`čHr}eŚHs‡±řHsŁXDVÁDV×DWˇDW¶AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—hDó.DđxD§X.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWˇ. Underweight ANNYYNEGDV÷DW†DW†DWÓDXsNEG....YNNNNYYDVÁ........DV÷DW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW’DWýDWýCpBĽB]BkCĐBŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1009 10091234100912341009AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20245 DVÁDÎ@DWü.DWüDVÁDVÁDÎ@DVÖDÄŕDVÁDÎ@DVÖDÄŕ....Hr`?ŔHr{ĺŕHr`?ŔHr{ĺŕ..DVÁDVÖ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DÎ@DÄŕ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWU. Normal weightA NNYYNEGDVůDWŤDW“..NEG....YNNNNYYDVÁ........DVůDW“YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýC€B¸BpCĐBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091237100912371009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVÁ20246 DVÁDÝôDWú..DVÁDVÁDÝôDV×DÇtDVÁDÝôDV×DÇt....Hr`OtHr}9ôHr`OtHr}9ô..DVÁDV×..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÝôDÇt....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Normal weightA NNYYNEGDV÷DW‹DW‹..NEG....YNNNNYYDVÁ........DV÷DW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCpB·BpCĐBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091238100912381009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20251 DVÁDôtDW´.DW´DVÁDVÁDôtDW‘D¸tDVÁDôtDVŐDßÔDW|DóDW‘D¸tHr`eôHsraôHr`eôHrzŻTHsVíHsraôDVÁDVŐDW|DW‘AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DôtDßÔ.DóD¸t.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWkDW|. Normal weightA NNYYNEGDVńDWjDW{DW´DXNNEG....YNNNNYNDVÁ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWjDWýDWýCB–B‚B“CĐBŞ10-11 monthsA°5-6 months A`4-5 monthsAP11-12 monthsAŔ . ...C4591001C4591001 1009 10091240100912401009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20252 DVÁDřčDW‘.DW‘DVÁDVÁDřčDVÔDřpDVÁDřčDVÔDřp....Hr`jhHryvpHr`jhHryvp..DVÁDVÔ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DřčDřp....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Overweight A0YNYYNEGDVđDW†DW†..NEG....YNNNNYYDVÁ........DVđDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýC B˝BmCĐBĐ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091246100912461009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20314 DVÂDáxDWĹ.DWĹDVÂDVÂDáxDW§DŢ0DVÂDáxDVŐDćdDW’DßÔDW§DŢ0Hra¤xHsŹ°Hra¤xHrzµäHssÚÔHsŹ°DVÂDVŐDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DáxDćd.DßÔDŢ0.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDV÷DW„DW„DWĹDXdNEG....YNNNNYYDVÂ........DV÷DW„YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBąBlBpCŔBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1009 10091247100912471009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20316 DVÂDčDDW“.DW“DVÂDVÂDčDDVÖDđ<DVÂDčDDVÖDđ<....Hra«DHr|<Hra«DHr|<..DVÂDVÖ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. DčDDđ<....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWp. Normal weightA NNYYNEGDVňDWŤDW“..NEG....YNNNNYYDVÂ........DVňDW“YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýC€B¸BpCŔBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091249100912491009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20320 DVÂEXDWĘ.DWĘDVÂDVÂEXDW¨DŮřDVÂEXDVŘD´xDW’DÉĚDW¨DŮřHraŘ€HsŐřHraŘ€Hr~xxHssÄĚHsŐřDVÂDVŘDW’DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. EXD´x.DÉĚDŮř.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0NNYYNEGDVôDWŤDW‘DWĘDXePOS....YNNNNYNDVÂ........DVô.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýC`B¶BlBpCŔBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1009 10091250100912501009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20323 DVÂE_€DW’.DW’DVÂDVÂE_€DVŘDłÄDVÂE_€DVŘDłÄ....HraŘřHr~wÄHraŘřHr~wÄ..DVÂDVŘ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. E_€DłÄ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWb. Normal weightA NNYYNEGDVôDWŤDW’..NEG....YNNNNYYDVÂ........DVôDW’YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýC`B¶BpCŔBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1009 10091265100912651009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20505 DVęDŇ<DWĽ.DWĽDVęDVęDŇ<DV˙D‚PDVęDŇ<DV˙D‚P....Hr–Q<Hr±°ĐHr–Q<Hr±°Đ..DVęDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇ<D‚P....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Obese A@YNYYNEGDWDWŚDWĽ..NEG....YNNNNYYDVę........DWDWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB˙BŽBqC@BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091266100912661009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20506 DVęDˇ@DWv..DVęDVęDˇ@DWZD©8DVęDˇ@DVţDłDWGD±0DWZD©8Hr– @Hs)Đ8Hr– @Hr°HsË°Hs)Đ8DVęDVţDWGDWZAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ@Dł.D±0D©8.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWG. Overweight A0NYYYNEGDWDW<DWFDWvDXNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýCB?B·BÁC@BS9-10 months A 2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091267100912671009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20511 DVęDşĚDWÉ.DWÉDVęDVęDşĚDW¦DśDVęDşĚDV˙D·DW‘D×(DW¦DśHr–9ĚHsŤőHr–9ĚHr±ĺŚHsr€¨HsŤőDVęDV˙DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DşĚD·.D×(Dś.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDWDWŤDWDWÉDXcNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB˙BŹBmBpC@B¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091269100912691009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20514 DVęDţDW°.DW°DVęDVęDţDWDýDVęDţDWDý....Hr–}Hrł}Hr–}Hrł}..DVęDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DţDý....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DWY. Normal weightA NNYYNEGDWDWŻDWŻ..POS....YNNNNYYDVę........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŻDWýDWýBţB°BNC@BĆ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ..DWC4591001C4591001 1009 10091270100912701009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20629 DVęDţDW°.DW°DVęDVęDţDWDţÄDVęDţDWDţÄ....Hr–}Hrł~ÄHr–}Hrł~Ä..DVęDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DţDţÄ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DWY. Normal weightA NNYYNEGDWDWŻDWŻ..NEG....YNNNNYYDVę........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŻDWýDWýBţB°BNC@BĆ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091272100912721009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20631 DVëDľŚDWć.DWćDVëDVëDľŚDV˙DłÄDVëDľŚDV˙DłÄ....Hr—ŹHr±âDHr—ŹHr±âD..DVëDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DľŚDłÄ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“.. Underweight ANYYYNEGDWDW’DWć..NEG....YNNNNYYDVë........DWDWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýB˙B”BkC0B¨9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091273100912731009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20633 DVëDżDWĚ.DWĚDVëDVëDżDWŞDŇđDVëDżDV˙D´xDW•Dĺ8DWŞDŇđHr—Ź„Hs“qđHr—Ź„Hr±âřHswÔ¸Hs“qđDVëDV˙DW•DWŞAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DżD´x.Dĺ8DŇđ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWrDW•. Underweight ANNYYNEGDWDWqDW”DWĚDXgNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWqDWýDWýB˙BsBiBŚC0B‡9-10 months A 4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091274100912741009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20635 DVëDű@DWó.DWóDVëDVëDű@DWŇDy,DVëDű@DWDĽDWżDËčDWŇDy,Hr—ËŔHsÇÔ,Hr—ËŔHrą—<HsŻhHsÇÔ,DVëDWDWżDWŇAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dű@DĽ.DËčDy,.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW·DWż. Underweight ANNYYNEGDW#DW¶DWľDWóDXŹNEG....YNNNNYNDVë........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýBůB˛B?BGC0BĚ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091275100912751009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20786 DVëDúČDWó.DWóDVëDVëDúČDWŇDyhDVëDúČDWDDDWżDĚ$DWŇDyhHr—ËHHsÇÔhHr—ËHHrą–ÄHsŻ¤HsÇÔhDVëDWDWżDWŇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DúČDD.DĚ$Dyh.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW·DWż. Normal weightA NNYYNEGDW#DW¶DWľDWóDXŹNEG....YNNNNYNDVë........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýBůB˛B?BGC0BĚ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091277100912771009AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20787 DVěDŘDWŰ.DWŰDVěDVěDŘDW»DČ DVěDŘDWD»DDW¨DË¬DW»DČ HrúHs©Ń HrúHrĽuÄHsÇ¬Hs©Ń DVěDWDW¨DW»AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWpBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘD»D.DË¬DČ .33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW¨. Overweight A0YNYYNEGDW$DW”DW§DWŰDXxNEG....YNNNNYNDVě........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýB÷BŽBVBiC B©8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091280100912801009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20789 DVěE'@DW¶.DW¶DVěDVěE'@DV˙D’ôDVěE'@DV˙D’ô....Hr™4tHr±ÁtHr™4tHr±Át..DVěDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. E'@D’ô....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DW[. Underweight ANNYYNEGDWDW°DW°..NEG....YNNNNYYDVě........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWµDWýDWýB˙B·BHC BĘ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091281100912811009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20791 DVěDóŔDW±.DW±DVěDVěDóŔDV˙D“äDVěDóŔDV˙D“ä....Hr™ŔHr±ÂdHr™ŔHr±Âd..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. DóŔD“ä....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW±DWg. Underweight ANNYYNEGDWDW°DW°..NEG....YNNNNYYDVě........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW°DWýDWýB˙B˛BMC BĹ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091282100912821009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20914 DVěDňDWĺ.DWĺDVěDVěDňDWÉDĹDVěDňDV˙DĐDW´D×ÜDWÉDĹHr™HsĽBśHr™Hr±ÇPHs ĄÜHsĽBśDVěDV˙DW´DWÉAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DňDĐ.D×ÜDĹ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŻDW´. Normal weightA NNYYNEGDWDW®DW®DWĺDX†NEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW®DWýDWýB˙B°BJBOC BĂ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ..DW)C4591001C4591001 1009 10091283100912831009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20915 DVěDřpDWé..DVěDVěDřpDWĚD`DVěDřpDWDŽ€DW¶D’|DWĚD`Hr™pHsŔ`Hr™pHrł€HsŁ|HsŔ`DVěDWDW¶DWĚAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DřpDŽ€.D’|D`.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW´DW¶. Normal weightA NYYYNEGDW#DW±DW±DWéDX‰NEG....YNNNNYYDVě........DW#DW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWłDWýDWýBţB´BHBJC BČ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091284100912841009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20919 DVěDů$DW´.DW´DVěDVěDů$DWDŽřDVěDů$DWDŽř....Hr™$HrłřHr™$Hrłř..DVěDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWa .. Dů$DŽř....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DWa. Underweight ANNYYNEGDW#DW±DW±..NEG....YNNNNYYDVě........DW#DW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWłDWýDWýBţB´BJC BČ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091287100912871009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20922 DVíD˝śDWŕ.DWŕDVíDVíD˝śDWDŔlDVíD˝śDWDŔl....Hrš1Hrł@lHrš1Hrł@l..DVíDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŕOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝śDŔl....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Underweight ANYYYNEGDWDW<DW±..NEG....YNNNNYYDVí........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW<DWŕDWŕBáB=B¤BôBP8-9 months A2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1009 10091288100912881009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21011 DVíDľDW´.DW´DVíDVíDľDWDŔ0DVíDľDWDŔ0....Hrš1”Hrł@0Hrš1”Hrł@0..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DľDŔ0....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DW]. Normal weightA NNYYNEGDWDW±DW±..NEG....YNNNNYYDVí........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWłDWýDWýBţB´BJCBÇ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091289100912891009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21012 DVíDŃÄDWµ.DWµDVíDVíDŃÄDWDžčDVíDŃÄDWDžč....HršEDHrłčHršEDHrłč..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŃÄDžč....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWDWŤDWµ..NEG....YNNNNYYDVí........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBţBŽBpCBˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091292100912921009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí21014 DVíDŰ`DWś.DWśDVíDVíDŰ`DWyDĺěDVíDŰ`DWD©ěDWdDčřDWyDĺěHršNŕHsRëlHršNŕHrł)ěHs7>řHsRëlDVíDWDWdDWyAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰ`D©ě.DčřDĺě.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWdDWd. Normal weightA NNYYNEGDWDWcDWcDWśDX6NEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWcDWýDWýBţBdBšBšCBw9-10 months A 3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1009 10091293100912931009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí21015 DVíDúŚDWâ.DWâDVíDVíDúŚDW©D× DVíDúŚDWDĹXDW“Dĺ°DW©D× HršnHs’% HršnHrłEXHsu20Hs’% DVíDWDW“DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DúŚDĹX.Dĺ°D× .33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW“. Underweight ANNYYNEGDW!DW’DW’DWËDXfNEG....YNNNNYNDVí........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBţB“BkBkCB¦9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091294100912941009AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21177 DVđDŁDWŘ.DWŘDVđDVđDŁDW~D†ÄDVđDŁDWD‡DWhD¸DW~D†ÄHržHsY#ÄHržHrąž€Hs<¸HsY#ÄDVđDWDWhDW~AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁD‡.D¸D†Ä.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWdDWh. Underweight ANNYYNEGDW!DWcDWgDW DX;NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWcDWýDWýBůB_B–BšCŕBt8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1009 10091295100912951009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21178 DVđDÎôDW¶.DW¶DVđDVđDÎôDWDÄhDVđDÎôDWDÄh....Hrž6ôHr»-hHrž6ôHr»-h..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DÎôDÄh....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DWV. Underweight ANNYYNEGDW"DWµDWµ..NEG....YNNNNYYDVđ........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWµDWýDWýBřB°BHCŕBĆ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091296100912961009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21182 DVđDÎ|DWď..DVđDVđDÎ|DWÍD}dDVđDÎ|DWDĂđDW·DÓhDWÍD}dHrž6|HsÁ@äHrž6|Hr»,đHs¤•čHsÁ@äDVđDWDW·DWÍAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ|DĂđ.DÓhD}d.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¶DW·. Normal weightA NNYYNEGDW"DWµDWµDWďDXŠNEG....YNNNNYYDVđ........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWµDWýDWýBřB°BGBHCŕBĆ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091297100912971009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21188 DVđDŮřDWç.DWçDVđDVđDŮřDWD˛ DVđDŮřDWD˛ ....HržAřHrąÉ HržAřHrąÉ ..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DŮřD˛ ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDWw. Normal weightA NYYYNEGDW"DW´DW´..NEG....YNNNNYYDVđ........DW"DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýBůB°BICŕBĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091298100912981009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21300 DVđDčĽDWć.DWćDVđDVđDčĽDWDÚ¬DVđDčĽDWDÚ¬....HržPĽHrąň,HržPĽHrąň,..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DčĽDÚ¬....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWZ. Normal weightA NNYYNEGDW!DW’DWĽ..NEG....YNNNNYYDVđ........DW!DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýBůBŽBkCŕBŁ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091300100913001009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21302 DVđDţÄDW´.DW´DVđDVđDţÄDWDÍPDVđDţÄDWDÍP....HržfÄHrąäĐHržfÄHrąäĐ..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DţÄDÍP....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DW\. Normal weightA NNYYNEGDW$DWłDW´..NEG....YNNNNYYDVđ........DW$DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWłDWýDWýBůBŻBJCŕBÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091301100913011009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21303 DVđDţLDWö.DWöDVđDVđDţLDW´Dć(DVđDţLDWDĚśDW Dű¸DW´Dć(HržfLHs ´(HržfLHrąäHs†k¸Hs ´(DVđDWDW DW´AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DţLDĚś.Dű¸Dć(.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW€DW„. Normal weightA NYYYNEGDW$DWDWźDW×DXqNEG....YNNNNYNDVđ........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBůB{B^B~CŕB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091303100913031009AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21304 DVńD´đDWé.DWéDVńDVńD´đDWÉD¶”DVńD´đDWDądDW´Dż@DWÉD¶”HrźnpHsĽ4HrźnpHrąĐäHs Ť@HsĽ4DVńDWDW´DWÉAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D´đDąd.Dż@D¶”.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW´. Underweight ANNYYNEGDW%DW—DWłDWéDX†NEG....YNNNNYNDVń........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW—DWýDWýBůB“BJBfCĐB§8-9 months A5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091304100913041009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21537 DVńDěôDW».DW»DVńDVńDěôDWDďDVńDěôDWDď....Hrź¦tHr»XHrź¦tHr»X..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DěôDď....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NYYYNEGDW$DW‘DW»..NEG....YNNNNYYDVń........DW$DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBřBŚBlCĐBˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091305100913051009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21543 DVńDý DWý.DWýDVńDVńDý DWkD¬DDVńDý DWD–DWVD«TDWkD¬DHrź¶ Hs@<ÄHrź¶ Hrş˙Hs$ŚTHs@<ÄDVńDWDWVDWkAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dý D–.D«TD¬D.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWV. Normal weightA NNYYNEGDW#DW<DWUDW‡DX(NEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýBřB7B¨BÁCĐBL8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091306100913061009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21546 DVńDü¨DWý.DWýDVńDVńDü¨DWˇDŕDVńDü¨DWD–xDWŽDÍDWˇDŕHrź¶(Hs‡J`Hrź¶(Hrş˙xHsn‚Hs‡J`DVńDWDWŽDWˇAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dü¨D–x.DÍDŕ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDW#DWŤDWŤDWÄDX^NEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBřBBpBpCĐBť8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1009 10091307100913071009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21547 DVňD‡xDWű.DWűDVňDVňD‡xDWD‚ČDVňD‡xDWD‚Č....Hr ’xHrĽ=HHr ’xHrĽ=H..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWűWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D‡xD‚Č....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWľDW[. Obese A@YNYYNEGDW#DWĽDWĽ..NEG....YNNNNYYDVň........DW#DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW˝DWűDWűBőB·B>C BĚ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091308100913081009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21650 DVňD‡đDWű.DWűDVňDVňD‡đDWD‚ŚDVňD‡đDWD‚Ś....Hr ’đHrĽ=Hr ’đHrĽ=..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWűWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D‡đD‚Ś....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWľDW[. Underweight ANNYYNEGDW#DWĽDWĽ..NEG....YNNNNYYDVň........DW#DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW˝DWűDWűBőB·B>C BĚ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091309100913091009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21652 DVňD¤DWµ.DWµDVňDVňD¤DWDÓŕDVňD¤DWDÓŕ....Hr ŻHr»<ŕHr ŻHr»<ŕ..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤DÓŕ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW"DWDWµ..NEG....YNNNNYYDVň........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBřB‹BmCŔBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091310100913101009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21653 DVňD¦hDW·.DW·DVňDVňD¦hDWDĆ„DVňD¦hDWDĆ„....Hr ±hHr»/„Hr ±hHr»/„..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¦hDĆ„....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW(DWDW·..NEG....YNNNNYYDVň........DW(DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBřB‹BmCŔBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091311100913111009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21655 DVňDĂDWĘ.DWĘDVňDVňDĂDW§D´xDVňDĂDWDwÄDW‘Dě¸DW§D´xHr ÎHsŹ^řHr ÎHrąŹDHsr–8HsŹ^řDVňDWDW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂDwÄ.Dě¸D´x.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW!DWŤDWDWĘDXdNEG....YNNNNYNDVň........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBůB‰BmBpCŔBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091312100913121009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21782 DVňDŰśDWŮ.DWŮDVňDVňDŰśDW¸DĹXDVňDŰśDWD©ěDW DĂDW¸DĹXHr ćśHsĄŮXHr ćśHr»ěHs†3HsĄŮXDVňDWDW DW¸AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWrBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰśD©ě.DĂDĹX.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW . Normal weightA NYYYNEGDW)DWDWźDWŮDXuNEG....YNNNNYNDVň........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹B^BmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091313100913131009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21778 DVňDÚčDW˝..DVňDVňDÚčDWD©tDVňDÚčDWD©t....Hr ĺčHr»tHr ĺčHr»t..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÚčD©t....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWh.. Normal weightA NNYYNEGDW)DWgDW˝..NEG....YNNNNYYDVň........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWgDWýDWýBřBbB–CŔBv8-9 months A3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1009 10091314100913141009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21783 DVňDčĽDWŢ..DVňDVňDčĽDWŢD—,DVňDčĽDWDŇ<DWĂDµŕDWŢD—,Hr óĽHs×Ä,Hr óĽHrĽŚĽHs´J`Hs×Ä,DVňDWDWĂDWŢAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčĽDŇ<.DµŕD—,.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWľDWĂ. Normal weightA NNYYNEGDW(DWĽDWĽDXDX›POS....YNNNNYYDVň........DW(DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDW˝DWýDWýB÷B·B;B@CŔBĚ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091315100913151009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21785 DVňEB€DW´.DW´DVňDVňEB€DWDťĽDVňEB€DWDťĽ....Hrˇ(Hrąµ<Hrˇ(Hrąµ<..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. EB€DťĽ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŻDW]. Normal weightA NNYYNEGDW%DW®DW´..NEG....YNNNNYYDVň........DW%DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW®DWýDWýBůBŞBOCŔB˝8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091316100913161009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21813 DVňE7@DW‡.DW‡DVňDVňE7@DWjD“¨DVňE7@DWDťDWTDÔDWjD“¨HrˇtHs>Ň¨HrˇtHrą´Hs"Hs>Ň¨DVňDWDWTDWjAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. E7@Dť.DÔD“¨.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWT. Normal weightA NNYYNEGDW%DW<DWSDW‡DX'NEG....YNNNNYNDVň........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýBůB8BŞBÁCŔBK8-9 months A2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091317100913171009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21814 DVóD DWé.DWéDVóDVóD DWĚDśDVóD DWD·„DW¸D°DWĚDśHrˇü”HsŔHrˇü”Hr» „HsĄÄHsŔDVóDWDW¸DWĚAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. D D·„.D°Dś.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¶DW¸. Overweight A0YNYYNEGDW#DWµDWµDWéDX‰NEG....YNNNNYYDVó........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWµDWýDWýBřB°BFBHC°BĂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091318100913181009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21821 DVóD¸tDW¶..DVóDVóD¸tDWD˛ DVóD¸tDWD˛ ....Hr˘ôHr» Hr˘ôHr» ..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. D¸tD˛ ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DW\. Underweight ANNYYNEGDW#DWµDWµ..NEG....YNNNNYYDVó........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWµDWýDWýBřB°BHC°BĂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091319100913191009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21823 DVóDË4DWµ..DVóDVóDË4DWDDVóDË4DWD....Hr˘'´HrşčHr˘'´Hrşč..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DË4D....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWY. Underweight ANNYYNEGDW)DWDWµ..NEG....YNNNNYYDVó........DW)DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBřB‹BmC°Bž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091320100913201009AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21957 DVóDÍDWő.DWőDVóDVóDÍDW»DĄđDVóDÍDWDÍČDW Dě@DW»DĄđHr˘)”Hs©®pHr˘)”HrĽHHs†\@Hs©®pDVóDWDW DW»AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN NYhad important protocol deviation(s) as determined by the clinician for Efficacy (prior to the first post(*ESC*){unicode 2013}Dose 2 N-binding antibody test) PopulationNY DW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍDÍČ.Dě@DĄđ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW DW . Normal weightA NNYYNEGDW%DWźDWźDWŰDXxNEGDVó.DVóDVóYNNNNYNDVó........DW%.NY NYNYYnot eligible for the study at randomization Yhad important protocol deviation(s) as determined by the clinician for Efficacy (within 7 days post Dose 2), Immunogenicity (on or before 3 weeks post Dose 1) Population(s) Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2 NNNYYYN YNNYNY NYDWźDWýDWýB÷B™B^B^C°B8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091321100913211009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21958 DVóDÚpDW·..DVóDVóDÚpDWDÄ¤DVóDÚpDWDÄ¤....Hr˘6đHrĽ$Hr˘6đHrĽ$..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. DÚpDÄ¤....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW·DWg. Normal weightA NNYYNEGDW%DW¶DW·..NEG....YNNNNYYDVó........DW%DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW¶DWýDWýB÷B°BGC°BÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091322100913221009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21959 DVóDćÜDWű.DWűDVóDVóDćÜDWDč€DVóDćÜDWDč€....Hr˘C\HrĽŁHr˘C\HrĽŁ..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DćÜDč€....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWżDWb. Underweight ANNYYNEGDW$DW˝DW˝..NEG....YNNNNYYDVó........DW$DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWľDWýDWýB÷B¸B?C°BĚ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091323100913231009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21964 DVóDçDWó.DWóDVóDVóDçDW×D‹8DVóDçDWDčDWĂD‡DW×D‹8Hr˘DHsÎ}¸Hr˘DHrĽ˘Hs´€HsÎ}¸DVóDWDWĂDW×AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDč.D‡D‹8.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWżDWĂ. Normal weightA NNYYNEGDW$DW˝DW˝DWóDX”NEG....YNNNNYYDVó........DW$DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWľDWýDWýB÷B¸B;B?C°BĚ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091324100913241009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22066 DVôD–đDWî..DVôDVôD–đDWîDě@DVôD–đDWDŚ(DWÚDłÄDWîDě@HrŁDđHsí1@HrŁDđHr˝(HsŇšÄHsí1@DVôDWDWÚDWîAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–đDŚ(.DłÄDě@.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWÚ. Normal weightA NNYYNEGDW(DW»DW»DXDX«NEG....YNNNNYYDVô........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĽDWýDWýBöBµB$BAC BÉ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DW‰C4591001C4591001 1009 10091325100913251009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22067 DVôD—¤DW˝.DW˝DVôDVôD—¤DWD‹tDVôD—¤DWD‹t....HrŁE¤Hr˝—tHrŁE¤Hr˝—t..DVôDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. D—¤D‹t....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˝DW]. Underweight ANNYYNEGDW(DW»DW»..NEG....YNNNNYYDVô........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĽDWýDWýBöBµBAC BÉ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091326100913261009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22072 DVôDš8DWŮ.DWŮDVôDVôDš8DW¸DŕÄDVôDš8DWDŤDW›DŁ\DW¸DŕÄHrŁH8HsĄôÄHrŁH8HrĽHHs{ÜHsĄôÄDVôDWDW›DW¸AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš8DŤ.DŁ\DŕÄ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW›. Underweight ANNYYNEGDW%DW”DWšDWŮDXuNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýB÷BŽBcBiC Bˇ8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091328100913281009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22075 DVôDÁÔDWż.DWżDVôDVôDÁÔDWD PDVôDÁÔDWD P....HrŁoÔHrĽZĐHrŁoÔHrĽZĐ..DVôDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÁÔD P....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW)DWDWż..NEG....YNNNNYYDVô........DW)DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýB÷BŠBmC Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091329100913291009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22149 DVôDÁ\DWŃ..DVôDVôDÁ\DW°DŘDVôDÁ\DWD ČDWśDĘDW°DŘHrŁo\Hs›`HrŁo\HrĽ[HHs€ôHs›`DVôDWDWśDW°AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÁ\D Č.DĘDŘ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWś. Normal weightA NNYYNEGDW)DWDW›DWŃDXmNEG....YNNNNYNDVô........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB÷BŠBbBmC Bť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091330100913301009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22151 DVôDŔäDWú.DWúDVôDVôDŔäDWŮD–xDVôDŔäDWDźŘDWÄD’¸DWŮD–xHrŁnäHsŃ+řHrŁnäHrĽZXHsµx¸HsŃ+řDVôDWDWÄDWŮAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔäDźŘ.D’¸D–x.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĂDWÄ. Normal weightA NNYYNEGDW)DWżDWżDWúDX–POS....YNNNNYYDVô........DW)DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÂDWýDWýB÷BĽB:B;C BĎ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091331100913311009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22157 DVôDŇđDWĆ.DWĆDVôDVôDŇđDWD¨„DVôDŇđDWD¨„....HrŁ€đHrĽcHrŁ€đHrĽc..DVôDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DŇđD¨„....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW]. Normal weightA NNYYNEGDW%DWŤDW¸..NEG....YNNNNYYDVô........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýB÷B‡BpC Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091332100913321009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22160 DVôDÓŕDWŢ.DWŢDVôDVôDÓŕDWD¨üDVôDÓŕDWD¨ü....HrŁŕHrĽc|HrŁŕHrĽc|..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÓŕD¨ü....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWv.. Overweight A0NNYYNEGDW%DWuDW¸..NEG....YNNNNYYDVô........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWuDWŢDWŢBŘBoBiBëB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091333100913331009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22198 DVôDŮřDW·.DW·DVôDVôDŮřDWDşTDVôDŮřDWDşT....HrŁ‡řHrĽtÔHrŁ‡řHrĽtÔ..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŮřDşT....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW·DW[. Normal weightA NNYYNEGDW%DW¶DW¶..NEG....YNNNNYYDVô........DW%DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¶DWýDWýB÷B°BGC BĂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091334100913341009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22199 DVôEÉ€DWÉ.DWÉDVôDVôEÉ€DW§Dî\DVôEÉ€DWD´<DW“Dń,DW§Dî\HrŁşHsŹÜHrŁşHr˝Ŕ<Hsu=¬HsŹÜDVôDWDW“DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. EÉ€D´<.Dń,Dî\.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW“. Normal weightA NYYYNEGDW%DW’DW’DWÉDXdNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBöB‹BkBkC Bź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091335100913351009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22200 DVôD˙DWĽ.DWĽDVôDVôD˙DWD—ŕDVôD˙DWD—ŕ....HrŁHr˝ŁŕHrŁHr˝Łŕ..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˙D—ŕ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Normal weightA NNYYNEGDW%DW<DWĽ..NEG....YNNNNYYDVô........DW%DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW<DWýDWýBöB5BÁC BI8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1009 10091336100913361009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22201 DVôD˙xDWá..DVôDVôD˙xDWáDîDVôD˙xDWDXDWÍDwÄDWáDîHrŁxHsÜHrŁxHr˝¤XHsÁ;DHsÜDVôDWDWÍDWáAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWrBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˙xDX.DwÄDî.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWżDWÍ. Normal weightA NNNNPOSDW%DWĽDWĽDXDXžPOS....YNNNNYYDVô........DW%DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWľDWýDWýBöB·B1B?C BË8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1009 10091337100913371009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22329 DV÷DťDDWü.DWüDV÷DV÷DťDDW§D¸ěDV÷DťDDWDŐHDW’DŹčDW§D¸ěHr§?ÄHsŹclHr§?ÄHrĂ'HHssŠčHsŹclDV÷DWDW’DW§AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDDŐH.DŹčD¸ě.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Underweight ANNYYNEGDW)DWDW‘DWĘDXdNEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBňB…BlBmCpBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091338100913381009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22331 DV÷DÄ,DWć..DV÷DV÷DÄ,DWćD$DV÷DÄ,DV÷DÄ,DWŃDťDWćD$Hr§f¬HsâI$Hr§f¬Hr§f¬HsĆ¦HsâI$DV÷.DWŃDWćAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. DW NO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN DWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄ,..DťD$.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWµDWŃ. Underweight ANNYYNEGDW6DW´DWËDX DXŁPOS....YNNNNYNDV÷........DW6.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW´DWýDWýB-BICpBľ0-1 month A0-1 month A1-2 monthsA 9-10 months A . ..DW C4591001C4591001 1009 10091339100913391009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22332 DV÷DÄ¤DWŃ.DWŃDV÷DV÷DÄ¤DWDš8DV÷DÄ¤DWDš8....Hr§g$HrŐa8Hr§g$HrŐa8..DV÷DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DÄ¤Dš8....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDWV. Normal weightA NNYYNEGDW6DW´DWŃ..NEG....YNNNNYYDV÷........DW6DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýBäB›BICpBľ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1009 10091340100913401009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22339 DV÷Dé¬DWľ.DWľDV÷DV÷Dé¬DWDä„DV÷Dé¬DWDä„....Hr§Ś,HrĂ6„Hr§Ś,HrĂ6„..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. Dé¬Dä„....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW\. Obese A@YNYYNEGDW/DW’DWľ..NEG....YNNNNYYDV÷........DW/DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBňB‡BkCpBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091341100913411009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22451 DV÷E7@DWó.DWóDV÷DV÷E7@DWŇD~DV÷E7@DWDňXDWżD»DWŇD~Hr§ĄôHsÇŮHr§ĄôHrĂDXHsŻ HsÇŮDV÷DWDWżDWŇAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. E7@DňX.D»D~.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWż. Underweight ANNYYNEGDW,DW»DW»DWóDXŹNEG....YNNNNYYDV÷........DW,DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWĽDWýDWýBňB±B?BACpBĆ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ..DWC4591001C4591001 1009 10091342100913421009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22452 DV÷E/ŔDW˝.DW˝DV÷DV÷E/ŔDWDń¤DV÷E/ŔDWDń¤....Hr§Ą|HrĂC¤Hr§Ą|HrĂC¤..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. E/ŔDń¤....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˝DW]. Normal weightA NNYYNEGDW,DW»DW»..NEG....YNNNNYYDV÷........DW,DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWĽDWýDWýBňB±BACpBĆ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091343100913431009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22454 DVřD´xDWĂ.DWĂDVřDVřD´xDW DźśDVřD´xDW Dźś....Hr¨¨xHrÄCHr¨¨xHrÄC..DVřDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. D´xDźś....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĂDW\. Normal weightA NNYYNEGDW,DWżDWż..POS....YNNNNYYDVř........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWÂDWýDWýBńB¶B;C`BË8-9 months A6-7 months Ap0-1 month A9-10 months A . ..DW C4591001C4591001 1009 10091344100913441009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22458 DVřDłÄDWŰ..DVřDVřDłÄDWZDŕDVřDłÄDWDŞ(DWDDĺtDWZDŕHr¨§ÄHs*Hr¨§ÄHrÂü(Hs tHs*DVřDWDWDDWZAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DłÄDŞ(.DĺtDŕ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW?DWD. Normal weightA NNYYNEGDW)DW>DWCDWvDXNEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW>DWýDWýBňB3BşBżC`BG8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091345100913451009AŔYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22618 DVřDÖ°DWú.DWúDVřDVřDÖ°DW DŇđDVřDÖ°DW DŇđ....Hr¨Ę°HrÄvpHr¨Ę°HrÄvp..DVřDW ..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DÖ°DŇđ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˝DWV. Normal weightA YYYYNEGDW,DWĽDWĽ..NEG....YNNNNYYDVř........DW,DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĽDWýDWýBńB°BAC`BĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091346100913461009AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22621 DVřDÖ8DW„.DW„DVřDVřDÖ8DWhDăXDVřDÖ8DW DÓhDWUDäŔDWhDăXHr¨Ę8Hs<XHr¨Ę8HrÄvčHs#t@Hs<XDVřDW DWUDWhAđYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖ8DÓh.DäŔDăX.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWU. Overweight A0NNYYNEGDW,DW<DWTDW„DX%NEG....YNNNNYNDVř........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýBńB0B©BÁC`BE8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091347100913471009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22625 DVřDÚ4DWá..DVřDVřDÚ4DWáDäüDVřDÚ4DWDťDWĆD¤ÄDWáDäüHr¨Î4HsÜ|Hr¨Î4HrĹ’Hs¸-ÄHsÜ|DVřDWDWĆDWáAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚ4Dť.D¤ÄDäü.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWżDWĆ. Normal weightA NNYYNEGDW,DWľDWľDXDXžNEG....YNNNNYYDVř........DW,DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWľDWýDWýBđB±B8B?C`BÇ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1009 10091348100913481009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22626 DVřDÚ¬DWż.DWżDVřDVřDÚ¬DWDśĚDVřDÚ¬DWDśĚ....Hr¨Î¬HrĹ‘ĚHr¨Î¬HrĹ‘Ě..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. DÚ¬DśĚ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWżDW`. Normal weightA NNYYNEGDW,DWľDWľ..NEG....YNNNNYYDVř........DW,DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWľDWýDWýBđB±B?C`BÇ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091349100913491009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22701 DVřDúČDWď.DWďDVřDVřDúČDW¦DďÄDVřDúČDWDů`DW’DíäDW¦DďÄHr¨îČHsŽHÄHr¨îČHrĹî`HssčäHsŽHÄDVřDWDW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWhBNT162b2 (30 (*ESC*){unicode 03BC}g).. DúČDů`.DíäDďÄ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDW+DWDW‘DWĹDXcNEG....YNNNNYNDVř........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBđBBlBmC`B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091350100913501009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22702 DVůD™üDWŕ..DVůDVůD™üDWŕDę$DVůD™üDWD©°DWËDßÔDWŕDę$Hr©ß|HsÚş$Hr©ß|HrĆđ0HsżTHsÚş$DVůDWDWËDWŕAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. D™üD©°.DßÔDę$.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĆDWË. Overweight A0YNYYNEGDW+DWĹDWĹDXDXťNEG....YNNNNYYDVů........DW+DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĹDWýDWýBďB·B3B8CPBÍ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1009 10091351100913511009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22706 DVůD¶XDWľ.DWľDVůDVůD¶XDWDĂ´DVůD¶XDWDĂ´....Hr©űŘHrĹ¸´Hr©űŘHrĹ¸´..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. D¶XDĂ´....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWľDWY. Underweight ANNYYNEGDW*DW˝DW˝..NEG....YNNNNYYDVů........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW˝DWýDWýBđB°B@CPBĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091353100913531009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22707 DVůD»DDWĘ.DWĘDVůDVůD»DDWDô8DVůD»DDWDô8....HrŞÄHrĹé8HrŞÄHrĹé8..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D»DDô8....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW*DWĘDWĘ..NEG....YNNNNYYDVů........DW*DWĘYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBđBđ..CPCP8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1009 10091354100913541009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22906 DVůDĎlDWĹ.DWĹDVůDVůDĎlDWDŤTDVůDĎlDWDŤT....HrŞěHrĆÓÔHrŞěHrĆÓÔ..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DĎlDŤT....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW\. Normal weightA NNYYNEGDW+DW“DWĹ..NEG....YNNNNYYDVů........DW+DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýBďB…BjCPB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091355100913551009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22907 DVůDęśDWô.DWôDVůDVůDęśDWDŕÄDVůDęśDWDŕÄ....HrŞ0HrČxÄHrŞ0HrČxÄ..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DęśDŕÄ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWËDW]. Underweight ANNYYNEGDW2DWĆDWĆ..NEG....YNNNNYYDVů........DW2DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWĘDWýDWýBîB»B3CPBŇ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091356100913561009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22909 DVůDőÜDWĆ.DWĆDVůDVůDőÜDW¦DwÄDVůDőÜDWDő DW‘Dâ,DW¦DwÄHrŞ;\HsŤĐÄHrŞ;\HrĂG Hsr‹¬HsŤĐÄDVůDWDW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DőÜDő .Dâ,DwÄ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW1DWŤDWDWĆDXcNEG....YNNNNYNDVů........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BmBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091357100913571009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22912 DVúD–DW„..DVúDVúD–DWgDŽřDVúD–DW DŹčDWSDČdDWgDŽřHr«-Hs:ŮxHr«-HrÄ3hHs ´äHs:ŮxDVúDW DWSDWgAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–DŹč.DČdDŽř.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWS. Overweight A0YNYYNEGDW)DW<DWRDW„DX$NEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýBńB0B«BÁC@BC8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1009 10091358100913581009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23001 DVúD•LDWő.DWőDVúDVúD•LDWDŘDVúD•LDWDŘ....Hr«,LHrĹvŘHr«,LHrĹvŘ..DVúDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D•LDŘ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW`. Underweight ANNYYNEGDW,DW“DWÄ..NEG....YNNNNYYDVú........DW,DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýBđB†BjC@Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091359100913591009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23002 DVúD·HDWŢ.DWŢDVúDVúD·HDW¦DÁ\DVúD·HDWDĚ$DW‘D˝ŘDW¦DÁ\Hr«NHHsŽ\Hr«NHHrĹÁ$HsrgXHsŽ\DVúDWDW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. D·HDĚ$.D˝ŘDÁ\.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW*DWŚDWDWĹDXcNEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091360100913601009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23003 DVúD·üDWÉ.DWÉDVúDVúD·üDWDĚśDVúD·üDWDĚś....Hr«NüHrĹÁśHr«NüHrĹÁś..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWa .. D·üDĚś....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŠDWa. Overweight A0NNNNPOSDW*DW‰DWÉ..POS....YNNNNYYDVú........DW*DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDW‰DWýDWýBđB|BtC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091361100913611009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23012 DVúDÇěDWĐ.DWĐDVúDVúDÇěDW¦D«DVúDÇěDW DđxDW‘DóDW¦D«Hr«^ěHsŽHr«^ěHrÄ“řHsrśŚHsŽDVúDW DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇěDđx.DóD«.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW)DWŚDWDWĐDXcNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091362100913621009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23181 DVúDĺěDWĐ.DWĐDVúDVúDĺěDWDÝ@DVúDĺěDWDÝ@....Hr«|ěHrĚiŔHr«|ěHrĚiŔ..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. DĺěDÝ@....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĐDWp. Underweight ANNYYNEGDW/DWĘDWĘ..NEG....YNNNNYYDVú........DW/DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWĎDWýDWýBëB˝B.C@BÖ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091363100913631009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23186 DVúDĺtDW÷.DW÷DVúDVúDĺtDW÷DáđDVúDĺtDVúDĺtDWŰDśDW÷DáđHr«|tHsůpHr«|tHr«|tHsÓŐHsůpDVú.DWŰDW÷AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. DWNO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN DWpBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺt..DśDáđ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŃDWÚ. Underweight ANNYYNEGDW0DWĐDWĐDXDX´POS....YNNNNYYDVú........DW0DWĐYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWĐDWýDWýB#B-C@B×0-1 month A0-1 month A1-2 monthsA 9-10 months A . ..DWC4591001C4591001 1009 10091364100913641009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23189 DVúDěDWÓ.DWÓDVúDVúDěDWD× DVúDěDWD× ....Hr«HrÖđ Hr«HrÖđ ..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DěD× ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWÓDW[. Obese A@YNYYNEGDW7DWŃDWŃ..NEG....YNNNNYYDVú........DW7DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŇDWýDWýBăB¸B+C@BŮ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091365100913651009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23191 DVúDě¸DWď..DVúDVúDě¸DWďDŕLDVúDě¸DWDŘDWŃDÄ¤DWďDŕLHr«¸HsîvĚHr«¸HrÖđHsĆÎ$HsîvĚDVúDWDWŃDWďAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě¸DŘ.DÄ¤DŕL.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDWŃ. Normal weightA NNYYNEGDW7DW—DWĐDXDX¬NEG....YNNNNYNDVú........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW—DWýDWýBăB}B-BfC@Bž8-9 months A4-5 months AP1-2 monthsA 9-10 months A . ..DWoC4591001C4591001 1009 10091366100913661009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23213 DVúDđ<DWú.DWúDVúDVúDđ<DWúD|°DVúDđ<DWADäHDWćD€¬DWúD|°Hr«‡<Hsü“°Hr«‡<Hs ČHsâ9¬Hsü“°DVú.DWćDWúAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANNYY NN DW]BNT162b2 (30 (*ESC*){unicode 03BC}g)DWA.Placebo Dđ<.DäHD€¬D|°.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWáDWć. Normal weightA NNYYNEGDWdDWŕDWĺDXDX·POS....YNNNNYNDVú........DW,.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWŕDWýDWýBBC@Bç0-1 month A0-1 month A0-1 month A9-10 months A . ..DWC4591001C4591001 1009 10091369100913691009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23214 DVűDš°DWË.DWËDVűDVűDš°DW¨D‰DVűDš°DWD„¨DW•D‹°DW¨D‰Hr¬0Hs…Hr¬0HrČ¨Hsw{0Hs…DVűDWDW•DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš°D„¨.D‹°D‰.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW3DWŚDW”DWËDXeNEG....YNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BiBqC0B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091370100913701009AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23215 DVűD ŚDWô.DWôDVűDVűD ŚDWD¶XDVűD ŚDWD¶X....Hr¬‰HrČNXHr¬‰HrČNX..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. D ŚD¶X....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWżDWg. Underweight ANNYYNEGDW,DWľDWż..NEG....YNNNNYYDVű........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWľDWýDWýBîBŻB?C0BÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1009 10091371100913711009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23216 DVűDżôDWŇ.DWŇDVűDVűDżôDWD©ěDVűDżôDWD©ě....Hr¬¨tHrČAěHr¬¨tHrČAě..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DżôD©ě....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW,DWÄDWÄ..NEG....YNNNNYYDVű........DW,DWÄYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBîBî..C0C08-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1009 10091372100913721009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23435 DVűDŐHDWż.DWżDVűDVűDŐHDWDČ(DVűDŐHDWDČ(....Hr¬˝ČHrČ`(Hr¬˝ČHrČ`(..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DŐHDČ(....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NYNYPOSDW2DWżDWż..POS....YNNNNYYDVű........DW2DWżYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWý.DWýBîBî..C0C08-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1009 10091373100913731009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23441 DVűDŕLDWâ..DVűDVűDŕLDWâDÜPDVűDŕLDWDäŔDWÍDâhDWâDÜPHr¬ČĚHsÝOPHr¬ČĚHrČ|ŔHsÁĄčHsÝOPDVűDWDWÍDWâAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕLDäŔ.DâhDÜP.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĚDWÍ. Normal weightA NNYYNEGDW,DWËDWĚDXDXźNEG....YNNNNYYDVű........DW,DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWËDWýDWýBîBĽB1B2C0BŃ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1009 10091374100913741009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23442 DVţD¨HDWÍ.DWÍDVţDVţD¨HDWD°ôDVţD¨HDWDűDWDÔDWD°ôHr°…HHs—DtHr°…HHrĚ‡„Hs{¸Hs—DtDVţDWDWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨HDű.DÔD°ô.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW. Overweight A0NNYYNEGDW/DW’DW—DWÍDXjNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBëB€BfBkCB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091375100913751009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23444 DVţD¨ŔDWÉ.DWÉDVţDVţD¨ŔDWDúŚDVţD¨ŔDWDúŚ....Hr°…ŔHrĚ‡Hr°…ŔHrĚ‡..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D¨ŔDúŚ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW`. Normal weightA NNYYNEGDW/DW’DWÉ..NEG....YNNNNYYDVţ........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBëB€BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091376100913761009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23805 DVţDÄŕDWĹ..DVţDVţDÄŕDWDÝ¸DVţDÄŕDWDÝ¸....Hr°ˇŕHrĚj8Hr°ˇŕHrĚj8..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DÄŕDÝ¸....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWb. Obese A@YNYYNEGDW3DW’DWĹ..NEG....YNNNNYYDVţ........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBëB€BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091377100913771009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23808 DVţDŢ¨DWÉ.DWÉDVţDVţDŢ¨DWD’DVţDŢ¨DWD’....Hr°»¨HrÍpHr°»¨HrÍp..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. DŢ¨D’....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWd. Normal weightA NNYYNEGDW6DW‘DWÉ..NEG....YNNNNYYDVţ........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBęB~BlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1009 10091378100913781009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23812 DVţDß DWî..DVţDVţDß DWîDëŚDVţDß DWD‘ŚDW×Dż|DWîDëŚHr°Ľ Hsí0ŚHr°Ľ HrÍoŚHsÎ±üHsí0ŚDVţDWDW×DWîAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWdBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß D‘Ś.Dż|DëŚ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŇDW×. Normal weightA NNYYNEGDW6DWÉDWÉDXDX«NEG....YNNNNYYDVţ........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŃDWýDWýBęBľB'B,CBÔ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1009 10091379100913791009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23814 DV˙DÉTDWĘ.DWĘDV˙DV˙DÉTDW¨D„lDV˙DÉTDWDzĐDW“DŹ¬DW¨D„lHr±÷ÔHs€lHr±÷ÔHrĎűĐHstÜ,Hs€lDV˙DWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉTDzĐ.DŹ¬D„l.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Underweight ANNYYNEGDW6DW‘DW’DWĘDXeNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBčB|BkBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1009 10091380100913801009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24802 DWDčDDWî.DWîDWDWDčDDWÉDµ¤DWDčDDWDÝ¸DW¶DşTDWÉDµ¤Hr»QDHsĽ3$Hr»QDHrÖö8HsŁ+THsĽ3$DWDWDW¶DWÉAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWhBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDÝ¸.DşTDµ¤.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWšDW¶. Normal weightA NNYYNEGDW=DW™DWµDWîDX†NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW™DWýDWýBăBBHBdBřB”8-9 months A4-5 months AP2-3 monthsA08-9 months A . ...C4591001C4591001 1009 10091381100913811009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24806 DWDˇ@DWĘ.DWĘDWDWDˇ@DWDx´DWDˇ@DWDx´....Hr˝@HrÖ‘4Hr˝@HrÖ‘4..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. Dˇ@Dx´....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWd. Underweight ANNYYNEGDW7DWDWĘ..NEG....YNNNNYYDW........DW7DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBăBvBmBöB‰8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1009 10091382100913821009AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24808 DWDčDWż.DWżDWDWDčDWˇD‹8DWDčDW!DäüDWŽD€pDWˇD‹8HrĂ:Hs‡L¸HrĂ:HrŢć|Hsn5pHs‡L¸DWDW!DWŽDWˇAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDäü.D€pD‹8.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDW@DWŚDWŤDWżDX^NEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBpBqBňB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1009 10091383100913831009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 24810 DW DżôDWá.DWáDW DW DżôDW!D±0DW DżôDW!D±0....HrÄctHrŢ˛°HrÄctHrŢ˛°..DW DW!..AđYEARS. 12-15 YearsAWHITE AWHITE ADWáOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DżôD±0....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Normal weightA NYYYNEGDW<DW<DWĐ..NEG....YNNNNYYDW ........DWDDWĐYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDW<DWáDWáBÁBBĄBŐB06-7 months Ap1-2 months A 0-1 month A7-8 months A€ . ...C4591001C4591001 1009 10091384100913841009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25498 DW Dż|DWv..DW DW Dż|DWSDŽDW Dż|DW!D°@DW>D—,DWSDŽHrÄbüHs zHrÄbüHrŢ±ŔHsÔ,Hs zDW DW!DW>DWSAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dż|D°@.D—,DŽ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW:DW>. Underweight ANNYYNEGDW9DW9DW=DWvDXNEG....YNNNNYNDW ........DW>.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW9DWýDWýBÝBBŔBÄBńB-7-8 months A€0-1 month A6-7 monthsAp8-9 months A . ...C4591001C4591001 1009 10091385100913851009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25502 DW DĆDWĘ.DWĘDW DW DĆDW®D´đDW DĆDW"DßDWDź`DW®D´đHrÄiŚHs™đHrÄiŚHrŕ2Hs{`Hs™đDW DW"DWDW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆDß.Dź`D´đ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW. Overweight A0YNYYNEGDW?DW’DW—DWĘDXkNEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBÜBqBfBkBńB†7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1009 10091386100913861009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25505 DWD˛ DWŇ.DWŇDWDWD˛ DW!D‹8DWD˛ DW!D‹8....HrĹ§ HrŢŚ¸HrĹ§ HrŢŚ¸..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWo .. D˛ D‹8....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWo. Normal weightA NNYYNEGDWADW‘DWŇ..NEG....YNNNNYYDW........DWADWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBÝBqBlBđB„7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1009 10091387100913871009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25506 DWDÇ°DWŰ.DWŰDWDWDÇ°DW$DďLDWDÇ°DW$DďL....HrĹĽ°HrâĺLHrĹĽ°HrâĺL..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇ°DďL....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDWHDW‘DWŰ..NEG....YNNNNYYDW........DWHDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBÚBnBlBđB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091388100913881009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25872 DWDćÜDWÉ.DWÉDWDWDćÜDW¦D·HDWDćÜDW$DßÔDW“D·üDW¦D·HHrĹŰÜHsŽHHrĹŰÜHrâŐÔHsu|HsŽHDWDW$DW“DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWoBNT162b2 (30 (*ESC*){unicode 03BC}g).. DćÜDßÔ.D·üD·H.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Normal weightA NNYYNEGDW@DW‘DW’DWÉDXcNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÚBnBkBlBđB„7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1009 10091389100913891009AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25878 DWDílDWŮ.DWŮDWDWDílDW!Dń¤DWDílDW!Dń¤....HrĹâlHrŢó$HrĹâlHrŢó$..DWDW!..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DílDń¤....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Normal weightA NNYYNEGDW<DW<DWŮ..NEG....YNNNNYYDW........DW@DWŮYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDW<DWýDWýBÝBBÁBđB/7-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1009 10091390100913901009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25879 DWD·HDWó..DWDWD·HDWóDíäDWD·HDW$D|8DWŢDŞ(DWóDíäHrĆýČHsóĘdHrĆýČHrâr8Hs××(HsóĘdDWDW$DWŢDWóAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. D·HD|8.DŞ(Díä.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŮDWŢ. Normal weightA NNYYNEGDWADWŘDWŘDXDX°NEG....YNNNNYYDW........DWADWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŘDWýDWýBÚBµB B%BďBĘ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1009 10091391100913911009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26073 DWDĚŘDWŢ.DWŢDWDWDĚŘDW%Dą(DWDĚŘDW%Dą(....HrÇXHrä¨HrÇXHrä¨..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DĚŘDą(....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW]. Underweight ANYYYNEGDWDDW‘DWŢ..NEG....YNNNNYYDW........DWDDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŮBmBlBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091392100913921009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26075 DWDÍPDWď.DWďDWDWDÍPDWÓD·ŔDWDÍPDW%Dą DWľD‡đDWÓD·ŔHrÇĐHsÉd@HrÇĐHrä Hs„đHsÉd@DWDW%DWľDWÓAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍPDą .D‡đD·Ŕ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWľ. Normal weightA NYYYNEGDWDDWĽDW˝DWďDXNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĽDWýDWýBŮBB@BABďB®7-8 months A€5-6 months A`2-3 monthsA08-9 months A . ...C4591001C4591001 1009 10091393100913931009AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25880 DWDËčDWŘ.DWŘDWDWDËčDW#D´´DWDËčDW#D´´....HrÇhHráY4HrÇhHráY4..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DËčD´´....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DWb. Normal weightA NNYYNEGDWDDW“DWŘ..NEG....YNNNNYYDW........DWDDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBŰBqBjBďB…7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1009 10091394100913941009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26076 DWDÝ¸DWŕ.DWŕDWDWDÝ¸DW#DĹDWDÝ¸DW#DĹ....HrÇ$8HráiśHrÇ$8Hráiś..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DÝ¸DĹ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DW]. Normal weightA NNYYNEGDWDDW”DWŕ..NEG....YNNNNYYDW........DWDDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBŰBrBiBďB†7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1009 10091395100913951009AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26079 DWDÝDWÍ.DWÍDWDWDÝDWDštDWDÝDW#DĹ”DWšDĚ$DWDštHrÇ#„Hs—-ôHrÇ#„HrájHs~S$Hs—-ôDWDW#DWšDWAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝDĹ”.DĚ$Dšt.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DWš. Underweight ANNYYNEGDWDDW”DW™DWÍDXjNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýBŰBrBdBiBďB†7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1009 10091396100913961009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26113 DWDčDWç.DWçDWDWDčDW"DáDWDčDW"Dá....HrÇ.Hrŕ4HrÇ.Hrŕ4..DWDW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DčDá....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWv.. Normal weightA NNYYNEGDW@DWuDWç..NEG....YNNNNYYDW........DW@DWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWuDWýDWýBÜBTBBďBg7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091398100913981009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26114 DWDřčDWö.DWöDWDWDřčDW$DóüDWDřčDW$Dóü....HrÇ?hHrâéüHrÇ?hHrâéü..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DřčDóü....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW\.. Normal weightA NYYYNEGDWADW[DWŢ..NEG....YNNNNYYDW........DWADWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW[DWýDWýBÚB8B˘BďBM7-8 months A€2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1009 10091399100913991009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26115 DWD¨ŔDWđ..DWDWD¨ŔDWđDçDWD¨ŔDW%DˇDWŰDŻPDWđDçHrČ@ŔHsďĎHrČ@ŔHrăč„HsÓçĐHsďĎDWDW%DWŰDWđAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨ŔDˇ.DŻPDç.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÚDWŰ. Underweight ANNYYNEGDWADWŮDWÚDXDXPOS....YNNNNYYDW........DWADWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŮDWýDWýBŮBµB#B$BîBĘ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ..DW%C4591001C4591001 1009 10091400100914001009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26119 DWD˝`DWú.DWúDWDWD˝`DWúDéčDWD˝`DW3DŠŔDWúDéčDWúDéčHrČU`HsýčHrČU`HröG@HsýčHsýčDWDW3DWú.AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. D˝`DŠŔ.Déč..33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWçDWú. Underweight ANNYYNEGDWODWâDWâDX4DXÎNEG....YNNNNYYDW........DWODWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWćDWýDWýBËB´A@BBîB×7-8 months A€6-7 months Ap0-1 month A8-9 months A . ..DWhC4591001C4591001 1009 10091401100914011009AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26375 DWDĐDWó..DWDWDĐDWóDć(DWDĐDW%Dß DWŢD¸8DWóDć(HrČhHsóÂ¨HrČhHrä& Hs×ĺ8HsóÂ¨DWDW%DWŢDWóAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWnBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐDß .D¸8Dć(.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWŢ. Underweight ANNYYNEGDWADW×DW×DXDX°NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW×DWýDWýBŮBłB B&BîBČ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1009 10091402100914021009AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26377 DWDĐ DWŘ.DWŘDWDWDĐ DW%DßÔDWDĐ DW%DßÔ....HrČh Hrä'THrČh Hrä'T..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWn .. DĐ DßÔ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŘDWn. Underweight ANNYYNEGDWADW×DW×..NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW×DWýDWýBŮBłB&BîBČ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1009 10091403100914031009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26378 DWDÜŚDWu..DWDWDÜŚDWVDĂ<DWDÜŚDW#DDW?Dâ¤DWVDĂ<HrČtŚHs$¤<HrČtŚHrá'„Hsq$Hs$¤<DWDW#DW?DWVAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜŚD.Dâ¤DĂ<.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DW?. Obese A@YNYYNEGDW<DW<DW>DWuDXNEG....YNNNNYNDW........DW?.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW<DWýDWýBŰBBżBÁBîB-7-8 months A€0-1 month A6-7 monthsAp8-9 months A . ...C4591001C4591001 1009 10091404100914041009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26380 DWDě|DWŘ.DWŘDWDWDě|DW%D†LDWDě|DW%D†L....HrČ„|HrăÍĚHrČ„|HrăÍĚ..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWv .. Dě|D†L....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Underweight ANYYYNEGDWADWŘDWŘ..NEG....YNNNNYYDW........DWADWŘYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBŮBŮ..BîBî7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1009 10091405100914051009AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26445 DWEDWď..DWDWEDWďDäDWEDW%D‚ŚDWŮD¬DWďDäHrČŕHsîzŚHrČŕHrăĘHsŃC,HsîzŚDWDW%DWŮDWďAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWrBNT162b2 (30 (*ESC*){unicode 03BC}g).. ED‚Ś.D¬Dä.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWŮ. Normal weightA NNYYNEGDWADW×DW×DXDX¬NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW×DWýDWýBŮBłB%B&BîBČ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1009 10091406100914061009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26447 DWE€DWď..DWDWE€DWďDăĐDWE€DW%D‚PDWŘDądDWďDăĐHrČhHsîzPHrČhHrăÉĐHsĎýdHsîzPDWDW%DWŘDWďAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWrBNT162b2 (30 (*ESC*){unicode 03BC}g).. E€D‚P.DądDăĐ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWŘ. Underweight ANNYYNEGDWADW×DW×DXDX¬NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW×DWýDWýBŮBłB&B&BîBČ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1009 10091407100914071009AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26450 DWDµ¤DWŕ.DWŕDWDWDµ¤DW(D«TDWDµ¤DW(D«T....HrĚB$HrççTHrĚB$HrççT..DWDW(..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. Dµ¤D«T....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWp. Underweight ANNYYNEGDWDDWDWŕ..NEG....YNNNNYYDW........DWDDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÖBiBmBëB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091408100914081009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26453 DWD÷řDWç.DWçDWDWD÷řDW)DöTDWD÷řDW)DöT....HrĚ„xHréÔHrĚ„xHréÔ..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW„ .. D÷řDöT....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWçDW„. Underweight ANNNYPOSDWHDWâDWâ..POS....YNNNNYYDW........DWHDWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWćDWýDWýBŐBľBBëBÔ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1009 10091409100914091009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26737 DWD÷€DWç.DWçDWDWD÷€DW)DőÜDWD÷€DW)DőÜ....HrĚ„Hré\HrĚ„Hré\..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW„ .. D÷€DőÜ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWçDW„. Underweight ANNYYNEGDWHDWâDWâ..NEG....YNNNNYYDW........DWHDWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWćDWýDWýBŐBľBBëBÔ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1009 10091410100914101009AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26740 DWD‰ĐDW×.DW×DWDWD‰ĐDW(DęŘDWD‰ĐDW(DęŘ....HrÍgĐHrč&ŘHrÍgĐHrč&Ř..DWDW(..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW` .. D‰ĐDęŘ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW`. Underweight ANNYYNEGDWDDWŚDW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÖBeBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091411100914111009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26743 DWD•LDWĘ.DWĘDWDWD•LDW§DśDWD•LDW(D× DW”D˘äDW§DśHrÍsLHsŹGHrÍsLHrč Hsv@äHsŹGDWDW(DW”DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWwBNT162b2 (30 (*ESC*){unicode 03BC}g).. D•LD× .D˘äDś.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW”. Underweight ANNYYNEGDWHDW’DW“DWĘDXdNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBÖBkBjBkBęB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1009 10091412100914121009AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26744 DWDŮĽDWđ..DWDWDŮĽDWđDÔDWDŮĽDW(D†LDWŰD×(DWđDÔHrÍ·ĽHsďĽHrÍ·ĽHrçÂLHsÔ¨HsďĽDWDW(DWŰDWđAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮĽD†L.D×(DÔ.33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWŰ. Normal weightA NYYYNEGDWRDW×DW×DXDXNEG....YNNNNYYDW........DWRDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW×DWýDWýBÖB°B#B&BęBÄ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ..DWDC4591001C4591001 1009 10091413100914131009AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26916 DWDŢ¨DWĺ.DWĺDWDWDŢ¨DW*Dĺ°DWDŢ¨DW*Dĺ°....HrÍĽ¨HręÄ°HrÍĽ¨HręÄ°..DWDW*..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWg .. DŢ¨Dĺ°....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWg. Normal weightA NYYYNEGDWHDWDWĺ..NEG....YNNNNYYDW........DWHDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÔBgBmBęB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1009 10091414100914141009AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26920 DWDîÔDWŢ.DWŢDWDWDîÔDW+DčĽDWDîÔDW+DčĽ....HrÍĚÔHrě<HrÍĚÔHrě<..DWDW+..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWr .. DîÔDčĽ....33285 Christensen, Shane Glade ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŢDWr. Normal weightA NNYYNEGDWHDWÚDWÚ..NEG....YNNNNYYDW........DWHDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÝDWýDWýBÓBłB BęBĘ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1013 10131821101318211013AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20333 DVéD˝`DW´.DW´DVéDVéD˝`DVţDÝ|DVéD˝`DVţDÝ|....Hr”ęŕHr°ş|Hr”ęŕHr°ş|..DVéDVţ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D˝`DÝ|....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DW#. Overweight A0YNYYNEGDWDWłDW´..NEG....YNNNNYYDVé........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWłDWýDWýCB¶BJCPBË9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131822101318221013AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20332 DVéDĽ¬DWö.DWöDVéDVéDĽ¬DVţDÜČDVéDĽ¬DVţDÜČ....Hr”ę,Hr°ąČHr”ę,Hr°ąČ..DVéDVţ..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DĽ¬DÜČ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DW#. Normal weightA NNYYNEGDWDWłDW´..NEG....YNNNNYYDVé........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWłDWýDWýCB¶BJCPBË9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131823101318231013AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20335 DVęD·üDWć..DVęDVęD·üDWĘDăXDVęD·üDV˙DĐ DW¶DŠ„DWĘDăXHr–6üHs˝˛XHr–6üHr±ţ Hs˘ű„Hs˝˛XDVęDV˙DW¶DWĘAđYEARSBYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. D·üDĐ .DŠ„DăX.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW¶. Obese A@YNYYNEGDWDW’DWµDWćDX‡NEG....YNNNNYYDVę........DWDW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW’DWýDWýB˙B”BHBkC@B©9-10 months A 5-6 months A`2-3 monthsA09-10 months A . ..DWC4591001C4591001 1013 10131824101318241013AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20554 DVęD¸°DWß..DVęDVęD¸°DV˙DĐDVęD¸°DV˙DĐ....Hr–7°Hr±˙Hr–7°Hr±˙..DVęDV˙..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. D¸°DĐ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW. Normal weightA NNYYNEGDWDW’DWµ..NEG....YNNNNYYDVę........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýB˙B”BkC@B©9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DW)C4591001C4591001 1013 10131826101318261013AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20558 DVęDçĚDWĐ.DWĐDVęDVęDçĚDW´DÜČDVęDçĚDWDé4DWˇD‡đDW´DÜČHr–fĚHs ŞČHr–fĚHrłi4Hs‡IpHs ŞČDVęDWDWˇDW´AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçĚDé4.D‡đDÜČ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW DWˇ. Normal weightA NNYYNEGDWDWźDW DWĐDXqNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWźDWýDWýBţB B]B^C@B¶9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131828101318281013AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20559 DVëD” DW¨.DW¨DVëDVëD” DWDŐHDVëD” DWDŐH....Hr—d HrĽŹČHr—d HrĽŹČ..DVëDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. D” DŐH....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW$. Underweight ANNYYNEGDW$DWDW¨..NEG....YNNNNYYDVë........DW$DW¨YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýB÷BŠBmC0B¦8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131830101318301013AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVë20564 DVëD–xDWŚ.DWŚDVëDVëD–xDWD× DVëD–xDWD× ....Hr—fřHrłW Hr—fřHrłW ..DVëDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWŚWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. D–xD× ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDWDW˝DW˝..NEG....YNNNNYNDVë........DW.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWŚ.DWŚBŤBŤ..B˘B˘5-6 months A`5-6 months A` .5-6 months A` . ...C4591001C4591001 1013 10131835101318351013AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20676 DVëD˛ DWĐ.DWĐDVëDVëD˛ DW®DČ(DVëD˛ DV˙DČdDWšDëŚDW®DČ(Hr—‚ Hs(Hr—‚ Hr±öäHs~rŚHs(DVëDV˙DWšDW®AŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ DČd.DëŚDČ(.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DWš. Normal weightA NNYYNEGDWDW“DW™DWĐDXkNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýB˙B•BdBjC0B©9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131836101318361013AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20681 DVëD˛DW®.DW®DVëDVëD˛DV˙DČÜDVëD˛DV˙DČÜ....Hr—Hr±÷\Hr—Hr±÷\..DVëDV˙..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. D˛DČÜ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW. Obese A@YNYYNEGDWDW“DW®..NEG....YNNNNYYDVë........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýB˙B•BjC0B©9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1013 10131839101318391013AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVë20682 DVëDşTDWË.DWËDVëDVëDşTDWDĐ DVëDşTDWDĐ ....Hr—ŠÔHrłP Hr—ŠÔHrłP ..DVëDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DşTDĐ ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWľDW. Normal weightA NNYYNEGDWDW˝DWË..NEGDWż.DWżDWżYNNNNYYDVë........DWDWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW˝DWýDWýBţBľB@C0BÓ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131841101318411013AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20736 DVëDě¸DW°.DW°DVëDVëDě¸DV˙DÚ4DVëDě¸DV˙DÚ4....Hr—˝8Hr˛´Hr—˝8Hr˛´..DVëDV˙..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. Dě¸DÚ4....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DW. Normal weightA NNYYNEGDWDWŻDW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŻDWýDWýB˙B±BNC0BĹ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131842101318421013AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20738 DVëDí0DWŃ.DWŃDVëDVëDí0DWŃDáDVëDí0DV˙DŘĚDW°DßDWŃDáHr—˝°HsĆę€Hr—˝°Hr˛LHs›gHsĆę€DVëDV˙DW°DWŃAđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dí0DŘĚ.DßDá.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW°DW°. Normal weightA NNYYNEGDWDWŻDWŻDWôDXŽNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŻDWýDWýB˙B±BNBNC0BĹ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1013 10131843101318431013AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20684 DVëDďDWß.DWßDVëDVëDďDV˙Dâ,DVëDďDV˙Dâ,....Hr—ŔHr˛¬Hr—ŔHr˛¬..DVëDV˙..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DďDâ,....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW#. Normal weightA NYYYNEGDW#DW’DWĚ..NEG....YNNNNYYDVë........DW#DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýB˙B”BkC0B¨9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DWßC4591001C4591001 1013 10131844101318441013AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20743 DVëDďDWě.DWěDVëDVëDďDWĚDęŘDVëDďDV˙DâŕDW·DěDWĚDęŘHr—żHsŔ\ŘHr—żHr˛`Hs¤®„HsŔ\ŘDVëDV˙DW·DWĚAĐYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďDâŕ.DěDęŘ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW·. Overweight A0YNYYNEGDW#DW’DW¶DWěDX‰NEG....YNNNNYNDVë........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýB˙B”BGBkC0B¨9-10 months A 5-6 months A`2-3 monthsA09-10 months A . ..DWŽC4591001C4591001 1013 10131845101318451013AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20744 DVěDŚ DW´.DW´DVěDVěDŚ DWDČdDVěDŚ DWDČd....Hr® HrłHdHr® HrłHd..DVěDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DŚ DČd....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW. Normal weightA NNYYNEGDWDW’DW´..NEG....YNNNNYYDVě........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýBţB“BkC B§9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1013 10131846101318461013AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20821 DVěDĄđDWŽ.DWŽDVěDVěDĄđDV˙DßÔDVěDĄđDV˙DßÔ....HrÇđHr˛THrÇđHr˛T..DVěDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĄđDßÔ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDWDWĽDWĽ..NEG....YNNNNYNDVě........DW.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWŽ.DWŽBB..BŁBŁ5-6 months A`5-6 months A` .5-6 months A` . ...C4591001C4591001 1013 10131848101318481013AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVě20825 DVěD¦hDWŽ.DWŽDVěDVěD¦hDV˙DŰŘDVěD¦hDV˙DŰŘ....HrČhHr˛ XHrČhHr˛ X..DVěDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¦hDŰŘ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANNYYNEGDWDWĽDWĽ..NEG....YNNNNYNDVě........DW.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWŽ.DWŽBB..BŁBŁ5-6 months A`5-6 months A` .5-6 months A` . ...C4591001C4591001 1013 10131850101318501013AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20827 DVěD·üDW´.DW´DVěDVěD·üDWDŘĚDVěD·üDWDŘĚ....HrŮüHrłXĚHrŮüHrłXĚ..DVěDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW! .. D·üDŘĚ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŻDW!. Overweight A0NNYYNEGDW!DW®DW´..NEG....YNNNNYYDVě........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW®DWýDWýBţBŻBOC BĂ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131851101318511013AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20828 DVđDž4DWű.DWűDVđDVđDž4DW×DĘDVđDž4DWDČdDW´DÉĚDW×DĘHrž4HsÎĽHrž4HrąßäHs —ĚHsÎĽDVđDWDW´DW×AđYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW!BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4DČd.DÉĚDĘ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW´DW´. Normal weightA NNYYNEGDW!DWłDWłDWűDX”NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWłDWýDWýBůBŻBJBJCŕBÄ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1013 10131852101318521013AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21153 DVđD¦hDWŇ.DWŇDVđDVđD¦hDWµDČÜDVđD¦hDWDßÔDW D× DWµDČÜHržhHsˇč\HržhHrą÷THs†G Hsˇč\DVđDWDW DWµAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¦hDßÔ.D× DČÜ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW . Normal weightA NNYYNEGDW!DW—DWźDWŇDXrNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW—DWýDWýBůB“B^BfCŕB¨8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131855101318551013AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21154 DVńD ŚDW¶.DW¶DVńDVńD ŚDWDć(DVńD ŚDWDć(....HrźZHr»O(HrźZHr»O(..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D ŚDć(....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DW#. Normal weightA NNYYNEGDW#DWµDW¶..NEG....YNNNNYYDVń........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWµDWýDWýBřB°BHCĐBĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131856101318561013AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21671 DVňD´DW‹.DW‹DVňDVňD´DWDŕDVňD´DWDŕ....Hr żHrĽ›Hr żHrĽ›..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADW‹WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. D´Dŕ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW/DWÄDWÄ..NEG....YNNNNYNDVň........DW/.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDW‹.DW‹B…B…..BšBš4-5 months AP4-5 months AP .5-6 months A` . ...C4591001C4591001 1013 10131858101318581013AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21164 DVňD˛DWű.DWűDVňDVňD˛DW®D× DVňD˛DWDËpDW’DŢ¨DW®D× Hr ˝HsĽ Hr ˝Hr»4pHssŮ¨HsĽ DVňDWDW’DW®AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW"BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛DËp.DŢ¨D× .347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Underweight ANNYYNEGDW"DWDW‘DWŃDXkNEG....YNNNNYNDVň........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹BlBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131859101318591013AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21155 DVňD±0DW˝.DW˝DVňDVňD±0DWD…DVňD±0DWD…....Hr Ľ0Hr˝‘Hr Ľ0Hr˝‘..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D±0D…....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˝DW). Underweight ANNYYNEGDW)DWĽDW˝..NEG....YNNNNYYDVň........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĽDWýDWýBöBµBACŔBË8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1013 10131860101318601013AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21673 DVňDŇxDWĚ.DWĚDVňDVňDŇxDW®DŘĚDVňDŇxDWDŃÄDWšDŐHDW®DŘĚHr ÝxHs˝ĚHr ÝxHr»:ÄHs~\HHs˝ĚDVňDWDWšDW®AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇxDŃÄ.DŐHDŘĚ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWš. Normal weightA NNYYNEGDW#DW’DW™DWĚDXkNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBřBŤBdBkCŔBˇ8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131861101318611013AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVó21677 DVóD–xDWő.DWőDVóDVóD–xDWDÇ8DVóD–xDWDÇ8....HrˇňřHrĂ8HrˇňřHrĂ8..DVóDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D–xDÇ8....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWőDW2. Underweight ANNYYNEGDW2DWôDWő..NEG....YNNNNYYDVó........DW2DWőYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWôDWýDWýBňBéAC°C 8-9 months A8-9 months A0-1 month A9-10 months A . ...C4591001C4591001 1013 10131862101318621013AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21678 DVóDŻDWí.DWíDVóDVóDŻDWDĐDVóDŻDWDĐ....Hr˘”Hr»9Hr˘”Hr»9..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWíWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŻDĐ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWš.. Overweight A0NNYYNEGDW#DW™DWĂ..NEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW™DWíDWíBčB”BTBűB§8-9 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1013 10131863101318631013AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21983 DVóDčDWĘ.DWĘDVóDVóDčDWDČdDVóDčDWDŐ„DWDßÔDWDČdHr˘DHs—[äHr˘DHrĽHs{ĂÔHs—[äDVóDWDWDWAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDŐ„.DßÔDČd.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW. Underweight ANNYYNEGDW#DWDW—DWĘDXjNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB÷BŠBfBmC°Bž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131865101318651013AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21987 DV÷D›dDWĹ.DWĹDV÷DV÷D›dDWDŕDV÷D›dDWDŕ....Hr§=äHrĹŐHr§=äHrĹŐ..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. D›dDŕ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW1. Obese A@YNYYNEGDW*DW“DWĹ..NEG....YNNNNYYDV÷........DW*DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBđB†BjCpBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131866101318661013AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21990 DV÷Dš°DWĹ.DWĹDV÷DV÷Dš°DWDßDV÷Dš°DWDß....Hr§=0HrĹÔHr§=0HrĹÔ..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. Dš°Dß....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW1. Overweight A0YNYYNEGDW*DW“DWĹ..NEG....YNNNNYYDV÷........DW*DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBđB†BjCpBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131867101318671013AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú21992 DVúD°@DWŢ.DWŢDVúDVúD°@DW˝Dč€DVúD°@DW Dß DW DËčDW˝Dč€Hr«G@Hs¬”Hr«G@HrÄ‚ Hs†;čHs¬”DVúDW DW DW˝AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°@Dß .DËčDč€.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW . Underweight ANYYYNEGDW*DWDWźDWŢDXzNEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýBńB„B^BmC@B—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DW…C4591001C4591001 1013 10131868101318681013AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23579 DVţD› DW’.DW’DVţDVţD› DWDŃÄDVţD› DWDŃÄ....Hr°x HrÍŻÄHr°x HrÍŻÄ..DVţDW..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0DW’WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D› DŃÄ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDW2DWŃDWŃ..NEG....YNNNNYNDVţ........DW2.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDW’.DW’BB..B•B•4-5 months AP4-5 months AP .5-6 months A` . ...C4591001C4591001 1013 10131869101318691013AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ117929DVţD©ěDWˇ.DWˇDVţDVţD©ěDWDŕÄDVţD©ěDWDŕÄ....Hr°†ěHrĎDHr°†ěHrĎD..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWˇWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D©ěDŕÄ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWˇDW6. Underweight ANNYYNEGDW6DW DWŇ..NEG....YNNNNYNDVţ........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW DWˇDWˇBŤBŚAB¤BŁ5-6 months A`5-6 months A`0-1 month A5-6 months A` . ...C4591001C4591001 1013 10131870101318701013AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23583 DVţDŞ DWx.DWxDVţDVţDŞ DWDŕDVţDŞ DWDŕ....Hr°‡ HrĎHr°‡ HrĎ..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWxWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DŞ Dŕ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDW6DWŇDWŇ..NEG....YNNNNYNDVţ........DW6.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWx.DWxBdBd..B{B{3-4 months A@3-4 months A@ .4-5 months AP . ...C4591001C4591001 1013 10131871101318711013AĐYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23585 DVţD˝`DWĂ.DWĂDVţDVţD˝`DWDáDVţD˝`DWDá....Hr°š`HrĚm€Hr°š`HrĚm€..DVţDW..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. D˝`Dá....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW/. Underweight ANNYYNEGDW/DW‘DWĂ..NEG....YNNNNYYDVţ........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBëBBlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131872101318721013AŔYEARSMAMULTIPLE A`HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23586 DVţDĽ¬DWç..DVţDVţDĽ¬DWDßÔDVţDĽ¬DWDßÔ....Hr°™¬HrĚlTHr°™¬HrĚlT..DVţDW..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DĽ¬DßÔ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW/. Underweight ANNYYNEGDW/DW‘DWĂ..NEG....YNNNNYYDVţ........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBëBBlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131873101318731013AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24005 DV˙D·HDWŃ.DWŃDV˙DV˙D·HDWDĆ„DV˙D·HDWDĆ„....Hr±ĺČHrÎöHr±ĺČHrÎö..DV˙DW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D·HDĆ„....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Overweight A0YNYYNEGDW*DWŃDWŃ..NEG....YNNNNYYDV˙........DW*DWŃYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBéBé..B˙B˙8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1013 10131874101318741013AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24002 DV˙D¬DWç..DV˙DV˙D¬DWçDĂ´DV˙D¬DWDÄŕDWŃDÜPDWçDĂ´Hr±ÚHsăÎ4Hr±ÚHrÎô`HsĆĺĐHsăÎ4DV˙DWDWŃDWçAŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬DÄŕ.DÜPDĂ´.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŃDWŃ. Overweight A0YNYYNEGDW*DWĐDWĐDX DX¤NEG....YNNNNYNDV˙........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĐDWýDWýBéBĽB-B-B˙BŇ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1013 10131875101318751013AŕYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24004 DV˙D¬ĽDWĐ.DWĐDV˙DV˙D¬ĽDWDÉDV˙D¬ĽDWDß DWDŃÄDWDÉHr±Ű<Hs—\Hr±Ű<HrĎ Hs{µÄHs—\DV˙DWDWDWAŕYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬ĽDß .DŃÄDÉ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DW. Normal weightA NNYYNEGDW1DW“DW—DWĐDXjNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýBéBBfBjB˙B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1013 10131876101318761013AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24008 DV˙D¸8DWÉ.DWÉDV˙DV˙D¸8DWDĆŔDV˙D¸8DWDĆŔ....Hr±ć¸HrÍ¤ŔHr±ć¸HrÍ¤Ŕ..DV˙DW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D¸8DĆŔ....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW7. Normal weightA NNYYNEGDW7DWDWÉ..NEG....YNNNNYYDV˙........DW7DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBęB}BmB˙B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131877101318771013AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24167 DWDŠHDWĘ.DWĘDWDWDŠHDWDăDWDŠHDWDă....Hrł HHrĎśHrł HHrĎś..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DŠHDă....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWD. Normal weightA NNYYNEGDWDDWDWĘ..NEG....YNNNNYYDW........DWDDWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBéB|BmBţB‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131878101318781013AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24174 DWD‘PDW™.DW™DWDWD‘PDWDŢ¨DWD‘PDWDŢ¨....HrłPHrĎ(HrłPHrĎ(..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW™WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D‘PDŢ¨....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW‘DW7. Normal weightA NNYYNEGDW7DWDWŇ..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDW™DW™B…B|ABšB‘4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1013 10131879101318791013AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24168 DWDŹčDWŻ.DWŻDWDWDŹčDW“DÜŚDWDŹčDWDĺ8DW~DÝDW“DÜŚHrłčHsu)HrłčHrĚq¸HsYzHsu)DWDWDW~DW“AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹčDĺ8.DÝDÜŚ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWxDW~. Underweight ANNYYNEGDW/DWwDW}DWŻDXPNEG....YNNNNYNDW........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWwDWýDWýBëBeB€B†BţBx8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1013 10131880101318801013AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24173 DWDŽDDWĂ.DWĂDWDWDŽDDWDĺ°DWDŽDDWDĺ°....HrłDHrĚr0HrłDHrĚr0..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DŽDDĺ°....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW/. Overweight A0YNYYNEGDW/DWDWĂ..NEG....YNNNNYYDW........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBëB~BmBţB‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1013 10131881101318811013AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24361 DWDĄ<DWĚ.DWĚDWDWDĄ<DWDÔXDWDĄ<DWDÔX....HrąĽĽHrŘ>XHrąĽĽHrŘ>X..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DĄ<DÔX....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĚDW. Normal weightA NYYYNEGDW8DWËDWĚ..NEG....YNNNNYYDW........DW8DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWËDWýDWýBâB°B2BůBÇ8-9 months A6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1013 10131882101318821013AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24365 DWD™„DWĆ.DWĆDWDWD™„DW¦DĺtDWD™„DWDÔXDW‘DŇđDW¦DĺtHrĽTHsŽ>tHrĽTHrÖěŘHsr|pHsŽ>tDWDWDW‘DW¦AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. D™„DÔX.DŇđDĺt.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW9DWŚDWDWĆDXcNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBmBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1013 10131883101318831013AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24366 DWDš°DWĹ.DWĹDWDWDš°DW©Dâ¤DWDš°DWDčřDW”DęŘDW©Dâ¤Hr˝¦°Hs’0$Hr˝¦°HrŮ¤xHsvŘHs’0$DWDWDW”DW©AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš°Dčř.DęŘDâ¤.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Underweight ANNYYNEGDW?DWDW“DWĹDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBáBtBjBmBöB‰8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1013 10131884101318841013AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24368 DWDŤĚDWî.DWîDWDWDŤĚDW$Dé¬DWDŤĚDW$Dé¬....HrĆÔLHrâß¬HrĆÔLHrâß¬..DWDW$..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. DŤĚDé¬....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW$. Normal weightA NNYYNEGDW@DWDWî..NEG....YNNNNYYDW........DW@DWîYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÚBmBmBďB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1013 10131885101318851013AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25893 DWDŽřDWĘ.DWĘDWDWDŽřDW®DÉDWDŽřDW"DŕDW›DÉDW®DÉHrĆŐxHs®HrĆŐxHrŕ3Hs˘Hs®DWDW"DW›DW®AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽřDŕ.DÉDÉ.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW›. Underweight ANNYYNEGDW?DW‘DWšDWĘDXkNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÜBpBcBlBďB7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1013 10131886101318861013AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25894 DWDpDWĆ.DWĆDWDWDpDW©Dá´DWDpDW#DŘĚDW“DhDW©Dá´HrĆóđHs’/4HrĆóđHrá}LHstÔčHs’/4DWDW#DW“DW©AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpDŘĚ.DhDá´.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDW?DWDW’DWĆDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBŰBnBkBmBďB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1016 10161307101613071016AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20025 DV»D¬řDWú.DWúDV»DV»D¬řDW©Dš°DV»D¬řDVĎD’|DW“D™„DW©Dš°HrX5xHs‘č0HrX5xHrrxüHstćHs‘č0DV»DVĎDW“DW©AĐYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬řD’|.D™„Dš°.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Obese A@YNYYNEGDVěDW€DW€DWĆDXfNEG....YNNNNYYDV»........DVěDW€YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCđBľBkBqC0BŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161308101613081016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20032 DV»D®`DWÉ.DWÉDV»DV»D®`DWD‚PDV»D®`DVÎD†LDWšDŠŔDWD‚PHrX6ŕHs—ĐHrX6ŕHrqLHs~ŔHs—ĐDV»DVÎDWšDWAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. D®`D†L.DŠŔD‚P.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Underweight ANYYYNEGDVđDWDWDWÉDXjNEG....YNNNNYYDV»........DVđDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCBżBdBqC0BŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161309101613091016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20035 DV»DŃDWö.DWöDV»DV»DŃDV×DŁÔDV»DŃDV×DŁÔ....HrXZHr}THrXZHr}T..DV»DV×..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DŃDŁÔ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDVůDWŚDWŤ..NEG....YNNNNYYDV»........DVůDWŤYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCpB¶BqC0BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161310101613101016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20036 DV»DÔ”DW™.DW™DV»DV»DÔ”DVĎD„0DV»DÔ”DVĎD„0....HrX]Hrrj°HrX]Hrrj°..DV»DVĎ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DÔ”D„0....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDVëDWDW..NEG....YNNNNYYDV»........DVëDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCđBľBqC0BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161311101613111016AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20052 DV»DÚpDWś..DV»DV»DÚpDVÎDĘDV»DÚpDVÎDĘ....HrXbđHrq_HrXbđHrq_..DV»DVÎ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÚpDĘ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Obese A@YYYYNEGDVëDW?DW..NEG....YNNNNYYDV»........DVëDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW?DWýDWýCBrBľC0B…10-11 monthsA°4-5 months AP0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161314101613141016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVĽ20053 DVĽDťĽDWš.DWšDVĽDVĽDťĽDVĐDŚ(DVĽDťĽDVĐDŚ(....HrYwĽHrsÄ(HrYwĽHrsÄ(..DVĽDVĐ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DťĽDŚ(....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDVíDW€DW€..NEG....YNNNNYYDVĽ........DVíDW€YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýCŕCŕ..C C 10-11 monthsA°10-11 monthsA° .11-12 monthsAŔ . ...C4591001C4591001 1016 10161315101613151016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20055 DVĽDÓ,DWÄ.DWÄDVĽDVĽDÓ,DW¨DŢ¨DVĽDÓ,DVŃD”ÔDW”DÎ@DW¨DŢ¨HrY,HsÚ¨HrY,HruTHsvl@HsÚ¨DVĽDVŃDW”DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓ,D”Ô.DÎ@DŢ¨.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Normal weightA NNYYNEGDVíDWDWDWÄDXePOS....YNNNNYYDVĽ........DVíDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWýDWýCĐBŔBjBmC BŐ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ..DW0C4591001C4591001 1016 10161316101613161016AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20058 DVĽDŐHDWo..DVĽDVĽDŐHDWSDĚśDVĽDŐHDVĽDŐHDW@DĎlDWSDĚśHrYŻHHs ąHrYŻHHrYŻHHsŻlHs ąDVĽ.DW@DWSAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. DVĚNO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐH..DĎlDĚś.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW>DW@. Normal weightA NNYYNEGDV÷DW=DW?DWoDXPOS....YNNNNYNDVĽ........DV÷.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW=DWýDWýBľBŔC B‚0-1 month A0-1 month A6-7 monthsAp11-12 monthsAŔ . ..DVÍC4591001C4591001 1016 10161318101613181016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20099 DVĽDÜDWŘ.DWŘDVĽDVĽDÜDWĽDĐÔDVĽDÜDVĎDĐ DW©DÖ8DWĽDĐÔHrY¶Hs«*ÔHrY¶Hrr¶ Hs’#¸Hs«*ÔDVĽDVĎDW©DWĽAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜDĐ .DÖ8DĐÔ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW©. Overweight A0YNYYNEGDVíDWDWDWŘDXyNEG....YNNNNYYDVĽ........DVíDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCđBľBUBqC BŃ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161319101613191016AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20103 DVĽDß\DWÉ..DVĽDVĽDß\DWDŐüDVĽDß\DVĎDÎ|DW™Dâ¤DWDŐüHrYą\Hs—i|HrYą\Hrr´üHs}$Hs—i|DVĽDVĎDW™DWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß\DÎ|.Dâ¤DŐü.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW™. Obese A@YYYYNEGDVëDWDWDWÉDXjPOS....YNNNNYYDVĽ........DVëDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‘DWýDWýCđBĂBeBlC BÖ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ..DVŐC4591001C4591001 1016 10161320101613201016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20176 DVÁDśTDW‘.DW‘DVżDVÁDśTDVÔDŽ€DVÁDśTDVÔDŽ€....Hr` ÔHry€Hr` ÔHry€..DVÁDVÔ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DśTDŽ€....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDVńDW„DW„..NEG....YNNNNYYDVÁ........DVńDW„YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýC B˝BmCĐBĐ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161322101613221016AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20107 DVżD¦ŕDWŤ.DWŤDVżDVżD¦ŕDVÔD’¸DVżD¦ŕDVÔD’¸....Hr]u`Hry¸Hr]u`Hry¸..DVżDVÔ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D¦ŕD’¸....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Overweight A0NNYYNEGDVđDW„DW„..NEG....YNNNNYYDVż........DVđDW„YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýC BąBqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161323101613231016AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20108 DVżDĹĐDWŤ.DWŤDVżDVżDĹĐDVÔD¤DVżDĹĐDVÔD¤....Hr]”PHry"Hr]”PHry"..DVżDVÔ..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DĹĐD¤....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Normal weightA NNYYNEGDVđDWŚDWŚ..NEG....YNNNNYYDVż........DVđDWŚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýC BąBqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161324101613241016AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVż20109 DVżDĹXDWĚ.DWĚDVżDVżDĹXDW°DÉĚDVżDĹXDVÔDĄDW›DŇđDW°DÉĚHr]“ŘHs›QĚHr]“ŘHry#Hs«pHs›QĚDVżDVÔDW›DW°AđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĹXDĄ.DŇđDÉĚ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Normal weightA NYYYNEGDVđDWŚDWŚDWĚDXmNEG....YNNNNYYDVż........DVđDWŚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýC BąBcBqCđBÎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161325101613251016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20110 DVżDŇxDWú.DWúDVżDVżDŇxDVŐDßDVżDŇxDVŐDß....Hr] řHrzŻHr] řHrzŻ..DVżDVŐ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DŇxDß....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Overweight A0NNYYNEGDVńDW…DW…..NEG....YNNNNYYDVż........DVńDW…YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCB¸BqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161326101613261016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20114 DVŔD‰XDWŤ.DWŤDVŔDVŔD‰XDVŐD—ŕDVŔD‰XDVŐD—ŕ....Hr^©XHrzg`Hr^©XHrzg`..DVŔDVŐ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D‰XD—ŕ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NYYYNEGDVńDW‡DW‡..NEG....YNNNNYYDVŔ........DVńDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCB¸BqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161327101613271016AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20120 DVŔD‰XDWŃ..DVŔDVŔD‰XDWµD¸DVŔD‰XDVŐD—¤DW DÖtDWµD¸Hr^©XHsˇŁ8Hr^©XHrzg$Hs†FtHsˇŁ8DVŔDVŐDW DWµAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‰XD—¤.DÖtD¸.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW . Underweight ANYYYNEGDVńDW‡DW‡DWŃDXrNEG....YNNNNYYDVŔ........DVńDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCB¸B^BqCŕBÍ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161329101613291016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20171 DVŔDŠüDWÎ..DVŔDVŔDŠüDW¨Dß\DVŔDŠüDVŐDć DW“DÔ”DW¨Dß\Hr^ŞüHsŰ\Hr^ŞüHrz¶ Hsu!HsŰ\DVŔDVŐDW“DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŠüDć .DÔ”Dß\.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Obese A@YYYYNEGDV÷DW‡DW‡DWÄDXeNEG....YNNNNYYDVŔ........DV÷DW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýCBĽBkBmCŕBŃ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161330101613301016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20174 DVŔDŇ´DWŤ.DWŤDVŔDVŔDŇ´DVÖDâ¤DVŔDŇ´DVÖDâ¤....Hr^ň´Hr|¤Hr^ň´Hr|¤..DVŔDVÖ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DŇ´Dâ¤....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDVôDW‹DW‹..NEG....YNNNNYYDVŔ........DVôDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýC€B·BqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161331101613311016AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20172 DVŔDŃDWĺ.DWĺDVŔDVŔDŃDWD§ĐDVŔDŃDVÖDđ<DWšDăXDWD§ĐHr^ńHs—;PHr^ńHr|<Hs~jXHs—;PDVŔDVÖDWšDWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃDđ<.DăXD§Đ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DWš. Overweight A0NNYYNEGDVňDW†DW†DWÉDXjNEG....YNNNNYYDVŔ........DVňDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýC€BĽBdBlCŕBŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161332101613321016AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20229 DVÁDÍDWŤ.DWŤDVÁDVÁDÍDVÔDŁÔDVÁDÍDVÔDŁÔ....Hr`>”Hry!ÔHr`>”Hry!Ô..DVÁDVÔ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DÍDŁÔ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Overweight A0NNYYNEGDVđDWŚDWŚ..NEG....YNNNNYYDVÁ........DVđDWŚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýC BąBqCĐBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161334101613341016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20231 DVÁDŇ´DWË.DWËDVÁDVÁDŇ´DW®D‡´DVÁDŇ´DVÖDß\DW›DćÜDW®D‡´Hr`D4Hsl´Hr`D4Hr|\Hsż\Hsl´DVÁDVÖDW›DW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ´Dß\.DćÜD‡´.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW›. Normal weightA NYYYNEGDVóDW‡DW‡DWËDXkNEG....YNNNNYYDVÁ........DVóDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýC€B»BcBmCĐBĐ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161335101613351016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20240 DVÁDěôDWđ..DVÁDVÁDěôDVÖD“0DVÁDěôDVÖD“0....Hr`^tHr{´0Hr`^tHr{´0..DVÁDVÖ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DěôD“0....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWA. Obese A@YNYYNEGDVňDWŚDWŚ..NEG....YNNNNYYDVÁ........DVňDWŚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýC€B»BmCĐBĐ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161336101613361016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20258 DVÁDílDWó.DWóDVÁDVÁDílDW×D§XDVÁDílDVÖD“¨DWĂDśĚDW×D§XHr`^ěHsÎ™ŘHr`^ěHr{´¨Hs´1LHsÎ™ŘDVÁDVÖDWĂDW×AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DílD“¨.DśĚD§X.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWĂ. Normal weightA NNYYNEGDVňDWŚDWŚDWóDX”NEG....YNNNNYYDVÁ........DVňDWŚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýC€B»B;BmCĐBĐ10-11 monthsA°6-7 months Ap2-3 monthsA011-12 monthsAŔ . ...C4591001C4591001 1016 10161337101613371016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20236 DVÁDčDDW§.DW§DVÁDVÁDčDDWŠDćÜDVÁDčDDVŐDĺ°DWuDä„DWŠDćÜHr`YÄHsiUÜHr`YÄHrzµ0HsM¤HsiUÜDVÁDVŐDWuDWŠAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDĺ°.Dä„DćÜ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWYDWu. Normal weightA NNYYNEGDVňDWXDWtDW§DXGNEG....YNNNNYNDVÁ........DVň.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWXDWýDWýCB„B‰BĄCĐB10-11 monthsA°4-5 months AP4-5 monthsAP11-12 monthsAŔ . ...C4591001C4591001 1016 10161338101613381016AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20259 DVÂDŽřDWŽ.DWŽDVÂDVÂDŽřDVŐDśDVÂDŽřDVŐDś....HraQřHrzkHraQřHrzk..DVÂDVŐ..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DŽřDś....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW,. Underweight ANNYYNEGDWDW„DW„..NEG....YNNNNYYDVÂ........DWDW„YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýCBąBpCŔBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161339101613391016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20262 DVÂD›(DW’.DW’DVÂDVÂD›(DVŐD`DVÂD›(DVŐD`....Hra^(Hrz_ŕHra^(Hrz_ŕ..DVÂDVŐ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D›(D`....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW*. Normal weightA NNYYNEGDVňDW…DW…..NEG....YNNNNYYDVÂ........DVňDW…YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýCBąBpCŔBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161340101613401016AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20263 DVÂD›dDWĐ.DWĐDVÂDVÂD›dDW®D†ÄDVÂD›dDVŐD$DWšDŠüDW®D†ÄHra^dHskÄHra^dHrz_¤Hs~üHskÄDVÂDVŐDWšDW®AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D›dD$.DŠüD†Ä.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Obese A@YYYYNEGDVňDW…DW…DWĐDXkNEG....YNNNNYYDVÂ........DVňDW…YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýCBąBdBpCŔBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161343101613431016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20301 DVÂDę$DWŽ.DWŽDVÂDVÂDę$DVŘDĆŔDVÂDę$DVŘDĆŔ....Hra$Hr~ŠŔHra$Hr~ŠŔ..DVÂDVŘ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. Dę$DĆŔ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW,. Overweight A0NNYYNEGDVôDW‹DW‹..NEG....YNNNNYYDVÂ........DVôDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýC`B¶BpCŔBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1016 10161344101613441016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20306 DVÂDëPDWÂ.DWÂDVÂDVÂDëPDW¦Dĺ°DVÂDëPDVÖDŰśDW“D‹°DW¦Dĺ°Hra®PHsŽ>°Hra®PHr{üśHstŘ0HsŽ>°DVÂDVÖDW“DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëPDŰś.D‹°Dĺ°.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDVóDW†DW†DWÂDXcNEG....YNNNNYYDVÂ........DVóDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýC€B»BkBmCŔBĎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1016 10161350101613501016AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20309 DVéD“¨DWĺ.DWĺDVéDVéD“¨DVţD ŚDVéD“¨DVţD Ś....Hr”Á(Hr°}ŚHr”Á(Hr°}Ś..DVéDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D“¨D Ś....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW). Underweight ANYYYNEGDWDWDW®..NEG....YNNNNYYDVé........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCB“BmCPB¨9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1016 10161351101613511016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20308 DVéD’DWĺ.DWĺDVéDVéD’DWÉD… DVéD’DVţDŚÜDWDŽ€DWÉD… Hr”ż„HsĽ Hr”ż„Hr°iÜHs—"HsĽ DVéDVţDWDWÉAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. D’DŚÜ.DŽ€D… .80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NYYYNEGDWDWŤDW¬DWĺDX†NEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBBQBpCPBĄ9-10 months A 5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1016 10161352101613521016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20410 DVéDŢlDWĐ.DWĐDVéDVéDŢlDW´D¨DVéDŢlDVţDÍŚDW D‹8DW´D¨Hr•ěHs vHr•ěHr°ŞŚHs…ű8Hs vDVéDVţDW DW´AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢlDÍŚ.D‹8D¨.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW . Underweight ANYYYNEGDWDWŤDWźDWĐDXqNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBB^BpCPBĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1016 10161353101613531016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20411 DVéDčĽDWÉ.DWÉDVéDVéDčĽDWD—,DVéDčĽDWD” DWDčDWD—,Hr•<Hs—*¬Hr•<Hrł Hs{ĚHs—*¬DVéDWDWDWAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčĽD” .DčD—,.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNYYNEGDWDWŤDW—DWÉDXjNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBţBŽBfBpCPBĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1016 10161354101613541016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20412 DVëDŽ€DW·..DVëDVëDŽ€DWDŕDVëDŽ€DWDŕ....Hr—_HrłŕHr—_Hrłŕ..DVëDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DŽ€Dŕ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW*. Normal weightA NNYYNEGDWDWŤDW·..NEG....YNNNNYYDVë........DWDW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBţBŽBpC0BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1016 10161356101613561016AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20416 DVëD›(DW°.DW°DVëDVëD›(DV˙DŹpDVëD›(DV˙DŹp....Hr—k¨Hr±˝đHr—k¨Hr±˝đ..DVëDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D›(DŹp....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Normal weightA NNYYNEGDWDWŚDW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB˙BŽBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1016 10161357101613571016AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20653 DVëD˘0DW®.DW®DVëDVëD˘0DV˙D•LDVëD˘0DV˙D•L....Hr—r°Hr±ĂĚHr—r°Hr±ĂĚ..DVëDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D˘0D•L....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW7. Normal weightA NNYYNEGDWDWŤDW®..NEG....YNNNNYYDVë........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB˙BŹBpC0BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1016 10161358101613581016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVě20657 DVěD‰DWµ.DWµDVěDVěD‰DV˙DĘ€DVěD‰DV˙DĘ€....Hr«Hr±ůHr«Hr±ů..DVěDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D‰DĘ€....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDWDWµDWµ..NEG....YNNNNYYDVě........DWDWµYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýB˙B˙..C C 9-10 months A 9-10 months A .9-10 months A . ...C4591001C4591001 1016 10161361101613611016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20658 DVíD“lDWÂ.DWÂDVíDVíD“lDW¦DĐ DVíD“lDWD™DW‘DÁ\DW¦DĐ HršěHsŽ) HršěHrłHsrjÜHsŽ) DVíDWDW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWBNT162b2 (30 (*ESC*){unicode 03BC}g).. D“lD™.DÁ\DĐ .80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWDWŚDWDWÂDXcPOS....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDWŚDWýDWýBţBŤBmBqCB 9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1016 10161362101613621016AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20659 DVíDŰŘDW¶.DW¶DVíDVíDŰŘDWDÍČDVíDŰŘDWDÍČ....HršOXHrąĺHHršOXHrąĺH..DVíDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DŰŘDÍČ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Underweight ANYNYPOSDW"DWŚDW¶..POS....YNNNNYYDVí........DW"DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŚDWýDWýBůBBqCB 8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1016 10161363101613631016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21477 DVńDâ¤DW¶.DW¶DVńDVńDâ¤DWDÖtDVńDâ¤DWDÖt....Hrźś$HrąíôHrźś$Hrąíô..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. Dâ¤DÖt....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW#. Normal weightA NNNNPOSDW"DWDW¶..POS....YNNNNYYDVń........DW"DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWýDWýBůBŚBmCĐB 8-9 months A5-6 months A`0-1 month A9-10 months A . ..DW>C4591001C4591001 1016 10161364101613641016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21478 DVňDÚčDW».DW»DVňDVňDÚčDWDťDVňDÚčDWDť....Hr ĺčHr˝©Hr ĺčHr˝©..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DÚčDť....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŠDW+. Underweight ANNYYNEGDW+DW‰DW»..NEG....YNNNNYYDVň........DW+DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‰DWýDWýBöB‚BtCŔB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1016 10161365101613651016AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21481 DVóD¤DWĹ.DWĹDVóDVóD¤DW©DśDVóD¤DWDŚ(DW‘DÔ”DW©DśHr˘Hs‘ŢHr˘Hrşő(Hsr~Hs‘ŢDVóDWDW‘DW©AĐYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤DŚ(.DÔ”Dś.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Overweight A0YNYYNEGDW#DWŤDWDWĹDXfNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBřBBmBpC°B›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1016 10161366101613661016AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř21488 DVřDŰŘDWć..DVřDVřDŰŘDWÄDŮ€DVřDŰŘDWDëPDW“DçDWÄDŮ€Hr¨ĎŘHsµż€Hr¨ĎŘHrÇ1ĐHsu3Hsµż€DVřDWDW“DWÄAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰŘDëP.DçDŮ€.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDW8DWDW’DWćDXNEG....YNNNNYNDVř........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBďB‚BkBmC`B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1016 10161367101613671016AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24585 DWD™üDWÉ.DWÉDWDWD™üDWD«DWD™üDWD›dDWDĚ`DWD«Hr»üHs—>Hr»üHrÖłäHs{°`Hs—>DWDWDWDWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™üD›d.DĚ`D«.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Obese A@YNYYNEGDW=DWŤDW—DWÉDXjNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBăBsBfBpBřB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1016 10161368101613681016AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24589 DWDáxDWű..DWDWDáxDW¨DčĽDWDáxDWDÔĐDW“DŰ`DW¨DčĽHrĽ›řHsäĽHrĽ›řHrÖíPHsu'ŕHsäĽDWDWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DáxDÔĐ.DŰ`DčĽ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Underweight ANNYYNEGDW:DWDW’DWÄDXeNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBăBvBkBmB÷BŠ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1016 10161369101613691016AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24594 DWDĺ8DWó..DWDWDĺ8DW#DáxDWDĺ8DW#Dáx....HrĽź¸Hrá…řHrĽź¸Hrá…ř..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dĺ8Dáx....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDWFDWDWÔ..NEG....YNNNNYYDW........DWFDWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŰBnBmB÷BŠ7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161370101613701016AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24595 DWDŁ\DWŮ.DWŮDWDWDŁ\DW!DčřDWDŁ\DW!Dčř....HrÂő\HrŢęxHrÂő\HrŢęx..DWDW!..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW! .. DŁ\Dčř....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW!. Normal weightA NNYYNEGDWADW‘DWŮ..NEG....YNNNNYYDW........DWADWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBÝBqBlBňB†7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1016 10161371101613711016AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25234 DWDÚčDWÉ.DWÉDWDWDÚčDWDć(DWDÚčDW"DÝôDW™DÜŚDWDć(HrĂ,čHs—y¨HrĂ,čHrŕ0ôHs}Hs—y¨DWDW"DW™DWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW"BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚčDÝô.DÜŚDć(.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Normal weightA NNYYNEGDW>DWDWDWÉDXjNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÜBoBeBmBňB…7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1016 10161372101613721016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25237 DW DŢäDWľ.DWľDW DW DŢäDW˘DŢ¨DW DŢäDW#DáDWŤDć(DW˘DŢ¨HrÄ‚dHsń¨HrÄ‚dHrá…€HsmI¨Hsń¨DW DW#DWŤDW˘AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢäDá.Dć(DŢ¨.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Overweight A0YNYNPOSDW@DWŚDWŚDWľDX_POS....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBŰBjBqBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ..DW#C4591001C4591001 1016 10161373101613731016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25238 DW DçDWŇ.DWŇDW DW DçDW#DŤDW DçDW#DŤ....HrÄŠHrá1HrÄŠHrá1..DW DW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DçDŤ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW#. Overweight A0YNYYNEGDW?DWŚDWŇ..NEG....YNNNNYYDW ........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161374101613741016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25244 DWDŻPDWŕ..DWDWDŻPDW$DĄ<DWDŻPDW$DĄ<....HrĹ¤PHrâ›<HrĹ¤PHrâ›<..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. DŻPDĄ<....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW$. Normal weightA NNYYNEGDWADWŚDWŕ..NEG....YNNNNYYDW........DWADWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161375101613751016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25790 DWDâŕDWĂ.DWĂDWDWDâŕDW¦Dš°DWDâŕDW#DßDW‘DëPDW¦Dš°HrĹ×ŕHsŤó°HrĹ×ŕHrá„Hsr”ĐHsŤó°DWDW#DW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâŕDß.DëPDš°.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW?DWŚDWDWĂDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1016 10161376101613761016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25795 DWD©°DW×.DW×DWDWD©°DW"Dˇ¸DWD©°DW"Dˇ¸....HrĆđ0Hrßô¸HrĆđ0Hrßô¸..DWDW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. D©°Dˇ¸....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW". Normal weightA NNYYNEGDW>DW‚DW×..NEG....YNNNNYYDW........DW>DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‚DWýDWýBÜBaB{BďBt7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161377101613771016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25793 DWD©ěDW×.DW×DWDWD©ěDW"D˘0DWD©ěDW"D˘0....HrĆđlHrßő0HrĆđlHrßő0..DWDW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. D©ěD˘0....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW". Normal weightA NNYYNEGDW>DWŚDW×..NEG....YNNNNYYDW........DW>DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161378101613781016AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25796 DWDâhDWő..DWDWDâhDWőDćÜDWDâhDW"DčDDWŕDčDDWőDćÜHrÇ(čHsöf\HrÇ(čHrŕ;DHsÚ¸DHsöf\DWDW"DWŕDWőAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâhDčD.DčDDćÜ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW×DWŕ. Underweight ANNNYPOSDW>DWÔDWÔDXDX˛POS....YNNNNYYDW........DW>DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÖDWýDWýBÜBµBB'BďBČ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1016 10161379101613791016AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26104 DWDě|DWŮ.DWŮDWDWDě|DW»D“¨DWDě|DWDě|DW D¬ĽDW»D“¨HrÇ2üHs©ś(HrÇ2üHrÇ2üHs†ĽHs©ś(DW.DW DW»AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. DW,NO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě|..D¬ĽD“¨.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW . Normal weightA NNYYNEGDWMDWŤDWźDWŮDXxPOS....YNNNNYNDW........DWM.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWŤDWýDWýB^BpBďB0-1 month A0-1 month A3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1016 10161381101613811016AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26105 DWD–DWü.DWüDWDWD–DW$DźśDWD–DW$Dźś....HrČ.Hrâ•śHrČ.Hrâ•ś..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. D–Dźś....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW$. Normal weightA NNYYNEGDW@DWŚDWŕ..NEG....YNNNNYYDW........DW@DWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DWüC4591001C4591001 1016 10161382101613821016AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26106 DWDštDW×.DW×DWDWDštDW$DŰ$DWDštDW$DŰ$....HrČ2tHrâŃ$HrČ2tHrâŃ$..DWDW$..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. DštDŰ$....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW$. Normal weightA NNYYNEGDWADWŚDW×..NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161383101613831016AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26107 DWD™ŔDW˝.DW˝DWDWD™ŔDW Dš°DWD™ŔDW$DÚčDWŤDŮ€DW Dš°HrČ1ŔHs† °HrČ1ŔHrâĐčHsm=Hs† °DWDW$DWŤDW AŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™ŔDÚč.DŮ€Dš°.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWADWŚDWŚDW˝DX]NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBqBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1016 10161384101613841016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26170 DWD DW×.DW×DWDWD DW#Dč€DWD DW#Dč€....HrČ8HráŤHrČ8HráŤ..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D Dč€....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW#. Normal weightA NNYYNEGDW?DWŚDW×..NEG....YNNNNYYDW........DW?DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161385101613851016AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26172 DWDŇđDWŢ.DWŢDWDWDŇđDW%D„¨DWDŇđDW%D„¨....HrČjđHrăĚ(HrČjđHrăĚ(..DWDW%..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DŇđD„¨....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANNNYPOSDWADWŢDWŢ..POS....YNNNNYYDW........DWADWŢYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NNDWý.DWýBŮBŮ..BîBî7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1016 10161386101613861016AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26179 DWDŘĚDWÔ.DWÔDWDWDŘĚDW DÉDWDŘĚDW$D¤DWŤDňXDW DÉHrČpĚHs†9HrČpĚHrâšHsmUŘHs†9DWDW$DWŤDW AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘĚD¤.DňXDÉ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW@DWŚDWŚDWĽDX]NEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBqBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1016 10161387101613871016AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26180 DWDâhDWŇ.DWŇDWDWDâhDW#DÔĐDWDâhDW#DÔĐ....HrČzhHráyPHrČzhHráyP..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DâhDÔĐ....80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Obese A@YNYYNEGDW?DWŤDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1016 10161388101613881016AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26698 DWDäHDW´.DW´DWDWDäHDWDŤĚDWDäHDW)DÉDW…D“lDWDŤĚHrĚpČHs{qĚHrĚpČHréWHsbjěHs{qĚDWDW)DW…DWAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäHDÉ.D“lDŤĚ.80863 Finn, Daniel J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW…. Overweight A0YNYYNEGDWEDW‚DW„DW´DXUNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‚DWýDWýBŐBZByB{BëBp7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391246103912461039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20459 DVęD~TDWq..DVęDVęD~TDWUDš°DVęD~TDVţD‚DWADm°DWUDš°Hr•ýTHs#*0Hr•ýTHr°_Hsź0Hs#*0DVęDVţDWADWUAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D~TD‚.Dm°Dš°.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW>DWA. Normal weightA NNYYNEGDWDW=DW@DWqDXNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW=DWýDWýCB@B˝BŔC@BT9-10 months A 2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1039 10391247103912471039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20460 DVęD€¬DW.DWDVęDVęD€¬DVţD‚ŚDVęD€¬DVţD‚Ś....Hr•˙¬Hr°_ŚHr•˙¬Hr°_Ś..DVęDVţ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D€¬D‚Ś....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Underweight ANNYYNEGDWDW‹DW..NEG....YNNNNYYDVę........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýCBŽBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1039 10391250103912501039AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20465 DVíD†DWĂ.DWĂDVíDVíD†DWDwDVíD†DWDw....Hr™úHrąŽHr™úHrąŽ..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D†Dw....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW#DW‹DWĂ..NEG....YNNNNYYDVí........DW#DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBůB‡BrCBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391251103912511039AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20467 DVđDsDWđ.DWđDVđDVđDsDW@DlŔDVđDsDWDqčDW)DwDW@DlŔHrťŰHsLŔHrťŰHrÂĂčHréHsLŔDVđDWDW)DW@AđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DsDqč.DwDlŔ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW)DW). Normal weightA NNYYNEGDW(DW(DW(DW\DWđNEG....YNNNNYNDVđ........DW).YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW(DWýDWýBňBBŐBŐCŕB98-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1039 10391252103912521039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21109 DVđDxDWŽ.DWŽDVđDVđDxDWqDĂ<DVđDxDWDťĽDW\DÄŕDWqDĂ<HrťŕHsH<ĽHrťŕHrąµ<Hs,ŽŕHsH<ĽDVđDWDW\DWqAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DxDťĽ.DÄŕDĂ<.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWVDW\. Overweight A0NNYYNEGDW#DWUDW[DWŽDX.NEG....YNNNNYNDVđ........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWUDWýDWýBůBQB˘B¨CŕBf8-9 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1039 10391253103912531039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21111 DVđD$DWĺ.DWĺDVđDVđD$DWDž4DVđD$DWDž4....Hrťé$Hrąµ´Hrťé$Hrąµ´..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADWĺLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D$Dž4....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWU. Overweight A0YNYYNEGDW#DW‹DWÂ..NEG....YNNNNYNDVđ........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWĺDWĺBáB‡BZBöBś8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391255103912551039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21112 DVđD©°DWŇ.DWŇDVđDVđD©°DWDˇDVđD©°DWDˇ....Hrž°Hr» Hrž°Hr» ..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D©°Dˇ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW#DW‹DWÉ..NEG....YNNNNYYDVđ........DW#DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391256103912561039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21201 DVđD´<DWŇ.DWŇDVđDVđD´<DW˘DŻČDVđD´<DWD DWŤD·üDW˘DŻČHrž<HsÂČHrž<Hr» Hsm|HsÂČDVđDWDWŤDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´<D .D·üDŻČ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW#DW‹DWŚDWľDX_NEG....YNNNNYNDVđ........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW‹DWýDWýBřB†BqBrCŕBś8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391258103912581039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21113 DVđD˛ DWĂ.DWĂDVđDVđD˛ DW D©8DVđD˛ DWD±¨DWŤDµ¤DW D©8Hrž Hs†8Hrž HrąÉ(Hsm$Hs†8DVđDWDWŤDW AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ D±¨.Dµ¤D©8.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Overweight A0NYYYNEGDW$DW‹DWŚDWĂDX]NEG....YNNNNYNDVđ........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCŕBś8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391259103912591039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21202 DVđDżôDWż.DWżDVđDVđDżôDWŁDądDVđDżôDWD¤DWŽDĂ<DWŁDądHrž'ôHsŠäHrž'ôHrąĽHsnx<HsŠäDVđDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DżôD¤.DĂ<Dąd.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Overweight A0YNYYNEGDW!DW‹DWŤDWżDX`NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BpBrCŕBś8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391260103912601039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21209 DVđDÉĚDWŮ.DWŮDVđDVđDÉĚDWDĹXDVđDÉĚDWDĹX....Hrž1ĚHrąÜŘHrž1ĚHrąÜŘ..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÉĚDĹX....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW!DW‹DW»..NEG....YNNNNYYDVđ........DW!DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBůB‡BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391262103912621039AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21212 DVńDtôDWµ.DWµDVńDVńDtôDWDq4DVńDtôDWDq4....Hrź.tHrşÚ4Hrź.tHrşÚ4..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DtôDq4....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW$DWDWµ..NEG....YNNNNYYDVń........DW$DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBřB‹BmCĐB 8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391263103912631039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21357 DVńDxđDWŕ.DWŕDVńDVńDxđDWDpDVńDxđDWDp....Hrź2pHrşŮHrź2pHrşŮ..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DxđDp....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW$DWDWµ..NEG....YNNNNYYDVń........DW$DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBřB‹BmCĐB 8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391264103912641039AŔYEARSFA ASIAN A@HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21361 DVńD§”DW§.DW§DVńDVńD§”DWDÄhDVńD§”DWDˇDWDÄhDWDÄhHrźaHs{¨hHrźaHr» Hs{¨hHs{¨hDVńDWDW.AŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0DW§WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D§”Dˇ.DÄh..406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWDW§WITHDRAWAL BY SUBJECTUnderweight ANNYYNEGDWDDWŚDW—DWŇDXlNEG....YNNNNYNDVń........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW§DW§B˘B‡BBB·Bś5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1039 10391265103912651039AŔYEARSMAASIAN A@HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21364 DVńD«DWĽ.DWĽDVńDVńD«DWD®ŘDVńD«DWD®Ř....HrźdHr»ŘHrźdHr»Ř..DVńDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D«D®Ř....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANYYYNEGDWDDWŚDWĽ..NEG....YNNNNYYDVń........DWDDWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBřB‡BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391266103912661039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21368 DVńDşDWĹ.DWĹDVńDVńDşDW˘DĹĐDVńDşDWDXDWŽDÇ°DW˘DĹĐHrźtHsŘĐHrźtHr»XHsn|°HsŘĐDVńDWDWŽDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DşDX.DÇ°DĹĐ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDW"DW‹DWŤDWĹDX_NEG....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BpBrCĐB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391267103912671039AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21434 DVńDĂxDWż.DWżDVńDVńDĂxDWD{ŔDVńDĂxDWD{Ŕ....Hrź|řHrą“@Hrź|řHrą“@..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂxD{Ŕ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWR.. Normal weightA NNYYNEGDW!DWQDWż..NEG....YNNNNYYDVń........DW!DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWQDWýDWýBůBMB¬CĐBa8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1039 10391268103912681039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21430 DVńD˝ŘDWż.DWżDVńDVńD˝ŘDWŁD¸ěDVńD˝ŘDWDpDWŤDŽřDWŁD¸ěHrźwXHsŠlHrźwXHrą‡HslňxHsŠlDVńDWDWŤDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝ŘDp.DŽřD¸ě.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW!DW‹DWŚDWżDX`NEG....YNNNNYNDVń........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCĐB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ..DW%C4591001C4591001 1039 10391269103912691039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21431 DVńDŔ¨DWż.DWżDVńDVńDŔ¨DWDpřDVńDŔ¨DWDpř....Hrźz(HrąxHrźz(Hrąx..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŔ¨Dpř....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW!DW‹DWż..NEG....YNNNNYYDVń........DW!DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBůB‡BrCĐB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391270103912701039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21437 DVňDˇôDWľ.DWľDVňDVňDˇôDW˘D{„DVňDˇôDWDŚdDWŤD{DW˘D{„Hr ¬ôHsŽ„Hr ¬ôHrąŁäHslŢŚHsŽ„DVňDWDWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DˇôDŚd.D{D{„.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW!DW‹DWŚDWľDX_NEG....YNNNNYNDVň........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCŔBš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391271103912711039AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21721 DVňDĂđDWľ.DWľDVňDVňDĂđDW˘D¬DVňDĂđDWDşDWŤDśTDW˘D¬Hr ÎđHsżHr ÎđHrąŃHsl˙ÔHsżDVňDWDWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂđDş.DśTD¬.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW!DW‹DWŚDWľDX_NEG....YNNNNYNDVň........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCŔBš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391272103912721039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21723 DVňD¶DW˝.DW˝DVňDVňD¶DWDłDVňD¶DWDł....Hr ÁHrąËHr ÁHrąË..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¶Dł....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW!DW‹DW˝..NEG....YNNNNYYDVň........DW!DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBůB‡BrCŔBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391273103912731039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21717 DVňDÄhDWľ.DWľDVňDVňDÄhDW˘D¬DVňDÄhDWDąÜDWŤDśDW˘D¬Hr ĎhHsżHr ĎhHrąŃ\Hsl˙HsżDVňDWDWŤDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄhDąÜ.DśD¬.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW!DW‹DWŚDWľDX_NEG....YNNNNYNDVň........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCŔBš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391274103912741039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22739 DVůD{„DWĂ.DWĂDVůDVůD{„DWŁDqčDVůD{„DWDpDDWŽDštDWŁDqčHr©ÁHs‰ÖhHr©ÁHrÂÂDHsnOtHs‰ÖhDVůDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D{„DpD.DštDqč.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW(DWŚDWŤDWĂDX`NEG....YNNNNYNDVů........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBpBqCPB”8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391275103912751039AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů21727 DVůDx´DW».DW»DVůDVůDx´DWD¸°DVůDx´DWD¸°....Hr©ľ4HrĂ °Hr©ľ4HrĂ °..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dx´D¸°....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW(DW‹DW»..NEG....YNNNNYYDVů........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBňB€BrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391276103912761039AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22740 DVůD”ÔDWĽ.DWĽDVůDVůD”ÔDW D‹°DVůD”ÔDW D‹°....Hr©ÚTHrÄ/0Hr©ÚTHrÄ/0..DVůDW ..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D”ÔD‹°....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Overweight A0YNYYNEGDW,DW‹DWĽ..NEG....YNNNNYYDVů........DW,DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBńBBrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391277103912771039AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22742 DVůDDWĂ.DWĂDVůDVůDDWŁD ČDVůDDWDŁ\DWŤDĽDWŁD ČHr©ÝśHsŠHHr©ÝśHrĹ\Hslă<HsŠHDVůDWDWŤDWŁAŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDŁ\.DĽD Č.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW,DW‹DWŚDWĂDX`NEG....YNNNNYNDVů........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBđB~BqBrCPB“8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391278103912781039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22747 DVůD¨HDWż.DWżDVůDVůD¨HDW D‰ĐDVůD¨HDW D‰Đ....Hr©íČHrÄ-PHr©íČHrÄ-P..DVůDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨HD‰Đ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW0DW‹DWż..NEG....YNNNNYYDVů........DW0DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBńBBrCPB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391279103912791039AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22813 DVůDŻPDWĂ.DWĂDVůDVůDŻPDW¦D–<DVůDŻPDWDÁÔDW‘DžpDW¦D–<Hr©ôĐHsŤď<Hr©ôĐHrĹ¶ÔHsrGđHsŤď<DVůDWDW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŻPDÁÔ.DžpD–<.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW/DWŚDWDWĂDXcNEG....YNNNNYNDVů........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1039 10391280103912801039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22814 DVúD„äDWé.DWéDVúDVúD„äDWŁDČdDVúD„äDWD“lDWŽD{ŔDWŁDČdHr«äHsŠ,äHr«äHrĆŮěHsn0ŔHsŠ,äDVúDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D„äD“l.D{ŔDČd.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0YNYYNEGDW+DWŚDWŤDWĂDX`NEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BpBqC@B“8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391281103912811039AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22816 DVúDĂxDWÔ.DWÔDVúDVúDĂxDW DËčDVúDĂxDW DËč....Hr«ZxHrÄohHr«ZxHrÄoh..DVúDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂxDËč....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW0.. Overweight A0YNYYNEGDW)DW/DWĽ..NEG....YNNNNYYDVú........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW/DWýDWýBńB#BÎC@B68-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1039 10391282103912821039AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű22818 DVűDzĐDWË.DWËDVűDVűDzĐDWDĽ¬DVűDzĐDWDĽ¬....Hr¬cPHrČT¬Hr¬cPHrČT¬..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DzĐDĽ¬....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW,DWŚDWË..NEG....YNNNNYYDVű........DW,DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391283103912831039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23270 DVűD‚ŚDWľ.DWľDVűDVűD‚ŚDW˘DĽ4DVűD‚ŚDWDl„DWŤDsDW˘DĽ4Hr¬kHsĎ4Hr¬kHrĆłHslÖ”HsĎ4DVűDWDWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‚ŚDl„.DsDĽ4.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANYYYNEGDW+DWŚDWŚDWľDX_NEG....YNNNNYNDVű........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BqBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391284103912841039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23272 DVűD„äDWý.DWýDVűDVűD„äDWDn(DVűD„äDWDn(....Hr¬mdHrĆ´¨Hr¬mdHrĆ´¨..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D„äDn(....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NYYYNEGDW+DW‹DWĂ..NEG....YNNNNYYDVű........DW+DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBďB}BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391285103912851039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23275 DVűDŚdDW×.DW×DVűDVűDŚdDWŁDt@DVűDŚdDWD|tDWŽDx´DWŁDt@Hr¬täHs‰ŘŔHr¬täHrČtHsn-´Hs‰ŘŔDVűDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚdD|t.Dx´Dt@.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDW,DW‹DWŤDWÉDX`NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBîB|BpBrC0B‘8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391286103912861039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23276 DVűDŹ4DWÍ.DWÍDVűDVűDŹ4DWD|8DVűDŹ4DWD|8....Hr¬w´HrČ8Hr¬w´HrČ8..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DŹ4D|8....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW]. Underweight ANNYYNEGDW,DW‹DWÍ..NEG....YNNNNYYDVű........DW,DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391287103912871039AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23326 DVűD™HDWĂ.DWĂDVűDVűD™HDW˘D†DVűD™HDWD{HDWŤDşDW˘D†Hr¬ČHs™Hr¬ČHrČHHsmHs™DVűDWDWŤDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™HD{H.DşD†.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NYYYNEGDW/DWŚDWŚDWĂDX_NEG....YNNNNYNDVű........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BqBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391289103912891039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23327 DVűD¤DWů.DWůDVűDVűD¤DWD˛\DVűD¤DWD˛\....Hr¬ŤHrČJ\Hr¬ŤHrČJ\..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤D˛\....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW,DW‹DWÉ..NEG....YNNNNYYDVű........DW,DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391290103912901039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23328 DVűD¶XDWĘ.DWĘDVűDVűD¶XDWD¤DVűD¶XDWD¤....Hr¬žŘHrČ ¤Hr¬žŘHrČ ¤..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¶XD¤....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW,DWŚDWĘ..NEG....YNNNNYYDVű........DW,DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391291103912911039AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23373 DVűDĹĐDWŽ.DWŽDVűDVűDĹĐDWrDy,DVűDĹĐDWD—ŕDW]D¨ŔDWrDy,Hr¬®PHsID,Hr¬®PHrČ/ŕHs-Ä@HsID,DVűDWDW]DWrAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĹĐD—ŕ.D¨ŔDy,.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWUDW]. Normal weightA NNYYNEGDW,DWTDW\DWŽDX/NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWTDWýDWýBîBEBˇB©C0BZ8-9 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1039 10391292103912921039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23332 DVűDŔ¨DWĂ.DWĂDVűDVűDŔ¨DWŁDvÔDVűDŔ¨DWDŻPDWŽD{DWŁDvÔHr¬©(Hs‰ŰTHr¬©(HrČGPHsn0Hs‰ŰTDVűDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔ¨DŻP.D{DvÔ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW,DWŚDWŤDWĂDX`NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BpBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391293103912931039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23378 DVţD°|DWĚ..DVţDVţD°|DWDŻŚDVţD°|DWDŻŚ....Hr°Ť|HrĚ<Hr°Ť|HrĚ<..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D°|DŻŚ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW/DWŚDWĚ..NEG....YNNNNYYDVţ........DW/DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1039 10391294103912941039AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23381 DVţD˛ÔDWÄ.DWÄDVţDVţD˛ÔDWŁDŤDVţD˛ÔDWDm°DWŽDvDWŁDŤHr°ŹÔHs‰ńHr°ŹÔHrÎť0Hsn+Hs‰ńDVţDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ÔDm°.DvDŤ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW1DWŚDWŤDWÄDX`NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBéBxBpBqCBŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1039 10391295103912951039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23384 DWDxDWü.DWüDWDWDxDWD§ĐDWDxDWD§Đ....HrşáHrÖŔPHrşáHrÖŔP..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DxD§Đ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Obese A@YNYYNEGDW>DW‹DWĘ..NEG....YNNNNYYDW........DW>DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBřB†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391296103912961039AĐYEARSMAWHITE ANOT REPORTED A0 .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24563 DWD‚PDWî..DWDWD‚PDWŁDŠŔDWD‚PDWDr$DWŽDŚÜDWŁDŠŔHrşëPHs‰ď@HrşëPHrÖŠ¤HsnAÜHs‰ď@DWDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‚PDr$.DŚÜDŠŔ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW>DWŚDWŤDWżDX`NEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391297103912971039AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24564 DWD‡xDWŃ.DWŃDWDWD‡xDWDkDWD‡xDWDk....HrşđxHrÖśHrşđxHrÖś..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‡xDk....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW=DWŚDWŃ.. ....YNNNNNYDW.........DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391298103912981039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24565 DWDŠHDWĘ..DWDWDŠHDWDŕDWDŠHDWDŕ....HrşóHHrÖˇ`HrşóHHrÖˇ`..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠHDŕ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW>DWŚDWĘ..NEG....YNNNNYYDW........DW>DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391299103912991039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24568 DWDŤĚDWż.DWżDWDWDŤĚDWŁDŹpDWDŤĚDWDqpDWŽD‹ěDWŁDŹpHrşöĚHs‰óđHrşöĚHrÖ‰đHsn@ěHs‰óđDWDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤĚDqp.D‹ěDŹp.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NYYYNEGDW=DWŚDWŤDWżDX`NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391300103913001039AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24664 DWDŞ(DWÓ.DWÓDWDWDŞ(DWDsPDWDŞ(DWDsP....Hr»(HrŮ.ĐHr»(HrŮ.Đ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŞ(DsP....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Normal weightA NNYYNEGDW=DW‹DWÓ.. ....YNNNNYYDW........DW=DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‹DWýDWýBáBoBrBřB†8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391301103913011039AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24665 DWD©tDWË.DWËDWDWD©tDWŁD˝śDWD©tDWDsŚDWŤD©tDWŁD˝śHr»tHsŠ"Hr»tHrŮ/HsmôHsŠ"DWDWDWŤDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D©tDsŚ.D©tD˝ś.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NYYYNEGDW=DW‹DWŚDWĘDX`NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBáBoBqBrBřB†8-9 months A3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391302103913021039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24666 DWD±0DWď.DWďDWDWD±0DWD˛\DWD±0DWD˛\....Hr»0HrŐy\Hr»0HrŐy\..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D±0D˛\....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW=DWŚDW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391303103913031039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24667 DWDżôDWĂ.DWĂDWDWDżôDWŁDr`DWDżôDWDk”DWŤD±lDWŁDr`Hr»(ôHs‰ÖŕHr»(ôHrŮ'HsměHs‰ÖŕDWDWDWŤDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DżôDk”.D±lDr`.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW>DWŚDWŚDWĂDX`NEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBqBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391304103913041039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24754 DWDÂÄDWĘ.DWĘDWDWDÂÄDWD¨HDWDÂÄDWD¨H....Hr»+ÄHrÖŔČHr»+ÄHrÖŔČ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÂÄD¨H....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANYYYNEGDW?DWŚDWĘ..NEG....YNNNNYYDW........DW?DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1039 10391305103913051039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24759 DWD˝$DWÉ.DWÉDWDWD˝$DWŁDąÜDWD˝$DW!DtDWŽDáDWŁDąÜHrĹ˛$HsŠ\HrĹ˛$HrŢu„Hsn–HsŠ\DWDW!DWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝$Dt.DáDąÜ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW=DWŚDWŤDWÉDX`NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBpBqBđB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391306103913061039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24762 DWD˝śDWŮ.DWŮDWDWD˝śDW!DsČDWD˝śDW!DsČ....HrĹ˛śHrŢuHHrĹ˛śHrŢuH..DWDW!..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝śDsČ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW=DWŚDWŮ..NEG....YNNNNYYDW........DW=DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391307103913071039AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24764 DWDĆŔDWż.DWżDWDWDĆŔDWŁD–´DWDĆŔDW#D´´DWŽDŔ0DWŁD–´HrĹ»ŔHs‰ű4HrĹ»ŔHráY4Hsnu0Hs‰ű4DWDW#DWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆŔD´´.DŔ0D–´.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW?DWŚDWŤDWżDX`NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBpBqBđB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391308103913081039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25749 DWDĆüDWÓ.DWÓDWDWDĆüDW#D´đDWDĆüDW#D´đ....HrĹ»üHráYpHrĹ»üHráYp..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĆüD´đ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW?DWŚDWÓ..NEG....YNNNNYYDW........DW?DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391309103913091039AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25752 DWDrŘDWŃ.DWŃDWDWDrŘDW§D¸°DWDrŘDW#DÇ8DW‘D„äDW§D¸°HrĆąXHsŹc0HrĆąXHrák¸Hsr.dHsŹc0DWDW#DW‘DW§AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DrŘDÇ8.D„äD¸°.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW?DWŚDWDWŃDXdNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391310103913101039AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25759 DWD{DWĂ.DWĂDWDWD{DW¦DXDWD{DW"D|8DWŽDÄ¤DW¦DXHrĆÁŚHsŤńXHrĆÁŚHrßĎ8Hsny¤HsŤńXDWDW"DWŽDW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D{D|8.DÄ¤DX.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0YNYYNEGDW>DWŚDWŤDWĂDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBpBqBďB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391311103913111039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25918 DWD‘ČDWŇ.DWŇDWDWD‘ČDW%D„äDWD‘ČDW%D„ä....HrĆŘHHrăĚdHrĆŘHHrăĚd..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‘ČD„ä....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDDWŚDWŇ..NEG....YNNNNYYDW........DWDDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391312103913121039AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25760 DWDŽřDWć.DWćDWDWDŽřDW$DĽDWDŽřDW$DĽ....HrĆŐxHrâuĽHrĆŐxHrâuĽ..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽřDĽ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDDWŚDWć..NEG....YNNNNYYDW........DWDDWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391313103913131039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25920 DWDˇ|DWĂ..DWDWDˇ|DW˘D”ÔDWDˇ|DW$D”\DWŽD˛ DW˘D”ÔHrĆçüHs§ÔHrĆçüHrâŠ\Hsng Hs§ÔDWDW$DWŽDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ|D”\.D˛ D”Ô.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDWEDWŚDWŤDWĂDX_NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBpBqBďB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391314103913141039AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25921 DWD¨DWĂ.DWĂDWDWD¨DW¦DqčDWD¨DW$DłLDW‘DpDW¦DqčHrĆîŚHsŤĘčHrĆîŚHrâ©LHsrHsŤĘčDWDW$DW‘DW¦AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨DłL.DpDqč.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW@DWŚDWDWĂDXcNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391315103913151039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25924 DWDĂ´DWÓ.DWÓDWDWDĂ´DW#DÄhDWDĂ´DW#DÄh....HrÇ 4HráhčHrÇ 4Hráhč..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂ´DÄh....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW?DWŤDWÓ..NEG....YNNNNYYDW........DW?DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391316103913161039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26039 DWDÄ,DWÓ.DWÓDWDWDÄ,DW#DÄ,DWDÄ,DW#DÄ,....HrÇ ¬Hráh¬HrÇ ¬Hráh¬..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÄ,DÄ,....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW?DWŤDWÓ..NEG....YNNNNYYDW........DW?DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391317103913171039AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26040 DWDÄ¤DWľ.DWľDWDWDÄ¤DW˘DrśDWDÄ¤DW$DľPDWŽDŐüDW˘DrśHrÇ$Hs…śHrÇ$Hrâ´PHsnŠüHs…śDWDW$DWŽDW˘AŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄ¤DľP.DŐüDrś.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYNPOSDWADWŚDWŤDWľDX_POS....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÚBiBpBqBďB~7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ..DW$C4591001C4591001 1039 10391318103913181039AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26041 DWDÔ”DWó.DWóDWDWDÔ”DW%DÄhDWDÔ”DW%DÄh....HrÇHräčHrÇHräč..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÔ”DÄh....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‹.. Overweight A0NNYYNEGDWADWŠDWĺ..NEG....YNNNNYYDW........DWADWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŠDWýDWýBŮBfBsBďB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391319103913191039AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26042 DWDu0DWĆ.DWĆDWDWDu0DWŞDĆŔDWDu0DW%DźśDW”DĹDWŞDĆŔHrČ 0Hs“eŔHrČ 0HrăçHsvcHs“eŔDWDW%DW”DWŞAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Du0Dźś.DĹDĆŔ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDWEDWŚDW“DWĆDXgNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBjBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391320103913201039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26184 DWD‘DWó.DWóDWDWD‘DW%D’DWD‘DW%D’....HrČ)HrăŮ„HrČ)HrăŮ„..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‘D’....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Underweight ANNYYNEGDWADW‹DWó..NEGDW‘.DW‘DW‘YNNNNYYDW........DWADWóYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŮBgBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391321103913211039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26182 DWDŚ DWĘ.DWĘDWDWDŚ DW§DÂDWDŚ DW%Dm8DW‘Dp€DW§DÂHrČ$ HsŹmHrČ$ Hră´¸HsrHsŹmDWDW%DW‘DW§AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ Dm8.Dp€DÂ.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWDDWŚDWDWĘDXdNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBmBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391322103913221039AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26187 DWD¶”DWÔ.DWÔDWDWD¶”DW%DˇôDWD¶”DW%Dˇô....HrČN”HrăétHrČN”Hrăét..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¶”Dˇô....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWADWŚDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391323103913231039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26191 DWDşĚDWÔ.DWÔDWDWDşĚDW%D»€DWDşĚDW%D»€....HrČRĚHräHrČRĚHrä..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DşĚD»€....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWADWŤDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŮBiBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391324103913241039AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26398 DWDÜČDWů.DWůDWDWDÜČDW%D˝`DWDÜČDW%D˝`....HrČtČHräŕHrČtČHräŕ..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÜČD˝`....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWADWŚDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391325103913251039AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26403 DWD´´DWĂ.DWĂDWDWD´´DW˘DxxDWD´´DW(Dv\DWŤDŤDW˘DxxHrĚA4Hs‹xHrĚA4Hrç˛\HslńHs‹xDWDW(DWŤDW˘AĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´´Dv\.DŤDxx.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDWGDWŚDWŚDWĂDX_NEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBqBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391326103913261039AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26405 DWD´xDWĺ.DWĺDWDWD´xDW(DwÄDWD´xDW(DwÄ....HrĚ@řHrçłÄHrĚ@řHrçłÄ..DWDW(..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´xDwÄ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWj.. Normal weightA NYYYNEGDWGDWiDWĺ..NEG....YNNNNYYDW........DWGDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWiDWýDWýBÖBBB”BëBW7-8 months A€2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1039 10391327103913271039AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26408 DWD¸°DWŮ..DWDWD¸°DW(DzĐDWD¸°DW(DzĐ....HrĚE0Hrç¶ĐHrĚE0Hrç¶Đ..DWDW(..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¸°DzĐ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDWEDWŚDWŮ..NEGDWŹ.DWŹDWŹYNNNNYYDW........DWEDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391328103913281039AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26639 DWDşTDWĹ.DWĹDWDWDşTDWŁD·üDWDşTDW)DkĐDWŽDŻPDWŁD·üHrĚFÔHsŠ|HrĚFÔHrčůPHsndPHsŠ|DWDW)DWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DşTDkĐ.DŻPD·ü.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDWEDWŚDWŤDWĹDX`NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBpBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391329103913291039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26644 DWDÔXDWĆ.DWĆDWDWDÔXDW©D˝śDWDÔXDW(Dy¤DW”DĹXDW©D˝śHrĚ`ŘHs’HrĚ`ŘHrçµ¤HsvcXHs’DWDW(DW”DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔXDy¤.DĹXD˝ś.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Overweight A0YNYYNEGDWEDWŚDW“DWĆDXfNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBjBqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391330103913301039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26640 DWDŇ´DWć.DWćDWDWDŇ´DW)DľČDWDŇ´DW)DľČ....HrĚ_4HréLHHrĚ_4HréLH..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇ´DľČ....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWq.. Normal weightA NNYYNEGDWHDWpDWć..NEG....YNNNNYYDW........DWHDWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWpDWýDWýBŐBHBŤBëB^7-8 months A€2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1039 10391331103913311039AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26648 DWDr`DW×.DW×DWDWDr`DW(Dx<DWDr`DW(Dx<....HrÍP`Hrç´<HrÍP`Hrç´<..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dr`Dx<....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWEDWŚDW×..NEG....YNNNNYYDW........DWEDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÖBeBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391332103913321039AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26769 DWD|°DW©.DW©DWDWD|°DW)Dp€DWD|°DW)Dp€....HrÍZ°HrčţHrÍZ°Hrčţ..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW©WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. D|°Dp€....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWrDWL. Underweight ANNYYNEGDWLDWqDWć..NEG....YNNNNYNDW........DWL.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWqDW©DW©BBIB8B–B^4-5 months AP2-3 months A00-1 month A5-6 months A` . ...C4591001C4591001 1039 10391333103913331039AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26770 DWD‡DWĆ.DWĆDWDWD‡DWŞDÇtDWD‡DW)Du0DW•DĆHDWŞDÇtHrÍeHs“ftHrÍeHré°HswµČHs“ftDWDW)DW•DWŞAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡Du0.DĆHDÇt.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDWEDWŚDW”DWĆDXgNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBiBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391334103913341039AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26772 DWD‡đDWĆ.DWĆDWDWD‡đDWŞDÇ8DWD‡đDW)DtôDW•DĆ„DWŞDÇ8HrÍeđHs“f8HrÍeđHrétHsw¶Hs“f8DWDW)DW•DWŞAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡đDtô.DĆ„DÇ8.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Underweight ANNYYNEGDWEDWŚDW”DWĆDXgNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBiBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1039 10391335103913351039AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26817 DWDŁ DWć.DWćDWDWDŁ DW)D|°DWDŁ DW)D|°....HrÍ Hré 0HrÍ Hré 0..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŁ D|°....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWG.. Underweight ANNNNPOSDWFDWFDWć..POS....YNNNNYYDW........DWGDWćYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NNDWFDWýDWýBŐBB·BęB37-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1039 10391336103913361039AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26780 DWD˘¨DWć..DWDWD˘¨DW)D|tDWD˘¨DW)D|t....HrÍ€¨Hré ôHrÍ€¨Hré ô..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˘¨D|t....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NYNYPOSDWGDWŚDWć..POS....YNNNNYYDW........DWGDWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBŐBdBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391337103913371039AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26822 DWDŞÜDWż..DWDWDŞÜDWŁDźśDWDŞÜDW*DndDWŽD ČDWŁDźśHrÍÜHsŠHrÍÜHręMdHsnUČHsŠDWDW*DWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞÜDnd.D ČDźś.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDWLDWŚDWŤDWżDX`NEG....YNNNNYNDW........DWL.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBpBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1039 10391338103913381039AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26823 DWDĐDWß..DWDWDĐDW*DwDWDĐDW*Dw....HrÍ®HręVHrÍ®HręV..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĐDw....406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWGDWŚDWß..NEG....YNNNNYYDW........DWGDWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÔBcBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1039 10391339103913391039AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26828 DWDŃDWŢ.DWŢDWDWDŃDW¦DrśDWDŃDW*DxDW’D~DW¦DrśHrÍŻHsŤËśHrÍŻHręWHssyHsŤËśDWDW*DW’DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃDx.D~Drś.406048 Crook, Gretchen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDWGDWŚDW‘DWĹDXcNEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBlBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441251104412511044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20354 DVéDŇ´DW¶.DW¶DVéDVéDŇ´DV˙D§DVéDŇ´DV˙D§....Hr•4Hr±ŐśHr•4Hr±Őś..DVéDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DŇ´D§....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW. Normal weightA NNYYNEGDWDWŚDW¶..NEG....YNNNNYYDVé........DWDW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB˙BŽBqCPB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1044 10441252104412521044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20360 DVéDäHDWĂ.DWĂDVéDVéDäHDW¦Dť€DVéDäHDVţD4DW‘D—hDW¦Dť€Hr•ČHsŤö€Hr•ČHr°Š4Hsr@čHsŤö€DVéDVţDW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWxBNT162b2 (30 (*ESC*){unicode 03BC}g).. DäHD4.D—hDť€.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWDWŚDWDWĂDXcNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCBŹBmBqCPB¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441253104412531044AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20439 DVéDřčDWĽ.DWĽDVéDVéDřčDVţD§XDVéDřčDVţD§X....Hr•&hHr°„XHr•&hHr°„X..DVéDVţ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWx .. DřčD§X....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWx. Underweight ANNYYNEGDWDWŚDW®..NEG....YNNNNYYDVé........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCBŹBqCPB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1044 10441255104412551044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20440 DVęD˘¨DW¸.DW¸DVęDVęD˘¨DVţDĂ´DVęD˘¨DVţDĂ´....Hr–!¨Hr° ´Hr–!¨Hr° ´..DVęDVţ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW† .. D˘¨DĂ´....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW†. Overweight A0YNYYNEGDWDWŤDW¸..NEG....YNNNNYYDVę........DWDW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýCBBpC@B¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1044 10441256104412561044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20444 DVęD˘äDWÄ.DWÄDVęDVęD˘äDW¨D—,DVęD˘äDVţDĂđDW‘DĽ4DW¨D—,Hr–!äHs“,Hr–!äHr° đHsre´Hs“,DVęDVţDW‘DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW†BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘äDĂđ.DĽ4D—,.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDWDWŤDWDWÄDXeNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBBmBpC@B¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441257104412571044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20567 DVęDŘTDW˝.DW˝DVęDVęDŘTDWDá´DVęDŘTDWDá´....Hr–WTHrła´Hr–WTHrła´..DVęDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW„ .. DŘTDá´....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW„. Normal weightA NNYYNEGDWDWŚDW˝..NEG....YNNNNYYDVę........DWDW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBţBŤBqC@BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1044 10441259104412591044AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20569 DVęDě|DW°.DW°DVęDVęDě|DV˙DĄ<DVęDě|DV˙DĄ<....Hr–k|Hr±ÓĽHr–k|Hr±ÓĽ..DVęDV˙..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. Dě|DĄ<....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWy. Normal weightA NNYYNEGDWDWŤDW°..NEG....YNNNNYYDVę........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB˙BŹBpC@B¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1044 10441260104412601044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20576 DVęDů$DWľ.DWľDVęDVęDů$DW˘Dá´DVęDů$DV˙DÎDWŽDŢäDW˘Dá´Hr–x$Hsô´Hr–x$Hr±ü„Hsn“äHsô´DVęDV˙DWŽDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dů$DÎ.DŢäDá´.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDWDWŤDWŤDWľDX_NEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýB˙BŹBpBpC@B¤9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1044 10441261104412611044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20618 DVęDůŘDWż.DWżDVęDVęDůŘDWŁDäüDVęDůŘDV˙DäŔDWŽDÂDWŁDäüHr–xŘHsŠI|Hr–xŘHr˛@HsnwHsŠI|DVęDV˙DWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW}BNT162b2 (30 (*ESC*){unicode 03BC}g).. DůŘDäŔ.DÂDäü.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Overweight A0NNYYNEGDWDWŤDWŤDWżDX`NEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB˙BŹBpBpC@B¤9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1044 10441263104412631044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20623 DVđDÓŕDWµ.DWµDVđDVđDÓŕDWDĆHDVđDÓŕDWDĆH....Hrž;ŕHrąÝČHrž;ŕHrąÝČ..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW€ .. DÓŕDĆH....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW€. Normal weightA NNYYNEGDW!DWŚDWµ..NEG....YNNNNYYDVđ........DW!DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCŕBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441264104412641044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20624 DVđDíäDWó..DVđDVđDíäDWóD•ÄDVđDíäDWDź$DW×D×dDWóD•ÄHržUäHsórDHržUäHrą¶¤HsÎÉäHsórDDVđDWDW×DWóAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. DíäDź$.D×dD•Ä.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĹDW×. Obese A@YNYYNEGDW(DW»DW»DXDX°POS....YNNNNYYDVđ........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÄDWýDWýBůBŔB'B9CŕBŐ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWC4591001C4591001 1044 10441265104412651044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21287 DVđDöDWĹ.DWĹDVđDVđDöDW¨DÇ°DVđDöDWDžpDW“DĂxDW¨DÇ°Hrž^HsĂ°Hrž^HrąµđHsuřHsĂ°DVđDWDW“DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DöDžp.DĂxDÇ°.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW"DWŚDW’DWĹDXeNEG....YNNNNYNDVđ........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBkBqCŕBť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441266104412661044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21289 DVńD˘¨DW».DW»DVńDVńD˘¨DWD»DDVńD˘¨DWD»D....Hrź\(HrąŇÄHrź\(HrąŇÄ..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. D˘¨D»D....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Overweight A0NNYYNEGDW%DW»DW»..NEG....YNNNNYYDVń........DW%DW»YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBůBů..CĐCĐ8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1044 10441267104412671044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21290 DVńD©°DWÉ.DWÉDVńDVńD©°DW¨DčDVńD©°DWDŘDW“D ČDW¨DčHrźc0Hs©čHrźc0Hrą¨XHstíHHs©čDVńDWDW“DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. D©°DŘ.D ČDč.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŹDW“. Normal weightA NNYYNEGDW!DWŽDW’DWÉDXeNEG....YNNNNYNDVń........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŽDWýDWýBůBŠBkBoCĐBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441268104412681044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21294 DVńD´đDWż.DWżDVńDVńD´đDWDŢ¨DVńD´đDWDŢ¨....HrźnpHrąö(HrźnpHrąö(..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWx .. D´đDŢ¨....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Obese A@YNYYNEGDW!DWżDWż..NEG....YNNNNYYDVń........DW!DWżYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWý.DWýBůBů..CĐCĐ8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1044 10441270104412701044AĐYEARSFA NOT REPORTED ApHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21417 DVńDŮDWľ.DWľDVńDVńDŮDWD ŚDVńDŮDWD Ś....Hrź’Hr˝¬ŚHrź’Hr˝¬Ś..DVńDW..AĐYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DŮD Ś....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Underweight ANNYYNEGDW$DWŚDWľ..NEG....YNNNNYYDVń........DW$DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBöB…BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441271104412711044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21420 DVńD˙xDWą..DVńDVńD˙xDWDŘĚDVńD˙xDWDŘĚ....Hrź¸řHrąđLHrź¸řHrąđL..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˙xDŘĚ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDW%DWŚDWą..NEGDW.DWDWYNNNNYYDVń........DW%DWąYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441273104412731044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21423 DVńEë@DWĂ.DWĂDVńDVńEë@DWDÍDVńEë@DWDÍ....HrźČ4Hrąä”HrźČ4Hrąä”..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. Eë@DÍ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDW$DWŚDWż..NEG....YNNNNYYDVń........DW$DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441274104412741044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21428 DVńEç€DWk..DVńDVńEç€DWODÎDVńEç€DWDĹĐDW8DťDDWODÎHrźÇřHst„HrźÇřHrąÝPHrüńDHst„DVńDWDW8DWOAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Eç€DĹĐ.DťDDÎ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW0DW8. Normal weightA NNYYNEGDW$DW/DW7DWkDXNEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW/DWýDWýBůB+BĆBÎCĐB?8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1044 10441275104412751044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21621 DVňD–´DWÄ.DWÄDVňDVňD–´DW¨DŹpDVňD–´DWDžpDW‘D·HDW¨DŹpHr ˇ´Hs‹pHr ˇ´Hr»pHsr`ČHs‹pDVňDWDW‘DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW†BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–´Džp.D·HDŹp.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW%DWŚDWDWÄDXeNEG....YNNNNYNDVň........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqCŔB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441276104412761044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21623 DVňDŞdDW».DW»DVňDVňDŞdDWDź`DVňDŞdDWDź`....Hr µdHr»`Hr µdHr»`..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. DŞdDź`....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW‡. Underweight ANNYYNEGDW!DWŤDW»..NEG....YNNNNYYDVň........DW!DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBřBBpCŔBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441277104412771044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21632 DVňDĆüDWĂ.DWĂDVňDVňDĆüDW§D…DVňDĆüDWD•DW‘Dě|DW§D…Hr ŃüHsŹ0Hr ŃüHrşţHsr•üHsŹ0DVňDWDW‘DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆüD•.Dě|D….374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW‘. Underweight ANNYYNEGDW#DWDWDWĂDXdNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹BmBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441278104412781044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21631 DVňDĆHDW˝.DW˝DVňDVňDĆHDWDß DVňDĆHDWDß ....Hr ŃHHr»H Hr ŃHHr»H ..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DĆHDß ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Obese A@YNYYNEGDW#DWŚDW˝..NEG....YNNNNYYDVň........DW#DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441279104412791044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21789 DVňDüäDWĂ.DWĂDVňDVňDüäDWD”DVňDüäDWD”....HrˇäHrşýHrˇäHrşý..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DüäD”....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW1.. Normal weightA NNYYNEGDW$DW0DWĂ..NEG....YNNNNYYDVň........DW$DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW0DWýDWýBřB+BÍCŔB?8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1044 10441280104412801044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21792 DVňDü¨DWç..DVňDVňDü¨DW8DÍDVňDü¨DWD“äDW$DŹ4DW8DÍHrˇ¨Hrý!Hrˇ¨HrşüäHrâ…4Hrý!DVňDWDW$DW8AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dü¨D“ä.DŹ4DÍ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW"DW$. Normal weightA NYYYNEGDW!DW!DW#DWTDWçNEG....YNNNNYNDVň........DW$.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW!DWýDWýBřBBÚBÜCŔB08-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1044 10441281104412811044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21795 DVňE`€DWľ.DWľDVňDVňE`€DWDpDVňE`€DWDp....HrˇHr»pHrˇHr»p..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. E`€Dp....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Normal weightA NNYYNEGDW#DWŚDWľ..NEG....YNNNNYYDVň........DW#DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBřB‡BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441282104412821044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21799 DVňEF@DWw..DVňDVňEF@DW[DŔäDVňEF@DWDĎ¨DWFDťĽDW[DŔäHrˇdHs+9dHrˇdHrĽŠ(HsfĽHs+9dDVňDWDWFDW[AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. EF@DĎ¨.DťĽDŔä.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DWF. Normal weightA NYYYNEGDW#DW<DWEDWwDXNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýB÷B6B¸BÁCŔBK8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1044 10441283104412831044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21840 DVóDDW˝.DW˝DVóDVóDDWDčDVóDDWDč....HrˇôśHr»čHrˇôśHr»č..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DDč....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW%DWŤDW˝..NEG....YNNNNYYDVó........DW%DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBřBBpC°B›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441284104412841044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21843 DVóDÖěDWľ.DWľDVóDVóDÖěDW˘DŃLDVóDÖěDWDËčDWŤDÖěDW˘DŃLHr˘3lHsäLHr˘3lHr»4čHsm:lHsäLDVóDWDWŤDW˘AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖěDËč.DÖěDŃL.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDWŤ. Normal weightA NNYYNEGDW"DW‚DWŚDWľDX_NEG....YNNNNYNDVó........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‚DWýDWýBřB}BqB{C°B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1044 10441285104412851044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21845 DVóDäHDWż.DWżDVóDVóDäHDWD’|DVóDäHDWD’|....Hr˘@ČHrĽLüHr˘@ČHrĽLü..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWx .. DäHD’|....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW%DWżDWż..NEG....YNNNNYYDVó........DW%DWżYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWý.DWýB÷B÷..C°C°8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1044 10441286104412861044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô21848 DVôDšěDWÄ.DWÄDVôDVôDšěDW¦D¦ŕDVôDšěDWDć(DW‘D¦,DW¦D¦ŕHrŁHěHsŤ˙ŕHrŁHěHrĽ ¨HsrO¬HsŤ˙ŕDVôDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DšěDć(.D¦,D¦ŕ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW#DWŚDWDWÄDXcNEG....YNNNNYNDVô........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441288104412881044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22749 DVůDˇ|DW°.DW°DVůDVůDˇ|DWDĂđDVůDˇ|DWDĂđ....Hr©ćüHrĹ¸đHr©ćüHrĹ¸đ..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. Dˇ|DĂđ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW|. Underweight ANNYYNEGDW/DWŤDW°..NEG....YNNNNYYDVů........DW/DW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBđB€BpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441289104412891006AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVů22751 DVůDÚčDWî.DWîDVůDVůDÚčDWDŇDVůDÚčDWDŇ....HrŞ hHrĚ^€HrŞ hHrĚ^€..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWîWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÚčDŇ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANYYYNEGDW/DWĐDWĐ..NEG....YNNNNYNDVů........DW/.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWî.DWîBÜBÜ..BöBö7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1044 10441290104412901044AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26233 DWDÂÄDWÚ.DWÚDVůDWDÂÄDW%DĂđDWDÂÄDW%DĂđ....HrČZÄHräpHrČZÄHräp..DWDW%..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. DÂÄDĂđ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW|. Underweight ANNYYNEGDWADWŤDWÚ..NEG....YNNNNYYDW........DWADWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŮBiBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441291104412911044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22752 DVúDÄŕDWż.DWżDVúDVúDÄŕDWDę`DVúDÄŕDWDę`....Hr«[ŕHrĹß`Hr«[ŕHrĹß`..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‹ .. DÄŕDę`....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW‹. Underweight ANNYYNEGDW*DWŚDWż..NEG....YNNNNYYDVú........DW*DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441292104412921044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22759 DVúDÎDW..DVúDVúDÎDWcD·„DVúDÎDW D¦,DWMDŐHDWcD·„Hr«eHs5ĽHr«eHrÄI¬HsŘČHs5ĽDVúDW DWMDWcAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎD¦,.DŐHD·„.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWM. Underweight ANNYYNEGDW+DWJDWLDWDX NEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWJDWýDWýBńB>B±BłC@BQ8-9 months A2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1044 10441293104412931044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23195 DVúE7@DW´.DW´DVúDVúE7@DWŽDçDVúE7@DW DđDWŽDçDWŽDçHr«štHsnśHr«štHrÄ“€HsnśHsnśDVúDW DWŽ.AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. E7@Dđ.Dç..374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽDW´PROTOCOL DEVIATION Normal weightA NNYYNEGDW+DWŚDWŤDWČDXbNEGDWŁ.DWŁDWŁYNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BpBqC@B“8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1044 10441294104412941044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23196 DVúE;DWż.DWżDVúDVúE;DWŽDçTDVúE;DW DďÄDWŽDçTDWŽDçTHr«š°HsnśTHr«š°HrÄ“DHsnśTHsnśTDVúDW DWŽ.AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. E;DďÄ.DçT..374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽDWżPROTOCOL DEVIATION Normal weightA NNYYNEGDW+DWŚDWŤDWżDXbNEGDWŁ.DWŁDWŁYNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BpBqC@B“8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1044 10441295104412951044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23198 DVűDŕDW×.DW×DVűDVűDŕDWDŹ¬DVűDŕDWDŹ¬....Hr¬q`HrČ'¬Hr¬q`HrČ'¬..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DŕDŹ¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDW1DWŚDW×..NEG....YNNNNYYDVű........DW1DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441296104412961044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23202 DV˙DĆDWÉ.DWÉDV˙DV˙DĆDWDXDV˙DĆDWDX....Hr±ôŚHrĚ$ŘHr±ôŚHrĚ$Ř..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĆDX....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW6DWŤDWÉ..NEG....YNNNNYYDV˙........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBëB{BpB˙BŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441297104412971044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24157 DWDŕDWĚ.DWĚDWDWDŕDWDŘĚDWDŕDWDŘĚ....HrłŕHrĎLHrłŕHrĎL..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DŕDŘĚ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Underweight ANNYYNEGDW1DWŚDWĚ..NEG....YNNNNYYDW........DW1DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqBţBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1044 10441298104412981044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24160 DWD§DWŰ.DWŰDWDWD§DW±DÁÔDWD§DWD•ÄDWśDĚŘDW±DÁÔHrł'Hsś›THrł'HrÎĹDHs€öŘHsś›TDWDWDWśDW±AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW|BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§D•Ä.DĚŘDÁÔ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DWś. Underweight ANNYYNEGDW1DW‘DW›DWÍDXnNEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBéB}BbBlBţB’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1044 10441299104412991044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24161 DWDć DWĂ.DWĂDWDWDć DWŁDŇ<DWDć DWDŰŘDWŤD‘PDWŁDŇ<Hrąţ HsŠ6ĽHrąţ HrÖôXHslôĐHsŠ6ĽDWDWDWŤDWŁAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć DŰŘ.D‘PDŇ<.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW…DWŤ. Normal weightA NNYYNEGDW7DW„DWŚDWĂDX`NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW„DWýDWýBăBjBqByBůB€8-9 months A3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441300104413001044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24163 DWDúPDWü.DWüDWDWDúPDWD¬DWDúPDWD¬....HrşĐHrŐt¬HrşĐHrŐt¬..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. DúPD¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW|. Overweight A0YNYYNEGDW6DWŚDWŃ..NEG....YNNNNYYDW........DW6DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1044 10441301104413011044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24721 DWDŇxDWÉ.DWÉDWDWDŇxDWD˘lDWDŇxDWD˘l....Hr»;xHrŐilHr»;xHrŐil..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇxD˘l....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWi.. Underweight ANNYYNEGDW6DWhDWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWhDWýDWýBäBOB•BřBc8-9 months A2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1044 10441302104413021044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24723 DWDíäDWĂ.DWĂDWDWDíäDW¦D’@DWDíäDWDô8DW‘DâhDW¦D’@Hr»VäHsŤë@Hr»VäHr×¸Hsr‹čHsŤë@DWDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DíäDô8.DâhD’@.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW=DWŚDWDWĂDXcNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBmBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441303104413031044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24722 DWDî\DW.DWDWDWDî\DWŤD’DWDî\DWDóüDWvDśĚDWŤD’Hr»W\Hslő„Hr»W\Hr×|HsNĚHslő„DWDWDWvDWŤAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dî\Dóü.DśĚD’.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWrDWv. Underweight ANNYYNEGDW=DWqDWuDWDXJNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWqDWýDWýBăBWBBŚBřBl8-9 months A3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441304104413041044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24728 DWDű¸DWË.DWËDWDWDű¸DWDÓŕDWDű¸DWDÓŕ....Hr»d¸HrÖě`Hr»d¸HrÖě`..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. Dű¸DÓŕ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWw. Normal weightA NNYYNEGDW>DW‘DWË..NEG....YNNNNYYDW........DW>DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBăBwBlBřBŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1044 10441306104413061044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24861 DWD¨ŔDWÉ.DWÉDWDWD¨ŔDWD‘PDWD¨ŔDWD‘P....HrĽc@HrŐXPHrĽc@HrŐXP..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. D¨ŔD‘P....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWy. Normal weightA NNYYNEGDW=DW¬DWÉ..NEG....YNNNNYYDW........DW=DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¬DWýDWýBäB“BQB÷B¦8-9 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1044 10441307104413071044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24863 DWD¨üDWí..DWDWD¨üDWíD`DWD¨üDWD‘ŚDWíD`DWíD`HrĽc|HsëŕHrĽc|HrŐXŚHsëŕHsëŕDWDWDWí.AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. D¨üD‘Ś.D`..374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÉDWí. Normal weightA NNYYNEGDW=DWČDWÉDX'DXÁNEG....YNNNNYYDW........DW=DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWČDWýDWýBäBŻBB5B÷BÂ8-9 months A6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1044 10441308104413081044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24869 DWD®`DWÄ.DWÄDWDWD®`DW¨DĂxDWD®`DWDÚ¬DW‘DĆüDW¨DĂxHrĽhŕHsżxHrĽhŕHrŘD¬Hsrp|HsżxDWDWDW‘DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. D®`DÚ¬.DĆüDĂx.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW=DWŚDWDWÄDXeNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBmBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441309104413091044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24871 DWDąÜDWÍ.DWÍDWDWDąÜDWDÂLDWDąÜDWDÂL....HrĽt\HrŐ‰LHrĽt\HrŐ‰L..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DąÜDÂL....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Overweight A0YNYYNEGDW6DWÉDWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBäBä..B÷B÷8-9 months A8-9 months A .8-9 months A . ...C4591001C4591001 1044 10441310104413101044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24958 DWDÎ@DWŇ.DWŇDWDWDÎ@DWDÉĚDWDÎ@DWDÉĚ....HrĽŔHrŐĚHrĽŔHrŐĚ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DÎ@DÉĚ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW8DWŇDWŇ..NEG....YNNNNYYDW........DW8DWŇYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBäBä..B÷B÷8-9 months A8-9 months A .8-9 months A . ...C4591001C4591001 1044 10441311104413111044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24959 DWD—,DWŃ.DWŃDWDWD—,DW!D’DWD—,DW!D’....HrÂé,HrŢ“„HrÂé,HrŢ“„..DWDW!..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. D—,D’....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW=DWŃDWŃ..NEG....YNNNNYYDW........DW=DWŃYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBÝBÝ..BňBň7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1044 10441312104413121044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24966 DWD”DW˝.DW˝DWDWD”DWˇD ČDWD”DW"DłÄDWŽDÁ DWˇD ČHrÂę”Hs‡bHHrÂę”HrŕÄHsnv Hs‡bHDWDW"DWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. D”DłÄ.DÁ D Č.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANYYYNEGDW?DWŚDWŤDW˝DX^NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBpBqBňB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441313104413131044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24968 DWD§DWí..DWDWD§DWíDŽ€DWD§DW!D–<DW×DłDWíDŽ€HrÂůHsë‚HrÂůHrŢ—ĽHsÎ¦Hsë‚DWDW!DW×DWíAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW‡BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§D–<.DłDŽ€.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW×DW×. Underweight ANNYYNEGDW?DWÖDWÖDXDXŞNEG....YNNNNYYDW........DW?DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÖDWýDWýBÝB¶B'B'BňBË7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1044 10441314104413141044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25210 DWDČdDWŢ.DWŢDWDWDČdDW!DÜPDWDČdDW!DÜP....HrĂdHrŢÝĐHrĂdHrŢÝĐ..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DČdDÜP....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDW@DWŚDWŢ..NEG....YNNNNYYDW........DW@DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441315104413151044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25212 DWDČ(DWĂ.DWĂDWDWDČ(DW§DŤDWDČ(DW!DÜDW‘Dđ´DW§DŤHrĂ(HsŹ8HrĂ(HrŢÝ”Hsrš4HsŹ8DWDW!DW‘DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DČ(DÜ.Dđ´DŤ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW@DWŚDWDWĂDXdNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBmBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441316104413161044AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25213 DWDŰŘDWŃ.DWŃDWDWDŰŘDW!D´đDWDŰŘDW!D´đ....HrĂ-ŘHrŢ¶pHrĂ-ŘHrŢ¶p..DWDW!..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWŚ .. DŰŘD´đ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWŚ. Normal weightA NNYYNEGDW>DWŤDWŃ..NEG....YNNNNYYDW........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441317104413171044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25214 DWDâ¤DWĆ.DWĆDWDWDâ¤DW¨D¸8DWDâ¤DW#DÚpDW“DĽ4DW¨D¸8HrĂ4¤Hs´8HrĂ4¤Hrá~đHsu´Hs´8DWDW#DW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ¤DÚp.DĽ4D¸8.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW“. Underweight ANNYYNEGDW?DW’DW’DWĆDXeNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpBkBkBňB‡7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441318104413181044AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25392 DW D—ŕDWĂ.DWĂDW DW D—ŕDWŁDĚ`DW D—ŕDW!D” DWŽDŞÜDWŁDĚ`HrÄ;`HsŠ0ŕHrÄ;`HrŢ• Hsn_ÜHsŠ0ŕDW DW!DWŽDWŁAŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWyBNT162b2 (30 (*ESC*){unicode 03BC}g).. D—ŕD” .DŞÜDĚ`.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDWADWŚDWŤDWĂDX`NEG....YNNNNYNDW ........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBpBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441319104413191044AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25394 DW DDWŢ.DWŢDW DW DDW!D”\DW DDW!D”\....HrÄ;śHrŢ•ÜHrÄ;śHrŢ•Ü..DW DW!..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DD”\....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Underweight ANNYYNEGDWADWŚDWŢ..NEG....YNNNNYYDW ........DWADWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441320104413201044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25395 DW DµŕDWż.DWżDW DW DµŕDWŁDÄ,DW DµŕDW"D¬DWŽDČdDWŁDÄ,HrÄY`HsŠ(¬HrÄY`Hrß˙Hsn}dHsŠ(¬DW DW"DWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DµŕD¬.DČdDÄ,.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDWEDWŚDWŤDWżDX`NEG....YNNNNYNDW ........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBpBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441321104413211044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25396 DW Dż|DWß.DWßDW DW Dż|DW"DĆ„DW Dż|DW"DĆ„....HrÄbüHrŕ„HrÄbüHrŕ„..DW DW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW} .. Dż|DĆ„....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW}. Obese A@YNYYNEGDW>DWŚDWß..NEG....YNNNNYYDW ........DW>DWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441322104413221044AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25521 DW DÚ4DWŤ.DWŤDW DW DÚ4DW#Dę$DW DÚ4DW#Dę$....HrÄ}´HráŽ¤HrÄ}´HráŽ¤..DW DW#..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DWPWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DÚ4Dę$....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWN.. Obese A@YNYYNEGDWEDWMDWŕ.. ....YNNNNNNDW ..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNNNY NNDWMDWPDWPB.B+A0BDBA1-2 months A 1-2 months A 0-1 month A2-3 months A0 . ...C4591001C4591001 1044 10441323104413231044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25525 DW DóDWĂ.DWĂDW DW DóDW§DŤĚDW DóDW$DÂLDW‘DđđDW§DŤĚHrÄ–ŚHsŹ8LHrÄ–ŚHrâ¸LHsršpHsŹ8LDW DW$DW‘DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DóDÂL.DđđDŤĚ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW@DWŚDWDWĂDXdNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBmBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DW‹C4591001C4591001 1044 10441324104413241044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25529 DW Ed@DWĂ.DWĂDW DW Ed@DW˘D’DW Ed@DW!DźśDWŽDŐHDW˘D’HrÄ©ÄHsĄHrÄ©ÄHrŢˇHsnŠHHsĄDW DW!DWŽDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW…BNT162b2 (30 (*ESC*){unicode 03BC}g).. Ed@Dźś.DŐHD’.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NYYYNEGDW=DWŤDWŤDWĂDX_NEG....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÝBmBpBpBńB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441325104413251044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25531 DW Es@DW×.DW×DW DW Es@DW"Dę$DW Es@DW"Dę$....HrÄŞ´Hrŕ=$HrÄŞ´Hrŕ=$..DW DW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW€ .. Es@Dę$....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW€. Normal weightA NNYYNEGDW>DWŤDW×..NEG....YNNNNYYDW ........DW>DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÜBlBpBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441326104413261044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25645 DWD“äDWÉ.DWÉDWDWD“äDW¨DĹDWD“äDW!D´<DW“DČdDW¨DĹHrĹäHsÁHrĹäHrŢµĽHsuäHsÁDWDW!DW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW‡BNT162b2 (30 (*ESC*){unicode 03BC}g).. D“äD´<.DČdDĹ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Underweight ANNYYNEGDW>DW‘DW’DWÉDXeNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÝBqBkBlBđB„7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441327104413271044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25647 DWD” DWÉ.DWÉDWDWD” DW¨DĹXDWD” DW!D´xDW“DČ(DW¨DĹXHrĹ‰ HsÁXHrĹ‰ HrŢµřHsu¨HsÁXDWDW!DW“DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW‡BNT162b2 (30 (*ESC*){unicode 03BC}g).. D” D´x.DČ(DĹX.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Normal weightA NNYYNEGDW>DW‘DW’DWÉDXeNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÝBqBkBlBđB„7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441328104413281044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25648 DWD¦ŕDWß.DWßDWDWD¦ŕDW"D‘PDWD¦ŕDW"D‘P....HrĹ›ŕHrßäPHrĹ›ŕHrßäP..DWDW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. D¦ŕD‘P....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW|. Normal weightA NNYYNEGDW>DWŚDWß..NEG....YNNNNYYDW........DW>DWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441329104413291044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25652 DWDĂxDWć.DWćDWDWDĂxDW#DŕDWDĂxDW#Dŕ....HrĹ¸xHrá…HrĹ¸xHrá…..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂxDŕ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWADWŚDWć..NEG....YNNNNYYDW........DWADWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441330104413301044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25778 DWDŮDDWü..DWDWDŮDDW§DËčDWDŮDDW#DŃDW“D¶DW§DËčHrĹÎDHsŹvhHrĹÎDHrávHsuśHsŹvhDWDW#DW“DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW“BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDDŃ.D¶DËč.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW“. Underweight ANNYYNEGDW?DW’DW’DWÄDXdNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpBkBkBđB…7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441331104413311044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25780 DWDřčDW×.DW×DWDWDřčDW#DęśDWDřčDW#Dęś....HrĹíčHráŹHrĹíčHráŹ..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW„ .. DřčDęś....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW„. Underweight ANNYYNEGDWEDWŤDW×..NEG....YNNNNYYDW........DWEDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441332104413321044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25782 DWDů$DWĂ.DWĂDWDWDů$DWŁDäHDWDů$DW#DęŘDWŽDÉDWŁDäHHrĹî$HsŠHČHrĹî$HráŹXHsn~HsŠHČDWDW#DWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW„BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dů$DęŘ.DÉDäH.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDWEDWŤDWŤDWĂDX`NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBpBpBđB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441333104413331044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25783 DWE†DWŢ.DWŢDWDWE†DW#DÍDWE†DW#DÍ....HrĹý`Hráq”HrĹý`Hráq”..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. E†DÍ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Underweight ANNYYNEGDWADWŚDWŇ..NEG....YNNNNYYDW........DWADWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441334104413341044AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25905 DWD’@DWß.DWßDWDWD’@DW"DŽřDWD’@DW"DŽř....HrĆŘŔHrßářHrĆŘŔHrßář..DWDW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D’@DŽř....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWHDWŚDWß..NEG....YNNNNYYDW........DWHDWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441335104413351044AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25910 DWDŮĽDWĹ.DWĹDWDWDŮĽDW¦Dć(DWDŮĽDW%D× DW’DęśDW¦Dć(HrÇ <HsŽ?(HrÇ <Hrä HssĺśHsŽ?(DWDW%DW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮĽD× .DęśDć(.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDWHDWŤDW‘DWÄDXcNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŮBiBlBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441336104413361044AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25913 DWDé4DWŘ.DWŘDWDWDé4DW$Dä„DWDé4DW$Dä„....HrÇ/´HrâÚ„HrÇ/´HrâÚ„..DWDW$..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‹ .. Dé4Dä„....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW‹. Underweight ANNYYNEGDW@DWŚDWŘ..NEG....YNNNNYYDW........DW@DWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441337104413371044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25916 DWD$DWĂ.DWĂDWDWD$DW¦D¦hDWD$DW%D“¨DW“D–<DW¦D¦hHrČ($HsŤ˙hHrČ($HrăŰ(HstâĽHsŤ˙hDWDW%DW“DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D$D“¨.D–<D¦h.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Underweight ANNYYNEGDWADWŤDW’DWĂDXcNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŮBiBkBpBîB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441338104413381044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26229 DWD$DWŮ.DWŮDWDWD$DW%D˘0DWD$DW%D˘0....HrČ($Hrăé°HrČ($Hrăé°..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D$D˘0....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANNYYNEGDWADWŮDWŮ..NEG....YNNNNYYDW........DWADWŮYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýBŮBŮ..BîBî7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1044 10441339104413391044AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26234 DWDáxDWß.DWßDWDWDáxDW%DÝôDWDáxDW%DÝô....HrČyxHrä%tHrČyxHrä%t..DWDW%..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DáxDÝô....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Normal weightA NNYYNEGDWEDWŚDWß..NEG....YNNNNYYDW........DWEDWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441340104413401044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26326 DWDâhDWĂ.DWĂDWDWDâhDW D¦,DWDâhDW%Dß\DWŤDÝôDW D¦,HrČzhHs†,HrČzhHrä&ÜHsmAtHs†,DWDW%DWŤDW AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâhDß\.DÝôD¦,.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWEDWŚDWŚDWĂDX]NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBqBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441341104413411044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26235 DWDâ¤DWĂ.DWĂDWDWDâ¤DW D¦hDWDâ¤DW%DßÔDWŤDÝôDW D¦hHrČz¤Hs†hHrČz¤Hrä'THsmAtHs†hDWDW%DWŤDW AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWyBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ¤DßÔ.DÝôD¦h.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDWEDWŚDWŚDWĂDX]NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBqBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441342104413421044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26334 DWD‘PDWÓ.DWÓDWDWD‘PDW$DÚ¬DWD‘PDW$DÚ¬....HrÉzĐHrâĐ¬HrÉzĐHrâĐ¬..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWŠ .. D‘PDÚ¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWŠ. Underweight ANNYYNEGDWDDWŚDWÓ..NEG....YNNNNYYDW........DWDDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBíB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441343104413431044AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26335 DWD’@DWÚ.DWÚDWDWD’@DW%DŮDWD’@DW%DŮ....HrÉ{ŔHrä HrÉ{ŔHrä ..DWDW%..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. D’@DŮ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Underweight ANNYYNEGDWADWŚDWÚ..NEG....YNNNNYYDW........DWADWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBíB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441344104413441044AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26336 DWD’DWo..DWDWD’DWSD”DWD’DW%DŘĚDW:DłLDWSD”HrÉ{„Hs HrÉ{„Hrä LHr˙ŞLHs DWDW%DW:DWSAđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. DW/OTHER Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D’DŘĚ.DłLD”.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW1DW:. Overweight A0NNYYNEGDW0DW0DW9DWoDX ....YNNNNNNDW..........YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 7 days but prior to 14 days post Dose 2 NYNYYYN YNNYNY NNDW0DWýDWýBŮAŔBÄBÍBíB 7-8 months A€0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1044 10441345104413451044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26477 DWD˘äDWĂ.DWĂDWDWD˘äDW¦D“0DWD˘äDW$DŢ0DW‘D™üDW¦D“0HrÉŚdHsŤě0HrÉŚdHrâÔ0HsrC|HsŤě0DWDW$DW‘DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW}BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘äDŢ0.D™üD“0.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWEDWŚDWDWĂDXcNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBmBqBíB|7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441346104413461044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26470 DWD˘lDW×.DW×DWDWD˘lDW$DŹ¬DWD˘lDW$DŹ¬....HrÉ‹ěHrâ…¬HrÉ‹ěHrâ…¬..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. D˘lDŹ¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Normal weightA NNYYNEGDWEDWŚDW×..NEG....YNNNNYYDW........DWEDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBíB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441347104413471044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26478 DWDŁDWś.DWśDWDWDŁDW%D·ŔDWDŁDW%D·Ŕ....HrÉŤHră˙@HrÉŤHră˙@..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWśWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŁD·Ŕ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Normal weightA NNYYNEGDWFDWŤDWâ..NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWśDWśBxBiAđBŚB}4-5 months AP3-4 months A@0-1 month A5-6 months A` . ...C4591001C4591001 1044 10441348104413481044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26494 DWD¬€DWĂ.DWĂDWDWD¬€DW§DŕLDWD¬€DW$DŃÄDW‘DÜPDW§DŕLHrÉ–HsŹŠĚHrÉ–HrâÇÄHsr…ĐHsŹŠĚDWDW$DW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWyBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬€DŃÄ.DÜPDŕL.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW@DWŤDWDWĂDXdNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBmBpBíB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441349104413491044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26479 DWD4DWŢ.DWŢDWDWD4DW%D’¸DWD4DW%D’¸....HrÉ–´HrăÚ8HrÉ–´HrăÚ8..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. D4D’¸....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW‡. Normal weightA NNYYNEGDWADWDWŢ..NEG....YNNNNYYDW........DWADWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŮBlBmBíB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441350104413501044AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26500 DWD´DWŘ.DWŘDWDWD´DW%D°ôDWD´DW%D°ô....HrÉť€HrăřtHrÉť€Hrăřt..DWDW%..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´D°ô....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWu.. Normal weightA NNYYNEGDWADWtDWŘ..NEG....YNNNNYYDW........DWADWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWtDWýDWýBŮBPB‰BíBd7-8 months A€2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1044 10441351104413511044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26502 DWDŽĽDWó..DWDWDŽĽDWóDß DWDŽĽDW(DáDWßDĺtDWóDß HrĘÉĽHsó» HrĘÉĽHrčHsŮcôHsó» DWDW(DWßDWóAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW‡BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽĽDá.DĺtDß .374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÚDWß. Overweight A0NNYYNEGDWGDWŮDWÚDXDX°NEG....YNNNNYYDW........DWGDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŮDWýDWýBÖB˛BB$BěBČ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1044 10441352104413521044AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26504 DWD`DWá.DWáDWDWD`DW%D¶ĐDWD`DW%D¶Đ....HrĘË`HrăţPHrĘË`HrăţP..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW€ .. D`D¶Đ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW€. Normal weightA NNYYNEGDWEDWŚDWá..NEG....YNNNNYYDW........DWEDWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBěB{7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441353104413531044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26508 DWD‘DWÚ.DWÚDWDWD‘DW(DÚ¬DWD‘DW(DÚ¬....HrĘĚHrč¬HrĘĚHrč¬..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWx .. D‘DÚ¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWx. Normal weightA NNYYNEGDWDDWŤDWÚ..NEG....YNNNNYYDW........DWDDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÖBfBpBěB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441354104413541044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26509 DWD˘lDWĆ..DWDWD˘lDW¨DŹčDWD˘lDW%D˛ DW“D•DW¨DŹčHrĘÝlHs‹čHrĘÝlHrăů HstâHs‹čDWDW%DW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘lD˛ .D•DŹč.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANYYYNEGDWADWŚDW’DWĆDXeNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBkBqBěB{7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441355104413551044AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26513 DWD˘¨DWŮ.DWŮDWDWD˘¨DW%D˛DWD˘¨DW%D˛....HrĘÝ¨HrăúHrĘÝ¨Hrăú..DWDW%..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˘¨D˛....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NYYYNEGDWADWŚDWŮ..NEG....YNNNNYYDW........DWADWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBěB{7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441356104413561044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26514 DWDŁDWÚ.DWÚDWDWDŁDW)DôěDWDŁDW)Dôě....HrĘŢHré‚lHrĘŢHré‚l..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŁDôě....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANYYYNEGDWKDWÚDWÚ..NEGDWŽ.DWŽDWŽYNNNNYYDW........DWKDWÚYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýBŐBŐ..BěBě7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1044 10441357104413571044AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26521 DWD°¸DWÄ.DWÄDWDWD°¸DW¦DćdDWD°¸DW%D×dDW’DęŘDW¦DćdHrĘë¸HsŽ?dHrĘë¸HrääHssĺŘHsŽ?dDWDW%DW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°¸D×d.DęŘDćd.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDWHDWŤDW‘DWÄDXcNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŮBiBlBpBěB|7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441358104413581044AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26522 DWD°DWĺ.DWĺDWDWD°DW(DĽ¬DWD°DW(DĽ¬....HrĘëHrçř¬HrĘëHrçř¬..DWDW(..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. D°DĽ¬....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW‡. Underweight ANNYYNEGDWHDWŤDWĺ..NEG....YNNNNYYDW........DWHDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÖBfBpBěB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441359104413591044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26528 DWDŤĚDWó.DWóDWDWDŤĚDW@DíäDWDŤĚDW@Díä....HrĚLHsÍäHrĚLHsÍä..DWDW@..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NY YDWx .. DŤĚDíä....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWx. Normal weightA NNYYNEGDW\DW‘DWó..NEG....YNNNNYYDW........DW\DWóYY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YYNNNY NYDW‘DWýDWýBľBRBlBëB6-7 months Ap2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1044 10441360104413601044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26524 DWDŤDWÄ.DWÄDWDWDŤDW¦DęŘDWDŤDW@Dî DW‘D—¤DW¦DęŘHrĚHsŽCŘHrĚHsÎ HsrA$HsŽCŘDWDW@DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN Y NY YDWxBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤDî .D—¤DęŘ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW\DWŚDWDWÄDXcNEG....YNNNNYNDW........DW\.YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWŚDWýDWýBľBMBmBqBëBz6-7 months Ap2-3 months A03-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441361104413611044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26589 DWD˛ÔDWŮ.DWŮDWDWD˛ÔDW*D¶DWD˛ÔDW*D¶....HrĚ?THrę•HrĚ?THrę•..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. D˛ÔD¶....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW‡. Underweight ANYYYNEGDWLDWŤDWŮ..NEG....YNNNNYYDW........DWLDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÔBdBpBëB{7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441362104413621044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26593 DWDÂÄDWż.DWżDWDWDÂÄDWŁDŃDWDÂÄDW*DXDWŤDçDWŁDŃHrĚODHsŠ5HrĚODHręwXHsmKHsŠ5DWDW*DWŤDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂÄDX.DçDŃ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANYYYNEGDWGDWŚDWŚDWżDX`NEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBqBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441363104413631044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26595 DWDÎôDWĂ.DWĂDWDWDÎôDWŁDÝDWDÎôDW(DĹXDWŽDÚpDWŁDÝHrĚ[tHsŠA„HrĚ[tHrčXHsnŹpHsŠA„DWDW(DWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎôDĹX.DÚpDÝ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDWFDWŚDWŤDWĂDX`NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBpBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441364104413641044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26596 DWDÖ°DWŕ.DWŕDWDWDÖ°DW*DÚčDWDÖ°DW*DÚč....HrĚc0HręąčHrĚc0Hręąč..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW} .. DÖ°DÚč....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW}. Overweight A0NNYYNEGDWGDW“DWŕ..NEG....YNNNNYYDW........DWGDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBÔBjBjBëB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441365104413651044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26675 DWDÜČDWĂ.DWĂDWDWDÜČDWˇD”\DWDÜČDW)D×ÜDWŤDĂxDWˇD”\HrĚiHHs‡UÜHrĚiHHrée\Hsm&řHs‡UÜDWDW)DWŤDWˇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČD×Ü.DĂxD”\.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWFDWŚDWŚDWĂDX^NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBqBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441366104413661044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26676 DWDÜPDWŢ.DWŢDWDWDÜPDW)D× DWDÜPDW)D× ....HrĚhĐHrée HrĚhĐHrée ..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DÜPD× ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDWFDWŚDWŢ..NEG....YNNNNYYDW........DWFDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441367104413671044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26677 DWDî DWŮ.DWŮDWDWDî DW*D¨„DWDî DW*D¨„....HrĚz Hrę‡„HrĚz Hrę‡„..DWDW*..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dî D¨„....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Obese A@YNYYNEGDWLDWŚDWŮ..NEG....YNNNNYYDW........DWLDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÔBcBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441368104413681044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26678 DWDő DW}..DWDWDő DWaDŘTDWDő DW*DĂ´DWLDŰ`DWaDŘTHrĚ‚ Hs39ÔHrĚ‚ Hrę˘´HsŤ`Hs39ÔDWDW*DWLDWaAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dő DĂ´.DŰ`DŘT.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWL. Normal weightA NNYYNEGDWJDWJDWKDW}DXNEG....YNNNNYNDW........DWL.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDWJDWýDWýBÔB!B˛BłBëB87-8 months A€1-2 months A 6-7 monthsAp8-9 months A . ...C4591001C4591001 1044 10441369104413691044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26725 DWDůśDWß.DWßDWDWDůśDW)Dí¨DWDůśDW)Dí¨....HrĚ†Hré{(HrĚ†Hré{(..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DůśDí¨....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Obese A@YNYYNEGDWFDWŚDWß..NEG....YNNNNYYDW........DWFDWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441370104413701044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26729 DWDů`DWŃ.DWŃDWDWDů`DW´Dź$DWDů`DW)DílDW DĐ\DW´Dź$HrĚ…ŕHs m$HrĚ…ŕHrézěHs†@\Hs m$DWDW)DW DW´AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dů`Díl.DĐ\Dź$.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW . Underweight ANNYYNEGDWFDWŚDWźDWŃDXqNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdB^BqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441371104413711044AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26730 DWEkŔDWß.DWßDWDWEkŔDW)DĆŔDWEkŔDW)DĆŔ....HrĚ“<HréT@HrĚ“<HréT@..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE ADWßWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. EkŔDĆŔ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDWHDWćDWć..NEG....YNNNNYNDW........DWH.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWß.DWßB·B·..BÍBÍ6-7 months Ap6-7 months Ap .7-8 months A€ . ...C4591001C4591001 1044 10441372104413721044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26731 DWEhDWß.DWßDWDWEhDW)DĆ„DWEhDW)DĆ„....HrĚ“HréTHrĚ“HréT..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWßWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. EhDĆ„....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWHDWŚDWć..NEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWßDWßB·BdBSBÍBz6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1044 10441373104413731044AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26782 DWD”\DWÄ.DWÄDWDWD”\DW§D‡<DWD”\DW+DŤDW‘D–´DW§D‡<HrÍr\HsŹ1ĽHrÍr\HrëľHsr@4HsŹ1ĽDWDW+DW‘DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW‡BNT162b2 (30 (*ESC*){unicode 03BC}g).. D”\DŤ.D–´D‡<.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWLDWŚDWDWÄDXdNEG....YNNNNYNDW........DWL.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÓBbBmBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441374104413741044AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26784 DWDŁ DWđ..DWDWDŁ DWđD PDWDŁ DW)D•LDWđD PDWđD PHrÍ HsďPHrÍ Hré"ĚHsďPHsďPDWDW)DWđ.AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DŁ D•L.D P..374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWđ. Underweight ANNYYNEGDWFDW×DWŘDX*DXÄNEG....YNNNNYYDW........DWFDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW×DWýDWýBŐBŻAŕB&BęBÄ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ..DW7C4591001C4591001 1044 10441375104413751044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26786 DWD˛DWÚ.DWÚDWDWD˛DW)Dˇ¸DWD˛DW)Dˇ¸....HrÍHré/8HrÍHré/8..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˛Dˇ¸....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWEDWŚDWÚ..NEG....YNNNNYYDW........DWEDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441376104413761044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26792 DWD˛ÔDWÚ.DWÚDWDWD˛ÔDW)Dˇ|DWD˛ÔDW)Dˇ|....HrÍÔHré.üHrÍÔHré.ü..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW‡ .. D˛ÔDˇ|....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW‡. Underweight ANYYYNEGDWEDWDWÚ..NEG....YNNNNYYDW........DWEDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŐBhBmBęB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441377104413771044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26911 DW(D˝śDWő.DWőDWDW(D˝śDW=DÜPDW(D˝śDW=DÜP....HrçůśHsÇĐHrçůśHsÇĐ..DW(DW=..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW… .. D˝śDÜP....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW…. Underweight ANNYYNEGDWYDWŤDWő..NEG....YNNNNYYDW(........DWYDWőYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÁBQBpBÖBf6-7 months Ap2-3 months A00-1 month A7-8 months A€ . ...C4591001C4591001 1044 10441378104413781044AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26843 DWDĚ$DWŢ.DWŢDWDWDĚ$DW+DŕLDWDĚ$DW+DŕL....HrÍŞ$HrěĚHrÍŞ$HrěĚ..DWDW+..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĚ$DŕL....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWKDWŚDWŢ..NEG....YNNNNYYDW........DWKDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÓBbBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441379104413791044AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26845 DWDĚ`DWŢ.DWŢDWDWDĚ`DW+DŕDWDĚ`DW+Dŕ....HrÍŞ`HrěHrÍŞ`Hrě..DWDW+..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĚ`Dŕ....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWKDWŚDWŢ..NEG....YNNNNYYDW........DWKDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÓBbBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441380104413801044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26849 DWDä„DWľ.DWľDWDWDä„DW˘DŢ0DWDä„DW*DëŚDWŤDĂđDW˘DŢ0HrÍÂ„Hsń0HrÍÂ„HręĘŚHsm'pHsń0DWDW*DWŤDW˘AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW}BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dä„DëŚ.DĂđDŢ0.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDWGDWŚDWŚDWľDX_NEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBqBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441381104413811044AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26851 DWDĺ°DWĆ.DWĆDWDWDĺ°DWŞDŃDWDĺ°DW(DĄxDW‘Dé¬DWŞDŃHrÍĂ°Hs“pHrÍĂ°HrçáxHsr“,Hs“pDWDW(DW‘DWŞAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW€BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺ°DĄx.Dé¬DŃ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDWHDWŤDWDWĆDXgNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÖBfBmBpBęBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1044 10441382104413821044AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26901 DWDůŘDW˝.DW˝DWDWDůŘDWˇDŰśDWDůŘDW*DÖ8DWŤDéčDWˇDŰśHrÍ×ŘHs‡ťHrÍ×ŘHręµ8HsmMhHs‡ťDWDW*DWŤDWˇAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW†BNT162b2 (30 (*ESC*){unicode 03BC}g).. DůŘDÖ8.DéčDŰś.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWKDWŚDWŚDW˝DX^NEG....YNNNNYNDW........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBqBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1044 10441383104413831044AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26902 DWDůśDWÚ.DWÚDWDWDůśDW*DŐüDWDůśDW*DŐü....HrÍ×śHrę´üHrÍ×śHrę´ü..DWDW*..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW† .. DůśDŐü....374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW†. Normal weightA NNYYNEGDWKDWŚDWÚ..NEG....YNNNNYYDW........DWKDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÔBcBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1044 10441384104413841044AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26912 DWDúČDWĂ.DWĂDWDWDúČDW§DÜŚDWDúČDW+DílDW”DŘĚDW§DÜŚHrÍŘČHsŹ‡HrÍŘČHrěěHsvvĚHsŹ‡DWDW+DW”DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWxBNT162b2 (30 (*ESC*){unicode 03BC}g).. DúČDíl.DŘĚDÜŚ.374169 Hartman, Aaron N. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Obese A@YNYYNEGDWGDWŤDW“DWĂDXdNEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÓBcBjBpBęBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571376105713761057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21117 DVđD•ÄDW».DW»DVđDVđD•ÄDWDĂ<DVđD•ÄDWDĂ<....HrťýÄHrĂ<HrťýÄHrĂ<..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D•ÄDĂ<....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW(DWŤDW»..NEG....YNNNNYYDVđ........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBňB‚BpCŕBž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571377105713771057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVđ21119 DVđDŃDWő.DWőDVđDVđDŃDWDťřDVđDŃDWDťř....Hrž9HrąµxHrž9Hrąµx..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWőWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŃDťř....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW!DWŚDWÂ..NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWőDWőBńBBiC`Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571378105713781057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21122 DVđD×(DWő.DWőDVđDVđD×(DWDž¬DVđD×(DWDž¬....Hrž?(Hrą¶,Hrž?(Hrą¶,..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADWőWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D×(Dž¬....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Obese A@YNYYNEGDW!DWŚDWÂ..NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWőDWőBńBBiC`Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571379105713791057AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21127 DVđDčĽDWĂ.DWĂDVđDVđDčĽDWŁD˘äDVđDčĽDWDďÄDWŤDĺ8DWŁD˘äHržPĽHsŠdHržPĽHrĽŞDHsmH¸HsŠdDVđDWDWŤDWŁAŕYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčĽDďÄ.Dĺ8D˘ä.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW$DWŚDWŚDWżDX`NEG....YNNNNYNDVđ........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BqBqCŕBť8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1057 10571380105713801057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21345 DVńDŠ„DWÔ.DWÔDVńDVńDŠ„DWD~DVńDŠ„DWD~....HrźDHrÂĐHrźDHrÂĐ..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠ„D~....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW,DWŤDWĂ..NEG....YNNNNYYDVń........DW,DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBňB‚BpCĐBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571382105713821057AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21352 DVńDč€DWý.DWýDVńDVńDč€DW D’ôDVńDč€DW D’ô....Hrź˘HrÄ6tHrź˘HrÄ6t..DVńDW ..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dč€D’ô....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NYNYPOSDW)DWŤDWĽ..POS....YNNNNYYDVń........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBńBBpCĐBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571383105713831057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21346 DVńDßDWď.DWďDVńDVńDßDWŞD¨ŔDVńDßDWDâŕDW‘Dă”DWŞD¨ŔHrź™Hs“GŔHrź™HrĽť`HsrŤHs“GŔDVńDWDW‘DWŞAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DßDâŕ.Dă”D¨Ŕ.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW$DWŚDWDWÍDXgNEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BmBqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWďC4591001C4591001 1057 10571384105713841057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21348 DVńDćÜDWí.DWíDVńDVńDćÜDWŃD–xDVńDćÜDWD’@DWĽDÄhDWŃD–xHrź \HsĆźřHrź \Hrą©ŔHs«hHsĆźřDVńDWDWĽDWŃAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DćÜD’@.DÄhD–x.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWĽ. Underweight ANNYYNEGDW"DWŚDW»DWíDXŽNEG....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBBBqCĐBś8-9 months A4-5 months AP2-3 monthsA09-10 months A . ...C4591001C4591001 1057 10571385105713851057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21504 DVńDëŚDWÓ.DWÓDVńDVńDëŚDWDÎôDVńDëŚDWDÎô....HrźĄHrąćtHrźĄHrąćt..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWÓOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DëŚDÎô....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW3.. Normal weightA NNYYNEGDW!DW2DWż..NEG....YNNNNYYDVń........DW!DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW2DWÓDWÓBĎB.BˇBăBB7-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1057 10571386105713861057AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21508 DVńDëPDWµ.DWµDVńDVńDëPDWDßDVńDëPDWDß....Hrź¤ĐHr»HHrź¤ĐHr»H..DVńDW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DëPDß....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Obese A@YNNYPOSDW"DWŚDWµ..POS....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBřB‡BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571387105713871057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21509 DVňDĹ”DWá.DWáDVňDVňDĹ”DW¶DăĐDVňDĹ”DWDÁ\DWˇDÚpDW¶DăĐHr Đ”HsŁTĐHr Đ”HrąŘÜHs‡›đHsŁTĐDVňDWDWˇDW¶AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĹ”DÁ\.DÚpDăĐ.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWšDWˇ. Normal weightA NNYYNEGDW#DW™DW DWŇDXsNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW™DWýDWýBůB•B]BdCŔB¨8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571388105713881057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21512 DVňDĘDWÉ.DWÉDVňDVňDĘDWD™üDVňDĘDWD™ü....Hr ŐHrą±|Hr ŐHrą±|..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DĘD™ü....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Underweight ANNYYNEGDW*DWŚDWÉ..NEG....YNNNNYYDVň........DW*DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571389105713891057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21705 DVňDË4DWÉ.DWÉDVňDVňDË4DWDęŘDVňDË4DWDęŘ....Hr Ö4HrĂ<ŘHr Ö4HrĂ<Ř..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DË4DęŘ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW[. Underweight ANNYYNEGDW*DWŚDWÉ..NEGDW—.DW—DW—YNNNNYYDVň........DW*DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571390105713901057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21706 DVňDĎlDWŰ.DWŰDVňDVňDĎlDWDĐDVňDĎlDWDĐ....Hr ÚlHrąčHr ÚlHrąč..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŰOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĎlDĐ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Overweight A0NNYYNEGDW$DWŤDW·..NEG....YNNNNYYDVň........DW$DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWŰDWŰB×B‰BNBęBś7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1057 10571391105713911057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21711 DVňDĐDWp..DVňDVňDĐDWTDÝ@DVňDĐDWDŃLDW?DŮDWTDÝ@Hr ŰHs"@Hr ŰHrąčĚHsgHs"@DVňDWDW?DWTAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐDŃL.DŮDÝ@.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW:DW?. Normal weightA NNYYNEGDW$DW9DW>DWpDXNEG....YNNNNYNDVň........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW9DWýDWýBůB5BżBÄCŔBH8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1057 10571392105713921057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21712 DVňDáDWÓ.DWÓDVňDVňDáDWDĹ”DVňDáDWDĹ”....Hr ěHrąÝHr ěHrąÝ..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWÓOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DáDĹ”....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW3.. Normal weightA NNYYNEGDW#DW2DW¶..NEG....YNNNNYYDVň........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW2DWÓDWÓBĎB.BˇBâBA7-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1057 10571393105713931057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21754 DVňDäHDWĘ.DWĘDVňDVňDäHDW®DăXDVňDäHDWDĆüDW›DÚ¬DW®DăXHr ďHHsČXHr ďHHrąŢ|Hsł,HsČXDVňDWDW›DW®AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäHDĆü.DÚ¬DăX.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Underweight ANNYYNEGDW%DWŚDWšDWĘDXkNEG....YNNNNYNDVň........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBcBqCŔB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571394105713941057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21756 DVňDčDDWĹ.DWĹDVňDVňDčDDW§Dß\DVňDčDDWDĹXDW‘DÝ¸DW§Dß\Hr óDHsŹ‰ÜHr óDHr».XHsr‡8HsŹ‰ÜDVňDWDW‘DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDĹX.DÝ¸Dß\.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0NNYYNEGDW"DWŚDWDWĹDXdNEG....YNNNNYNDVň........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqCŔB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571395105713951057AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21757 DVňDę$DWŻ.DWŻDVňDVňDę$DWDäŔDVňDę$DWDäŔ....Hr ő$HrĐeŔHr ő$HrĐeŔ..DVňDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. Dę$DäŔ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW8. Overweight A0NNYYNEGDW8DWŤDWÓ..NEG....YNNNNYNDVň........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŤDWýDWýBčBxBpCŔBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571396105713961057AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21761 DVóDÎ¸DWő..DVóDVóDÎ¸DWDĆDVóDÎ¸DWDĆ....Hr˘+8HrąÝŚHr˘+8HrąÝŚ..DVóDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NY YDWE .. DÎ¸DĆ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW9. Underweight ANYYYNEGDW(DWŤDW´..NEG....YNNNNYYDVó........DW(DW´YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YYNNNYYNYDWŤDWýDWýBůB‰BpC°B›8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWőC4591001C4591001 1057 10571397105713971057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21949 DVóDăXDW¶..DVóDVóDăXDWDŰśDVóDăXDWDŰś....Hr˘?ŘHrĽ–Hr˘?ŘHrĽ–..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DăXDŰś....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW#DWŚDW¶..NEG....YNNNNYYDVó........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571398105713981057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21951 DVóDäüDWľ.DWľDVóDVóDäüDW˘DÄhDVóDäüDWDŔ¨DW‘DÁ\DW˘DÄhHr˘A|Hs×hHr˘A|HrĽ{(HsrjÜHs×hDVóDWDW‘DW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäüDŔ¨.DÁ\DÄh.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW#DWŚDWDWľDX_NEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BmBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DW‡C4591001C4591001 1057 10571399105713991057AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21954 DVóDé4DW¶.DW¶DVóDVóDé4DWDŐHDVóDé4DWDŐH....Hr˘E´Hr»>HHr˘E´Hr»>H..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dé4DŐH....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDW#DWŚDW¶..NEG....YNNNNYYDVó........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ..DW®C4591001C4591001 1057 10571400105714001057AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô21956 DVôD™„DWŕ.DWŕDVôDVôD™„DW¦DÖěDVôD™„DWD{HDW‘DÄŕDW¦DÖěHrŁG„HsŽ/ěHrŁG„HrĽ5ČHsrn`HsŽ/ěDVôDWDW‘DW¦AĐYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™„D{H.DÄŕDÖě.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNNYPOSDW(DWŚDWDWŕDXcPOS....YNNNNYNDVô........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDWŚDWýDWýB÷B†BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571401105714011057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22057 DVôD¬DW.DWDVôDVôD¬DWDÄhDVôD¬DWDÄh....HrŁZHrĽ~čHrŁZHrĽ~č..DVôDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¬DÄh....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW$DWŤDW..NEG....YNNNNYYDVô........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB÷B‡BpC Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571402105714021057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22058 DV÷DăĐDWw..DV÷DV÷DăĐDW[DŕLDV÷DăĐDWDĐ DWFDćdDW[DŕLHr§†PHs+XĚHr§†PHrĹĹ HsŻdHs+XĚDV÷DWDWFDW[AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DăĐDĐ .DćdDŕL.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DWF. Obese A@YNYYNEGDW*DW5DWEDWwDXNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýBđB(B¸BČCpB?8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1057 10571403105714031057AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22059 DV÷Dé¬DW».DW»DV÷DV÷Dé¬DWDÄŕDV÷Dé¬DWDÄŕ....Hr§Ś,HrĂŕHr§Ś,HrĂŕ..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dé¬DÄŕ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW)DWŤDW»..NEG....YNNNNYYDV÷........DW)DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBňB‚BpCpB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571404105714041057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22062 DVůDźŘDWď.DWďDVůDVůDźŘDWŇDËčDVůDźŘDWDŐŔDW»DÔ”DWŇDËčHr©ĺXHsČ&čHr©ĺXHrĂ'ŔHs©ÝHsČ&čDVůDWDW»DWŇAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DźŘDŐŔ.DÔ”DËč.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DW». Overweight A0NYYYNEGDW7DWşDWşDWďDXŹNEG....YNNNNYNDVů........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWşDWýDWýBňBŻBCBCCPBÂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1057 10571405105714051057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22896 DVůDé4DWí..DVůDVůDé4DW DáxDVůDé4DW Dáx....HrŞ.´HrÄ„řHrŞ.´HrÄ„ř..DVůDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dé4Dáx....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW)DWŚDWľ..NEG....YNNNNYYDVů........DW)DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571406105714061057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22901 DVůDę`DWÂ..DVůDVůDę`DW¦DĂ<DVůDę`DW Dâ¤DW‘Dâ,DW¦DĂ<HrŞ/ŕHsŽ<HrŞ/ŕHrÄ†$Hsr‹¬HsŽ<DVůDW DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę`Dâ¤.Dâ,DĂ<.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW)DWŚDWDWÂDXcNEG....YNNNNYNDVů........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BmBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571407105714071057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22903 DVúDËčDW€..DVúDVúDËčDWdD—ŕDVúDËčDW Dß DWOD¨„DWdD—ŕHr«bčHs6íŕHr«bčHrÄ‚ HsOHs6íŕDVúDW DWODWdAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DËčDß .D¨„D—ŕ.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW3DWO. Underweight ANNYYNEGDW)DW2DWNDW€DX!NEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW2DWýDWýBńB&BŻBËC@B98-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1057 10571408105714081057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23052 DVúDÍČDWË.DWËDVúDVúDÍČDWŻDËčDVúDÍČDW DßDW™DÝ@DWŻDËčHr«dČHsšhHr«dČHrÄHs}ŔHsšhDVúDW DW™DWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍČDß.DÝ@DËč.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW™. Normal weightA NNYYNEGDW)DWŚDWDWËDXlNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BeBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571409105714091057AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22902 DVúDĆüDWĽ.DWĽDVúDVúDĆüDW DŕDVúDĆüDW Dŕ....Hr«]üHrÄ„Hr«]üHrÄ„..DVúDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DĆüDŕ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Underweight ANNYYNEGDW)DWŚDWĽ..NEG....YNNNNYYDVú........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBńB€BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571410105714101057AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23056 DVúDăXDWÄ.DWÄDVúDVúDăXDW¨DŠHDVúDăXDW DĂDW“DÁ DW¨DŠHHr«zXHs†HHr«zXHrÄf€Hsu Hs†HDVúDW DW“DW¨AŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DăXDĂ.DÁ DŠH.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW)DWŚDW’DWÄDXeNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BkBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571411105714111057AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23059 DVúDęŘDW¸.DW¸DVúDVúDęŘDWDŠŔDVúDęŘDWDŠŔ....Hr«ŘHrĹŔHr«ŘHrĹŔ..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DęŘDŠŔ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW*DWŤDW¸..NEG....YNNNNYYDVú........DW*DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBđB€BpC@B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571412105714121057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23060 DVúDëDWŇ.DWŇDVúDVúDëDWDŠüDVúDëDWDŠü....Hr«‚HrĹüHr«‚HrĹü..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DëDŠü....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWU. Normal weightA NNNNPOSDW*DWŤDWŇ..POS....YNNNNYYDVú........DW*DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŤDWýDWýBđB€BpC@B”8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1057 10571413105714131057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USANYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg)A€ . . .BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23709 DVţ.DVţ.DVţDVţ......................AĐYEARS. 12-15 YearsAWHITE AWHITE ADVţNO LONGER MEETS ELIGIBILITY CRITERIADVţNO LONGER MEETS ELIGIBILITY CRITERIABNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. ......350735 Chalhoub, Fadi .. .A@Phase 3<65 Years 12-15 YearsAA. . ... Normal weightA NN ..... ....NNNNNNN...........YN YNN Ydid not receive Dose 1 as randomized did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNNNNN YNNNN NNDVţ.DVţ..0-1 month A0-1 month A .0-1 month A . ...C4591001C4591001 1057 10571414105714141057AđYEARSFA MULTIPLE A`HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23710 DVţD× DW§.DW§DVţDVţD× DWDÜPDVţD× DWDÜP....Hr°´ HrÍşPHr°´ HrÍşP..DVţDW..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0DW§WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D× DÜP....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANNYYNEGDW1DWŃDWŃ..NEG....YNNNNYNDVţ........DW1.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDW§.DW§B”B”..BŞBŞ5-6 months A`5-6 months A` .6-7 months Ap . ...C4591001C4591001 1057 10571415105714151057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23714 DVţDŘDWâ.DWâDVţDVţDŘDWĆD¨DVţDŘDWDÜPDW˘DĹXDWĆD¨Hr°µHs¸1Hr°µHrĐ]PHsŘXHs¸1DVţDWDW˘DWĆAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘDÜP.DĹXD¨.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW˘. Underweight ANNYYNEGDWODWŚDWˇDWâDXNEG....YNNNNYNDVţ........DWO.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBčBwB\BqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571416105714161057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23716 DVţDŮřDWĐ.DWĐDVţDVţDŮřDWDŢ¨DVţDŮřDWDŢ¨....Hr°¶řHrĎ(Hr°¶řHrĎ(..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮřDŢ¨....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNNYPOSDWVDWŚDWĐ..POS....YNNNNYYDVţ........DWVDWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBéBxBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571417105714171057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23793 DVţDŰŘDWÉ.DWÉDVţDVţDŰŘDWDÎ@DVţDŰŘDWDÝ|DW‘DĎlDWDÎ@Hr°¸ŘHs—aŔHr°¸ŘHrĚiüHsrxěHs—aŔDVţDWDW‘DWAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰŘDÝ|.DĎlDÎ@.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0YNNYPOSDW7DWŚDWDWÉDXjPOS....YNNNNYNDVţ........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBëBzBmBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571418105714181057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23800 DV˙DŮDDW÷.DW÷DV˙DV˙DŮDDWDĘřDV˙DŮDDWDĘř....Hr˛ÄHrĚWxHr˛ÄHrĚWx..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW÷WITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮDDĘř....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YNYYNEGDW/DWŤDWĐ..NEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDW÷DW÷BĺB{BjBůBŹ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1057 10571419105714191057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23803 DV˙DŰ$DWŽ..DV˙DV˙DŰ$DWD§DV˙DŰ$DWD§....Hr˛ ¤HrĚ3śHr˛ ¤HrĚ3ś..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŰ$D§....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW7DWŤDWĐ..NEG....YNNNNYNDV˙........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBëB{BpB˙BŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571420105714201057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW23804 DWDťĽDW?.DW?DWDWDťĽDWDĄ´DWDťĽDWDĄ´....HrłĽHrĚ24HrłĽHrĚ24..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW?WITHDRAWAL BY PARENT/GUARDIAN DW?WITHDRAWAL BY PARENT/GUARDIAN BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DťĽDĄ´....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDW6DWĐDWĐ.. ....YNNNNNNDW..........YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNNNY NNDW?.DW?B-B-..B@B@1-2 months A 1-2 months A .2-3 months A0 . ...C4591001C4591001 1057 10571421105714211057AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24261 DWDÍPDWĆ.DWĆDWDWDÍPDWDÝ|DWDÍPDWDÝ|....HrłMPHrĚiüHrłMPHrĚiü..DWDW..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA DWĆWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÍPDÝ|....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Obese A@YNYYNEGDW/DWĐDWĐ..NEG....YNNNNYNDW........DW/.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWĆ.DWĆB´B´..BÇBÇ6-7 months Ap6-7 months Ap .7-8 months A€ . ...C4591001C4591001 1057 10571422105714221057AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24265 DWDŢ¨DWĹ.DWĹDWDWDŢ¨DWDß DWDŢ¨DWDß ....Hrł^¨HrĎ Hrł^¨HrĎ ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŢ¨Dß ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YYYYNEGDW1DWŤDWĹ..NEG....YNNNNYYDW........DW1DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBéByBpBţBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571423105714231057AđYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24269 DWD‰”DWÉ.DWÉDWDWD‰”DWDŽDDWD‰”DWDŽD....Hr´[HrŃ`ÄHr´[HrŃ`Ä..DWDW..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‰”DŽD....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NYYYNEGDW3DWŚDWÉ..NEG....YNNNNYYDW........DW3DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBçBvBqBýBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1057 10571424105714241057AŔYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24271 DWDhDWĹ.DWĹDWDWDhDW¨D‰DWDhDWDŹpDW‘D«DW¨D‰Hr´YčHs…Hr´YčHrŃađHsrTHs…DWDWDW‘DW¨AŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DhDŹp.D«D‰.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0YYYYNEGDW3DWŚDWDWĹDXeNEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBçBvBmBqBýBŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1057 10571425105714251057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24301 DWDśDWĚ.DWĚDWDWDśDWDĹDWDśDWDĹ....Hr´nHrÍŁHr´nHrÍŁ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWĚWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DśDĹ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDW7DWŚDWŃ..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWĚDWĚBąByB@BĚBŚ6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1057 10571426105714261057AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24305 DWDžčDWŢ.DWŢDWDWDžčDWDć DWDžčDWDć ....Hr´phHrŮ˘ Hr´phHrŮ˘ ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADWŢWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DžčDć ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Underweight ANNYYNEGDW?DWŚDWÚ..NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWŢDWŢBÂBpBRBŢBŚ6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ..DWFC4591001C4591001 1057 10571427105714271057AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24306 DWD PDWŢ.DWŢDWDWD PDWDäüDWD PDWDäü....Hr´qĐHrŮ |Hr´qĐHrŮ |..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D PDäü....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWF. Underweight ANNYYNEGDW?DWŚDWŢ..POS....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBáBpBqBýBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1057 10571428105714281057AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24307 DWD¤DWŢ.DWŢDWDWD¤DWDć DWD¤DWDć ....Hr´uHrŮ˘ Hr´uHrŮ˘ ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D¤Dć ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW8. Underweight ANNYYNEGDW?DWŚDWŢ..NEG....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBáBpBqBýBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1057 10571429105714291057AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24309 DWDĄDWŢ.DWŢDWDWDĄDWDä„DWDĄDWDä„....Hr´v€HrŮ Hr´v€HrŮ ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DĄDä„....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Normal weightA NNYNPOSDW?DWŚDWŢ..POS....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBáBpBqBýBŚ8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1057 10571430105714301057AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24310 DWDÍŚDWŽ..DWDWDÍŚDWDĆDWDÍŚDWDĆ....Hr»6ŚHrŐŤHr»6ŚHrŐŤ..DWDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÍŚDĆ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YNNYPOSDW6DWŤDW×..POS....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBäBtBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1057 10571431105714311057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24313 DWDĘĽDWĐ.DWĐDWDWDĘĽDW´D×ÜDWDĘĽDWDĂ´DW›DÝDW´D×ÜHrĽ…<Hs ĄÜHrĽ…<HrŐŠ´Hsµ„Hs ĄÜDWDWDW›DW´AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘĽDĂ´.DÝD×Ü.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Normal weightA NNYYNEGDW6DWŚDWšDWĐDXqNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBcBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571432105714321057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24314 DWDÎDWĽ.DWĽDWDWDÎDW DŢ0DWDÎDWDáxDWŤDÔDW DŢ0HrĽ„Hs†N0HrĽ„HrŐ¨xHsm7śHs†N0DWDWDWŤDW AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎDáx.DÔDŢ0.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW=DWŚDWŚDWĽDX]NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBqBqB÷B†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1057 10571433105714331057AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25022 DWDçDWÍ.DWÍDWDWDçDWD{DWDçDWD{....HrĽ˘HrÚHrĽ˘HrÚ..DWDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DçD{....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNNNPOSDW:DWŤDWÍ..POS....YNNNNYYDW........DW:DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBŕBpBpB÷B‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1057 10571434105714341057AĐYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25023 DWDž4DWŘ.DWŘDWDWDž4DWĽD¦¤DWDž4DWDŰ`DW©DŁDWĽD¦¤Hr˝Ş4Hs«¤Hr˝Ş4HrŮ–ŕHs‘ńHs«¤DWDWDW©DWĽAĐYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4DŰ`.DŁD¦¤.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW©. Obese A@YNYYNEGDW9DWŚDW¨DWŘDXyNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBUBqBöB…8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ..DW|C4591001C4591001 1057 10571435105714351057AŔYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25024 DWDĚŘDWŇ.DWŇDWDWDĚŘDW!D‡đDWDĚŘDW!D‡đ....HrĂŘHrŢ‰pHrĂŘHrŢ‰p..DWDW!..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĚŘD‡đ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµ.. Overweight A0YYYYNEGDW>DW´DWŇ..NEG....YNNNNYYDW........DW>DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýBÝB”BIBňB©7-8 months A€5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1057 10571436105714361057AŕYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25025 DWDÍČDWí..DWDWDÍČDWíDŢlDWDÍČDW!D‰ĐDWÓD’@DWíDŢlHrĂČHsëŃěHrĂČHrŢ‹PHsÉ>ŔHsëŃěDWDW!DWÓDWíAŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍČD‰Đ.D’@DŢl.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWµDWÓ. Normal weightA NYNYPOSDW>DW´DWŇDXDXŞPOS....YNNNNYYDW........DW>DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW´DWýDWýBÝB”B+BIBňB©7-8 months A€5-6 months A`1-2 monthsA 8-9 months A . ..DW!C4591001C4591001 1057 10571437105714371057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25257 DWDä„DWć..DWDWDä„DWćD™HDWDä„DW!DÝ|DWŃDÓ¤DWćD™HHrĂ6„HsâRHHrĂ6„HrŢŢüHsĆÝ$HsâRHDWDW!DWŃDWćAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dä„DÝ|.DÓ¤D™H.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĐDWŃ. Normal weightA NNYYNEGDWDDWĎDWĐDX DXŁNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĎDWýDWýBÝBŻB-B.BňBÄ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1057 10571438105714381057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25260 DWDçDWŃ.DWŃDWDWDçDW!DÜŚDWDçDW!DÜŚ....HrĂ9HrŢŢHrĂ9HrŢŢ..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DçDÜŚ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĐDWD. Normal weightA NNNYPOSDWDDWĎDWŃ..POS....YNNNNYYDW........DWDDWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWĎDWýDWýBÝBŻB.BňBÄ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1057 10571439105714391057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25263 DWDČdDWÂ.DWÂDWDWDČdDW¦DĎ¨DWDČdDW!DâŕDW“DŇxDW¦DĎ¨HrĹ˝dHsŽ(¨HrĹ˝dHrŢä`HsuřHsŽ(¨DWDW!DW“DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DČdDâŕ.DŇxDĎ¨.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDWDDWŚDW’DWÂDXcNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBkBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571440105714401057AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25264 DWDâhDWĐ.DWĐDWDWDâhDW#DĚśDWDâhDW#DĚś....HrĹ×hHráqHrĹ×hHráq..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DâhDĚś....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNNYPOSDW?DWŚDWĐ..POS....YNNNNYYDW........DW?DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571441105714411057AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25802 DWDĺěDWÄ.DWÄDWDWDĺěDW¨DëŚDWDĺěDW#DŮřDW“DâhDW¨DëŚHrĹÚěHsçŚHrĹÚěHrá~xHsu.čHsçŚDWDW#DW“DW¨AĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĺěDŮř.DâhDëŚ.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW?DWŚDW’DWÄDXeNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571442105714421057AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25803 DWDˇDWď.DWďDWDWDˇDWÓDŤDWDˇDW%DĄDWśD™üDWÓDŤHrĆç„HsÉ:HrĆç„Hrăě€Hs€ĂüHsÉ:DWDW%DWśDWÓAĐYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DˇDĄ.D™üDŤ.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWś. Normal weightA NNNYPOSDWEDWŚDW›DWďDXPOS....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBŮBhBbBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571443105714431057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25806 DWDźśDWç.DWçDWDWDźśDW$DÍČDWDźśDW$DÍČ....HrČ7śHrâĂČHrČ7śHrâĂČ..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DźśDÍČ....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW@. Normal weightA NNYYNEGDW@DWŚDWç..NEG....YNNNNYYDW........DW@DWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571444105714441057AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25808 DWDˇ@DWç.DWçDWDWDˇ@DW$DĐ\DWDˇ@DW$DĐ\....HrČ9@HrâĆ\HrČ9@HrâĆ\..DWDW$..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. Dˇ@DĐ\....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW@. Normal weightA NNYYNEGDW@DWŚDWç..NEG....YNNNNYYDW........DW@DWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571445105714451057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26531 DWDśTDWß.DWßDWDWDśTDW(D¨üDWDśTDW(D¨ü....HrĚ(ÔHrçäüHrĚ(ÔHrçäü..DWDW(..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DśTD¨ü....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW|DWV. Overweight A0NNYYNEGDWHDW{DWß..NEG....YNNNNYYDW........DWHDWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW{DWýDWýBÖBTB‚BëBi7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571446105714461057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26533 DWDĘDWü.DWüDWDWDĘDW(DŕLDWDĘDW(DŕL....HrĚVHrčLHrĚVHrčL..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWüWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĘDŕL....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NYYYNEGDWGDWĺDWĺ..NEG....YNNNNYNDW........DWG.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWü.DWüBŐBŐ..BęBę7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1057 10571447105714471057AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26537 DWDčřDWÂ.DWÂDWDWDčřDW¦D} DWDčřDW(DŢlDW’DŢ¨DW¦D} HrĚuxHsŤÖ HrĚuxHrčlHssŮ¨HsŤÖ DWDW(DW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DčřDŢl.DŢ¨D} .350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Obese A@YNNYPOSDWFDWŚDW‘DWÂDXcPOS....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÖBeBlBqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571448105714481057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26539 DWDëDW×.DW×DWDWDëDW(DŢ¨DWDëDW(DŢ¨....HrĚw”Hrč¨HrĚw”Hrč¨..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. DëDŢ¨....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWF. Normal weightA NNYYNEGDWFDWŚDW×..NEG....YNNNNYYDW........DWFDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÖBeBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571449105714491057AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26799 DWDťřDWĂ.DWĂDWDWDťřDW§DŢ0DWDťřDW)DÎ@DW”DßDW§DŢ0HrÍ{řHsŹ°HrÍ{řHré[ŔHsv}HsŹ°DWDW)DW”DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťřDÎ@.DßDŢ0.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDWEDWŚDW“DWĂDXdNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBjBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571450105714501057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26801 DWDź`DWö.DWöDWDWDź`DW)DÄ¤DWDź`DW)DÄ¤....HrÍ}`HréR$HrÍ}`HréR$..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWöWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. Dź`DÄ¤....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDWE. Normal weightA NYYYNEGDWEDWŚDWć..NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWöDWöBÎBdBjBăBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571451105714511057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26802 DWDË4DWŘ.DWŘDWDWDË4DW)DĆ„DWDË4DW)DĆ„....HrÍ©4HréTHrÍ©4HréT..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DË4DĆ„....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWE. Underweight ANNYYNEGDWEDWŤDWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŐBeBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DWĚC4591001C4591001 1057 10571452105714521057AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26804 DWDĚ`DWŮ.DWŮDWDWDĚ`DW*DŐHDWDĚ`DW*DŐH....HrÍŞ`Hrę´HHrÍŞ`Hrę´H..DWDW*..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DĚ`DŐH....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWR. Normal weightA NNYYNEGDWHDWŤDWŮ..NEG....YNNNNYYDW........DWHDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÔBdBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1057 10571453105714531057AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26895 DWDáDWÂ.DWÂDWDWDáDW¦Dż¸DWDáDW(DĐÔDW‘DŕDW¦Dż¸HrÍżHsŽ¸HrÍżHrčÔHsr‰HsŽ¸DWDW(DW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. DáDĐÔ.DŕDż¸.350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDWDDWŚDWDWÂDXcNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÖBeBmBqBęBy7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1057 10571454105714541057AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26891 DWDŕDWŢ.DWŢDWDWDŕDW*DĎlDWDŕDW*DĎl....HrÍľHrę®lHrÍľHrę®l..DWDW*..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. DŕDĎl....350735 Chalhoub, Fadi ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWF. Underweight ANNYYNEGDWFDWŤDWŢ..NEG....YNNNNYYDW........DWFDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÔBdBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1066 10661394106613941066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21555 DVňDž4DWĚ.DWĚDVęDVňDž4DW®DľDVňDž4DWD˘äDW’Dv\DW®DľHr ©4HsŁHr ©4HrĽ]dHssq\HsŁDVňDWDW’DW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4D˘ä.Dv\Dľ.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYNPOSDW#DWDW‘DWĚDXkPOS....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDWDWýDWýB÷BŠBlBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1066 10661395106613951066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20590 DVęDÍČDW®.DW®DVęDVęDÍČDVţD˛ DVęDÍČDVţD˛ ....Hr–LČHr°Ź Hr–LČHr°Ź ..DVęDVţ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DÍČD˛ ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWD. Obese A@YNYYNEGDWDWDW®..NEG....YNNNNYYDVę........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCB“BmC@B§9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1066 10661397106613971066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20591 DVęDődDWÄ.DWÄDVęDVęDődDW¨D¦ŕDVęDődDV˙Dá<DW“D{„DW¨D¦ŕHr–tdHs˘ŕHr–tdHr˛ĽHstČHs˘ŕDVęDV˙DW“DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DődDá<.D{„D¦ŕ.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDWDWDW’DWÄDXeNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB˙B’BkBmC@B§9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661401106614011066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20593 DVëDŇđDWĹ.DWĹDVëDVëDŇđDW¦DxxDVëDŇđDVţDÎ¸DW“DÝ|DW¦DxxHr—ŁpHsŤŃxHr—ŁpHr°«¸Hsu)üHsŤŃxDVëDVţDW“DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇđDÎ¸.DÝ|Dxx.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDWDWDW’DWĹDXcNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýCB“BkBmC0B¦9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661402106614021066AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20598 DVëDŢ¨DW°.DW°DVëDVëDŢ¨DVţDŢ¨DVëDŢ¨DVţDŢ¨....Hr—Ż(Hr°»¨Hr—Ż(Hr°»¨..DVëDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DŢ¨DŢ¨....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWE. Normal weightA NNYYNEGDWDWDW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCB“BmC0B¦9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1066 10661403106614031066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20829 DVěD¤LDWÄ.DWÄDVěDVěD¤LDW¨D„äDVěD¤LDWD–<DW’D®`DW¨D„äHrĆLHs€äHrĆLHrł<Hss©`Hs€äDVěDWDW’DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤LD–<.D®`D„ä.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDW$DWDW‘DWÄDXeNEG....YNNNNYNDVě........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBţB‘BlBmC BĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661404106614041066AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20834 DVěD¤DWŻ.DWŻDVěDVěD¤DWD–xDVěD¤DWD–x....HrĆHrłxHrĆHrłx..DVěDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. D¤D–x....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWG. Normal weightA NNYYNEGDW$DWDWŻ..NEG....YNNNNYYDVě........DW$DWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBţB‘BmC BĄ9-10 months A 5-6 months A`0-1 month A9-10 months A . ..DWšC4591001C4591001 1066 10661405106614051066AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20838 DVěDĺ8DWÂ.DWÂDVěDVěDĺ8DW¦DÍŚDVěDĺ8DV˙D§”DW’DČ(DW¦DÍŚHr™8HsŽ&ŚHr™8Hr±ÖHssĂ(HsŽ&ŚDVěDV˙DW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺ8D§”.DČ(DÍŚ.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Underweight ANNYYNEGDWDWDW‘DWÂDXcNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýB˙B’BlBmC BĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661407106614071066AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20840 DVíDXDW°.DW°DVíDVíDXDV˙D€čDVíDXDV˙D€č....HršŘHr±ŻhHršŘHr±Żh..DVíDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NY YDWM .. DXD€č....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWM. Normal weightA NNYYNEGDWDWDW°..NEG....YNNNNYYDVí........DWDW°YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YYNNNY NYDWDWýDWýB˙B’BmCB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1066 10661408106614081066AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21549 DVńDčĽDWŢ.DWŢDVńDVńDčĽDWDÂDVńDčĽDWDÂ....Hrź˘<HrąÚHrź˘<HrąÚ..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DčĽDÂ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW2.. Normal weightA NNYYNEGDW"DW1DWµ..NEG....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW1DWŢDWŢBÚB-BBîBA7-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1066 10661409106614091066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21550 DVńDé4DWµ.DWµDVńDVńDé4DWDÂÄDVńDé4DWDÂÄ....Hrź˘´HrąÚDHrź˘´HrąÚD..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. Dé4DÂÄ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWK. Underweight ANNYYNEGDW"DWDWµ..NEG....YNNNNYYDVń........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBůBŚBmCĐB 8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1066 10661410106614101066AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21557 DVňDÂDWĹ.DWĹDVňDVňDÂDW§D¬DVňDÂDWDÚčDW’Dµ¤DW§D¬Hr ÍHsŹX,Hr ÍHr»CčHss°¤HsŹX,DVňDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂDÚč.Dµ¤D¬.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDW#DWDW‘DWĹDXdNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹BlBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661411106614111066AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21801 DVňDěDW¶.DW¶DVňDVňDěDWDŔlDVňDěDWDŔl....Hr ÷Hr»)lHr ÷Hr»)l..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DěDŔl....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW2.. Normal weightA NNYYNEGDW$DW1DW¶..NEG....YNNNNYYDVň........DW$DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW1DWýDWýBřB,BĚCŔB@8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1066 10661412106614121066AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21808 DVňDëŚDWŃ.DWŃDVňDVňDëŚDW¨DÇtDVňDëŚDWDŔ0DW’Dn(DW¨DÇtHr öŚHsĂtHr öŚHr»)0Hssi(HsĂtDVňDWDW’DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DëŚDŔ0.Dn(DÇt.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NYYYNEGDW$DWDW‘DWŃDXeNEG....YNNNNYNDVň........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBřB‹BlBmCŔBź8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661414106614141066AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21812 DV÷DŢ¨DW».DW»DV÷DV÷DŢ¨DWD©°DV÷DŢ¨DWD©°....Hr§(HrÂű°Hr§(HrÂű°..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. DŢ¨D©°....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW»DWK. Overweight A0YNYYNEGDW(DWşDW»..NEG....YNNNNYYDV÷........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWşDWýDWýBňBŻBCCpBÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1066 10661415106614151066AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷21809 DV÷DÜČDWó.DWóDV÷DV÷DÜČDW×D•DV÷DÜČDWD©tDWÂD‘PDW×D•Hr§HHsÎHr§HHrÂűtHs˛ÔPHsÎDV÷DWDWÂDW×AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČD©t.D‘PD•.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DWÂ. Obese A@YNNYPOSDW(DWşDW»DWóDX”POS....YNNNNYYDV÷........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWşDWýDWýBňBŻB<BCCpBÄ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ..DWuC4591001C4591001 1066 10661416106614161066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22668 DVřDćÜDWË.DWËDVřDVřDćÜDWŻD¸DVřDćÜDW DŮřDW™DŮDDWŻD¸Hr¨ÚÜHs™ş8Hr¨ÚÜHrÄ}xHs}ÄHs™ş8DVřDW DW™DWŻAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DćÜDŮř.DŮDD¸.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Underweight ANNYYNEGDW)DWDWDWËDXlNEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBńB„BeBmC`B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661417106614171066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22672 DVůDŃÄDWî.DWîDVůDVůDŃÄDWD× DVůDŃÄDWD× ....HrŞDHrĹĚ HrŞDHrĹĚ ..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŃÄD× ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW1DWDWî..NEG....YNNNNYYDVů........DW1DWîYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBđBBmCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1066 10661418106614181066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22674 DVůDÖěDWŃ.DWŃDVůDVůDÖěDW°D…\DVůDÖěDW D× DW”DÉDW°D…\HrŞlHs› \HrŞlHrÄ{ HsvgHs› \DVůDW DW”DW°AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖěD× .DÉD…\.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Normal weightA NNYYNEGDW)DWDW“DWŃDXmNEG....YNNNNYNDVů........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBńB„BjBmCPB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661419106614191066AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22675 DVůDáDWĐ.DWĐDVůDVůDáDWDÂDVůDáDWDÂ....HrŞ&€HrĹ·HrŞ&€HrĹ·..DVůDW..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DáDÂ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW*DWDWĐ..NEG....YNNNNYYDVů........DW*DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBđBBmCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1066 10661420106614201066AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23169 DVúDŮ€DWK..DVúDVúDŮ€DW DáDVúDŮ€DW Dá....Hr«p€HrÄ„€Hr«p€HrÄ„€..DVúDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮ€Dá....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWK.. Normal weightA NNYYNEGDW*DWJDWĘ..NEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWJDWýDWýBńB>BłC@BQ8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1066 10661421106614211066AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23175 DV˙D”ÔDWĚ.DWĚDV˙DV˙D”ÔDW°DśDV˙D”ÔDWDŤDW“D¨ŔDW°DśHr±ĂTHs›śHr±ĂTHrÎ˝Hstő@Hs›śDV˙DWDW“DW°AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D”ÔDŤ.D¨ŔDś.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDW2DWDW’DWĚDXmNEG....YNNNNYNDV˙........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBéB|BkBmB˙B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1066 10661422106614221066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23176 DV˙D•LDWĹ.DWĹDV˙DV˙D•LDWDŤTDV˙D•LDWDŤT....Hr±ĂĚHrÎĽÔHr±ĂĚHrÎĽÔ..DV˙DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D•LDŤT....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW2DWDWĹ..NEG....YNNNNYYDV˙........DW2DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBéB|BmB˙B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1066 10661423106614231066AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23177 DWDu0DWÉ.DWÉDWDWDu0DWD®śDWDu0DW"D{HDW“DÔĐDWD®śHrĽ/°Hs—BHrĽ/°HrßÎHHsu!PHs—BDWDW"DW“DWAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Du0D{H.DÔĐD®ś.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Overweight A0YNYYNEGDW>DW‘DW’DWÉDXjNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÜBpBkBlB÷B‹7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1066 10661424106614241066AŕYEARSMANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24922 DWDŘDWŮ.DWŮDWDWDŘDWDŁ DWDŘDWDŁ ....HrĽKXHrŘ HrĽKXHrŘ ..DWDW..AŕYEARS. 12-15 YearsANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DŘDŁ ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWL. Normal weightA NNYYNEGDW?DWDWŮ..NEG....YNNNNYYDW........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBâBuBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ..DWvC4591001C4591001 1066 10661425106614251066AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 24924 DW Dá<DWĹ.DWĹDW DW Dá<DW§D”ÔDW Dá<DW"DĎäDW”Dx´DW§D”ÔHrÄ„ĽHsŹ?THrÄ„ĽHrŕ"äHsv´HsŹ?TDW DW"DW”DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dá<DĎä.Dx´D”Ô.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Normal weightA NNYYNEGDWEDWDW“DWĹDXdNEG....YNNNNYNDW ........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÜBoBjBmBńB„7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1066 10661426106614261066AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24926 DWD›ÜDWÂ.DWÂDWDWD›ÜDW¦D‚ČDWD›ÜDW$D’|DW“DXDW¦D‚ČHrĹÜHsŤŰČHrĹÜHrâ|HstäŘHsŤŰČDWDW$DW“DW¦AđYEARSAđYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. D›ÜD’|.DXD‚Č.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Underweight ANNYYNEGDWGDWDW’DWÂDXcNEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÚBmBkBmBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1066 10661427106614271066AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24930 DWDśDWŇ.DWŇDWDWDśDW#D’@DWDśDW#D’@....HrĹ‘Hrá6ŔHrĹ‘Hrá6Ŕ..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DśD’@....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWF. Normal weightA NNYYNEGDWFDWDWŇ..NEG....YNNNNYYDW........DWFDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŰBnBmBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1066 10661428106614281066AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25737 DWD¶ĐDW.DWDWDWD¶ĐDWgDądDWD¶ĐDW"DÔ”DWRDŰ$DWgDądHrĹ«ĐHs;äHrĹ«ĐHrŕ'”Hsv$Hs;äDWDW"DWRDWgAđYEARSBYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . DW2OTHER Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶ĐDÔ”.DŰ$Dąd.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW2DWR. Normal weightA NYYYNEGDW1DW1DWQDWDX$ ....YNNNNNNDW..........YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW1DWýDWýBÜBB¬BĚBđB$7-8 months A€0-1 month A6-7 monthsAp8-9 months A . ...C4591001C4591001 1066 10661429106614291066AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25738 DWDŢ¨DWě..DWDWDŢ¨DWěDÚ¬DWDŢ¨DW#DÜPDW×D”ÔDWěDÚ¬HrĹÓ¨Hsę|¬HrĹÓ¨Hrá€ĐHsÎ‡THsę|¬DWDW#DW×DWěAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢ¨DÜP.D”ÔDÚ¬.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŇDW×. Normal weightA NNYYNEGDWFDWŃDWÖDXDX©NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŃDWýDWýBŰBŻB'B,BđBÄ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1066 10661430106614301066AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25740 DWDp€DWŘ.DWŘDWDWDp€DW"Dg DWDp€DW"Dg ....HrĆ·Hrßş HrĆ·Hrßş ..DWDW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. Dp€Dg ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWE. Obese A@YNYYNEGDWEDWDWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÜBoBmBďB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1066 10661431106614311066AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25745 DWD©ěDWŮ.DWŮDWDWD©ěDW#DoĚDWD©ěDW#DoĚ....HrĆđlHráLHrĆđlHráL..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŮOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D©ěDoĚ....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWU. Normal weightA NNYYNEGDWFDWDWŕ..NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWŮDWŮB·BnBIBËB‚6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1066 10661432106614321066AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25990 DWDpDWË.DWËDWDWDpDW¨D»ĽDWDpDW"D˝$DW’D—,DW¨D»ĽHrĆóđHs·ĽHrĆóđHrŕ$Hss’,Hs·ĽDWDW"DW’DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD˝$.D—,D»Ľ.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDWFDWDW‘DWËDXeNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÜBoBlBmBďB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1066 10661433106614331066AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25991 DWDáDWĹ.DWĹDWDWDáDW¦D©°DWDáDW"DÔXDW“D‰DW¦D©°HrÇ'€HsŽ°HrÇ'€Hrŕ'XHstŐśHsŽ°DWDW"DW“DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DáDÔX.D‰D©°.270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW“. Normal weightA NNYYNEGDWDDWDW’DWĹDXcNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÜBoBkBmBďB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1066 10661434106614341066AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25995 DWD®śDWŰ.DWŰDWDWD®śDW)D ŚDWD®śDW)D Ś....HrÍŚśHré.HrÍŚśHré...DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. D®śD Ś....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWL. Normal weightA NNYYNEGDWLDWDWŰ..NEG....YNNNNYYDW........DWLDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŐBhBmBęB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1066 10661435106614351066AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25998 DWD®`DWŰ.DWŰDWDWD®`DW)D ČDWD®`DW)D Č....HrÍŚ`Hré.HHrÍŚ`Hré.H..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. D®`D Č....270090 Butuk, David J. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWL. Underweight ANNYYNEGDWLDWDWŰ..NEG....YNNNNYYDW........DWLDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŐBhBmBęB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1077 10771274107712741077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20843 DVěDÓhDW®.DW®DVěDVěDÓhDV˙Dę$DVěDÓhDV˙Dę$....HrőhHr˛¤HrőhHr˛¤..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÓhDę$....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWDWŤDW®..NEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýB˙BŹBpC B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1077 10771275107712751077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20844 DVěDÓ¤DWÄ.DWÄDVěDVěDÓ¤DW¦DÂDVěDÓ¤DV˙DęŘDW‘DČdDW¦DÂHrő¤HsŽHrő¤Hr˛XHsrqäHsŽDVěDV˙DW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓ¤DęŘ.DČdDÂ.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDWDWŤDWDWÄDXcNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB˙BŹBmBpC B˘9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1077 10771277107712771077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20846 DVíD‰”DWŃ.DWŃDVíDVíD‰”DWŻD¬DDVíD‰”DWDŽ€DWD«DWŻD¬DHr™ýHs™âÄHr™ýHrł€Hs{ŹHs™âÄDVíDWDWDWŻAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‰”DŽ€.D«D¬D.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNYYNEGDWDWŤDW—DWŃDXlNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBţBŽBfBpCBˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1077 10771278107712781077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20852 DVíD‰DWŻ.DWŻDVíDVíD‰DWDŽĽDVíD‰DWDŽĽ....Hr™üśHrłĽHr™üśHrłĽ..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‰DŽĽ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDWDWŤDWŻ..NEG....YNNNNYYDVí........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBţBŽBpCBˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1077 10771279107712791077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22249 DV÷DśDW˝.DW˝DV÷DV÷DśDWD‚DV÷DśDWD‚....Hr§$HrÂÔHr§$HrÂÔ..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DśD‚....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW)DWŤDW˝..NEG....YNNNNYYDV÷........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBňB‚BpCpB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1077 10771280107712801077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22250 DV÷D€čDWÍ.DWÍDV÷DV÷D€čDW±DštDV÷D€čDWD‚ŚDWśD¶XDW±DštHr§#hHsśsôHr§#hHrÂÔŚHs€ŕXHsśsôDV÷DWDWśDW±AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D€čD‚Ś.D¶XDšt.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWś. Normal weightA NYYYNEGDW)DWŤDW›DWÍDXnNEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BbBpCpB—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1077 10771281107712811077AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22251 DV÷D‹tDWĹ.DWĹDV÷DV÷D‹tDWDÔ”DV÷D‹tDWDÔ”....Hr§-ôHrĂ&”Hr§-ôHrĂ&”..DV÷DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹tDÔ”....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Overweight A0NNYYNEGDW)DWŤDWĹ..NEG....YNNNNYYDV÷........DW)DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBňB‚BpCpB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1077 10771282107712821077AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV÷22253 DV÷DđđDW‘.DW‘DV÷DV÷DđđDW DčĽDV÷DđđDW DčĽ....Hr§“pHrÄŚ<Hr§“pHrÄŚ<..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW‘WITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DđđDčĽ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW+DWŚDWĘ..NEGDWŹ.DWŹDWŹYNNNNYNDV÷........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW‘DW‘B…B€APB›B–4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1077 10771283107712831077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22476 DVřD‚ČDWÄ.DWÄDVřDVřD‚ČDW§DuäDVřD‚ČDWDrśDW‘DvÔDW§DuäHr¨vČHsŹ dHr¨vČHrĹgśHsr THsŹ dDVřDWDW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‚ČDrś.DvÔDuä.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDW*DWŤDWDWÄDXdNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BmBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1077 10771284107712841077AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22478 DVřD‚PDW».DW»DVřDVřD‚PDWDr$DVřD‚PDWDr$....Hr¨vPHrĹg$Hr¨vPHrĹg$..DVřDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‚PDr$....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWA.. Normal weightA NNYYNEGDW*DW@DW»..NEG....YNNNNYYDVř........DW*DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW@DWýDWýBđB3B˝C`BI8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1077 10771285107712851077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22479 DVřD@DWÄ.DWÄDVřDVřD@DW¦D|8DVřD@DWDyŕDW’Dr`DW¦D|8Hr¨w@HsŤŐ8Hr¨w@HrĆŔ`Hssm`HsŤŐ8DVřDWDW’DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D@Dyŕ.Dr`D|8.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDW,DWŤDW‘DWÄDXcNEG....YNNNNYNDVř........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBďBBlBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1077 10771286107712861077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22483 DVřDĹ”DWż.DWżDVřDVřDĹ”DWDž4DVřDĹ”DWDž4....Hr¨ą”HrÂđ4Hr¨ą”HrÂđ4..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĹ”Dž4....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW*DWŤDWż..NEG....YNNNNYYDVř........DW*DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBňB‚BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1077 10771287107712871077AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22545 DVřDĘĽDWĂ.DWĂDVřDVřDĘĽDWD«DVřDĘĽDWD«....Hr¨ľĽHrĹ Hr¨ľĽHrĹ ..DVřDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĘĽD«....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW6DWŤDWĂ..NEG....YNNNNYYDVř........DW6DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBđB€BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1077 10771288107712881077AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22554 DVůDŮřDWÉ.DWÉDVůDVůDŮřDWD—¤DVůDŮřDWD—¤....HrŞxHrĹŚ¤HrŞxHrĹŚ¤..DVůDW..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮřD—¤....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW+DWŤDWÉ..NEG....YNNNNYYDVů........DW+DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBđB€BpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1077 10771289107712891077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVű22555 DVűDÔDWŽ.DWŽDVűDVűDÔDWDÍPDVűDÔDWDÍP....Hr¬ĽśHrČePHr¬ĽśHrČeP..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÔDÍP....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDW3DWŚDWÍ..NEGDWŽ.DWŽDWŽYNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWŽDWŽBB}A B”B’4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1077 10771290107712901077AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVű22556 DVűDÔXDWŽ.DWŽDVűDVűDÔXDWDÍČDVűDÔXDWDÍČ....Hr¬ĽŘHrČeČHr¬ĽŘHrČeČ..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÔXDÍČ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Normal weightA NNYYNEGDW3DWŤDWÍ..NEGDWŽ.DWŽDWŽYNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWŽDWŽBB~AB”B“4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1077 10771291107712911077AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23397 DVűDăXDW˝.DW˝DVűDVűDăXDWDŻŚDVűDăXDWDŻŚ....Hr¬ËŘHrĹ¤ŚHr¬ËŘHrĹ¤Ś..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DăXDŻŚ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWA.. Normal weightA NNYYNEGDW1DW@DW˝..NEG....YNNNNYYDVű........DW1DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW@DWýDWýBđB3B˝C0BF8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1077 10771292107712921077AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23398 DVűDă”DW’.DW’DVűDVűDă”DWDŻČDVűDă”DWDŻČ....Hr¬ĚHrĹ¤ČHr¬ĚHrĹ¤Č..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW’WITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dă”DŻČ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‹.. Underweight ANNYYNEGDW1DWŠDWË..NEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWŠDW’DW’B…B}A€BB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1077 10771293107712931077AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USANYY Placebo PLACEBO Not Treated NOTTRT Placebo A . . .Placebo (b)(6) . DVű23401 DVű.DVű.DVűDVű......................AŔYEARS. 12-15 YearsAWHITE AWHITE ADVűWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. ......74381 Patel, Suchet R. .. .A@Phase 3<65 Years 12-15 YearsAA. . ... Normal weightA NN Y ..... ....NNNNNNN...........YN YNN Ydid not receive Dose 1 as randomized did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNNNNN YNNNN NNDVű.DVű..0-1 month A0-1 month A .0-1 month A . ...C4591001C4591001 1077 10771294107712941077AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23404 DWDľDWÍ.DWÍDWDWDľDW±DÇ8DWDľDWD»DWDĐ DW±DÇ8HrąŐ”Hsś ¸HrąŐ”HrŘ%Hs{´ Hsś ¸DWDWDWDW±AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DľD».DĐ DÇ8.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNYYNEGDW=DWŤDW—DWÍDXnNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBâBrBfBpBůB‰8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1077 10771295107712951077AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24443 DWDĆ„DWó..DWDWDĆ„DWTDÂDWDĆ„DWDĹXDW@DßÔDWTDÂHrąŢHs"HrąŢHrŘ/XHsżÔHs"DWDWDW@DWTAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆ„DĹX.DßÔDÂ.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DW@. Normal weightA NNYYNEGDW8DW<DW?DWpDXNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýBâB!BľBÁBůB88-9 months A1-2 months A 6-7 monthsAp8-9 months A . ...C4591001C4591001 1077 10771296107712961077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24444 DWD¨ŔDWÄ.DWÄDWDWD¨ŔDWDťDWD¨ŔDWDť....Hr»ŔHrŘHr»ŔHrŘ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨ŔDť....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANYYYNEGDW8DWŤDWÄ..NEG....YNNNNYYDW........DW8DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBâBrBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1077 10771297107712971077AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24445 DWDĎ¨DWŰ.DWŰDWDWDĎ¨DW$DŢ¨DWDĎ¨DW$DŢ¨....HrĹÄ¨HrâÔ¨HrĹÄ¨HrâÔ¨..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĎ¨DŢ¨....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Overweight A0YNYYNEGDW@DWŤDWŰ..NEG....YNNNNYYDW........DW@DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1077 10771298107712981077AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24446 DWDpDWÄ.DWÄDWDWDpDWŁDß\DWDpDW#D¶XDWŽDĺ8DWŁDß\HrĆóđHsŠCÜHrĆóđHráZŘHsnš8HsŠCÜDWDW#DWŽDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD¶X.Dĺ8Dß\.74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Underweight ANNYYNEGDW?DWŤDWŤDWÄDX`NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBpBpBďB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1077 10771299107712991077AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25979 DWDË¬DWŇ.DWŇDWDWDË¬DW#DŔ¨DWDË¬DW#DŔ¨....HrÇ,Hráe(HrÇ,Hráe(..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DË¬DŔ¨....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDWADWŤDWŇ..NEG....YNNNNYYDW........DWADWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1077 10771300107713001077AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25982 DWDéčDWÓ.DWÓDWDWDéčDW#DäŔDWDéčDW#DäŔ....HrÇ0hHrá‰@HrÇ0hHrá‰@..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DéčDäŔ....74381 Patel, Suchet R. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0NNYYNEGDW?DW‚DWÓ..NEG....YNNNNYYDW........DW?DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‚DWýDWýBŰB`B{BďBt7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841541108415411084AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22033 DVôDŤĚDWú.DWúDVôDVôDŤĚDWDÝ|DVôDŤĚDWDÝ|....HrŁ;ĚHrĽ—üHrŁ;ĚHrĽ—ü..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DŤĚDÝ|....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Overweight A0YNYYNEGDW%DWŚDW¸..NEG....YNNNNYYDVô........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWúC4591001C4591001 1084 10841542108415421084AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVô22034 DVôD©ěDWľ.DWľDVôDVôD©ěDWDŮřDVôD©ěDWDŮř....HrŁWěHrĽ”xHrŁWěHrĽ”x..DVôDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DWľNO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. D©ěDŮř....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW3. Normal weightA NNYYNEGDW%DWŚDWÄ..NEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWľDWľB¸B†B2BËB™6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1084 10841543108415431084AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű22037 DVűDčDDWÂ.DWÂDVűDVűDčDDW¦DŰ`DVűDčDDWDŕLDW‘DäüDW¦DŰ`Hr¬ĐÄHsŽ4`Hr¬ĐÄHrČxLHsrŽ|HsŽ4`DVűDWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDŕL.DäüDŰ`.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW,DWŤDWDWÂDXcNEGDW¦.DW¦DW¦YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BmBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1084 10841544108415441084AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű22039 DVűDó„DW˝.DW˝DVűDVűDó„DWDçĚDVűDó„DWDçĚ....Hr¬ÜHrĹÜĚHr¬ÜHrĹÜĚ..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. Dó„DçĚ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW,. Normal weightA NNYYNEGDW,DWŤDW˝..NEG....YNNNNYYDVű........DW,DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBđB€BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1084 10841545108415451084AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23459 DVűDôěDWĂ.DWĂDVűDVűDôěDW¨D€DVűDôěDWDčĽDW’DçĚDW¨D€Hr¬ÝlHs{€Hr¬ÝlHrĹÝĽHssâĚHs{€DVűDWDW’DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DôěDčĽ.DçĚD€.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDW,DWŤDW‘DWĂDXeNEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BlBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1084 10841546108415461084AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23462 DVűDöDW˝.DW˝DVűDVűDöDWDépDVűDöDWDép....Hr¬ŢHrĹŢpHr¬ŢHrĹŢp..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DöDép....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW,. Underweight ANNYYNEGDW,DWŤDW˝..NEG....YNNNNYYDVű........DW,DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBđB€BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1084 10841547108415471084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23463 DVţDŚ DWÄ.DWÄDVţDVţDŚ DW¨DťřDVţDŚ DWDÓŕDW•D€4DW¨DťřHr°i Hs™řHr°i HrĎ`Hswo´Hs™řDVţDWDW•DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ DÓŕ.D€4Dťř.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Obese A@YYYYNEGDW1DWŚDW”DWÄDXeNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBéBxBiBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1084 10841548108415481084AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23465 DVţDÍPDWĆ.DWĆDVţDVţDÍPDWDßÔDVţDÍPDWDßÔ....Hr°ŞPHrĎTHr°ŞPHrĎT..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DÍPDßÔ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW3. Normal weightA NNYYNEGDW3DWŤDWĆ..NEG....YNNNNYYDVţ........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBéByBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1084 10841549108415491084AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23666 DVţD¦ŕDWÉ.DWÉDVţDVţD¦ŕDWD”DVţD¦ŕDWD”....Hr°ŕHrĚ!Hr°ŕHrĚ!..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. D¦ŕD”....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW1. Overweight A0YNYYNEGDW1DWŤDWÉ..NEG....YNNNNYYDVţ........DW1DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBëB{BpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1084 10841550108415501084AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23669 DVţDÎ|DWő.DWőDVţDVţDÎ|DWőDŹ¬DVţDÎ|DWDÜŚDWŢDÄ¤DWőDŹ¬Hr°«|Hsö,Hr°«|HrĎHs×ń¤Hsö,DVţDWDWŢDWőAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ|DÜŚ.DÄ¤DŹ¬.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŢDWŢ. Normal weightA NNNNPOSDW3DWŇDWŇDXDX˛POS....YNNNNYNDVţ........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÝDWýDWýBéBÉB B CBŕ8-9 months A7-8 months A€1-2 monthsA 9-10 months A . ...C4591001C4591001 1084 10841551108415511084AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23670 DVţDĎäDWŢ.DWŢDVţDVţDĎäDWDŰŘDVţDĎäDWDŰŘ....Hr°¬äHrĎXHr°¬äHrĎX..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DĎäDŰŘ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW3DWŢDWŢ..NEG....YNNNNYYDVţ........DW3DWŢYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBéBé..CC8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1084 10841552108415521084AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23671 DVţDŃLDWĘ.DWĘDVţDVţDŃLDWŞD»ĽDVţDŃLDWDäDWDëČDWŞD»ĽHr°®LHs“ZĽHr°®LHrĚpŚHs{ĎČHs“ZĽDVţDWDWDWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃLDä.DëČD»Ľ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNNNPOSDW/DWŤDW—DWĘDXgPOS....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBëB{BfBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1084 10841553108415531084AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23853 DVţDäDWÄ..DVţDVţDäDWDśDVţDäDWDś....Hr°ÁHrĚ(Hr°ÁHrĚ(..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DäDś....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDWÄ..NEG....YNNNNYYDVţ........DW1DWÄYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 7 days but prior to 14 days post Dose 2 NYNYYYN YYNNNY NYDWDWýDWýBëABâCB8-9 months A0-1 month A0-1 month A9-10 months A . ...C4591001C4591001 1084 10841555108415551084AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23854 DVţDčDWđ..DVţDVţDčDWđD“0DVţDčDWDŐüDWŰDÜDWđD“0Hr°ĹHsď{0Hr°ĹHrĚb|HsÔ”Hsď{0DVţDWDWŰDWđAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDŐü.DÜD“0.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW×DWŰ. Normal weightA NNYYNEGDW/DWĐDWĐDXDXNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÖDWýDWýBëBÄB#B'CBŮ8-9 months A7-8 months A€1-2 monthsA 9-10 months A . ...C4591001C4591001 1084 10841556108415561084AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23862 DWDťDWĐ.DWĐDWDWDťDWD`DWDťDWD`....Hrą´HrŐH`Hrą´HrŐH`..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DťD`....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW=. Overweight A0NNYYNEGDW=DWŚDWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841557108415571084AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW23860 DWD“äDWŤ.DWŤDWDWD“äDWD|DWD“äDWD|....Hrą«dHrŐJ|Hrą«dHrŐJ|..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŤWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. D“äD|....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW@. Obese A@YNYYNEGDW@DWŚDW×..NEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWŤDWŤBtBsAB‰B4-5 months AP4-5 months AP0-1 month A4-5 months AP . ...C4591001C4591001 1084 10841558108415581084AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24419 DWDşDWÉ.DWÉDWDWDşDWDŹ4DWDşDWDŹ4....HrąŃHrŐV4HrąŃHrŐV4..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DşDŹ4....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW=. Obese A@YYYYNEGDW=DWŚDWÉ..NEG....YNNNNYYDW........DW=DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841559108415591084AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24423 DWDŔäDWÉ.DWÉDWDWDŔäDWDŤDWDŔäDWDŤ....HrąŘdHrŐTHrąŘdHrŐT..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DŔäDŤ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW=. Obese A@YYYYNEGDW=DWŤDWÉ..NEG....YNNNNYYDW........DW=DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpBůB‰8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841560108415601084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24418 DWD´xDWĐ.DWĐDWDWD´xDW´D ČDWD´xDWDîÔDWśDĐDW´D ČHrąËřHs nČHrąËřHrÚűÔHs€úHs nČDWDWDWśDW´AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´xDîÔ.DĐD Č.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DWś. Normal weightA NNYYNEGDW@DW“DW›DWĐDXqNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýBŕBvBbBjBůBŹ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841561108415611084AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24428 DWDĂDWÂ.DWÂDWDWDĂDW¦DĆüDWDĂDWD”DW‘Dć(DW¦DĆüHrąÚ€HsŽüHrąÚ€HrŐ[HsrŹ¨HsŽüDWDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂD”.Dć(DĆü.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW=DWŚDWDWÂDXcNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBmBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841562108415621084AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24492 DWDáDWÉ.DWÉDWDWDáDWDXDWDáDWDX....Hrąř€HrŐ_XHrąř€HrŐ_X..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DáDX....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW=DWÉDWÉ..NEG....YNNNNYYDW........DW=DWÉYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBäBä..BůBů8-9 months A8-9 months A .8-9 months A . ...C4591001C4591001 1084 10841563108415631084AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24494 DWDśDWÉ.DWÉDWDWDśDWD DWDśDWD ....HrĽVHrŐgHrĽVHrŐg..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DśD ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW=. Underweight ANNYYNEGDW=DWDWÉ..NEG....YNNNNYYDW........DW=DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBäBwBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841564108415641084AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24497 DWDśĚDWá.DWáDWDWDśĚDWŞDÍŚDWDśĚDWDśTDW•DĂ<DWŞDÍŚHrĽWLHs“lŚHrĽWLHrŐcTHsw˛ĽHs“lŚDWDWDW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśĚDśT.DĂ<DÍŚ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Normal weightA NNYYNEGDW=DWDW”DWáDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBäBwBiBmB÷BŠ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841565108415651084AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24499 DWD«TDWÄ.DWÄDWDWD«TDWŞDÎ@DWD«TDWDćÜDW•D€¬DWŞDÎ@HrĽeÔHs“m@HrĽeÔHrŘPÜHswp,Hs“m@DWDWDW•DWŞAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D«TDćÜ.D€¬DÎ@.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Normal weightA NNYYNEGDW=DWDW”DWÄDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBâBuBiBmB÷BŠ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841566108415661084AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24971 DWDŔlDW×.DW×DWDWDŔlDWD–xDWDŔlDWD–x....HrĽzěHrŐ]xHrĽzěHrŐ]x..DWDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DŔlD–x....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW=. Normal weightA NNYYNEGDW=DWŤDW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpB÷B‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841567108415671084AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24972 DWDÉTDWÉ.DWÉDWDWDÉTDWDŰ`DWDÉTDWDŰ`....HrĽÔHrŐ˘`HrĽÔHrŐ˘`..DWDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DÉTDŰ`....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Normal weightA NNYYNEGDW?DWŚDWÉ..NEG....YNNNNYYDW........DW?DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841568108415681084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24977 DWD×ÜDW®.DW®DWDWD×ÜDWD™HDWD×ÜDWD™H....HrĽ’\HrŐ`HHrĽ’\HrŐ`H..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADW®WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D×ÜD™H....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW DWK. Normal weightA NNYYNEGDWKDWźDW×..NEG....YNNNNYNDW........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWźDW®DW®B•B†AđB¨B™5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1084 10841569108415691084AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24979 DWDčĽDWÄ.DWÄDWDWDčĽDWŞD›ÜDWDčĽDWDę`DW•DęŘDWŞD›ÜHrĽŁ<Hs“:ÜHrĽŁ<HrÚ÷`HswÚXHs“:ÜDWDWDW•DWŞAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčĽDę`.DęŘD›Ü.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW=DWŚDW”DWÄDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŕBoBiBqB÷B†8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841570108415701084AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25066 DWDépDWÄ.DWÄDWDWDépDWŞDśTDWDépDWDé¬DW•DëPDWŞDśTHrĽŁđHs“;THrĽŁđHrÚö¬HswÚĐHs“;TDWDWDW•DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DépDé¬.DëPDśT.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Underweight ANYYYNEGDW=DWŚDW”DWÄDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŕBoBiBqB÷B†8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841571108415711084AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25071 DWDëDWü.DWüDWDWDëDWŕDöDWDëDWDŐ„DW•DÎ@DWŕDöHrĽĄ”HsÚĆHrĽĄ”HrŘ?„Hsw˝ŔHsÚĆDWDWDW•DWŕAđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëDŐ„.DÎ@Dö.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW=DWŚDW”DWüDXťNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBiBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841572108415721084AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW116601DWDŹpDWÍ..DWDWDŹpDW±DÍDWDŹpDW!Dć DWśDŕÄDW±DÍHrÂápHsś¦”HrÂápHrŢč Hs ÄHsś¦”DWDW!DWśDW±AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹpDć .DŕÄDÍ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DWś. Normal weightA NNYYNEGDW?DW”DW›DWÍDXnNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýBÝBtBbBiBňB‰7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841573108415731084AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25075 DWDčDWŮ.DWŮDWDWDčDW#DÜČDWDčDW#DÜČ....HrĂ:HráHHrĂ:HráH..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DčDÜČ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWA. Overweight A0NNYYNEGDWADWŤDWŮ..NEG....YNNNNYYDW........DWADWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841574108415741084AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25076 DWDéčDWŮ.DWŮDWDWDéčDW#DÚ4DWDéčDW#DÚ4....HrĂ;čHrá~´HrĂ;čHrá~´..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DéčDÚ4....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWA. Overweight A0YNYYNEGDWADWŤDWŮ..NEG....YNNNNYYDW........DWADWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841575108415751084AđYEARSMAASIAN A@HISPANIC OR LATINO AOTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25317 DWDî\DW˝..DWDWDî\DW‡DĺěDWDî\DW#Dő DWrDëŚDW‡DĺěHrĂ@\Hse`lHrĂ@\Hráš HsI¶ŚHse`lDWDW#DWrDW‡AđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. Dî\Dő .DëŚDĺě.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWqDWr. Underweight ANNYYNEGDWADWpDWqDW˝DXDNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWpDWýDWýBŰBNBŚBŤBňBe7-8 months A€2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1084 10841576108415761084AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25320 DWDŚ(DWĐ.DWĐDWDWDŚ(DW!D€¬DWDŚ(DW!D€¬....HrĹ(HrŢ‚,HrĹ(HrŢ‚,..DWDW!..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DŚ(D€¬....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW=. Normal weightA NYYYNEGDW=DW’DWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBÝBrBkBđB…7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841577108415771084AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25326 DWD´´DWÄ.DWÄDWDWD´´DW¨DśDWD´´DW#DßDW”Dĺ8DW¨DśHrĹ©´HsŚśHrĹ©´Hrá„Hsv8HsŚśDWDW#DW”DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´´Dß.Dĺ8Dś.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDW?DWŤDW“DWÄDXeNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBjBpBđB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841578108415781084AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25327 DWDµ,DWŮ.DWŮDWDWDµ,DW#DâŕDWDµ,DW#Dâŕ....HrĹŞ,Hrá‡`HrĹŞ,Hrá‡`..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. Dµ,Dâŕ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW?. Normal weightA NNYYNEGDW?DWŤDWŮ..NEG....YNNNNYYDW........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841579108415791084AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25727 DWDČÜDW.DWDWDWDČÜDW#Dđ<DWDČÜDW#Dđ<....HrĹ˝ÜHrá”ĽHrĹ˝ÜHrá”Ľ..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWNO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DČÜDđ<....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW@. Normal weightA NNYYNEGDW@DWŚDWŕ..NEGDWŽ.DWŽDWŽYNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWDWBvBjAŔB‹B4-5 months AP3-4 months A@0-1 month A4-5 months AP . ...C4591001C4591001 1084 10841580108415801084AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25728 DWDÉDWÔ.DWÔDWDWDÉDW#DňĐDWDÉDW#DňĐ....HrĹľHrá—PHrĹľHrá—P..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW@ .. DÉDňĐ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW@. Normal weightA NNYYNEGDW@DWŤDWÔ..NEG....YNNNNYYDW........DW@DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841581108415811084AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25729 DWDÜPDWŕ.DWŕDWDWDÜPDW¦DŕDWDÜPDW#DÔDW‘DŞÜDW¦DŕHrĹŃPHsŽ9HrĹŃPHráxśHsrT\HsŽ9DWDW#DW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜPDÔ.DŞÜDŕ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW?DWŚDWDWĂDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841582108415821084AŔYEARSMAASIAN A@HISPANIC OR LATINO AOTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25733 DWDßDW×.DW×DWDWDßDW#Dő(DWDßDW#Dő(....HrĹÔHrá™¨HrĹÔHrá™¨..DWDW#..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DßDő(....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWA. Underweight ANNYYNEGDWADW‘DW×..NEG....YNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŰBoBlBđB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841583108415831084AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26194 DWD—¤DWŕ.DWŕDWDWD—¤DW#DëČDWD—¤DW#DëČ....HrČ/¤HráHHrČ/¤HráH..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. D—¤DëČ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWA. Overweight A0YNYYNEGDWADWŤDWŕ..NEG....YNNNNYYDW........DWADWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841584108415841084AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26195 DWDź`DW×.DW×DWDWDź`DW%DÉDWDź`DW%DÉ....HrČ7`HräHrČ7`Hrä..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. Dź`DÉ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DWD. Overweight A0YNYYNEGDWDDW”DW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBŮBpBiBîB…7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1084 10841586108415861084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26196 DWD¬€DWÄ.DWÄDWDWD¬€DWŞD€4DWD¬€DW%Dź$DW”DĐÔDWŞD€4HrČD€Hs“4HrČD€Hrăć¤HsvnÔHs“4DWDW%DW”DWŞAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬€Dź$.DĐÔD€4.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Obese A@YNYYNEGDWADWŤDW“DWÄDXgNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŮBiBjBpBîB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841587108415871084AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26202 DWD·DWÄ.DWÄDWDWD·DW¨DŹ¬DWD·DW%D„0DW”DĎ¨DW¨DŹ¬HrČOHs‹¬HrČOHrăË°Hsvm¨Hs‹¬DWDW%DW”DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D·D„0.DĎ¨DŹ¬.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDWADWŚDW“DWÄDXeNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBjBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841588108415881084AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26278 DWDŔ¨DWÄ.DWÄDWDWDŔ¨DWŞD–´DWDŔ¨DW#DÓ,DW•Dę$DWŞD–´HrČX¨Hs“5´HrČX¨Hráw¬HswŮ¤Hs“5´DWDW#DW•DWŞAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔ¨DÓ,.Dę$D–´.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW•. Obese A@YYYYNEGDWADW‘DW”DWÄDXgNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBŰBoBiBlBîB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841589108415891084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26277 DWDĽpDWÔ..DWDWDĽpDW%DťřDWDĽpDW%Dťř....HrČTpHrăĺxHrČTpHrăĺx..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DĽpDťř....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Obese A@YNYYNEGDWADWÔDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýBŮBŮ..BîBî7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1084 10841590108415901084AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26337 DWDŇ´DWÄ.DWÄDWDWDŇ´DW¦D‹tDWDŇ´DW%D$DW‘DşDW¦D‹tHrČj´HsŤätHrČj´Hră×¤HsrdHsŤätDWDW%DW‘DW¦AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇ´D$.DşD‹t.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDWDDWŚDWDWÄDXcNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBmBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841591108415911084AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26286 DWDŇDWÔ.DWÔDWDWDŇDW%DŚÜDWDŇDW%DŚÜ....HrČjHrăÔ\HrČjHrăÔ\..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DŇDŚÜ....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWD. Underweight ANNYYNEGDWDDWŚDWÔ..NEG....YNNNNYYDW........DWDDWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841592108415921084AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26281 DWDË¬DWŰ.DWŰDWDWDË¬DW#DťřDWDË¬DW#Dťř....HrČc¬HráBxHrČc¬HráBx..DWDW#..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DË¬Dťř....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWF. Underweight ANNYYNEGDWFDWŤDWŰ..NEG....YNNNNYYDW........DWFDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841593108415931084AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26341 DWDŮĽDWÔ.DWÔDWDWDŮĽDW%D¦,DWDŮĽDW%D¦,....HrČqĽHrăí¬HrČqĽHrăí¬..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DŮĽD¦,....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWA. Underweight ANNYYNEGDWADWŤDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŮBiBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841594108415941084AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26343 DWDĺěDWŰ.DWŰDWDWDĺěDW%D©tDWDĺěDW%D©t....HrČ}ěHrăđôHrČ}ěHrăđô..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DĺěD©t....215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWA. Normal weightA NNYYNEGDWADWDWŰ..NEG....YNNNNYYDW........DWADWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŮBlBmBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1084 10841595108415951084AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26346 DWDçĚDWÂ.DWÂDWDWDçĚDW¦DŃDWDçĚDW#Dě|DW‘DęśDW¦DŃHrČĚHsŽ*HrČĚHráüHsr”HsŽ*DWDW#DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçĚDě|.DęśDŃ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW?DWŚDWDWÂDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841596108415961084AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26414 DWDé4DWĂ.DWĂDWDWDé4DW¦D‰ĐDWDé4DW%D°|DW‘D¬řDW¦D‰ĐHrČ4HsŤâĐHrČ4Hră÷üHsrVxHsŤâĐDWDW%DW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. Dé4D°|.D¬řD‰Đ.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDWADWŚDWDWĂDXcNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBmBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1084 10841597108415971084AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26417 DWDęŘDWĽ.DWĽDWDWDęŘDWśDŰ`DWDęŘDW#Dä„DW‡DČÜDWśDŰ`HrČ‚ŘHs`HrČ‚ŘHrá‰HseC\Hs`DWDW#DW‡DWśAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DęŘDä„.DČÜDŰ`.215414 Denham, Douglas Scott ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWwDW‡. Overweight A0YYYYNEGDWADWvDW†DWĽDXYNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWvDWýDWýBŰBTBwB‡BîBg7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1091 10911394109113941091AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë117070DVëD˝śDW°.DW°DVëDVëD˝śDVţDłDVëD˝śDVţDł....Hr—ŽHr°Hr—ŽHr°..DVëDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝śDł....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW;.. Normal weightA NNYYNEGDWDW:DW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW:DWýDWýCB=BĂC0BP9-10 months A 2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1091 10911395109113951091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20579 DVëD˝$DW°..DVëDVëD˝$DVţDłDVëD˝$DVţDł....Hr—Ť¤Hr°Hr—Ť¤Hr°..DVëDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝$Dł....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°.. Underweight ANNYYNEGDWDWŻDW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŻDWýDWýCB˛BNC0BĹ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1091 10911396109113961091AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20583 DVëDäHDWľ.DWľDVëDVëDäHDW D›(DVëDäHDVţDÚ4DWŚD„äDW D›(Hr—´ČHs†(Hr—´ČHr°·4Hsk–äHs†(DVëDVţDWŚDW AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäHDÚ4.D„äD›(.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DWŚ. Normal weightA NNYYNEGDWDW…DW‹DWľDX]NEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýCBBrBxC0B›9-10 months A 4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1091 10911399109113991091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20586 DVíD™„DWŇ.DWŇDVíDVíD™„DWDčDVíD™„DWDč....Hrš HrÇ.Hrš HrÇ...DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D™„Dč....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Underweight ANYYYNEGDW+DW‘DWŇ..NEG....YNNNNYYDVí........DW+DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBďBBlCBĄ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911400109114001091AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20962 DVíD ČDWô.DWôDVíDVíD ČDWĂDŮDDVíD ČDWDÜPDW DŇ<DWĂDŮDHršHHs´mÄHršHHr»EPHs†B<Hs´mÄDVíDWDW DWĂAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D ČDÜP.DŇ<DŮD.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW™DW . Overweight A0NNYYNEGDW#DWDWźDWôDX€NEG....YNNNNYNDVí........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýBřB“B^BeCB¬8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911402109114021091AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20966 DVđDŽ€DW˝.DW˝DVđDVđDŽ€DWD–DVđDŽ€DWD–....Hrťö€Hrş˙Hrťö€Hrş˙..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽ€D–....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW#DWŚDW˝..NEG....YNNNNYYDVđ........DW#DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBřB‡BqCŕBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911403109114031091AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20967 DVđDŁÔDWµ.DWµDVđDVđDŁÔDWD€4DVđDŁÔDWD€4....HržÔHrşé4HržÔHrşé4..DVđDW..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DŁÔD€4....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWb. Underweight ANNYYNEGDW"DW‘DWµ..NEG....YNNNNYYDVđ........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBřBŚBlCŕB˘8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1091 10911404109114041091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVđ20969 DVđDżôDWË.DWËDVđDVđDżôDWD¨„DVđDżôDWD¨„....Hrž'ôHrąŔHrž'ôHrąŔ..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DżôD¨„....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWĂ.. Overweight A0YYYYNEGDW0DWÂDWË..POS....YNNNNYYDVđ........DW0DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÂDWýDWýBůBľB;CŕBÓ8-9 months A6-7 months Ap0-1 month A9-10 months A . ..DW!C4591001C4591001 1091 10911405109114051091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21240 DVđDßDWŇ.DWŇDVđDVđDßDWŻD¬ĽDVđDßDWD¨HDW›D«TDWŻD¬ĽHržGHs™ă<HržGHrążČHsÔHs™ă<DVđDWDW›DWŻAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DßD¨H.D«TD¬Ľ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Normal weightA NNYYNEGDW$DWŚDWšDWŇDXlNEG....YNNNNYNDVđ........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBcBqCŕBť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911406109114061091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21242 DVđDé¬DW®.DW®DVđDVđDé¬DWD˘lDVđDé¬DWD˘l....HržQ¬HrąąěHržQ¬Hrąąě..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dé¬D˘l....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW®.. Normal weightA NNYYNEGDW!DWDW..NEG....YNNNNYYDVđ........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBůB©BPCŕBľ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1091 10911407109114071091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21243 DVńDß\DWű.DWűDVńDVńDß\DWßD´DVńDß\DWDŕLDWËDÍČDWßD´HrźÜHsŮ2€HrźÜHrą÷ĚHsľîHHsŮ2€DVńDWDWËDWßAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW“BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß\DŕL.DÍČD´.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĂDWË. Underweight ANYYYNEGDW!DWľDWľDWűDXśPOS....YNNNNYYDVń........DW!DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDWÂDWýDWýBůBľB3B;CĐBŇ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWC4591001C4591001 1091 10911408109114081091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21247 DVńDßÔDW».DW»DVńDVńDßÔDWDÄhDVńDßÔDWDÄh....Hrź™THrĽ~čHrź™THrĽ~č..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DßÔDÄh....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWb.. Normal weightA NNYYNEGDW$DWaDW»..NEG....YNNNNYYDVń........DW$DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWaDWýDWýB÷B[BśCĐBq8-9 months A3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1091 10911409109114091091AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21611 DVňD–´DWš.DWšDVňDVňD–´DWD‡DVňD–´DWD‡....Hr ˇ´Hrąž€Hr ˇ´Hrąž€..DVňDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DWšWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–´D‡....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW(DWŚDWÂ..NEG....YNNNNYNDVň........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWšDWšB–BAŕB©B›5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1091 10911410109114101091AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21612 DVňD§XDW·.DW·DVňDVňD§XDWDˇ|DVňD§XDWDˇ|....Hr ˛XHrą¸üHr ˛XHrą¸ü..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D§XDˇ|....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Underweight ANNYYNEGDW#DW‘DW·..NEG....YNNNNYYDVň........DW#DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBůBŤBlCŔB 8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1091 10911411109114111091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21613 DVňD¨HDWß.DWßDVňDVňD¨HDW·Dž¬DVňD¨HDWDˇ¸DW Dš°DW·Dž¬Hr łHHs¤a,Hr łHHrąą8Hs† °Hs¤a,DVňDWDW DW·AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨HDˇ¸.Dš°Dž¬.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW . Underweight ANNYYNEGDW#DW‘DWźDW×DXtNEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBůBŤB^BlCŔB 8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911412109114121091AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21742 DVňDäüDW¶.DW¶DVňDVňDäüDWDÝôDVňDäüDWDÝô....Hr ďüHrĽtHr ďüHrĽt..DVňDW..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. DäüDÝô....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DWh. Overweight A0YNYYNEGDW#DWµDWµ..NEG....YNNNNYYDVň........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWµDWýDWýB÷BŻBHCŔBÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1091 10911413109114131091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21617 DVňDäDWľ.DWľDVňDVňDäDWD»€DVňDäDWD»€....Hr ďHrÇHr ďHrÇ..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DäD»€....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NYYYNEGDW0DW—DWľ..NEG....YNNNNYYDVň........DW0DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW—DWýDWýBďB‰BfCŔB¦8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911414109114141091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21741 DVňDä„DWľ.DWľDVňDVňDä„DW™DôěDVňDä„DW™Dôě....Hr ď„Hs}*lHr ď„Hs}*l..DVň...AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . DW™.BNT162b2 (30 (*ESC*){unicode 03BC}g) Dä„.Dôě...110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0YYYYNEGDW—DW—DXV..NEG....YNNNNYNDVň........DW0.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDW—DWýDWýBfCŔB¦0-1 month A0-1 month A0-1 month A9-10 months A . ...C4591001C4591001 1091 10911415109114151091AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21751 DVóD›dDWÓ.DWÓDVóDVóD›dDWµDÜPDVóD›dDWDÝ@DW DćÜDWµDÜPHrˇ÷äHsˇűĐHrˇ÷äHr»F@Hs†VÜHsˇűĐDVóDWDW DWµAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D›dDÝ@.DćÜDÜP.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW . Normal weightA NNYYNEGDW#DW’DWźDWÓDXrNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBřBŤB^BkC°B 8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911416109114161091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21890 DVóD´DWÄ.DWÄDVóDVóD´DWDŇđDVóD´DWDŇđ....Hr˘€HrĽŤpHr˘€HrĽŤp..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´DŇđ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW}.. Normal weightA NNYYNEGDW#DW|DWÄ..NEG....YNNNNYYDVó........DW#DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW|DWýDWýB÷BvBC°BŠ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911417109114171091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21891 DVóD´<DWŕ.DWŕDVóDVóD´<DW¨DĂđDVóD´<DWDŇ<DW’DzĐDW¨DĂđHr˘ĽHsżđHr˘ĽHrĽŚĽHssuĐHsżđDVóDWDW’DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´<DŇ<.DzĐDĂđ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW#DWŚDW‘DWŕDXeNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BlBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911418109114181091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21752 DVóDŞ DWí.DWíDVóDVóDŞ DW¦D¬DVóDŞ DWD°|DW‘D÷DDW¦D¬Hr˘ HsŽHr˘ HrĽjüHsr ÄHsŽDVóDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞ D°|.D÷DD¬.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDW#DWŚDWDWĂDXcNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BmBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911419109114191091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21934 DVóDŢlDW¶.DW¶DVóDVóDŢlDWD°¸DVóDŢlDWD°¸....Hr˘:ěHrĽk8Hr˘:ěHrĽk8..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŢlD°¸....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”.. Underweight ANNYYNEGDW#DW“DW¶..NEG....YNNNNYYDVó........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýB÷BŤBjC°Bˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1091 10911420109114201091AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21894 DVóDÝ|DW».DW»DVóDVóDÝ|DWDčĽDVóDÝ|DWDčĽ....Hr˘9üHrĽŁ<Hr˘9üHrĽŁ<..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÝ|DčĽ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”.. Normal weightA NNYYNEGDW#DW“DW»..NEG....YNNNNYYDVó........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýB÷BŤBjC°Bˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1091 10911421109114211091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21896 DVóDÝ¸DWĂ.DWĂDVóDVóDÝ¸DW§Dĺ°DVóDÝ¸DWDé4DW”Es@DW§Dĺ°Hr˘:8HsŹ0Hr˘:8HrĽŁ´HsvĄ4HsŹ0DVóDWDW”DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝ¸Dé4.Es@Dĺ°.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DW”. Normal weightA NNYYNEGDW#DW“DW“DWĂDXdNEG....YNNNNYNDVó........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýB÷BŤBjBjC°Bˇ8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911422109114221091AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21936 DV÷D“äDWĂ.DWĂDV÷DV÷D“äDWDyhDV÷D“äDWDyh....Hr§6dHrĹnhHr§6dHrĹnh..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWj .. D“äDyh....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DWj. Normal weightA NNNYPOSDW*DWŻDWĂ..POS....YNNNNYYDV÷........DW*DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŻDWýDWýBđB˘BNCpBą8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1091 10911423109114231091AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷21937 DV÷D” DWó.DWóDV÷DV÷D” DWŇDÜČDV÷D” DWD’|DW˝DĎ¨DWŇDÜČHr§6 HsČ7ČHr§6 HrĹ‡|Hs¬{(HsČ7ČDV÷DWDW˝DWŇAŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWnBNT162b2 (30 (*ESC*){unicode 03BC}g).. D” D’|.DĎ¨DÜČ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW·DW˝. Normal weightA NNYYNEGDW1DW¶DWĽDWóDXŹNEG....YNNNNYNDV÷........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýBđB©BABGCpBŔ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1091 10911424109114241091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22509 DVřDˇ|DWÄ.DWÄDVřDVřDˇ|DW¦Dt|DVřDˇ|DWDŹčDW“DzDW¦Dt|Hr¨•|HsŤÍ|Hr¨•|HrÂáčHstĆśHsŤÍ|DVřDWDW“DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ|DŹč.DzDt|.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Normal weightA NNYYNEGDW(DW‘DW’DWÄDXcNEG....YNNNNYNDVř........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW‘DWýDWýBňB†BkBlC`Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911425109114251091AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř21940 DVřD°ôDWÉ.DWÉDVřDVřD°ôDWDťĽDVřD°ôDW D¬DWDčřDWDťĽHr¨¤ôHs—1<Hr¨¤ôHrÄOHs{ĚřHs—1<DVřDW DWDWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°ôD¬.DčřDťĽ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW. Normal weightA NYYYNEGDW)DW’DW—DWÉDXjNEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBńB†BfBkC`B›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911426109114261091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22510 DVůD˝`DWľ.DWľDVůDVůD˝`DWDÇ8DVůD˝`DWDÇ8....HrŞŕHrÇ ¸HrŞŕHrÇ ¸..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝`DÇ8....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW+DWŤDWľ..NEG....YNNNNYYDVů........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBďBBpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911427109114271091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVů22518 DVůDÎDWĆ.DWĆDVůDVůDÎDWD¦¤DVůDÎDWD¦¤....HrŞ„HrĹ›¤HrŞ„HrĹ›¤..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÎD¦¤....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW’.. Underweight ANNYYNEGDW1DW‘DWĆ..NEG....YNNNNYYDVů........DW1DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBđB„BlCPB™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911428109114281091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22520 DVůDÎ|DW˝.DW˝DVůDVůDÎ|DWD¦,DVůDÎ|DWD¦,....HrŞüHrĹ›,HrŞüHrĹ›,..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÎ|D¦,....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Underweight ANNYYNEGDW1DW‘DW˝..NEG....YNNNNYYDVů........DW1DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBđB„BlCPB™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911429109114291091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22869 DVůDŮDW›.DW›DVůDVůDŮDW}DčDDVůDŮDWDsDWcD–DW}DčDHrŞHsX3ÄHrŞHrĹhHs5š€HsX3ÄDVůDWDWcDW}AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDs.D–DčD.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWbDWc. Normal weightA NNYYNEGDW+DWaDWbDW›DX:NEG....YNNNNYNDVů........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWaDWýDWýBđBTB›BśCPBi8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1091 10911430109114301091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22874 DVůDŕÄDWÄ.DWÄDVůDVůDŕÄDW¦D…\DVůDŕÄDWDÉĚDW”Dý DW¦D…\HrŞ&DHsŤŢ\HrŞ&DHrĂĚHsv› HsŤŢ\DVůDWDW”DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕÄDÉĚ.Dý D…\.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW)DWŤDW“DWÄDXcNEG....YNNNNYNDVů........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BjBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911431109114311091AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22879 DVúD“lDWľ.DWľDVúDVúD“lDWDqpDVúD“lDWDqp....Hr«*lHrÍOpHr«*lHrÍOp..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D“lDqp....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Overweight A0YNYYNEGDW2DW‘DWľ..NEG....YNNNNYYDVú........DW2DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBęB~BlC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911432109114321091AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22876 DVúD’ôDW´.DW´DVúDVúD’ôDWDÇěDVúD’ôDWDÇě....Hr«)ôHrĹĽěHr«)ôHrĹĽě..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. D’ôDÇě....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWb. Underweight ANNYYNEGDW)DWŚDW©..NEG....YNNNNYYDVú........DW)DW©YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911433109114331091AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVú23077 DVúDŮřDW™.DW™DVúDVúDŮřDWDčĽDVúDŮřDWDčĽ....Hr«přHrÇ/<Hr«přHrÇ/<..DVúDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮřDčĽ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW™.. Normal weightA NYYYNEGDW/DWDWĚ..NEG....YNNNNYNDVú........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBďBŠBeC@Bź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911434109114341091AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23076 DVúDŮ€DWÉ.DWÉDVúDVúDŮ€DW©D`DVúDŮ€DWDşDW”Dš8DW©D`Hr«p€Hs‘ÝŕHr«p€HrÇHsv88Hs‘ÝŕDVúDWDW”DW©AŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮ€Dş.Dš8D`.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Underweight ANNYYNEGDW+DW‘DW“DWÉDXfNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBďBBjBlC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911435109114351091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23078 DVúDě¸DWľ.DWľDVúDVúDě¸DWDëDVúDě¸DWDë....Hr«¸HrÇ1”Hr«¸HrÇ1”..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. Dě¸Dë....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWp. Underweight ANNYYNEGDW+DW‘DWľ..NEG....YNNNNYYDVú........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBďBBlC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911436109114361091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23082 DVúDílDW˝.DW˝DVúDVúDílDWD,DVúDílDWD,....Hr«„lHrĹ},Hr«„lHrĹ},..DVúDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DílD,....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW+DWŤDW˝..NEG....YNNNNYYDVú........DW+DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBđB€BpC@B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911437109114371091AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23134 DVúDí¨DWË..DVúDVúDí¨DW®DăDVúDí¨DWDhDWšDć(DW®DăHr«„¨HsČHr«„¨HrĹ}hHs~m(HsČDVúDWDWšDW®AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dí¨Dh.Dć(Dă.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Underweight ANNYYNEGDW+DWŤDW™DWËDXkNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BdBpC@B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911438109114381091AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23136 DVűD–xDWĂ.DWĂDVűDVűD–xDWD¸DVűD–xDWD¸....Hr¬~řHrČ¸Hr¬~řHrČ¸..DVűDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–xD¸....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•.. Normal weightA NNYYNEGDW3DW”DWĂ..NEG....YNNNNYYDVű........DW3DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBîB…BiC0Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911439109114391091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23139 DVűD–đDWŇ.DWŇDVűDVűD–đDW¶DĚśDVűD–đDWD„0DWˇDČ DW¶DĚśHr¬pHsŁ=śHr¬pHrČ0Hs‡Š HsŁ=śDVűDWDWˇDW¶AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–đD„0.DČ DĚś.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DWˇ. Normal weightA NNYYNEGDW3DW‘DW DWŇDXsNEG....YNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBîB‚B]BlC0B—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911440109114401091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23140 DVűD›ÜDWĂ.DWĂDVűDVűD›ÜDWD†ÄDVűD›ÜDWD†Ä....Hr¬„\HrČÄHr¬„\HrČÄ..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D›ÜD†Ä....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW/DWŤDWĂ..NEG....YNNNNYYDVű........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911441109114411091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23253 DVűDśDW§.DW§DVűDVűDśDW§D{„DVűDśDWD‡<DW’D—ŕDW§D{„Hr¬…HsŹ&Hr¬…HrČ<Hss’ŕHsŹ&DVűDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśD‡<.D—ŕD{„.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW/DWŤDW‘DWĘDXdNEG....YNNNNYNDVű........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BlBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911442109114421091AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23254 DVűDťDW§.DW§DVűDVűDťDW§D{üDVűDťDWD‡´DW’DDW§D{üHr¬…HsŹ&|Hr¬…HrČ´Hss“HsŹ&|DVűDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DťD‡´.DD{ü.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NYYYNEGDW/DWŤDW‘DWĘDXdNEG....YNNNNYNDVű........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BlBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911443109114431091AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23263 DVţDÖ8DWč.DWčDVţDVţDÖ8DWDĽDVţDÖ8DWDĽ....Hr°ł8HrŃR<Hr°ł8HrŃR<..DVţDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÖ8DĽ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW3DWŤDWč..NEG....YNNNNYYDVţ........DW3DWčYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBçBwBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911444109114441091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23259 DVţDĐÔDWÉ.DWÉDVţDVţDĐÔDWD‘PDVţDĐÔDWD‘P....Hr°ÔHrĚĐHr°ÔHrĚĐ..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. DĐÔD‘P....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW. Normal weightA NNYYNEGDW/DWŤDWÉ..NEG....YNNNNYYDVţ........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBëB{BpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911445109114451091AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23765 DVţDÖ°DWÉ.DWÉDVţDVţDÖ°DWDŐ„DVţDÖ°DWDÇěDW”EzŔDWDŐ„Hr°ł°Hs—iHr°ł°HrĚTlHsvĄ¬Hs—iDVţDWDW”DWAĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖ°DÇě.EzŔDŐ„.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW”. Normal weightA NNYYNEGDW=DW’DW“DWÉDXjNEG....YNNNNYNDVţ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBëB€BjBkCB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DW”C4591001C4591001 1091 10911446109114461091AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23766 DV˙D‡xDWű.DWűDV˙DV˙D‡xDWDxđDV˙D‡xDWDxđ....Hr±µřHrÎ¨pHr±µřHrÎ¨p..DV˙DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‡xDxđ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•.. Overweight A0YNYYNEGDW1DW”DWË..NEG....YNNNNYYDV˙........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBéB€BiB˙B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911447109114471091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23767 DV˙D–<DWĹ.DWĹDV˙DV˙D–<DWD ŚDV˙D–<DWD Ś....Hr±ÄĽHrĐ!ŚHr±ÄĽHrĐ!Ś..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–<D Ś....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWT.. Normal weightA NNYYNEGDW6DWSDWĹ..NEG....YNNNNYYDV˙........DW6DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWSDWýDWýBčB>BŞB˙BU8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1091 10911448109114481091AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23768 DV˙D–xDWĂ.DWĂDV˙DV˙D–xDW¦DsŚDV˙D–xDWDŻPDW’DwLDW¦DsŚHr±ÄřHsŤĚŚHr±ÄřHrĐ0PHssrLHsŤĚŚDV˙DWDW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. D–xDŻP.DwLDsŚ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW6DWŚDW‘DWĂDXcNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBčBwBlBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911449109114491091AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙23950 DV˙Dˇ|DWŽ.DWŽDV˙DV˙Dˇ|DWDÇtDV˙Dˇ|DWDÇt....Hr±ĎüHrĚSôHr±ĎüHrĚSô..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dˇ|DÇt....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Normal weightA NNYYNEGDW/DWŤDWĐ..NEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBëB{BpB˙BŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1091 10911450109114501091AĐYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23951 DV˙DŘDWÄ.DWÄDV˙DV˙DŘDW¨D€čDV˙DŘDWD}ÜDW•D…ÔDW¨D€čHr˛Hs|čHr˛HrĎţÜHswuTHs|čDV˙DWDW•DW¨AĐYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘD}Ü.D…ÔD€č.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW•. Normal weightA NNYYNEGDW8DW‘DW”DWÄDXeNEG....YNNNNYNDV˙........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBčB|BiBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911451109114511091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USANYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg)A€ . . .BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23954 DV˙.DW.DWDV˙......................AđYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. ......110670 Arora, Samir .. .A@Phase 3<65 Years 12-15 YearsAA. . ... Overweight A0YN ..... ....NNNNNNN...........YN YNN Ydid not receive Dose 1 as randomized did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNNNNN YNNNN NNDW.DW..0-1 month A0-1 month A .0-1 month A . ...C4591001C4591001 1091 10911452109114521091AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24105 DV˙DęśDWÉ.DWÉDV˙DV˙DęśDWD®$DV˙DęśDWDyhDW”DülDWD®$Hr˛Hs—A¤Hr˛HrÎ¨čHsvšlHs—A¤DV˙DWDW”DWAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DęśDyh.DülD®$.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Overweight A0NNYYNEGDW1DW‘DW“DWÉDXjNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBéB}BjBlB˙B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1091 10911453109114531091AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23959 DV˙DäDWĘ.DWĘDV˙DV˙DäDWDŘDV˙DäDWDŘ....Hr˛ŚHrÍnŘHr˛ŚHrÍnŘ..DV˙DW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DäDŘ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW=.. Normal weightA NNYYNEGDW8DW<DWĘ..NEG....YNNNNYYDV˙........DW8DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW<DWýDWýBęB)BÁB˙B>8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1091 10911454109114541091AŕYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24107 DWDßÔDWŇ.DWŇDWDWDßÔDWD›ÜDWDßÔDWD›Ü....Hrą÷THrŐbÜHrą÷THrŐbÜ..DWDW..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW“ .. DßÔD›Ü....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŇDW“. Normal weightA NNYYNEGDW6DWŃDWŇ..NEG....YNNNNYYDW........DW6DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŃDWýDWýBäB¸B,BůBÍ8-9 months A6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1091 10911455109114551091AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24109 DWD•DW×.DW×DWDWD•DWDśDWD•DWDś....HrşţHrÖšHrşţHrÖš..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D•Dś....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NYYYNEGDWADWŚDW×..NEGDWŤ.DWŤDWŤYNNNNYYDW........DWADW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911456109114561091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24796 DWDí0DWĚ.DWĚDWDWDí0DWDÍDWDí0DWDÍ....Hr»V0HrŐ”Hr»V0HrŐ”..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dí0DÍ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Overweight A0YNYYNEGDW6DWŚDWĚ..NEGDWŤ.DWŤDWŤYNNNNYYDW........DW6DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911457109114571091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24797 DWDílDWĚ.DWĚDWDWDílDWDÍŚDWDílDWDÍŚ....Hr»VlHrŐ”ŚHr»VlHrŐ”Ś..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DílDÍŚ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW6DWŚDWĚ..NEG....YNNNNYYDW........DW6DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911458109114581091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24111 DWDě@DWĘ.DWĘDWDWDě@DWD«ĚDWDě@DWD«Ě....Hr»U@HrÖÄLHr»U@HrÖÄL..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dě@D«Ě....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Underweight ANNYYNEGDW9DW‘DWĘ..NEG....YNNNNYYDW........DW9DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBăBwBlBřBŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911459109114591091AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24795 DWDě|DWĘ.DWĘDWDWDě|DW©D“0DWDě|DWD¬DDW”DęśDW©D“0Hr»U|Hs‘ŕ°Hr»U|HrÖÄÄHsvśHs‘ŕ°DWDWDW”DW©AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě|D¬D.DęśD“0.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Normal weightA NNYYNEGDW9DW‘DW“DWĘDXfNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBăBwBjBlBřBŚ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1091 10911460109114601091AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24800 DWD¬DDWĘ.DWĘDWDWD¬DDWDČÜDWD¬DDWDČÜ....HrĽfÄHrÖá\HrĽfÄHrÖá\..DWDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¬DDČÜ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNNNPOSDW8DWŚDWĘ..POS....YNNNNYYDW........DW8DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBăBrBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ..DWC4591001C4591001 1091 10911461109114611091AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24873 DWD¬€DWĘ.DWĘDWDWD¬€DWDÉTDWD¬€DWDÉT....HrĽgHrÖáÔHrĽgHrÖáÔ..DWDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¬€DÉT....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW8DWŚDWĘ..NEGDW“.DW“DW“YNNNNYYDW........DW8DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911462109114621091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24875 DWDˇ¸DWŘ.DWŘDWDWDˇ¸DW#DžčDWDˇ¸DW#Džč....HrÂó¸HráChHrÂó¸HráCh..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dˇ¸Džč....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•.. Overweight A0YNYYNEGDW?DW”DWŘ..NEG....YNNNNYYDW........DW?DWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBŰBrBiBňB‰7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1091 10911463109114631091AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24877 DWDé4DWÄ.DWÄDWDWDé4DW¦D„äDWDé4DW#DÜPDW‘D÷ĽDW¦D„äHrĂ;4HsŤÝäHrĂ;4Hrá€ĐHsrˇ<HsŤÝäDWDW#DW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW„BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dé4DÜP.D÷ĽD„ä.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW@DWŚDWDWÄDXcNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1091 10911464109114641091AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24879 DWDé¬DWÚ.DWÚDWDWDé¬DW#DÜŚDWDé¬DW#DÜŚ....HrĂ;¬HráHrĂ;¬Hrá..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW„ .. Dé¬DÜŚ....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW„. Underweight ANNYYNEGDW@DWŚDWÚ..NEG....YNNNNYYDW........DW@DWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1091 10911465109114651091AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25413 DW D˘0DWŢ.DWŢDW DW D˘0DW#D’|DW D˘0DW#D’|....HrÄE°Hrá6üHrÄE°Hrá6ü..DW DW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˘0D’|....110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNYYNEGDW?DW‹DWŢ..NEG....YNNNNYYDW ........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŰBiBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1091 10911466109114661091AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25414 DWD×dDWŃ.DWŃDWDWD×dDW¦DŰŘDWD×dDW)DčDW’Dđ<DW¦DŰŘHrĚcäHsŽ4ŘHrĚcäHréuHssë<HsŽ4ŘDWDW)DW’DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D×dDč.Dđ<DŰŘ.110670 Arora, Samir ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDWKDWŤDW‘DWŃDXcNEG....YNNNNYNDW........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŐBeBlBpBëB{7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231422112314221123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVę20486 DVęDŕDW¨.DW¨DVęDVęDŕDVţDŕDVęDŕDVţDŕ....Hr–ŕHr°eŕHr–ŕHr°eŕ..DVęDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE ADW¨WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. DŕDŕ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW‘DWK. Normal weightA NNYYNEGDWDWDW»..NEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDW¨DW¨B«B“BBżB§6-7 months Ap5-6 months A`0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231425112314251123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20487 DVëD‡xDW».DW»DVëDVëD‡xDVţD‚ŚDVëD‡xDVţD‚Ś....Hr—WřHr°_ŚHr—WřHr°_Ś..DVëDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. D‡xD‚Ś....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWH. Obese A@YNYYNEGDWDW’DW°..NEG....YNNNNYYDVë........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýCB•BkC0B¨9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1123 11231428112314281123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20491 DVěDŐHDW®.DW®DVěDVěDŐHDV˙DDVěDŐHDV˙D....Hr÷HHr±±„Hr÷HHr±±„..DVěDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŐHD....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW[. Underweight ANNYYNEGDWDW‘DW®..NEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýB˙B“BlC B¦9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1123 11231431112314311123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20492 DVíD,DWÄ.DWÄDVíDVíD,DW¦DŤDVíD,DWD¨„DW’DépDW¦DŤHr™ű¬HsŤćHr™ű¬Hrł(„HssäpHsŤćDVíDWDW’DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. D,D¨„.DépDŤ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDW!DWŤDW‘DWÄDXcNEG....YNNNNYNDVí........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýBţBŽBlBpCBˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231432112314321123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20939 DVíD‡´DW±.DW±DVíDVíD‡´DWD¨ŔDVíD‡´DWD¨Ŕ....Hr™ű4Hrł(ŔHr™ű4Hrł(Ŕ..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D‡´D¨Ŕ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWK. Normal weightA NNYYNEGDW!DWŤDW±..NEG....YNNNNYYDVí........DW!DW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBţBŽBpCBˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1123 11231434112314341123AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVđ20941 DVđD$DWŤ.DWŤDVđDVđD$DWD‚ČDVđD$DWD‚Č....Hrťř$HrąšHHrťř$HrąšH..DVđDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADWŤWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D$D‚Č....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW%DWŚDWÂ..NEG....YNNNNYNDVđ........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWŤDWŤB‰BABžBť4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1123 11231438112314381123AŕYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń20942 DVńD”\DW®.DW®DVńDVńD”\DWDŽ€DVńD”\DWDŽ€....HrźMÜHrĹ€HrźMÜHrĹ€..DVńDW..AŕYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0DW®LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D”\DŽ€....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW“DWF. Normal weightA NNYYNEGDW+DW’DWË..NEG....YNNNNYNDVń........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW’DW®DW®BˇB…BBľB˘5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231439112314391123AŔYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń20944 DVńD“äDWÄ.DWÄDVńDVńD“äDWD’DVńD“äDWD’....HrźMdHrĹ‡HrźMdHrĹ‡..DVńDW..AŔYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D“äD’....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWF. Obese A@YNYYNEGDW+DW’DWÄ..NEG....YNNNNYYDVń........DW+DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýBđB…BkCĐB˘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231440112314401123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21600 DVňD‡xDW».DW»DVňDVňD‡xDWD‚PDVňD‡xDWD‚P....Hr ’xHrą™ĐHr ’xHrą™Đ..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. D‡xD‚P....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWG. Overweight A0YNYYNEGDW!DW’DWµ..NEG....YNNNNYYDVň........DW!DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýBůBŽBkCŔBˇ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1123 11231441112314411123AŕYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21602 DVňD¨HDWŠ.DWŠDVňDVňD¨HDWDÇ°DVňD¨HDWDÇ°....Hr łHHrĂ°Hr łHHrĂ°..DVňDW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA DWŠLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨HDÇ°....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Overweight A0YNYYNEGDW,DWÉDWÉ..NEG....YNNNNYNDVň........DW,.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWŠ.DWŠBB..B™B™4-5 months AP4-5 months AP .5-6 months A` . ...C4591001C4591001 1123 11231442112314421123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21604 DVňD°|DWÔ.DWÔDVňDVňD°|DWµDĂDVňD°|DWDÂDWšDŇđDWµDĂHr »|Hsˇâ€Hr »|HrĂHs~YđHsˇâ€DVňDWDWšDWµAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. D°|DÂ.DŇđDĂ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWšDWš. Obese A@YNYYNEGDW(DW™DW™DWÔDXrNEG....YNNNNYNDVň........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW™DWýDWýBňBŽBdBdCŔB¨8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231443112314431123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21607 DVňD°DWĂ.DWĂDVňDVňD°DWDÂÄDVňD°DWDÂÄ....Hr »HrĂÄHr »HrĂÄ..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWĂLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. D°DÂÄ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWG. Normal weightA NNYYNEGDW(DWDWÉ..NEG....YNNNNYNDVň........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWĂDWĂB¸B…B3BŇBź6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1123 11231445112314451123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVň21729 DVňDÍDW©.DW©DVňDVňDÍDWDŮřDVňDÍDWDŮř....Hr ŘHrĽ”xHr ŘHrĽ”x..DVňDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW©WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DÍDŮř....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW’DW[. Underweight ANNYYNEGDW#DW‘DWÄ..NEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DW©DW©BŁB‹BB¸B 5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231446112314461123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21731 DVňDŃÄDW˝.DW˝DVňDVňDŃÄDWDÚpDVňDŃÄDWDÚp....Hr ÜÄHrĽ”đHr ÜÄHrĽ”đ..DVňDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW˝LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŃÄDÚp....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW6.. Underweight ANYYYNEGDW#DW5DWÄ..NEG....YNNNNYNDVň........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW5DW˝DW˝B·B/BBĚBD6-7 months Ap1-2 months A 0-1 month A7-8 months A€ . ...C4591001C4591001 1123 11231447112314471123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21732 DVóDŐüDW˝.DW˝DVóDVóDŐüDWD–´DVóDŐüDWD–´....Hr˘2|Hrş˙´Hr˘2|Hrş˙´..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. DŐüD–´....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWG. Normal weightA NYYYNEGDW(DW‘DW˝..NEG....YNNNNYYDVó........DW(DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBřBŚBlC°Bź8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1123 11231448112314481123AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVô21735 DVôDĽDWv.DWvDVôDVôDĽDWD„0DVôDĽDWD„0....HrŁ-ĽHrĽ>°HrŁ-ĽHrĽ>°..DVôDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA DWvLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DĽD„0....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Obese A@YNYYNEGDW*DWÄDWÄ..NEG....YNNNNYNDVô........DW*.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWv.DWvBpBp..BB4-5 months AP4-5 months AP .4-5 months AP . ...C4591001C4591001 1123 11231449112314491123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22018 DVôDŹčDW÷.DW÷DVôDVôDŹčDWDćdDVôDŹčDWDćd....HrŁ=čHrĽ äHrŁ=čHrĽ ä..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DŹčDćd....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWV. Obese A@YNYYNEGDW%DW‘DW¶..NEG....YNNNNYYDVô........DW%DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýB÷B‹BlC Bž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231450112314501123AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22023 DVôD–´DWË.DWËDVôDVôD–´DWŻD|DVôD–´DWDÄ¤DWšDÝ|DWŻD|HrŁD´Hs™ąüHrŁD´HrĽ$Hs~d|Hs™ąüDVôDWDWšDWŻAđYEARSBYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D–´DÄ¤.DÝ|D|.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWšDWš. Normal weightA NNYYNEGDW%DW™DW™DWËDXlNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW™DWýDWýB÷B“BdBdC B¦8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ..DWVC4591001C4591001 1123 11231451112314511123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22026 DVřD‰DW».DW»DVřDVřD‰DWDäüDVřD‰DWDäü....Hr¨}HrĂ6üHr¨}HrĂ6ü..DVřDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. D‰Däü....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWH. Overweight A0YNYYNEGDW+DW’DW»..NEG....YNNNNYYDVř........DW+DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBňB‡BkC`B›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231452112314521123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22027 DVřDŇxDW˝.DW˝DVřDVřDŇxDWšDĆŔDVřDŇxDWD¸DW‡DŁ\DWšDĆŔHr¨ĆxHs~MŔHr¨ĆxHrÂŐ¸HseÜHs~MŔDVřDWDW‡DWšAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇxD¸.DŁ\DĆŔ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW„DW‡. Normal weightA NNYYNEGDW(DWDW†DW˝DXWNEG....YNNNNYNDVř........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBňBxBwBzC`BŚ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1123 11231453112314531123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22610 DVřDŐüDWĘ.DWĘDVřDVřDŐüDWDŮDVřDŐüDWDŮ....Hr¨ÉüHrÇHr¨ÉüHrÇ..DVřDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. DŐüDŮ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWG. Normal weightA YNYYNEGDW/DWDWĘ..NEG....YNNNNYYDVř........DW/DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBďB‚BmC`B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231454112314541123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22607 DVřDÖtDWn..DVřDVřDÖtDWRDĐ DVřDÖtDWDŘDW;D°@DWRDĐ Hr¨ĘtHsk Hr¨ĘtHrÇHsřŔHsk DVřDWDW;DWRAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖtDŘ.D°@DĐ .113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW;. Underweight ANNYYNEGDW/DW5DW:DWnDXNEG....YNNNNYNDVř........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýBďB'BĂBČC`B>8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1123 11231455112314551123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22614 DVřDń,DWĽ.DWĽDVřDVřDń,DWDě¸DVřDń,DWDě¸....Hr¨ĺ,HrĂ>¸Hr¨ĺ,HrĂ>¸..DVřDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. Dń,Dě¸....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWU. Normal weightA NNYYNEGDW)DW‘DWĽ..NEG....YNNNNYYDVř........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBňB†BlC`Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231456112314561123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22615 DVůDŠüDWĂ.DWĂDVůDVůDŠüDW§DDVůDŠüDWDĹDW’D…ÔDW§DHr©Đ|HsŹ)Hr©Đ|HrĂHss€ÔHsŹ)DVůDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŠüDĹ.D…ÔD.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW)DWŚDW‘DWĂDXdPOS....YNNNNYNDVů........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBňBBlBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231457112314571123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22835 DVůDµŕDWż.DWżDVůDVůDµŕDWŁDŠDVůDµŕDWD‘DWŽD—,DWŁDŠHr©ű`Hs‰îŚHr©ű`HrÂăHsnL,Hs‰îŚDVůDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DµŕD‘.D—,DŠ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW(DWŚDWŤDWżDX`NEG....YNNNNYNDVů........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBpBqCPB”8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1123 11231458112314581123AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22837 DVůDÎ|DWç..DVůDVůDÎ|DWDá<DVůDÎ|DWDá<....HrŞüHrĂ3<HrŞüHrĂ3<..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DÎ|Dá<....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWH. Normal weightA NNYYNEGDW(DW‘DWŢ..NEG....YNNNNYYDVů........DW(DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‘DWýDWýBňB†BlCPB™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231459112314591123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22841 DVůDÝDWÉ.DWÉDVůDVůDÝDWDÓ,DVůDÝDWDÓ,....HrŞ"„HrĂ%,HrŞ"„HrĂ%,..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÝDÓ,....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW6.. Overweight A0NNYYNEGDW(DW5DWÉ..NEG....YNNNNYYDVů........DW(DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW5DWýDWýBňB*BČCPB=8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1123 11231460112314601123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22842 DVúD˛\DWj..DVúDVúD˛\DWMDÜŚDVúD˛\DWDÉDW8DďLDWMDÜŚHr«I\HsŕHr«I\HrČaHrýCLHsŕDVúDWDW8DWMAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛\DÉ.DďLDÜŚ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW8. Normal weightA NNYYNEGDW,DW5DW7DWjDX NEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWýDWýBîB&BĆBČC@B<8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1123 11231461112314611123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23027 DVúD¶”DWĽ..DVúDVúD¶”DW D…ÔDVúD¶”DW D…Ô....Hr«M”HrÄ)THr«M”HrÄ)T..DVúDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¶”D…Ô....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW9.. Normal weightA NNYYNEGDW*DW8DWĽ..NEG....YNNNNYYDVú........DW*DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW8DWýDWýBńB,BĹC@B?8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1123 11231462112314621123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23028 DVúD×(DWż.DWżDVúDVúD×(DWDŮDVúD×(DWDŮ....Hr«n(HrČqHr«n(HrČq..DVúDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D×(DŮ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWF. Normal weightA NNYYNEGDW/DWŚDWż..NEG....YNNNNYYDVú........DW/DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231463112314631123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23031 DVűD´đDWÍ.DWÍDVűDVűD´đDW°DŁ DVűD´đDWD… DWšDĚ$DW°DŁ Hr¬ťpHs›+ Hr¬ťpHrĆË Hs~S$Hs›+ DVűDWDWšDW°AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. D´đD… .DĚ$DŁ .113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWš. Underweight ANNYYNEGDW+DW’DW™DWÍDXmNEG....YNNNNYNDVű........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBďB„BdBkC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231465112314651123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23032 DVűDÍČDWÄ.DWÄDVűDVűDÍČDW¨DĆDVűDÍČDWDĐ DW•DÇ8DW¨DĆHr¬¶HHsÂHr¬¶HHrČh Hsw¶¸HsÂDVűDWDW•DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍČDĐ .DÇ8DĆ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW•. Normal weightA NNYYNEGDW1DW’DW”DWÄDXeNEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBîBBiBkC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231466112314661123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23425 DVűDŘDW˝.DW˝DVűDVűDŘDWDÍČDVűDŘDWDÍČ....Hr¬ÁHrĹÂČHr¬ÁHrĹÂČ..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DŘDÍČ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWF. Underweight ANNYYNEGDW*DW‘DW˝..NEG....YNNNNYYDVű........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBđB„BlC0B—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231467112314671123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23427 DVţD‚ČDW˝.DW˝DVţDVţD‚ČDWˇD€čDVţD‚ČDWDŠ„DWŽDštDWˇD€čHr°_ČHs‡BhHr°_ČHrĚHsnOtHs‡BhDVţDWDWŽDWˇAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‚ČDŠ„.DštD€č.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NYYYNEGDW6DWŚDWŤDW˝DX^NEG....YNNNNYNDVţ........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBpBqCBŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1123 11231468112314681123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23430 DVţD|DWé.DWéDVţDVţD|DW¶D‹°DVţD|DWDxxDWŁDŽDW¶D‹°Hr°`|Hs˘ü°Hr°`|HrĚřHs‰ňHs˘ü°DVţDWDWŁDW¶AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. D|Dxx.DŽD‹°.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWŁ. Overweight A0NYYYNEGDW0DW’DW˘DWÔDXsNEG....YNNNNYNDVţ........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBëB€B[BkCB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWaC4591001C4591001 1123 11231469112314691123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23432 DVţDˇ|DWÍ.DWÍDVţDVţDˇ|DWD’|DVţDˇ|DWD’|....Hr°~|HrÍp|Hr°~|HrÍp|..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. Dˇ|D’|....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWV. Normal weightA NNYYNEGDW2DWDWÍ..NEG....YNNNNYYDVţ........DW2DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBęB}BmCB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231470112314701123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23673 DVţD¬DWĚ.DWĚDVţDVţD¬DW®D™„DVţD¬DWDŐDWšDĆHDW®D™„Hr°‰Hs~„Hr°‰HrĎŚHs~MHHs~„DVţDWDWšDW®AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬DŐ.DĆHD™„.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWš. Normal weightA NNYYNEGDW1DWDW™DWĚDXkNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBéB|BdBmCB“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231472112314721123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23676 DVţD´<DWĂ.DWĂDVţDVţD´<DWD… DVţD´<DWD… ....Hr°‘<HrÍc Hr°‘<HrÍc ..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D´<D… ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWK. Underweight ANNYYNEGDW7DW‘DWĂ..NEG....YNNNNYYDVţ........DW7DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBęB~BlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231473112314731123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23678 DVţDµ,DWĂ.DWĂDVţDVţDµ,DW§DŞ(DVţDµ,DWDŃLDW’Dî\DW§DŞ(Hr°’,HsŹT¨Hr°’,HrÍŻLHssé\HsŹT¨DVţDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dµ,DŃL.Dî\DŞ(.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDW0DWDW‘DWĂDXdNEG....YNNNNYNDVţ........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBęB}BlBmCB“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231474112314741123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23830 DVţDÓ¤DWĎ.DWĎDVţDVţDÓ¤DWD}(DVţDÓ¤DWD}(....Hr°°¤HrĚ ¨Hr°°¤HrĚ ¨..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DÓ¤D}(....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWO. Normal weightA NNYYNEGDW6DW’DWÉ..NEG....YNNNNYYDVţ........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBëB€BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231475112314751123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23681 DVţDÓ,DWĎ.DWĎDVţDVţDÓ,DWD|°DVţDÓ,DWD|°....Hr°°,HrĚ 0Hr°°,HrĚ 0..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DÓ,D|°....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWO. Normal weightA NNYYNEGDW6DW’DWÉ..NEG....YNNNNYYDVţ........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBëB€BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231476112314761123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23831 DVţDŰ$DW˝.DW˝DVţDVţDŰ$DWˇD«DVţDŰ$DWDÁDWŽD¬DDWˇD«Hr°¸$Hs‡lHr°¸$HrĚNHsnaDHs‡lDVţDWDWŽDWˇAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰ$DÁ.D¬DD«.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW/DWŚDWŤDW˝DX^NEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBpBqCBŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1123 11231477112314771123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23837 DVţDčĽDWĐ.DWĐDVţDVţDčĽDWD›(DVţDčĽDWD›(....Hr°ĹĽHrĚ'¨Hr°ĹĽHrĚ'¨..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DčĽD›(....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWH. Underweight ANNYYNEGDW/DWDWĐ.. ....YNNNNYYDVţ........DW(DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWýDWýBëB~BmCB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231478112314781123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23865 DVţDé4DW¨.DW¨DVţDVţDé4DWDšěDVţDé4DWDšě....Hr°Ć4HrĚ'lHr°Ć4HrĚ'l..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW¨WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. Dé4Dšě....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW‘DWH. Normal weightA NNYYNEGDW/DWDWĐ..NEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDW¨DW¨B–B~BB«B“5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231479112314791123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23833 DVţDŕDWŽ.DWŽDVţDVţDŕDWDĎlDVţDŕDWDĎl....Hr°˝HrĚ[ěHr°˝HrĚ[ě..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŕDĎl....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW6DWŚDWĐ..NEG....YNNNNYNDVţ........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWŽDWŽB|BzA B‘BŹ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1123 11231481112314811123AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23869 DVţDďDWß.DWßDVţDVţDďDWDŻČDVţDďDWDŻČ....Hr°ĚHrÍŤČHr°ĚHrÍŤČ..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DďDŻČ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW\. Underweight ANNYYNEGDW1DW’DWß..NEG....YNNNNYYDVţ........DW1DWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBęBBkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231482112314821123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23871 DV˙D@DWĆ.DWĆDV˙DV˙D@DWDÖ8DV˙D@DWDÖ8....Hr±±ŔHrĚb¸Hr±±ŔHrĚb¸..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. D@DÖ8....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWH. Normal weightA NNYYNEGDW3DWŚDWĆ..NEG....YNNNNYYDV˙........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231483112314831123AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙23872 DV˙D‹8DW©.DW©DV˙DV˙D‹8DWD,DV˙D‹8DWD,....Hr±ą¸HrĚ¬Hr±ą¸HrĚ¬..DV˙DW..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0DW©LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹8D,....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW“.. Normal weightA NNYYNEGDW0DW’DWĐ..NEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DW©DW©B—B€BB«B”5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231484112314841123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23977 DV˙DŘDWÍ.DWÍDV˙DV˙DŘDWD†ÄDV˙DŘDWD†Ä....Hr±żXHrÍdÄHr±żXHrÍdÄ..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DŘD†Ä....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWR. Underweight ANNYYNEGDW3DW’DWÍ..NEG....YNNNNYYDV˙........DW3DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBęBBkB˙B”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231485112314851123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23982 DV˙Dź$DWÔ.DWÔDV˙DV˙Dź$DW¶D×dDV˙Dź$DWD„0DWˇDŠüDW¶D×dHr±Í¤HsŁHdHr±Í¤HrÍb0Hs‡L|HsŁHdDV˙DWDWˇDW¶AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dź$D„0.DŠüD×d.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWˇ. Underweight ANYYYNEGDW0DW’DW DWÔDXsNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBęBB]BkB˙B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231486112314861123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23984 DV˙D¤ÄDWŇ.DWŇDV˙DV˙D¤ÄDWDĆDV˙D¤ÄDWDĆ....Hr±ÓDHrĚRŚHr±ÓDHrĚRŚ..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWŇLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. D¤ÄDĆ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Normal weightA NNYYNEGDW/DWŚDWĐ..NEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWŇDWŇBŔBzBFBÔBŽ6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1123 11231487112314871123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23980 DV˙DźŘDWĚ.DWĚDV˙DV˙DźŘDW®DŐHDV˙DźŘDWDŃDWšDäDW®DŐHHr±ÎXHsşHHr±ÎXHrĚ^Hs~kHsşHDV˙DWDWšDW®AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. DźŘDŃ.DäDŐH.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWš. Overweight A0NNYYNEGDW1DW’DW™DWĚDXkNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBëB€BdBkB˙B”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231488112314881123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24049 DV˙DĐ DWÉ.DWÉDV˙DV˙DĐ DWD˘äDV˙DĐ DWD˘ä....Hr±ţ HrÎŇdHr±ţ HrÎŇd..DV˙DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DĐ D˘ä....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWH. Underweight ANNYYNEGDW8DW‘DWÉ..NEG....YNNNNYYDV˙........DW8DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBéB}BlB˙B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231489112314891123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24096 DV˙DŘDWÖ.DWÖDV˙DV˙DŘDWD¬DV˙DŘDWD¬....Hr˛HrĚ8Hr˛HrĚ8..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DŘD¬....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWV. Underweight ANNYYNEGDW3DW‘DWĹ..NEG....YNNNNYYDV˙........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBëBBlB˙B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231491112314911123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙24097 DV˙DáxDW¨.DW¨DV˙DV˙DáxDWDĄxDV˙DáxDWDĄx....Hr˛řHrĚ1řHr˛řHrĚ1ř..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW¨WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DáxDĄx....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW‘DWV. Underweight ANNYYNEGDW3DWDWĐ..NEG....YNNNNYNDV˙........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDW¨DW¨B–B~BBŞB’5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1123 11231492112314921123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24100 DWDŹ¬DWÄ..DWDWDŹ¬DW¦DŔlDWDŹ¬DWD|ěDW’DčDW¦DŔlHrł¬HsŽlHrł¬HrÎ¬lHssăHsŽlDWDWDW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹ¬D|ě.DčDŔl.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0YNYYNEGDW2DWŤDW‘DWÄDXcNEG....YNNNNYNDW........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBéByBlBpBţBŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231493112314931123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24103 DWD”DWË.DWËDWDWD”DWDĘDDWD”DWDĘD....Hrł”HrŃśÄHrł”HrŃśÄ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D”DĘD....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWT. Obese A@YNYNPOSDW3DW’DWË..POS....YNNNNYYDW........DW3DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW’DWýDWýBçB|BkBţB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231494112314941123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24237 DWDˇ@DWÉ.DWÉDWDWDˇ@DWDŰ`DWDˇ@DWDŰ`....Hrł!@HrĐ\`Hrł!@HrĐ\`..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. Dˇ@DŰ`....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWS. Normal weightA NYYYNEGDW2DW’DWÉ..NEG....YNNNNYYDW........DW2DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBčB}BkBţB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231495112314951123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24238 DWD©°DWĚ.DWĚDWDWD©°DWDÍŚDWD©°DWDÍŚ....Hrł)°HrÎýHrł)°HrÎý..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D©°DÍŚ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWT. Normal weightA NNYYNEGDW1DWDWĚ..NEG....YNNNNYYDW........DW1DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBéB|BmBţB‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1123 11231496112314961123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24240 DWD©tDWË..DWDWD©tDWŻD—hDWD©tDWDÍPDW™Dá<DWŻD—hHrł)tHs™ÍčHrł)tHrÎüĐHs}ĽHs™ÍčDWDWDW™DWŻAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D©tDÍP.Dá<D—h.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Underweight ANNYYNEGDW1DWDWDWËDXlNEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBéB|BeBmBţB‘8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231497112314971123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24243 DWDµ,DWŃ.DWŃDWDWDµ,DW±DÇtDWDµ,DWD„0DWśDć DW±DÇtHrł5,Hsś ôHrł5,Hr×î0Hs Hsś ôDWDWDWśDW±AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dµ,D„0.Dć DÇt.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWś. Normal weightA NNYYNEGDW9DW’DW›DWŃDXnNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBâBwBbBkBţB“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1123 11231499112314991123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24335 DWDŹ¬DW˝.DW˝DWDWDŹ¬DWˇDŠHDWDŹ¬DWDŚÜDWŽDŤĚDWˇDŠHHrą§,Hs‡KČHrą§,HrŐSÜHsnBĚHs‡KČDWDWDWŽDWˇAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWhBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹ¬DŚÜ.DŤĚDŠH.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW6DWŚDWŤDW˝DX^NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBpBqBůB8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1123 11231500112315001123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24336 DWD•ÄDW®.DW®DWDWD•ÄDWDŚ DWD•ÄDWDŚ ....HrąDHrŐS HrąDHrŐS ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. D•ÄDŚ ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWh. Normal weightA NYYYNEGDW6DWŚDW×..NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231501112315011123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24341 DWD°DWĆ.DWĆDWDWD°DWŞDŔ¨DWD°DW9DŮDW•DÝ@DWŞDŔ¨HrąÇ„Hs“_¨HrąÇ„Hrţ~HswĚŔHs“_¨DWDW9DW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D°DŮ.DÝ@DŔ¨.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW•. Normal weightA NNYYNEGDWYDW‘DW”DWĆDXgPOS....YNNNNYNDW........DWY.YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NNDW‘DWýDWýBĹBYBiBlBůBŤ7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1123 11231502112315021123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24342 DWD°|DWĘ.DWĘDWDWD°|DWDć(DWD°|DWDć(....HrąÇüHrÖţ¨HrąÇüHrÖţ¨..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. D°|Dć(....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWV. Normal weightA NNYYNEGDW9DW‘DWĘ..NEG....YNNNNYYDW........DW9DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBăBwBlBůBŤ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231503112315031123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24406 DWDpDWĹ.DWĹDWDWDpDW¨DĆ„DWDpDWD„äDW•DÇ8DW¨DĆ„HrąÄđHsÂ„HrąÄđHrŐKäHsw¶¸HsÂ„DWDWDW•DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD„ä.DÇ8DĆ„.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Underweight ANNYNPOSDW9DWŚDW”DWĹDXeNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBäBsBiBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231504112315041123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24412 DWDŮřDWĐ.DWĐDWDWDŮřDWD†ÄDWDŮřDWD†Ä....HrąńxHrŐMÄHrąńxHrŐMÄ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŮřD†Ä....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW[. Normal weightA NNYYNEGDW8DW’DWÉ..NEG....YNNNNYYDW........DW8DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBäByBkBůBŽ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231505112315051123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24411 DWDÚ4DWŃ.DWŃDWDWDÚ4DWµD“äDWDÚ4DWD†DW D—ŕDWµD“äHrąń´HsˇłdHrąń´HrŐMHs†ŕHsˇłdDWDWDW DWµAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚ4D†.D—ŕD“ä.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW . Underweight ANNYYNEGDW8DW’DWźDWŃDXrNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBäByB^BkBůBŽ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231506112315061123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24415 DWDá<DWű.DWűDWDWDá<DWDź`DWDá<DWDź`....HrąřĽHrŐf`HrąřĽHrŐf`..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. Dá<Dź`....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW\. Normal weightA NNYYNEGDW6DW‘DWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBäBxBlBůBŤ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231507112315071123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24505 DWDí0DWš.DWšDWDWDí0DWD¦hDWDí0DWD¦h....Hrş°HrŐmhHrş°HrŐmh..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. Dí0D¦h....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWZ. Normal weightA NNYYNEGDW7DWŤDW×..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpBůB‰8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231508112315081123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24508 DWDílDWË.DWËDWDWDílDWD¸DWDílDWD¸....HrşěHr×í¸HrşěHr×í¸..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DílD¸....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW:DWŚDWË..NEG....YNNNNYYDW........DW:DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231509112315091123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24510 DWD©°DWĚ.DWĚDWDWD©°DW°DŇDWD©°DWDĘ€DWšDäüDW°DŇHr»°Hs›ZHr»°HrŮ†Hs~küHs›ZDWDWDWšDW°AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. D©°DĘ€.DäüDŇ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Normal weightA NNYYNEGDW@DWŚDW™DWĚDXm ....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBdBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231510112315101123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24512 DWD˛DWĚ..DWDWD˛DW®D¦ŕDWD˛DWDŐ„DW™DŘTDW®D¦ŕHr»Hs‹ŕHr»HrÖîHs} ÔHs‹ŕDWDWDW™DW®AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛DŐ„.DŘTD¦ŕ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Normal weightA NNYYNEGDW8DWDWDWĚDXkNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBăBvBeBmBřB‹8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231511112315111123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24850 DWD`DWŠ.DWŠDWDWD`DWDŰŘDWD`DWDŰŘ....HrĽJŕHrÖôXHrĽJŕHrÖôX..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŠLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D`DŰŘ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW=DWŘDWŘ..NEG....YNNNNYNDW........DW=.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWŠ.DWŠBpBp..B„B„4-5 months AP4-5 months AP .4-5 months AP . ...C4591001C4591001 1123 11231512112315121123AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24852 DWDśDWŠ.DWŠDWDWDśDWDÜDWDśDWDÜ....HrĽKHrÖô”HrĽKHrÖô”..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŠLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DśDÜ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW=DWŘDWŘ..NEG....YNNNNYNDW........DW=.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWŠ.DWŠBpBp..B„B„4-5 months AP4-5 months AP .4-5 months AP . ...C4591001C4591001 1123 11231513112315131123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24856 DWD–DWŮ.DWŮDWDWD–DW˝DŽĽDWD–DWDÇ°DWŞDš8DW˝DŽĽHrĽP€Hs¬:<HrĽP€HrŘ1°Hs“98Hs¬:<DWDWDWŞDW˝AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. D–DÇ°.Dš8DŽĽ.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWŞ. Underweight ANNYYNEGDW>DWDW©DWŮDXzNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBâBuBTBmB÷BŠ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231514112315141123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24860 DWDÇ8DWĚ.DWĚDWDWDÇ8DW®D™HDWDÇ8DWDĆDW™D DW®D™HHrĽ¸Hs~HHrĽ¸HrŐŤHs|Ő”Hs~HDWDWDW™DW®AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇ8DĆ.D D™H.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW™. Normal weightA NNYYNEGDW9DW‘DWDWĚDXkNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBäBxBeBlB÷B‹8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231515112315151123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25042 DWDß\DWś.DWśDWDWDß\DWDĹ”DWDß\DWDĹ”....HrĽ™ÜHrŐŚ”HrĽ™ÜHrŐŚ”..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADWśWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. Dß\DĹ”....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW“DW[. Normal weightA NNYYNEGDW6DW’DW×..NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWśDWśBByA B–BŚ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ..DWwC4591001C4591001 1123 11231516112315161123AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25047 DWDĺ8DWč.DWčDWDWDĺ8DWĹDâ,DWDĺ8DWDĐÔDW®DáđDWĹDâ,HrĽź¸Hs·¬HrĽź¸HrŘ:ÔHsĆđHs·¬DWDWDW®DWĹAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺ8DĐÔ.DáđDâ,.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW®. Overweight A0NYYYNEGDW9DW’DWDWčDX‚NEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBâBwBPBkB÷BŚ8-9 months A4-5 months AP2-3 monthsA08-9 months A . ...C4591001C4591001 1123 11231517112315171123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25041 DWDŰ$DWË.DWËDWDWDŰ$DWD´xDWDŰ$DWD´x....HrĽ•¤HrŐ{xHrĽ•¤HrŐ{x..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŰ$D´x....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“.. Underweight ANNYYNEGDW:DW’DWË..NEG....YNNNNYYDW........DW:DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBäByBkB÷BŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231518112315181123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25046 DWDäüDWË.DWËDWDWDäüDWDŃDWDäüDWDŃ....HrĽź|HrŘ;HrĽź|HrŘ;..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DäüDŃ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWZ. Obese A@YNYYNEGDW9DW’DWË..NEG....YNNNNYYDW........DW9DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBâBwBkB÷BŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231519112315191123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25077 DWDî\DWË.DWËDWDWDî\DWDž4DWDî\DWDž4....HrĽ¨ÜHrŘ4HrĽ¨ÜHrŘ4..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. Dî\Dž4....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW[. Obese A@YNYYNEGDW8DW’DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBâBwBkB÷BŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231520112315201123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25082 DWDňXDWÉ.DWÉDWDWDňXDWŞD‰XDWDňXDWDłLDW•DŕLDWŞD‰XHrĽ¬ŘHs“(XHrĽ¬ŘHrŐzLHswĎĚHs“(XDWDWDW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DňXDłL.DŕLD‰X.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW•. Underweight ANNYYNEGDW6DW”DW”DWÉDXgNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýBäB{BiBiB÷BŽ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231521112315211123AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25080 DWDňXDWÉ.DWÉDWDWDňXDWDłÄDWDňXDWDłÄ....HrĽ¬ŘHrŐzÄHrĽ¬ŘHrŐzÄ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DňXDłÄ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW6DWDWÉ.. ....YNNNNNYDW.........DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWýDWýBäBwBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1123 11231522112315221123AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25083 DW DÄ¤DWÄ.DWÄDW DW DÄ¤DW§Dż¸DW DÄ¤DW"DÜDW’D¨ŔDW§Dż¸HrÄh$HsŹj8HrÄh$Hrŕ/HssŁŔHsŹj8DW DW"DW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄ¤DÜ.D¨ŔDż¸.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW@DWŤDW‘DWÄDXdNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÜBlBlBpBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231523112315231123AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25489 DW DÄ¤DWÄ.DWÄDW DW DÄ¤DW§DżôDW DÄ¤DW"DÜPDW’D©ěDW§DżôHrÄh$HsŹjtHrÄh$Hrŕ/PHss¤ěHsŹjtDW DW"DW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄ¤DÜP.D©ěDżô.113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW@DWŤDW‘DWÄDXdNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÜBlBlBpBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1123 11231524112315241123AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25490 DW DÝ@DWÓ.DWÓDW DW DÝ@DW$DăĐDW DÝ@DW$DăĐ....HrÄ€ŔHrâŮĐHrÄ€ŔHrâŮĐ..DW DW$..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DÝ@DăĐ....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Normal weightA NNYYNEGDW@DWŚDWÓ..NEG....YNNNNYYDW ........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1123 11231525112315251123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25493 DWDčřDWŮ.DWŮDWDWDčřDW%DÚ4DWDčřDW%DÚ4....HrÇ/xHrä!´HrÇ/xHrä!´..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DčřDÚ4....113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWb. Normal weightA NNYYNEGDWGDW‘DWŮ..NEG....YNNNNYYDW........DWGDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŮBmBlBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1123 11231526112315261123AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25495 DWD†LDW˝.DW˝DWDWD†LDW™Dß DWD†LDW%DŘDW™Dß DW™Dß HrČLHs} HrČLHrăÉXHs} Hs} DWDW%DW™.AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE ADW˝LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. D†LDŘ.Dß ..113680 Essink, Brandon James ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW™. Overweight A0YNYYNEGDWFDW‘DWDWÓDXmNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DW˝DW˝B™BmB%B,B®B‚5-6 months A`3-4 months A@1-2 monthsA 6-7 months Ap . ..DW„C4591001C4591001 1124 11241236112412361124AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV÷22307 DV÷Dž¬DW .DW DV÷DV÷Dž¬DWDXDV÷Dž¬DWDX....Hr§A,HrÂęXHr§A,HrÂęX..DV÷DW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DW WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dž¬DX....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW(DWŚDWÉ..NEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW DW B•BBBŞB–5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1124 11241238112412381124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22311 DV÷DÖ°DW˝.DW˝DV÷DV÷DÖ°DWDŢ0DV÷DÖ°DWDŢ0....Hr§y0HrĹÓ0Hr§y0HrĹÓ0..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÖ°DŢ0....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW*DWŚDW˝..NEG....YNNNNYYDV÷........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241239112412391124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22312 DV÷D×ÜDW˝.DW˝DV÷DV÷D×ÜDWDĺěDV÷D×ÜDWDĺě....Hr§z\HrĹÚěHr§z\HrĹÚě..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D×ÜDĺě....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW*DWŚDW˝..NEG....YNNNNYYDV÷........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241240112412401124AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22314 DV÷DŕDWË.DWËDV÷DV÷DŕDW¨Dâ¤DV÷DŕDWDŃDW‘DáxDW¨Dâ¤Hr§HsŢ¤Hr§HrĂ#HsrŠřHsŢ¤DV÷DWDW‘DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕDŃ.DáxDâ¤.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW‘. Normal weightA NNYYNEGDW*DW…DWDWËDXeNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýBňBzBmBxCpBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241241112412411124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22365 DV÷DŕLDWË.DWËDV÷DV÷DŕLDW¨DăDV÷DŕLDWDŃDW‘DáDW¨DăHr§‚ĚHsßHr§‚ĚHrĂ#HsrŠ€HsßDV÷DWDW‘DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕLDŃ.DáDă.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW‘. Normal weightA NYYYNEGDW*DW…DWDWËDXeNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýBňBzBmBxCpBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241242112412421124AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV÷22368 DV÷DďÄDW´.DW´DV÷DV÷DďÄDW DĐ\DV÷DďÄDW DĐ\....Hr§’DHrÄsÜHr§’DHrÄsÜ..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW´LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DďÄDĐ\....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Obese A@YNYYNEGDW+DWŤDWĘ..NEG....YNNNNYNDV÷........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDW´DW´B¨BB'BľB—6-7 months Ap4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1124 11241243112412431124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22370 DVřDżôDWĽ.DWĽDVřDVřDżôDW Dę$DVřDżôDW Dę$....Hr¨łôHrÄŤ¤Hr¨łôHrÄŤ¤..DVřDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DżôDę$....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Obese A@YNYYNEGDW0DWDWĽ..NEG....YNNNNYYDVř........DW0DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńB„BmC`B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241244112412441124AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22376 DVřDË¬DWĽ.DWĽDVřDVřDË¬DW DÄŕDVřDË¬DW DÄŕ....Hr¨ż¬HrÄh`Hr¨ż¬HrÄh`..DVřDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DË¬DÄŕ....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW/DWDWĽ..NEG....YNNNNYYDVř........DW/DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBńB„BmC`B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241245112412451124AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22629 DVřDńŕDWË.DWËDVřDVřDńŕDWDű¸DVřDńŕDWDű¸....Hr¨ĺŕHrĹđ¸Hr¨ĺŕHrĹđ¸..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DńŕDű¸....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW2DWŤDWË..NEG....YNNNNYYDVř........DW2DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBđB€BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241246112412461124AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22632 DVřDńhDW˝.DW˝DVřDVřDńhDWDü0DVřDńhDWDü0....Hr¨ĺhHrĹń0Hr¨ĺhHrĹń0..DVřDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DńhDü0....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW2DWŤDW˝.. ....YNNNNNYDVř.........DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBđB€BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241247112412471124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22633 DVůD‡đDWÓ..DVůDVůD‡đDWÓDĺtDVůD‡đDW DĂđDWĽDî DWÓDĺtHr©ÍpHsÉ‘ôHr©ÍpHrÄgpHs«H HsÉ‘ôDVůDW DWĽDWÓAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡đDĂđ.Dî Dĺt.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWĽ. Overweight A0YNYYNEGDW1DWDW»DWöDXNEG....YNNNNYNDVů........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBńB„BBBmCPB8-9 months A4-5 months AP2-3 monthsA09-10 months A . ...C4591001C4591001 1124 11241248112412481124AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22640 DVůD–DWĹ.DWĹDVůDVůD–DW¨DÜŚDVůD–DWD‰ĐDW‘DŰśDW¨DÜŚHr©Ű€HsŘŚHr©Ű€HrĹ~ĐHsr…HsŘŚDVůDWDW‘DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–D‰Đ.DŰśDÜŚ.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW‘. Normal weightA NNYYNEGDW*DW…DWDWĹDXeNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW…DWýDWýBđBxBmBxCPBŤ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWmC4591001C4591001 1124 11241249112412491124AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22859 DVůDĘ€DWŇ.DWŇDVůDVůDĘ€DWDâ¤DVůDĘ€DWDâ¤....HrŞHrĂ4¤HrŞHrĂ4¤..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĘ€Dâ¤....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW/DWDWŇ..NEG....YNNNNYYDVů........DW/DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBňB…BmCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241250112412501124AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22865 DVúDä„DWĂ.DWĂDVúDVúDä„DW¦Dĺ8DVúDä„DWDé4DW‘DăXDW¦Dĺ8Hr«{„HsŽ>8Hr«{„HrÇ/´HsrŚŘHsŽ>8DVúDWDW‘DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dä„Dé4.DăXDĺ8.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW‘. Underweight ANYYYNEGDW+DW…DWDWĂDXcNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýBďBwBmBxC@BŚ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241251112412511124AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű22867 DVűDŠDWÍ.DWÍDVűDVűDŠDWDĄ<DVűDŠDWDĄ<....Hr¬rŚHrČ=<Hr¬rŚHrČ=<..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠDĄ<....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW,DWŚDWÍ..NEG....YNNNNYYDVű........DW,DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241252112412521124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű22866 DVűDhDWĹ.DWĹDVűDVűDhDW§DĆ„DVűDhDWDĄđDW’DÍDW§DĆ„Hr¬pčHsŹqHr¬pčHrČ=đHssČHsŹqDVűDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DhDĄđ.DÍDĆ„.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW,DWŚDW‘DWĹDXdNEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BlBqC0B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241253112412531124AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23356 DVűDŇDWÔ.DWÔDVűDVűDŇDWD§DVűDŇDWD§....Hr¬ş€HrČ?Hr¬ş€HrČ?..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇD§....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW1DWDWÔ..NEG....YNNNNYYDVű........DW1DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBîBBmC0B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241254112412541124AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23350 DVűDŃLDWŰ.DWŰDVűDVűDŃLDWD¦¤DVűDŃLDWD¦¤....Hr¬ąĚHrČ>¤Hr¬ąĚHrČ>¤..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŃLD¦¤....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW1DWDWŰ..NEG....YNNNNYYDVű........DW1DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBîBBmC0B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241255112412551124AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23359 DVűDí0DWÉ.DWÉDVűDVűDí0DW¨DŮDDVűDí0DWDę$DW“DŢ0DW¨DŮDHr¬Ő°HsŐDHr¬Ő°HrĹß$Hsu*°HsŐDDVűDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dí0Dę$.DŢ0DŮD.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Normal weightA NNYYNEGDW1DWŤDW’DWÉDXeNEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BkBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241256112412561124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23360 DVţD®$DW•.DW•DVţDVţD®$DWDŢ¨DVţD®$DWDŢ¨....Hr°‹$HrĎ(Hr°‹$HrĎ(..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW•LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®$DŢ¨....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDW1DWŚDWŇ..NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW•DW•BBxABBŹ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1124 11241257112412571124AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24118 DV˙DâŕDWÄ.DWÄDV˙DV˙DâŕDW§DçDV˙DâŕDWDŮřDW‘DđxDW§DçHr˛`HsŹ‘Hr˛`HrÍ·řHsr™řHsŹ‘DV˙DWDW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâŕDŮř.DđxDç.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Underweight ANNYYNEGDW6DWŤDWDWÄDXdNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBęBzBmBpB˙BŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241258112412581124AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24120 DWD§”DWĂ.DWĂDWDWD§”DW§DÝ|DWD§”DWDá<DW‘DŕDW§DÝ|Hrł'”HsŹ‡üHrł'”HrĐb<Hsr‰HsŹ‡üDWDWDW‘DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§”Dá<.DŕDÝ|.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0NNYYNEGDW2DWŚDWDWĂDXdNEG....YNNNNYNDW........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBčBwBmBqBţBŤ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1124 11241259112412591124AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24125 DWD¦¤DWË.DWËDWDWD¦¤DWDăXDWD¦¤DWDăX....Hrł&¤HrĐdXHrł&¤HrĐdX..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¦¤DăX....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDW2DWŚDWË..NEG....YNNNNYYDW........DW2DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqBţBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241260112412601124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24128 DWD¨ŔDWĆ.DWĆDWDWD¨ŔDWDŕDWD¨ŔDWDŕ....Hrł(ŔHrĎHrł(ŔHrĎ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨ŔDŕ....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Overweight A0YNYYNEGDW1DWDWĆ..NEG....YNNNNYYDW........DW1DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBéB|BmBţB‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1124 11241261112412611124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24227 DWD˛DW¶.DW¶DWDWD˛DWDßDWD˛DWDß....Hrł2HrĎHrł2HrĎ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW¶WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˛Dß....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW1DWŤDWŇ..NEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWŤDW¶DW¶B˘ByB)B·BŽ5-6 months A`4-5 months AP0-1 month A6-7 months Ap . ...C4591001C4591001 1124 11241262112412621124AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24228 DWDÎ¸DWĆ.DWĆDWDWDÎ¸DWDę`DWDÎ¸DWDę`....HrłN¸HrĚvŕHrłN¸HrĚvŕ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWĆLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÎ¸Dę`....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“.. Normal weightA NYYYNEGDW8DW’DWĐ..NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWĆDWĆB´B€B4BÇB“6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1124 11241263112412631124AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24232 DWDŤDWÉ.DWÉDWDWDŤDW©DÔDWDŤDWD‹tDW’DÍČDW©DÔHrşöHs’!śHrşöHrŐRtHssČČHs’!śDWDWDW’DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤD‹t.DÍČDÔ.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Normal weightA NNYYNEGDW9DWŤDW‘DWÉDXfNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBäBtBlBpBřB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241264112412641124AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24234 DWDŤĚDWÉ.DWÉDWDWDŤĚDW©DÔDWDŤĚDWD‹8DW’DÎ@DW©DÔHrşöĚHs’!śHrşöĚHrŐR8HssÉ@Hs’!śDWDWDW’DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤĚD‹8.DÎ@DÔ.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW’. Underweight ANNYYNEGDW9DW…DW‘DWÉDXfNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýBäBlBlBxBřB€8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241265112412651124AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24623 DWD®`DWŃ.DWŃDWDWD®`DWDŠ„DWD®`DWDŠ„....Hr»`HrŐQ„Hr»`HrŐQ„..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®`DŠ„....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW8DWŤDWĐ..NEG....YNNNNYYDW........DW8DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1124 11241266112412661124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24625 DWDŻPDWĐ.DWĐDWDWDŻPDWDŠDWDŻPDWDŠ....Hr»PHrŐQHr»PHrŐQ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŻPDŠ....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW8DWŤDWĐ..NEG....YNNNNYYDW........DW8DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1124 11241267112412671124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24626 DWD°DWĂ.DWĂDWDWD°DW¦DäüDWD°DWDŠHDW‘DđDW¦DäüHr»HsŽ=üHr»HrŐQHHsr™€HsŽ=üDWDWDW‘DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°DŠH.DđDäü.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW†DW‘. Underweight ANNYYNEGDW8DW…DWDWĂDXcNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW…DWýDWýBäBlBmBxBřB€8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241268112412681124AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24631 DWDĂđDWĂ.DWĂDWDWDĂđDW§DŮĽDWDĂđDW#DľDW’DŃDW§DŮĽHrĂđHsŹ„<HrĂđHráb”HssĚHsŹ„<DWDW#DW’DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂđDľ.DŃDŮĽ.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0NNYYNEGDWFDWŤDW‘DWĂDXdNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBlBpBňB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241269112412691124AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25306 DWDçDWŃ.DWŃDWDWDçDW!D×dDWDçDW!D×d....HrĂ9HrŢŘäHrĂ9HrŢŘä..DWDW!..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DçD×d....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Underweight ANNYYNEGDW=DW=DWŃ..NEG....YNNNNYYDW........DW?DWŃYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDW=DWýDWýBÝBBŔBňB27-8 months A€1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1124 11241270112412701124AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25308 DW Dá´DWo.DWoDW DW Dá´DWSD× DW Dá´DW"DŃÄDW>DÝ¸DWSD× HrÄ…4Hs Ä HrÄ…4Hrŕ$ÄHs¸Hs Ä DW DW"DW>DWSAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dá´DŃÄ.DÝ¸D× .28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW>DW>. Normal weightA NNYYNEGDW=DW=DW=DWoDXNEG....YNNNNYNDW ........DW>.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW=DWýDWýBÜBBŔBŔBńB17-8 months A€1-2 months A 6-7 monthsAp8-9 months A . ...C4591001C4591001 1124 11241271112412711124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25313 DW DílDWŇ.DWŇDW DW DílDW"DćdDW DílDW"Dćd....HrÄěHrŕ9dHrÄěHrŕ9d..DW DW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DílDćd....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“.. Normal weightA NYYYNEGDW>DW’DWŇ..NEG....YNNNNYYDW ........DW>DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBÜBqBkBńB†7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1124 11241272112412721124AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25315 DW DńhDWĘ.DWĘDW DW DńhDW¨DŇxDW DńhDW#DŔ0DW’DëDW¨DŇxHrÄ”čHsÎxHrÄ”čHrád°HssćHsÎxDW DW#DW’DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DńhDŔ0.DëDŇx.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDWEDWŤDW‘DWĘDXeNEG....YNNNNYNDW ........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBlBpBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241273112412731124AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25847 DWD÷ĽDWŇ.DWŇDWDWD÷ĽDW#DîDWD÷ĽDW#Dî....HrĹěĽHrá“HrĹěĽHrá“..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D÷ĽDî....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW?DWŤDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1124 11241274112412741124AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25849 DWD÷DWË.DWËDWDWD÷DW¨DîÔDWD÷DW#DěDW“DŢ¨DW¨DîÔHrĹěHsęÔHrĹěHrá„Hsu+(HsęÔDWDW#DW“DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷Dě.DŢ¨DîÔ.28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Underweight ANNYYNEGDW?DWŤDW’DWËDXeNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBkBpBđB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1124 11241275112412751124AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25852 DWD×(DWç.DWçDWDWD×(DW#Dę`DWD×(DW#Dę`....HrČo(HráŽŕHrČo(HráŽŕ..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D×(Dę`....28769 Fried, David L. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDWADWDWç..NEG....YNNNNYYDW........DWADWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŰBnBmBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1125 11251241112512411125AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21093 DVđDřDW¸.DW¸DVđDVđDřDWD…\DVđDřDWD…\....HrťçřHrĽ?ÜHrťçřHrĽ?Ü..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DřD…\....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Overweight A0NNNYPOSDW#DWDW¸..POS....YNNNNYYDVđ........DW#DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWýDWýB÷BŠBmCŕBˇ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1125 11251242112512421125AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21096 DVđD…\DWÉ.DWÉDVđDVđD…\DW¦Dě¸DVđD…\DWDDDW‘DülDW¦Dě¸Hrťí\HsŽE¸Hrťí\Hrą–ÄHsrĄěHsŽE¸DVđDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D…\DD.DülDě¸.399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW(DWŚDWDWÉDXcNEG....YNNNNYNDVđ........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBmBqCŕBť8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1125 11251244112512441125AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21097 DVńEF@DWâ.DWâDVńDVńEF@DWĆDţDVńEF@DWDˇ¸DW°DťřDWĆDţHrź˝äHs¸‡Hrź˝äHrĽ\8Hs›%řHs¸‡DVńDWDW°DWĆAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. EF@Dˇ¸.DťřDţ.399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW°. Underweight ANNYYNEGDW%DWŤDWŻDWâDXNEG....YNNNNYNDVń........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BNBpCĐBť8-9 months A4-5 months AP2-3 monthsA09-10 months A . ...C4591001C4591001 1125 11251246112512461125AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21100 DVóDŽřDW¶.DW¶DVóDVóDŽřDWDłLDVóDŽřDWDłL....HrˇëxHrĽmĚHrˇëxHrĽmĚ..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽřDłL....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YNYYNEGDW#DWŤDW¶..NEG....YNNNNYYDVó........DW#DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB÷B‡BpC°B›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1125 11251248112512481125AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVô22113 DVôDĘĽDWľ.DWľDVôDVôDĘĽDWDżDVôDĘĽDWDż....HrŁxĽHrĽy„HrŁxĽHrĽy„..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĘĽDż....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYNPOSDW#DWŚDWľ..NEG....YNNNNYYDVô........DW#DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1125 11251249112512491125AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22116 DVôDÔDWÉ.DWÉDVôDVôDÔDW§DŇDVôDÔDWDčřDW‘DůŘDW§DŇHrŁ‚HsŹ|€HrŁ‚HrĽŁxHsrŁXHsŹ|€DVôDWDW‘DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔDčř.DůŘDŇ.399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW%DWŚDWDWÉDXdNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1125 11251250112512501125AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22121 DV÷D¨üDW˝.DW˝DV÷DV÷D¨üDWDěDV÷D¨üDWDě....Hr§K|HrĹáHr§K|HrĹá..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨üDě....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNNYPOSDW*DWŚDW˝..POS....YNNNNYYDV÷........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1125 11251251112512511125AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22124 DV÷D°DW˝.DW˝DV÷DV÷D°DWDÉDV÷D°DWDÉ....Hr§R„HrĹľHr§R„HrĹľ..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D°DÉ....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW*DWŚDW˝..NEG....YNNNNYYDV÷........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1125 11251252112512521125AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22885 DVůDĎ¨DWĹ.DWĹDVůDVůDĎ¨DWDyŕDVůDĎ¨DWDyŕ....HrŞ(HrÎ©`HrŞ(HrÎ©`..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĎ¨Dyŕ....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NNNNPOSDW3DWŚDWĹ..POS....YNNNNYYDVů........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBéBxBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1125 11251253112512531125AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22886 DVůDâhDWŃ.DWŃDVůDVůDâhDW®D€pDVůDâhDWEö€DW™D”\DW®D€pHrŞ'čHsepHrŞ'čHrĆhHs|ÉÜHsepDVůDWDW™DW®AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâhEö€.D”\D€p.399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Underweight ANNYYNEGDW1DWŤDWDWŃDXkNEG....YNNNNYNDVů........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BeBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1125 11251254112512541125AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW22888 DWD§XDWÉ.DWÉDWDWD§XDW§DçĚDWD§XDWDŠŔDW’DăXDW§DçĚHrąľŘHsŹ’LHrąľŘHr×ôŔHssŢXHsŹ’LDWDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§XDŠŔ.DăXDçĚ.399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW:DWŚDW‘DWÉDXdNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBlBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1125 11251255112512551125AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW22892 DWDđDW×.DW×DWDWDđDW#Dě|DWDđDW#Dě|....HrĹĺHráüHrĹĺHráü..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW×LOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DđDě|....399369 Harper, Charles Harold ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNNYPOSDW?DWŕDWŕ..POS....YNNNNYNDW........DW?.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW×.DW×BµBµ..BĘBĘ6-7 months Ap6-7 months Ap .7-8 months A€ . ...C4591001C4591001 1126 11261229112612291126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20421 DVéDŔäDWŻ.DWŻDVéDVéDŔäDVţD•ÄDVéDŔäDVţD•Ä....Hr”îdHr°rÄHr”îdHr°rÄ..DVéDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŔäD•Ä....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NNYYNEGDWDWŚDWŻ..NEG....YNNNNYYDVé........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBŹBqCPB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261230112612301013AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20422 DVéDăXDWö.DWöDVéDVéDăXDVţDË4DVéDăXDVţDË4....Hr•ŘHr°¨4Hr•ŘHr°¨4..DVéDVţ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DăXDË4....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWR. Normal weightA NNYYNEGDWDWŚDWö..NEG....YNNNNYYDVé........DWDWöYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCBŹBqCPB¤9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261233112612331126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20423 DVęD§”DWÄ.DWÄDVęDVęD§”DW¨DŔ¨DVęD§”DV˙D” DW“D’|DW¨DŔ¨Hr–&”HsĽ¨Hr–&”Hr±Â HstŢüHsĽ¨DVęDV˙DW“DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D§”D” .D’|DŔ¨.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDWDWŚDW’DWÄDXeNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB˙BŽBkBqC@BŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261235112612351126AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20430 DVęDÜŚDWĆ.DWĆDVęDVęDÜŚDW§D¤LDVęDÜŚDWDŠHDW’DŘDW§D¤LHr–[ŚHsŹNĚHr–[ŚHrł HHss‹ŘHsŹNĚDVęDWDW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜŚDŠH.DŘD¤L.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NYYYNEGDWDWŚDW‘DWĆDXdNEG....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBlBqC@BŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261239112612391126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20686 DVëDŚ DWÉ.DWÉDVëDVëDŚ DW¦DŚ(DVëDŚ DVţD{„DW‘D©°DW¦DŚ(Hr—] HsŤĺ(Hr—] Hr°X„HsrS0HsŤĺ(DVëDVţDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ D{„.D©°DŚ(.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDWDWŚDWDWÉDXcNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCBŹBmBqC0B˘9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261240112612401126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20687 DVëDŚÜDWÉ.DWÉDVëDVëDŚÜDW©D·ŔDVëDŚÜDVţD{HDW•DÄhDW©D·ŔHr—]\Hs’@Hr—]\Hr°XHHswłčHs’@DVëDVţDW•DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚÜD{H.DÄhD·Ŕ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDWDWŚDW”DWÉDXfNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCBŹBiBqC0B˘9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261241112612411126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20690 DVëD DWé.DWéDVëDVëD DVţD¬€DVëD DVţD¬€....Hr—p”Hr°‰€Hr—p”Hr°‰€..DVëDVţ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D D¬€....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWDWŚDW..NEG....YNNNNYYDVë........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBŹBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261243112612431126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20694 DVëD±lDWŮ.DWŮDVëDVëD±lDVţD‡đDVëD±lDVţD‡đ....Hr—ěHr°dđHr—ěHr°dđ..DVëDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWo .. D±lD‡đ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWo. Overweight A0YNYYNEGDWDWŚDW..NEG....YNNNNYYDVë........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBŹBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261246112612461126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20761 DVëD×dDWµ.DWµDVëDVëD×dDWD’DVëD×dDWD’....Hr—§äHrłHr—§äHrł..DVëDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. D×dD’....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Normal weightA NNYYNEGDWDWŚDWµ..NEG....YNNNNYYDVë........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBţBŤBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261249112612491126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20763 DVëDúPDW±.DW±DVëDVëDúPDV˙DČdDVëDúPDV˙DČd....Hr—ĘĐHr±öäHr—ĘĐHr±öä..DVëDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWh .. DúPDČd....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWh. Underweight ANNYYNEGDWDWŚDW±..NEG....YNNNNYYDVë........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB˙BŽBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261250112612501126AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20764 DVëDűDWÍ.DWÍDVëDVëDűDW®DăXDVëDűDV˙DÉDW“DŞdDW®DăXHr—Ë„HsČXHr—Ë„Hr±÷HstöäHsČXDVëDV˙DW“DW®AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DűDÉ.DŞdDăX.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDWDWŚDW’DWÍDXkNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB˙BŽBkBqC0B˘9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261253112612531126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20765 DVěD±äDWĂ.DWĂDVěDVěD±äDW§D¤DVěD±äDWDŁ DW‘DŤTDW§D¤HrÓäHsŹ3$HrÓäHrł# Hsr6ÔHsŹ3$DVěDWDW‘DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D±äDŁ .DŤTD¤.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDWDWŚDWDWĂDXdNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBmBqC Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261254112612541126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20904 DVěDÜČDWď.DWďDVěDVěDÜČDWÉDŚdDVěDÜČDW"DÍŚDWµDÎ¸DWÉDŚdHrţČHsĽ äHrţČHrŕ ŚHsˇî8HsĽ äDVěDW"DWµDWÉAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDÍŚ.DÎ¸DŚd.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWµDWµ. Underweight ANNYYNEGDW?DW´DW´DWĺDX†NEG....YNNNNYNDVě........DW?.YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDW´DWýDWýBÜB“BIBIC BÉ7-8 months A€5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1126 11261255112612551126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20907 DVěDÝ¸DWß.DWßDVěDVěDÝ¸DWDźŘDVěDÝ¸DWDźŘ....Hr˙¸HrłŘHr˙¸HrłŘ..DVěDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWR .. DÝ¸DźŘ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDWR. Underweight ANNYYNEGDW"DW´DWµ..NEG....YNNNNYYDVě........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW´DWýDWýBţBµBIC BÉ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1126 11261258112612581126AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20910 DVěDůśDWű.DWűDVěDVěDůśDV˙D‡đDVěDůśDV˙D‡đ....Hr™śHr±¶pHr™śHr±¶p..DVěDV˙..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DůśD‡đ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĽDWZ. Overweight A0NNYYNEGDWDW»DWĽ..NEG....YNNNNYYDVě........DWDWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW»DWýDWýB˙B˝BBC BĐ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1126 11261262112612621126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20911 DVíDăDWĐ..DVíDVíDăDWFD®śDVíDăDWD˝śDW1DŇxDWFD®śHršVśHswśHršVśHrł=śHróëřHswśDVíDWDW1DWFAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DăD˝ś.DŇxD®ś.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW0DW1. Normal weightA NNYYNEGDWDW/DW0DWbDXNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW/DWýDWýBţB0BÍBÎCBC9-10 months A 1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1126 11261263112612631126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21033 DVíDěôDW·.DW·DVíDVíDěôDWDÜDVíDěôDWDÜ....Hrš`tHrł\Hrš`tHrł\..DVíDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DěôDÜ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW·DWN. Normal weightA NNYYNEGDWDW¶DW·..NEG....YNNNNYYDVí........DWDW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¶DWýDWýBţB·BGCBĘ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1126 11261264112612641126AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21038 DVíDűDW¸.DW¸DVíDVíDűDWDĘDVíDűDWDĘ....Hršn„HrłJHršn„HrłJ..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DűDĘ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW!DWŚDW¸..NEG....YNNNNYYDVí........DW!DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBţBŤBqCB 9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1126 11261265112612651126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷21040 DV÷D˙<DWÉ.DWÉDV÷DV÷D˙<DWDŞ(DV÷D˙<DWD€čDW“DĂDWDŞ(Hr§ˇĽHs—=¨Hr§ˇĽHrÂŇčHsu€Hs—=¨DV÷DWDW“DWAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˙<D€č.DĂDŞ(.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW(DWŚDW’DWÉDXjNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBkBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261266112612661126AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷21042 DV÷D†DWÉ.DWÉDV÷DV÷D†DWDŞ DV÷D†DWD`DW“DĂDWDŞ Hr§)Hs—> Hr§)HrÂÓ`Hsu€Hs—> DV÷DWDW“DWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D†D`.DĂDŞ .280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW(DWŚDW’DWÉDXjNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBkBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261267112612671126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22342 DV÷DŘDWÉ.DWÉDV÷DV÷DŘDWŞDŕDV÷DŘDWDĺ°DW•DŢlDWŞDŕHr§3XHs“'ŕHr§3XHrĂ7°HswÍěHs“'ŕDV÷DWDW•DWŞAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŘDĺ°.DŢlDŕ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Underweight ANNYYNEGDW*DWDW”DWÉDXgNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýBňB…BiBmCpBš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261268112612681126AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22343 DV÷DśDWÄ.DWÄDV÷DV÷DśDW Dâ,DV÷DśDW Dâ,....Hr§?HrÄ…¬Hr§?HrÄ…¬..DV÷DW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DśDâ,....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Underweight ANNYYNEGDW,DWŚDWÄ..NEG....YNNNNYYDV÷........DW,DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261269112612691126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22344 DV÷D·ŔDWÉ.DWÉDV÷DV÷D·ŔDWD¤LDV÷D·ŔDWD¤L....Hr§Z@HrĹ™LHr§Z@HrĹ™L..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. D·ŔD¤L....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWO. Normal weightA NYYYNEGDW*DWŚDWÉ..NEG....YNNNNYYDV÷........DW*DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261270112612701126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22352 DV÷DĐ DWĹ.DWĹDV÷DV÷DĐ DW©D‹tDV÷DĐ DWD¨üDW”DâŕDW©D‹tHr§r Hs‘ŘôHr§r HrĹťüHsv€ŕHs‘ŘôDV÷DWDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐ D¨ü.DâŕD‹t.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Underweight ANNYYNEGDW*DWŤDW“DWĹDXfNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BjBpCpB—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261271112612711126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22440 DV÷DäŔDWÍ.DWÍDV÷DV÷DäŔDWDČdDV÷DäŔDWDČd....Hr§‡@HrĹ˝dHr§‡@HrĹ˝d..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DäŔDČd....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NYYYNEGDW*DWŚDWÍ..NEG....YNNNNYYDV÷........DW*DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261273112612731126AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22442 DV÷Dű¸DWĘ.DWĘDV÷DV÷Dű¸DWDí¨DV÷Dű¸DWDí¨....Hr§ž8HrĹâ¨Hr§ž8HrĹâ¨..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dű¸Dí¨....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW0DWŚDWĘ..NEG....YNNNNYYDV÷........DW0DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261274112612741126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22446 DVřDŞÜDWĘ.DWĘDVřDVřDŞÜDW©EE@DVřDŞÜDWD›dDW”Dć DW©EE@Hr¨žÜHs’aÔHr¨žÜHrÂídHsv„ Hs’aÔDVřDWDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞÜD›d.Dć EE@.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDW*DWŤDW“DWĘDXfNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BjBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261275112612751126AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22690 DVřDćÜDWö.DWöDVřDVřDćÜDWFDĽ4DVřDćÜDWDń¤DW/DáDWFDĽ4Hr¨ÚÜHs…4Hr¨ÚÜHrĹć¤HrńW€Hs…4DVřDWDW/DWFAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DćÜDń¤.DáDĽ4.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW+DW/. Normal weightA NNNYPOSDW*DW*DW.DWgDWöPOS....YNNNNYNDVř........DW/.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NNDW*DWýDWýBđBBĎBÓC`B38-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1126 11261276112612761126AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22448 DVřDçDWö..DVřDVřDçDWFD»řDVřDçDWDń¤DW/Dá<DWFD»řHr¨ŰHs„řHr¨ŰHrĹć¤HrńWĽHs„řDVřDWDW/DWFAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDń¤.Dá<D»ř.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW+DW/. Overweight A0NNYYNEGDW*DW*DW.DWgDWöNEG....YNNNNYNDVř........DW/.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW*DWýDWýBđBBĎBÓC`B38-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1126 11261277112612771126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22693 DVřDďDWĘ.DWĘDVřDVřDďDW DÍŚDVřDďDW DÍŚ....Hr¨ăHrÄqHr¨ăHrÄq..DVřDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DďDÍŚ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW€DWU. Underweight ANNYYNEGDW)DWDWĘ..NEG....YNNNNYYDVř........DW)DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńBsB~C`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261278112612781126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22695 DVřDű|DWĘ.DWĘDVřDVřDű|DW DÎDVřDű|DW DÎ....Hr¨ď|HrÄq„Hr¨ď|HrÄq„..DVřDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. Dű|DÎ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW€DWU. Normal weightA NNYYNEGDW)DWDWĘ..NEG....YNNNNYYDVř........DW)DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńBsB~C`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261279112612791126AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22700 DVůD‹tDWĆ.DWĆDVůDVůD‹tDWŞD·ŔDVůD‹tDWDŮ€DW”DÇ°DWŞD·ŔHr©ĐôHs“VŔHr©ĐôHrÇ Hsve°Hs“VŔDVůDWDW”DWŞAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‹tDŮ€.DÇ°D·Ŕ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NYYYNEGDW+DWŤDW“DWĆDXgNEG....YNNNNYNDVů........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBďBBjBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261280112612801126AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22799 DVůDŚ(DWĆ.DWĆDVůDVůDŚ(DWŞD·üDVůDŚ(DWDÚpDW”DČ(DWŞD·üHr©Ń¨Hs“VüHr©Ń¨HrÇ đHsvf(Hs“VüDVůDWDW”DWŞAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ(DÚp.DČ(D·ü.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Underweight ANNYYNEGDW+DWŤDW“DWĆDXgNEG....YNNNNYNDVů........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBďBBjBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261281112612811126AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22802 DVůD¤ÄDWĚ.DWĚDVůDVůD¤ÄDWDćdDVůD¤ÄDWDćd....Hr©ęDHrÇ,äHr©ęDHrÇ,ä..DVůDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤ÄDćd....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW3DWŚDWĚ..NEG....YNNNNYYDVů........DW3DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBďB~BqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261282112612821126AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22803 DVůD«DW˝.DW˝DVůDVůD«DWD PDVůD«DWD P....Hr©đHrĹ•PHr©đHrĹ•P..DVůDW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D«D P....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Underweight ANNYYNEGDW*DWŚDW˝..NEG....YNNNNYYDVů........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261283112612831126AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22808 DVůDÉTDWÄ.DWÄDVůDVůDÉTDW¨DŃLDVůDÉTDWDÜPDW‘Dć DW¨DŃLHrŞÔHsÍLHrŞÔHrĹŃPHsr HsÍLDVůDWDW‘DW¨AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉTDÜP.Dć DŃL.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW1DWŚDWDWÄDXeNEG....YNNNNYNDVů........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261284112612841126AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22929 DVůDÓŕDWĆ.DWĆDVůDVůDÓŕDW¦DŐŔDVůDÓŕDWDÖěDW‘DŰŘDW¦DŐŔHrŞ`HsŽ.ŔHrŞ`HrĹËěHsr…XHsŽ.ŔDVůDWDW‘DW¦AĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓŕDÖě.DŰŘDŐŔ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDW*DWŚDWDWĆDXcNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261285112612851126AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22936 DVůDďDW˝.DW˝DVůDVůDďDWDŹ¬DVůDďDWDŹ¬....HrŞ5HrĹ„¬HrŞ5HrĹ„¬..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DďDŹ¬....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYNPOSDW*DWŚDW˝..POS....YNNNNYYDVů........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1126 11261286112612861126AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22937 DVůDđxDWÄ.DWÄDVůDVůDđxDWD˝`DVůDđxDWD˝`....HrŞ5řHrÎěŕHrŞ5řHrÎěŕ..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DđxD˝`....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW1DWŚDWÄ..NEG....YNNNNYYDVů........DW1DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261287112612871126AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22939 DVůDđđDWĹ.DWĹDVůDVůDđđDW©DˇDVůDđđDVůDđđDW”D§XDW©DˇHrŞ6pHs‘î„HrŞ6pHrŞ6pHsvEXHs‘î„DVů.DW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. DWNO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dđđ..D§XDˇ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW1DWŚDW“DWĹDXfPOS....YNNNNYNDVů........DW1.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWŚDWýDWýBjBqCPB”0-1 month A0-1 month A3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1126 11261288112612881126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22980 DVůDôěDWĂ.DWĂDVůDVůDôěDWD¦,DVůDôěDWD¦,....HrŞ:lHrĹ›,HrŞ:lHrĹ›,..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DôěD¦,....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW+DWŚDWĂ.. ....YNNNNNNDVů..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YYNNNY NNDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261289112612891126AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22981 DVúD»DDWÄ.DWÄDVúDVúD»DDW¨DĐ\DVúD»DDWDÍPDW‘DĐ DW¨DĐ\Hr«RDHsĚ\Hr«RDHrĹÂPHsry HsĚ\DVúDWDW‘DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWdBNT162b2 (30 (*ESC*){unicode 03BC}g).. D»DDÍP.DĐ DĐ\.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0NNYYNEGDW*DWŚDWDWÄDXeNEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBđBBmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261290112612901126AŔYEARSMANOT REPORTED ApNOT REPORTED A0 .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22984 DVúDăĐDWÍ.DWÍDVúDVúDăĐDW¨DĆŔDVúDăĐDW DĎ¨DW’DŮřDW¨DĆŔHr«zĐHsÂŔHr«zĐHrÄs(HssÔřHsÂŔDVúDW DW’DW¨AŔYEARSAŔYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DăĐDĎ¨.DŮřDĆŔ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Overweight A0YNYYNEGDW)DWŚDW‘DWÍDXeNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BlBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261291112612911126AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22983 DVúDÚčDWĚ.DWĚDVúDVúDÚčDWDŘDVúDÚčDWDŘ....Hr«qčHrÇHr«qčHrÇ..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÚčDŘ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW+DWŚDWĚ..NEG....YNNNNYYDVú........DW+DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBďB~BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261292112612921126AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23229 DVúDóüDWĹ.DWĹDVúDVúDóüDW¦D˘¨DVúDóüDWDäüDW‘D˝$DW¦D˘¨Hr«ŠüHsŤű¨Hr«ŠüHrÇ+|Hsrf¤HsŤű¨DVúDWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DóüDäü.D˝$D˘¨.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW+DWŚDWDWĹDXcNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261293112612931126AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23232 DVűD€pDWÎ.DWÎDVűDVűD€pDWDđDVűD€pDWDđ....Hr¬hđHrČHr¬hđHrČ..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. D€pDđ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWV. Obese A@YYYYNEGDW,DWŚDWÍ..NEG....YNNNNYYDVű........DW,DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261294112612941126AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23234 DVűD§DWâ..DVűDVűD§DWâD’|DVűD§DWDĽ¬DWÍD«ĚDWâD’|Hr¬ŹśHsÝ|Hr¬ŹśHrČT¬HsÁoLHsÝ|DVűDWDWÍDWâAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. D§DĽ¬.D«ĚD’|.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĂDWÍ. Overweight A0NNYYNEGDW,DWÂDWĂDXDXźNEG....YNNNNYYDVű........DW,DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÂDWýDWýBîBłB1B;C0BČ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1126 11261295112612951126AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23239 DVűDÁ\DWÄ.DWÄDVűDVűDÁ\DWDŰ$DVűDÁ\DWDŰ$....Hr¬©ÜHrČs$Hr¬©ÜHrČs$..DVűDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DÁ\DŰ$....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NYYYNEGDW,DWŚDWÄ..NEG....YNNNNYYDVű........DW,DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261296112612961126AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23452 DVűDŰ$DW.DWDVűDVűDŰ$DW|DÖtDVűDŰ$DWDŢ¨DWiD•ÄDW|DÖtHr¬Ă¤HsVĐtHr¬Ă¤HrČv¨Hs=DHsVĐtDVűDWDWiDW|AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰ$DŢ¨.D•ÄDÖt.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWhDWi. Normal weightA NNYYNEGDW,DWgDWhDWDX9NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWgDWýDWýBîBXB•B–C0Bm8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1126 11261297112612971126AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23453 DVűDÚčDWË.DWËDVűDVűDÚčDW¨DßDVűDÚčDWDß DW“DépDW¨DßHr¬ĂhHsŰHr¬ĂhHrČw Hsu5đHsŰDVűDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚčDß .DépDß.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW,DWŚDW’DWËDXeNEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BkBqC0B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261298112612981126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23454 DVűDäŔDWľ.DWľDVűDVűDäŔDWDě¸DVűDäŔDWDě¸....Hr¬Í@HrÇ38Hr¬Í@HrÇ38..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. DäŔDě¸....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWO. Underweight ANNYYNEGDW1DWŚDWľ..NEG....YNNNNYYDVű........DW1DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBďB~BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261299112612991126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23455 DVţD°DWĐ.DWĐDVţDVţD°DWDŘĚDVţD°DWDŘĚ....Hr°ŤHrÍ¶ĚHr°ŤHrÍ¶Ě..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. D°DŘĚ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWY. Normal weightA NNYYNEGDW0DWŚDWĐ..NEG....YNNNNYYDVţ........DW0DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261300112613001126AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23963 DV˙DwDWĆ.DWĆDV˙DV˙DwDWŞDÓ,DV˙DwDWDn(DW“D‰XDWŞDÓ,Hr±¦Hs“r,Hr±¦HrËú¨HstŐŘHs“r,DV˙DWDW“DWŞAĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DwDn(.D‰XDÓ,.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW/DWŚDW’DWĆDXgNEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBkBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261301112613011126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23967 DV˙D˝ŘDWĹ.DWĹDV˙DV˙D˝ŘDWDŢ0DV˙D˝ŘDWDŢ0....Hr±ěXHrĐ_0Hr±ěXHrĐ_0..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D˝ŘDŢ0....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Normal weightA NNYYNEGDW3DWŚDWĹ..NEG....YNNNNYYDV˙........DW3DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1126 11261302112613021126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23968 DWDŔäDWĆ..DWDWDŔäDWŞDĹ”DWDŔäDWDÎDW•Dă”DWŞDĹ”Hrł@äHs“d”Hrł@äHrŮ‰„HswÓHs“d”DWDWDW•DWŞAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔäDÎ.Dă”DĹ”.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW9DWŚDW”DWĆDXg ....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBáBpBiBqBţBŤ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1126 11261303112613031126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23971 DWDťřDWÉ.DWÉDWDWDťřDWDăXDWDťřDWDăX....Hr»řHrŐŞXHr»řHrŐŞX..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. DťřDăX....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW DWd. Obese A@YNYYNEGDW7DWźDW×..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWźDWýDWýBäB†B^BřBš8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1126 11261304112613041126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24671 DWDźśDWÉ.DWÉDWDWDźśDWDăĐDWDźśDWDăĐ....Hr»śHrŐŞĐHr»śHrŐŞĐ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. DźśDăĐ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW DWd. Normal weightA NYYYNEGDW7DWźDW×..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWźDWýDWýBäB†B^BřBš8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1126 11261305112613051126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24674 DWDŁ\DWr..DWDWDŁ\DWTD‘DWDŁ\DWDČ(DW?DŁ DWTD‘HrĽ]ÜHs!ĎHrĽ]ÜHrŮ¨Hs1 Hs!ĎDWDWDW?DWTAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ\DČ(.DŁ D‘.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DW?. Normal weightA NNYYNEGDW<DW<DW>DWrDXNEG....YNNNNYNDW........DW?.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW<DWýDWýBáB BżBÁB÷B68-9 months A1-2 months A 6-7 monthsAp8-9 months A . ...C4591001C4591001 1126 11261306112613061126AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24677 DWD¤DWĂ.DWĂDWDWD¤DW§D‰DWD¤DWDÇ°DW’DŚÜDW§D‰HrĽ^HsŹ3śHrĽ^HrŮ0Hss‡ÜHsŹ3śDWDWDW’DW§AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤DÇ°.DŚÜD‰.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW?DWŚDW‘DWĂDXdNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBlBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261307112613071126AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24680 DWDçDWŇ.DWŇDWDWDçDW!DŐHDWDçDW!DŐH....HrĂ9HrŢÖČHrĂ9HrŢÖČ..DWDW!..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DçDŐH....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Overweight A0NNYYNEGDW=DWŚDWŇ..NEG....YNNNNYYDW........DW=DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261308112613081126AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25330 DWDčDDWâ.DWâDWDWDčDDWĆD¸°DWDčDDW!DŐHDW±D‰XDWĆD¸°HrĂ:DHs¸A°HrĂ:DHrŢÖČHsśbŘHs¸A°DWDW!DW±DWĆAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDŐH.D‰XD¸°.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW±. Normal weightA NNYYNEGDW=DWŚDW°DWâDXNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBMBqBňB7-8 months A€3-4 months A@2-3 monthsA08-9 months A . ...C4591001C4591001 1126 11261309112613091126AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25331 DWDčřDWĺ.DWĺDWDWDčřDW!DŐüDWDčřDW!DŐü....HrĂ:řHrŢ×|HrĂ:řHrŢ×|..DWDW!..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DčřDŐü....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Normal weightA NNYYNEGDW=DWŚDWŇ..NEG....YNNNNYYDW........DW=DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261310112613101126AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25333 DW D’DWŃ..DW DW D’DW"DšěDW D’DW"Dšě....HrÄ5„HrßíěHrÄ5„Hrßíě..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. D’Dšě....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŃDWp. Obese A@YNYYNEGDWADWĐDWŃ..NEG....YNNNNYYDW ........DWADWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĐDWýDWýBÜBŻB-BńBÄ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1126 11261311112613111126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25338 DW DŐ„DWÓ.DWÓDW DW DŐ„DW´D‡´DW DŐ„DW#DÄŕDWˇDĺ8DW´D‡´HrÄyHs U´HrÄyHrái`Hs‡¦¸Hs U´DW DW#DWˇDW´AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐ„DÄŕ.Dĺ8D‡´.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DWˇ. Overweight A0YNYYNEGDW?DW’DW DWÓDXqNEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpB]BkBńB†7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261312112613121126AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25593 DW DÝDWÉ.DWÉDW DW DÝDW¨D‡đDW DÝDW!DÔXDW’D´xDW¨D‡đHrÄ€„HsđHrÄ€„HrŢŐŘHssŻxHsđDW DW!DW’DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝDÔX.D´xD‡đ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW=DWŚDW‘DWÉDXeNEG....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBlBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261313112613131126AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25600 DWDĚ$DW×.DW×DWDWDĚ$DW$D×dDWDĚ$DW$D×d....HrĹÁ$HrâÍdHrĹÁ$HrâÍd..DWDW$..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĚ$D×d....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWFDWŚDW×..NEG....YNNNNYYDW........DWFDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261314112613141126AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25599 DWDÉDWÄ.DWÄDWDWDÉDW¦DăXDWDÉDW%DÚčDW“D¦ŕDW¦DăXHrĹľHsŽpUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25603 DWDúPDWÔ.DWÔDWDWDúPDW%DĹXDWDúPDW%DĹX....HrĹďPHräŘHrĹďPHräŘ..DWDW%..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DúPDĹX....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Underweight ANNYYNEGDWADWŚDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261316112613161126AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25942 DWD‹8DWÔ.DWÔDWDWD‹8DW#DtôDWD‹8DW#Dtô....HrĆŃ¸HrátHrĆŃ¸Hrát..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹8Dtô....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW1.. Normal weightA NNYYNEGDW0DW0DWÔ..NEG....YNNNNYYDW........DW?DWÔYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDW0DWýDWýBŰAŕBÍBďB"7-8 months A€0-1 month A0-1 month A8-9 months A . ...C4591001C4591001 1126 11261317112613171126AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25943 DWD‹ěDWú.DWúDWDWD‹ěDW¨DŢlDWD‹ěDW#Du¨DW‘D“0DW¨DŢlHrĆŇlHsÚlHrĆŇlHrá(Hsr<°HsÚlDWDW#DW‘DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‹ěDu¨.D“0DŢl.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDW?DWŚDWDWÉDXeNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261318112613181126AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25949 DWDşTDWô..DWDWDşTDWôDă”DWDşTDW#DÝDWáD…DWôDă”HrÇÔHső”HrÇÔHrá„HsŰ§Hső”DWDW#DWáDWôAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DşTDÝ.D…Dă”.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWáDWá. Underweight ANYYYNEGDW@DWŕDWŕDXDX±NEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŕDWýDWýBŰBľBBBďBŇ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1126 11261319112613191126AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25950 DWD× DWŕ.DWŕDWDWD× DW#D¦ŕDWD× DW#D¦ŕ....HrÇ HráK`HrÇ HráK`..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. D× D¦ŕ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWV. Overweight A0YNYYNEGDW?DWŚDWŕ..NEG....YNNNNYYDW........DW?DWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261320112613201126AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26133 DWDíäDWĂ.DWĂDWDWDíäDW§DĆ„DWDíäDW$D»DDW’DĐ DW§DĆ„HrÇ4dHsŹqHrÇ4dHrâ±DHssË HsŹqDWDW$DW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DíäD»D.DĐ DĆ„.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW@DWŚDW‘DWĂDXdNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBlBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261321112613211126AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26136 DWDűôDWÓ.DWÓDWDWDűôDW$DäDWDűôDW$Dä....HrÇBtHrâÚHrÇBtHrâÚ..DWDW$..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DűôDä....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWY. Underweight ANNYYNEGDWDDWŤDWÓ..NEG....YNNNNYYDW........DWDDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBďB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261322112613221126AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26138 DWDülDWÉ.DWÉDWDWDülDWDhDWDülDW$DăĐDWDëŚDWDhHrÇBěHs—čHrÇBěHrâŮĐHs{ĎŚHs—čDWDW$DWDWAĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DülDăĐ.DëŚDh.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANYYYNEGDWDDWŤDW—DWÉDXjNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBfBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1126 11261323112613231126AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26141 DWDëČDW×.DW×DWDWDëČDW$DëČDWDëČDW$DëČ....HrČČHrâáČHrČČHrâáČ..DWDW$..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. DëČDëČ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWY. Normal weightA NNYYNEGDWDDWŚDW×.. ....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNYY NNDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261324112613241126AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26421 DWDě@DW×.DW×DWDWDě@DW$DëPDWDě@DW$DëP....HrČ„@HrâáPHrČ„@HrâáP..DWDW$..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. Dě@DëP....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWY. Normal weightA NNYYNEGDWDDWŚDW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNYY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1126 11261325112613251126AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26422 DWDőÜDWĂ.DWĂDWDWDőÜDW§DÇ°DWDőÜDW%DăĐDW’DĆHDW§DÇ°HrČŤÜHsŹr0HrČŤÜHrä+PHssÁHHsŹr0DWDW%DW’DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DőÜDăĐ.DĆHDÇ°.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDWEDWŚDW‘DWĂDXdNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBlBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311275113112751131AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20973 DVíDž¬DWű.DWűDVíDVíDž¬DWD¬DVíDž¬DWD¬....Hrš,Hrł-¬Hrš,Hrł-¬..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW! .. Dž¬D¬....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW!. Normal weightA NNYYNEGDWDWŤDW´..NEG....YNNNNYYDVí........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBţBŽBpCBˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1131 11311277113112771131AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń20974 DVńD°@DWľ.DWľDVńDVńD°@DWD·„DVńD°@DWD·„....HrźiŔHr» „HrźiŔHr» „..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D°@D·„....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Underweight ANNYYNEGDW"DWľDWľ..NEG....YNNNNYYDVń........DW"DWľYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýBřBř..CĐCĐ8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1131 11311278113112781131AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń20977 DVńDň”DW».DW»DVńDVńDň”DWDÖěDVńDň”DWDÖě....Hrź¬HrĽ‘lHrź¬HrĽ‘l..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. Dň”DÖě....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Underweight ANNYYNEGDW#DWŤDW»..NEG....YNNNNYYDVń........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýB÷B‡BpCĐBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1131 11311280113112801131AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú20978 DVúE,DWý.DWýDVúDVúE,DWßD–´DVúE,DWDń¤DWĹDé4DWßD–´Hr«™ŔHsŮ4Hr«™ŔHrÇ8$Hs· ´HsŮ4DVúDWDWĹDWßAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. E,Dń¤.Dé4D–´.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĹDWĹ. Underweight ANNYYNEGDW+DWÄDWÄDWýDXśPOS....YNNNNYYDVú........DW+DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWÄDWýDWýBďB¶B9B9C@BË8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ..DWC4591001C4591001 1131 11311281113112811131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23841 DVţDćdDWĆ.DWĆDVţDVţDćdDWDäŔDVţDćdDWDäŔ....Hr°ĂdHrĚq@Hr°ĂdHrĚq@..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DćdDäŔ....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW/. Obese A@YNYYNEGDW/DWDWĆ..NEG....YNNNNYYDVţ........DW/DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBëB~BmCB“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1131 11311282113112821131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23845 DV˙DšěDWĘ.DWĘDV˙DV˙DšěDWDÉDV˙DšěDWDÉ....Hr±ÉlHrĐJHr±ÉlHrĐJ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DšěDÉ....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW3DW%. Overweight A0NNYYNEGDW2DW2DWĘ..NEG....YNNNNYYDV˙........DW2DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW2DWýDWýBčBBËB˙B48-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1131 11311283113112831131AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23847 DV˙DîÔDWÍ.DWÍDV˙DV˙DîÔDW°DčřDV˙DîÔDWDčřDWšD×dDW°DčřHr˛THs›přHr˛THrĚuxHs~^dHs›přDV˙DWDWšDW°AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DîÔDčř.D×dDčř.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DWš. Normal weightA NNYYNEGDW6DWDW™DWÍDXmNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBëB~BdBmB˙B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1131 11311285113112851131AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23850 DWDĄ´DWŕ.DWŕDWDWDĄ´DWÄDĘ€DWDĄ´DWD× DWDÎôDWÄDĘ€Hrł%´Hsµ°€Hrł%´HrŃŞ Hs—btHsµ°€DWDWDWDWÄAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄ´D× .DÎôDĘ€.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW. Underweight ANNYYNEGDW3DW‘DW¬DWŕDXNEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBçB{BQBlBţB’8-9 months A4-5 months AP2-3 monthsA09-10 months A . ...C4591001C4591001 1131 11311286113112861131AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24573 DWD” DWÉ.DWÉDWDWD” DWD ŚDWD” DWD Ś....Hrşý HrŐgŚHrşý HrŐgŚ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D” D Ś....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW6. Underweight ANNYYNEGDW6DW‘DWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBäBxBlBřBŚ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1131 11311287113112871131AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24580 DWD˘äDWË..DWDWD˘äDWŻD™DWD˘äDWD»€DW™D»DDWŻD™Hr»äHs™ĎŚHr»äHrŐ‚€Hs|đÄHs™ĎŚDWDWDW™DWŻAŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘äD»€.D»DD™.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW™. Normal weightA NNYYNEGDW6DW’DWDWËDXlNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBäByBeBkBřBŤ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311288113112881131AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24581 DWDŁ\DWË.DWËDWDWDŁ\DWŻDĐDWDŁ\DWD»ĽDW™D»ĽDWŻDĐHr»\Hs™ĎPHr»\HrŐ‚ĽHs|ń<Hs™ĎPDWDWDW™DWŻAŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ\D»Ľ.D»ĽDĐ.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW™. Normal weightA NNYYNEGDW6DW’DWDWËDXlNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBäByBeBkBřBŤ8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311289113112891131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24583 DWD®$DWű.DWűDWDWD®$DWDŽDDWD®$DWDŽD....HrĽh¤HrŮIÄHrĽh¤HrŮIÄ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®$DŽD....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Underweight ANNYYNEGDW=DWDWŮ..NEG....YNNNNYYDW........DW=DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBáBtBmB÷BŠ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1131 11311290113112901131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24938 DWDłDWË.DWËDWDWDłDWDďDWDłDWDď....HrĽnHrŘYHrĽnHrŘY..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. DłDď....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW>DWËDWË..NEG....YNNNNYYDW........DW>DWËYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBâBâ..B÷B÷8-9 months A8-9 months A .8-9 months A . ...C4591001C4591001 1131 11311291113112911131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24939 DWDĎlDWË.DWËDWDWDĎlDWDŽĽDWDĎlDWDŽĽ....HrĽ‰ěHr×řĽHrĽ‰ěHr×řĽ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DĎlDŽĽ....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWqDW#. Normal weightA NNYYNEGDW8DWpDWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWpDWýDWýBâBUBŤB÷Bj8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1131 11311292113112921131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24940 DWDâ,DWú.DWúDWDWDâ,DWúD±lDWDâ,DWDDŰ`DWúD±lDWúD±lHrĂ4,HsüČlHrĂ4,Hs `HsüČlHsüČlDWDWDDWú.AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NY YDWb .. Dâ,DŰ`.D±l..220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW÷DWú. Overweight A0NNYYNEGDWbDWöDWůDX4DXÎNEG....YNNNNYYDW........DWbDWúYY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWöDWýDWýBşBłA@ApBňBë6-7 months Ap6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1131 11311293113112931131AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24944 DWDóŔDWý.DWýDWDWDóŔDWßD–<DWDóŔDW"Dî\DWĘDŽDWßD–<HrĂEŔHsŮĽHrĂEŔHrŕA\Hs˝]HsŮĽDWDW"DWĘDWßAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DóŔDî\.DŽD–<.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĆDWĘ. Underweight ANNYNPOSDW@DWĹDWÉDWýDXśPOS....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWĹDWýDWýBÜB¤B4B8BňBş7-8 months A€5-6 months A`1-2 monthsA 8-9 months A . ..DW"C4591001C4591001 1131 11311294113112941131AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25581 DW EŔDWŃ.DWŃDW DW EŔDW"DöDW EŔDW"Dö....HrÄŁ¬HrŕIHrÄŁ¬HrŕI..DW DW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. EŔDö....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Underweight ANNYYNEGDWADWŃDWŃ..NEG....YNNNNYYDW ........DWADWŃYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBÜBÜ..BńBń7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1131 11311295113112951131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25585 DWDĆ„DWÉ.DWÉDWDWDĆ„DWD×dDWDĆ„DW$DÇtDW’DŰ`DWD×dHrÇ Hs—jäHrÇ Hrâ˝tHssÖ`Hs—jäDWDW$DW’DWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆ„DÇt.DŰ`D×d.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW’. Normal weightA NNYYNEGDWDDWDW‘DWÉDXjNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBÚBmBlBmBďB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311296113112961131AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25588 DWD¤DWś.DWśDWDWD¤DW€DŻDWD¤DW#D°ôDWkD©ěDW€DŻHrČ<Hs[ďHrČ<HráUtHs@:lHs[ďDWDW#DWkDW€AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤D°ô.D©ěDŻ.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWgDWk. Normal weightA NNYYNEGDW?DWfDWjDWśDX=NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWfDWýDWýBŰBDB“B—BîBW7-8 months A€2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1131 11311297113112971131AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25590 DWD¤ÄDWŢ.DWŢDWDWD¤ÄDW#D±0DWD¤ÄDW#D±0....HrČ<ÄHráU°HrČ<ÄHráU°..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D¤ÄD±0....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW#. Normal weightA NNYYNEGDW?DWDWŢ..NEG....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŰBnBmBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1131 11311298113112981131AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26303 DWD¤ÄDWÔ.DWÔDWDWD¤ÄDW%DÜČDWD¤ÄDW%DÜČ....HrČ<ÄHrä$HHrČ<ÄHrä$H..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤ÄDÜČ....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDWHDWDWÔ..NEG....YNNNNYYDW........DWHDWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŮBlBmBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1131 11311299113112991131AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26304 DWDůśDWű..DWDWDůśDW©D–<DWDůśDW%DňXDW”Dż¸DW©D–<HrČ‘śHs‘ăĽHrČ‘śHrä9ŘHsv]¸Hs‘ăĽDWDW%DW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DůśDňX.Dż¸D–<.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Normal weightA NNYYNEGDWFDWDW“DWĹDXfNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBŮBlBjBmBîB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311300113113001131AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26306 DWDúDWĹ..DWDWDúDW©D–´DWDúDW%Dň”DW”Dż|DW©D–´HrČ’Hs‘ä4HrČ’Hrä:Hsv]|Hs‘ä4DWDW%DW”DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DúDň”.Dż|D–´.220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW”. Normal weightA NNYYNEGDWFDWDW“DWĹDXfNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBŮBlBjBmBîB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1131 11311301113113011131AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26309 DWDĐDWĺ.DWĺDWDWDĐDW,DĆHDWDĐDW,DĆH....HrĚ]HríHHHrĚ]HríHH..DWDW,..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW! .. DĐDĆH....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW!. Underweight ANNYYNEGDWODW‘DWĺ..NEG....YNNNNYYDW........DWODWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŇBfBlBëB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1131 11311302113113021131AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26710 DWDúŚDWá.DWáDWDWDúŚDW(DśĚDWDúŚDW(DśĚ....HrĚ‡HrçŘĚHrĚ‡HrçŘĚ..DWDW(..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0DWáOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DúŚDśĚ....220331 Randall, William ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWD. Underweight ANNYYNEGDWDDW‘DWŰ..NEG....YNNNNYYDW........DWDDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWáDWáBşBjBPBĎB6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1139 11391144113911441139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22092 DVôDŢäDW·.DW·DVęDVôDŢäDWD»€DVôDŢäDWD»€....HrŁŚäHrĽvHrŁŚäHrĽv..DVôDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DŢäD»€....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW#. Underweight ANNYYNEGDW#DW‹DW·..NEG....YNNNNYYDVô........DW#DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýB÷B…BrC B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391145113911451139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20472 DVęD˘lDWĽ.DWĽDVęDVęD˘lDVţDşDVęD˘lDVţDş....Hr–!lHr°—Hr–!lHr°—..DVęDVţ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. D˘lDş....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW%. Underweight ANNYYNEGDWDW‹DWĽ..NEG....YNNNNYYDVę........DWDWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýCBŽBrC@B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1139 11391151113911511139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20475 DVíDË4DW±.DW±DVíDVíDË4DWD¬DDVíDË4DWD¬D....Hrš>´Hrł,DHrš>´Hrł,D..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DË4D¬D....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWDWŚDW±..NEG....YNNNNYYDVí........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBţBŤBqCB 9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1139 11391152113911521139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20476 DVíDôěDWľ.DWľDVíDVíDôěDW˘DÁ\DVíDôěDWDŮřDWŤDŔ¨DW˘DÁ\HršhlHsÔ\HršhlHrąńxHsm$(HsÔ\DVíDWDWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DôěDŮř.DŔ¨DÁ\.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW#DW‹DWŚDWľDX_NEG....YNNNNYNDVí........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCBź8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391154113911541139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20479 DVíD÷DWľ.DWľDVíDVíD÷DW˘Dĺ°DVíD÷DWDßÔDWŤD·üDW˘Dĺ°HršjHsř°HršjHrą÷THsm|Hsř°DVíDWDWŤDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷DßÔ.D·üDĺ°.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Underweight ANNYYNEGDW%DW‹DWŚDWľDX_NEG....YNNNNYNDVí........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BqBrCBź8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391155113911551139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí21025 DVíD÷řDWí.DWíDVíDVíD÷řDWDŘĚDVíD÷řDWDŘĚ....HrškxHrąđLHrškxHrąđL..DVíDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. D÷řDŘĚ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW:DW%. Normal weightA NNYYNEGDW%DW9DWĹ..NEG....YNNNNYYDVí........DW%DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW9DWýDWýBůB5BÄCBM8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1139 11391156113911561139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21026 DVđD›dDWµ.DWµDVđDVđD›dDWDŮřDVđD›dDWDŮř....HrždHr»BřHrždHr»Bř..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. D›dDŮř....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW(. Normal weightA NNYYNEGDW(DW‹DWµ..NEG....YNNNNYYDVđ........DW(DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBřB†BrCŕBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391157113911571139AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21027 DVńD ŚDW„.DW„DVńDVńD ŚDWhDşTDVńD ŚDWD·üDWRDż¸DWhDşTHrźZHs BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21031 DVńD×(DWľ.DWľDVńDVńD×(DW˘DČ(DVńD×(DWD¸ěDWŽDż¸DW˘DČ(Hrź¨HsŰ(Hrź¨Hr»!ěHsnt¸HsŰ(DVńDWDWŽDW˘AĐYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D×(D¸ě.Dż¸DČ(.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW"DW‹DWŤDWľDX_NEG....YNNNNYNDVń........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BpBrCĐB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391159113911591139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21387 DVńDŇxDWč.DWčDVńDVńDŇxDW©DłLDVńDŇxDWD˛ÔDW”D»€DW©DłLHrź‹řHs’ĚHrź‹řHr»ÔHsvY€Hs’ĚDVńDWDW”DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇxD˛Ô.D»€DłL.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW%DWŚDW“DWčDXfNEG....YNNNNYNDVń........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BjBqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391161113911611139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21389 DVńDâ¤DW¶.DW¶DVńDVńDâ¤DWD¬řDVńDâ¤DWD¬ř....Hrźś$Hr»řHrźś$Hr»ř..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. Dâ¤D¬ř....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Normal weightA NNYYNEGDW(DWŚDW¶..NEG....YNNNNYYDVń........DW(DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391162113911621139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21391 DVńDă”DWµ.DWµDVńDVńDă”DWDĽpDVńDă”DWDĽp....HrźťHr»%pHrźťHr»%p..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. Dă”DĽp....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW0DW(. Normal weightA NNYYNEGDW(DW/DWµ..NEG....YNNNNYYDVń........DW(DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW/DWýDWýBřB*BÎCĐB?8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1139 11391163113911631139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21392 DVńDä„DWĹ.DWĹDVńDVńDä„DWŁDÔXDVńDä„DWD˝$DWŽDŇDWŁDÔXHrźžHsŠ8ŘHrźžHr»&$Hsn‡HsŠ8ŘDVńDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dä„D˝$.DŇDÔX.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW(DW‹DWŤDWĹDX`NEG....YNNNNYNDVń........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BpBrCĐB›8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391165113911651139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22089 DVôDŕÄDW§.DW§DVôDVôDŕÄDWDÉDVôDŕÄDWDÉ....HrŁŽÄHrĽHrŁŽÄHrĽ..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DŕÄDÉ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW1. Normal weightA NNYYNEGDW*DWŚDW§..NEG....YNNNNYYDVô........DW*DW§YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391166113911661139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22094 DVôDâhDWp..DVôDVôDâhDWND»DDVôDâhDWDĚ`DW7D±¨DWND»DHrŁhHsDHrŁhHrĽ†ŕHrű´(HsDDVôDWDW7DWNAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DâhDĚ`.D±¨D»D.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW/DW7. Normal weightA NNYYNEGDW.DW.DW6DWpDXNEG....YNNNNYNDVô........DW0.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW.DWýDWýB÷B(BÇBĎC B;8-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1139 11391168113911681139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22097 DVôDä„DWč.DWčDVôDVôDä„DW©DäŔDVôDä„DWDŕDW”Dż¸DW©DäŔHrŁ’„Hs’2@HrŁ’„HrĽ›Hsv]¸Hs’2@DVôDWDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dä„Dŕ.Dż¸DäŔ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW(DWŚDW“DWčDXfNEG....YNNNNYNDVô........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB÷B†BjBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391169113911691139AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVř22485 DVřDťĽDWĹ.DWĹDVřDVřDťĽDWD¶”DVřDťĽDWD¶”....Hr¨‘ĽHrĐ7”Hr¨‘ĽHrĐ7”..DVřDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DťĽD¶”....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW8. Normal weightA NNYYNEGDW8DWŚDWĹ..NEGDW‹.DW‹DW‹YNNNNYYDVř........DW8DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBčBwBqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391170113911701139AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22486 DVřDžčDWĹ.DWĹDVřDVřDžčDWD¶”DVřDžčDWD¶”....Hr¨’čHrĐ7”Hr¨’čHrĐ7”..DVřDW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DžčD¶”....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW8. Overweight A0YNYYNEGDW8DWŚDWĹ..NEG....YNNNNYYDVř........DW8DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBčBwBqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391171113911711139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVř22487 DVřD PDW÷.DW÷DVřDVřD PDW D˛ÔDVřD PDW D˛Ô....Hr¨”PHrÄVTHr¨”PHrÄVT..DVřDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. D PD˛Ô....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDWM. Underweight ANNYYNEGDWMDWŚDW÷..NEGDW“.DW“DW“YNNNNYYDVř........DWMDW÷YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391172113911721139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22494 DVřDŢ0DWź.DWźDVřDVřDŢ0DW D±0DVřDŢ0DW D±0....Hr¨Ň0HrÄT°Hr¨Ň0HrÄT°..DVřDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DŢ0D±0....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Underweight ANNYYNEGDW/DWŚDWĘ..NEG....YNNNNYNDVř........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391173113911731139AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22598 DVřDô°DWÍ.DWÍDVřDVřDô°DWDđ<DVřDô°DWDđ<....Hr¨č°HrÇ6ĽHr¨č°HrÇ6Ľ..DVřDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. Dô°Dđ<....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DW1. Overweight A0YNYYNEGDW1DWŻDWÍ..NEG....YNNNNYYDVř........DW1DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŻDWýDWýBďBˇBNC`B¸8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1139 11391174113911741139AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22599 DVřDő DWî.DWîDVřDVřDő DWÍDĘDVřDő DWDń,DW±Dą(DWÍDĘHr¨é HsÁŤHr¨é HrÇ7¬Hsś’¨HsÁŤDVřDWDW±DWÍAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dő Dń,.Dą(DĘ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW°DW±. Overweight A0NYYYNEGDW1DWŻDW°DWîDXŠNEG....YNNNNYNDVř........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŻDWýDWýBďBˇBMBNC`B¸8-9 months A5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1139 11391175113911751139AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22595 DVřDň”DWľ.DWľDVřDVřDň”DW˘D°@DVřDň”DW DęŘDWŽDÇ8DW˘D°@Hr¨ć”HsĂ@Hr¨ć”HrÄŽXHsn|8HsĂ@DVřDW DWŽDW˘AŕYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dň”DęŘ.DÇ8D°@.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NYYYNEGDW)DW‹DWŤDWľDX_NEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBńBBpBrC`B”8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391177113911771139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22602 DVúD¦hDWĐ..DVúDVúD¦hDWDČdDVúD¦hDWDČd....Hr«=hHrŃšäHr«=hHrŃšä..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. D¦hDČd....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW3. Normal weightA NNYYNEGDW3DWŚDWĐ..NEG....YNNNNYYDVú........DW3DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBçBvBqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391178113911781139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23293 DVűD¶XDW÷.DW÷DVűDVűD¶XDWDß DVűD¶XDWDß ....Hr¬žŘHrČw Hr¬žŘHrČw ..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D¶XDß ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW,. Normal weightA NNYYNEGDW,DWŤDWÉ..NEG....YNNNNYYDVű........DW,DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391179113911791139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23295 DVűDÓ¤DWř.DWřDVűDVűDÓ¤DWDÜPDVűDÓ¤DWDÜP....Hr¬Ľ$HrČtPHr¬Ľ$HrČtP..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DÓ¤DÜP....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW,. Normal weightA NNYYNEGDW,DW‹DWÉ..NEG....YNNNNYYDVű........DW,DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBîB|BrC0B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391180113911801139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23297 DVűD× DWÄ.DWÄDVűDVűD× DW˘D4DVűD× DWDóDWŽD´DW˘D4Hr¬Ŕ HsŔ4Hr¬Ŕ HrÇ9ŚHsniHsŔ4DVűDWDWŽDW˘AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. D× Dó.D´D4.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW/DWŚDWŤDWÄDX_NEG....YNNNNYNDVű........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BpBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391181113911811139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23299 DVűDÓhDWj..DVűDVűDÓhDWKD·HDVűDÓhDWDĘDDW6D·üDWKD·HHr¬»čHsČHr¬»čHrÇÄHrúhüHsČDVűDWDW6DWKAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓhDĘD.D·üD·H.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW0DW6. Normal weightA NYYYNEGDW*DW/DW5DWjDXNEG....YNNNNYNDVű........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW/DWýDWýBďB!BČBÎC0B58-9 months A1-2 months A 7-8 monthsA€9-10 months A . ...C4591001C4591001 1139 11391182113911821139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23338 DVűDŮDDWĹ.DWĹDVűDVűDŮDDWŁDpDVűDŮDDWDËčDWŽDµhDWŁDpHr¬ÁÄHsŠđHr¬ÁÄHrČcčHsnjhHsŠđDVűDWDWŽDWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDDËč.DµhDp.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW3DWŚDWŤDWĹDX`NEG....YNNNNYNDVű........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BpBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391183113911831139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23339 DVűDî DWĚ..DVűDVűDî DWDĹĐDVűDî DWDĹĐ....Hr¬Ö HrČ]ĐHr¬Ö HrČ]Đ..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. Dî DĹĐ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Normal weightA NNYYNEGDW,DWŚDWĚ..NEG....YNNNNYYDVű........DW,DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391185113911851139AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23342 DVűDďDWÄ.DWÄDVűDVűDďDW˘D®śDVűDďDWDÄ,DWŤD±¨DW˘D®śHr¬×HsÁśHr¬×HrÍ˘,Hsm(HsÁśDVűDWDWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďDÄ,.D±¨D®ś.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW1DWŚDWŚDWÄDX_NEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBqBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391186113911861139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23343 DVţD§DWĆ.DWĆDVţDVţD§DWDĐÔDVţD§DWDĐÔ....Hr°„HrĚ]THr°„HrĚ]T..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. D§DĐÔ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW3. Underweight ANNYYNEGDW3DWŚDWĆ..NEG....YNNNNYYDVţ........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391187113911871139AŕYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23565 DVţD¨HDWč.DWčDVţDVţD¨HDWŞDµhDVţD¨HDWDŰ$DW•D¶DWŞDµhHr°…HHs“ThHr°…HHrÍą$HswĄśHs“ThDVţDWDW•DWŞAŕYEARSAđYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨HDŰ$.D¶Dµh.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW0DWŚDW”DWčDXgNEG....YNNNNYNDVţ........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBiBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391188113911881139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23569 DVţD¬DDWĐ.DWĐDVţDVţD¬DDWDŮDDVţD¬DDWDŮD....Hr°‰DHrÍ·DHr°‰DHrÍ·D..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D¬DDŮD....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW6. Normal weightA NNYYNEGDW6DW‹DWĐ..NEG....YNNNNYYDVţ........DW6DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391189113911891139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23572 DVţDä„DWŤ.DWŤDVţDVţDä„DWDËpDVţDä„DWDËp....Hr°Á„HrĚWđHr°Á„HrĚWđ..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWŤWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dä„DËp....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Underweight ANNYYNEGDW1DW‹DWĐ..NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWŤDWŤB{ByA BBŽ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1139 11391190113911901139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23734 DVţDč€DWĚ.DWĚDVţDVţDč€DWDÖ°DVţDč€DWDÖ°....Hr°Ĺ€HrĚc0Hr°Ĺ€HrĚc0..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dč€DÖ°....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW1DWŚDWĚ..NEG....YNNNNYYDVţ........DW1DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391191113911911139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23737 DVţDé¬DWĚ.DWĚDVţDVţDé¬DWD× DVţDé¬DWD× ....Hr°Ć¬HrĚd Hr°Ć¬HrĚd ..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. Dé¬D× ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW1. Underweight ANNYYNEGDW1DWŚDWĚ..NEG....YNNNNYYDVţ........DW1DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391192113911921139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23575 DVţDçTDWË.DWËDVţDVţDçTDWDÍPDVţDçTDWDÍP....Hr°ÄTHrĚYĐHr°ÄTHrĚYĐ..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DçTDÍP....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW1. Underweight ANYYYNEGDW1DWŚDWË..NEG....YNNNNYYDVţ........DW1DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391193113911931139AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23733 DVţDĺěDWľ.DWľDVţDVţDĺěDW˘DÓ¤DVţDĺěDWDÎ|DWŤDÓŕDW˘DÓ¤Hr°ÂěHsć¤Hr°ÂěHrĚZüHsm7`Hsć¤DVţDWDWŤDW˘AŔYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĺěDÎ|.DÓŕDÓ¤.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW1DWŚDWŚDWľDX_NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBqBqCBŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391195113911951139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23740 DVţDëDWŘ.DWŘDVţDVţDëDWŞD±lDVţDëDWD©tDWŽDěôDWŞD±lHr°ČHs“PlHr°ČHrĚ5ôHsnˇôHs“PlDVţDWDWŽDWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëD©t.DěôD±l.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW1DW‹DWŤDWŘDXgNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391196113911961139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23770 DVţDě|DWŘ.DWŘDVţDVţDě|DW˘DÁ\DVţDě|DWD©tDWŽDâ,DW˘DÁ\Hr°É|HsÔ\Hr°É|HrĚ5ôHsn—,HsÔ\DVţDWDWŽDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě|D©t.Dâ,DÁ\.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANYYYNEGDW1DW‹DWŤDWŘDX_NEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBëByBpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1139 11391197113911971139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23774 DV˙D©ěDWÉ.DWÉDV˙DV˙D©ěDWDâ,DV˙D©ěDWDâ,....Hr±ŘlHrÍŔ,Hr±ŘlHrÍŔ,..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D©ěDâ,....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW2. Normal weightA NNYYNEGDW2DWŚDWÉ..NEG....YNNNNYYDV˙........DW2DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391198113911981139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23776 DV˙D§”DWé.DWéDV˙DV˙D§”DWŞD˝$DV˙D§”DWDŐüDW•DŘDWŞD˝$Hr±ÖHs“\$Hr±ÖHrŮ‘|HswČHs“\$DV˙DWDW•DWŞAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§”DŐü.DŘD˝$.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW>DWŚDW”DWéDXgNEG....YNNNNYNDV˙........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBiBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391199113911991139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23778 DV˙DĄđDWĹ.DWĹDV˙DV˙DĄđDWDĚ`DV˙DĄđDWDĚ`....Hr±ÔpHrĐM`Hr±ÔpHrĐM`..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DĄđDĚ`....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWA. Underweight ANNYYNEGDWADWŚDWĹ..NEG....YNNNNYYDV˙........DWADWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391200113912001139AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23917 DV˙D¨üDWĂ.DWĂDV˙DV˙D¨üDWDî\DV˙D¨üDWDî\....Hr±×|HrÍĚ\Hr±×|HrÍĚ\..DV˙DW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D¨üDî\....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Underweight ANNYYNEGDW0DWŚDWĂ..NEG....YNNNNYYDV˙........DW0DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391201113912011139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23921 DV˙DÓhDWŕ.DWŕDV˙DV˙DÓhDWDčDV˙DÓhDWDč....Hr˛čHrÍĆHr˛čHrÍĆ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŕOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DÓhDč....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW\DW3. Normal weightA NYYYNEGDW3DW[DWÉ..NEG....YNNNNYYDV˙........DW3DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW[DWŕDWŕBÍBHB…BâB]7-8 months A€2-3 months A00-1 month A8-9 months A . ...C4591001C4591001 1139 11391202113912021139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23922 DV˙DÔXDWč.DWčDV˙DV˙DÔXDW°Dâ¤DV˙DÔXDWDč€DWšDÇěDW°Dâ¤Hr˛ŘHs›j¤Hr˛ŘHrÍĆ€Hs~NěHs›j¤DV˙DWDWšDW°AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW3BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔXDč€.DÇěDâ¤.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Underweight ANNYYNEGDW3DWŚDW™DWčDXmNEG....YNNNNYNDV˙........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBdBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391203113912031139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23923 DV˙Dě¸DW}.DW}DV˙DV˙Dě¸DWhDŇđDV˙Dě¸DWDßÔDWhDŇđDWhDŇđHr˛8Hs BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24026 DV˙DçĚDWî.DWîDV˙DV˙DçĚDWÍDÔDV˙DçĚDWDĹ”DW±DľDWÍDÔHr˛LHsÁ—śHr˛LHrÍŁ”Hsś—”HsÁ—śDV˙DWDW±DWÍAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçĚDĹ”.DľDÔ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˘DW±. Overweight A0NNYYNEGDW1DWˇDW°DWîDXŠNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWˇDWýDWýBęBŽBMB\B˙BŁ8-9 months A5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1139 11391206113912061139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24029 DV˙DčřDWĚ.DWĚDV˙DV˙DčřDWDńŕDV˙DčřDWDńŕ....Hr˛xHrÍĎŕHr˛xHrÍĎŕ..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DčřDńŕ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Underweight ANNYYNEGDW0DWŚDWĘ..NEG....YNNNNYYDV˙........DW0DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391207113912071139AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24032 DV˙Dę$DWč.DWčDV˙DV˙Dę$DW©DčDV˙Dę$DWDŐHDW”D¸°DW©DčHr˛¤Hs‘űhHr˛¤HrÍłHHsvV°Hs‘űhDV˙DWDW”DW©AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę$DŐH.D¸°Dč.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDW1DWŚDW“DWčDXfNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBjBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391208113912081139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24059 DV˙DëPDWč.DWčDV˙DV˙DëPDW©DčDV˙DëPDWDŐ„DW”D¸tDW©DčHr˛ĐHs‘űhHr˛ĐHrÍł„HsvVtHs‘űhDV˙DWDW”DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëPDŐ„.D¸tDč.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDW1DWŚDW“DWčDXfNEG....YNNNNYNDV˙........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBjBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1139 11391209113912091139AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24060 DWD–DWŮ.DWŮDV˙DWD–DWDÁÔDWD–DWDÁÔ....HrłHrĐBÔHrłHrĐBÔ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D–DÁÔ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW8. Underweight ANNYYNEGDW8DWŚDWŮ..NEG....YNNNNYYDW........DW8DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqBţBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1139 11391210113912101139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24064 DWD¬DWč.DWčDWDWD¬DW±D´xDWD¬DWDÓ¤DWšDÜŚDW±D´xHrąĹ,HsśŤřHrąĹ,HrÖě$Hs~cŚHsśŤřDWDWDWšDW±AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬DÓ¤.DÜŚD´x.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Normal weightA NNYYNEGDW6DWŚDW™DWčDXnNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBdBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391211113912111139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24066 DWD·üDWË.DWËDWDWD·üDWD¶DWD·üDWD¶....HrąĎ|HrÖÎśHrąĎ|HrÖÎś..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D·üD¶....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW7. Normal weightA NNYYNEGDW7DWŚDWË..NEG....YNNNNYYDW........DW7DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391212113912121139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24347 DWD¶”DWp..DWDWD¶”DWRDăXDWD¶”DWD˛DW:DŕDWRDăXHrąÎHs~XHrąÎHrÖËHr˙×Hs~XDWDWDW:DWRAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶”D˛.DŕDăX.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW3DW:. Normal weightA NYYYNEGDW2DW2DW9DWpDXNEG....YNNNNYNDW........DW:.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW2DWýDWýBăBBÄBËBůB.8-9 months A0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1139 11391213113912131139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24349 DWDÂDWß.DWßDWDWDÂDWDÚpDWDÂDWDÚp....HrąŮHrÖňđHrąŮHrÖňđ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DÂDÚp....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW=. Underweight ANYYYNEGDW=DWŚDWË..NEG....YNNNNYYDW........DW=DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391214113912141139AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24351 DWDŐüDWĐ.DWĐDWDWDŐüDWDĄ<DWDŐüDWDĄ<....Hrąí|HrŮ`ĽHrąí|HrŮ`Ľ..DWDW..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW: .. DŐüDĄ<....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW:. Overweight A0NNYYNEGDW:DWŚDWĐ..NEG....YNNNNYYDW........DW:DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBáBpBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391215113912151139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24354 DWD©ěDWĂ.DWĂDWDWD©ěDWŁDż@DWD©ěDWDŐŔDWŽDíäDWŁDż@Hr»ěHsŠ#ŔHr»ěHrÖî@Hsn˘äHsŠ#ŔDWDWDWŽDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D©ěDŐŔ.DíäDż@.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW:DWŚDWŤDWĂDX`NEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391216113912161139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24554 DWD¨üDWŕ.DWŕDWDWD¨üDWDĎ¨DWD¨üDWDĎ¨....Hr»üHrÖč(Hr»üHrÖč(..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. D¨üDĎ¨....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW=. Normal weightA NNYYNEGDW=DWŚDWŕ..NEG....YNNNNYYDW........DW=DWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391217113912171139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24557 DWD¶”DWĹ.DWĹDWDWD¶”DW§DÚ¬DWD¶”DWDÚpDW”DäüDW§DÚ¬Hr»”HsŹ…,Hr»”HrÖňđHsv‚üHsŹ…,DWDWDW”DW§AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶”DÚp.DäüDÚ¬.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW8DWŚDW“DWĹDXdNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBjBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391218113912181139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24558 DWDŢ0DWî.DWîDWDWDŢ0DWD—,DWDŢ0DWD—,....Hr»G0HrÖŻ¬Hr»G0HrÖŻ¬..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. DŢ0D—,....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW8. Underweight ANNYYNEGDW8DWŚDWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391219113912191139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24559 DWDÜČDWż.DWżDWDWDÜČDW˘DĂ´DWDÜČDWDťDWŤDĘDDW˘DĂ´Hr»EČHsÖ´Hr»EČHrÖµHsm-ÄHsÖ´DWDWDWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDť.DĘDDĂ´.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW8DW‹DWŚDWżDX_NEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBăBqBqBrBřB†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ..DWcC4591001C4591001 1139 11391220113912201139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24693 DWDß DWé.DWéDWDWDß DW©D·ŔDWDß DWDŻČDW”DĂ´DW©D·ŔHr»H Hs’@Hr»H HrŮkHHsva´Hs’@DWDWDW”DW©AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß DŻČ.DĂ´D·Ŕ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Overweight A0YNYYNEGDW?DWŚDW“DWéDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBáBpBjBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391221113912211139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24694 DWD¸8DWŢ.DWŢDWDWD¸8DW"DŔ¨DWD¸8DW"DŔ¨....HrĂ 8Hrŕ¨HrĂ 8Hrŕ¨..DWDW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. D¸8DŔ¨....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Normal weightA NYYYNEGDW?DWŚDWŢ..NEG....YNNNNYYDW........DW?DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391222113912221139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24698 DWDľPDWé.DWéDWDWDľPDWŞDŕDWDľPDW"D× DW”DÜDWŞDŕHrĂPHs“HrĂPHrŕ* HsvzHs“DWDW"DW”DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DľPD× .DÜDŕ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW?DWŚDW“DWéDXgNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBjBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391223113912231139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24700 DWD¶DWŃ.DWŃDWDWD¶DW"DÇěDWD¶DW"DÇě....HrĂHrŕěHrĂHrŕě..DWDW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. D¶DÇě....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWA. Normal weightA NNYYNEGDWADWŚDWŃ..NEG....YNNNNYYDW........DWADWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391224113912241139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25140 DWDÎôDWÄ.DWÄDWDWDÎôDW˘DâŕDWDÎôDW!DÜČDWŤDĽ¬DW˘DâŕHrĂ ôHsőŕHrĂ ôHrŢŢHHsm ,HsőŕDWDW!DWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎôDÜČ.DĽ¬Dâŕ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW>DWŚDWŚDWÄDX_NEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBqBqBňB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391225113912251139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25143 DWDĽčDWŢ.DWŢDWDWDĽčDW$DĘĽDWDĽčDW$DĘĽ....HrĂčHrâŔĽHrĂčHrâŔĽ..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DĽčDĘĽ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWH. Normal weightA NNYYNEGDWHDWŚDWŢ..NEG....YNNNNYYDW........DWHDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391226113912261139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25146 DW D«DWá.DWáDW DW D«DW$DĆüDW D«DW$DĆü....HrÄOHrâĽüHrÄOHrâĽü..DW DW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D«DĆü....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW2. Normal weightA NNYYNEGDW@DWŚDWá..NEG....YNNNNYYDW ........DW@DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391227113912271139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25148 DW D¬DDWÍ.DWÍDW DW D¬DDWŞD´<DW D¬DDW$DĆŔDW•DŃDWŞD´<HrÄOÄHs“S<HrÄOÄHrâĽŔHswŔHs“S<DW DW$DW•DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW2BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬DDĆŔ.DŃD´<.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW@DWŚDW”DWÍDXgNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBiBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391228113912281139AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25378 DW D°DWé.DWéDW DW D°DWŞDą DW D°DW"D¶XDW”DÄŕDWŞDą HrÄS„Hs“X HrÄS„Hrŕ XHsvbŕHs“X DW DW"DW”DWŞAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D°D¶X.DÄŕDą .121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDWDDWŚDW“DWéDXgNEG....YNNNNYNDW ........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBjBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391229113912291139AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25380 DW D¬DWé.DWéDW DW D¬DW©DËčDW D¬DW$DĚŘDW”DÇ8DW©DËčHrÄQ,Hs’hHrÄQ,HrâÂŘHsve8Hs’hDW DW$DW”DW©AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬DĚŘ.DÇ8DËč.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDWFDWŚDW“DWéDXfNEG....YNNNNYNDW ........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBjBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391230113912301139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25382 DW DŻDWŘ.DWŘDW DW DŻDW"D¶DW DŻDW"D¶....HrÄR”Hrŕ HrÄR”Hrŕ ..DW DW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DŻD¶....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Normal weightA NNYYNEGDW>DWŚDWŘ..NEG....YNNNNYYDW ........DW>DWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391231113912311139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25388 DW DçDWŇ.DWŇDW DW DçDW"DÚčDW DçDW"DÚč....HrÄ‹Hrŕ-čHrÄ‹Hrŕ-č..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DçDÚč....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW DW?. Normal weightA NNYYNEGDW?DWźDWŇ..NEG....YNNNNYYDW ........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWźDWýDWýBÜB~B^BńB“7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1139 11391232113912321139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25475 DW DčĽDWó.DWóDW DW DčĽDW"DŮDDW DčĽDW"DŮD....HrÄŚ<Hrŕ,DHrÄŚ<Hrŕ,D..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DčĽDŮD....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŃDW?. Normal weightA NNYYNEGDW?DWĐDWó..NEG....YNNNNYYDW ........DW?DWóYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĐDWýDWýBÜBŻB-BńBÄ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1139 11391233113912331139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25478 DW DéčDWŇ.DWŇDW DW DéčDW"DŮřDW DéčDW"DŮř....HrÄŤhHrŕ,řHrÄŤhHrŕ,ř..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DéčDŮř....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW?DWŇDWŇ..NEG....YNNNNYYDW ........DW?DWŇYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBÜBÜ..BńBń7-8 months A€7-8 months A€ .8-9 months A . ...C4591001C4591001 1139 11391235113912351139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25479 DW DěDWg..DW DW DěDWKDłDW DěDW$DÔXDW6DÚ¬DWKDłHrÄŹ„HsHrÄŹ„HrâĘXHrú‹¬HsDW DW$DW6DWKAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. DW6OTHER Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DěDÔX.DÚ¬Dł.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW/DW6. Normal weightA NNYYNEGDW.DW.DW5DWgDX ....YNNNNNNDW ..........YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 7 days but prior to 14 days post Dose 2 NYNYYYN YNNYNY NNDW.DWýDWýBÚA°BČBĎBńB"7-8 months A€0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1139 11391236113912361139AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25480 DW Dí0DWŮ.DWŮDW DW Dí0DW!DÇ8DW Dí0DW!DÇ8....HrÄ°HrŢČ¸HrÄ°HrŢČ¸..DW DW!..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. Dí0DÇ8....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Normal weightA NNYYNEGDW?DWŚDWŮ..NEG....YNNNNYYDW ........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391237113912371139AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25969 DWDëČDWĚ.DWĚDWDWDëČDW°DÝ@DWDëČDW$DęŘDWšDÁ\DW°DÝ@HrÇ2HHs›e@HrÇ2HHrâŕŘHs~H\Hs›e@DWDW$DWšDW°AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DëČDęŘ.DÁ\DÝ@.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Underweight ANNYYNEGDWEDWŚDW™DWĚDXmNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBdBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391238113912381139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25972 DWDéčDWÍ.DWÍDWDWDéčDW%DŃLDWDéčDW%DŃL....HrÇ0hHräĚHrÇ0hHräĚ..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DéčDŃL....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW%. Obese A@YNYYNEGDWADWŚDWÍ..NEG....YNNNNYYDW........DWADWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391239113912391139AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25973 DWDí0DWě.DWěDWDWDí0DWŞDĐ DWDí0DW$DČÜDW•DáxDWŞDĐ HrÇ3°Hs“o HrÇ3°HrâľÜHswĐřHs“o DWDW$DW•DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dí0DČÜ.DáxDĐ .121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Underweight ANNYYNEGDW=DWŤDW”DWěDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBiBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391240113912401139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25976 DWDÄ,DWŰ.DWŰDWDWDÄ,DW$DÄ¤DWDÄ,DW$DÄ¤....HrČ\,Hrâş¤HrČ\,Hrâş¤..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DÄ,DÄ¤....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW3. Normal weightA NNYYNEGDW@DW‹DWŰ..NEG....YNNNNYYDW........DW@DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÚBhBrBîB|7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391241113912411139AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26254 DWDć DWě.DWěDWDWDć DWŞDâhDWDć DW$Dĺ8DW”Dę`DWŞDâhHrČ~ Hs“hHrČ~ HrâŰ8Hsv`Hs“hDWDW$DW”DWŞAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć Dĺ8.Dę`Dâh.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDWFDWŚDW“DWěDXgNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBjBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391242113912421139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26258 DWDęŘDWó.DWóDWDWDęŘDW%DŔ0DWDęŘDW%DŔ0....HrČ‚ŘHrä°HrČ‚ŘHrä°..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. DęŘDŔ0....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWA. Normal weightA NNYYNEGDWADWŚDWÔ..NEG....YNNNNYYDW........DWADWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391243113912431139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26259 DWDč€DWÉ.DWÉDWDWDč€DW©DÎDWDč€DW%Dä„DW”DŃÄDW©DÎHrČ€€Hs’„HrČ€€Hrä,HsvoÄHs’„DWDW%DW”DW©AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dč€Dä„.DŃÄDÎ.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDWADWŚDW“DWÉDXfNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBjBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391244113912441139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26263 DWDépDWî.DWîDWDWDépDW%Dă”DWDépDW%Dă”....HrČpHrä+HrČpHrä+..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DépDă”....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW%. Underweight ANNYYNEGDWADWŚDWî..NEG....YNNNNYYDW........DWADWîYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391245113912451139AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26313 DWDô°DWç.DWçDWDWDô°DW)DĎlDWDô°DW)DĎl....HrČŚ°Hré\ěHrČŚ°Hré\ě..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dô°DĎl....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDWKDWŚDWç..NEG....YNNNNYYDW........DWKDWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391246113912461139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26319 DWDí0DWě.DWěDWDWDí0DW©D¦¤DWDí0DW%DĂ<DW”Dě@DW©D¦¤HrČ…0Hs‘ô$HrČ…0Hrä ĽHsvŠ@Hs‘ô$DWDW%DW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dí0DĂ<.Dě@D¦¤.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDWADWŚDW“DWěDXfNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBjBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391247113912471139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26322 DWDđDWľ.DWľDWDWDđDW˘DŢ¨DWDđDW%DČdDWŤDé¬DW˘DŢ¨HrČHsń¨HrČHrääHsmM,Hsń¨DWDW%DWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DđDČd.Dé¬DŢ¨.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NYYYNEGDWFDW‹DWŚDWľDX_NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŮBgBqBrBîB|7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391248113912481139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26324 DWDń,DWÔ.DWÔDWDWDń,DW%DëŚDWDń,DW%DëŚ....HrČ‰,Hrä3HrČ‰,Hrä3..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. Dń,DëŚ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWY. Obese A@YNYYNEGDWYDWŤDWÔ..NEG....YNNNNYYDW........DWYDWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŮBiBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391249113912491139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26568 DWDÉTDWő.DWőDWDWDÉTDW(DŞdDWDÉTDW(DŞd....HrĚUÔHrçćdHrĚUÔHrçćd..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DÉTDŞd....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NNYYNEGDWFDWŚDWâ..NEG....YNNNNYYDW........DWFDWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÖBeBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391250113912501139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26569 DWDÝôDW§.DW§DWDWDÝôDW‹DŢäDWDÝôDW(D¨ŔDWvDËčDW‹DŢäHrĚjtHsjźdHrĚjtHrçäŔHsNÜčHsjźdDWDW(DWvDW‹AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝôD¨Ŕ.DËčDŢä.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWuDWv. Normal weightA NNYYNEGDWGDWtDWuDW§DXHNEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWtDWýDWýBÖBMBB‰BëBb7-8 months A€2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391251113912511139AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26571 DWDŔlDWň..DWDWDŔlDW(D´DWDŔlDW(D´....HrĚLěHrçđHrĚLěHrçđ..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DŔlD´....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW1. Normal weightA NYYYNEGDWEDW‹DWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÖBdBrBëBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391252113912521139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26572 DWDÁDWľ.DWľDWDWDÁDW˘DżDWDÁDW(DłÄDWŤDĐ DW˘DżHrĚNHsŇHrĚNHrçďÄHsm3 HsŇDWDW(DWŤDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÁDłÄ.DĐ Dż.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDWEDW‹DWŚDWľDX_NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBqBrBëBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391253113912531139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26613 DWDß\DWŰ.DWŰDWDWDß\DW(DĂđDWDß\DW(DĂđ....HrĚkÜHrç˙đHrĚkÜHrç˙đ..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. Dß\DĂđ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW1. Normal weightA NNYYNEGDWADW‹DWŰ..NEG....YNNNNYYDW........DWADWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÖBdBrBëBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391254113912541139AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26621 DWDŕDWÔ.DWÔDWDWDŕDWŁDÔXDWDŕDW(DĂđDWŽDŮřDWŁDÔXHrĚmHsŠ8ŘHrĚmHrç˙đHsnŽřHsŠ8ŘDWDW(DWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕDĂđ.DŮřDÔX.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Underweight ANNYYNEGDWADW‹DWŤDWÔDX`NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÖBdBpBrBëBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391255113912551139AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26622 DWDâ¤DW×.DW×DWDWDâ¤DW(D°¸DWDâ¤DW(D°¸....HrĚo$Hrçě¸HrĚo$Hrçě¸..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. Dâ¤D°¸....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW*. Normal weightA NNYYNEGDWDDW‹DW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBÖBdBrBëBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391256113912561139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26760 DWDÍČDWŘ.DWŘDWDWDÍČDW(DŃDWDÍČDW(DŃ....HrÍ«ČHrč HrÍ«ČHrč ..DWDW(..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DÍČDŃ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWE. Underweight ANYYYNEGDWEDWŤDWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÖBfBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391257113912571139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26624 DWD°ôDWě.DWěDWDWD°ôDWŞDłDWD°ôDW)D¸°DW•D±0DWŞDłHrÍŽôHs“RHrÍŽôHréF0Hsw °Hs“RDWDW)DW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°ôD¸°.D±0Dł.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW•. Underweight ANNYYNEGDWEDW‹DW”DWěDXgNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŐBcBiBrBęBx7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391258113912581139AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26762 DWDăĐDWÔ.DWÔDWDWDăĐDWŁDŞdDWDăĐDW)DßDWŽD˛DWŁDŞdHrÍÁĐHsŠäHrÍÁĐHrémHsngHsŠäDWDW)DWŽDWŁAŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DăĐDß.D˛DŞd.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDWEDWŚDWŤDWÔDX`NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBpBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1139 11391259113912591139AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26763 DWD˛ÔDWŢ.DWŢDWDWD˛ÔDW)DĘĽDWD˛ÔDW)DĘĽ....HrÍÔHréX<HrÍÔHréX<..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D˛ÔDĘĽ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWK. Normal weightA NNYYNEGDWKDWŤDWŢ..NEG....YNNNNYYDW........DWKDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŐBeBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1139 11391260113912601139AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26764 DWDć(DWě.DWěDWDWDć(DWŞDľPDWDć(DW)DŐDW•DÁDWŞDľPHrÍÄ(Hs“]PHrÍÄ(HrébŚHsw±Hs“]PDWDW)DW•DWŞAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć(DŐ.DÁDľP.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NNYYNEGDWFDWŤDW”DWěDXgNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŐBeBiBpBęBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1139 11391261113912611139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26833 DWDâŕDWß.DWßDWDWDâŕDW)D·HDWDâŕDW)D·H....HrÍŔŕHréDČHrÍŔŕHréDČ..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE ADWßOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DâŕD·H....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW/DW). Underweight ANNYYNEGDW.DW.DWŘ..NEG....YNNNNYYDW........DW?DWŘYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded prior to 7 days post Dose 2 NNNYNYN YYNNNY NYDW.DWßDWßB·A`B±BĚB6-7 months Ap0-1 month A0-1 month A7-8 months A€ . ...C4591001C4591001 1139 11391262113912621139AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26834 DWDďDWŕ.DWŕDWDWDďDW+DÜŚDWDďDW+DÜŚ....HrÍÍHrě HrÍÍHrě ..DWDW+..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŕOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DďDÜŚ....121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWrDW+. Normal weightA NYYYNEGDWMDWqDWč..NEG....YNNNNYNDW........DWM.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWqDWŕDWŕB¶BGBoBÍB^6-7 months Ap2-3 months A00-1 month A7-8 months A€ . ...C4591001C4591001 1139 11391263113912631139AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26837 DWDńŕDWn..DWDWDńŕDWODŘTDWDńŕDW(D¶XDW:DäŔDWODŘTHrÍĎŕHs~ÔHrÍĎŕHrçňXHr˙ŰŔHs~ÔDWDW(DW:DWOAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. DW:OTHER Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DńŕD¶X.DäŔDŘT.121963 Walter, Emmanuel Benjamin ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW0DW:. Underweight ANNYYNEGDW/DW/DW9DWnDX ....YNNNNNNDW..........YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 7 days but prior to 14 days post Dose 2 NYNYYYN YNNYNY NNDW/DWýDWýBÖA€BÄBÎBęB7-8 months A€0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1140 11401323114013231140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21921 DVóDČdDWĆ.DWĆDVóDVóDČdDWDŻPDVóDČdDWDŻP....Hr˘$äHrÉĐHr˘$äHrÉĐ..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DČdDŻP....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWH. Overweight A0YNYYNEGDW1DWŚDWĆ..NEG....YNNNNYYDVó........DW1DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401324114013241140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21923 DVóDÉDWĆ.DWĆDVóDVóDÉDWŞDĚ$DVóDÉDWD¦hDW•DÝ|DWŞDĚ$Hr˘&Hs“k$Hr˘&HrÉŹčHswĚüHs“k$DVóDWDW•DWŞAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWHBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉD¦h.DÝ|DĚ$.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW1DWŚDW”DWĆDXgNEG....YNNNNYNDVó........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBíB|BiBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401325114013251140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21927 DVóDÓhDWó..DVóDVóDÓhDWóD©8DVóDÓhDWD©tDWŕDźśDWóD©8Hr˘/čHsó…¸Hr˘/čHrĆďôHsÚośHsó…¸DVóDWDWŕDWóAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓhD©t.DźśD©8.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŕ. Overweight A0NNYYNEGDW1DWŤDWżDXDX°NEG....YNNNNYYDVó........DW1DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBďBBBpC°B›8-9 months A4-5 months AP1-2 monthsA 9-10 months A . ...C4591001C4591001 1140 11401326114013261140AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21930 DVóDÔ”DWż.DWżDVóDVóDÔ”DWD¨üDVóDÔ”DWD¨ü....Hr˘1HrĆď|Hr˘1HrĆď|..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DÔ”D¨ü....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Normal weightA NNYYNEGDW1DWżDWż..NEG....YNNNNYYDVó........DW1DWżYY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWý.DWýBďBď..C°C°8-9 months A8-9 months A .9-10 months A . ...C4591001C4591001 1140 11401327114013271140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22102 DVôDĎ¨DWÉ.DWÉDVôDVôDĎ¨DW§DÍŚDVôDĎ¨DW DäüDW‘DĚ`DW§DÍŚHrŁ}¨HsŹxHrŁ}¨HrÄ|HsruŕHsŹxDVôDW DW‘DW§AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĎ¨Däü.DĚ`DÍŚ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW)DWŚDWDWÉDXdNEG....YNNNNYNDVô........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBńB€BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401328114013281140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22105 DV÷DĆŔDW˝.DW˝DV÷DV÷DĆŔDW DÂLDV÷DĆŔDW DÂL....Hr§i@HrÄeĚHr§i@HrÄeĚ..DV÷DW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĆŔDÂL....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW,.. Obese A@YNYYNEGDW+DW+DW˝..NEG....YNNNNYYDV÷........DW,DW˝YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNYYNYDW+DWýDWýBńBBŇCpB58-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1140 11401329114013291140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22110 DV÷Dß\DWÉ.DWÉDV÷DV÷Dß\DW DŘDV÷Dß\DW DŘ....Hr§ÜHrÄ|Hr§ÜHrÄ|..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. Dß\DŘ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWL. Normal weightA NNYYNEGDW)DWŚDWÉ..NEG....YNNNNYYDV÷........DW)DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401330114013301140AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22112 DVřD” DWĂ.DWĂDVřDVřD” DW§Dĺ8DVřD” DWD…\DW‘DŕDW§Dĺ8Hr¨ HsŹŹ¸Hr¨ HrĆËÜHsrŠHsŹŹ¸DVřDWDW‘DW§AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D” D…\.DŕDĺ8.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANYYYNEGDW,DWŚDWDWĂDXdNEG....YNNNNYNDVř........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BmBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401331114013311140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22763 DVůDźśDW÷.DW÷DVůDVůDźśDWD¤DVůDźśDWD¤....Hr©ĺHrĹ™Hr©ĺHrĹ™..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. DźśD¤....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWM. Normal weightA NNYYNEGDW*DWŚDWŢ..NEG....YNNNNYYDVů........DW*DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401332114013321140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22764 DVůD ŚDWŢ.DWŢDVůDVůD ŚDWD¤DVůD ŚDWD¤....Hr©ćHrĹ™Hr©ćHrĹ™..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. D ŚD¤....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWM. Normal weightA NNYYNEGDW*DWŚDWŢ..NEG....YNNNNYYDVů........DW*DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401333114013331140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22766 DVůDá´DWÄ.DWÄDVůDVůDá´DW§DßDVůDá´DWDŕLDW’DÓŕDW§DßHrŞ'4HsŹŠHrŞ'4HrĹŐLHssÎŕHsŹŠDVůDWDW’DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dá´DŕL.DÓŕDß.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW,DWŚDW‘DWÄDXdNEG....YNNNNYNDVů........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBlBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401334114013341140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22767 DVůDâ¤DWÄ.DWÄDVůDVůDâ¤DW§DŕDVůDâ¤DWDŕÄDW’DŇđDW§DŕHrŞ($HsŹŠHrŞ($HrĹŐÄHssÍđHsŹŠDVůDWDW’DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ¤DŕÄ.DŇđDŕ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW,DWŚDW‘DWÄDXdNEG....YNNNNYNDVů........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBlBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401335114013351140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23014 DVúD˝śDWÄ.DWÄDVúDVúD˝śDW¦D‡DVúD˝śDWDĂxDW‘DÂDW¦D‡Hr«TśHsŤŕHr«TśHrĹ¸xHsrkHsŤŕDVúDWDW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝śDĂx.DÂD‡.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW1DWŚDWDWÄDXcNEG....YNNNNYNDVú........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBđBBmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401336114013361140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23017 DVúDĂxDWĆ.DWĆDVúDVúDĂxDWDĹ”DVúDĂxDWDĹ”....Hr«ZxHrČ]”Hr«ZxHrČ]”..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DĂxDĹ”....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Normal weightA NNYYNEGDW0DWŚDWĆ..NEG....YNNNNYYDVú........DW0DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401337114013371140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23018 DVúDŘTDWĽ.DWĽDVúDVúDŘTDW Dť€DVúDŘTDW Dť€....Hr«oTHrÄAHr«oTHrÄA..DVúDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DŘTDť€....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Overweight A0NNYYNEGDW0DWŚDWĽ..NEG....YNNNNYYDVú........DW0DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBńB€BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401338114013381140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23020 DVúDăDWÄ.DWÄDVúDVúDăDW¦D‰”DVúDăDWDáđDW‘DŚ DW¦D‰”Hr«zHsŤâ”Hr«zHrÇ(pHsr6 HsŤâ”DVúDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DăDáđ.DŚ D‰”.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW+DWŚDWDWÄDXcNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401340114013401140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23542 DVţD…\DWÄ.DWÄDVţDVţD…\DW¨DŞ DVţD…\DWDÝDW•DŽĽDW¨DŞ Hr°b\Hs¦ Hr°b\HrĚi„Hsw~<Hs¦ DVţDWDW•DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. D…\DÝ.DŽĽDŞ .1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NNYYNEGDW1DWŤDW”DWÄDXeNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBëB{BiBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401343114013431140AĐYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23544 DVţD×dDWÍ.DWÍDVţDVţD×dDWDÚpDVţD×dDWDÚp....Hr°´dHrĎ đHr°´dHrĎ đ..DVţDW..AĐYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D×dDÚp....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Obese A@YNYYNEGDW1DWŚDWÍ..NEG....YNNNNYYDVţ........DW1DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401344114013441140AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23543 DVţD×ÜDWÍ.DWÍDVţDVţD×ÜDWDŰ$DVţD×ÜDWDŰ$....Hr°´ÜHrĎ ¤Hr°´ÜHrĎ ¤..DVţDW..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D×ÜDŰ$....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Normal weightA NNYYNEGDW1DWŚDWÍ..NEG....YNNNNYYDVţ........DW1DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401345114013451140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23545 DV˙D‡DWĂ.DWĂDV˙DV˙D‡DW¦DÍČDV˙D‡DWDĂDW’DŮřDW¦DÍČHr±µ€HsŽ&ČHr±µ€HrĚO€HssÔřHsŽ&ČDV˙DWDW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡DĂ.DŮřDÍČ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NYYYNEGDW6DWŚDW‘DWĂDXcNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBlBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401346114013461140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USANYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg)A€ . . .BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23903 DV˙.DV˙.DV˙DV˙......................AŕYEARS. 12-15 YearsAWHITE AWHITE ADV˙NO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. ......1449872Thomas, Stephen .. .A@Phase 3<65 Years 12-15 YearsAA. . ... Obese A@YN ..... ....NNNNNNN...........YN YNN Ydid not receive Dose 1 as randomized did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNNNNN YNNNN NNDV˙.DV˙..0-1 month A0-1 month A .0-1 month A . ...C4591001C4591001 1140 11401347114013471140AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23908 DV˙DŽ€DWÄ.DWÄDV˙DV˙DŽ€DW¨DťDV˙DŽ€DWD|tDW“DĘDW¨DťHr±˝Hs™Hr±˝HrÎ«ôHsuHs™DV˙DWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽ€D|t.DĘDť.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Obese A@YNYYNEGDW8DWŚDW’DWÄDXeNEG....YNNNNYNDV˙........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBéBxBkBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401348114013481140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23909 DV˙DŹpDWÄ.DWÄDV˙DV˙DŹpDW¨DśDV˙DŹpDWD}(DW“DĘ€DW¨DśHr±˝đHsHr±˝đHrÎ¬¨HsuHsDV˙DWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹpD}(.DĘ€Dś.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW8DWŚDW’DWÄDXeNEG....YNNNNYNDV˙........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBéBxBkBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401349114013491140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23911 DV˙D”\DWË.DWËDV˙DV˙D”\DWD|ěDV˙D”\DWD|ě....Hr±ÂÜHrÍZěHr±ÂÜHrÍZě..DV˙DW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWn .. D”\D|ě....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWn. Underweight ANNYYNEGDW7DWŚDWË..NEG....YNNNNYYDV˙........DW7DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401350114013501140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24010 DV˙D¬DWĘ.DWĘDV˙DV˙D¬DWDpDV˙D¬DWDp....Hr±Ü,HrÎÜđHr±Ü,HrÎÜđ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWĘWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWi .. D¬Dp....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĘDWi. Normal weightA NNYYNEGDW8DWÉDWŇ..NEG....YNNNNYNDV˙........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÉDWĘDWĘB¶BµABĚBË6-7 months Ap6-7 months Ap0-1 month A7-8 months A€ . ...C4591001C4591001 1140 11401351114013511140AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24011 DV˙D®`DWó..DV˙DV˙D®`DWóD©ěDV˙D®`DWDčDWßDŔ0DWóD©ěHr±ÜŕHsó†lHr±ÜŕHrÎÝhHsŮ>°Hsó†lDV˙DWDWßDWóAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. D®`Dč.DŔ0D©ě.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĆDWß. Normal weightA NNYYNEGDW8DWĹDWĆDXDX°NEG....YNNNNYYDV˙........DW8DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĹDWýDWýBéB±BB8B˙BÇ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1140 11401352114013521140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24019 DV˙DŻDWĘ.DWĘDV˙DV˙DŻDWD®`DV˙DŻDWD®`....Hr±Ý”HrÎÝŕHr±Ý”HrÎÝŕ..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWĘWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŻD®`....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĘ.. Normal weightA NNYYNEGDW8DWÉDWŇ..NEG....YNNNNYNDV˙........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÉDWĘDWĘB¶BµABĚBË6-7 months Ap6-7 months Ap0-1 month A7-8 months A€ . ...C4591001C4591001 1140 11401353114013531140AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24020 DV˙DŇxDWŮ.DWŮDV˙DV˙DŇxDWŞD•DV˙DŇxDWDŰŘDW•DßÔDWŞD•Hr˛řHs“4Hr˛řHrÍąŘHswĎTHs“4DV˙DWDW•DWŞAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇxDŰŘ.DßÔD•.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Overweight A0YNYYNEGDW0DWŚDW”DWĆDXgNEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBiBqB˙BŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401354114013541140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24178 DWD‹°DWÄ.DWÄDWDWD‹°DWDŃDWD‹°DWDŃ....Hrł°HrĎHrł°HrĎ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D‹°DŃ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW†DWT. Normal weightA NNYYNEGDW9DW…DWÄ..NEG....YNNNNYYDW........DW9DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW…DWýDWýBéBqBxBţB†8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401356114013561140AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24183 DWD˝ŘDWĚ.DWĚDWDWD˝ŘDWŞDť€DWD˝ŘDWD›(DW”DŹ4DWŞDť€Hrł=ŘHs“<€Hrł=ŘHrÎĘ¨Hsv-4Hs“<€DWDWDW”DWŞAŕYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝ŘD›(.DŹ4Dť€.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDW1DWŤDW“DWĚDXgNEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBéByBjBpBţBŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1140 11401357114013571140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24186 DWDĆ„DWŽ.DWŽDWDWDĆ„DWDŇxDWDĆ„DWDŇx....HrłF„HrĚ^řHrłF„HrĚ^ř..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŽWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĆ„DŇx....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Overweight A0NYYYNEGDW/DWŚDWĐ..NEGDWŤ.DWŤDWŤYNNNNYNDW........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWŽDWŽB|BzA BŹBŤ4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1140 11401358114013581140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24290 DWDŢlDWÄ.DWÄDWDWDŢlDWDşTDWDŢlDWDşT....Hrł^lHrÎéÔHrł^lHrÎéÔ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DŢlDşT....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Underweight ANNYYNEGDW1DWŚDWÄ..NEG....YNNNNYYDW........DW1DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqBţBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401359114013591140AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24188 DWDÝ|DWĐ.DWĐDWDWDÝ|DWDŐ„DWDÝ|DWDŐ„....Hrł]|HrĎHrł]|HrĎ..DWDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DÝ|DŐ„....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Underweight ANNYYNEGDW8DWŚDWĐ..NEG....YNNNNYYDW........DW8DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqBţBŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1140 11401361114013611140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24291 DWD¨HDWĚ.DWĚDWDWD¨HDWD–DWD¨HDWD–....HrążČHrÖ®€HrążČHrÖ®€..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨HD–....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YNYYNEGDW9DWŤDWĚ..NEG....YNNNNYYDW........DW9DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBăBsBpBůB‰8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401362114013621140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24292 DWD©°DWÄ.DWÄDWDWD©°DW¦D•ÄDWD©°DWDµhDW‘DÂÄDW¦D•ÄHrąÁ0HsŤîÄHrąÁ0HrŘhHsrlDHsŤîÄDWDWDW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. D©°Dµh.DÂÄD•Ä.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDW9DWŚDWDWÄDXcNEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBmBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401363114013631140AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24294 DWD¶”DWĆ.DWĆDWDWD¶”DWŞDÝôDWD¶”DWDąÜDW•DÜDWŞDÝôHrąÎHs“|ôHrąÎHrŘ#ÜHswË”Hs“|ôDWDWDW•DWŞAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶”DąÜ.DÜDÝô.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NNYYNEGDWADWŤDW”DWĆDXgNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBâBrBiBpBůB‰8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401364114013641140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24430 DWDĆŔDWĹ.DWĹDWDWDĆŔDW¨DŇDWDĆŔDWDÇ8DW•D’@DW¨DŇHrąŢ@HsÎHrąŢ@HrÖß¸HswŔHsÎDWDWDW•DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆŔDÇ8.D’@DŇ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Underweight ANNYYNEGDW:DWŤDW”DWĹDXeNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBăBsBiBpBůB‰8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401365114013651140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24439 DWDĆDWŰ.DWŰDWDWDĆDWDĆHDWDĆDWDĆH....HrąÝŚHrÖŢČHrąÝŚHrÖŢČ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DĆDĆH....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDWb. Overweight A0NNYYNEGDW:DW‹DWŰ..NEG....YNNNNYYDW........DW:DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBăBqBrBůB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401366114013661140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24435 DWDÇ°DWĹ.DWĹDWDWDÇ°DW¨DŇxDWDÇ°DWDĆŔDW•D’¸DW¨DŇxHrąß0HsÎxHrąß0HrÖß@Hsw‚8HsÎxDWDWDW•DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇ°DĆŔ.D’¸DŇx.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Overweight A0YNYYNEGDW:DWŤDW”DWĹDXeNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBăBsBiBpBůB‰8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401367114013671140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24440 DWDŰŘDWÍ.DWÍDWDWDŰŘDWD‡´DWDŰŘDWD‡´....HrąóXHr×ń´HrąóXHr×ń´..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. DŰŘD‡´....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Underweight ANNYYNEGDW8DWŚDWÍ..NEG....YNNNNYYDW........DW8DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBůB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401369114013691140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24599 DWDťDDWĂ.DWĂDWDWDťDDW¦DÝôDWDťDDWDÎ¸DW“DŢäDW¦DÝôHr»DHsŽ6ôHr»DHrŘ8¸Hsu+dHsŽ6ôDWDWDW“DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDDÎ¸.DŢäDÝô.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNNYPOSDW8DWŚDW’DWĂDXcPOS....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBâBqBkBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401370114013701140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24601 DWD«DWÍ.DWÍDWDWD«DWD¤LDWD«DWD¤L....Hr»HrŮ_ĚHr»HrŮ_Ě..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D«D¤L....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWU. Normal weightA NYYYNEGDW9DWŤDWÍ..NEG....YNNNNYYDW........DW9DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBáBqBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401371114013711140AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24603 DWD°DWĐ.DWĐDWDWD°DWDłLDWD°DWDłL....Hr»HrŘLHr»HrŘL..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D°DłL....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Underweight ANNYYNEGDW8DWŚDWĐ..NEG....YNNNNYYDW........DW8DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401372114013721140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24606 DWD°¸DWĹ.DWĹDWDWD°¸DW¨D†DWD°¸DWDłÄDW’DČ DW¨D†Hr»¸Hs‚Hr»¸HrŘÄHssĂ Hs‚DWDWDW’DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°¸DłÄ.DČ D†.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW8DWŚDW‘DWĹDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBlBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401373114013731140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24646 DWDµŕDWÍ.DWÍDWDWDµŕDWD¶”DWDµŕDWD¶”....Hr»ŕHrŘ ”Hr»ŕHrŘ ”..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. DµŕD¶”....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Normal weightA NNYYNEGDW:DWŚDWÍ..NEG....YNNNNYYDW........DW:DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401374114013741140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24649 DWDż¸DWĐ.DWĐDWDWDż¸DW±D˛ DWDż¸DWD˛\DWśDźśDW±D˛ Hr»(¸Hsś‹ Hr»(¸HrÖĘÜHs€ÉśHsś‹ DWDWDWśDW±AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dż¸D˛\.DźśD˛ .1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWś. Normal weightA NNYYNEGDW:DWŚDW›DWĐDXnNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBbBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401375114013751140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24652 DWDŇđDWÄ.DWÄDWDWDŇđDW¨D–xDWDŇđDWDÉDW•DÉĚDW¨D–xHr»;đHs’xHr»;đHrŘ3HswąLHs’xDWDWDW•DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇđDÉ.DÉĚD–x.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW8DWŚDW”DWÄDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBiBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401376114013761140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24653 DWDŃDWË.DWËDWDWDŃDWDÉDWDŃDWDÉ....Hr»:HrŘ3Hr»:HrŘ3..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŃDÉ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NNYYNEGDW8DWŚDWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401377114013771140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24707 DWDŇDWÄ.DWÄDWDWDŇDW¨D–DWDŇDWDĘDW•DÉTDW¨D–Hr»;Hs’Hr»;HrŘ4Hsw¸ÔHs’DWDWDW•DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇDĘ.DÉTD–.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDW8DWŚDW”DWÄDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBiBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401378114013781140AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24710 DWD× DWË.DWËDWDWD× DWDčDWD× DWDč....Hr»@ HrŘčHr»@ HrŘč..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. D× Dč....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Normal weightA NNYYNEGDW9DWŚDWË..NEG....YNNNNYYDW........DW9DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401379114013791140AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24715 DWDŤTDWĆ.DWĆDWDWDŤTDW¦Dć DWDŤTDW#D$DW‘DĎ¨DW¦Dć HrĽGÔHsŽ? HrĽGÔHrá%¤Hsry(HsŽ? DWDW#DW‘DW¦AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŤTD$.DĎ¨Dć .1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDWSDWŚDWDWĆDXcNEG....YNNNNYNDW........DWS.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqB÷B†7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DWbC4591001C4591001 1140 11401380114013801140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24716 DWDŹ¬DWŢ.DWŢDWDWDŹ¬DWDŇ´DWDŹ¬DWDŇ´....HrĽJ,HrÖë4HrĽJ,HrÖë4..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DŹ¬DŇ´....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWH. Normal weightA NNYYNEGDWHDWŚDWŢ..NEG....YNNNNYYDW........DWHDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401381114013811140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24840 DWDťřDWÍ.DWÍDWDWDťřDWDŃDWDťřDWDŃ....HrĽXxHrŮŤHrĽXxHrŮŤ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWM .. DťřDŃ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWM. Overweight A0YNYYNEGDW9DWŚDWÍ..NEG....YNNNNYYDW........DW9DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBáBpBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1140 11401382114013821140AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24843 DWDž¬DWÍ.DWÍDWDWDž¬DWDŇDWDž¬DWDŇ....HrĽY,HrŮŤ€HrĽY,HrŮŤ€..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dž¬DŇ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Normal weightA NNYYNEGDW9DW?DWÍ..NEG....YNNNNYYDW........DW9DWÍYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW?DWýDWýBáB#BľB÷B98-9 months A1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1140 11401383114013831140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24846 DWD˘lDWÉ.DWÉDWDWD˘lDWŞD‘ŚDWD˘lDWDštDW•DDWŞD‘ŚHrĽ\ěHs“0ŚHrĽ\ěHrÖ˛ôHswr„Hs“0ŚDWDWDW•DWŞAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘lDšt.DD‘Ś.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NNYYNEGDW7DWŤDW”DWÉDXgNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBăBsBiBpB÷B‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401384114013841140AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24847 DWD¬ĽDWĹ.DWĹDWDWD¬ĽDW¨DŕDWD¬ĽDWDŃÄDW‘DăDW¨DŕHrĽg<HsÜHrĽg<HrŘ;ÄHsrŚśHsÜDWDWDW‘DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬ĽDŃÄ.DăDŕ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW:DWŚDWDWĹDXeNEG....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBâBqBmBqB÷B†8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401385114013851140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24946 DWDĆüDWÔ.DWÔDWDWDĆüDW#DÓhDWDĆüDW#DÓh....HrĹ»üHráwčHrĹ»üHráwč..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DĆüDÓh....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWb. Normal weightA NNYYNEGDW?DWDWÔ..NEG....YNNNNYYDW........DW?DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBŰBnBmBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401386114013861140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24955 DW D¬ĽDWÝ.DWÝDWDW D¬ĽDW#DĄ<DW D¬ĽDW#DĄ<....HrÄP<HráIĽHrÄP<HráIĽ..DW DW#..AđYEARS. 12-15 YearsAWHITE AWHITE ADWÝWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¬ĽDĄ<....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’.. Normal weightA NNYYNEGDW@DW‘DWŕ..NEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWÝDWÝB»BoBLBŃB…6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1140 11401387114013871140AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24947 DWDĆüDWĆ.DWĆDWDWDĆüDW¨DşTDWDĆüDW$D~DW“D…\DW¨DşTHrÇ |Hs¶THrÇ |HrâtHstŃÜHs¶TDWDW$DW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆüD~.D…\DşT.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Overweight A0YNYYNEGDW@DWŚDW’DWĆDXeNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBkBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401388114013881140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 24956 DW DĘ€DWÉ.DWÉDW DW DĘ€DW©DĂ´DW DĘ€DW#DĎ¨DW“Dˇ|DW©DĂ´HrÄnHs’4HrÄnHrát(HstíüHs’4DW DW#DW“DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘ€DĎ¨.Dˇ|DĂ´.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDWADWŚDW’DWÉDXfNEG....YNNNNYNDW ........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401389114013891140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25461 DW DË4DWÉ.DWÉDW DW DË4DW©DĂ<DW DË4DW#DĐ DW“DXDW©DĂ<HrÄn´Hs’ĽHrÄn´Hrát HstäŘHs’ĽDW DW#DW“DW©AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DË4DĐ .DXDĂ<.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Overweight A0YNYYNEGDWADWŚDW’DWÉDXfNEG....YNNNNYNDW ........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401390114013901140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25466 DW DŰ$DWÔ.DWÔDW DW DŰ$DW#DČ(DW DŰ$DW#DČ(....HrÄ~¤Hrál¨HrÄ~¤Hrál¨..DW DW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DŰ$DČ(....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWV. Overweight A0NYYYNEGDW?DWŚDWÔ..NEG....YNNNNYYDW ........DW?DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401391114013911140AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25469 DWD|DWŘ.DWŘDWDWD|DW$DĽDWD|DW$DĽ....HrĹx|HrâuĽHrĹx|HrâuĽ..DWDW$..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWK .. D|DĽ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWK. Normal weightA NNYYNEGDWADWŤDWŘ..NEG....YNNNNYYDW........DWADWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401392114013921140AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25470 DWD‘PDWľ.DWľDWDWD‘PDW¨Dż|DWD‘PDW#Dż|DW“DŞdDW¨Dż|HrĹ†PHs»|HrĹ†PHrácüHstöäHs»|DWDW#DW“DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‘PDż|.DŞdDż|.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Normal weightA NNYYNEGDWFDWŤDW’DWľDXeNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŰBkBkBpBđB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401393114013931140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25715 DWDË4DWŘ.DWŘDWDWDË4DW#DËpDWDË4DW#DËp....HrĹŔ4HráođHrĹŔ4Hráođ..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DË4DËp....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWN. Normal weightA NNYYNEGDW?DWŚDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401394114013941140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25716 DWDÝ@DWâ.DWâDWDWDÝ@DW$DÉĚDWDÝ@DW$DÉĚ....HrĹŇ@HrâżĚHrĹŇ@HrâżĚ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DÝ@DÉĚ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWT. Obese A@YNYYNEGDWFDWŚDWâ..NEG....YNNNNYYDW........DWFDWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401395114013951140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25719 DWD±lDW×.DW×DWDWD±lDWŞDŠŔDWD±lDW$D ČDW”DôDWŞDŠŔHrĆ÷ěHs“)ŔHrĆ÷ěHrâ–ČHsv!ôHs“)ŔDWDW$DW”DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. D±lD Č.DôDŠŔ.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDWDDWŤDW“DWÉDXgNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBjBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401396114013961140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25720 DWDÖěDWĹ.DWĹDWDWDÖěDW©D§”DWDÖěDW$DÔ”DW“DÝDW©D§”HrÇlHs‘őHrÇlHrâĘ”Hsu)„Hs‘őDWDW$DW“DW©AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖěDÔ”.DÝD§”.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Overweight A0NNYYNEGDW@DWŚDW’DWĹDXfNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBkBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401397114013971140AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26159 DWDŹčDWĆ.DWĆDWDWDŹčDW¦Dá<DWDŹčDW$DÄŕDW‘DÝôDW¦Dá<HrČ'čHsŽ:<HrČ'čHrâşŕHsr‡tHsŽ:<DWDW$DW‘DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹčDÄŕ.DÝôDá<.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDWDDWŤDWDWĆDXcNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBmBpBîB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401398114013981140AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26163 DWD¸°DWŕ.DWŕDWDWD¸°DW$D¸ěDWD¸°DW$D¸ě....HrČP°Hrâ®ěHrČP°Hrâ®ě..DWDW$..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. D¸°D¸ě....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWT. Overweight A0YNYYNEGDWADWŤDWŕ..NEG....YNNNNYYDW........DWADWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401399114013991140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26164 DWDądDWŕ.DWŕDWDWDądDW$Dą DWDądDW$Dą ....HrČQdHrâŻ HrČQdHrâŻ ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWT .. DądDą ....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWT. Normal weightA NNYYNEGDWADWŤDWŕ..NEG....YNNNNYYDW........DWADWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401400114014001140AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26165 DWDÁDWŕ.DWŕDWDWDÁDWŞDÚ4DWDÁDW$DĎ¨DW“DÖ°DWŞDÚ4HrČYHs“y4HrČYHrâĹ¨Hsu#0Hs“y4DWDW$DW“DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÁDĎ¨.DÖ°DÚ4.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Underweight ANNYYNEGDWADWŤDW’DWŕDXgNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBkBpBîB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401401114014011140AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26270 DWDżDWŰ.DWŰDWDWDżDW$DŔlDWDżDW$DŔl....HrČWHrâ¶lHrČWHrâ¶l..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DżDŔl....1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWH. Underweight ANNYYNEGDWHDWŚDWŰ..NEG....YNNNNYYDW........DWHDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1140 11401402114014021140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26271 DWDäüDWĆ.DWĆDWDWDäüDW¨D¤LDWDäüDW$D«ĚDW•DŐ„DW¨D¤LHrČ|üHs LHrČ|üHrâˇĚHswĹHs LDWDW$DW•DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DäüD«Ě.DŐ„D¤L.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Underweight ANNYYNEGDWADWŚDW”DWĆDXeNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBiBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1140 11401403114014031140AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26273 DWDĺěDWĆ.DWĆDWDWDĺěDW¨D¤ÄDWDĺěDW$D¬€DW•DŐüDW¨D¤ÄHrČ}ěHs ÄHrČ}ěHrâ˘€HswĹ|Hs ÄDWDW$DW•DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĺěD¬€.DŐüD¤Ä.1449872Thomas, Stephen ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDWADWŚDW”DWĆDXeNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBiBqBîB}7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1142 11421318114213181142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVę20529 DVęDpDWŽ..DVęDVęDpDVţD•DVęDpDVţD•....Hr–,pHr°rHr–,pHr°r..DVęDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DpD•....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Overweight A0NNYYNEGDWDW»DW»..NEG....YNNNNYNDVę........DW.YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NYDWý.DWýCC..C@C@9-10 months A 9-10 months A .9-10 months A . ...C4591001C4591001 1142 11421319114213191142AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20531 DVęDżDWŻ.DWŻDVęDVęDżDVţDÄ,DVęDżDVţDÄ,....Hr–>Hr°ˇ,Hr–>Hr°ˇ,..DVęDVţ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. DżDÄ,....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŻDWb. Obese A@YNYYNEGDWDW®DW®..NEG....YNNNNYYDVę........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW®DWýDWýCB±BOC@BĹ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421321114213211142AŔYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20533 DVëD‘ČDW´.DW´DVëDVëD‘ČDVţD„0DVëD‘ČDVţD„0....Hr—bHHr°a0Hr—bHHr°a0..DVëDVţ..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D‘ČD„0....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW´DW). Obese A@YYYYNEGDWDWłDW´..NEG....YNNNNYYDVë........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWłDWýDWýCB¶BJC0BÉ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421323114213231142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20536 DVěDť€DWđ..DVěDVěDť€DWđD•ÄDVěDť€DV˙DŢ¨DWŮDŰśDWđD•ÄHrż€Hsď}ÄHrż€Hr˛ (HsŃqHsď}ÄDVěDV˙DWŮDWđAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dť€DŢ¨.DŰśD•Ä.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW°DWŮ. Obese A@YNYYNEGDWDWŻDWŻDXDX ....YNNNNNYDVě.........DWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŻDWýDWýB˙B±B%BNC BÄ9-10 months A 6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421324114213241142AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20805 DVěD›ÜDW°.DW°DVěDVěD›ÜDV˙DÜČDVěD›ÜDV˙DÜČ....Hr˝ÜHr˛HHr˝ÜHr˛H..DVěDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. D›ÜDÜČ....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW°DW1. Underweight ANNYYNEGDWDWŻDWŻ..NEG....YNNNNYYDVě........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŻDWýDWýB˙B±BNC BÄ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421325114213251142AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20808 DVěDŢ0DWË.DWËDVěDVěDŢ0DWDĽ4DVěDŢ0DV˙DŕDWDÁDWDĽ4Hr™0Hs—O´Hr™0Hr±·`Hs{ĄHs—O´DVěDV˙DWDWAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢ0Dŕ.DÁDĽ4.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW. Underweight ANNYYNEGDWDW”DW—DWËDXjNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýB˙B–BfBiC B©9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1142 11421326114213261142AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20810 DVěDÝ@DWË.DWËDVěDVěDÝ@DWD»€DVěDÝ@DV˙D‰ĐDWDŔäDWD»€Hr˙@Hs—OHr˙@Hr±¸PHs{¤äHs—ODVěDV˙DWDWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝ@D‰Đ.DŔäD»€.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW. Underweight ANNYYNEGDWDW”DW—DWËDXjNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW”DWýDWýB˙B–BfBiC B©9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1142 11421327114213271142AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20806 DVěDĚ$DWí.DWíDVěDVěDĚ$DV˙DßDVěDĚ$DV˙Dß....Hrî$Hr˛Hrî$Hr˛..DVěDV˙..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DĚ$Dß....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW·DW(. Normal weightA NNYYNEGDWDW¶DW¶..NEG....YNNNNYYDVě........DWDW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¶DWýDWýB˙B¸BGC BË9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421329114213291142AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20950 DVíD“äDWć.DWćDVíDVíD“äDWŁD‘ŚDVíD“äDWD„¨DWŽD‡<DWŁD‘ŚHršdHs‰öHršdHrł¨Hsn<<Hs‰öDVíDWDWŽDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. D“äD„¨.D‡<D‘Ś.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNNYPOSDWDWŚDWŤDWćDX`POS....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBţBŤBpBqCB 9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1142 11421330114213301142AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20949 DVíD”DWŇ.DWŇDVíDVíD”DWD†ÄDVíD”DWD†Ä....HršHrłÄHršHrłÄ..DVíDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D”D†Ä....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW,. Normal weightA NNYYNEGDWDW‹DW±..NEG....YNNNNYYDVí........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW‹DWýDWýBţBŚBrCBź9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1142 11421333114213331142AĐYEARSMANOT REPORTED ApHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVű22848 DVűDŠŔDWç.DWçDVűDVűDŠŔDWDÁ\DVűDŠŔDWDÁ\....Hr¬s@HrÇÜHr¬s@HrÇÜ..DVűDW..AĐYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0DWçWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DŠŔDÁ\....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWÓDW+. Underweight ANYNYPOSDW+DWĚDWĚ..POS....YNNNNYNDVű........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŇDWçDWçBŮBÄBBíBŘ7-8 months A€7-8 months A€0-1 month A8-9 months A . ...C4591001C4591001 1142 11421335114213351142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20951 DVíDËčDWđ..DVíDVíDËčDWđD°¸DVíDËčDWDĹXDWŰD…ÔDWđD°¸Hrš?hHsď¸Hrš?hHrłEXHsÓľTHsď¸DVíDWDWŰDWđAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DËčDĹX.D…ÔD°¸.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¸DWŰ. Overweight A0NNYYNEGDWDW·DW·DXDXNEG....YNNNNYYDVí........DWDW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW·DWýDWýBţB¸B#BFCBË9-10 months A 6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421340114213401142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21129 DVđD—hDWĂ.DWĂDVđDVđD—hDWD¸DVđD—hDWD¸....Hrť˙hHrą›8Hrť˙hHrą›8..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. D—hD¸....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĂDW(. Normal weightA NNYYNEGDW!DW»DW»..NEG....YNNNNYYDVđ........DW!DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÂDWýDWýBůBľB;CŕBÓ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421341114213411142AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20958 DVđD—¤DW¶.DW¶DVđDVđD—¤DWD… DVđD—¤DWD… ....Hrť˙¤Hrąś Hrť˙¤Hrąś ..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. D—¤D… ....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW%. Obese A@YNYYNEGDW!DWŤDW¶..NEG....YNNNNYYDVđ........DW!DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBůB‰BpCŕBž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421342114213421142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21131 DVđD±0DWŞ.DWŞDVđDVđD±0DW}DŰŘDVđD±0DWDĺ8DWhDßDW}DŰŘHrž0HsX'XHrž0HrĽź¸Hs<{HsX'XDVđDWDWhDW}AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D±0Dĺ8.DßDŰŘ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWcDWh. Normal weightA NNYYNEGDW%DWbDWgDWŞDX:NEG....YNNNNYNDVđ........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWbDWýDWýB÷B\B–B›CŕBs8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1142 11421343114213431142AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21132 DVńDŹ¬DW´.DW´DVńDVńDŹ¬DWD@DVńDŹ¬DWD@....HrźI,HrąšŔHrźI,HrąšŔ..DVńDW..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DŹ¬D@....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW3. Normal weightA NNYYNEGDW$DWŚDW´..NEG....YNNNNYYDVń........DW$DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421344114213441142AĐYEARSFA NOT REPORTED ApHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21136 DVńDą(DWó..DVńDVńDą(DWóDŇxDVńDą(DWD•LDWóDŇxDWóDŇxHrźr¨Hsó®řHrźr¨Hrą¬ĚHsó®řHsó®řDVńDWDWó.AĐYEARSAŕYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. Dą(D•L.DŇx..281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DWó. Normal weightA NNYYNEGDW%DWşDW»DX-DXÇNEG....YNNNNYYDVń........DW%DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWşDWýDWýBůB¶A°BCCĐBĘ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421345114213451142AđYEARSFA NOT REPORTED ApHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21393 DVńDşDWű..DVńDVńDşDWűDľČDVńDşDWD“äDWűDľČDWűDľČHrźtHsţ'HHrźtHrą«dHsţ'HHsţ'HDVńDWDWű.AđYEARSAđYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DşD“ä.DľČ..281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DWó. Overweight A0NNYYNEGDW%DWşDW»DX5DXĎNEG....YNNNNYYDVń........DW%DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWşDWýDWýBůB¶A0BCCĐBĘ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421346114213461142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21398 DVóD—¤DW¸..DVóDVóD—¤DWD’|DVóD—¤DWD’|....Hrˇô$Hrşű|Hrˇô$Hrşű|..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D—¤D’|....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¸DW). Normal weightA NYYYNEGDW#DW·DW·..NEG....YNNNNYYDVó........DW#DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW·DWýDWýBřB˛BFC°BĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421348114213481142AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21399 DVóD—hDW¸.DW¸DVóDVóD—hDWD©tDVóD—hDWD©t....HrˇóčHr˝µtHrˇóčHr˝µt..DVóDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D—hD©t....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DW). Normal weightA NNYYNEGDW)DWµDW¸..NEG....YNNNNYYDVó........DW)DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWµDWýDWýBöB®BHC°BĂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421349114213491142AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21404 DVóDĽ4DWđ..DVóDVóDĽ4DWđDŇxDVóDĽ4DWDăXDWÚD†DWđDŇxHr˘´HsďşxHr˘´HrĽťŘHsŇmHsďşxDVóDWDWÚDWđAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽ4DăX.D†DŇx.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWÚ. Underweight ANNYYNEGDW#DW»DW»DXDXNEG....YNNNNYYDVó........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĽDWýDWýB÷B¶B$BAC°BĘ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421350114213501142AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21899 DVóDµŕDWż.DWżDVóDVóDµŕDWD¤DVóDµŕDWD¤....Hr˘`HrĽ^Hr˘`HrĽ^..DVóDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DµŕD¤....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW). Normal weightA NYYYNEGDW)DWDWż..NEG....YNNNNYYDVó........DW)DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýB÷BŠBmC°Bž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421351114213511142AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô21900 DVôD–DWđ..DVôDVôD–DWđDˇôDVôD–DWD¦ŕDWŮD†DWđDˇôHrŁDHsď‰ôHrŁDHrĽa`HsŃHsď‰ôDVôDWDWŮDWđAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–D¦ŕ.D†Dˇô.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DWŮ. Overweight A0YNYYNEGDW%DW¸DW¸DXDXNEG....YNNNNYYDVô........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWşDWýDWýB÷B´B%BCC BÇ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWŮC4591001C4591001 1142 11421352114213521142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô21906 DVôDÔXDWđ..DVôDVôDÔXDWđDą DVôDÔXDWDÚčDWđDą DWđDą HrŁ‚XHsďˇ HrŁ‚XHrĂ,čHsďˇ Hsďˇ DVôDWDWđ.AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DÔXDÚč.Dą ..281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÉDWđ. Normal weightA NNYYNEGDW(DWĆDWĆDX*DXÄNEG....YNNNNYYDVô........DW(DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWČDWýDWýBňB˝AŕB5C BŐ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421353114213531142AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô21901 DVôDŐHDWľ.DWľDVôDVôDŐHDWD‡´DVôDŐHDWD‡´....HrŁHHr˝“´HrŁHHr˝“´..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DŐHD‡´....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW%. Normal weightA NNYYNEGDW%DWDWľ..NEG....YNNNNYYDVô........DW%DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBöB‰BmC Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421354114213541142AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22161 DVôDÖ8DW˝.DW˝DVôDVôDÖ8DWDă”DVôDÖ8DWDă”....HrŁ„8HrĽžHrŁ„8HrĽž..DVôDW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DÖ8Dă”....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW+. Normal weightA NNYYNEGDW%DWDW˝..NEG....YNNNNYYDVô........DW%DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýB÷BŠBmC Bť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421355114213551142AŔYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22165 DV÷D—,DWě..DV÷DV÷D—,DWěDĂDV÷D—,DWD’¸DWŘD˝`DWěDĂHr§9¬HsęeHr§9¬HrÂä¸HsĐ`HsęeDV÷DWDWŘDWěAŔYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—,D’¸.D˝`DĂ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĂDWŘ. Overweight A0YNYYNEGDW,DW»DW»DXDX©NEG....YNNNNYYDV÷........DW,DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÂDWýDWýBňB·B&B;CpBĚ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWěC4591001C4591001 1142 11421356114213561142AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22167 DV÷Dš°DWě..DV÷DV÷Dš°DWěDĂxDV÷Dš°DWD‘ŚDWŘDŔ0DWěDĂxHr§=0HsęexHr§=0HrÂăŚHsĐ0HsęexDV÷DWDWŘDWěAŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš°D‘Ś.DŔ0DĂx.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWŘ. Normal weightA NNYYNEGDW,DW»DW»DXDX©NEG....YNNNNYYDV÷........DW,DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĽDWýDWýBňB±B&BACpBĆ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421358114213581142AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22172 DVřDĐDWË.DWËDVřDVřDĐDW Dě¸DVřDĐDW Dě¸....Hr¨ŚĐHrÄ8Hr¨ŚĐHrÄ8..DVřDW ..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DĐDě¸....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW+. Normal weightA NNYYNEGDW+DWŤDWĐ..NEG....YNNNNYYDVř........DW+DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBńBBpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421359114213591142AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22536 DVřDŔ¨DWË.DWËDVřDVřDŔ¨DW¨DŇđDVřDŔ¨DWDŔ¨DWDŇ<DW¨DŇđHr¨´¨HsÎđHr¨´¨HrĂ¨Hs{¶<HsÎđDVřDWDWDW¨AđYEARSAđYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔ¨DŔ¨.DŇ<DŇđ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Obese A@YNYYNEGDW(DWŤDW—DWËDXeNEG....YNNNNYNDVř........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BfBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1142 11421360114213601142AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22537 DVřDżDWé.DWéDVřDVřDżDWDÂLDVřDżDWDÂL....Hr¨łHrĂLHr¨łHrĂL..DVřDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DżDÂL....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW(. Obese A@YNYYNEGDW(DWŤDWé..NEG....YNNNNYYDVř........DW(DWéYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBňB‚BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421361114213611142AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22541 DVůDŹ¬DWđ..DVůDVůDŹ¬DWđDŃÄDVůDŹ¬DWDŠHDWÚD‡đDWđDŃÄHr©Ő,HsďąÄHr©Ő,HrÂÜHHsŇnđHsďąÄDVůDWDWÚDWđAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŹ¬DŠH.D‡đDŃÄ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˝DWÚ. Normal weightA NNYYNEGDW(DW»DW»DXDXNEG....YNNNNYYDVů........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĽDWýDWýBňB±B$BACPBÄ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421362114213621142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22544 DVůD“0DWĽ.DWĽDVůDVůD“0DWD±0DVůD“0DWD±0....Hr©Ř°HrĂ0Hr©Ř°HrĂ0..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D“0D±0....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW). Normal weightA NYYYNEGDW)DWŚDWĽ..NEG....YNNNNYYDVů........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBňBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421363114213631142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22846 DVůDĆHDWú.DWúDVůDVůDĆHDW*D‚DVůDĆHDW*D‚....HrŞČHręaHrŞČHręa..DVůDW*..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN Y NY Y. .. DĆHD‚....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ... Underweight ANNYYNEGDWFDWúDWú..NEG....YNNNNYNDVů........DWF.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YYNNNY NYDWý.DWýBÔBÔ..CPCP7-8 months A€7-8 months A€ .9-10 months A . ...C4591001C4591001 1142 11421364114213641142AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű22851 DVűD¸tDWĘ.DWĘDVűDVűD¸tDWDâhDVűD¸tDWDâh....Hr¬ ôHrČzhHr¬ ôHrČzh..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D¸tDâh....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW,. Normal weightA NYYYNEGDW,DWŚDWĘ..NEG....YNNNNYYDVű........DW,DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421365114213651142AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű22852 DVűDŐüDWć.DWćDVűDVűDŐüDWÄDŘDVűDŐüDWDÝ¸DW±DÝ@DWÄDŘHr¬ľ|HsµgŘHr¬ľ|HrÇ$8Hsś¶ŔHsµgŘDVűDWDW±DWÄAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐüDÝ¸.DÝ@DŘ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŻDW±. Underweight ANNYYNEGDW1DW®DW°DWćDXNEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW®DWýDWýBďB BMBOC0B´8-9 months A5-6 months A`2-3 monthsA09-10 months A . ...C4591001C4591001 1142 11421366114213661142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23602 DVţDťDWě..DVţDVţDťDWěDÜČDVţDťDWDÓhDWŘDŇđDWěDÜČHr°zHsę~ČHr°zHrĚ_čHsĐđHsę~ČDVţDWDWŘDWěAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDÓh.DŇđDÜČ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĘDWŘ. Normal weightA NNYYNEGDW/DWÉDWÉDXDX©NEG....YNNNNYYDVţ........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÉDWýDWýBëB·B&B4CBĚ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1142 11421367114213671142AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23605 DVţDž4DWĘ.DWĘDVţDVţDž4DWDŐHDVţDž4DWDŐH....Hr°{4HrĚaČHr°{4HrĚaČ..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. Dž4DŐH....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĘDW/. Normal weightA NNYYNEGDW/DWÉDWÉ..NEG....YNNNNYYDVţ........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÉDWýDWýBëB·B4CBĚ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421368114213681142AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23610 DVţD—ŕDWĹ.DWĹDVţDVţD—ŕDW¨D˝śDVţD—ŕDWD˝`DW“DŕÄDW¨D˝śHr°tŕHsąśHr°tŕHrÍ›`Hsu-DHsąśDVţDWDW“DW¨AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—ŕD˝`.DŕÄD˝ś.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Underweight ANNYYNEGDW0DWŤDW’DWĹDXeNEG....YNNNNYNDVţ........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBęBzBkBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1142 11421369114213691142AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23612 DVţDĹĐDWŃ.DWŃDVţDVţDĹĐDWDÔXDVţDĹĐDWDÔX....Hr°˘ĐHrŃ¦ŘHr°˘ĐHrŃ¦Ř..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. DĹĐDÔX....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW3. Normal weightA NYYYNEGDW3DWŚDWŃ..NEG....YNNNNYYDVţ........DW3DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBçBvBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421370114213701142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23728 DVţDÇ8DWú.DWúDVţDVţDÇ8DWúDäHDVţDÇ8DWDĽ4DWĺD˝$DWúDäHHr°¤8HsüűHHr°¤8HrĚH´Hsá$¤HsüűHDVţDWDWĺDWúAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇ8DĽ4.D˝$DäH.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĂDWĺ. Overweight A0NNYYNEGDW/DWÂDWĂDXDX·NEG....YNNNNYYDVţ........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÂDWýDWýBëB°BB;CBĹ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1142 11421371114213711142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23730 DVţDÇtDWÉ.DWÉDVţDVţDÇtDWDŰ$DVţDÇtDWDŰ$....Hr°¤tHrĚg¤Hr°¤tHrĚg¤..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DÇtDŰ$....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Normal weightA NNYYNEGDW/DWŚDWÉ..NEG....YNNNNYYDVţ........DW/DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421372114213721142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23731 DV˙D” DWĘ.DWĘDV˙DV˙D” DWDĎäDV˙D” DWDĎä....Hr±Â HrĚ\dHr±Â HrĚ\d..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. D” DĎä....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Overweight A0YNYYNEGDW/DWŚDWĘ..NEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421373114213731142AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23732 DV˙D–DWĘ.DWĘDV˙DV˙D–DWŁDˇ¸DV˙D–DWDß DWŽDŢ¨DWŁDˇ¸Hr±Ä€HsŠ8Hr±Ä€HrÍ˝ Hsn“¨HsŠ8DV˙DWDWŽDWŁAđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–Dß .DŢ¨Dˇ¸.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Obese A@YNYYNEGDW0DW‹DWŤDWĘDX`NEG....YNNNNYNDV˙........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBęBxBpBrB˙BŤ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1142 11421374114213741142AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23925 DV˙D—,DWĘ.DWĘDV˙DV˙D—,DWDŕDV˙D—,DWDŕ....Hr±Ĺ¬HrÍľHr±Ĺ¬HrÍľ..DV˙DW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D—,Dŕ....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW0. Normal weightA NNYYNEGDW0DW‹DWÄ..NEG....YNNNNYYDV˙........DW0DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBęBxBrB˙BŤ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421375114213751142AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23928 DV˙D˝`DWĹ.DWĹDV˙DV˙D˝`DWŁDÄ,DV˙D˝`DWD×ÜDWŽDĂđDWŁDÄ,Hr±ëŕHsŠ(¬Hr±ëŕHrĚd\HsnxđHsŠ(¬DV˙DWDWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝`D×Ü.DĂđDÄ,.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Obese A@YNYYNEGDW/DWŚDWŤDWĹDX`NEG....YNNNNYNDV˙........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBpBqB˙BŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1142 11421376114213761142AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23932 DV˙D»DDWĹ.DWĹDV˙DV˙D»DDWDŰśDV˙D»DDWDŰś....Hr±éÄHrĐ\śHr±éÄHrĐ\ś..DV˙DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D»DDŰś....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW2. Overweight A0YNYYNEGDW2DWŚDWĹ..NEG....YNNNNYYDV˙........DW2DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1142 11421377114213771142AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23935 DV˙D˝$DWČ.DWČDV˙DV˙D˝$DWŁDŘDV˙D˝$DWD…DWŽDßÔDWŁDŘHr±ë¤HsŠ<Hr±ë¤HrÎµHsn”ÔHsŠ<DV˙DWDWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW2BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝$D….DßÔDŘ.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDW2DWŤDWŤDWČDX`NEG....YNNNNYNDV˙........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBéByBpBpB˙BŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1142 11421379114213791142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24322 DWD‘ČDWÍ.DWÍDWDWD‘ČDWŞDÓ,DWD‘ČDWDá´DW•DŠüDWŞDÓ,Hrą©HHs“r,Hrą©HHrŘK´Hswz|Hs“r,DWDWDW•DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‘ČDá´.DŠüDÓ,.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW•. Underweight ANNYYNEGDW=DW‹DW”DWÍDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBâBpBiBrBůB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1142 11421380114213801142AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24323 DWDľPDWě..DWDWDľPDWěDá<DWDľPDWDŢlDWŮDŕDWěDá<HrąŐĐHsę<HrąŐĐHrÖöěHsŃuHsę<DWDWDWŮDWěAđYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DľPDŢl.DŕDá<.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÓDWŮ. Normal weightA NNYYNEGDW>DWŇDWŘDXDX©NEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŇDWýDWýBăB¸B%B+BůBÎ8-9 months A6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1142 11421383114213831142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24327 DWD‘PDWË.DWËDWDWD‘PDWD×ÜDWD‘PDWD×Ü....HrşúPHrÖđ\HrşúPHrÖđ\..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. D‘PD×Ü....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW,. Normal weightA NNYYNEGDW=DWDWË..NEG....YNNNNYYDW........DW=DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBăBvBmBřB‹8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1142 11421384114213841142AĐYEARSFA NOT REPORTED ApHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24332 DWDĚŘDWá.DWáDWDWDĚŘDWDßDWDĚŘDWDß....Hr»5ŘHrŘIHr»5ŘHrŘI..DWDW..AĐYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĚŘDß....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW=DWŚDWá..NEG....YNNNNYYDW........DW=DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1142 11421385114213851142AđYEARSMANOT REPORTED ApHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25103 DWD–xDW×.DW×DWDWD–xDWD‹ěDWD–xDWD‹ě....Hr˝˘xHrÚěHr˝˘xHrÚě..DWDW..AđYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. D–xD‹ě....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚDW=. Normal weightA NYYYNEGDW=DW‹DWŃ..NEG....YNNNNYYDW........DW=DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBŕBnBrBöB„8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1142 11421386114213861142AĐYEARSMANOT REPORTED ApHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25106 DWDXDWŃ.DWŃDWDWDXDWˇD„äDWDXDWDŤĚDWŽDŠŔDWˇD„äHr˝¤XHs‡FdHr˝¤XHrÚšĚHsn?ŔHs‡FdDWDWDWŽDWˇAĐYEARSAŕYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DXDŤĚ.DŠŔD„ä.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW=DWŚDWŤDWŃDX^NEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŕBoBpBqBöB…8-9 months A3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1142 11421388114213881142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25108 DW DśDW”.DW”DW DW DśDW"DšěDW DśDW"Dšě....HrÄ4HrßíěHrÄ4Hrßíě..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DśDšě....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDW*. Obese A@YNYYNEGDWTDW‹DWß.. ....YNNNNYNDW ........DWT.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBÜBjBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DW:C4591001C4591001 1142 11421389114213891142AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25110 DWD” DWŢ.DWŢDWDWD” DW#D…DWD” DW#D…....HrĹ‰ Hrá*HrĹ‰ Hrá*..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. D” D…....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDWDDWŚDWŢ..NEG....YNNNNYYDW........DWDDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1142 11421390114213901142AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25655 DWD–xDWŃ..DWDWD–xDW"DŕLDWD–xDW"DŕL....HrĹ‹xHrŕ3LHrĹ‹xHrŕ3L..DWDW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D–xDŕL....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DW0. Overweight A0NNYYNEGDW?DW”DWŃ..NEG....YNNNNYYDW........DW?DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW”DWýDWýBÜBsBiBđB‡7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1142 11421391114213911142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25656 DWD¶ĐDWĹ.DWĹDWDWD¶ĐDW¨DľPDWD¶ĐDW%D¸8DW“DâhDW¨DľPHrĹ«ĐHsşPHrĹ«ĐHră˙¸Hsu.čHsşPDWDW%DW“DW¨AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶ĐD¸8.DâhDľP.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Underweight ANYYYNEGDW>DWŤDW’DWĹDXeNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŮBiBkBpBđB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1142 11421392114213921142AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25663 DWD‘DWŮ.DWŮDWDWD‘DW%Dá<DWD‘DW%Dá<....HrČ)Hrä(ĽHrČ)Hrä(Ľ..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. D‘Dá<....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŮDW%. Underweight ANNYYNEGDWHDWŘDWŮ..NEG....YNNNNYYDW........DWHDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŘDWýDWýBŮB´B%BîBÉ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1142 11421393114213931142AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25664 DWDż|DWű..DWDWDż|DWűD°¸DWDż|DW$D`DWűD°¸DWűD°¸HrČW|Hsţ8HrČW|Hrâ†`Hsţ8Hsţ8DWDW$DWű.AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. Dż|D`.D°¸..281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŘDWű. Overweight A0NNYYNEGDWADW×DWáDX5DXĎNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW×DWýDWýBÚB´A0B&BîBČ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ..DW$C4591001C4591001 1142 11421394114213941142AŕYEARSMANOT REPORTED ApHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26542 DWDĐDWŘ.DWŘDWDWDĐDW)D¤DWDĐDW)D¤....HrĚ%PHré$HrĚ%PHré$..DWDW)..AŕYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DĐD¤....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Normal weightA NNYYNEGDWLDWŚDWŘ..NEG....YNNNNYYDW........DWLDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1142 11421395114213951142AĐYEARSMAMULTIPLE A`HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26547 DWDšěDWŕ.DWŕDWDWDšěDW(DŽřDWDšěDW(DŽř....HrĚ'lHrçĘřHrĚ'lHrçĘř..DWDW(..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DšěDŽř....281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŕDW(. Underweight ANNYYNEGDWDDWßDWŕ..NEG....YNNNNYYDW........DWDDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWßDWýDWýBÖB¸BBëBÍ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1142 11421396114213961142AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26548 DWD¶XDWö.DWöDWDWD¶XDWöD©8DWD¶XDW(Dź$DWáD»DWöD©8HrĚBŘHs÷z8HrĚBŘHrçŰ$HsŰÜHs÷z8DWDW(DWáDWöAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶XDź$.D»D©8.281273 Rupp, Richard Earl ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŮDWá. Underweight ANNYYNEGDWDDWŘDWßDXDXłNEG....YNNNNYYDW........DWDDWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŘDWýDWýBÖB±BB%BëBĆ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1147 11471261114712611147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVő22227 DVőDĂ´DWż.DWżDVęDVőDĂ´DWDź`DVőDĂ´DWDź`....Hr¤Ă4HrÂń`Hr¤Ă4HrÂń`..DVőDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. DĂ´Dź`....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDW-DWŚDWż..NEG....YNNNNYYDVő........DW-DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471262114712621147AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVő22209 DVőD€¬DWż.DWżDVęDVőD€¬DWD’|DVőD€¬DWD’|....Hr¤€,HrÂä|Hr¤€,HrÂä|..DVőDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW~ .. D€¬D’|....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW~. Normal weightA NNYYNEGDW-DWŚDWż..NEG....YNNNNYYDVő........DW-DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBňBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471263114712631147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVî21047 DVîD•DW».DW»DVîDVîD•DWD°@DVîD•DWD°@....Hr›ZHrąÇŔHr›ZHrąÇŔ..DVîDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D•D°@....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW-DWŚDW»..NEG....YNNNNYYDVî........DW-DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471264114712641147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVî21049 DVîDŁ\DWÄ.DWÄDVîDVîDŁ\DWŁD~DVîDŁ\DWD$DWŽD}dDWŁD~Hr›h\Hs‰âHr›h\Hrą§¤Hsn2dHs‰âDVîDWDWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ\D$.D}dD~.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW&DW‹DWŤDWÄDX`NEG....YNNNNYNDVî........DW&.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BpBrCBž8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471268114712681147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVî21054 DVîD˝`DW˝.DW˝DVîDVîD˝`DWDš°DVîD˝`DWDš°....Hr›‚`Hrą˛0Hr›‚`Hrą˛0..DVîDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˝`Dš°....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘.. Normal weightA NNYYNEGDW&DWˇDW˝..NEG....YNNNNYYDVî........DW&DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýBůBťB\CB´8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1147 11471269114712691147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVî21056 DVîDĂđDWu..DVîDVîDĂđDWVD‚DVîDĂđDWDż¸DW?DöDWVD‚Hr›đHs$cHr›đHrą×8Hs…Hs$cDVîDWDW?DWVAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂđDż¸.DöD‚.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW8DW?. Underweight ANNYYNEGDW&DW7DW>DWuDXNEG....YNNNNYNDVî........DW&.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW7DWýDWýBůB3BżBĆCBJ8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1147 11471270114712701147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVî21058 DVîDÄhDWu..DVîDVîDÄhDWVD@DVîDÄhDWDÁ DW?DöDWVD@Hr›‰hHs$d@Hr›‰hHrąŘ Hs„Hs$d@DVîDWDW?DWVAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÄhDÁ .DöD@.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW8DW?. Normal weightA NNYYNEGDW&DW7DW>DWuDXNEG....YNNNNYNDVî........DW&.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW7DWýDWýBůB3BżBĆCBJ8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1147 11471271114712711147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVî21063 DVîDÁDWu..DVîDVîDÁDWVDôDVîDÁDWDÇ8DW?D÷DDWVDôHr›†Hs$dôHr›†HrąŢ¸Hs…ÄHs$dôDVîDWDW?DWVAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÁDÇ8.D÷DDô.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW8DW?. Normal weightA NN Y DW&DW7DW>DWuDXNEG....NNNNNYN.........DW&.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW7DWýDWýBůB3BżBĆCBJ8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1147 11471273114712731147AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVî21067 DVîDĎlDW´.DW´DVîDVîDĎlDWD•ÄDVîDĎlDWD•Ä....Hr›”lHrąDHr›”lHrąD..DVîDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĎlD•Ä....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Overweight A0YNYYNEGDW&DW‹DW´..NEG....YNNNNYYDVî........DW&DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‹DWýDWýBůB‡BrCBž8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471274114712741147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVî21068 DVîDŐHDW´.DW´DVîDVîDŐHDWDź$DVîDŐHDWDź$....Hr›šHHrą¶¤Hr›šHHrą¶¤..DVîDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŐHDź$....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANN Y DW+DWŚDW´..NEG....NNNNNYY.........DW+DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŚDWýDWýBůBBqCBź8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471275114712751147AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVî21069 DVîDŮDDWÄ.DWÄDVîDVîDŮDDWŁD‰ĐDVîDŮDDWDťĽDWŽD…ÔDWŁD‰ĐHr›žDHs‰îPHr›žDHrąµ<Hsn:ÔHs‰îPDVîDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW}BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDDťĽ.D…ÔD‰Đ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW/DW‹DWŤDWÄDX`NEG....YNNNNYNDVî........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBůB‡BpBrCBž8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471277114712771147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21072 DVńE @DWµ.DWµDVńDVńE @DWD¬DDVńE @DWD¬D....Hrźş$HrąĂÄHrźş$HrąĂÄ..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. E @D¬D....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDW&DWŚDWµ..NEG....YNNNNYNDVń........DW&.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471278114712781147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21078 DVńE/ŔDWÍ.DWÍDVńDVńE/ŔDWD`DVńE/ŔDWDďDWDDWD`HrźĽ|Hs—ŕHrźĽ|Hr»XHs{cHs—ŕDVńDWDWDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. E/ŔDď.DD`.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Normal weightA NNYYNEGDW$DW‹DW—DWÍDXjNEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBřB†BfBrCĐB›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1147 11471279114712791147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21079 DVńEŔDWż.DWżDVńDVńEŔDWDŘTDVńEŔDWDŘT....Hrźą¬HrąďÔHrźą¬HrąďÔ..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. EŔDŘT....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Underweight ANNYYNEGDW&DWŚDW´..NEG....YNNNNYYDVń........DW&DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471280114712801147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23792 DWD‡đDWÍ.DWÍDVńDWD‡đDWD€4DWD‡đDWD‡đDWD€4DWD€4HrÂŮđHs—´HrÂŮđHrÂŮđHs{d4Hs—´DW.DWDWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. DW=NO LONGER MEETS ELIGIBILITY CRITERIAPlacebo ANNYY NN .BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡đ..D€4D€4.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW. Normal weightA NNYYNEGDW=DW‹DW—DWÍDXjPOS....YNNNNYNDW........DW=.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW‹DWýDWýBfBrBňB€0-1 month A0-1 month A3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1147 11471281114712811147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVő22214 DVőD–đDWÄ.DWÄDVőDVőD–đDW˘D” DVőD–đDWDé¬DWŽDÍPDW˘D” Hr¤–pHs§ Hr¤–pHrĂ;¬Hsn‚PHs§ DVőDWDWŽDW˘AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–đDé¬.DÍPD” .31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW-DW‹DWŤDWÄDX_NEG....YNNNNYNDVő........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BpBrCB—8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471282114712821147AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVő22218 DVőDźśDW».DW»DVőDVőDźśDWDŻČDVőDźśDWDŻČ....Hr¤źHrĂČHr¤źHrĂČ..DVőDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DźśDŻČ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Normal weightA NNYYNEGDW/DWŚDW»..NEG....YNNNNYYDVő........DW/DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBňBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471283114712831147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVő22225 DVőDŁÔDW¸.DW¸DVőDVőDŁÔDWD‰DVőDŁÔDWD‰....Hr¤ŁTHrÂŰHr¤ŁTHrÂŰ..DVőDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DŁÔD‰....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Overweight A0YNYYNEGDW-DWŚDW¸..NEG....YNNNNYYDVő........DW-DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471284114712841147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVő22219 DVőD§DWĺ.DWĺDVőDVőD§DWDÉDVőD§DWDÉ....Hr¤¦śHrĂHr¤¦śHrĂ..DVőDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D§DÉ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Underweight ANNYYNEGDW-DW‹DWĺ..NEGDWž.DWžDWžYNNNNYYDVő........DW-DWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BrCB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471285114712851147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVő22226 DVőDźŘDW˝.DW˝DVőDVőDźŘDWźD´đDVőDźŘDWD—ŕDWŤDÄŕDWźD´đHr¤źXHs„ÓpHr¤źXHrÂéŕHsm(`Hs„ÓpDVőDWDWŤDWźAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DźŘD—ŕ.DÄŕD´đ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW-DW‹DWŚDW˝DX\NEG....YNNNNYNDVő........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BqBrCB—8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471286114712861147AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVő22231 DVőDÉDWÄ.DWÄDVőDVőDÉDW˘D‡´DVőDÉDWD$DWŽDŐüDW˘D‡´Hr¤ÉHsš´Hr¤ÉHrÂâ$HsnŠüHsš´DVőDWDWŽDW˘AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉD$.DŐüD‡´.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Overweight A0NNYYNEGDW-DW‹DWŤDWÄDX_NEG....YNNNNYNDVő........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBňB€BpBrCB—8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471287114712871147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVő22234 DVőDĚ$DWÄ.DWÄDVőDVőDĚ$DWDĘDVőDĚ$DWDĘ....Hr¤Ë¤HrĂHr¤Ë¤HrĂ..DVőDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DĚ$DĘ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Normal weightA NNYYNEGDW-DWŚDWÄ..NEG....YNNNNYYDVő........DW-DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471288114712881147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVő22235 DVőDÔXDWÄ.DWÄDVőDVőDÔXDW˘D§ĐDVőDÔXDWDŽřDWŤDÇ8DW˘D§ĐHr¤ÓŘHsşĐHr¤ÓŘHrÂŕřHsm*¸HsşĐDVőDWDWŤDW˘AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÔXDŽř.DÇ8D§Đ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Overweight A0YNYYNEGDW-DWŚDWŚDWÄDX_NEG....YNNNNYNDVő........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBqBqCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471289114712891147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü22236 DVüDŽřDWÉ.DWÉDVüDVüDŽřDWDĹXDVüDŽřDWDĹX....HrČřHrÉ®ŘHrČřHrÉ®Ř..DVüDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽřDĹX....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŚ.. Underweight ANNNYPOSDW-DW‹DWÉ..POS....YNNNNYYDVü........DW-DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‹DWýDWýBíB{BrC B8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1147 11471290114712901147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü23498 DVüDźśDWÄ..DVüDVüDźśDW˘D†DVüDźśDWD‚ŚDWŤDÍČDW˘D†HrŮśHs™HrŮśHrÉlHsm1HHs™DVüDWDWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DźśD‚Ś.DÍČD†.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Overweight A0NYYYNEGDW-DW‹DWŚDWÄDX_ ....YNNNNNNDVü..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBíB{BqBrC B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471291114712911147AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü22241 DVüDŽřDW±.DW±DVüDVüDŽřDW”Dˇ¸DVüDŽřDWD˝$DW~Dî\DW”Dˇ¸HrČřHsv?¸HrČřHrÉ¦¤HsY‹\Hsv?¸DVüDWDW~DW”AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽřD˝$.Dî\Dˇ¸.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWUDW~. Normal weightA NNYYNEGDW-DWTDW}DW±DXQNEG....YNNNNYNDVü........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWTDWýDWýBíBDB€B©C BY8-9 months A2-3 months A04-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471292114712921147AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü23494 DVüD™üDWĂ.DWĂDVüDVüD™üDW§DŠ„DVüD™üDWD‚DW’DěôDW§DŠ„HrÓüHsŹ5HrÓüHrÉk”HssçôHsŹ5DVüDWDW’DW§AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™üD‚.DěôDŠ„.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW-DW‹DW‘DWĂDXdNEG....YNNNNYNDVü........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BlBrC B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1147 11471294114712941147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23496 DVüD—ŕDWÄ.DWÄDVüDVüD—ŕDWD€čDVüD—ŕDWD€č....HrŃŕHrÉjhHrŃŕHrÉjh..DVüDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. D—ŕD€č....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW|. Underweight ANNYYNEGDW-DWŚDWÄ..NEG....YNNNNYYDVü........DW-DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471295114712951147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü23508 DVüDĄDWÄ.DWÄDVüDVüDĄDW˘DÝ@DVüDĄDWD¨„DWŤDçDW˘DÝ@HrßHsđ@HrßHrÉ’HsmKHsđ@DVüDWDWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWyBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄD¨„.DçDÝ@.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Overweight A0YNYYNEGDW-DW‹DWŚDWÄDX_NEG....YNNNNYNDVü........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BqBrC B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471296114712961147AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23512 DVüD§DWż.DWżDVüDVüD§DWD¨üDVüD§DWD¨ü....HráHrÉ’|HráHrÉ’|..DVüDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. D§D¨ü....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Overweight A0YNYYNEGDW-DWŚDWż..NEG....YNNNNYYDVü........DW-DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471297114712971147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23502 DVüDź`DWĂ.DWĂDVüDVüDź`DWDµ¤DVüDź`DWDµ¤....HrŮ`HrÉź$HrŮ`HrÉź$..DVüDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW} .. Dź`Dµ¤....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW}. Normal weightA NNYYNEGDW-DWŚDWĂ..NEG....YNNNNYYDVü........DW-DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471298114712981013AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü23513 DVüDŞ DW˝.DW˝DVüDVüDŞ DWˇD™HDVüDŞ DWD‰DWŽDĘřDWˇD™HHrä Hs‡ZČHrä HrÉrśHsnřHs‡ZČDVüDWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞ D‰.DĘřD™H.347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW-DW‹DWŤDW˝DX^NEG....YNNNNYNDVü........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BpBrC B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471299114712991147AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23515 DVüD´´DWÄ.DWÄDVüDVüD´´DWDŠDVüD´´DWDŠ....Hrî´HrÉsŚHrî´HrÉsŚ..DVüDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´´DŠ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW-DWŚDWÄ..NEG....YNNNNYYDVü........DW-DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471300114713001147AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVü23517 DVüD˛ DWí.DWíDVüDVüD˛ DWD’@DVüD˛ DWD ŚDW•D´<DWD’@Hrě Hs—%ŔHrě HrÉŠHswŁĽHs—%ŔDVüDWDW•DWAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ D Ś.D´<D’@.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW•. Overweight A0NNYYNEGDW1DW‹DW”DWíDXj ....YNNNNNNDVü..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBíB{BiBrC B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1147 11471301114713011147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23521 DVüD¸ěDWÄ.DWÄDVüDVüD¸ěDWD˝$DVüD¸ěDWD˝$....HrňěHrÉ¦¤HrňěHrÉ¦¤..DVüDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¸ěD˝$....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW1DWŚDWÄ.. ....YNNNNNYDVü.........DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471302114713021147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVü23525 DVüDĘřDWÄ..DVüDVüDĘřDWD`DVüDĘřDWD`....Hr®řHrÉyŕHr®řHrÉyŕ..DVüDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĘřD`....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NNYYNEGDW-DWŚDWÄ..NEG....YNNNNYYDVü........DW-DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqC B‘8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471303114713031147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVţ23528 DVţDŠHDWĂ.DWĂDVţDVţDŠHDWD„0DVţDŠHDWD„0....Hr°gHHrÉm°Hr°gHHrÉm°..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠHD„0....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW-DW‹DWĂ..NEG....YNNNNYYDVţ........DW-DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BrCBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471304114713041147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23556 DVţDŤĚDWË.DWËDVţDVţDŤĚDWD€4DVţDŤĚDWD€4....Hr°jĚHrÉi´Hr°jĚHrÉi´..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DŤĚD€4....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Normal weightA NNYYNEGDW-DWŚDWË..NEG....YNNNNYYDVţ........DW-DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471305114713051147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23560 DVţD”DWÄ.DWÄDVţDVţD”DWDďDVţD”DWDď....Hr°qHrĚ{Hr°qHrĚ{..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D”Dď....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW3DWŚDWÄ..NEG....YNNNNYYDVţ........DW3DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471306114713061147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23562 DVţD—,DWĂ.DWĂDVţDVţD—,DWŁD{ŔDVţD—,DWDśDWŽBđDWŁD{ŔHr°t,Hs‰ŕ@Hr°t,HrÉzHsmµđHs‰ŕ@DVţDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW}BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—,Dś.BđD{Ŕ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Normal weightA NNYYNEGDW-DW‹DWŤDWĂDX`NEG....YNNNNYNDVţ........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ..DWŁC4591001C4591001 1147 11471307114713071147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23564 DVţD™DWÄ.DWÄDVţDVţD™DW˘DŇđDVţD™DWDš8DWŤDĺ8DW˘DŇđHr°vHsĺđHr°vHrÉ¸HsmH¸HsĺđDVţDWDWŤDW˘AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™Dš8.Dĺ8DŇđ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Normal weightA NNYYNEGDW-DW‹DWŚDWÄDX_NEG....YNNNNYNDVţ........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BqBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471308114713081147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23689 DVţD°DWľ.DWľDVţDVţD°DWŁDÎDVţD°DWD·ŔDWŽD× DWŁDÎHr°ŤHsŠ2„Hr°ŤHrÉˇ@HsnŚ HsŠ2„DVţDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW€BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°D·Ŕ.D× DÎ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Overweight A0NNNYPOSDW-DW‹DWŤDWľDX`POS....YNNNNYNDVţ........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBíB{BpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471309114713091147AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23691 DVţDµ,DWĂ.DWĂDVţDVţDµ,DWDżDVţDµ,DWDż....Hr°’,HrÉ¨„Hr°’,HrÉ¨„..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW .. Dµ,Dż....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW. Normal weightA NNYNPOSDW-DWŚDWĂ..POS....YNNNNYYDVţ........DW-DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBíB|BqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471310114713101147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23696 DVţDĂDWĐ.DWĐDVţDVţDĂDWDČÜDVţDĂDWDČÜ....Hr° HrÉ˛\Hr° HrÉ˛\..DVţDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂDČÜ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW-DWŚDWĐ..NEG....YNNNNYYDVţ........DW-DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471311114713111147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23695 DVţDÂDWŃ.DWŃDVţDVţDÂDW D…DVţDÂDWDĆŔDWŤDÍŚDW D…Hr°źHs…őHr°źHrÉ°@Hsm1Hs…őDVţDWDWŤDW AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂDĆŔ.DÍŚD….31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŤ. Overweight A0YNYYNEGDW-DW‹DWŚDWŃDX]NEG....YNNNNYNDVţ........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BqBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471312114713121147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23781 DVţDÍDWÄ.DWÄDVţDVţDÍDWŁDŁÔDVţDÍDWDą(DWŽDčDDWŁDŁÔHr°ŞHsŠTHr°ŞHrÉ˘¨HsnťDHsŠTDVţDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍDą(.DčDDŁÔ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDWŽ. Obese A@YNYYNEGDW-DW‹DWŤDWÄDX`NEG....YNNNNYNDVţ........DW-.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBíB{BpBrCBŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1147 11471313114713131147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23786 DVţDÝ|DWé.DWéDVţDVţDÝ|DWD¶DVţDÝ|DWD¶....Hr°ş|HrÉźśHr°ş|HrÉźś..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWy .. DÝ|D¶....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWy. Normal weightA NNYYNEGDW-DWŚDWé..NEG....YNNNNYYDVţ........DW-DWéYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBíB|BqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471314114713141147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23788 DVţDß\DWĆ.DWĆDVţDVţDß\DWD—hDVţDß\DWD—h....Hr°Ľ\HrÉ€čHr°Ľ\HrÉ€č..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dß\D—h....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NN Y DW-DWŚDWĆ..NEG....NNNNNYY.........DW-DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBíB|BqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1147 11471315114713151147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25187 DWDµ¤DWŘ.DWŘDWDWDµ¤DWD©tDWDµ¤DWD©t....HrĂ¤HrÜôHrĂ¤HrÜô..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dµ¤D©t....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW=DWŚDWŘ.. ....YNNNNNYDW.........DWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBßBnBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471316114713161147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25190 DWD·HDWĐ.DWĐDWDWD·HDW°D‚ČDWD·HDWDŤDW›D{HDW°D‚ČHrĂ HHs› ČHrĂ HHrŰëHsSČHs› ČDWDWDW›DW°AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWwBNT162b2 (30 (*ESC*){unicode 03BC}g).. D·HDŤ.D{HD‚Č.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW›. Normal weightA NNYYNEGDW=DW‹DWšDWĐDXmNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBßBmBcBrBňB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471317114713171013AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25193 DWDĂDWü.DWüDWDWDĂDWD”ÔDWDĂDWD”Ô....HrĂHrŰóTHrĂHrŰóT..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĂD”Ô....347220 Dever, Michael Edward ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW@DWŚDWü..NEG....YNNNNYYDW........DW@DWüYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBßBnBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471318114713181147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25196 DWDôěDWµ.DWµDWDWDôěDW”DčDDWDôěDW$Dě¸DW~DďÄDW”DčDHrĂFěHsv†DHrĂFěHrââ¸HsYŚÄHsv†DDWDW$DW~DW”AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANNYY NN Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DôěDě¸.DďÄDčD.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWvDW~. Normal weightA NNYYNEGDW@DWuDW}DWµDXQ ....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNYNY NNDWuDWýDWýBÚBRB€BBňBj7-8 months A€2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1147 11471319114713191147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25402 DW DŤDWŮ.DWŮDW DW DŤDW$D–đDW DŤDW$D–đ....HrÄ0HrâŚđHrÄ0HrâŚđ..DW DW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŤD–đ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NNNYPOSDW@DWŚDWŮ..POS....YNNNNYYDW ........DW@DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBÚBiBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471320114713201147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25403 DW D› DWŇ.DWŇDW DW D› DW#DŤĚDW D› DW#DŤĚ....HrÄ? Hrá2LHrÄ? Hrá2L..DW DW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D› DŤĚ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Obese A@YNYYNEGDW@DW~DWŇ..NEG....YNNNNYYDW ........DW@DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW~DWýDWýBŰB\BBńBr7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471321114713211147AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25407 DW DËčDWč.DWčDW DW DËčDW¦D•ÄDW DËčDW$DşDW’DŐHDW¦D•ÄHrÄohHsŤîÄHrÄohHrâ°HssĐHHsŤîÄDW DW$DW’DW¦AđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DËčDş.DŐHD•Ä.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Obese A@YNYYNEGDW@DW‹DW‘DWĘDXcNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBlBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471322114713221147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25409 DW DĐÔDWâ..DW DW DĐÔDW#DDW DĐÔDW#D....HrÄtTHrá'„HrÄtTHrá'„..DW DW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DĐÔD....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NYYYNEGDWKDW‹DWŕ.. DWŽ.DWŽDWŽYNNNNYNDW ........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNYNY NNDW‹DWýDWýBŰBiBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471323114713231147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25557 DW DćdDWŇ.DWŇDW DW DćdDW#Dđ´DW DćdDW#Dđ´....HrÄ‰äHrá•4HrÄ‰äHrá•4..DW DW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DćdDđ´....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Overweight A0NNYYNEGDW@DW‹DWŇ..NEGDWŽ.DWŽDWŽYNNNNYYDW ........DW@DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBrBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471324114713241147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25559 DW DçDWĂ.DWĂDW DW DçDW¦DĂxDW DçDW#DńhDW‘DŔäDW¦DĂxHrÄŠHsŽxHrÄŠHrá•čHsrjdHsŽxDW DW#DW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDńh.DŔäDĂx.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW‘. Normal weightA NNYYNEGDW@DW‹DWDWĂDXc ....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‹DWýDWýBŰBiBmBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471325114713251147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25560 DW Dĺ°DWŇ.DWŇDW DW Dĺ°DW#DíäDW Dĺ°DW#Díä....HrÄ‰0Hrá’dHrÄ‰0Hrá’d..DW DW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dĺ°Díä....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWx.. Overweight A0NNYYNEGDWDDWwDWŇ..NEG....YNNNNYYDW ........DWDDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWwDWýDWýBŰBUB†BńBk7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471326114713261147AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25564 DW DÔDWŮ.DWŮDW DW DÔDW#DßÔDW DÔDW#DßÔ....HrÄwśHrá„THrÄwśHrá„T..DW DW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÔDßÔ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW@DWŚDWŮ..NEG....YNNNNYYDW ........DW@DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471327114713271147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25570 DW DńhDWŮ.DWŮDW DW DńhDW DńhDW DńhDW Dńh....HrÄ”čHrÄ”čHrÄ”čHrÄ”č..DW ...AŕYEARS. 12-15 YearsAWHITE AWHITE A. DWADVERSE EVENT BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. Dńh.....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDW@DWŚDWŮ..NEGDW‡.DW‡DW‡YNNNNYYDW ........DW@DWŮYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDWŚDWýDWýBqBńB€0-1 month A0-1 month A0-1 month A8-9 months A . ...C4591001C4591001 1147 11471328114713281147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25576 DW DďDWî.DWîDW DW DďDWÔDŮřDW DďDW$D™HDWľDëČDWÔDŮřHrÄ’HsĘ×řHrÄ’HrâŹHHsčČHsĘ×řDW DW$DWľDWÔAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďD™H.DëČDŮř.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DWľ. Obese A@YYNYPOSDWDDW”DW˝DWîDX‘POS....YNNNNYNDW ........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW”DWýDWýBÚBqB@BiBńB7-8 months A€4-5 months AP2-3 monthsA08-9 months A . ...C4591001C4591001 1147 11471329114713291147AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25577 DW DřpDWÍ.DWÍDW DW DřpDWŞD·DW DřpDW#D¶XDW•DĐÔDWŞD·HrÄ›đHs“VHrÄ›đHráZŘHswŔTHs“VDW DW#DW•DWŞAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DřpD¶X.DĐÔD·.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW•. Obese A@YNYYNEGDW@DW‹DW”DWÍDXgNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBiBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471330114713301147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25605 DW DúČDWÍ.DWÍDW DW DúČDWDŮDDW DúČDW$Dđ´DW’DîDWDŮDHrÄžHHs—lÄHrÄžHHrâć´HsséHs—lÄDW DW$DW’DWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DúČDđ´.DîDŮD.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Normal weightA NNYYNEGDW@DW‹DW‘DWÍDXjNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBlBrBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471331114713311147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25580 DW DűôDW›.DW›DW DW DűôDW$DďDW DűôDW$Dď....HrÄźtHrâĺHrÄźtHrâĺ..DW DW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DűôDď....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Obese A@YYYYNEGDW@DWŚDWá..NEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471332114713321147AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25607 DWDĐDWí.DWíDWDWDĐDW©D¨ŔDWDĐDW$DĐDW’DßDW©D¨ŔHrĹŤĐHs‘ö@HrĹŤĐHrâĆHssÚHs‘ö@DWDW$DW’DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWvBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐDĐ.DßD¨Ŕ.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW’. Overweight A0NNYYNEGDW@DW‹DW‘DWÍDXfNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBlBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471333114713331147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25615 DWDźŘDWŮ.DWŮDWDWDźŘDW*Dę$DWDźŘDW*Dę$....HrĹ”ŘHręÉ$HrĹ”ŘHręÉ$..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DźŘDę$....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YYYYNEGDWFDWŚDWŮ.. ....YNNNNYYDW........DWFDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBÔBcBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471334114713341147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25610 DWDˇDWŇ.DWŇDWDWDˇDW#D~DWDˇDW#D~....HrĹ–Hrá#HrĹ–Hrá#..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW€ .. DˇD~....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW€. Underweight ANNYYNEGDW@DWŚDWŇ.. ....YNNNNYYDW........DW@DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471335114713351147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25681 DWDˇôDWŇ.DWŇDWDWDˇôDW#DĽDWDˇôDW#DĽ....HrĹ–ôHrá$<HrĹ–ôHrá$<..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW€ .. DˇôDĽ....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚDW€. Normal weightA NNYYNEGDW@DW‹DWŇ..NEGDW”.DW”DW”YNNNNYYDW........DW@DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471336114713361147AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25682 DWDłDWÉ..DWDWDłDW#Dˇ@DWDłDW#Dˇ@....HrĹ¨HráEŔHrĹ¨HráEŔ..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DłDˇ@....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŚ.. Normal weightA NNYYNEGDW@DW‹DWŕ..NEGDWÓ.DWÓDWÓYNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBŰBiBrBđB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471337114713371147AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25683 DWDąÜDWŇ.DWŇDWDWDąÜDW#DÝ|DWDąÜDW#DÝ|....HrĹ®ÜHráüHrĹ®ÜHráü..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. DąÜDÝ|....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW|. Normal weightA NNYYNEGDW@DWŚDWŇ..NEG....YNNNNYYDW........DW@DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471338114713381147AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25688 DWDĚ`DWŇ.DWŇDWDWDĚ`DW#DśDWDĚ`DW#Dś....HrĹÁ`Hrá&HrĹÁ`Hrá&..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. DĚ`Dś....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Normal weightA NNYYNEGDWDDWŚDWŇ..NEG....YNNNNYYDW........DWDDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471339114713391147AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25761 DWDÎ@DWŕ.DWŕDWDWDÎ@DWĽD©ěDWDÎ@DW$DĎlDW§D˛ DWĽD©ěHrĹĂ@Hs«ěHrĹĂ@HrâĹlHsŹ\ Hs«ěDWDW$DW§DWĽAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ@DĎl.D˛ D©ě.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW§. Normal weightA NYYYNEGDW@DW‹DW¦DWŘDXyNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBWBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471340114713401147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25764 DWDĺ°DWŮ.DWŮDWDWDĺ°DW#DĚśDWDĺ°DW#DĚś....HrĹÚ°HráqHrĹÚ°Hráq..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW| .. Dĺ°DĚś....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW|. Underweight ANNYYNEGDW@DWŚDWŮ..NEG....YNNNNYYDW........DW@DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471341114713411147AŕYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25771 DWDđ´DWŕ.DWŕDWDWDđ´DW®Dż|DWDđ´DW#DÂÄDW™DÄŕDW®Dż|HrĹĺ´Hs¤|HrĹĺ´HrágDHs|ú`Hs¤|DWDW#DW™DW®AŕYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dđ´DÂÄ.DÄŕDż|.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW™. Normal weightA NNYYNEGDW@DW’DWDWŕDXkNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpBeBkBđB…7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471342114713421147AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25860 DWDđ<DWŕ.DWŕDWDWDđ<DW®DŔ0DWDđ<DW#DÂDW™DĹXDW®DŔ0HrĹĺ<HsĄ0HrĹĺ<HráfHs|úŘHsĄ0DWDW#DW™DW®AŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dđ<DÂ.DĹXDŔ0.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW™. Overweight A0YNYYNEGDW@DW’DWDWŕDXkNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpBeBkBđB…7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471343114713431147AĐYEARSMANOT REPORTED ApNOT REPORTED A0 .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25768 DWDî\DWŮ.DWŮDWDWDî\DW$DăXDWDî\DW$DăX....HrĹă\HrâŮXHrĹă\HrâŮX..DWDW$..AĐYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dî\DăX....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWFDWŚDWŮ..NEG....YNNNNYYDW........DWFDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471344114713441147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25864 DWDöDWé.DWéDWDWDöDW3DíäDWDöDW3Díä....HrĹëHröŞdHrĹëHröŞd..DWDW3..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DöDíä....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWODWŚDWé..NEG....YNNNNYYDW........DWODWéYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBËBZBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471345114713451147AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25866 DWD÷řDWÍ.DWÍDWDWD÷řDW¨DÇ8DWD÷řDW$DîDW“D×(DW¨DÇ8HrĹěřHsĂ8HrĹěřHrâäHsu#¨HsĂ8DWDW$DW“DW¨AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW~BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷řDî.D×(DÇ8.31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŚDW“. Obese A@YNYYNEGDW@DW‹DW’DWÍDXeNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‹DWýDWýBÚBhBkBrBđB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1147 11471346114713461147AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25867 DWDýÔDWÓ.DWÓDWDWDýÔDW#DşDWDýÔDW#Dş....HrĹňÔHrá^HrĹňÔHrá^..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DýÔDş....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0YNYYNEGDWADWŚDWÓ.. ....YNNNNNYDW.........DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1147 11471347114713471147AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25881 DWEŔDWÓ.DWÓDWDWEŔDW$Dä„DWEŔDW$Dä„....HrĹő,HrâÚ„HrĹő,HrâÚ„..DWDW$..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. EŔDä„....31313 Garcia-Diaz, Julia ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWADWŚDWÓ..NEG....YNNNNYYDW........DWADWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501118115011181150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20002 DV»D‚PDW’.DW’DV»DV»D‚PDVÎDúDV»D‚PDVÎDú....HrX ĐHrqŹHrX ĐHrqŹ..DV»DVÎ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D‚PDú....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Underweight ANNYYNEGDVëDW‹DW‹..NEG....YNNNNYYDV»........DVëDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBżBqC0BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501119115011191150AŕYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20005 DV»D¤ÄDWŤ.DWŤDV»DV»D¤ÄDVĐDÇ°DV»D¤ÄDVĐDÇ°....HrX-DHrs˙°HrX-DHrs˙°..DV»DVĐ..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤ÄDÇ°....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANYYYNEGDVěDWŚDWŤ..NEG....YNNNNYYDV»........DVěDWŤYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCŕB˝BqC0BŇ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501120115011201150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20007 DV»DĽpDWĹ.DWĹDV»DV»DĽpDW©DÎDV»DĽpDVŃD¬DW”DŢ¨DW©DÎHrXDđHs’„HrXDđHru7,Hsv|¨Hs’„DV»DVŃDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽpD¬.DŢ¨DÎ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Underweight ANNYYNEGDVňDWŚDWŽDWĹDXfNEG....YNNNNYNDV»........DVň.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCĐBĽBjBqC0BŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501121115011211150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20010 DV»Dé4DWÉ.DWÉDV»DV»Dé4DW©DňXDV»Dé4DVÎD—ŕDW”DDW©DňXHrXq´Hs’?ŘHrXq´Hrq,ŕHsv6Hs’?ŘDV»DVÎDW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dé4D—ŕ.DDňX.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDVëDW‹DW‹DWÉDXfNEG....YNNNNYYDV»........DVëDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCBżBjBqC0BŇ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501123115011231150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20075 DVĽD¨DWľ.DWľDVĽDVĽD¨DW˘Dč€DVĽD¨DVĐDčřDWŤDëPDW˘Dč€HrY‚Hsű€HrY‚Hrt řHsmNĐHsű€DVĽDVĐDWŤDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨Dčř.DëPDč€.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Overweight A0NNYYNEGDVíDWŚDWŚDWľDX_NEG....YNNNNYNDVĽ........DVí.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCŕB˝BqBqC BŃ10-11 monthsA°6-7 months Ap4-5 monthsAP11-12 monthsAŔ . ...C4591001C4591001 1150 11501124115011241150AĐYEARSMAASIAN A@HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20076 DVżD†ÄDWŤ.DWŤDVżDVżD†ÄDVŐDęśDVżD†ÄDVŐDęś....Hr]UDHrzşHr]UDHrzş..DVżDVŐ..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D†ÄDęś....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDVńDWŚDWŤ..NEG....YNNNNYYDVż........DVńDWŤYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýCB¸BqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501125115011251150AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVż20077 DVżD˘äDWĚ.DWĚDVżDVżD˘äDW©D—¤DVżD˘äDVÔDé¬DW’Dě@DW©D—¤Hr]qdHs‘ĺ$Hr]qdHryg¬Hssç@Hs‘ĺ$DVżDVÔDW’DW©AŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘äDé¬.Dě@D—¤.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Overweight A0YNYYNEGDVńDWŚDW‘DWĚDXfNEG....YNNNNYNDVż........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýC BąBlBqCđBÎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501126115011261150AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20078 DVżD®$DWá.DWáDVżDVżD®$DVÔDďÄDVżD®$DVÔDďÄ....Hr]|¤HrymÄHr]|¤HrymÄ..DVżDVÔ..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®$DďÄ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDVđDWŚDWŤ..NEG....YNNNNYYDVż........DVđDWŤYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýC BąBqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501127115011271150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVż20122 DVżDÄ,DWß.DWßDVżDVżDÄ,DVÖDčĽDVżDÄ,DVÖDčĽ....Hr]’¬Hr| ĽHr]’¬Hr| Ľ..DVżDVÖ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DÄ,DčĽ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Obese A@YNYYNEGDVňDWŚDW‘..NEG....YNNNNYYDVż........DVňDW‘YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýC€B·BqCđBÎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501128115011281150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVż20127 DVżDůśDWÂ.DWÂDVżDVżDůśDW¦Dż¸DVżDůśDVŐDäüDW‘DŘDW¦Dż¸Hr]ČHsŽ¸Hr]ČHrz´|Hsr+XHsŽ¸DVżDVŐDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. DůśDäü.DŘDż¸.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDVřDWŚDWDWÂDXcNEG....YNNNNYNDVż........DVř.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCB¸BmBqCđBÎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501129115011291150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20131 DVŔD{„DWÄ.DWÄDVŔDVŔD{„DW DépDVŔD{„DVŐDt|DWŤDŚ(DW DépHr^›„Hs†YpHr^›„HrzCüHslď¨Hs†YpDVŔDVŐDWŤDW AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D{„Dt|.DŚ(Dép.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDVřDWŚDWŚDWÄDX]NEG....YNNNNYNDVŔ........DVř.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýCB¸BqBqCŕBÍ10-11 monthsA°6-7 months Ap4-5 monthsAP11-12 monthsAŔ . ...C4591001C4591001 1150 11501130115011301150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20132 DVŔDöDWŽ.DWŽDVŔDVŔDöDVÔDŠHDVŔDöDVÔDŠH....Hr_HryHHr_HryH..DVŔDVÔ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DöDŠH....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW). Obese A@YNNYPOSDVôDWŚDWŽ..POS....YNNNNYYDVŔ........DVôDWŽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŚDWýDWýC BąBqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501131115011311150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20200 DVŔD÷DWŞ..DVŔDVŔD÷DWRDôDVŔD÷DVÔDŠDW>D PDWRDôHr_HsôHr_HryHsÝPHsôDVŔDVÔDW>DWRAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷DŠ.D PDô.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW7DW>. Overweight A0NYYYNEGDVôDW6DW=DWnDXNEG....YNNNNYNDVŔ........DVô.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW6DWýDWýC BcBŔBÇCŕBw10-11 monthsA°3-4 months A@6-7 monthsAp11-12 monthsAŔ . ...C4591001C4591001 1150 11501132115011321150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20201 DVŔDöĚDWŽ.DWŽDVŔDVŔDöĚDVÔDŠDVŔDöĚDVÔDŠ....Hr_ĚHryHr_ĚHry..DVŔDVÔ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. DöĚDŠ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Overweight A0YNYYNEGDVôDWŚDWŽ..NEG....YNNNNYYDVŔ........DVôDWŽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýC BąBqCŕBÍ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501133115011331150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20202 DVÁD‡đDW‹.DW‹DVÁDVÁD‡đDVŐDŔäDVÁD‡đDVŐDŔä....Hr_ůpHrzdHr_ůpHrzd..DVÁDVŐ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‡đDŔä....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW2.. Normal weightA NNYYNEGDVńDW1DW‹..NEG....YNNNNYYDVÁ........DVńDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW1DWýDWýCB]BĚCĐBq10-11 monthsA°3-4 months A@0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501134115011341150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20204 DVÁD±0DWÂ..DVÁDVÁD±0DW¦Dá´DVÁD±0DVŐDŞdDW‘DĚŘDW¦Dá´Hr`"°HsŽ:´Hr`"°HrzyäHsrvXHsŽ:´DVÁDVŐDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D±0DŞd.DĚŘDá´.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDVňDW…DW…DWÂDXcNEG....YNNNNYYDVÁ........DVňDW…YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCB¸BmBqCĐBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501135115011351150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20218 DVÁDłÄDWŤ..DVÁDVÁDłÄDVŘD¬řDVÁDłÄDVŘD¬ř....Hr`%DHr~přHr`%DHr~př..DVÁDVŘ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DłÄD¬ř....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDV÷DWŠDWŠ..NEG....YNNNNYYDVÁ........DV÷DWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýC`BµBqCĐBĚ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1150 11501136115011361150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20220 DVÁDäHDWĂ..DVÁDVÁDäHDW§D¦,DVÁDäHDVŐD÷DDW‘DůŘDW§D¦,Hr`UČHsŹP¬Hr`UČHrzĆÄHsrŁXHsŹP¬DVÁDVŐDW‘DW§AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäHD÷D.DůŘD¦,.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDVńDWŚDWDWĂDXdNEG....YNNNNYNDVÁ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýCB¸BmBqCĐBĚ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1150 11501166115011661150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20222 DVéD ŚDWĂ.DWĂDVéDVéD ŚDW§DřDVéD ŚDV˙D@DW”D‚DW§DřHr”ÎHsŹ*xHr”ÎHr±±ŔHsv HsŹ*xDVéDV˙DW”DW§AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D ŚD@.D‚Dř.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDWDWŚDW“DWĂDXdNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB˙BŽBjBqCPB¤9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501168115011681150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20228 DVëDÇ8DWŞ.DWŞDVëDVëDÇ8DWD¦¤DVëDÇ8DWD¦¤....Hr——¸Hrł&¤Hr——¸Hrł&¤..DVëDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW” .. DÇ8D¦¤....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW”. Normal weightA NNYYNEGDW(DWŚDWŞ..NEG....YNNNNYYDVë........DW(DWŞYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBţBŤBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1150 11501171115011711150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20799 DVěD‰”DW°.DW°DVěDVěD‰”DWDXDVěD‰”DWDX....Hr«”Hr´iŘHr«”Hr´iŘ..DVěDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D‰”DX....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Normal weightA NNYYNEGDW!DWŚDW°..NEGDWü.DWüDWüYNNNNYYDVě........DW!DW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBýBŚBqC Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1150 11501176115011761150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20801 DVíD™üDWĂ.DWĂDVíDVíD™üDW§DĄ<DVíD™üDWDÂDW’DŔ¨DW§DĄ<Hrš |HsŹOĽHrš |HrłBHss»¨HsŹOĽDVíDWDW’DW§AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D™üDÂ.DŔ¨DĄ<.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDWDWŚDW‘DWĂDXdNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBlBqCB 9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501178115011781150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20803 DVđD˛\DW».DW»DVđDVđD˛\DWDődDVđD˛\DWDőd....Hrž\HrşäHrž\Hrşä..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. D˛\Dőd....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWD. Normal weightA NNYYNEGDW"DWŚDW»..NEG....YNNNNYYDVđ........DW"DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCŕBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501179115011791150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20804 DVđDŕDWż.DWżDVđDVđDŕDWŁDŁÔDVđDŕDWD¸DWŽD§”DWŁDŁÔHržHHsŠTHržHHrą›8Hsn\”HsŠTDVđDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕD¸.D§”DŁÔ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDW%DWŚDWŤDWżDX`NEG....YNNNNYNDVđ........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBůBBpBqCŕBť8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501180115011801150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21334 DVńD‚ŚDW».DW»DVńDVńD‚ŚDWDhDVńD‚ŚDWDh....Hrź<HrĽBčHrź<HrĽBč..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. D‚ŚDh....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NNYYNEGDW#DWŚDW»..NEG....YNNNNYYDVń........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB÷B†BqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ..DW…C4591001C4591001 1150 11501182115011821150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21339 DVńD´´DWq.DWqDVńDVńD´´DWUD¬DVńD´´DWDXDW@DčDWUD¬Hrźn4Hs#;Hrźn4HrąŻŘHsŤčHs#;DVńDWDW@DWUAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´´DX.DčD¬.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW7DW@. Normal weightA NNYYNEGDW$DW6DW?DWqDXNEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW6DWýDWýBůB2BľBÇCĐBF8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1150 11501183115011831150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21341 DVńDµ,DW¸.DW¸DVńDVńDµ,DWDĐDVńDµ,DWDĐ....Hrźn¬Hrą°PHrźn¬Hrą°P..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dµ,DĐ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NYYYNEGDW$DWŚDW¸..NEG....YNNNNYNDVń........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501185115011851150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21344 DVńDďDWż.DWżDVńDVńDďDW˘D¬DVńDďDWD®`DWŤDÉTDW˘D¬Hrź¨HsżHrź¨HrąĹŕHsm,ÔHsżDVńDWDWŤDW˘AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďD®`.DÉTD¬.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW!DWŚDWŚDWżDX_NEG....YNNNNYNDVń........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBůBBqBqCĐBś8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501186115011861150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21635 DVňDˇDWľ.DWľDVňDVňDˇDWD™DVňDˇDWD™....Hr ¬Hr»Hr ¬Hr»..DVňDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DˇD™....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NYYYNEGDW"DWŚDWľ..NEG....YNNNNYYDVň........DW"DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501187115011871150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21637 DVňDÇěDWÔ.DWÔDVňDVňDÇěDWD€4DVňDÇěDWD€4....Hr ŇěHrą—´Hr ŇěHrą—´..DVňDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇěD€4....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW"DWŚDWÔ..NEG....YNNNNYYDVň........DW"DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBůBBqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501189115011891150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21638 DVóD…ÔDWÄ.DWÄDVóDVóD…ÔDW¦DúDVóD…ÔDWDílDW‘DłDW¦DúHrˇâTHsŽSHrˇâTHr»VlHsr\HsŽSDVóDWDW‘DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. D…ÔDíl.DłDú.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW)DWŚDWDWÄDXcNEG....YNNNNYNDVó........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501190115011901150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21642 DVóD…\DWÄ.DWÄDVóDVóD…\DW¦DůŘDVóD…\DWDěôDW‘D˛ÔDW¦DůŘHrˇáÜHsŽRŘHrˇáÜHr»UôHsr\THsŽRŘDVóDWDW‘DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. D…\Děô.D˛ÔDůŘ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW)DWŚDWDWÄDXcNEG....YNNNNYNDVó........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501191115011911150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21850 DVóDštDW˝.DW˝DVóDVóDštDWDpDVóDštDWDp....HrˇöôHrĽgđHrˇöôHrĽgđ..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DštDp....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW1. Normal weightA NNYYNEGDW#DWŚDW˝..NEG....YNNNNYYDVó........DW#DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB÷B†BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501192115011921150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21851 DVóDµ¤DWĹ.DWĹDVóDVóDµ¤DW¨DßDVóDµ¤DWD¶XDW‘DŕDW¨DßHr˘$HsŰHr˘$Hr»XHsrŠHsŰDVóDWDW‘DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dµ¤D¶X.DŕDß.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Obese A@YYYYNEGDW(DWŚDWDWĹDXeNEG....YNNNNYNDVó........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501193115011931150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21852 DVóDÓhDW˝.DW˝DVóDVóDÓhDW Dv\DVóDÓhDWD’|DWŤDčDW Dv\Hr˘/čHs…ć\Hr˘/čHr˝ž|HsmhHs…ć\DVóDWDWŤDW AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓhD’|.DčDv\.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW(DWŚDWŚDW˝DX]NEG....YNNNNYNDVó........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBöB…BqBqC°Bš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501194115011941150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21853 DVóDđ´DW·.DW·DVóDVóDđ´DWDžpDVóDđ´DWDžp....Hr˘M4Hr˝ŞpHr˘M4Hr˝Şp..DVóDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. Dđ´Džp....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW0. Underweight ANNYYNEGDW)DWŚDW·..NEG....YNNNNYYDVó........DW)DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBöB…BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501195115011951150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22007 DVôD,DWĂ.DWĂDVôDVôD,DW¦D÷ĽDVôD,DWD…\DW‘D×(DW¦D÷ĽHrŁ6,HsŽPĽHrŁ6,Hr˝‘\Hsr€¨HsŽPĽDVôDWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. D,D…\.D×(D÷Ľ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW%DWŚDWDWĂDXcNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBöB…BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501196115011961150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22008 DVôD¤DWĂ.DWĂDVôDVôD¤DW¦Dř4DVôD¤DWD… DW‘DÖěDW¦Dř4HrŁ6¤HsŽQ4HrŁ6¤Hr˝‘ Hsr€lHsŽQ4DVôDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤D… .DÖěDř4.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW%DWŚDWDWĂDXcNEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBöB…BmBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501197115011971150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22012 DVôD¸tDW¶.DW¶DVôDVôD¸tDWDÄhDVôD¸tDWDÄh....HrŁftHrĽ~čHrŁftHrĽ~č..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. D¸tDÄh....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWw. Normal weightA NNYYNEGDW$DWŚDW¶..NEG....YNNNNYYDVô........DW$DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501198115011981150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22014 DVôD¸°DW¸.DW¸DVôDVôD¸°DWDâ¤DVôD¸°DWDâ¤....HrŁf°HrĽť$HrŁf°HrĽť$..DVôDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. D¸°Dâ¤....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW9. Normal weightA NNYYNEGDW$DWŚDW¸..NEG....YNNNNYYDVô........DW$DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501199115011991150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVô22137 DVôDŮĽDW“.DW“DVôDVôDŮĽDWD‚ČDVôDŮĽDWD‚Č....HrŁ‡ĽHrĽ=HHrŁ‡ĽHrĽ=H..DVôDW..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW“WITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŮĽD‚Č....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Normal weightA NNYYNEGDW$DWŚDWÄ..NEG....YNNNNYNDVô........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW“DW“BŤB†ApB B™5-6 months A`4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1150 11501200115012001150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22138 DVôDŕLDWĽ.DWĽDVôDVôDŕLDW DěDVôDŕLDWDłLDWŤDŔ¨DW DěHrŁŽLHs†\HrŁŽLHr˝żLHsm$(Hs†\DVôDWDWŤDW AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŕLDłL.DŔ¨Dě.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW%DWŚDWŚDWĽDX]NEG....YNNNNYNDVô........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBöB…BqBqC B™8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501201115012011150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22140 DVôDŕDW·.DW·DVôDVôDŕDWDłDVôDŕDWDł....HrŁŽHr˝żHrŁŽHr˝ż..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DŕDł....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW9. Normal weightA NNYYNEGDW%DWŚDW·..NEG....YNNNNYYDVô........DW%DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBöB…BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501202115012021150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22145 DV÷D~TDWÂ.DWÂDV÷DV÷D~TDW DýÔDV÷D~TDW DýÔ....Hr§ ÔHrÄˇTHr§ ÔHrÄˇT..DV÷DW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D~TDýÔ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW)DWŚDWÂ..NEG....YNNNNYYDV÷........DW)DWÂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501203115012031150AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22257 DV÷D…DWĂ.DWĂDV÷DV÷D…DWD|°DV÷D…DWD|°....Hr§(HrÂÎ°Hr§(HrÂÎ°..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D…D|°....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NYYYNEGDW*DWŚDWĂ..NEG....YNNNNYYDV÷........DW*DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501204115012041150AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22259 DV÷D†DWĂ.DWĂDV÷DV÷D†DW¦DrśDV÷D†DWD|tDW‘DŘDW¦DrśHr§(HsŤËśHr§(HrÂÎtHsr:XHsŤËśDV÷DWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D†D|t.DŘDrś.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0YNYYNEGDW*DWŚDWDWĂDXcNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBmBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DW,C4591001C4591001 1150 11501205115012051150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22262 DV÷D DWĽ.DWĽDV÷DV÷D DWD÷ĽDV÷D DWD÷Ľ....Hr§B”HrĂIĽHr§B”HrĂIĽ..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. D D÷Ľ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDW+DWŚDWĽ..NEG....YNNNNYYDV÷........DW+DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501206115012061150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22264 DV÷Dě¸DWÉ.DWÉDV÷DV÷Dě¸DWDę`DV÷Dě¸DWDđxDW™DęŘDWDę`Hr§Ź8Hs—}ŕHr§Ź8HrĹĺxHs} XHs—}ŕDV÷DWDW™DWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dě¸Dđx.DęŘDę`.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW™. Underweight ANNYYNEGDW*DWŚDWDWÉDXjNEG....YNNNNYNDV÷........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBeBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501207115012071150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22389 DV÷DňDWÄ.DWÄDV÷DV÷DňDW¨DčDV÷DňDWDý\DW’Dq¬DW¨DčHr§”śHsäHr§”śHrĂO\Hssl¬HsäDV÷DWDW’DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DňDý\.Dq¬Dč.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW(DWŚDW‘DWÄDXeNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBlBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501208115012081150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22393 DV÷DňXDWĂ.DWĂDV÷DV÷DňXDWDýDV÷DňXDWDý....Hr§”ŘHrĂOHr§”ŘHrĂO..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DňXDý....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW(. Normal weightA NNYYNEGDW(DWŚDWĂ..NEG....YNNNNYYDV÷........DW(DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBňBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501209115012091150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22399 DVřD‘ŚDWĽ..DVřDVřD‘ŚDWDĹXDVřD‘ŚDWDĹX....Hr¨…ŚHrĂXHr¨…ŚHrĂX..DVřDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D‘ŚDĹX....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW). Underweight ANYYYNEGDW)DWŚDWĽ..NEG....YNNNNYYDVř........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501210115012101150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22400 DVřDŐHDWŇ.DWŇDVřDVřDŐHDWDÚ¬DVřDŐHDWDŁDWDŐüDWDÚ¬Hr¨ÉHHs—n,Hr¨ÉHHrĆęHs{ąüHs—n,DVřDWDWDWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐHDŁ.DŐüDÚ¬.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW. Underweight ANNYYNEGDW+DWŚDW—DWĘDXjNEG....YNNNNYNDVř........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBďB~BfBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501211115012111150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22583 DVřDâhDWĆ.DWĆDVřDVřDâhDWDxDVřDâhDWDx....Hr¨ÖhHrĆľ€Hr¨ÖhHrĆľ€..DVřDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DâhDx....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW2.. Normal weightA NNYYNEGDW+DW1DWĆ..NEG....YNNNNYYDVř........DW+DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW1DWýDWýBďB#BĚC`B:8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1150 11501212115012121150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22587 DVřDâ,DWÂ.DWÂDVřDVřDâ,DWˇDâ,DVřDâ,DWDwÄDWŤDŔlDWˇDâ,Hr¨Ö,Hs‡Ł¬Hr¨Ö,HrĆľDHsm#ěHs‡Ł¬DVřDWDWŤDWˇAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ,DwÄ.DŔlDâ,.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW+DWŚDWŚDWÂDX^NEG....YNNNNYNDVř........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BqBqC`B•8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501213115012131150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22590 DVřDýÔDWľ..DVřDVřDýÔDWDľŚDVřDýÔDWDľŚ....Hr¨ńÔHrĂŚHr¨ńÔHrĂŚ..DVřDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DýÔDľŚ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Normal weightA NNYYNEGDW+DWŚDWľ..NEG....YNNNNYYDVř........DW+DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501214115012141150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22591 DVřD˙´DWË.DWËDVřDVřD˙´DW©DůŘDVřD˙´DWDę`DW’Dý DW©DůŘHr¨ó´Hs’GXHr¨ó´HrÇ0ŕHssř Hs’GXDVřDWDW’DW©AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˙´Dę`.Dý DůŘ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW1DWŚDW‘DWËDXfNEG....YNNNNYNDVř........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BlBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501215115012151150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22653 DVřD˙xDWË.DWËDVřDVřD˙xDW©DúDVřD˙xDWDę$DW’Dý\DW©DúHr¨óxHs’G”Hr¨óxHrÇ0¤Hssř\Hs’G”DVřDWDW’DW©AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˙xDę$.Dý\Dú.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW1DWŚDW‘DWËDXfNEG....YNNNNYNDVř........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BlBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501216115012161150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22654 DVůD¤ÄDWľ.DWľDVůDVůD¤ÄDWDů`DVůD¤ÄDWDů`....Hr©ęDHrĹî`Hr©ęDHrĹî`..DVůDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D¤ÄDů`....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Underweight ANNYYNEGDW*DWŚDWľ..NEG....YNNNNYYDVů........DW*DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501217115012171150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22657 DVůDđ´DWĽ.DWĽDVůDVůDđ´DW Dy¤DVůDđ´DW Dy¤....HrŞ64HrÄ$HrŞ64HrÄ$..DVůDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. Dđ´Dy¤....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NNYYNEGDW*DWŚDWĽ..NEG....YNNNNYYDVů........DW*DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBńB€BqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501218115012181150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22664 DVúD†ÄDWĂ.DWĂDVúDVúD†ÄDW§D¤DVúD†ÄDWDŢäDW‘DÁ\DW§D¤Hr«ÄHsŹ3$Hr«ÄHrĹÓäHsrjÜHsŹ3$DVúDWDW‘DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D†ÄDŢä.DÁ\D¤.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NYYYNEGDW*DWŚDWDWĂDXdNEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501219115012191150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22989 DVúDŠ„DWÄ.DWÄDVúDVúDŠ„DW DĂDVúDŠ„DW DĂ....Hr«!„HrÄf€Hr«!„HrÄf€..DVúDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŠ„DĂ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW0DWŚDWÄ..NEG....YNNNNYYDVú........DW0DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501220115012201150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22991 DVúD¨ŔDWĂ.DWĂDVúDVúD¨ŔDW¦DŞdDVúD¨ŔDWD¦,DW’DŢ¨DW¦DŞdHr«?ŔHsŽdHr«?ŔHrĹ›,HssŮ¨HsŽdDVúDWDW’DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨ŔD¦,.DŢ¨DŞd.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW,DWŚDW‘DWĂDXcNEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBlBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501221115012211150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú22994 DVúDĽ¬DWµ.DWµDVúDVúDĽ¬DWDĽ4DVúDĽ¬DWDĽ4....Hr«S¬HrČT4Hr«S¬HrČT4..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. DĽ¬DĽ4....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWMDW9. Overweight A0NYYYNEGDW3DWLDWµ..NEG....YNNNNYYDVú........DW3DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWLDWýDWýBîB=B±C@BS8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1150 11501222115012221150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22999 DVúDË4DWĽ.DWĽDVúDVúDË4DW DťDVúDË4DWDÎ@DWŤDżôDW DťHr«b4Hs† Hr«b4HrĹĂ@Hsm#tHs† DVúDWDWŤDW AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DË4DÎ@.DżôDť.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDW*DWŚDWŚDWĽDX]NEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBqBqC@B“8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501223115012231150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23063 DVúDŃDWĂ.DWĂDVúDVúDŃDW¦D~DVúDŃDWDťDDW‘D™üDW¦D~Hr«hHsŤ×Hr«hHrČ5DHsrC|HsŤ×DVúDWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃDťD.D™üD~.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYNPOSDW,DWŚDWDWĂDXcPOS....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBîB}BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1150 11501224115012241150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23067 DVúDđ´DWÂ.DWÂDVúDVúDđ´DW¦DÝ|DVúDđ´DWDÝ|DW’D|8DW¦DÝ|Hr«‡´HsŽ6|Hr«‡´HrČu|Hssw8HsŽ6|DVúDWDW’DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dđ´DÝ|.D|8DÝ|.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW3DWŚDW‘DWÂDXcNEG....YNNNNYNDVú........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BlBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501225115012251150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23070 DVúDđDWż.DWżDVúDVúDđDWDëPDVúDđDWDëP....Hr«‡HrČPHr«‡HrČP..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DđDëP....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWM.. Overweight A0YNYYNEGDW3DWLDWż..NEG....YNNNNYYDVú........DW3DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWLDWýDWýBîB=B±C@BS8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1150 11501226115012261150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23072 DVúDóHDWÂ.DWÂDVúDVúDóHDWDń,DVúDóHDWDń,....Hr«ŠHHrČ‰,Hr«ŠHHrČ‰,..DVúDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DóHDń,....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW0.. Normal weightA NNYYNEGDW/DW/DWÂ..NEG....YNNNNYYDVú........DW/DWÂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW/DWýDWýBîB BÎC@B68-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1150 11501227115012271150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23361 DVűDŇ´DW˝.DW˝DVűDVűDŇ´DWD¸tDVűDŇ´DWD¸t....Hr¬»4HrĹtHr¬»4HrĹt..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DŇ´D¸t....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Normal weightA NNYYNEGDW/DWŚDW˝..NEG....YNNNNYYDVű........DW/DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501228115012281150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23364 DVűDß DWľ.DWľDVűDVűDß DW˘DÁ\DVűDß DWDňDWŠD©ěDW˘DÁ\Hr¬Ç HsÔ\Hr¬Ç HrĹçHsiěHsÔ\DVűDWDWŠDW˘AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß Dň.D©ěDÁ\.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŠDWŠ. Normal weightA NNNNPOSDW,DW‰DW‰DWľDX_POS....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW‰DWýDWýBđB|BtBtC0BŹ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ..DWaC4591001C4591001 1150 11501229115012291150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVý23368 DVýD‡DWľ.DWľDVýDVýD‡DWˇDňĐDVýD‡DWDťDDWŽDĆ„DWˇDňĐHrŻ€Hs‡´PHrŻ€HrÍ{DHsn{„Hs‡´PDVýDWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW1BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‡DťD.DĆ„DňĐ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NYYYNEGDW1DWŚDWŤDWľDX^NEG....YNNNNYNDVý........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBpBqCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501230115012301150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVý23371 DVýD DWĂ.DWĂDVýDVýD DWDý\DVýD DWDý\....HrŻ+”HrĚ‰ÜHrŻ+”HrĚ‰Ü..DVýDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D Dý\....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW7. Underweight ANNNNPOSDW/DWŚDWĂ..POS....YNNNNYYDVý........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBëBzBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWkC4591001C4591001 1150 11501231115012311150AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVý23530 DVýD˝$DWÂ.DWÂDVýDVýD˝$DW¦DŽ€DVýD˝$DWDÚ¬DW‘Dx´DW¦DŽ€HrŻH¤HsŤç€HrŻH¤HrÍ¸¬Hsr"4HsŤç€DVýDWDW‘DW¦AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW2BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝$DÚ¬.Dx´DŽ€.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW2DWŚDWDWÂDXcNEG....YNNNNYNDVý........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBęByBmBqCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501232115012321150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23531 DVţD‚PDWí.DWíDVţDVţD‚PDW¦D$DVţD‚PDWDwLDW’D—¤DW¦D$Hr°_PHsŤÚ$Hr°_PHrĚĚHss’¤HsŤÚ$DVţDWDW’DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‚PDwL.D—¤D$.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Overweight A0NNYYNEGDW/DWŚDW‘DWÂDXcNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBlBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501233115012331150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23534 DVţD‚DW×.DW×DVţDVţD‚DWDwÄDVţD‚DWDwÄ....Hr°_HrĚDHr°_HrĚD..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. D‚DwÄ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Normal weightA NNYYNEGDW/DWŚDW×..NEG....YNNNNYYDVţ........DW/DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBëBzBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501234115012341150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23535 DVţDź`DWĹ.DWĹDVţDVţDź`DWDß DVţDź`DWDß ....Hr°|`HrĎ Hr°|`HrĎ ..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. Dź`Dß ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NYYYNEGDW6DWŚDWĹ..NEG....YNNNNYYDVţ........DW6DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501235115012351150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23638 DVţD±0DWÂ.DWÂDVţDVţD±0DW¦DĄ´DVţD±0DWDěDW’Dß DW¦DĄ´Hr°Ž0HsŤţ´Hr°Ž0HrĚx„HssÚ HsŤţ´DVţDWDW’DW¦AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. D±0Dě.Dß DĄ´.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NYYYNEGDW6DWŚDW‘DWÂDXcNEG....YNNNNYNDVţ........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBlBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501236115012361150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23640 DVţDĐÔDWý.DWýDVţDVţDĐÔDWDyŕDVţDĐÔDWDyŕ....Hr°ÔHrÍWŕHr°ÔHrÍWŕ..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW[ .. DĐÔDyŕ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW[. Underweight ANNYYNEGDW0DWŚDWÉ..NEG....YNNNNYYDVţ........DW0DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501237115012371150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23642 DVţDóüDWÉ.DWÉDVţDVţDóüDWŞDěDVţDóüDWDđxDW“Dµ¤DWŞDěHr°ĐüHs“‹Hr°ĐüHrĎřHsu$Hs“‹DVţDWDW“DWŞAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DóüDđx.Dµ¤Dě.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Obese A@YNYYNEGDW6DWŚDW’DWÉDXgNEG....YNNNNYNDVţ........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBéBxBkBqCBŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1150 11501238115012381150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23643 DV˙D,DWí.DWíDV˙DV˙D,DWDă”DV˙D,DWDă”....Hr±¶¬HrĐd”Hr±¶¬HrĐd”..DV˙DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D,Dă”....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Underweight ANNYYNEGDW6DWŚDWí..NEG....YNNNNYYDV˙........DW6DWíYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501239115012391150AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24073 DV˙Dß\DWĹ.DWĹDV˙DV˙Dß\DWDçDV˙Dß\DWDç....Hr˛ ÜHrĎHr˛ ÜHrĎ..DV˙DW..AĐYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. Dß\Dç....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW7. Normal weightA NNYYNEGDW2DWŚDWĹ..NEG....YNNNNYYDV˙........DW2DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBéBxBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501240115012401150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24074 DV˙DďDW˝.DW˝DV˙DV˙DďDWˇDň”DV˙DďDWDě|DWŽDÂDWˇDň”Hr˛Hs‡´Hr˛HrĐm|HsnwHs‡´DV˙DWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DďDě|.DÂDň”.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW3DWŚDWŤDW˝DX^NEG....YNNNNYNDV˙........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBčBwBpBqB˙BŽ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501241115012411150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙24077 DV˙EŃDWĆ.DWĆDV˙DV˙EŃDWDě¸DV˙EŃDWDě¸....Hr˛;HrĐm¸Hr˛;HrĐm¸..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWA .. EŃDě¸....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWA. Normal weightA NNYYNEGDW3DWŚDWĆ..NEG....YNNNNYYDV˙........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqB˙BŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1150 11501242115012421150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24080 DWD¬DW.DWDWDWD¬DWgD¤DWD¬DWD™üDWMDÎDWgD¤Hrł,Hs:ďHrł,HrŃl|HsŃ„Hs:ďDWDWDWMDWgAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬D™ü.DÎD¤.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWEDWM. Overweight A0YNYYNEGDW3DWDDWLDWDX$NEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDDWýDWýBçB.B±BąBţBE8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1150 11501243115012431150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24276 DWDÎ@DWľ.DWľDWDWDÎ@DW˘DŇxDWDÎ@DWDépDWŽDxDW˘DŇxHrłN@HsĺxHrłN@HrĚuđHsn-HsĺxDWDWDWŽDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ@Dép.DxDŇx.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANYYYNEGDW3DWŚDWŤDWľDX_NEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBëBzBpBqBţBŤ8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1150 11501244115012441150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24277 DWDśDWý.DWýDWDWDśDWKDĘDDWDśDWDçTDW8DŢ¨DWKDĘDHrą™Hs*ÄHrą™HrŘQTHrý2¨Hs*ÄDWDWDW8DWKAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DśDçT.DŢ¨DĘD.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW0DW8. Normal weightA NNYYNEGDW/DW/DW7DWiDWýNEG....YNNNNYNDW........DW8.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDW/DWýDWýBâBBĆBÎBůB+8-9 months A0-1 month A7-8 monthsA€8-9 months A . ...C4591001C4591001 1150 11501245115012451150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24279 DWD°¸DWý.DWýDWDWD°¸DWDó„DWD°¸DWDó„....HrąČ8Hr×HrąČ8Hr×..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D°¸Dó„....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW7. Underweight ANNNYPOSDW7DW“DWŃ..POS....YNNNNYYDW........DW7DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW“DWýDWýBăByBjBůBŹ8-9 months A4-5 months AP0-1 month A8-9 months A . ..DWC4591001C4591001 1150 11501246115012461150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24281 DWDéčDWç.DWçDWDWDéčDW%D—hDWDéčDW%D—h....HrşhHrăŢčHrşhHrăŢč..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DéčD—h....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWODWŚDWç..NEG....YNNNNYYDW........DWODWçYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBůB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501247115012471150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24526 DWD…ÔDWĘ.DWĘDWDWD…ÔDWDŁDWD…ÔDWDŁ....HrşîÔHrÖĽHrşîÔHrÖĽ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D…ÔDŁ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW7. Normal weightA NNYYNEGDW7DWŚDWĘ..NEG....YNNNNYYDW........DW7DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501248115012481150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24528 DWDˇ@DWÄ.DWÄDWDWDˇ@DW¨DÎ|DWDˇ@DWDëČDW“DäŔDW¨DÎ|Hr» @HsĘ|Hr» @Hr×HHsu1@HsĘ|DWDWDW“DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ@DëČ.DäŔDÎ|.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW7DWŚDW’DWÄDXeNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBkBqBřB‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501249115012491150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24529 DWDÇ8DWĂ.DWĂDWDWDÇ8DWŁDé4DWDÇ8DWDęŘDWŽDÔĐDWŁDé4Hr»08HsŠM´Hr»08Hr×XHsn‰ĐHsŠM´DWDWDWŽDWŁAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇ8DęŘ.DÔĐDé4.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW7DWŚDWŤDWĂDX`NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501250115012501150AĐYEARSFA NOT REPORTED ApHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24531 DWDĆŔDWĐ.DWĐDWDWDĆŔDWDę`DWDĆŔDWDę`....Hr»/ŔHr×ŕHr»/ŔHr×ŕ..DWDW..AĐYEARS. 12-15 YearsANOT REPORTED ApALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. DĆŔDę`....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW7. Normal weightA NNYYNEGDW7DWŚDWĐ..NEG....YNNNNYYDW........DW7DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501251115012511150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24744 DWDÖ°DW˝.DW˝DWDWDÖ°DWˇD‚DWDÖ°DWDśTDWŽD†DWˇD‚Hr»?°Hs‡C”Hr»?°HrŐcTHsn;Hs‡C”DWDWDWŽDWˇAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖ°DśT.D†D‚.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW6DWŚDWŤDW˝DX^NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501252115012521150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24746 DWDÝDWË.DWËDWDWDÝDWDĽčDWDÝDWDĽč....Hr»FHrŐčHr»FHrŐč..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DÝDĽč....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NNYYNEGDW6DWŚDWË..NEG....YNNNNYYDW........DW6DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501253115012531150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24747 DWDńŕDWÓ.DWÓDWDWDńŕDWDĄ<DWDńŕDWDĄ<....Hr»ZŕHrŐl<Hr»ZŕHrŐl<..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DńŕDĄ<....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NNYYNEGDW6DWŚDWÓ..NEG....YNNNNYYDW........DW6DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501254115012541150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24751 DWDř¬DWż.DWżDWDWDř¬DW˘D‡DWDř¬DWD¤ÄDWŤDŔ0DW˘D‡Hr»a¬HsšHr»a¬HrŐkÄHsm#°HsšDWDWDWŤDW˘AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dř¬D¤Ä.DŔ0D‡.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDW6DWŚDWŚDWżDX_NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBqBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501255115012551150AđYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24899 DWDŞ DWÉ.DWÉDWDWDŞ DWDđ´DWDŞ DWDđ´....HrĽe HrŐ·´HrĽe HrŐ·´..DWDW..AđYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DŞ Dđ´....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NYYYNEGDW6DWŚDWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501256115012561150AŔYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24900 DWDŞ(DWÉ.DWÉDWDWDŞ(DWDÔDWDŞ(DWDÔ....HrĽd¨HrŐ›HrĽd¨HrŐ›..DWDW..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DŞ(DÔ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW6. Normal weightA NYYYNEGDW6DWŚDWÉ..NEG....YNNNNYYDW........DW6DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBäBsBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501257115012571150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24905 DWDÂÄDW˝.DW˝DWDWDÂÄDWˇD‘DWDÂÄDWDz”DWŽD’ôDWˇD‘HrĽ}DHs‡R”HrĽ}DHrŐA”HsnGôHs‡R”DWDWDWŽDWˇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂÄDz”.D’ôD‘.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW6DWŚDWŤDW˝DX^NEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBpBqB÷B†8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501258115012581150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24906 DWDčDDWĘ.DWĘDWDWDčDDWŞDÜPDWDčDDWDXDW“Dę`DWŞDÜPHrĽ˘ÄHs“{PHrĽ˘ÄHrÚĄXHsu6ŕHs“{PDWDWDW“DWŞAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčDDX.Dę`DÜP.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW=DWŚDW’DWĘDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŕBoBkBqB÷B†8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501259115012591150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25032 DWDč€DWĘ.DWĘDWDWDč€DWŞDÜŚDWDč€DWDĐDW“DęśDWŞDÜŚHrĽŁHs“{ŚHrĽŁHrÚĄĐHsu7Hs“{ŚDWDWDW“DWŞAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dč€DĐ.DęśDÜŚ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW=DWŚDW’DWĘDXgNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŕBoBkBqB÷B†8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501260115012601150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25036 DWDý DWË.DWËDWDWDý DWDř¬DWDý DWDř¬....HrĽ· HrŘb¬HrĽ· HrŘb¬..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. Dý Dř¬....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW8. Normal weightA NNYYNEGDW8DWŚDWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqB÷B†8-9 months A4-5 months AP0-1 month A8-9 months A . ..DWbC4591001C4591001 1150 11501261115012611150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25037 DWD•DWÂ.DWÂDWDWD•DW˘D”DWD•DWDđ´DWŽDńŕDW˘D”Hr˝ˇHs§Hr˝ˇHrŘZ´Hsn¦ŕHs§DWDWDWŽDW˘AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D•Dđ´.DńŕD”.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYNPOSDW9DWŚDWŤDWÂDX_NEG....YNNNNYNDW........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBâBqBpBqBöB…8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501262115012621150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25040 DWDŽřDWá.DWáDWDWDŽřDWDđxDWDŽřDWDđx....Hr˝šřHrŘZxHr˝šřHrŘZx..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŽřDđx....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW9DWŚDWá..NEG....YNNNNYYDW........DW9DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBâBqBqBöB…8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1150 11501263115012631150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25126 DWD$DWĆ.DWĆDWDWD$DWŞD@DWD$DW"D±äDW“DßDWŞD@HrÂÓ$Hs“"@HrÂÓ$HrŕäHsu,Hs“"@DWDW"DW“DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D$D±ä.DßD@.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDW?DWŚDW’DWĆDXgNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBkBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501264115012641150AŕYEARSFA MULTIPLE A`HISPANIC OR LATINO AOTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25127 DWDŚ(DWĘ.DWĘDWDWDŚ(DW®DüäDWDŚ(DW!DwDWDřčDW®DüäHrÂŢ(HsáäHrÂŢ(HrŢyHs{ÜčHsáäDWDW!DWDW®AŕYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ(Dw.DřčDüä.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW. Normal weightA NNYYNEGDW=DWŚDW—DWĘDXkNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBfBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501265115012651150AŕYEARSFA NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPNOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25128 DWD¨üDWÓ.DWÓDWDWD¨üDW!Dî DWD¨üDW!Dî ....HrÂúüHrŢď HrÂúüHrŢď ..DWDW!..AŕYEARS. 12-15 YearsANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨üDî ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW=DWŚDWÓ..NEG....YNNNNYYDW........DW=DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501266115012661150AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25129 DWD®ŘDWŃ.DWŃDWDWD®ŘDW"DÜČDWD®ŘDW"DÜČ....HrĂŘHrŕ/ČHrĂŘHrŕ/Č..DWDW"..AŕYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D®ŘDÜČ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWEDWŚDWŃ..NEG....YNNNNYYDW........DWEDWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501267115012671150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25282 DWDô8DWĂ.DWĂDWDWDô8DW…DÔDWDô8DW!DÔXDWqDÔ”DW…DÔHrĂF8Hsb«śHrĂF8HrŢŐŘHsHNHsb«śDWDW!DWqDW…AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dô8DÔX.DÔ”DÔ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWpDWq. Normal weightA NNYYNEGDW=DWoDWpDWˇDXBNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWoDWýDWýBÝBOBŤBŽBňBd7-8 months A€2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1150 11501268115012681150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25283 DWDílDWŰ.DWŰDWDWDílDW!DÔĐDWDílDW!DÔĐ....HrĂ?lHrŢÖPHrĂ?lHrŢÖP..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. DílDÔĐ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW=. Normal weightA NNYYNEGDW=DWŚDWŰ..NEG....YNNNNYYDW........DW=DWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501269115012691150AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25287 DWDďDWŕ.DWŕDWDWDďDW"DäHDWDďDW"DäH....HrĂAHrŕ7HHrĂAHrŕ7H..DWDW"..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DďDäH....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Underweight ANNYYNEGDW>DWŚDWŕ..NEG....YNNNNYYDW........DW>DWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501270115012701150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25291 DWDń,DWĂ.DWĂDWDWDń,DW§D‚ČDWDń,DW#DčĽDW“Dz”DW§D‚ČHrĂC,HsŹ-HHrĂC,HráŤ<HstÇHsŹ-HDWDW#DW“DW§AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dń,DčĽ.Dz”D‚Č.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW@DWŚDW’DWĂDXdNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBňB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501271115012711150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25354 DW DĽDWż.DWżDW DW DĽDWˇDÝDW DĽDW!DzĐDWŽDäDWˇDÝHrÄ#<Hs‡ž„HrÄ#<HrŢ|PHsn™Hs‡ž„DW DW!DWŽDWˇAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽDzĐ.DäDÝ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNNNPOSDW>DWŚDWŤDWżDX^POS....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÝBlBpBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ..DW!C4591001C4591001 1150 11501272115012721150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25357 DW DDDWż.DWżDW DW DDDWˇDÝDW DDDW!D{DWŽDăĐDWˇDÝHrÄ"ÄHs‡ž„HrÄ"ÄHrŢ|ŚHsnĐHs‡ž„DW DW!DWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDD{.DăĐDÝ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNNNPOSDW>DWŚDWŤDWżDX^POS....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÝBlBpBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ..DW!C4591001C4591001 1150 11501273115012731150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25362 DW D‚ČDWÚ.DWÚDW DW D‚ČDW"Dz”DW D‚ČDW"Dz”....HrÄ&HHrßÍ”HrÄ&HHrßÍ”..DW DW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWG .. D‚ČDz”....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWG. Normal weightA NNYYNEGDW?DWŚDWÚ..NEG....YNNNNYYDW ........DW?DWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501274115012741150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25364 DW DÄ¤DWŃ.DWŃDW DW DÄ¤DW!DňDW DÄ¤DW!Dň....HrÄh$HrŢóśHrÄh$HrŢóś..DW DW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. DÄ¤Dň....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW?. Obese A@YNYYNEGDW?DWŚDWŃ..NEG....YNNNNYYDW ........DW?DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501275115012751150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25449 DW DÇěDWâ.DWâDW DW DÇěDW#DęŘDW DÇěDW#DęŘ....HrÄklHráŹXHrÄklHráŹX..DW DW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DÇěDęŘ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWD. Normal weightA NNYYNEGDWDDWŚDWŇ..NEG....YNNNNYYDW ........DWDDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DWâC4591001C4591001 1150 11501276115012761150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25451 DW DăDWÓ.DWÓDW DW DăDW"DéčDW DăDW"Déč....HrÄ†śHrŕ<čHrÄ†śHrŕ<č..DW DW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW> .. DăDéč....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW>. Normal weightA NNYYNEGDW>DWŚDWÓ..NEG....YNNNNYYDW ........DW>DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501277115012771150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25459 DW DílDWĂ.DWĂDW DW DílDW§D$DW DílDW#Dý\DW“DzXDW§D$HrÄěHsŹ:¤HrÄěHráˇÜHstĆŘHsŹ:¤DW DW#DW“DW§AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DílDý\.DzXD$.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDWADWŚDW’DWĂDXdNEG....YNNNNYNDW ........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501278115012781150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25460 DW Dű|DWĐ.DWĐDW DW Dű|DW´Dĺ8DW Dű|DW"Dň”DWšDîDW´Dĺ8HrÄžüHs ł8HrÄžüHrŕE”Hs~uHs ł8DW DW"DWšDW´AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dű|Dň”.DîDĺ8.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Overweight A0YNYYNEGDW?DWŚDW™DWĐDXqNEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBdBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501279115012791150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25629 DWD€DWŢ.DWŢDWDWD€DW!DÁ\DWD€DW!DÁ\....HrĹt€HrŢÂÜHrĹt€HrŢÂÜ..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D€DÁ\....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NYYYNEGDW=DWŚDWŢ..NEG....YNNNNYYDW........DW=DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501280115012801150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25632 DWDťĽDWĹ.DWĹDWDWDťĽDW©DëDWDťĽDW$Dě|DW“DŔäDW©DëHrĹ’ĽHs’8”HrĹ’ĽHrââ|Hsu dHs’8”DWDW$DW“DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťĽDě|.DŔäDë.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANNYYNEGDWEDWŚDW’DWĹDXfNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBkBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501281115012811150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25634 DWDĽpDWŮ.DWŮDWDWDĽpDW#DŢ0DWDĽpDW#DŢ0....HrĹ±pHrá‚°HrĹ±pHrá‚°..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĽpDŢ0....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW?DWŚDWŮ..NEG....YNNNNYYDW........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501282115012821150AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25635 DWDÜPDWÄ.DWÄDWDWDÜPDW¨DzDWDÜPDW$DđđDW‘D¤ÄDW¨DzHrĹŃPHsvHrĹŃPHrâćđHsrNDHsvDWDW$DW‘DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWnBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜPDđđ.D¤ÄDz.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDWADWŚDWDWÄDXeNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBmBqBđB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501283115012831150AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25823 DWDëDWĂ.DWĂDWDWDëDW˘D©tDWDëDW%DâŕDWŤDÜDW˘D©tHrĹŕHsĽtHrĹŕHrä*`Hsm?”HsĽtDWDW%DWŤDW˘AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWGBNT162b2 (30 (*ESC*){unicode 03BC}g).. DëDâŕ.DÜD©t.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWGDWŚDWŚDWĂDX_NEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBqBqBđB7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501284115012841150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25827 DWDťřDWÄ.DWÄDWDWDťřDW¦Dż|DWDťřDW#D{DW‘DŹčDW¦Dż|HrĆäxHsŽ|HrĆäxHráŚHsr9hHsŽ|DWDW#DW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťřD{.DŹčDż|.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW@DWŚDWDWÄDXcNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501285115012851150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25831 DWDČdDWŇ.DWŇDWDWDČdDW#D±lDWDČdDW#D±l....HrÇäHráUěHrÇäHráUě..DWDW#..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DČdD±l....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW?DWŚDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501286115012861150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25832 DWDČÜDWŇ.DWŇDWDWDČÜDW#D±¨DWDČÜDW#D±¨....HrÇ\HráV(HrÇ\HráV(..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DČÜD±¨....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW?DWŚDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501287115012871150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26004 DWDŇxDWŮ.DWŮDWDWDŇxDW$Dé4DWDŇxDW$Dé4....HrÇřHrâß4HrÇřHrâß4..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŇxDé4....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDDWŚDWŮ..NEG....YNNNNYYDW........DWDDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501288115012881150AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26007 DWD‡´DWÓ.DWÓDWDWD‡´DW$DĚŘDWD‡´DW$DĚŘ....HrČ´HrâÂŘHrČ´HrâÂŘ..DWDW$..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. D‡´DĚŘ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWD. Normal weightA NNYYNEGDWDDWŚDWÓ..NEG....YNNNNYYDW........DWDDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501289115012891150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26010 DWDĆŔDWľ.DWľDWDWDĆŔDW˘Dâ¤DWDĆŔDW%DŔlDWŽDăXDW˘Dâ¤HrČ^ŔHső¤HrČ^ŔHräěHsnXHső¤DWDW%DWŽDW˘AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆŔDŔl.DăXDâ¤.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDWADWŚDWŤDWľDX_NEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŮBhBpBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501290115012901150AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26011 DWD„0DWż.DWżDWDWD„0DWŁD–DWD„0DW(DëČDWŤD÷ĽDWŁD–HrĚ°Hs‰ú€HrĚ°Hrč'ČHsm[<Hs‰ú€DWDW(DWŤDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D„0DëČ.D÷ĽD–.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWFDWŚDWŚDWżDX`NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBqBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501291115012911150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26553 DWD˘¨DWĂ.DWĂDWDWD˘¨DW§DľČDWD˘¨DW*DŰ$DW“DúČDW§DľČHrĚ/(HsŹiHHrĚ/(Hręş$HsuGHHsŹiHDWDW*DW“DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘¨DŰ$.DúČDľČ.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDWFDWŚDW’DWĂDXdPOS....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÔBcBkBqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1150 11501292115012921150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26556 DWDŁ DWŮ.DWŮDWDWDŁ DW*DŰśDWDŁ DW*DŰś....HrĚ/ HręşśHrĚ/ Hręşś..DWDW*..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DŁ DŰś....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWF. Underweight ANNYYNEGDWFDWŚDWŮ..NEG....YNNNNYYDW........DWFDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÔBcBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501293115012931150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26560 DWD§ĐDWâ.DWâDWDWD§ĐDW3DÎôDWD§ĐDW3DÎô....HrĚ4PHrö‹tHrĚ4PHrö‹t..DWDW3..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D§ĐDÎô....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWD.. Normal weightA NNYYNEGDWCDWCDWâ..NEG....YNNNNYYDW........DWSDWâYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDWCDWýDWýBËBBşBëB17-8 months A€0-1 month A0-1 month A8-9 months A . ...C4591001C4591001 1150 11501294115012941150AŔYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26564 DWDĹĐDWĚ..DWDWDĹĐDWŻDă”DWDĹĐDW(DóDW›DÄŕDWŻDă”HrĚRPHsšHrĚRPHrč/Hsť`HsšDWDW(DW›DWŻAŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĹĐDó.DÄŕDă”.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW›. Normal weightA NYYYNEGDWFDWŚDWšDWĚDXlNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBcBqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1150 11501295115012951150AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26626 DWDÇěDWŃ.DWŃDWDWDÇěDW(Dě@DWDÇěDW(Dě@....HrĚTlHrč(@HrĚTlHrč(@..DWDW(..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW1 .. DÇěDě@....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW1. Underweight ANNNNPOSDWFDWŚDWŃ..POS....YNNNNYYDW........DWFDWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBÖBeBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DW(C4591001C4591001 1150 11501296115012961150AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26627 DWDđDWÂ.DWÂDWDWDđDWˇDÚpDWDđDW*Dě@DWŽDĎäDWˇDÚpHrĚ|€Hs‡›đHrĚ|€HręË@Hsn„äHs‡›đDWDW*DWŽDWˇAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DđDě@.DĎäDÚp.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDWFDWŚDWŤDWÂDX^NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBpBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501297115012971150AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26629 DWDôtDWá..DWDWDôtDW)DóHDWDôtDW)DóH....HrĚ€ôHré€ČHrĚ€ôHré€Č..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DôtDóH....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWE. Normal weightA NNYYNEGDWEDWŚDWá..NEG....YNNNNYYDW........DWEDWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501298115012981150AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26632 DWDž4DWĽ.DWĽDWDWDž4DW D†DWDž4DW(DŤDWŤDě|DW D†HrÍ|4Hs…öHrÍ|4HrçÉHsmOüHs…öDWDW(DWŤDW AĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dž4DŤ.Dě|D†.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Underweight ANNYYNEGDWFDWŚDWŚDWĽDX]NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBqBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501299115012991150AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26853 DWDĘřDW×.DW×DWDWDĘřDW(DŘDWDĘřDW(DŘ....HrÍ¨řHrç˝ŘHrÍ¨řHrç˝Ř..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DĘřDŘ....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWN. Underweight ANNYYNEGDWDDWŚDW×..NEG....YNNNNYYDW........DWDDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÖBeBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501300115013001150AŕYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26856 DWDçĚDWż.DWżDWDWDçĚDWŁDá<DWDçĚDW(DÜPDWŤDß DWŁDá<HrÍĹĚHsŠEĽHrÍĹĚHrčPHsmB HsŠEĽDWDW(DWŤDWŁAŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçĚDÜP.Dß Dá<.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Obese A@YNYYNEGDWDDWŚDWŚDWżDX`NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBqBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1150 11501301115013011150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26859 DWDę`DWĺ.DWĺDWDWDę`DW*DéčDWDę`DW*Déč....HrÍČ`HręČčHrÍČ`HręČč..DWDW*..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. Dę`Déč....36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NNYYNEGDWGDWŚDWĺ..NEG....YNNNNYYDW........DWGDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÔBcBqBęBy7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1150 11501302115013021150AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26863 DWDëPDW.DWDWDWDëPDW|DŢlDWDëPDW*DŐ„DWgDĐDW|DŢlHrÍÉPHsVŘlHrÍÉPHrę´„Hs;HsVŘlDWDW*DWgDW|AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëPDŐ„.DĐDŢl.36056 Senders, Shelly David ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWgDWg. Normal weightA NNYYNEGDWFDWfDWfDWDX9NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWfDWýDWýBÔB=B—B—BęBS7-8 months A€2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1152 11521604115216041152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20769 DVëDŐHDW„.DW„DVëDVëDŐHDWbD$DVëDŐHDVţDĐÔDWNDťDDWbD$Hr—ĄČHs4C$Hr—ĄČHr°ÔHsňDHs4C$DVëDVţDWNDWbAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐHDĐÔ.DťDD$.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWFDWN. Normal weightA NNNYPOSDWDWEDWMDW„DXNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWEDWýDWýCBHB°B¸C0B[9-10 months A 2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1152 11521605115216051152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20770 DVëDâ¤DW®.DW®DVëDVëDâ¤DV˙D•LDVëDâ¤DV˙D•L....Hr—ł$Hr±ĂĚHr—ł$Hr±ĂĚ..DVëDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dâ¤D•L....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWT.. Normal weightA NYYYNEGDWDWSDW®..NEG....YNNNNYYDVë........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWSDWýDWýB˙BUBŞC0Bi9-10 months A 3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1152 11521607115216071152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20772 DVěD¤LDWË.DWËDVěDVěD¤LDWŻDé¬DVěD¤LDWDźŘDWšDß\DWŻDé¬HrĆLHsš ,HrĆLHrłŘHs~f\Hsš ,DVěDWDWšDWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¤LDźŘ.Dß\Dé¬.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Underweight ANNYYNEGDWDWŚDW™DWËDXlNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBdBqC Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521608115216081152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20771 DVěD˘0DWŻ.DWŻDVěDVěD˘0DWDˇ¸DVěD˘0DWDˇ¸....HrÄ0Hrł!¸HrÄ0Hrł!¸..DVěDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWO .. D˘0Dˇ¸....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWO. Normal weightA NNYYNEGDWDWŚDWŻ..NEG....YNNNNYYDVě........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBţBŤBqC Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1152 11521611115216111152AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20884 DVěDÓhDW®.DW®DVěDVěDÓhDV˙DĂ´DVěDÓhDV˙DĂ´....HrőhHr±ň4HrőhHr±ň4..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWq .. DÓhDĂ´....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW®DWq. Normal weightA NNYYNEGDWDWDW®..NEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýB˙BŻBPC BÂ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521612115216121152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20882 DVěDĎ0DWő.DWőDVěDVěDĎ0DWËDĘDVěDĎ0DV˙DĆHDW¶DŐHDWËDĘHrń0HsľęHrń0Hr±ôČHsŁFHHsľęDVěDV˙DW¶DWËAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWqBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĎ0DĆH.DŐHDĘ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW®DW¶. Overweight A0NNYYNEGDWDWDW®DWőDXNEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB˙BŻBHBPC BÂ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1152 11521613115216131152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20877 DVěDÍŚDWő.DWőDVěDVěDÍŚDWËDĚ`DVěDÍŚDV˙DÉDW¶DÓ¤DWËDĚ`HrďŚHsľěŕHrďŚHr±řHsŁD¤HsľěŕDVěDV˙DW¶DWËAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWqBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÍŚDÉ.DÓ¤DĚ`.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW®DW¶. Overweight A0NNYYNEGDWDWDW®DWőDXNEG....YNNNNYYDVě........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB˙BŻBHBPC BÂ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1152 11521614115216141152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20886 DVěDÝ|DW°.DW°DVěDVěDÝ|DV˙DśDVěDÝ|DV˙Dś....Hr˙|Hr±ĘHr˙|Hr±Ę..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. DÝ|Dś....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWp. Overweight A0NYYYNEGDWDWŤDW°..NEG....YNNNNYYDVě........DWDW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýB˙BŹBpC B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1152 11521615115216151152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20925 DVěDß DWĹ.DWĹDVěDVěDß DW©D‡xDVěDß DV˙DŇxDW•D†LDW©D‡xHr™ Hs‘ÔřHr™ Hr˛řHswuĚHs‘ÔřDVěDV˙DW•DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWrBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dß DŇx.D†LD‡x.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDWDWŚDW”DWĹDXfNEG....YNNNNYNDVě........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB˙BŽBiBqC Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521617115216171152AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20928 DVěD÷ĽDWË.DWËDVěDVěD÷ĽDWDDDVěD÷ĽDWDD....Hr™ĽHrą–ÄHr™ĽHrą–Ä..DVěDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. D÷ĽDD....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWËDW". Normal weightA NYYYNEGDW"DWĘDWË..NEG....YNNNNYYDVě........DW"DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĘDWýDWýBůBĆB3C Bß8-9 months A7-8 months A€0-1 month A9-10 months A . ...C4591001C4591001 1152 11521619115216191152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20930 DVěD˙DW´.DW´DVěDVěD˙DV˙DŢäDVěD˙DV˙DŢä....Hr™!Hr˛ dHr™!Hr˛ d..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D˙DŢä....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW!DWŚDW´..NEG....YNNNNYYDVě........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB˙BŽBqC Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1152 11521625115216251152AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20988 DVíDŤDWĐ.DWĐDVíDVíDŤDWD«DVíDŤDWD«....HršHrł+HršHrł+..DVíDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWq .. DŤD«....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶DWq. Normal weightA NYYYNEGDWDWµDWµ..NEG....YNNNNYYDVí........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWµDWýDWýBţB¶BHCBÉ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521626115216261152AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20931 DVíD‹tDWď.DWďDVíDVíD‹tDWÓDÉDVíD‹tDWD§ĐDWĽDŞ DWÓDÉHr™ţôHsÉuHr™ţôHrł'ĐHs« HsÉuDVíDWDWĽDWÓAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWqBNT162b2 (30 (*ESC*){unicode 03BC}g).. D‹tD§Đ.DŞ DÉ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¶DWĽ. Normal weightA NNYYNEGDWDWµDWµDWďDXNEG....YNNNNYYDVí........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWµDWýDWýBţB¶BBBHCBÉ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1152 11521628115216281152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20989 DVíD–´DWŻ.DWŻDVíDVíD–´DWD˛\DVíD–´DWD˛\....Hrš 4Hrł2\Hrš 4Hrł2\..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWr .. D–´D˛\....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¨DWr. Overweight A0YNYYNEGDWDW§DWŻ..NEG....YNNNNYYDVí........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW§DWýDWýBţB¨BVCB»9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521629115216291152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20991 DVíD™üDWŇ.DWŇDVíDVíD™üDW!D†LDVíD™üDWDßÔDW DôDW!D†LHrš |HrŢ‡ĚHrš |Hrł_ÔHrÄ'tHrŢ‡ĚDVíDWDW DW!AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™üDßÔ.DôD†L.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW DW . Overweight A0NYYYNEGDWDWDWDWDDWŇNEG....YNNNNYNDVí........DW .YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 7 days but prior to 14 days post Dose 2 NYNYYYN YNNYNY NYDWDWýDWýBţAĐBńBńCB 9-10 months A 0-1 month A8-9 monthsA9-10 months A . ...C4591001C4591001 1152 11521633115216331152AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20992 DVđD–xDWŮ.DWŮDVđDVđD–xDW°DÖ°DVđD–xDWDÎ¸DW™DŕLDW°DÖ°HrťţxHs›^°HrťţxHrąć8Hs}ĚHs›^°DVđDWDW™DW°AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. D–xDÎ¸.DŕLDÖ°.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Normal weightA NYYYNEGDW!DWDWDWŮDXmNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBůBŚBeBmCŕBˇ8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521635115216351152AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21225 DVđD§XDW˝.DW˝DVđDVđD§XDWDź$DVđD§XDWDź$....HržXHrą¶¤HržXHrą¶¤..DVđDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADW˝PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D§XDź$....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDW!DWŚDWÂ..NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDW˝DW˝BąBB1BÎBť6-7 months Ap4-5 months AP0-1 month A7-8 months A€ . ...C4591001C4591001 1152 11521636115216361152AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21233 DVđD¨üDWç.DWçDVđDVđD¨üDWDzXDVđD¨üDWDzX....HržüHrą‘ŘHržüHrą‘Ř..DVđDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨üDzX....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWç.. Normal weightA NNYYNEGDW!DW´DW´..NEG....YNNNNYYDVđ........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWćDWýDWýBůBâBCŕB÷8-9 months A8-9 months A0-1 month A9-10 months A . ...C4591001C4591001 1152 11521637115216371152AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21236 DVđDą(DWĹ.DWĹDVđDVđDą(DW¨DÖ°DVđDą(DWDłLDW”D¨DW¨DÖ°Hrž!(HsŇ°Hrž!(HrąĘĚHsvFHsŇ°DVđDWDW”DW¨AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dą(DłL.D¨DÖ°.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Underweight ANNYYNEGDW!DWŤDW“DWĹDXeNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýBůB‰BjBpCŕBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521638115216381152AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21234 DVđDµ¤DW“.DW“DVđDVđDµ¤DWwDĐ DVđDµ¤DWDí0DWcDÄŕDWwDĐ Hrž¤HsP2 Hrž¤Hrş°Hs5É`HsP2 DVđDWDWcDWwAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dµ¤Dí0.DÄŕDĐ .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW`DWc. Obese A@YNYYNEGDW!DW_DWbDW“DX4NEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW_DWýDWýBůB[B›BžCŕBp8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1152 11521639115216391152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21312 DVđDÔXDWÄ.DWÄDVđDVđDÔXDW§D”DVđDÔXDWDÇěDW”D|DW§D”Hrž BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21317 DVđDŢäDWÄ.DWÄDVđDVđDŢäDW¨DăĐDVđDŢäDWDńŕDW”DŘĚDW¨DăĐHržFäHsßĐHržFäHrş `HsvvĚHsßĐDVđDWDW”DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢäDńŕ.DŘĚDăĐ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Obese A@YNYYNEGDW"DWŤDW“DWÄDXePOS....YNNNNYNDVđ........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBůB‰BjBpCŕBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1152 11521644115216441152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21323 DVđDń,DWĽ.DWĽDVđDVđDń,DWD” DVđDń,DWD” ....HržY,Hrą« HržY,Hrą« ..DVđDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. Dń,D” ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĽDW%. Normal weightA NYYYNEGDW%DW´DW´..NEG....YNNNNYYDVđ........DW%DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW»DWýDWýBůB·BBCŕBĚ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521645115216451152AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21327 DVńD@DWî.DWîDVńDVńD@DWîDîDVńD@DWDÄ¤DWŮDůśDWîDîHrź<ŔHsí3Hrź<ŔHrĽ$HsŃŹHsí3DVńDWDWŮDWîAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. D@DÄ¤.DůśDî.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWľDWŮ. Obese A@YYYYNEGDW#DW»DW»DXDX«NEG....YNNNNYYDVń........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW˝DWýDWýB÷B·B%B@CĐBÍ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1152 11521646115216461152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21329 DVńD´DWŮ.DWŮDVńDVńD´DWDé¬DVńD´DWDé¬....Hrźm€Hrş,Hrźm€Hrş,..DVńDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´Dé¬....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW!DWŚDW»..NEG....YNNNNYYDVń........DW!DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCĐBś8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521647115216471152AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21331 DVńDŃLDWÍ.DWÍDVńDVńDŃLDW±DzDVńDŃLDWDÄŕDWšDĚŘDW±DzHrźŠĚHsśSśHrźŠĚHrĹąŕHs~SŘHsśSśDVńDWDWšDW±AđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŃLDÄŕ.DĚŘDz.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Normal weightA NNYYNEGDW,DWŚDW™DWÍDXn ....YNNNNYNDVń........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBđBBdBqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521648115216481152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21527 DVńDÖtDW».DW»DVńDVńDÖtDWD‡<DVńDÖtDWD‡<....HrźŹôHrąžĽHrźŹôHrąžĽ..DVńDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. DÖtD‡<....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW»DW$. Underweight ANNYYNEGDW$DWşDW»..NEG....YNNNNYYDVń........DW$DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWşDWýDWýBůB¶BCCĐBĘ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521649115216491152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21531 DVńDŮDWü.DWüDVńDVńDŮDWßD©tDVńDŮDWDődDWĘDŽřDWßD©tHrź’HsŮ'ôHrź’HrĽŻäHs˝]řHsŮ'ôDVńDWDWĘDWßAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŮDőd.DŽřD©t.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¸DWĘ. Normal weightA NNYYNEGDW#DW·DW¸DWüDXśNEG....YNNNNYYDVń........DW#DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW·DWýDWýB÷B±B4BFCĐBÇ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1152 11521650115216501152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21532 DVńDäŔDWŢ.DWŢDVńDVńDäŔDWD¤LDVńDäŔDWD¤L....Hrźž@Hrą»ĚHrźž@Hrą»Ě..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŢOTHER . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DäŔD¤L....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWZ.. Underweight ANNYYNEGDW!DWYDW´..NEG....YNNNNYYDVń........DW!DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWYDWŢDWŢBÚBUB…BîBi7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521651115216511152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21533 DVńDëPDWĆ.DWĆDVńDVńDëPDW¦D DVńDëPDWD®`DW“D¸°DW¦D Hrź¤ĐHsŤůHrź¤ĐHr»`Hsu0HsŤůDVńDWDW“DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëPD®`.D¸°D .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW%DWŚDW’DWĆDXcNEG....YNNNNYNDVń........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BkBqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521652115216521152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21573 DVńDńŕDWĹ.DWĹDVńDVńDńŕDW DŚ DVńDńŕDWDÓŕDWŠDŇđDW DŚ Hrź«`Hs…ü Hrź«`Hrąë`HsiAđHs…ü DVńDWDWŠDW AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DńŕDÓŕ.DŇđDŚ .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‡DWŠ. Normal weightA NNYYNEGDW!DW†DW‰DWĹDX]NEG....YNNNNYNDVń........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW†DWýDWýBůB‚BtBwCĐB–8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1152 11521653115216531152AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21577 DVňDštDWµ.DWµDVňDVňDštDWDµŕDVňDštDWDµŕ....Hr ĄtHrąÍ`Hr ĄtHrąÍ`..DVňDW..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DštDµŕ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW!DWŚDWµ..NEG....YNNNNYYDVň........DW!DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBůBBqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521654115216541152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVň21581 DVňDĄ<DWě.DWěDVňDVňDĄ<DWĐDŽ€DVňDĄ<DWDŽĽDW»D§XDWĐDŽ€Hr °<HsĹF€Hr °<Hrş÷ĽHs©ŻŘHsĹF€DVňDWDW»DWĐAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄ<DŽĽ.D§XDŽ€.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWµDW». Obese A@YNYYNEGDW#DW´DWµDWěDXŤNEG....YNNNNYYDVň........DW#DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW´DWýDWýBřBŻBCBICŔBĂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1152 11521655115216551152AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVň21582 DVňD¬DWµ.DWµDVňDVňD¬DWD€čDVňD¬DWD€č....Hr ¸¬HrşéčHr ¸¬Hrşéč..DVňDW..AŔYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¬D€č....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Overweight A0NNYYNEGDW"DWŚDWµ..NEG....YNNNNYYDVň........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqCŔB›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521656115216561152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21914 DVóD› DWÄ.DWÄDVóDVóD› DWDÁ DVóD› DWDÁ ....Hrˇř HrĂ Hrˇř HrĂ ..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D› DÁ ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWÄDW). Underweight ANNYYNEGDW)DWĂDWÄ..NEG....YNNNNYYDVó........DW)DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWĂDWýDWýBňB¸B:C°BŃ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521657115216571152AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21915 DVóDŃDWµ.DWµDVóDVóDŃDWD°|DVóDŃDWD°|....Hr˘-Hr»|Hr˘-Hr»|..DVóDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. DŃD°|....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDW". Overweight A0YNYYNEGDW"DW´DWµ..NEG....YNNNNYYDVó........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW´DWýDWýBřBŻBIC°BÂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521658115216581152AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21917 DVóDŇđDWĐ.DWĐDVóDVóDŇđDWĐD–xDVóDŇđDWD˛DW·DŁÔDWĐD–xHr˘/pHsĹNxHr˘/pHr»Hs¤fTHsĹNxDVóDWDW·DWĐAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW"BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŇđD˛.DŁÔD–x.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWµDW·. Obese A@YNYYNEGDW"DW´DWµDWóDXŤNEG....YNNNNYYDVó........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW´DWýDWýBřBŻBGBIC°BÂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1152 11521659115216591152AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21993 DVóDáDWĹ.DWĹDVóDVóDáDW¦DŐHDVóDáDWDµ¤DW“DŻDW¦DŐHHr˘=€HsŽ.HHr˘=€Hr»¤Hstű”HsŽ.HDVóDWDW“DW¦AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. DáDµ¤.DŻDŐH.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Underweight ANYYYNEGDW$DWŚDW’DWĹDXcNEG....YNNNNYNDVó........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BkBqC°Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521660115216601152AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21918 DVóDŢäDWŘ.DWŘDVóDVóDŢäDWĽD¶”DVóDŢäDWD°¸DW¨D©°DWĽD¶”Hr˘;dHs«”Hr˘;dHrĂ¸HsĄ°Hs«”DVóDWDW¨DWĽAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢäD°¸.D©°D¶”.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW¨. Obese A@YNYYNEGDW(DWŤDW§DWŘDXyPOS....YNNNNYNDVó........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBňB‚BVBpC°B›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1152 11521661115216611152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21997 DVóDĺtDWË.DWËDVóDVóDĺtDWŻD×dDVóDĺtDWDŚ DWDĺtDWŻD×dHr˘AôHsš äHr˘AôHrşő Hs{ÉtHsš äDVóDWDWDWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĺtDŚ .DĺtD×d.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NNYYNEGDW)DWŤDW—DWËDXlNEG....YNNNNYNDVó........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýBřBBfBpC°B›8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521662115216621152AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21998 DVóDě¸DWµ.DWµDVóDVóDě¸DWD¨HDVóDě¸DWD¨H....Hr˘I8Hr»HHr˘I8Hr»H..DVóDW..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. Dě¸D¨H....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDW$. Normal weightA NNYYNEGDW$DW´DWµ..NEG....YNNNNYYDVó........DW$DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýBřBŻBIC°BÂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521663115216631152AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21999 DVóDń¤DWµ.DWµDVóDVóDń¤DWDČ DVóDń¤DWDČ ....Hr˘N$Hr»1 Hr˘N$Hr»1 ..DVóDW..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW" .. Dń¤DČ ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW". Overweight A0YNYYNEGDW"DWŤDWµ..NEG....YNNNNYYDVó........DW"DWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBřBBpC°B›8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521664115216641152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22081 DVôD—hDWđ.DWđDVôDVôD—hDWŇDŚ(DVôD—hDWDŽ€DWżD™HDWŇDŚ(HrŁEhHsÇç(HrŁEhHrĽIHs®çČHsÇç(DVôDWDWżDWŇAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. D—hDŽ€.D™HDŚ(.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW·DWż. Underweight ANNYYNEGDW#DW¶DW·DWđDXŹNEG....YNNNNYYDVô........DW#DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýB÷B°B?BGC BĂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ..DW+C4591001C4591001 1152 11521665115216651152AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22078 DVôD•LDW·.DW·DVôDVôD•LDWDŚ DVôD•LDWDŚ ....HrŁCLHrĽG HrŁCLHrĽG ..DVôDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. D•LDŚ ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW·DW+. Overweight A0YYYYNEGDW#DW¶DW·..NEG....YNNNNYYDVô........DW#DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¶DWýDWýB÷B°BGC BĂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521666115216661152AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22082 DVôD™HDWç.DWçDVôDVôD™HDWËD„0DVôD™HDWD$DW·DŘDWËD„0HrŁGHHsľ¤°HrŁGHHrĽJ¤Hs¤SXHsľ¤°DVôDWDW·DWËAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D™HD$.DŘD„0.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW·. Overweight A0NNYYNEGDW+DW’DW¶DWçDXPOS....YNNNNYNDVô........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW’DWýDWýB÷BŚBGBkC Bź8-9 months A5-6 months A`2-3 monthsA09-10 months A . ..DWC4591001C4591001 1152 11521667115216671152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22128 DVôDĄxDWĂ.DWĂDVôDVôDĄxDW¦DçDVôDĄxDWDˇôDW“D·HDW¦DçHrŁSxHsŽ@HrŁSxHrĽ\tHsuČHsŽ@DVôDWDW“DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄxDˇô.D·HDç.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW#DWŚDW’DWĂDXcNEG....YNNNNYNDVô........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýB÷B†BkBqC B™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521668115216681152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22085 DVôDŁ\DW».DW»DVôDVôDŁ\DWD¤ÄDVôDŁ\DWD¤Ä....HrŁQ\HrĽ_DHrŁQ\HrĽ_D..DVôDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DŁ\D¤Ä....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW#. Underweight ANNYYNEGDW#DWŚDW»..NEG....YNNNNYYDVô........DW#DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521669115216691152AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô22129 DVôD°|DWË.DWËDVôDVôD°|DWŻDëŚDVôD°|DWD„¨DWšDÝDWŻDëŚHrŁ^|Hsš"HrŁ^|HrĽ?(Hs~dHsš"DVôDWDWšDWŻAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°|D„¨.DÝDëŚ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Normal weightA NNYYNEGDW$DWŤDW™DWËDXlNEG....YNNNNYNDVô........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BdBpC Bš8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521670115216701152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22133 DVôDÇtDWá.DWáDVôDVôDÇtDWD‡´DVôDÇtDWD‡´....HrŁutHrĽB4HrŁutHrĽB4..DVôDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DÇtD‡´....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW(. Normal weightA NNYYNEGDW(DWŚDW¶..NEG....YNNNNYYDVô........DW(DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521671115216711152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22134 DV÷DŇ´DWÉ.DWÉDV÷DV÷DŇ´DWDí¨DV÷DŇ´DWDí¨....Hr§u4HrĂ?¨Hr§u4HrĂ?¨..DV÷DW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DŇ´Dí¨....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW(. Normal weightA NNYYNEGDW(DWŤDWÉ..NEG....YNNNNYYDV÷........DW(DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBňB‚BpCpB—8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521672115216721152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22414 DV÷DÚ¬DWĆ.DWĆDV÷DV÷DÚ¬DWŞD˝$DV÷DÚ¬DWDČÜDW”D†ÄDWŞD˝$Hr§},Hs“\$Hr§},HrĂÜHsv$ÄHs“\$DV÷DWDW”DWŞAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÚ¬DČÜ.D†ÄD˝$.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW(DWŚDW“DWĆDXgNEG....YNNNNYNDV÷........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBjBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521673115216731152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22416 DV÷DÜDWű.DWűDV÷DV÷DÜDWDĘDV÷DÜDWDĘ....Hr§~”HrĂHr§~”HrĂ..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DÜDĘ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW(. Normal weightA NNYYNEGDW(DWŚDW»..NEG....YNNNNYYDV÷........DW(DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521674115216741152AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷22417 DV÷DäHDWÄ.DWÄDV÷DV÷DäHDWD¬DV÷DäHDWD¬....Hr§†ČHrČE¬Hr§†ČHrČE¬..DV÷DW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DäHD¬....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Normal weightA NNYYNEGDW/DWŚDWÄ..NEG....YNNNNYYDV÷........DW/DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqCpB–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521675115216751152AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22420 DV÷Dć(DWŰ.DWŰDV÷DV÷Dć(DWDĐDV÷Dć(DWDźśDWDÝ|DWDĐHr§¨Hs—,PHr§¨HrÂńśHs{Á|Hs—,PDV÷DWDWDWAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć(Dźś.DÝ|DĐ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW. Normal weightA NNYYNEGDW)DWŚDW—DWŰDXjNEG....YNNNNYNDV÷........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBfBqCpB–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521676115216761152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV÷22462 DV÷Dő(DWĹ.DWĹDV÷DV÷Dő(DW¨DŐDV÷Dő(DWDáđDW•D,DW¨DŐHr§—¨HsŃHr§—¨HrĂ3đHsww¬HsŃDV÷DWDW•DW¨AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW9BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dő(Dáđ.D,DŐ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Underweight ANNYYNEGDW9DWŤDW”DWĹDXeNEG....YNNNNYNDV÷........DW9.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BiBpCpB—8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521677115216771152AŔYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22463 DVřD¨DW×.DW×DVřDVřD¨DWD‘ČDVřD¨DWD‘Č....Hr¨śHrÂăČHr¨śHrÂăČ..DVřDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¨D‘Č....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Obese A@YNYYNEGDW(DWŤDW×..NEG....YNNNNYYDVř........DW(DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBňB‚BpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521678115216781152AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22465 DVřD¬DWĘ.DWĘDVřDVřD¬DW®DĄDVřD¬DWD“äDW™DŁDW®DĄHr¨ˇ¬HsŠHr¨ˇ¬HrÂĺäHs|ŮHsŠDVřDWDW™DW®AŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¬D“ä.DŁDĄ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Overweight A0NNYYNEGDW(DWŤDWDWĘDXkNEG....YNNNNYNDVř........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BeBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521679115216791152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22472 DVřDŇxDW˝.DW˝DVřDVřDŇxDW DĐ\DVřDŇxDW DĐ\....Hr¨ĆxHrÄsÜHr¨ĆxHrÄsÜ..DVřDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DŇxDĐ\....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW+. Underweight ANYYYNEGDW+DWŚDW˝..NEG....YNNNNYYDVř........DW+DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBńB€BqC`B•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521680115216801152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22680 DVřDÜČDWż.DWżDVřDVřDÜČDWŁDĹDVřDÜČDW DÉDWŽD¦ŕDWŁDĹHr¨ĐČHsŠ)śHr¨ĐČHrÄlHsn[ŕHsŠ)śDVřDW DWŽDWŁAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDÉ.D¦ŕDĹ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Overweight A0YNYYNEGDW)DWŤDWŤDWżDX`NEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBńBBpBpC`B–8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1152 11521681115216811152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22683 DVřDçTDW÷.DW÷DVřDVřDçTDW÷Dą DVřDçTDW DĂ´DW×DĺěDW÷Dą Hr¨ŰTHsřÜ Hr¨ŰTHrÄg4HsÎŘlHsřÜ DVřDW DW×DW÷AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçTDĂ´.DĺěDą .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĽDW×. Overweight A0YNYYNEGDW)DW»DWĽDXDX´NEG....YNNNNYYDVř........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW»DWýDWýBńBŻB'BBC`BÄ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ...C4591001C4591001 1152 11521682115216821152AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22684 DVřDé4DWĹ.DWĹDVřDVřDé4DW DĆHDVřDé4DW DĆH....Hr¨Ý4HrÄiČHr¨Ý4HrÄiČ..DVřDW ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. Dé4DĆH....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĹDW). Obese A@YNYYNEGDW)DWÄDWĹ..NEG....YNNNNYYDVř........DW)DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÄDWýDWýBńB¸B9C`BÍ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521683115216831152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22686 DVřDđxDWĽ.DWĽDVřDVřDđxDW DŕDVřDđxDW Dŕ....Hr¨äxHrÄHr¨äxHrÄ..DVřDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DđxDŕ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW). Underweight ANNYYNEGDW)DWŤDWĽ..NEG....YNNNNYYDVř........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBńBBpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521684115216841152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22713 DVřDöĚDWÄ.DWÄDVřDVřDöĚDW DđxDVřDöĚDW Dđx....Hr¨ęĚHrÄ“řHr¨ęĚHrÄ“ř..DVřDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DöĚDđx....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW). Normal weightA NNYYNEGDW)DWŤDWÄ..NEG....YNNNNYYDVř........DW)DWÄYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBńBBpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521685115216851152AŕYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22716 DVřDů$DWĘ.DWĘDVřDVřDů$DW DčDVřDů$DW Dč....Hr¨í$HrÄQhHr¨í$HrÄQh..DVřDW ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. Dů$Dč....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĘDW+. Overweight A0NYYYNEGDW+DWĽDWĽ..NEG....YNNNNYYDVř........DW+DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÉDWýDWýBńB˝B4C`BŇ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521686115216861152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22717 DVůD¨üDWě.DWěDVůDVůD¨üDWěDŤTDVůD¨üDWDîDWÔDhDWěDŤTHr©î|Hsę/THr©î|HrĚ{HsĘ†hHsę/TDVůDWDWÔDWěAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨üDî.DhDŤT.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWÔ. Overweight A0NNYYNEGDW:DWŚDWĐDXDX©NEG....YNNNNYNDVů........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBëBzB*BqCPB”8-9 months A4-5 months AP1-2 monthsA 9-10 months A . ...C4591001C4591001 1152 11521687115216871152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22958 DVůDŢlDWÉ.DWÉDVůDVůDŢlDWDóHDVůDŢlDWDĺ°DWDń,DWDóHHrŞ#ěHs—†ČHrŞ#ěHrĹÚ°Hs{Ő,Hs—†ČDVůDWDWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢlDĺ°.Dń,DóH.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNYYNEGDW/DWŤDW—DWÉDXjNEG....YNNNNYNDVů........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BfBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521688115216881152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22721 DVůDÜŚDWÉ.DWÉDVůDVůDÜŚDWDĺtDVůDÜŚDWDäDWDîÔDWDĺtHrŞ"Hs—xôHrŞ"HrĹŮHs{ŇÔHs—xôDVůDWDWDWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜŚDä.DîÔDĺt.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NNYYNEGDW/DWŤDW—DWÉDXjNEG....YNNNNYNDVů........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BfBpCPB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521689115216891152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22959 DVůDĺtDWĽ.DWĽDVůDVůDĺtDW DŮDDVůDĺtDW DŮD....HrŞ*ôHrÄ|ÄHrŞ*ôHrÄ|Ä..DVůDW ..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DĺtDŮD....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW). Overweight A0YNYYNEGDW)DWŤDWĽ..NEG....YNNNNYYDVů........DW)DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBńBBpCPB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521690115216901152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22963 DVůDę`DWË.DWËDVůDVůDę`DWŻDŕÄDVůDę`DWD×ÜDWśDÝ¸DWŻDŕÄHrŞ/ŕHsšDHrŞ/ŕHrĹĚÜHs¸HsšDDVůDWDWśDWŻAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę`D×Ü.DÝ¸DŕÄ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWś. Normal weightA NNYYNEGDW*DWŚDW›DWËDXlNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBbBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521691115216911152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22960 DVůDçĚDW·.DW·DVůDVůDçĚDWDÓhDVůDçĚDWDÓh....HrŞ-LHrĹČhHrŞ-LHrĹČh..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DçĚDÓh....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW*. Normal weightA NNYYNEGDW*DWŚDW·..NEG....YNNNNYYDVů........DW*DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521692115216921152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22967 DVůDílDWá.DWáDVůDVůDílDWDŔ0DVůDílDWDŔ0....HrŞ2ěHrĹµ0HrŞ2ěHrĹµ0..DVůDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DílDŔ0....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW/. Normal weightA NNYYNEGDW/DWŚDW˝..NEG....YNNNNYYDVů........DW/DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBđBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521693115216931152AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22968 DVůDňXDWŃ.DWŃDVůDVůDňXDW§D…DVůDňXDWDśDW”D›dDW§D…HrŞ7ŘHsŹ0HrŞ7ŘHrĹ‘Hsv9dHsŹ0DVůDWDW”DW§AđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DňXDś.D›dD….11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Normal weightA NNYYNEGDW*DW‘DW“DWŃDXdNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYYY NYDW‘DWýDWýBđB„BjBlCPB™8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521694115216941152AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22974 DVůDő DW˝.DW˝DVůDVůDő DWDź`DVůDő DWDź`....HrŞ; HrĹ”`HrŞ; HrĹ”`..DVůDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. Dő Dź`....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW*. Normal weightA NNYYNEGDW*DW‘DW˝..NEG....YNNNNYYDVů........DW*DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNYYYNYDW‘DWýDWýBđB„BlCPB™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521695115216951152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22975 DVůDřpDWÍ.DWÍDVůDVůDřpDWŻDÚpDVůDřpDWDß\DWśDÜČDWŻDÚpHrŞ=đHsšđHrŞ=đHrĹÔ\HsČHsšđDVůDWDWśDWŻAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. DřpDß\.DÜČDÚp.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWś. Underweight ANNYYNEGDW*DWŚDW›DWÍDXlNEG....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBbBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521696115216961152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23241 DVúD˙đDWŢ.DWŢDVúDVúD˙đDWDÚčDVúD˙đDWDÚ¬DWDŢäDWDÚčHr«–đHs—nhHr«–đHrÇ!,Hs{ÂäHs—nhDVúDWDWDWAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˙đDÚ¬.DŢäDÚč.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW. Underweight ANNYYNEGDW+DWŚDW—DWÉDXjNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BfBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521697115216971152AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23243 DVűD× DWĆ.DWĆDVűDVűD× DWDÍDVűD× DWDÍ....Hr¬Ŕ HrČeHr¬Ŕ HrČe..DVűDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW3 .. D× DÍ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW3. Underweight ANNYYNEGDW3DWŤDWĆ..NEG....YNNNNYYDVű........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521698115216981152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVű23244 DVűDŮřDW’.DW’DVűDVűDŮřDWDÉTDVűDŮřDWDÉT....Hr¬ÂxHrČaTHr¬ÂxHrČaT..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW’PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DŮřDÉT....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽDW/. Underweight ANNYYNEGDW/DWŤDWÍ..NEGDWŹ.DWŹDWŹYNNNNYNDVű........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDW’DW’BB~APBB“4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1152 11521699115216991152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23250 DVűDŕLDWĂ.DWĂDVűDVűDŕLDWDĎ¨DVűDŕLDWDĎ¨....Hr¬ČĚHrČg¨Hr¬ČĚHrČg¨..DVűDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. DŕLDĎ¨....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWżDW2. Normal weightA NNYYNEGDW1DWľDWĂ..NEG....YNNNNYYDVű........DW1DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWľDWýDWýBîBŻB?C0BÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521700115217001152AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23471 DVűDâ¤DWË.DWËDVűDVűDâ¤DWDÇ°DVűDâ¤DWDÇ°....Hr¬Ë$HrČ_°Hr¬Ë$HrČ_°..DVűDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. Dâ¤DÇ°....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW/. Underweight ANNYYNEGDW/DWŤDWË..NEG....YNNNNYYDVű........DW/DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521701115217011152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23473 DVűDĺ°DWĚ.DWĚDVűDVűDĺ°DW°DęśDVűDĺ°DWDŮĽDWšDĐ DW°DęśHr¬Î0Hs›rśHr¬Î0HrĹÎĽHs~W Hs›rśDVűDWDWšDW°AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW*BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺ°DŮĽ.DĐ Dęś.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Underweight ANNYYNEGDW*DWŤDW™DWĚDXmNEG....YNNNNYNDVű........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŤDWýDWýBđB€BdBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521702115217021152AĐYEARSMAWHITE ANOT REPORTED A0 .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23475 DVţD’DWĂ.DWĂDVţDVţD’DWDăĐDVţD’DWDăĐ....Hr°oHrÍÁĐHr°oHrÍÁĐ..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. D’DăĐ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW7. Normal weightA NNYYNEGDW7DW‘DWĂ..NEG....YNNNNYYDVţ........DW7DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBęB~BlCB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521703115217031152AĐYEARSMAWHITE ANOT REPORTED A0 .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23476 DVţD” DW×.DW×DVţDVţD” DW»DŘDVţD” DWDâhDW™DëPDW»DŘHr°q Hs©™XHr°q HrÍŔhHs} ĐHs©™XDVţDWDW™DW»AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. D” Dâh.DëPDŘ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW™. Obese A@YNYYNEGDW7DW‘DWDW×DXxNEG....YNNNNYNDVţ........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBęB~BeBlCB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521704115217041152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23749 DVţDźśDWĂ.DWĂDVţDVţDźśDWD¨HDVţDźśDWD¨H....Hr°|śHrĚ4ČHr°|śHrĚ4Č..DVţDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DźśD¨H....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW/. Underweight ANNYYNEGDW/DW’DWĂ..NEG....YNNNNYYDVţ........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBëB€BkCB•8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521705115217051152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23751 DVţDĄ<DW’.DW’DVţDVţDĄ<DWpDŃDVţDĄ<DWDćdDW[DŐ„DWpDŃHr°‚<HsFůHr°‚<HrĚräHs+NHsFůDVţDWDW[DWpAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄ<Dćd.DŐ„DŃ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWZDW[. Normal weightA NNYYNEGDW0DWYDWZDW’DX-NEG....YNNNNYNDVţ........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWYDWýDWýBëBGBŁB¤CB\8-9 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1152 11521706115217061152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23752 DVţD°ôDWŇ.DWŇDVţDVţD°ôDWŻDĺ8DVţD°ôDWDŮDDW›Dí¨DWŻDĺ8Hr°ŤôHsš¸Hr°ŤôHrĚeÄHsĆ(Hsš¸DVţDWDW›DWŻAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. D°ôDŮD.Dí¨Dĺ8.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW›. Underweight ANNYYNEGDW/DW’DWšDWŇDXlNEG....YNNNNYNDVţ........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBëB€BcBkCB•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521707115217071152AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23755 DVţDČÜDWË.DWËDVţDVţDČÜDWDľČDVţDČÜDWDľČ....Hr°ĄÜHrĚKHHr°ĄÜHrĚKH..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DČÜDľČ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWËDW(. Underweight ANNYYNEGDW6DWĘDWË..NEG....YNNNNYYDVţ........DW6DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĘDWýDWýBëB¸B3CBÍ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521708115217081152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23878 DVţDŮĽDWĐ..DVţDVţDŮĽDWD¤DVţDŮĽDWD¤....Hr°¶ĽHrĚ0Hr°¶ĽHrĚ0..DVţDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DŮĽD¤....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĐDW/. Underweight ANNYYNEGDW/DWĎDWĐ..NEG....YNNNNYYDVţ........DW/DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWĎDWýDWýBëB˝B.CBŇ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521709115217091152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23881 DV˙D’¸DWŘ.DWŘDV˙DV˙D’¸DWDÔXDV˙D’¸DWDě@DWšDä„DWDÔXHr±Á8Hs—gŘHr±Á8HrÍĘ@Hs~k„Hs—gŘDV˙DWDWšDWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. D’¸Dě@.Dä„DÔX.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Normal weightA NNYYNEGDW6DWŤDW™DWŘDXjNEG....YNNNNYNDV˙........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBęBzBdBpB˙BŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521710115217101152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙23885 DV˙Dˇ@DWË.DWËDV˙DV˙Dˇ@DWŞD–đDV˙Dˇ@DWDÎôDW•DĎ0DWŞD–đHr±ĎŔHs“5đHr±ĎŔHrÍ¬ôHswľ°Hs“5đDV˙DWDW•DWŞAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ@DÎô.DĎ0D–đ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Underweight ANYYYNEGDW7DWŤDW”DWËDXgNEG....YNNNNYNDV˙........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBęBzBiBpB˙BŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521711115217111152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23886 DV˙D©ěDWĂ.DWĂDV˙DV˙D©ěDWDÄŕDV˙D©ěDWDÄŕ....Hr±ŘlHrÍ˘ŕHr±ŘlHrÍ˘ŕ..DV˙DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. D©ěDÄŕ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW6. Normal weightA NNYYNEGDW6DWŤDWĂ..NEG....YNNNNYYDV˙........DW6DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBęBzBpB˙BŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521712115217121152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV˙24144 DV˙DáđDWŮ.DWŮDV˙DV˙DáđDWŻDĚ$DV˙DáđDWDŘDWDäHDWŻDĚ$Hr˛pHsš¤Hr˛pHrÍ¶Hs{ČHHsš¤DV˙DWDWDWŻAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. DáđDŘ.DäHDĚ$.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NNYYNEGDW7DWŤDW—DWŮDXlNEG....YNNNNYNDV˙........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBęBzBfBpB˙BŹ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521713115217131152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24145 DWDĚśDWĂ.DWĂDWDWDĚśDWDÜŚDWDĚśDWDÜŚ....HrłLśHrÍşŚHrłLśHrÍşŚ..DWDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DĚśDÜŚ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĂDW6. Underweight ANNYYNEGDW6DWÂDWĂ..NEG....YNNNNYYDW........DW6DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÂDWýDWýBęBŻB;BţBĂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1152 11521714115217141152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24147 DWD×(DWÉ.DWÉDWDWD×(DWDŃDWD×(DWDĺěDW™DáđDWDŃHrłW(Hs—dHrłW(HrĎlHs}pHs—dDWDWDW™DWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D×(Dĺě.DáđDŃ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Normal weightA NNYYNEGDW3DWŤDWDWÉDXjNEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBéByBeBpBţBŽ8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1152 11521715115217151152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24148 DWDăXDWĂ.DWĂDWDWDăXDWDß DWDăXDWDß ....HrłcXHrĚk HrłcXHrĚk ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DăXDß ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW/. Normal weightA NNYYNEGDW/DWŤDWĂ..NEG....YNNNNYYDW........DW/DWĂYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBëB{BpBţBŽ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1152 11521716115217161152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24515 DWDçTDWŃ.DWŃDWDWDçTDWD›(DWDçTDWD›(....HrąţÔHrŐb(HrąţÔHrŐb(..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. DçTD›(....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW§DW6. Normal weightA NNYYNEGDW6DW¦DWŃ..NEG....YNNNNYYDW........DW6DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW¦DWýDWýBäBŤBWBůB˘8-9 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1152 11521717115217171152AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24518 DWDîÔDWĹ.DWĹDWDWDîÔDW¦DŢ0DWDîÔDWDĆHDW’DíäDW¦DŢ0HrşTHsŽ70HrşTHrŐŤHHssčäHsŽ70DWDWDW’DW¦AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DîÔDĆH.DíäDŢ0.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW6DWŚDW‘DWĹDXcNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBäBsBlBqBůB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521718115217181152AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24522 DWDź`DWĚ.DWĚDWDWDź`DWDŘĚDWDź`DWDŘĚ....Hr»`HrŮ”LHr»`HrŮ”L..DWDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. Dź`DŘĚ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW9. Normal weightA NNYYNEGDW9DW“DWĚ..NEG....YNNNNYYDW........DW9DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBáBwBjBřBŽ8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1152 11521719115217191152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24524 DWDŞ(DWĂ.DWĂDWDWDŞ(DW¦D’|DWDŞ(DWDť€DWŽD{„DW¦D’|Hr»(HsŤë|Hr»(HrŐd€Hsn0„HsŤë|DWDWDWŽDW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŞ(Dť€.D{„D’|.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW6DWŚDWŤDWĂDXcNEG....YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBäBsBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1152 11521720115217201152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24816 DWDÜČDWĐ.DWĐDWDWDÜČDW¨DŰŘDWDÜČDWDÝ|DW”Dę$DW¨DŰŘHr»EČHs×ŘHr»EČHrÖőüHsv$Hs×ŘDWDWDW”DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDÝ|.Dę$DŰŘ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Underweight ANNYYNEGDW7DWŤDW“DWĐDXeNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBăBsBjBpBřB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521721115217211152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24822 DWDŢlDWŮ.DWŮDWDWDŢlDWDŕDWDŢlDWDŕ....Hr»GlHrÖřHr»GlHrÖř..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. DŢlDŕ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW7. Underweight ANNYYNEGDW7DWŤDWŮ..NEG....YNNNNYYDW........DW7DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBăBsBpBřB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1152 11521722115217221152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24823 DWD®śDWű.DWűDWDWD®śDWDÜŚDWD®śDWDÜŚ....HrĽiHrŮHrĽiHrŮ..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. D®śDÜŚ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW9. Underweight ANNYYNEGDW9DWŤDWű..NEG....YNNNNYYDW........DW9DWűYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBáBqBpB÷B‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1152 11521723115217231152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24824 DWDŐ„DWÍ.DWÍDWDWDŐ„DW±DŁ DWDŐ„DWDçDW›DulDW±DŁ HrĽHsś| HrĽHrŘQHsMěHsś| DWDWDW›DW±AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐ„Dç.DulDŁ .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW›. Overweight A0NNYYNEGDW8DWŤDWšDWÍDXnNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBâBrBcBpB÷B‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521724115217241152AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25091 DWDí0DWĘ.DWĘDWDWDí0DWD«ĚDWDí0DWD«Ě....HrĽ§°HrŐrĚHrĽ§°HrŐrĚ..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW7 .. Dí0D«Ě....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW7. Overweight A0NNYYNEGDW7DWŤDWĘ..NEG....YNNNNYYDW........DW7DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBäBtBpB÷B‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1152 11521725115217251152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25090 DWDę`DWË.DWËDWDWDę`DWŻDśDWDę`DWD©°DW›DŰ$DWŻDśHrĽ¤ŕHs™ÇHrĽ¤ŕHrŐp°Hsł¤Hs™ÇDWDWDW›DWŻAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dę`D©°.DŰ$Dś.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW›. Normal weightA NNYYNEGDW7DWŤDWšDWËDXlNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBäBtBcBpB÷B‡8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521726115217261152AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW25092 DWDů`DW®.DW®DWDWDů`DWDâ,DWDů`DWDâ,....HrĽłŕHrŐ©,HrĽłŕHrŐ©,..DWDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DW®PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW6 .. Dů`Dâ,....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW¨DW6. Normal weightA NNYYNEGDW6DW§DW×..NEGDW«.DW«DW«YNNNNYNDW........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW§DW®DW®B•BŽApB¨Bˇ5-6 months A`5-6 months A`0-1 month A6-7 months Ap . ...C4591001C4591001 1152 11521727115217271152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25095 DWD™HDWĐ.DWĐDWDWD™HDW!D„¨DWD™HDW!D„¨....HrÂëHHrŢ†(HrÂëHHrŢ†(..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D™HD„¨....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW=DWŤDWĐ..NEG....YNNNNYYDW........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521728115217281152AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25221 DWDśĚDWÔ.DWÔDWDWDśĚDW!D|°DWDśĚDW!D|°....HrÂîĚHrŢ~0HrÂîĚHrŢ~0..DWDW!..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. DśĚD|°....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW). Normal weightA NNYYNEGDW=DWŤDWÔ..NEG....YNNNNYYDW........DW=DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBňB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521729115217291152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25228 DWD§ĐDWÉ.DWÉDWDWD§ĐDWDĘDDWD§ĐDW#DďLDWDĂđDWDĘDHrÂůĐHs—]ÄHrÂůĐHrá“ĚHs{§đHs—]ÄDWDW#DWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. D§ĐDďL.DĂđDĘD.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NNYYNEGDW?DWŤDW—DWÉDXjNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBŰBkBfBpBňB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521730115217301152AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25229 DWDŰ`DWÚ.DWÚDWDWDŰ`DW#DŮDWDŰ`DW#DŮ....HrĂ-`Hrá}HrĂ-`Hrá}..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DŰ`DŮ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŮDW#. Normal weightA NNYYNEGDWDDWŘDWÚ..NEG....YNNNNYYDW........DWDDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŘDWýDWýBŰB¶B%BňBÍ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1152 11521731115217311152AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25230 DWDďÄDWŠ.DWŠDWDWDďÄDWnDĂ<DWDďÄDW#DŇxDW[DvÔDWnDĂ<HrĂAÄHsDH<HrĂAÄHrávřHs*ďTHsDH<DWDW#DW[DWnAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďÄDŇx.DvÔDĂ<.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWTDW[. Overweight A0YNYYNEGDW?DWSDWZDWŠDX+NEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWSDWýDWýBŰB1BŁBŞBňBH7-8 months A€1-2 months A 5-6 monthsA`8-9 months A . ...C4591001C4591001 1152 11521732115217321152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25426 DW D‘ŚDWŇ.DWŇDW DW D‘ŚDW#DźŘDW D‘ŚDW#DźŘ....HrÄ5HráDXHrÄ5HráDX..DW DW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D‘ŚDźŘ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Normal weightA NNYYNEGDW?DWŤDWŇ..NEG....YNNNNYYDW ........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521733115217331152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25428 DW DäŔDWĆ.DWĆDW DW DäŔDWŞDçĚDW DäŔDW#DňDW•D×(DWŞDçĚHrÄ@Hs“†ĚHrÄ@Hrá–śHswĆ¨Hs“†ĚDW DW#DW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DäŔDň.D×(DçĚ.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Underweight ANNYYNEGDW?DWDW”DWĆDXgNEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWýDWýBŰBnBiBmBńB„7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521734115217341152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25430 DW DőÜDWŮ.DWŮDW DW DőÜDW#DéčDW DőÜDW#Déč....HrÄ™\HráŽhHrÄ™\HráŽh..DW DW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DőÜDéč....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŮDW#. Underweight ANNYYNEGDW?DWŘDWŮ..NEG....YNNNNYYDW ........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŘDWýDWýBŰB¶B%BńBĚ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1152 11521735115217351152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25435 DW D÷DWó.DWóDW DW D÷DWóDzDW D÷DW#Dč€DWŢDĘDDWóDzHrÄšHsóVśHrÄšHráŤHs×÷DHsóVśDW DW#DWŢDWóAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷Dč€.DĘDDz.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŮDWŢ. Normal weightA NNYYNEGDW?DWŘDWŮDXDX°NEG....YNNNNYYDW ........DW?DWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŘDWýDWýBŰB¶B B%BńBĚ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1152 11521736115217361152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25617 DW Dř¬DWĐ.DWĐDW DW Dř¬DW!Dż¸DW Dř¬DW!Dż¸....HrÄś,HrŢÁ8HrÄś,HrŢÁ8..DW DW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. Dř¬Dż¸....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW=. Normal weightA NNYYNEGDW=DWŤDWĐ..NEG....YNNNNYYDW ........DW=DWĐYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521737115217371152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25623 DWDˇ|DWß.DWßDWDWDˇ|DW!Dr$DWDˇ|DW!Dr$....HrĹ–|HrŢs¤HrĹ–|HrŢs¤..DWDW!..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW= .. Dˇ|Dr$....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW=. Normal weightA NYYYNEGDW=DWŤDWß..NEG....YNNNNYYDW........DW=DWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÝBmBpBđB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521738115217381152AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25627 DWDÜŚDWě.DWěDWDWDÜŚDWĐDá<DWDÜŚDW%DÝ@DWĽDÇ°DWĐDá<HrĹŃŚHsĹ™<HrĹŃŚHrä$ŔHs«!°HsĹ™<DWDW%DWĽDWĐAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜŚDÝ@.DÇ°Dá<.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW·DWĽ. Overweight A0NNYYNEGDWFDW¶DW»DWěDXŤNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýBŮB’BBBGBđB©7-8 months A€5-6 months A`2-3 monthsA08-9 months A . ...C4591001C4591001 1152 11521739115217391152AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25628 DWDÜČDWĆ.DWĆDWDWDÜČDWŞDß DWDÜČDW$DíäDW•DŢäDWŞDß HrÇ#HHs“~ HrÇ#HHrâăäHswÎdHs“~ DWDW$DW•DWŞAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÜČDíä.DŢäDß .11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW•. Underweight ANNYYNEGDWADW‘DW”DWĆDXgNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBÚBnBiBlBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521740115217401152AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26145 DWDëDWÉ.DWÉDWDWDëDWD¤DWDëDW#DĺtDWDÎôDWD¤HrÇ1”Hs—7HrÇ1”Hrá‰ôHs{˛ôHs—7DWDW#DWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DëDĺt.DÎôD¤.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Overweight A0NNYYNEGDW?DWŤDW—DWÉDXjNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBŰBkBfBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521741115217411152AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26149 DWDó„DWÉ.DWÉDWDWDó„DWDĄ´DWDó„DW#DáđDWDĐDWDĄ´HrÇ:Hs—94HrÇ:Hrá†pHs{´Hs—94DWDW#DWDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dó„Dáđ.DĐDĄ´.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Overweight A0NNYYNEGDW?DWŤDW—DWÉDXjNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBŰBkBfBpBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521742115217421152AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26150 DWD} DWÓ.DWÓDWDWD} DW$D~DWD} DW$D~....HrČ HrâtHrČ Hrât..DWDW$..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. D} D~....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW$. Underweight ANNYYNEGDW@DW‘DWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‘DWýDWýBÚBnBlBîB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521743115217431152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26151 DWD†ÄDWŇ.DWŇDWDWD†ÄDW#D§DWD†ÄDW#D§....HrČÄHráKśHrČÄHráKś..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D†ÄD§....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Underweight ANNYYNEGDW?DWŤDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521744115217441152AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26243 DWD,DWŇ.DWŇDWDWD,DW#D¨„DWD,DW#D¨„....HrČ ,HráMHrČ ,HráM..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. D,D¨„....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Underweight ANNYYNEGDW?DWŤDWŇ..NEG....YNNNNYYDW........DW?DWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521745115217451152AŕYEARSMAASIAN A@HISPANIC OR LATINO AOTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26245 DWDŮřDWâ.DWâDWDWDŮřDW$DË¬DWDŮřDW$DË¬....HrČqřHrâÁ¬HrČqřHrâÁ¬..DWDW$..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWL .. DŮřDË¬....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWâDWL. Underweight ANNYYNEGDW@DWáDWá..NEG....YNNNNYYDW........DW@DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWáDWýDWýBÚBľBBîBŇ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1152 11521746115217461152AŔYEARSFA ASIAN A@HISPANIC OR LATINO AOTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26251 DWDŰ`DWö..DWDWDŰ`DWöDż¸DWDŰ`DW$DÍPDWâD…DWöDż¸HrČs`Hs÷¸HrČs`HrâĂPHsÜřHs÷¸DWDW$DWâDWöAŔYEARSAŔYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWLBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŰ`DÍP.D…Dż¸.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWáDWâ. Underweight ANNYYNEGDW@DWŕDWáDXDXłNEG....YNNNNYYDW........DW@DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŕDWýDWýBÚB˝BBBîBŃ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1152 11521747115217471152AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26252 DWDěôDW×.DW×DWDWDěôDW”DŕDWDěôDW#DąÜDW”DŕDW”DŕHrČ„ôHsv~HrČ„ôHrá^\Hsv~Hsv~DWDW#DW”.AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE ADW×PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DěôDąÜ.Dŕ..11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDWKDWŤDW“DWÎDXhNEGDWŃ.DWŃDWŃYNNNNYNDW........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDW×DW×BµBkBDBJBČB~6-7 months Ap3-4 months A@2-3 monthsA07-8 months A€ . ...C4591001C4591001 1152 11521748115217481152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26433 DWDîÔDWŇ.DWŇDWDWDîÔDW#D»ĽDWDîÔDW#D»Ľ....HrČ†ÔHrá`<HrČ†ÔHrá`<..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW# .. DîÔD»Ľ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW#. Normal weightA NNYYNEGDWEDWŤDWŇ..NEG....YNNNNYYDW........DWEDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBŰBkBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521749115217491152AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26434 DWD˙đDWÓ.DWÓDWDWD˙đDW$DŰ$DWD˙đDW$DŰ$....HrČ—đHrâŃ$HrČ—đHrâŃ$..DWDW$..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW$ .. D˙đDŰ$....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW$. Underweight ANNYYNEGDWDDW’DWÓ..NEG....YNNNNYYDW........DWDDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBÚBoBkBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521750115217501152AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26443 DWEĹŔDWÉ.DWÉDWDWEĹŔDWDŞ(DWEĹŔDW$Dő DWDëPDWDŞ(HrČ¤\Hs—=¨HrČ¤\Hrâë Hs{ĎPHs—=¨DWDW$DWDWAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. EĹŔDő .DëPDŞ(.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Normal weightA NNYYNEGDWADWŤDW—DWÉDXjNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBfBpBîB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521751115217511152AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26444 DWD|°DW’.DW’DWDWD|°DW)D€DWD|°DW)D€....HrĚ 0Hré HrĚ 0Hré ..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW’PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. D|°D€....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽDW). Normal weightA NYYYNEGDWEDWŤDWć..NEGDW‘.DW‘DW‘YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDW’DW’BjBeAPB€B{3-4 months A@3-4 months A@0-1 month A4-5 months AP . ...C4591001C4591001 1152 11521752115217521152AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26603 DWD‰DWĐ.DWĐDWDWD‰DWDyhDWD‰DW)D|°DW™DŠŔDWDyhHrĚśHs—čHrĚśHré 0Hs|Ŕ@Hs—čDWDW)DW™DWAđYEARSAđYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D‰D|°.DŠŔDyh.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Normal weightA NNYYNEGDWEDWŤDWDWĐDXjNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYYY NYDWŤDWýDWýBŐBeBeBpBëB{7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1152 11521753115217531152AĐYEARSFA ASIAN A@NOT HISPANIC OR LATINOA JAPANESEAPUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26604 DWD‹°DWŘ.DWŘDWDWD‹°DW)D{„DWD‹°DW)D{„....HrĚ0Hré HrĚ0Hré ..DWDW)..AĐYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‹°D{„....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWEDWŤDWŘ..NEG....YNNNNYYDW........DWEDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNYY NYDWŤDWýDWýBŐBeBpBëB{7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521754115217541152AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26610 DWDëČDW•.DW•DWDWDëČDW(DăĐDWDëČDW(DăĐ....HrĚxHHrčĐHrĚxHHrčĐ..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE ADW•PROTOCOL DEVIATION . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. DëČDăĐ....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽDW(. Underweight ANNYYNEGDWDDWŤDWĺ..NEGDW”.DW”DW”YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDW•DW•BnBfA€BB{3-4 months A@3-4 months A@0-1 month A4-5 months AP . ..DW‹C4591001C4591001 1152 11521755115217551152AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26606 DWDé¬DWĺ.DWĺDWDWDé¬DW(DÝ@DWDé¬DW(DÝ@....HrĚv,Hrč@HrĚv,Hrč@..DWDW(..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. Dé¬DÝ@....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW(. Normal weightA NNYYNEGDWDDWŤDWĺ..NEG....YNNNNYYDW........DWDDWĺYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÖBfBpBëB{7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1152 11521756115217561152AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26745 DWE,DWß.DWßDWDWE,DW(DöDWE,DW(Dö....HrĚŹ@Hrč2HrĚŹ@Hrč2..DWDW(..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW( .. E,Dö....11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DW(. Underweight ANNNNPOSDWEDW‘DW×..POS....YNNNNYYDW........DWEDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW‘DWýDWýBÖBjBlBëB7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DW(C4591001C4591001 1152 11521757115217571152AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26747 DWEF@DWÄ.DWÄDWDWEF@DW¨D€pDWEF@DW)DhDW•DŹpDW¨D€pHrĚäHs|pHrĚäHréčHsw~đHs|pDWDW)DW•DW¨AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. EF@Dh.DŹpD€p.11354 Brandon, Donald M. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW•. Normal weightA NNYYNEGDWEDWŤDW”DWÄDXeNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBŐBeBiBpBëB{7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561243115612431156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20038 DV»DŕLDW•.DW•DV»DV»DŕLDVÎD¬DV»DŕLDVÎD¬....HrXhĚHrqB¬HrXhĚHrqB¬..DV»DVÎ..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DŕLD¬....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DWH. Underweight ANNYYNEGDVëDW‹DW‹..NEG....YNNNNYYDV»........DVëDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW”DWýDWýCBÇBiC0BÚ10-11 monthsA°7-8 months A€0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561244115612441156AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV»20039 DV»DĹĐDWĘ.DWĘDV»DV»DĹĐDW®D°DV»DĹĐDVÎD®`DW™DŁ\DW®D°HrXNPHs•HrXNPHrqC`Hs|ŘÜHs•DV»DVÎDW™DW®AĐYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWHBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĹĐD®`.DŁ\D°.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW•DW™. Normal weightA NNNYPOSDVëDW‹DW‹DWĘDXkPOS....YNNNNYYDV»........DVëDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW”DWýDWýCBÇBeBiC0BÚ10-11 monthsA°7-8 months A€3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561245115612451156AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV»20044 DV»DĆ„DW•.DW•DV»DV»DĆ„DVÎDŻDV»DĆ„DVÎDŻ....HrXOHrqDHrXOHrqD..DV»DVÎ..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DĆ„DŻ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW•DWH. Normal weightA NYYYNEGDVëDW‹DW‹..NEG....YNNNNYYDV»........DVëDW‹YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW”DWýDWýCBÇBiC0BÚ10-11 monthsA°7-8 months A€0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561246115612461156AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20285 DVÂDĐÔDWĹ.DWĹDV»DVÂDĐÔDWŞDëPDVÂDĐÔDVŐDš8DW•DĄ´DWŞDëPHra“ÔHs“ŠPHra“ÔHrzi¸Hsw•4Hs“ŠPDVÂDVŐDW•DWŞAŕYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĐÔDš8.DĄ´DëP.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Normal weightA NYYYNEGDVńDWDW’DWĹDXgNEG....YNNNNYNDVÂ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWýDWýCBĽBiBmCŔBĎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561247115612471156AŔYEARSMANOT REPORTED ApNOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20046 DVĽD“lDWÚ.DWÚDVĽDVĽD“lDW¸DĐ DVĽD“lDVĎD»ĽDWŁDťDW¸DĐ HrYmlHsĄä HrYmlHrr˘<HsŠHsĄä DVĽDVĎDWŁDW¸AŔYEARSAĐYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. D“lD»Ľ.DťDĐ .427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW›DWŁ. Overweight A0YYYYNEGDVňDWŠDWŠDWÚDXuNEG....YNNNNYYDVĽ........DVňDWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWšDWýDWýCđBĚB[BcC Bß10-11 monthsA°7-8 months A€3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561248115612481156AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVĽ20086 DVĽDŻDWď.DWďDVĽDVĽDŻDW DśĚDVĽDŻDVĎD×dDWŠDČÜDW DśĚHrY‰Hs†ĚHrY‰Hrr˝äHsi7ÜHs†ĚDVĽDVĎDWŠDW AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŻD×d.DČÜDśĚ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW}DWŠ. Normal weightA NNYYNEGDVëDW|DW‰DWĽDX]NEG....YNNNNYNDVĽ........DVë.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW|DWýDWýCđB®BtBC BÁ10-11 monthsA°6-7 months Ap4-5 monthsAP11-12 monthsAŔ . ...C4591001C4591001 1156 11561249115612491156AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVĽ20087 DVĽDąÜDW˘.DW˘DVĽDVĽDąÜDVĎD¸tDVĽDąÜDVĎD¸t....HrY“ÜHrržôHrY“ÜHrržô..DVĽDVĎ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DąÜD¸t....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘.. Normal weightA NYYYNEGDVěDW~DW~..NEG....YNNNNYYDVĽ........DVěDW~YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýCđBÓB\C Bć10-11 monthsA°7-8 months A€0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561250115612501156AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVĽ20090 DVĽDÜŚDW“..DVĽDVĽDÜŚDVĎDČÜDVĽDÜŚDVĎDČÜ....HrY¶ŚHrrŻ\HrY¶ŚHrrŻ\..DVĽDVĎ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DÜŚDČÜ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DW,. Normal weightA NNYYNEGDVëDW~DW~..NEG....YNNNNYYDVĽ........DVëDW~YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW’DWýDWýCđBÄBkC B×10-11 monthsA°7-8 months A€0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561253115612531156AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVż20094 DVżD«TDWŢ.DWŢDVżDVżD«TDW»D¤LDVżD«TDVÖDĄ´DW¦DáđDW»D¤LHr]yÔHs©¬ĚHr]yÔHr{Ć´HsŽ:đHs©¬ĚDVżDVÖDW¦DW»AĐYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D«TDĄ´.DáđD¤L.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW˘DW¦. Overweight A0YNYYNEGDVňDW†DW†DWŢDXxNEG....YNNNNYYDVż........DVňDW†YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWˇDWýDWýC€BĚBXB\CđBă10-11 monthsA°7-8 months A€3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561254115612541156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVż20151 DVżDá´DWć.DWćDVżDVżDá´DWĆDľDVżDá´DVÖD¦,DW±DÇ8DWĆDľHr]°4Hs¸GHr]°4Hr{Ç,Hsś ¸Hs¸GDVżDVÖDW±DWĆAŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dá´D¦,.DÇ8Dľ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW±. Normal weightA NYYYNEGDVóDWŠDWŠDWćDXNEG....YNNNNYYDVż........DVóDWŠYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¬DWýDWýC€B×BMBQCđBî10-11 monthsA°7-8 months A€2-3 monthsA011-12 monthsAŔ . ...C4591001C4591001 1156 11561255115612551156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVŔ20152 DVŔDĄDWĂ.DWĂDVŔDVŔDĄDW¦D§”DVŔDĄDVŐD™DW‘D¨HDW¦D§”Hr^ĹHsŽ”Hr^ĹHrzhŚHsrQČHsŽ”DVŔDVŐDW‘DW¦AŔYEARSAŔYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWjBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄD™.D¨HD§”.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW‘. Normal weightA NYYYNEGDVńDWDWDWĂDXcNEG....YNNNNYNDVŔ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýCBĽBmBmCŕBŃ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561256115612561156AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20155 DVŔDĄ´DW‘.DW‘DVŔDVŔDĄ´DVŐDĄđDVŔDĄ´DVŐDĄđ....Hr^Ĺ´HrzupHr^Ĺ´Hrzup..DVŔDVŐ..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWj .. DĄ´DĄđ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWj. Overweight A0NNYYNEGDVřDWDW‘..NEG....YNNNNYYDVŔ........DVřDW‘YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýCBĽBmCŕBŃ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561257115612571156AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20156 DVŔD¦ŕDW”.DW”DVŔDVŔD¦ŕDV×DĎ0DVŔD¦ŕDV×DĎ0....Hr^ĆŕHr}A°Hr^ĆŕHr}A°..DVŔDV×..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. D¦ŕDĎ0....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW*. Normal weightA NNYYNEGDVúDW“DW”..NEG....YNNNNYYDVŔ........DVúDW”YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýCpB˝BjCŕBÔ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561259115612591156AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVŔ20183 DVŔDňXDW¶.DW¶DVŔDVŔDňXDVŐD§DVŔDňXDVŐD§....Hr_XHrzvśHr_XHrzvś..DVŔDVŐ..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DňXD§....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¶.. Normal weightA NNYYNEGDVňDW‡DW‡..NEG....YNNNNYYDVŔ........DVňDW‡YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWµDWýDWýCBáBHCŕBö10-11 monthsA°8-9 months A0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561260115612601156AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20185 DVÁDĄxDW‘.DW‘DVÁDVÁDĄxDWqDťřDVÁDĄxDV×D`DW[DťĽDWqDťřHr`řHsHxHr`řHr}ŕHs+<HsHxDVÁDV×DW[DWqAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄxD`.DťĽDťř.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW=DW[. Overweight A0NNYYNEGDVóDW<DWZDW‘DX.NEG....YNNNNYNDVÁ........DVó.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW<DWýDWýCpBfBŁBÁCĐB|10-11 monthsA°3-4 months A@5-6 monthsA`11-12 monthsAŔ . ..DW(C4591001C4591001 1156 11561262115612621156AŕYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÁ20186 DVÁDÄ¤DW’.DW’DVÁDVÁDÄ¤DVÖD±äDVÁDÄ¤DVÖD±ä....Hr`6$Hr{ŇäHr`6$Hr{Ňä..DVÁDVÖ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWa .. DÄ¤D±ä....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWa. Normal weightA NYYYNEGDVóDW‘DW’..NEG....YNNNNYYDVÁ........DVóDW’YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýC€BĽBlCĐBŃ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561263115612631156AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÁ20189 DVÁDÖěDWÉ.DWÉDVÁDVÁDÖěDWDˇ|DVÁDÖěDVŐD”DW™D˘lDWDˇ|Hr`HlHs—4üHr`HlHrzhHs|×ěHs—4üDVÁDVŐDW™DWAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWjBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÖěD”.D˘lDˇ|.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW™. Overweight A0NNYYNEGDVńDWDW’DWÉDXjNEG....YNNNNYNDVÁ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýCBĽBeBmCĐBĐ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ..DV˙C4591001C4591001 1156 11561264115612641156AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVÂ20279 DVÂD¦¤DW’..DVÂDVÂD¦¤DVŐD¶”DVÂD¦¤DVŐD¶”....Hrai¤Hrz†Hrai¤Hrz†..DVÂDVŐ..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWa .. D¦¤D¶”....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DWa. Normal weightA NNYYNEGDV÷DWDW’..NEG....YNNNNYYDVÂ........DV÷DW’YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýCBĽBmCŔBĎ10-11 monthsA°6-7 months Ap0-1 month A11-12 monthsAŔ . ...C4591001C4591001 1156 11561265115612651156AŔYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVÂ20283 DVÂDÎ|DWÉ.DWÉDVÂDVÂDÎ|DWŞDëČDVÂDÎ|DVŐD›ÜDW•D¤DWŞDëČHra‘|Hs“ŠČHra‘|Hrzk\Hsw”Hs“ŠČDVÂDVŐDW•DWŞAŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ|D›Ü.D¤DëČ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW•. Underweight ANNYYNEGDVńDWDW’DWÉDXgNEG....YNNNNYNDVÂ........DVń.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýCBĽBiBmCŔBĎ10-11 monthsA°6-7 months Ap3-4 monthsA@11-12 monthsAŔ . ...C4591001C4591001 1156 11561303115613031156AđYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20287 DVéDĽpDWµ.DWµDVéDVéDĽpDV˙D¦¤DVéDĽpDV˙D¦¤....Hr”éđHr±Ő$Hr”éđHr±Ő$..DVéDV˙..AđYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĽpD¦¤....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµ.. Overweight A0NNYYNEGDWDWŻDWŻ..NEG....YNNNNYYDVé........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýB˙B¶BICPBĚ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561304115613041156AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20403 DVéDŇ´DWđ.DWđDVéDVéDŇ´DVţD›(DVéDŇ´DVţD›(....Hr•4Hr°x(Hr•4Hr°x(..DVéDVţ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DŇ´D›(....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘DWF. Obese A@YNYYNEGDWDWˇDW®..NEG....YNNNNYYDVé........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýCB¤B\CPBą9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561305115613051156AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20404 DVéDÓ¤DWó.DWóDVéDVéDÓ¤DWĐDÄhDVéDÓ¤DV˙D—ŕDW»DčDWĐDÄhHr•$HsĹ|hHr•$Hr±Ć`Hs©¶hHsĹ|hDVéDV˙DW»DWĐAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓ¤D—ŕ.DčDÄh.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW»DW». Overweight A0YNYYNEGDWDWşDWşDWóDXŤNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWşDWýDWýB˙BĽBCBCCPBŇ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ..DWŽC4591001C4591001 1156 11561306115613061156AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20405 DVęDťDWµ.DWµDVęDVęDťDV˙D¦¤DVęDťDV˙D¦¤....Hr–Hr±Ő$Hr–Hr±Ő$..DVęDV˙..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DťD¦¤....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµ.. Normal weightA NNYYNEGDWDWŻDWŻ..NEG....YNNNNYYDVę........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýB˙B¶BIC@BË9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561307115613071156AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20408 DVęD±lDWě.DWěDVęDVęD±lDWĚDŔäDVęD±lDVţDštDW¸DĎ0DWĚDŔäHr–0lHsŔ2äHr–0lHr°wtHsĄă0HsŔ2äDVęDVţDW¸DWĚAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D±lDšt.DĎ0DŔä.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¸DW¸. Normal weightA NNNNPOSDWDW·DW·DWěDX‰POS....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW·DWýDWýCBşBFBFC@BÎ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1156 11561308115613081156AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20542 DVęD±äDW¸.DW¸DVęDVęD±äDVţD™DVęD±äDVţD™....Hr–0äHr°vHr–0äHr°v..DVęDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. D±äD™....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW¸DWF. Normal weightA NYNYPOSDWDW·DW¸..POS....YNNNNYYDVę........DWDW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW·DWýDWýCBşBFC@BÎ9-10 months A 6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561309115613091156AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVę20549 DVęD˛ÔDWé.DWéDVęDVęD˛ÔDWĚDÁ DVęD˛ÔDVţDDW¸DĎlDWĚDÁ Hr–1ÔHsŔ3 Hr–1ÔHr°uHsĄălHsŔ3 DVęDVţDW¸DWĚAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˛ÔD.DĎlDÁ .427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¸DW¸. Underweight ANNNYPOSDWDW·DW·DWéDX‰POS....YNNNNYNDVę........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW·DWýDWýCBşBFBFC@BÎ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1156 11561310115613101156AŔYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20551 DVęDę$DWż.DWżDVęDVęDę$DWD•DVęDę$DWD•....Hr–i$HrĆŰHr–i$HrĆŰ..DVęDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW) .. Dę$D•....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘DW). Normal weightA NNYYNEGDW,DWˇDWż..NEG....YNNNNYYDVę........DW,DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýBďB“B\C@B¸8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561311115613111156AĐYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVë20552 DVëD“lDWÚ..DVëDVëD“lDW DÄ,DVëD“lDW DÄ,....Hr—cěHrÄg¬Hr—cěHrÄg¬..DVëDW ..AĐYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D“lDÄ,....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWÚDW0. Obese A@YYYYNEGDW*DWżDWż..NEG....YNNNNYYDVë........DW*DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŮDWýDWýBńBÍB$C0Bď8-9 months A7-8 months A€0-1 month A9-10 months A . ...C4591001C4591001 1156 11561312115613121156AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20661 DVëDŁ DWĺ.DWĺDVëDVëDŁ DWĂDˇ|DVëDŁ DV˙D”DW®D©tDWĂDˇ|Hr—s Hs´5üHr—s Hr±ÇHsŽtHs´5üDVëDV˙DW®DWĂAđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŁ D”.D©tDˇ|.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW®DW®. Normal weightA NNYYNEGDWDWDWDWĺDX€NEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýB˙BŻBPBPC0BĂ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1156 11561313115613131156AŕYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20663 DVëDŘĚDW·.DW·DVëDVëDŘĚDVţDą(DVëDŘĚDVţDą(....Hr—©LHr°–(Hr—©LHr°–(..DVëDVţ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. DŘĚDą(....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘DWD. Normal weightA NNYYNEGDWDWˇDW·..NEG....YNNNNYYDVë........DWDW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýCB¤B\C0B·9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561314115613141156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20665 DVěDž4DWŻ.DWŻDVěDVěDž4DWDĐDVěDž4DWDĐ....HrŔ4HrłĐHrŔ4HrłĐ..DVěDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. Dž4DĐ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘DWF. Overweight A0YYNYPOSDWDWˇDWŻ..POS....YNNNNYYDVě........DWDWŻYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWˇDWýDWýBţB˘B\C B¶9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561316115613161156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVě20666 DVěD¬DW†.DW†DVěDVěD¬DWDÎDVěD¬DWDÎ....HrĎ¬Hrąĺ„HrĎ¬Hrąĺ„..DVěDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA DW†WITHDRAWAL BY SUBJECT DWMPROTOCOL DEVIATION BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. D¬DÎ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDW(DWÂDWÂ.. ....YNNNNNNDVě..........YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNNNY NNDW†.DW†B‚B‚..B›B›4-5 months AP4-5 months AP .5-6 months A` . ...C4591001C4591001 1156 11561317115613171156AŕYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20859 DVěDŰśDW».DW»DVěDVěDŰśDWDŢlDVěDŰśDWDŢl....HrýśHrąőěHrýśHrąőě..DVěDW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DŰśDŢl....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŁDWF. Obese A@YYYYNEGDW"DW˘DW¶..NEG....YNNNNYYDVě........DW"DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW˘DWýDWýBůBžB[C B·8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561318115613181156AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVí20861 DVíD´DWĘ.DWĘDVíDVíD´DW DŁ\DVíD´DW DŁ\....Hrš'€HrÄFÜHrš'€HrÄFÜ..DVíDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D´DŁ\....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŁDW0. Overweight A0NNNYPOSDW*DW˘DWĘ..POS....YNNNNYYDVí........DW*DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW˘DWýDWýBńB–B[CB¶8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561319115613191156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20862 DVíDÇ°DWď.DWďDVíDVíDÇ°DWÓDµŕDVíDÇ°DWD´<DWľDŁ\DWÓDµŕHrš;0HsÉb`Hrš;0Hrł4<Hs \HsÉb`DVíDWDWľDWÓAŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÇ°D´<.DŁ\Dµŕ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW¶DWľ. Underweight ANNNYPOSDW!DW°DW°DWďDXPOS....YNNNNYYDVí........DW!DW°YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWµDWýDWýBţB¶B@BHCBÉ9-10 months A 6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1156 11561320115613201156AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVí20863 DVíDŢ0DW!.DW!DVíDVíDŢ0DWD©°DVíDŢ0DWD©°....HršQ°Hrł)°HršQ°Hrł)°..DVíDW..AŕYEARS. 12-15 YearsAWHITE AWHITE ADW!WITHDRAWAL BY PARENT/GUARDIAN DW!WITHDRAWAL BY SUBJECT BNT162b2 Phase 2/3 (30 mcg)A€NNYY NN Y. .. DŢ0D©°....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo ... Normal weightA NNYYNEGDW#DW˝DW˝.. ....YNNNNNNDVí..........YY YYN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNNNY NNDW!.DW!B"B"..B5B51-2 months A 1-2 months A .1-2 months A . ...C4591001C4591001 1156 11561321115613211156AŕYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21165 DVđD˛\DW».DW»DVđDVđD˛\DWD«TDVđD˛\DWD«T....Hrž\HrąÂÔHrž\HrąÂÔ..DVđDW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. D˛\D«T....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW˘DWE. Normal weightA NNYYNEGDW!DWˇDW»..NEG....YNNNNYYDVđ........DW!DW»YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWˇDWýDWýBůBťB\CŕB˛8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561322115613221156AŕYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21168 DVđDĂ<DWĂ.DWĂDVđDVđDĂ<DW¦DˇôDVđDĂ<DWDˇDW’DčDDW¦DˇôHrž+<HsŤúôHrž+<Hrą¸„HssăDHsŤúôDVđDWDW’DW¦AŕYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂ<Dˇ.DčDDˇô.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW’. Obese A@YYYYNEGDW!DW‘DW‘DWĂDXcNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBůBŤBlBlCŕB˘8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ..DW[C4591001C4591001 1156 11561323115613231156AŔYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ21173 DVđDĂđDWÉ.DWÉDVđDVđDĂđDW¦D¨ŔDVđDĂđDWD DW’Dé4DW¦D¨ŔHrž+đHsŽŔHrž+đHrą·”Hssä4HsŽŔDVđDWDW’DW¦AŔYEARSAĐYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĂđD .Dé4D¨Ŕ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW’. Normal weightA NNYYNEGDW!DW‘DW‘DWÉDXcNEG....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBůBŤBlBlCŕB˘8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ..DWhC4591001C4591001 1156 11561324115613241156AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21176 DVđDÄ¤DW¸.DW¸DVđDVđDÄ¤DWDĹ”DVđDÄ¤DWDĹ”....Hrž,¤HrĽ€Hrž,¤HrĽ€..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW* .. DÄ¤DĹ”....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW*. Normal weightA NYYYNEGDW(DW“DW¸..NEG....YNNNNYYDVđ........DW(DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW“DWýDWýB÷BŤBjCŕB¤8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561325115613251156AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21489 DVńDĺěDWż.DWżDVńDVńDĺěDWD•DVńDĺěDWD•....HrźźlHrą¬HrźźlHrą¬..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWF .. DĺěD•....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWµDWF. Overweight A0NYYYNEGDW"DW´DWż..NEG....YNNNNYYDVń........DW"DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW´DWýDWýBůB°BICĐBÄ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561327115613271156AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVó21492 DVóDčřDWľ.DWľDVóDVóDčřDW˘D›(DVóDčřDWDÓ¤DWŽDî DW˘D›(Hr˘ExHs®(Hr˘ExHr»<¤HsnŁ Hs®(DVóDWDWŽDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW%BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčřDÓ¤.Dî D›(.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW$DWŚDWŤDWľDX_NEG....YNNNNYNDVó........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BpBqC°Bš8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1156 11561328115613281156AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV÷21493 DV÷D¤DWî.DWîDV÷DV÷D¤DWDăDV÷D¤DWDă....Hr§GHrĂ5Hr§GHrĂ5..DV÷DW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW0 .. D¤Dă....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW0. Overweight A0YYYYNEGDW)DWDWî..NEG....YNNNNYYDV÷........DW)DWîYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBňB…BmCpBš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1156 11561330115613301156AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř21500 DVřDâ¤DW˝.DW˝DVřDVřDâ¤DWˇDŘĚDVřDâ¤DWDŇ´DWŽD÷ĽDWˇDŘĚHr¨Ö¤Hs‡šLHr¨Ö¤HrĂ$´Hsn¬ĽHs‡šLDVřDWDWŽDWˇAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ¤DŇ´.D÷ĽDŘĚ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW)DWŚDWŤDW˝DX^NEG....YNNNNYNDVř........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBňBBpBqC`B•8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1156 11561331115613311156AŕYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23109 DVúDŢ¨DW˝.DW˝DVúDVúDŢ¨DW DäDVúDŢ¨DW Dä....Hr«u¨HrÄ‡ŚHr«u¨HrÄ‡Ś..DVúDW ..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. DŢ¨Dä....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĽDW,. Normal weightA NNYYNEGDW)DW»DW˝..NEG....YNNNNYYDVú........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW»DWýDWýBńBŻBBC@BÂ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561332115613321156AđYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23113 DVúDâ,DWď.DWďDVúDVúDâ,DWÓDź$DVúDâ,DW Dä„DW˝DĎlDWÓDź$Hr«y,HsÉK¤Hr«y,HrÄHs¬zěHsÉK¤DVúDW DW˝DWÓAđYEARSAđYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW,BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dâ,Dä„.DĎlDź$.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĽDW˝. Underweight ANNYYNEGDW)DW»DWĽDWďDXNEG....YNNNNYNDVú........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW»DWýDWýBńBŻBABBC@BÂ8-9 months A6-7 months Ap2-3 monthsA09-10 months A . ...C4591001C4591001 1156 11561333115613331156AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23117 DVűDŔäDWĂ.DWĂDVűDVűDŔäDWŁDŮĽDVűDŔäDWDń¤DWŽDŢäDWŁDŮĽHr¬©dHsŠ><Hr¬©dHrÇ8$Hsn“äHsŠ><DVűDWDWŽDWŁAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŔäDń¤.DŢäDŮĽ.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANNYYNEGDW,DWŚDWŤDWĂDX`NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BpBqC0B’8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1156 11561334115613341156AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23120 DVűDĐÔDWÉ.DWÉDVűDVűDĐÔDWDśDVűDĐÔDWDś....Hr¬ąTHrČ(śHr¬ąTHrČ(ś..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWk .. DĐÔDś....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWk. Normal weightA NNNYPOSDW,DWŚDWÉ..NEG....YNNNNYYDVű........DW,DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1156 11561335115613351156AĐYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23613 DVţDťĽDWě..DVţDVţDťĽDWěDŔ¨DVţDťĽDWD”ÔDW×DćÜDWěDŔ¨Hr°zĽHsęb¨Hr°zĽHrÎÄTHsÎŮ\Hsęb¨DVţDWDW×DWěAĐYEARSAŕYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWjBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťĽD”Ô.DćÜDŔ¨.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWÍDW×. Normal weightA NNYYNEGDW2DWĘDWĘDXDX©NEG....YNNNNYYDVţ........DW2DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWĚDWýDWýBéB¸B'B1CBĎ8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWěC4591001C4591001 1156 11561336115613361156AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV˙23615 DV˙D°DW§.DW§DV˙DV˙D°DWD¦¤DV˙D°DWD¦¤....Hr±Ţ„HrĚ3$Hr±Ţ„HrĚ3$..DV˙DW..AđYEARS. 12-15 YearsAWHITE AWHITE ADW§NO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW8 .. D°D¦¤....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW§DW8. Normal weightA NNYYNEGDW3DW¦DWĐ..NEGDWŤ.DWŤDWŤYNNNNYNDV˙........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¦DW§DW§B•B”AB©B¨5-6 months A`5-6 months A`0-1 month A6-7 months Ap . ...C4591001C4591001 1156 11561337115613371156AŕYEARSFA BLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV˙23621 DV˙Dí¨DWĹ.DWĹDV˙DV˙Dí¨DWDáđDV˙Dí¨DWDáđ....Hr˛(HrĚnpHr˛(HrĚnp..DV˙DW..AŕYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. Dí¨Dáđ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWĹDW2. Obese A@YNYYNEGDW/DWÄDWĹ..NEG....YNNNNYYDV˙........DW/DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWÄDWýDWýBëB˛B9B˙BĆ8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1156 11561338115613381156AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23624 DWDŞ DWĆ.DWĆDWDWDŞ DWDĺěDWDŞ DWDĺě....Hrł* HrĚrlHrł* HrĚrl..DWDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DŞ Dĺě....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŻDWH. Underweight ANNYYNEGDW3DW®DWĆ..NEG....YNNNNYYDW........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW®DWýDWýBëBśBOBţBŻ8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1156 11561339115613391156AŔYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24385 DWD®$DWĂ.DWĂDWDWD®$DWDëDWD®$DWDë....HrąĹ¤Hr×”HrąĹ¤Hr×”..DWDW..AŔYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW9 .. D®$Dë....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW·DW9. Normal weightA NNYYNEGDW7DW¶DWŘ..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW¶DWýDWýBăBśBGBůB˛8-9 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1156 11561340115613401156AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24386 DWD·„DWË.DWËDWDWD·„DWDČ DWD·„DWDČ ....HrąĎHrÖá HrąĎHrÖá ..DWDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW? .. D·„DČ ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Normal weightA NNYYNEGDW8DW—DWË..NEG....YNNNNYYDW........DW8DWËYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW—DWýDWýBăB}BfBůB“8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1156 11561341115613411156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24388 DWDÂLDWĂ.DWĂDWDWDÂLDWŁD§”DWDÂLDWDëČDWŽDÖ°DWŁD§”Hr»+LHsŠHr»+LHr×HHsn‹°HsŠDWDWDWŽDWŁAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂLDëČ.DÖ°D§”.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDW7DWŚDWŤDWĂDX`NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBăBrBpBqBřB‡8-9 months A4-5 months AP4-5 monthsAP8-9 months A . ...C4591001C4591001 1156 11561342115613421156AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24389 DWDĂDWĚ.DWĚDWDWDĂDWDěôDWDĂDWDěô....Hr»,Hr×tHr»,Hr×t..DWDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW: .. DĂDěô....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW:. Underweight ANNYYNEGDW7DWŚDWĚ..NEG....YNNNNYYDW........DW7DWĚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBăBrBqBřB‡8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1156 11561343115613431156AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25174 DWD«DWĂ.DWĂDWDWD«DW¦D×ÜDWD«DW!D•LDW’DˇôDW¦D×ÜHrÂýHsŽ0ÜHrÂýHrŢ–ĚHssśôHsŽ0ÜDWDW!DW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D«D•L.DˇôD×Ü.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDW=DWŤDW‘DWĂDXcNEG....YNNNNYNDW........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÝBmBlBpBňB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561344115613441156AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25175 DWDć(DWß..DWDWDć(DW!DĐ DWDć(DW!DĐ ....HrĂ8(HrŢŃ HrĂ8(HrŢŃ ..DWDW!..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWD .. Dć(DĐ ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWD. Normal weightA NNYYNEGDW>DWŚDWß..NEG....YNNNNYYDW........DW>DWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561345115613451156AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25176 DW D˘äDWŰ.DWŰDW DW D˘äDWżDä„DW D˘äDW!D“äDWŞDÜDWżDä„HrÄFdHsŻ3HrÄFdHrŢ•dHs“{HsŻ3DW DW!DWŞDWżAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. D˘äD“ä.DÜDä„.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŞ. Normal weightA NNNYPOSDW=DWŚDW©DWŰDX|POS....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBÝBlBTBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561346115613461156AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25177 DWD¤DWÓ.DWÓDWDWD¤DW$DśDWD¤DW$Dś....HrĹ™Hrâ’HrĹ™Hrâ’..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. D¤Dś....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWE. Normal weightA NNYYNEGDWDDWŚDWÓ..NEG....YNNNNYYDW........DWDDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561347115613471156AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25701 DWDŔlDW×.DW×DWDWDŔlDW#D—¤DWDŔlDW#D—¤....HrĹµlHrá<$HrĹµlHrá<$..DWDW#..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŔlD—¤....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW@DWŚDW×..NEG....YNNNNYYDW........DW@DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561348115613481156AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25708 DWDđDWÉ.DWÉDWDWDđDWDŰ$DWDđDW"DčĽDWšDëPDWDŰ$HrĹĺHs—n¤HrĹĺHrŕ;ĽHs~rPHs—n¤DWDW"DWšDWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DđDčĽ.DëPDŰ$.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDWš. Normal weightA NNYYNEGDW@DW—DW™DWÉDXjNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW—DWýDWýBÜBvBdBfBđBŠ7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561349115613491156AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25702 DWDîDWŢ.DWŢDWDWDîDW"Dé¬DWDîDW"Dé¬....HrĹăHrŕ<¬HrĹăHrŕ<¬..DWDW"..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW+ .. DîDé¬....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW+. Overweight A0NNYYNEGDW@DW—DWŢ..NEG....YNNNNYYDW........DW@DWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW—DWýDWýBÜBvBfBđBŠ7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1156 11561351115613511156AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25709 DWD•DWÉ.DWÉDWDWD•DWD ŚDWD•DW$DťDDWD¨DWD ŚHrĆŰHs—4HrĆŰHrâ“DHs{ŚHs—4DWDW$DWDWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. D•DťD.D¨D Ś.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW. Underweight ANNYYNEGDW@DWŚDW—DWÉDXjNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÚBiBfBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561352115613521156AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25954 DWDĆ„DWÚ.DWÚDWDWDĆ„DW$DĘřDWDĆ„DW$DĘř....HrÇ HrâŔřHrÇ HrâŔř..DWDW$..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. DĆ„DĘř....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW%. Underweight ANNYYNEGDW@DWDWÚ..NEG....YNNNNYYDW........DW@DWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÚBmBmBďB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561353115613531156AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25956 DWDßDWĆ.DWĆDWDWDßDW‘DóHDWDßDW#Dâ¤DW‘DóHDW‘DóHHrÇ&HsrśČHrÇ&Hrá‡$HsrśČHsrśČDWDW#DW‘.AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWV .. DßDâ¤.DóH..427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘DWĆPROTOCOL DEVIATION Underweight ANNYYNEGDW?DWŚDWDWĆDXeNEGDW©.DW©DW©YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561354115613541156AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25957 DWDŕDWď.DWďDWDWDŕDW#Dă”DWDŕDW#Dă”....HrÇ'HráHrÇ'Hrá..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWE .. DŕDă”....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWE. Normal weightA NNYYNEGDW?DWŚDWď..NEG....YNNNNYYDW........DW?DWďYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ..DWŇC4591001C4591001 1156 11561355115613551156AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25963 DWDáxDWé..DWDWDáxDWéDż@DWDáxDW"DÔXDWÔD¤ÄDWéDż@HrÇ'řHsćlŔHrÇ'řHrŕ'XHsĘ˘ÄHsćlŔDWDW"DWÔDWéAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DáxDÔX.D¤ÄDż@.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWĐDWÔ. Underweight ANNNYPOSDW>DWĎDWÓDXDX¦POS....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWĎDWýDWýBÜB®B*B.BďBÁ7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1156 11561356115613561156AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26050 DWDâhDWâ.DWâDWDWDâhDW%DčĽDWDâhDW%DčĽ....HrÇ(čHrä0<HrÇ(čHrä0<..DWDW%..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWN .. DâhDčĽ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWN. Normal weightA NNYYNEGDWGDWŚDWâ..NEG....YNNNNYYDW........DWGDWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561357115613571156AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26052 DWDďÄDWĂ.DWĂDWDWDďÄDW¦DštDWDďÄDW#Dá´DW‘DóŔDW¦DštHrÇ6DHsŤótHrÇ6DHrá†4Hsrť@HsŤótDWDW#DW‘DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW$BNT162b2 (30 (*ESC*){unicode 03BC}g).. DďÄDá´.DóŔDšt.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Underweight ANNYYNEGDW@DWŚDWDWĂDXcNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBmBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1156 11561358115613581156AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26056 DWDđ´DWâ.DWâDWDWDđ´DW%DäDWDđ´DW%Dä....HrÇ74Hrä+ŚHrÇ74Hrä+Ś..DWDW%..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dđ´Dä....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Underweight ANNYYNEGDWODWŚDWâ..NEG....YNNNNYYDW........DWODWâYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŮBhBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561359115613591156AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26059 DWDštDW˝.DW˝DWDWDštDWŽDŻŚDWDštDW%D“äDWŽDŻŚDWŽDŻŚHrČ2tHsndŚHrČ2tHrăŰdHsndŚHsndŚDWDW%DWŽ.AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NN NYhad important protocol deviation(s) as determined by the clinician for Efficacy (prior to the first post(*ESC*){unicode 2013}Dose 2 N-binding antibody test) PopulationNY YDWL .. DštD“ä.DŻŚ..427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽDW˝PROTOCOL DEVIATION Overweight A0YYYYNEGDWGDWŚDWŤDW˝DXbNEGDW.DWDWYNNNNYNDW........DWG.YY NYNY Yhad important protocol deviation(s) as determined by the clinician for Efficacy (within 7 days post Dose 2), Immunogenicity (on or before 3 weeks post Dose 1) Population(s) Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWŚDWýDWýBŮBhBpBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1156 11561360115613601156AŕYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26217 DWDŻŚDWü.DWüDWDWDŻŚDW#D–đDWDŻŚDW#D–đ....HrČGŚHrá;pHrČGŚHrá;p..DWDW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DŻŚD–đ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŇDWH. Obese A@YYYYNEGDWADWŃDWŇ..NEG....YNNNNYYDW........DWADWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŃDWýDWýBŰBŻB,BîBÂ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1156 11561361115613611156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26218 DWD˝`DWá.DWáDWDWD˝`DW$DĹĐDWD˝`DW$DĹĐ....HrČU`Hrâ»ĐHrČU`Hrâ»Đ..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW% .. D˝`DĹĐ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW%. Underweight ANNYYNEGDW@DWŚDWá..NEG....YNNNNYYDW........DW@DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBîB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561362115613621156AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26225 DWDÇtDWî..DWDWDÇtDWîDÉĚDWDÇtDW#D–<DWîDÉĚDWîDÉĚHrČ_tHsíĚHrČ_tHrá:ĽHsíĚHsíĚDWDW#DWî.AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWH .. DÇtD–<.DÉĚ..427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŇDWî. Normal weightA NNYYNEGDWADWŃDWŕDX(DXÂNEG....YNNNNYNDW........DWA.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŃDWýDWýBŰBŻBB,BîBÂ7-8 months A€6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1156 11561363115613631156AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26226 DWDÝDWđ..DWDWDÝDWđDÖ°DWDÝDW%D–đDWŰD4DWđDÖ°HrČuHsďľ°HrČuHrăŢpHsÓĺ´Hsďľ°DWDW%DWŰDWđAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW)BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝD–đ.D4DÖ°.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŰDWŰ. Normal weightA NYYYNEGDWHDWÚDWÚDXDXNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWÚDWýDWýBŮB¶B#B#BîBË7-8 months A€6-7 months Ap1-2 monthsA 8-9 months A . ...C4591001C4591001 1156 11561364115613641156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26387 DWDđ<DWß.DWßDWDWDđ<DW%Dę$DWDđ<DW%Dę$....HrČ<Hrä1¤HrČ<Hrä1¤..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW, .. Dđ<Dę$....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW”DW,. Underweight ANNYYNEGDWADW“DWß..NEG....YNNNNYYDW........DWADWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW“DWýDWýBŮBoBjBîB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561365115613651156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26395 DWD¤DWĺ.DWĺDWDWD¤DW(D–xDWD¤DW(D–x....HrĚ0HrçŇxHrĚ0HrçŇx..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWĺWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D¤D–x....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤ.. Underweight ANNYYNEGDWDDWŚDWĺ..NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWĺDWĺBľBeBYBÓBz6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1156 11561366115613661156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26393 DWDŁDWĺ.DWĺDWDWDŁDW(D—,DWDŁDW(D—,....HrĚ0HrçÓ,HrĚ0HrçÓ,..DWDW(..AĐYEARS. 12-15 YearsAWHITE AWHITE ADWĺWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŁD—,....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDDWŚDWĺ..NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWĺDWĺBľBeBYBÓBz6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1156 11561367115613671156AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26396 DWDÎ|DW˝.DW˝DWDWDÎ|DWˇDÄ¤DWDÎ|DW(DË¬DWŽD×dDWˇDÄ¤HrĚZüHs‡†$HrĚZüHrč¬HsnŚdHs‡†$DWDW(DWŽDWˇAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÎ|DË¬.D×dDÄ¤.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDWDDWŚDWŤDW˝DX^NEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBpBqBëBz7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1156 11561368115613681156AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26662 DWDÜČDWŮ.DWŮDWDWDÜČDW(D” DWDÜČDW(D” ....HrĚiHHrçĐ HrĚiHHrçĐ ..DWDW(..AđYEARS. 12-15 YearsAWHITE AWHITE ADWŮOTHER . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW/ .. DÜČD” ....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW/. Normal weightA NNYYNEGDWGDWŤDWŘ..NEG....YNNNNYYDW........DWGDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWŮDWŮB˛BfBLBÇB{6-7 months Ap3-4 months A@0-1 month A7-8 months A€ . ...C4591001C4591001 1156 11561369115613691156AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26663 DWDÝ¸DW˝.DW˝DWDWDÝ¸DWˇD4DWDÝ¸DW(D”ÔDWŽDßÔDWˇD4HrĚj8Hs‡n´HrĚj8HrçĐÔHsn”ÔHs‡n´DWDW(DWŽDWˇAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÝ¸D”Ô.DßÔD4.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWŽ. Normal weightA NNYYNEGDWGDWŤDWŤDW˝DX^NEG....YNNNNYNDW........DWG.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÖBfBpBpBëB{7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1156 11561370115613701156AŔYEARSFA ASIAN A@HISPANIC OR LATINO AJAPANESEAPUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26666 DWDëČDWî.DWîDWDWDëČDW(Dá<DWDëČDW(Dá<....HrĚxHHrč<HrĚxHHrč<..DWDW(..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DëČDá<....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDWEDWDWî..NEG....YNNNNYYDW........DWEDWîYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNYY NYDWDWýDWýBÖBiBmBëB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561371115613711156AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26668 DWDĄ<DW.DWDWDWDĄ<DWgD›(DWDĄ<DW+D›ÜDWRD™üDWgD›(HrÍ<Hs:ĺ¨HrÍ<HrëĚ\Hs4üHs:ĺ¨DWDW+DWRDWgAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW2BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĄ<D›Ü.D™üD›(.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWHDWR. Normal weightA NNYYNEGDWGDWGDWQDWDX$NEG....YNNNNYNDW........DWH.YY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YNNYNY NYDWGDWýDWýBÓBB¬B¶BęB47-8 months A€1-2 months A 6-7 monthsAp8-9 months A . ...C4591001C4591001 1156 11561372115613721156AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26811 DWD¤ÄDWÚ.DWÚDWDWD¤ÄDW+D›dDWD¤ÄDW+D›d....HrÍ‚ÄHrëËäHrÍ‚ÄHrëËä..DWDW+..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. D¤ÄD›d....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘DW2. Overweight A0YNYYNEGDWHDWDWÚ..NEG....YNNNNYYDW........DWHDWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWýDWýBÓBfBmBęB}7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561373115613731156AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26813 DWDŻČDWÄ.DWÄDWDWDŻČDW˘DśDWDŻČDW(DáđDWŽDěôDW˘DśHrÍŤČHsŻHrÍŤČHrčđHsnˇôHsŻDWDW(DWŽDW˘AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW9BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŻČDáđ.DěôDś.427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Normal weightA NNYYNEGDWKDWŚDWŤDWÄDX_NEG....YNNNNYNDW........DWK.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÖBeBpBqBęBy7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1156 11561374115613741156AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26814 DWDăXDWŘ.DWŘDWDWDăXDW)D±lDWDăXDW)D±l....HrÍÁXHré>ěHrÍÁXHré>ě..DWDW)..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DăXD±l....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWFDWŤDWŘ..NEG....YNNNNYYDW........DWFDWŘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBŐBeBpBęBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1156 11561375115613751156AŔYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26816 DWDépDW“.DW“DWDWDépDW)DěôDWDépDW)Děô....HrÍÇpHréztHrÍÇpHrézt..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE ADW“WITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW2 .. DépDěô....427723 Rodriguez, Hector A ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŤDW2. Normal weightA NNYYNEGDWEDWŚDWć..NEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDW“DW“BkBdApB€By3-4 months A@3-4 months A@0-1 month A4-5 months AP . ...C4591001C4591001 1223 12231267122312671223AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26015 DWDâ¤DWÔ.DWÔDWDWDâ¤DW#DÜDWDâ¤DW#DÜ....HrÇ)$Hrá€”HrÇ)$Hrá€”..DWDW#..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. Dâ¤DÜ....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWb. Obese A@YNYYNEGDW@DW’DWÔ..NEG....YNNNNYYDW........DW@DWÔYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBŰBpBkBďB„7-8 months A€4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1223 12231268122312681223AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26017 DWDă”DWĆ..DWDWDă”DW©DŔlDWDă”DW#DŰ$DW”DťDW©DŔlHrÇ*Hs’ ěHrÇ*Hrá¤Hsv;Hs’ ěDWDW#DW”DW©AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dă”DŰ$.DťDŔl.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW”. Overweight A0NNYYNEGDW@DW’DW“DWĆDXfNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŰBpBjBkBďB„7-8 months A€4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231269122312691223AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26022 DWD÷DWĆ.DWĆDWDWD÷DW§D´<DWD÷DW%DŕDW”DĎ0DW§D´<HrÇ=HsŹ^ĽHrÇ=Hrä'Hsvm0HsŹ^ĽDWDW%DW”DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. D÷Dŕ.DĎ0D´<.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Normal weightA NNYYNEGDWHDW‘DW“DWĆDXdNEG....YNNNNYNDW........DWH.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBŮBmBjBlBďB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231270122312701223AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26024 DWD÷DWő.DWőDWDWD÷DW%DŕDWD÷DW%Dŕ....HrÇ=Hrä(HrÇ=Hrä(..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWi .. D÷Dŕ....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWi. Underweight ANNYYNEGDWHDW’DWŢ..NEG....YNNNNYYDW........DWHDWŢYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBŮBnBkBďB„7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231271122312711223AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26289 DWDáDWĺ.DWĺDWDWDáDW%D°¸DWDáDW%D°¸....HrČyHrăř8HrČyHrăř8..DWDW%..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWj .. DáD°¸....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWj. Overweight A0YNYYNEGDWHDW’DWŮ..NEG....YNNNNYYDW........DWHDWŮYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBŮBnBkBîB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231272122312721223AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26290 DWD“lDWĆ.DWĆDWDWD“lDW©DŤDWD“lDW%DÜDW•D¸8DW©DŤHrÉ|ěHs‘ÚHrÉ|ěHrä#”Hsw§¸Hs‘ÚDWDW%DW•DW©AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. D“lDÜ.D¸8DŤ.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DW•. Normal weightA NNYYNEGDWFDW“DW”DWĆDXfNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýBŮBoBiBjBíB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231273122312731223AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26295 DWD’|DWĆ.DWĆDWDWD’|DW©DŚ(DWD’|DW%DŰ`DW•Dą DW©DŚ(HrÉ{üHs‘Ů¨HrÉ{üHrä"ŕHsw© Hs‘Ů¨DWDW%DW•DW©AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. D’|DŰ`.Dą DŚ(.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW”DW•. Normal weightA NNYYNEGDWFDW“DW”DWĆDXfNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW“DWýDWýBŮBoBiBjBíB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231274122312741223AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26293 DWD”ÔDWô.DWôDWDWD”ÔDW%DŇ<DWD”ÔDW%DŇ<....HrÉ~THräĽHrÉ~THräĽ..DWDW%..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWb .. D”ÔDŇ<....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWb. Overweight A0YNYYNEGDWDDW‘DWô..NEG....YNNNNYYDW........DWDDWôYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŮBmBlBíB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231275122312751223AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26457 DWD›dDWŕ.DWŕDWDWD›dDW)DŇ´DWD›dDW)DŇ´....HrÉ„äHré`4HrÉ„äHré`4..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWi .. D›dDŇ´....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWi. Normal weightA NNYYNEGDWEDW’DWŕ..NEG....YNNNNYYDW........DWEDWŕYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBŐBjBkBíB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231276122312761223AŔYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26461 DWDťDDWĹ.DWĹDWDWDťDDW§DŮDDWDťDDW$DŮ€DW”D’DW§DŮDHrÉ†ÄHsŹÄHrÉ†ÄHrâĎ€Hsv0HsŹÄDWDW$DW”DW§AŔYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DťDDŮ€.D’DŮD.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW”. Underweight ANNYYNEGDW@DW’DW“DWĹDXdNEG....YNNNNYNDW........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBÚBoBjBkBíB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231277122312771223AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26459 DWDśTDWË.DWËDWDWDśTDWD«TDWDśTDW)DÓŕDW™DŞ DWD«THrÉ…ÔHs—>ÔHrÉ…ÔHréa`Hs|ŕ Hs—>ÔDWDW)DW™DWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. DśTDÓŕ.DŞ D«T.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW™. Normal weightA NNYYNEGDWEDW’DWDWËDXjNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBŐBjBeBkBíB‚7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231278122312781223AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26468 DWD§DWď.DWďDWDWD§DW)DůśDWD§DW)Důś....HrÉśHré‡HrÉśHré‡..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWc .. D§Důś....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWc. Normal weightA NNYYNEGDWFDW‘DWÓ..NEG....YNNNNYYDW........DWFDWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŐBiBlBíB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231279122312791223AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26484 DWD¨DWË.DWËDWDWD¨DWŞDśĚDWD¨DW)DęśDW“DŹčDWŞDśĚHrÉ‘ŚHs“;ĚHrÉ‘ŚHréxHstÜhHs“;ĚDWDW)DW“DWŞAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¨Dęś.DŹčDśĚ.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW“. Normal weightA NNYYNEGDWFDW‘DW’DWËDXgNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBŐBiBkBlBíB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231280122312801223AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26488 DWDŻDWú.DWúDWDWDŻDW$DĐÔDWDŻDW$DĐÔ....HrÉ”HrâĆÔHrÉ”HrâĆÔ..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWj .. DŻDĐÔ....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW“DWj. Underweight ANNYYNEGDW@DW’DWú..NEG....YNNNNYYDW........DW@DWúYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW’DWýDWýBÚBoBkBíB‚7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231281122312811223AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26489 DWDµŕDWć..DWDWDµŕDW)EDWDµŕDW)E....HrÉź`HréŹPHrÉź`HréŹP..DWDW)..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWp .. DµŕE....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWp. Normal weightA NNYYNEGDWFDW‘DWć..NEG....YNNNNYYDW........DWFDWćYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŐBiBlBíB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231283122312831223AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26490 DWD˝śDWć.DWćDWDWD˝śDW¨DŽDWD˝śDW%DÓ¤DW”DŘDW¨DŽHrÉ§HsŠHrÉ§Hrä$Hsv.ŘHsŠDWDW%DW”DW¨AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝śDÓ¤.DŘDŽ.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW’DW”. Overweight A0NNYYNEGDWEDW‘DW“DWĹDWĹNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW‘DWýDWýBŮBmBjBlBíB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1223 12231284122312841223AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26866 DWDÝDWú.DWúDWDWDÝDW)DÖěDWDÝDW)DÖě....HrÍ»HrédlHrÍ»Hrédl..DWDW)..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWi .. DÝDÖě....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWi. Underweight ANNYYNEGDWLDW‘DWő..NEG....YNNNNYYDW........DWLDWőYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŐBiBlBęB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231285122312851223AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26870 DWDÜDWú.DWúDWDWDÜDW)D×ÜDWDÜDW)D×Ü....HrÍşHrée\HrÍşHrée\..DWDW)..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWi .. DÜD×Ü....349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW’DWi. Underweight ANNYYNEGDWLDW‘DWő..NEG....YNNNNYYDW........DWLDWőYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW‘DWýDWýBŐBiBlBęB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1223 12231286122312861223AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26873 DWDçDWÉ.DWÉDWDWDçDWŞDŤDWDçDW*DÚčDW•D‘PDWŞDŤHrÍĹHs“,HrÍĹHręąčHsw€ĐHs“,DWDW*DW•DWŞAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWiBNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDÚč.D‘PDŤ.349998 Ogbuagu, Onyema E. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW“DW•. Normal weightA NNYYNEGDWFDW’DW”DWÉDXgNEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW’DWýDWýBÔBiBiBkBęB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1235 12351232123512321235AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20363 DVéD”\DWË.DWËDVéDVéD”\DW®Dˇ@DVéD”\DVţDŘDWDÄŕDW®Dˇ@Hr”ÁÜHs†@Hr”ÁÜHr°^ŘHs{¨ŕHs†@DVéDVţDWDW®AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D”\DŘ.DÄŕDˇ@.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW. Underweight ANNYYNEGDWDWŤDW—DWËDXkNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBBfBpCPBĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351233123512331235AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20364 DVéD–DW®.DW®DVéDVéD–DVţD$DVéD–DVţD$....Hr”Ă€Hr°^$Hr”Ă€Hr°^$..DVéDVţ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–D$....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWDWŤDW®..NEG....YNNNNYYDVé........DWDW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýCBBpCPBĄ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1235 12351234123512341235AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVé20370 DVéDµ,DW±.DW±DVéDVéDµ,DV˙D ČDVéDµ,DV˙D Č....Hr”â¬Hr±ĎHHr”â¬Hr±ĎH..DVéDV˙..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dµ,D Č....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDWDWŤDW±..NEG....YNNNNYYDVé........DWDW±YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB˙BŹBpCPBĄ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1235 12351235123512351235AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20371 DVéDĆHDWĂ.DWĂDVéDVéDĆHDW¦D’|DVéDĆHDVţDĽpDW’DÉDW¦D’|Hr”óČHsŤë|Hr”óČHr°™pHssÄHsŤë|DVéDVţDW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĆHDĽp.DÉD’|.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Underweight ANNYYNEGDWDWŤDW‘DWĂDXcNEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýCBBlBpCPBĄ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351236123512361235AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20711 DVëDČ(DW÷.DW÷DVëDVëDČ(DW¦DÎ@DVëDČ(DV˙D¤DW‘DĂđDW¦DÎ@Hr—¨HsŽ'@Hr—¨Hr±·$HsrmpHsŽ'@DVëDV˙DW‘DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DČ(D¤.DĂđDÎ@.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDWDWŤDWDWÉDXcNEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB˙BŹBmBpC0BŁ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351238123512381235AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ20712 DVđD“lDWá.DWáDVđDVđD“lDWD”ÔDVđD“lDWD”Ô....HrťűlHrą¬THrťűlHrą¬T..DVđDW..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D“lD”Ô....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW%DWŤDWá.. ....YNNNNYYDVđ........DW%DWáYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWŤDWýDWýBůB‰BpCŕBž8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1235 12351239123512391235AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVđ20714 DVđDˇ@DWÄ.DWÄDVđDVđDˇ@DW¦DĘDDVđDˇ@DWD DW’DĘDDW¦DĘDHrž @HsŽ#DHrž @Hrą·”HssĹDHsŽ#DDVđDWDW’DW¦AŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dˇ@D .DĘDDĘD.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0YYYYNEGDW!DWŤDW‘DWÄDXcPOS....YNNNNYNDVđ........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBůB‰BlBpCŕBž8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351242123512421235AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń20717 DVńD–´DW´.DW´DVńDVńD–´DWDy,DVńD–´DWDy,....HrźP4Hrą¬HrźP4Hrą¬..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D–´Dy,....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW$DWDW´..NEG....YNNNNYYDVń........DW$DW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBůBŚBmCĐB 8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1235 12351243123512431235AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21405 DVńD´DWĚ.DWĚDVńDVńD´DWDť€DVńD´DWDť€....Hrźm€HrĽXHrźm€HrĽX..DVńDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´Dť€....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Normal weightA NNYYNEGDW%DWŤDW¸..NEG....YNNNNYYDVń........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýB÷B‡BpCĐBť8-9 months A4-5 months AP0-1 month A9-10 months A . ..DW2C4591001C4591001 1235 12351244123512441235AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DVń21409 DVńD´đDWĚ.DWĚDVńDVńD´đDWD›(DVńD´đDWD›(....HrźnpHrĽU¨HrźnpHrĽU¨..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´đD›(....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWŽ.. Underweight ANNYYNEGDW%DWŤDW¸.. ....YNNNNYYDVń........DW%DW¸YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýB÷B‡BpCĐBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1235 12351245123512451235AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVń21411 DVńDÇ8DW¶.DW¶DVńDVńDÇ8DWD¤DVńDÇ8DWD¤....Hrź€¸HrĽC$Hrź€¸HrĽC$..DVńDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇ8D¤....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NYYYNEGDW%DWDW¶..NEG....YNNNNYYDVń........DW%DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýB÷BŠBmCĐB 8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1235 12351246123512461235AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř21415 DVřD‡đDWĆ.DWĆDVřDVřD‡đDW DŠHDVřD‡đDW DŠH....Hr¨{đHrÄ-ČHr¨{đHrÄ-Č..DVřDW ..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D‡đDŠH....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW/DWDWĆ.. ....YNNNNYYDVř........DW/DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWýDWýBńB„BmC`B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1235 12351247123512471235AđYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22501 DVřDhDWĆ.DWĆDVřDVřDhDW DŠüDVřDhDW DŠü....Hr¨|hHrÄ.|Hr¨|hHrÄ.|..DVřDW ..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DhDŠü....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW/DWŤDWĆ..NEG....YNNNNYYDVř........DW/DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBńBBpC`B–8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1235 12351248123512481235AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22503 DVřDš°DWÉ.DWÉDVřDVřDš°DW§D”\DVřDš°DWDÍPDW”D’ôDW§D”\Hr¨Ž°HsŹ>ÜHr¨Ž°HrĂPHsv0ôHsŹ>ÜDVřDWDW”DW§AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš°DÍP.D’ôD”\.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Normal weightA NNYYNEGDW,DWŤDW“DWÉDXdNEG....YNNNNYNDVř........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBňB‚BjBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351249123512491235AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22506 DVřDşĚDWÉ.DWÉDVřDVřDşĚDW§D”ÔDVřDşĚDWDÍČDW”D“¨DW§D”ÔHr¨®ĚHsŹ?THr¨®ĚHrĂČHsv1¨HsŹ?TDVřDWDW”DW§AđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DşĚDÍČ.D“¨D”Ô.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW”. Overweight A0NNYYNEGDW,DWŤDW“DWÉDXd ....YNNNNYNDVř........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŤDWýDWýBňB‚BjBpC`B–8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351250123512501235AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVř22507 DVřDÉĚDW˝.DW˝DVřDVřDÉĚDW DŔ¨DVřDÉĚDW DŔ¨....Hr¨˝ĚHrÄd(Hr¨˝ĚHrÄd(..DVřDW ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÉĚDŔ¨....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW‘.. Normal weightA NNYYNEGDW)DWDW˝..NEG....YNNNNYYDVř........DW)DW˝YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWýDWýBńB„BmC`B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1235 12351251123512511235AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23280 DVűDŚ DWĆ.DWĆDVűDVűDŚ DWŁDx<DVűDŚ DWDXDW‘DŘDWŁDx<Hr¬u Hs‰ÜĽHr¬u HrČ0XHsr+XHs‰ÜĽDVűDWDW‘DWŁAĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŚ DX.DŘDx<.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW‘. Normal weightA NNYYNEGDW,DWŤDWDWĆDX`NEG....YNNNNYNDVű........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBîB~BmBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351252123512521235AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVţ23281 DVţDÉDWĂ.DWĂDVţDVţDÉDW§DŚÜDVţDÉDWDÖ°DW‘Dš8DW§DŚÜHr°¦HsŹ7\Hr°¦HrÍ´°HsrC¸HsŹ7\DVţDWDW‘DW§AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÉDÖ°.Dš8DŚÜ.240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW‘DW‘. Normal weightA NNYYNEGDW1DWDWDWĂDXdNEG....YNNNNYNDVţ........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWýDWýBęB}BmBmCB“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1235 12351253123512531235AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23285 DWDŢ¨DWÓ.DWÓDWDWDŢ¨DW$DŁ DWDŢ¨DW$DŁ ....HrČv¨Hrâ™ HrČv¨Hrâ™ ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŢ¨DŁ ....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Normal weightA NNYYNEGDW@DWŤDWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1235 12351254123512541235AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23286 DWDß\DWÓ..DWDWDß\DW$DŁDWDß\DW$DŁ....HrČw\Hrâ™HrČw\Hrâ™..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. Dß\DŁ....240230 Vanchiere, John A. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Underweight ANNYYNEGDW@DWŤDWÓ..NEG....YNNNNYYDW........DW@DWÓYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÚBjBpBîB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701173127011731270AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20391 DVéD¦hDWĽ.DWĽDVéDVéD¦hDW D¤ÄDVéD¦hDVţDŚÜDWŤD¸ěDW D¤ÄHr”ÓčHs†ÄHr”ÓčHr°iÜHsmlHs†ÄDVéDVţDWŤDW AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¦hDŚÜ.D¸ěD¤Ä.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Normal weightA NNYYNEGDWDWŚDWŚDWĽDX]NEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýCBŹBqBqCPB¤9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1270 12701174127011741270AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVé20392 DVéD¦hDWĽ.DWĽDVéDVéD¦hDW D¤ÄDVéD¦hDVţDŚÜDWŤDą DW D¤ÄHr”ÓčHs†ÄHr”ÓčHr°iÜHsm Hs†ÄDVéDVţDWŤDW AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¦hDŚÜ.Dą D¤Ä.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŤ. Obese A@YYYYNEGDWDWŚDWŚDWĽDX]NEG....YNNNNYNDVé........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýCBŹBqBqCPB¤9-10 months A 5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1270 12701177127011771270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVę20394 DVęDÇěDW¶.DW¶DVęDVęDÇěDVţDŢäDVęDÇěDVţDŢä....Hr–FěHr°»äHr–FěHr°»ä..DVęDVţ..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DÇěDŢä....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDWDWŚDW¶..NEG....YNNNNYYDVę........DWDW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýCBŹBqC@BŁ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1270 12701180127011801270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20396 DVëDĽ4DWű.DWűDVëDVëDĽ4DV˙DĽpDVëDĽ4DV˙DĽp....Hr—Ś´Hr±ęđHr—Ś´Hr±ęđ..DVëDV˙..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DĽ4DĽp....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWS.. Normal weightA NNYYNEGDWDWRDW¶..NEG....YNNNNYYDVë........DWDW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWRDWýDWýB˙BTB«C0Bh9-10 months A 3-4 months A@0-1 month A9-10 months A . ..DWűC4591001C4591001 1270 12701181127011811270AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVë20722 DVëDĽ4DW„.DW„DVëDVëDĽ4DWhDÂDVëDĽ4DV˙DĽpDWUD·üDWhDÂHr—Ś´Hs<^Hr—Ś´Hr±ęđHs#G|Hs<^DVëDV˙DWUDWhAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DĽ4DĽp.D·üDÂ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWSDWU. Normal weightA NNYYNEGDWDWRDWTDW„DX%NEG....YNNNNYNDVë........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWRDWýDWýB˙BTB©B«C0Bh9-10 months A 3-4 months A@6-7 monthsAp9-10 months A . ...C4591001C4591001 1270 12701184127011841270AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVë20723 DVëDŢäDWµ..DVëDVëDŢäDWD¬DDVëDŢäDWD¬D....Hr—ŻdHrł,DHr—ŻdHrł,D..DVëDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. DŢäD¬D....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Normal weightA NNYYNEGDWDWŚDWµ..NEG....YNNNNYYDVë........DWDWµYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWŚDWýDWýBţBŤBqC0B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1270 12701187127011871270AđYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20724 DVěDx<DW®.DW®DVěDVěDx<DV˙D~DVěDx<DV˙D~....Hrš<Hr±Hrš<Hr±..DVěDV˙..AđYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. Dx<D~....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Normal weightA NNYYNEGDW%DWŚDW®..NEG....YNNNNYYDVě........DW%DW®YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýB˙BŽBqC Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1270 12701188127011881270AĐYEARSMAASIAN A@HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVě20728 DVěDx´DWË.DWËDVěDVěDx´DWD‘ČDVěDx´DV˙D~ĚDW’DÂÄDWD‘ČHrš´Hs—%HHrš´Hr±LHss˝ÄHs—%HDVěDV˙DW’DWAĐYEARSAĐYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dx´D~Ě.DÂÄD‘Č.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANYYYNEGDW%DWŚDW‘DWËDXjNEG....YNNNNYNDVě........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýB˙BŽBlBqC Bˇ9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701189127011891270AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20890 DVěD×dDW´.DW´DVěDVěD×dDV˙DĎäDVěD×dDV˙DĎä....HrůdHr±ţdHrůdHr±ţd..DVěDV˙..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. D×dDĎä....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDWd. Underweight ANYYYNEGDWDWŤDW´..NEG....YNNNNYYDVě........DWDW´YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýB˙BŹBpC B˘9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1270 12701191127011911270AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVě20894 DVěDě|DWĺ.DWĺDVěDVěDě|DWDčDVěDě|DWDč....Hr™|HrłhHr™|Hrłh..DVěDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. Dě|Dč....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW\. Underweight ANNYYNEGDWDWŚDWĽ..NEG....YNNNNYYDVě........DWDWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBţBŤBqC Bˇ9-10 months A 5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1270 12701192127011921270AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20898 DVíDš°DWÄ.DWÄDVíDVíDš°DW¦DXDVíDš°DWD–´DW’DŰ$DW¦DXHrš0HsŤńXHrš0Hr´h4HssÖ$HsŤńXDVíDWDW’DW¦AĐYEARSAŕYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dš°D–´.DŰ$DX.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Underweight ANNYYNEGDW$DWŚDW‘DWÄDXcNEG....YNNNNYNDVí........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBýBŚBlBqCB 9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701194127011941270AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVí20900 DVíDż|DWË.DWËDVíDVíDż|DWŻD¨HDVíDż|DWDŠüDW•DÄhDWŻD¨HHrš2üHs™ŢČHrš2üHrł üHswłčHs™ŢČDVíDWDW•DWŻAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. Dż|DŠü.DÄhD¨H.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW•. Normal weightA NNYYNEGDWDWŚDW”DWËDXlNEG....YNNNNYNDVí........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBţBŤBiBqCB 9-10 months A 5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701198127011981270AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVđ21213 DVđD«DWż.DWżDVđDVđD«DWD©tDVđD«DWD©t....HržHrĽcôHržHrĽcô..DVđDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWc .. D«D©t....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWc. Normal weightA NNYYNEGDW#DWŚDWż..NEG....YNNNNYYDVđ........DW#DWżYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqCŕBť8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701199127011991270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVń21214 DVńDŐ„DWĹ.DWĹDVńDVńDŐ„DW¦DzXDVńDŐ„DWD×(DW‘DŰŘDW¦DzXHrźŹHsŤÓXHrźŹHr»@(Hsr…XHsŤÓXDVńDWDW‘DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐ„D×(.DŰŘDzX.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Obese A@YNYYNEGDW#DWŚDWDWĹDXcNEG....YNNNNYNDVń........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBřB‡BmBqCĐBś8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701200127012001270AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVó21215 DVóDăĐDWľ..DVóDVóDăĐDWDŕÄDVóDăĐDWDŕÄ....Hr˘@PHr»IÄHr˘@PHr»IÄ..DVóDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DăĐDŕÄ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW#DWŚDWľ..NEG....YNNNNYYDVó........DW#DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBřB‡BqC°Bš8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701201127012011270AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVô21222 DVôDŽ€DWŢ..DVôDVôDŽ€DW…D{üDVôDŽ€DWDŚÜDWrDÝ|DW…D{üHrŁ<€HsbS|HrŁ<€HrÂŢÜHsI¨|HsbS|DVôDWDWrDW…AđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŽ€DŚÜ.DÝ|D{ü.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWqDWr. Normal weightA NYYYNEGDW/DWpDWqDW˘DXB ....YNNNNYNDVô........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWpDWýDWýBňBeBŚBŤC B}8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1270 12701202127012021270AđYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22186 DVôDĹDW·..DVôDVôDĹDWDćÜDVôDĹDWDćÜ....HrŁsHr˝ňÜHrŁsHr˝ňÜ..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWU .. DĹDćÜ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWU. Normal weightA NNYYNEGDW%DWŚDW·..NEG....YNNNNYYDVô........DW%DW·YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBöB…BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701203127012031270AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVô22187 DVôDĂ´DWŇ.DWŇDVôDVôDĂ´DWD™ŔDVôDĂ´DWD™Ŕ....HrŁq´HrĽT@HrŁq´HrĽT@..DVôDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DĂ´D™Ŕ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Normal weightA NNYYNEGDW$DWŚDW¶..NEG....YNNNNYYDVô........DW$DW¶YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýB÷B†BqC B™8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701204127012041270AŔYEARSMANOT REPORTED ApNOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22194 DVřD~DWÉ.DWÉDVřDVřD~DW¦DÉDVřD~DWDŮDW‘DĘ€DW¦DÉHr¨rHsŽ"Hr¨rHrĹÎHsrtHsŽ"DVřDWDW‘DW¦AŔYEARSAĐYEARS12-15 YearsANOT REPORTED ApALL OTHERS A0. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D~DŮ.DĘ€DÉ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW*DWŚDWDWÉDXcNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701205127012051270AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22196 DVřDĘDWĘ.DWĘDVřDVřDĘDWD‡<DVřDĘDW Dć(DW‘D|tDWD‡<Hr¨ľHs—ĽHr¨ľHrÄ‰¨Hsr%ôHs—ĽDVřDW DW‘DWAĐYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. DĘDć(.D|tD‡<.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW*DWŚDWDWĘDXjNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBńB€BmBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701206127012061270AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVř22641 DVřDÓŕDWŇ.DWŇDVřDVřDÓŕDWŻDŰ`DVřDÓŕDWDÝ¸DWšD× DWŻDŰ`Hr¨ÇŕHsšŕHr¨ÇŕHrĹŇ¸Hs~^ HsšŕDVřDWDWšDWŻAđYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DÓŕDÝ¸.D× DŰ`.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWš. Normal weightA NNYYNEGDW*DWŚDW™DWŇDXlNEG....YNNNNYNDVř........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBdBqC`B•8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701207127012071270AŕYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22645 DVůD€pDWĽ.DWĽDVůDVůD€pDW DĂ<DVůD€pDW DĂ<....Hr©ĹđHrÄfĽHr©ĹđHrÄfĽ..DVůDW ..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. D€pDĂ<....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Normal weightA NNYYNEGDW*DWŚDWĽ..NEG....YNNNNYYDVů........DW*DWĽYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBńB€BqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ..DW‘C4591001C4591001 1270 12701208127012081270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22647 DVůDłDWĐ.DWĐDVůDVůDłDWDÚ4DVůDłDWDĽ¬DW“Dˇ¸DWDÚ4Hr©ůHs—m´Hr©ůHrĹ±¬Hstî8Hs—m´DVůDWDW“DWAŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DłDĽ¬.Dˇ¸DÚ4.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NYYYNEGDW1DWŚDW’DWÍDXj ....YNNNNYNDVů........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWŚDWýDWýBđBBkBqCPB”8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701209127012091270AđYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22652 DVůDŃLDWľ.DWľDVůDVůDŃLDWD¦,DVůDŃLDWD¦,....HrŞĚHrÂř,HrŞĚHrÂř,..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DŃLD¦,....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Overweight A0NYYYNEGDW*DWŚDWľ..NEG....YNNNNYYDVů........DW*DWľYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701210127012101270AđYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22942 DVůDß\DWĆ.DWĆDVůDVůDß\DWD×dDVůDß\DWD×d....HrŞ$ÜHrĂ)dHrŞ$ÜHrĂ)d..DVůDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWw .. Dß\D×d....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW[DWw. Overweight A0NNYYNEGDW*DWZDWĆ..NEG....YNNNNYYDVů........DW*DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWZDWýDWýBňBOBŁCPBb8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1270 12701211127012111270AŕYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVů22944 DVůDß\DWĆ.DWĆDVůDVůDß\DWD×dDVůDß\DWD×d....HrŞ$ÜHrĂ)dHrŞ$ÜHrĂ)d..DVůDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWY .. Dß\D×d....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWY. Normal weightA NNYYNEGDW*DWŚDWĆ..NEG....YNNNNYYDVů........DW*DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBňBBqCPB”8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701212127012121270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVů22946 DVůDçDWŠ.DWŠDVůDVůDçDWkDŃDVůDçDWDâ,DWUDÖtDWkDŃHrŞ-Hs@aHrŞ-HrĹ×,Hs#eôHs@aDVůDWDWUDWkAđYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DçDâ,.DÖtDŃ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWTDWU. Overweight A0NNNYPOSDW*DWSDWTDWŠDX(POS....YNNNNYNDVů........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWSDWýDWýBđBFB©BŞCPB[8-9 months A2-3 months A06-7 monthsAp9-10 months A . ..DWC4591001C4591001 1270 12701213127012131270AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú22947 DVúD€čDWĐ.DWĐDVúDVúD€čDWDˇ¸DVúD€čDWD} DW‘D{„DWDˇ¸Hr«čHs—58Hr«čHrĆÄ Hsr%Hs—58DVúDWDW‘DWAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D€čD} .D{„Dˇ¸.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW+DWŚDWDWĐDXjNEG....YNNNNYNDVú........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBďB~BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701214127012141270AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23037 DVúDťĽDWĹ.DWĹDVúDVúDťĽDWDÚ¬DVúDťĽDWDÚ¬....Hr«4ĽHrČr¬Hr«4ĽHrČr¬..DVúDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DťĽDÚ¬....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Overweight A0YNYYNEGDW0DWŚDWĹ..NEG....YNNNNYYDVú........DW0DWĹYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŚDWýDWýBîB}BqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701215127012151270AŔYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVú23038 DVúD´´DWĆ.DWĆDVúDVúD´´DWDÁ DVúD´´DWDÁ ....Hr«K´HrĐB Hr«K´HrĐB ..DVúDW..AŔYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. D´´DÁ ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW3DWŚDWĆ..NEG....YNNNNYYDVú........DW3DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBčBwBqC@B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701216127012161270AŔYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23044 DVúDÂDW÷.DW÷DVúDVúDÂDW¦D ŚDVúDÂDWDĆDW‘DÉDW¦D ŚHr«YHsŤůŚHr«YHrĹ»HsrsHsŤůŚDVúDWDW‘DW¦AŔYEARSAŔYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DÂDĆ.DÉD Ś.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Normal weightA NNYYNEGDW*DWŚDWDWÄDXcNEG....YNNNNYNDVú........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBđBBmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701217127012171270AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23048 DVúDŐüDWË.DWËDVúDVúDŐüDWŻD¨HDVúDŐüDWDĘDDW‘DĚ$DWŻD¨HHr«lüHs™ŢČHr«lüHrČbDHsru¤Hs™ŢČDVúDWDW‘DWŻAŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DŐüDĘD.DĚ$D¨H.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW‘. Overweight A0YNYYNEGDW,DWŚDWDWËDXlNEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BmBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701218127012181270AŕYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVú23217 DVúDć DWĘ..DVúDVúDć DW®DľDVúDć DWDć DW“DĂ<DW®DľHr«} HsŁHr«} HrÇ- HsuĽHsŁDVúDWDW“DW®AŕYEARSAđYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dć Dć .DĂ<Dľ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW,DWŚDW’DWĘDXkNEG....YNNNNYNDVú........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWŚDWýDWýBďB~BkBqC@B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701219127012191270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23219 DVűDšěDWÄ.DWÄDVűDVűDšěDWD¤ÄDVűDšěDWD¤Ä....Hr¬lHrČ<ÄHr¬lHrČ<Ä..DVűDW..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DšěD¤Ä....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW/.. Overweight A0NNYYNEGDW.DW.DWÄ..NEG....YNNNNYYDVű........DW/DWÄYY YYNN Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2Yunblinded on or after 14 days but no later than 1 month post Dose 2 visit NYYYYYN YYNNNY NYDW.DWýDWýBîBBĎC0B48-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1270 12701220127012201270AĐYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23224 DVűD›dDWç.DWçDVűDVűD›dDWDĄ<DVűD›dDWDĄ<....Hr¬äHrČ=<Hr¬äHrČ=<..DVűDW..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW\ .. D›dDĄ<....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽDW\. Underweight ANNYYNEGDW/DWŤDWĘ..NEG....YNNNNYYDVű........DW/DWĘYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWŤDWýDWýBîB~BpC0B“8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701221127012211270AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23225 DVűD´´DWÉ.DWÉDVűDVűD´´DWDÔĐDVűD´´DWDĄđDWšD§ĐDWDÔĐHr¬ť4Hs—hPHr¬ť4HrĹšđHs~.ĐHs—hPDVűDWDWšDWAŔYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. D´´DĄđ.D§ĐDÔĐ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDWš. Overweight A0NNYYNEGDW*DWŤDW™DWÉDXjNEG....YNNNNYNDVű........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBđB€BdBpC0B“8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701222127012221270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVű23485 DVűDčDWâ.DWâDVűDVűDčDWDÉDVűDčDWDÉ....Hr¬ĐHrČaHr¬ĐHrČa..DVűDW..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DčDÉ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤ.. Normal weightA NNYYNEGDW,DWŚDWĆ..NEG....YNNNNYYDVű........DW,DWĆYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBîB}BqC0B’8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701223127012231270AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DVű23487 DVűDčřDWó.DWóDVűDVűDčřDW®D,DVűDčřDWDĺěDW”DÚčDW®D,Hr¬ŃxHsm,Hr¬ŃxHrČ}ěHsvxčHsm,DVűDWDW”DW®AĐYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW\BNT162b2 (30 (*ESC*){unicode 03BC}g).. DčřDĺě.DÚčD,.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW”. Normal weightA NNYYNEGDW1DWŚDW“DWĘDXkNEG....YNNNNYNDVű........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBîB}BjBqC0B’8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1270 12701224127012241270AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DVţ23488 DVţD·üDWÉ..DVţDVţD·üDWDâ,DVţD·üDWDâ,....Hr°”üHrÍŔ,Hr°”üHrÍŔ,..DVţDW..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWd .. D·üDâ,....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWd. Underweight ANNYYNEGDW7DWŚDWÉ..NEG....YNNNNYYDVţ........DW7DWÉYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBęByBqCBŹ8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1270 12701225127012251270AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23489 DWD”DWŇ.DWŇDWDWD”DW®DŘDWD”DWDŁ\DW™D—hDW®DŘHr»”HsuŘHr»”HrŐj\Hs|ĚčHsuŘDWDWDW™DW®AŕYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWhBNT162b2 (30 (*ESC*){unicode 03BC}g).. D”DŁ\.D—hDŘ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW™. Normal weightA NYYYNEGDW7DWŤDWDWĘDXkNEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBäBtBeBpBřB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701226127012261270AŕYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25346 DWDâ¤DW×.DW×DWDWDâ¤DW!D|°DWDâ¤DW!D|°....HrĂ4¤HrŢ~0HrĂ4¤HrŢ~0..DWDW!..AŕYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. Dâ¤D|°....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Normal weightA NNYYNEGDW=DWŚDW×..NEG....YNNNNYYDW........DW=DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÝBlBqBňB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701227127012271270AĐYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25347 DW DřDWÄ.DWÄDW DW DřDW§Dr`DW DřDW$DáDW’D×(DW§Dr`HrÄ#xHsŹŕHrÄ#xHrâ×HssŇ(HsŹŕDW DW$DW’DW§AĐYEARSAŕYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. DřDá.D×(Dr`.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0YNYYNEGDWEDWŤDW‘DWÄDXdNEG....YNNNNYNDW ........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÚBjBlBpBńB7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701228127012281270AŔYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25350 DW DXDW×.DW×DW DW DXDW˘DľŚDW DXDW"DťDWŽDłLDW˘DľŚHrÄ;ŘHsŃŚHrÄ;ŘHrßđHsnhLHsŃŚDW DW"DWŽDW˘AŔYEARSAŔYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DXDť.DłLDľŚ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Underweight ANYYYNEGDW>DWŚDWŤDWĂDX_NEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBpBqBńB€7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1270 12701229127012291270AĐYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25352 DW DŞ DWŃ.DWŃDW DW DŞ DW"DĄxDW DŞ DW"DĄx....HrÄN HrßřxHrÄN Hrßřx..DW DW"..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€NY Y NY Y. .. DŞ DĄx....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŽ.. Overweight A0YNYYNEGDW>DWŤDWŃ..NEG....YNNNNYYDW ........DW>DWŃYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŤDWýDWýBÜBlBpBńB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701230127012301270AđYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25533 DW D˝$DW.DWDW DW D˝$DW|DÔDW D˝$DW!Dĺ°DWgDš°DW|DÔHrÄ`¤HsVÎHrÄ`¤HrŢç0Hs:ĺ0HsVÎDW DW!DWgDW|AđYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝$Dĺ°.Dš°DÔ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWdDWg. Normal weightA NNYYNEGDW?DWcDWfDWDX9NEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWcDWýDWýBÝBCB—BšBńBW7-8 months A€2-3 months A05-6 monthsA`8-9 months A . ...C4591001C4591001 1270 12701231127012311270AĐYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25536 DW D˝$DWĹ.DWĹDW DW D˝$DW§DÂÄDW D˝$DW!Dß DW“D˘0DW§DÂÄHrÄ`¤HsŹmDHrÄ`¤HrŢŕ Hstî°HsŹmDDW DW!DW“DW§AĐYEARSAĐYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D˝$Dß .D˘0DÂÄ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Overweight A0YNYYNEGDW?DWŚDW’DWĹDXdNEG....YNNNNYNDW ........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÝBlBkBqBńB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701232127012321270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25541 DW DÚ4DWŇ.DWŇDW DW DÚ4DW#DÜPDW DÚ4DW#DÜP....HrÄ}´Hrá€ĐHrÄ}´Hrá€Đ..DW DW#..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. DÚ4DÜP....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Overweight A0NNYYNEGDWDDWŚDWŇ..NEG....YNNNNYYDW ........DWDDWŇYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŰBjBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701233127012331270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25543 DW Dâ¤DWó.DWóDW DW Dâ¤DW"DÜPDW Dâ¤DW"DÜP....HrÄ†$Hrŕ/PHrÄ†$Hrŕ/P..DW DW"..AŕYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWc .. Dâ¤DÜP....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWc. Underweight ANNYYNEGDW@DWŚDWÚ..NEG....YNNNNYYDW ........DW@DWÚYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÜBkBqBńB€7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701234127012341270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25667 DWD`DWß.DWßDWDWD`DW$D|°DWD`DW$D|°....HrĹv`Hrâr°HrĹv`Hrâr°..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D`D|°....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Normal weightA NNYYNEGDWADWŚDWß..NEG....YNNNNYYDW........DWADWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701235127012351270AŔYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25669 DWD’|DWß.DWßDWDWD’|DW$D~DWD’|DW$D~....HrĹ‡|HrâtHrĹ‡|Hrât..DWDW$..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWS .. D’|D~....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWS. Normal weightA NNYYNEGDWADWŚDWß..NEG....YNNNNYYDW........DWADWßYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBđB7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701236127012361270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25673 DWD×(DWÄ..DWDWD×(DW¦DĘDWD×(DW!DË¬DW’DÂLDW¦DĘHrĹĚ(HsŽ#HrĹĚ(HrŢÍ,Hss˝LHsŽ#DWDW!DW’DW¦AŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D×(DË¬.DÂLDĘ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW’. Overweight A0NNYYNEGDW>DWŤDW‘DWÄDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŤDWýDWýBÝBmBlBpBđB€7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701237127012371270AĐYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25675 DWD¤DWĘ.DWĘDWDWD¤DW“D‹tDWD¤DWD¤DW“D‹tDW“D‹tHrĆĎ$Hst×ôHrĆĎ$HrĆĎ$Hst×ôHst×ôDW.DW“.AĐYEARSAĐYEARS12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0DWĘWITHDRAWAL BY SUBJECT DW"NO LONGER MEETS ELIGIBILITY CRITERIABNT162b2 Phase 2/3 (30 mcg)A€NNYY NN . .. D¤..D‹t..280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŽDW“. Overweight A0YYYNPOSDWZDWŤDW’DWÍDXgPOS....YNNNNYNDW........DWZ.YY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDWŤDWĘDWĘB8B=BĽB0-1 month A0-1 month A2-3 monthsA06-7 months Ap . ..DWC4591001C4591001 1270 12701238127012381270AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26025 DWD©°DWÄ.DWÄDWDWD©°DW¦DŐüDWD©°DW"DÓ¤DW’DŇđDW¦DŐüHrĆđ0HsŽ.üHrĆđ0Hrŕ&¤HssÍđHsŽ.üDWDW"DW’DW¦AĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. D©°DÓ¤.DŇđDŐü.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDW>DWŚDW‘DWÄDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÜBkBlBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701239127012391270AĐYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26027 DWD´đDW×.DW×DWDWD´đDW$DľDWD´đDW$Dľ....HrĆűpHrâ´HrĆűpHrâ´..DWDW$..AĐYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDW] .. D´đDľ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDW]. Normal weightA NNYYNEGDW@DWŚDW×..NEG....YNNNNYYDW........DW@DW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701240127012401270AđYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26028 DWDŐHDWő.DWőDWDWDŐHDW$DÍDWDŐHDW$DÍ....HrÇČHrâĂHrÇČHrâĂ..DWDW$..AđYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. DŐHDÍ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Normal weightA NNYYNEGDWEDWŚDW×..NEG....YNNNNYYDW........DWEDW×YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBÚBiBqBďB~7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701241127012411270AĐYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26030 DWDŢ¨DWŇ.DWŇDWDWDŢ¨DWDŃDWDŢ¨DW#DÔDW“D‘ČDWDŃHrÇ%(Hs—eHrÇ%(HráxśHstŢHHs—eDWDW#DW“DWAĐYEARSAĐYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DŢ¨DÔ.D‘ČDŃ.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW“. Normal weightA NNYYNEGDW?DWŚDW’DWËDXjNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŰBjBkBqBďB~7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1270 12701242127012421270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26351 DWD¶”DWż.DWżDWDWD¶”DWŁDÄhDWD¶”DW*DĐDWŽD¬€DWŁDÄhHrČN”HsŠ(čHrČN”HręwĐHsna€HsŠ(čDWDW*DWŽDWŁAŕYEARSAŕYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. D¶”DĐ.D¬€DÄh.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDWŽ. Overweight A0NNYYNEGDWFDWŚDWŤDWżDX`NEG....YNNNNYNDW........DWF.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBÔBcBpBqBîB}7-8 months A€3-4 months A@4-5 monthsAP8-9 months A . ...C4591001C4591001 1270 12701243127012431270AŔYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg)A€ .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26352 DWDĺ8DWŰ.DWŰDWDWDĺ8DW)DÁÔDWDĺ8DW)DÁÔ....HrĚq¸HréOTHrĚq¸HréOT..DWDW)..AŔYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)A€YY Y NY YDWZ .. Dĺ8DÁÔ....280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWŤDWZ. Normal weightA NYYYNEGDWEDWŚDWŰ..NEG....YNNNNYYDW........DWEDWŰYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWŚDWýDWýBŐBdBqBëBz7-8 months A€3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1270 12701244127012441270AŕYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo ABNT162b2 Phase 2/3 (30 mcg)A€Placebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26359 DWDĺ8DWĐ.DWĐDWDWDĺ8DW¦DáxDWDĺ8DW)DĂ´DW’DÚčDW¦DáxHrĚq¸HsŽ:xHrĚq¸HréQ4HssŐčHsŽ:xDWDW)DW’DW¦AŕYEARSAđYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. Dĺ8DĂ´.DÚčDáx.280164 Klein, Nicola P. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWŤDW’. Normal weightA NNYYNEGDWEDWŚDW‘DWÉDXcNEG....YNNNNYNDW........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWŚDWýDWýBŐBdBlBqBëBz7-8 months A€3-4 months A@3-4 monthsA@8-9 months A . ...